PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD				Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD			The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C-elegans	CELL			English	Article							RECEPTOR TYROSINE KINASES; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE LIGANDS; NERVOUS-SYSTEM; CELL LINEAGE; ATTACHMENT; ZEBRAFISH; FAMILY; EXPRESSION; HYPODERMIS	The Eph receptor VAB-1 is required in neurons for epidermal morphogenesis during C. elegans embryogenesis. Two models were proposed for the nonautonomous role of VAB-1: neuronal VAB-1 might signal directly to epidermis, or VAB-1 signaling between neurons might be required for epidermal development. We show that the ephrin VAB-2 (also known as EFN-1) is a ligand for VAB-1 and can function in neurons to regulate epidermal morphogenesis. In the absence of VAB-1 signaling, ephrin-expressing neurons are disorganized. vab-2/efn-1 mutations synergize with vab-1 kinase alleles, suggesting that VAB-2/EFN-1 may partly function in a kinase-independent VAB-1 pathway. Our data indicate that ephrin signaling between neurons is required nonautonomously for epidermal morphogenesis in C. elegans.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537; Chin-Sang, Ian/0000-0001-7480-9775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araujo M, 1998, DEVELOPMENT, V125, P4195; BARD JB, 1992, MORPHOGENESIS; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cerretti DP, 1998, GENOMICS, V47, P131, DOI 10.1006/geno.1997.5088; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Conway G, 1997, P NATL ACAD SCI USA, V94, P3082, DOI 10.1073/pnas.94.7.3082; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GUARENTE L, 1993, TRENDS GENET, V9, P395; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Hodgkin Jonathan, 1997, V33, P881; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Kane DA, 1996, DEVELOPMENT, V123, P47; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; MADURO M, 1995, GENETICS, V141, P977; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452	46	125	131	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					781	790		10.1016/S0092-8674(00)81675-X	http://dx.doi.org/10.1016/S0092-8674(00)81675-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619431	Bronze			2022-12-24	WOS:000084488200011
J	Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R				Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R			Geomicrobiology of subglacial ice above Lake Vostok, Antarctica	SCIENCE			English	Article							PCR	Data from ice 3590 meters below Vostok Station indicate that the ice was accreted from liquid water associated with Lake Vostok. Microbes were observed at concentrations ranging from 2.8 x 10(3) to 3.6 x 10(4) cells per milliliter; no biological incorporation of selected organic substrates or bicarbonate was detected. Bacterial 16S ribosomal DNA genes revealed Low diversity in the gene population. The phylotypes were closely related to extant members of the alpha- and beta-Proteobacteria and the Actinomycetes. Extrapolation of the data from accretion ice to Lake Vostok implies that Lake Vostok may support a microbial population, despite more than 10(6) years of isolation from the atmosphere.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Montana State Univ, Dept Earth Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Phys, Bozeman, MT 59717 USA; Univ Alabama, Dept Geol, Tuscaloosa, AL 35487 USA; US Geol Survey, Reston, VA 20192 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; University of Alabama System; University of Alabama Tuscaloosa; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Welch, Kathleen/0000-0003-1028-3086				ABYZOV SS, 1993, ANTARCTIC MICROBIOLO, P265; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brunk CF, 1996, APPL ENVIRON MICROB, V62, P872, DOI 10.1128/AEM.62.3.872-879.1996; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; DREVER JI, 1988, GEOCHMISTRY NATURAL; HYNDMAN DW, 1985, PETROLOGY IGNEOUS ME; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; Kawamura K, 1996, GEOPHYS RES LETT, V23, P2665, DOI 10.1029/96GL02428; Killawee JA, 1998, GEOCHIM COSMOCHIM AC, V62, P3637, DOI 10.1016/S0016-7037(98)00268-3; LANGWAY CC, 1959, 62 SIPRE ARM COLD RE; LIESACK W, 1991, MICROBIAL ECOL, V21, P191, DOI 10.1007/BF02539153; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; *NAT SCI FDN WORKS, 1998, LAK VOST STUD CUR FO; ONEIL JR, 1968, J PHYS CHEM-US, V72, P3683, DOI 10.1021/j100856a060; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; TWICKLER MS, 1986, NATURE, V320, P156, DOI 10.1038/320156a0; VOYTEK MA, 1995, APPL ENVIRON MICROB, V56, P2430; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2; Welch KA, 1996, J CHROMATOGR A, V739, P257, DOI 10.1016/0021-9673(96)00044-1	24	289	317	4	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2141	2144		10.1126/science.286.5447.2141	http://dx.doi.org/10.1126/science.286.5447.2141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591642				2022-12-24	WOS:000084157300047
J	Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V				Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V			Perforin gene defects in familiar hemophagocytic lymphohistiocytosis	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; LYMPHOPROLIFERATIVE SYNDROME; FAS; AUTOIMMUNITY; EXHAUSTION; MUTATIONS; CHILDREN; MICE	Familiar hemophagocytic Lymphohistiocytosis (FHL) is a rare, rapidly fatal, autosomal recessive immune disorder characterized by uncontrolled activation of T cells and macrophages and overproduction of inflammatory cytokines. Linkage analyses indicate that FHL is genetically heterogeneous and Linked to 9q21.3-22, 10q21-22, or another as yet undefined Locus. Sequencing of the coding regions of the perforin gene of eight unrelated 10q21-22-linked FHL patients revealed homozygous nonsense mutations in four patients and missense mutations in the other four patients. Cultured Lymphocytes from patients had defective cytotoxic activity, and immunostaining revealed Little or no perforin in the granules. Thus, defects in perforin are responsible for 10q21-22-linked FHL. Perforin-based effector systems are, therefore, involved not only in the Lysis of abnormal cells but also in the downregulation of cellular immune activation.	INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; Univ Texas, SW Med Sch, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Grad Program Immunol, Dallas, TX 75235 USA; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Karolinska Inst, Karolinska Hosp, Dept Pediat Hematol & Oncol, S-17177 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of North Texas System; University of North Texas Health Science Center; Karolinska Institutet; Karolinska University Hospital	Saint Basile, GD (corresponding author), INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France.	sbasile@necker.fr	de Saint Basile, Genevieve/G-9731-2017	de Saint Basile, Genevieve/0000-0002-1913-5269; Henter, Jan-Inge/0000-0002-0629-2126; Nandwana, Sadhna/0000-0002-3021-3715; DOGNIAUX, Stephanie/0000-0003-3309-1204				Arico M, 1996, LEUKEMIA, V10, P197; Binder D, 1998, J EXP MED, V187, P1903, DOI 10.1084/jem.187.11.1903; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Dufourcq-Lagelouse R, 1999, AM J HUM GENET, V64, P172, DOI 10.1086/302194; Egeler RM, 1996, J PEDIAT HEMATOL ONC, V18, P340, DOI 10.1097/00043426-199611000-00002; Fadeel B, 1999, BRIT J HAEMATOL, V106, P406, DOI 10.1046/j.1365-2141.1999.01538.x; FAVARA BE, 1992, SEMIN DIAGN PATHOL, V9, P63; FINK TM, 1992, GENOMICS, V13, P1300, DOI 10.1016/0888-7543(92)90050-3; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Geldhof AB, 1998, BLOOD, V91, P196, DOI 10.1182/blood.V91.1.196.196_196_206; GILBERTSON SM, 1986, J IMMUNOL, V136, P3567; HENTER JI, 1993, ACTA PAEDIATR, V82, P369, DOI 10.1111/j.1651-2227.1993.tb12699.x; Henter JI, 1998, HEMATOL ONCOL CLIN N, V12, P417, DOI 10.1016/S0889-8588(05)70520-7; Hoang MP, 1998, HUM PATHOL, V29, P1074, DOI 10.1016/S0046-8177(98)90416-6; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Knight SC, 1997, ADV EXP MED BIOL, V417, P389; LANDMANPARKER J, 1993, BRIT J HAEMATOL, V85, P37, DOI 10.1111/j.1365-2141.1993.tb08642.x; Le Deist F., UNPUB; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Peng SL, 1998, J IMMUNOL, V160, P652; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sambhara S, 1998, CELL IMMUNOL, V187, P13, DOI 10.1006/cimm.1998.1314; Spaner D, 1998, J IMMUNOL, V160, P2655; Spaner D, 1999, J IMMUNOL, V162, P1192; Spielman J, 1998, J IMMUNOL, V161, P7063; Sullivan KE, 1998, PEDIATR RES, V44, P465, DOI 10.1203/00006450-199810000-00001; von Herrath M, 1999, J VIROL, V73, P5918, DOI 10.1128/JVI.73.7.5918-5925.1999	29	885	936	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1957	1959		10.1126/science.286.5446.1957	http://dx.doi.org/10.1126/science.286.5446.1957			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583959				2022-12-24	WOS:000084003400052
J	Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J				Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J			Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SMEARS; WOMEN; INFECTION; PRIMERS; RISK	Background: Infection with the human papillomavirus (HPV) has been established as a cause of cervical cancer, but the association between a positive test for HPV DNA and the risk of the subsequent development of invasive cervical cancer is unknown. Methods: In a study of women who participated in a population-based screening program for cancer of the cervix in Sweden from 1969 to 1995, we compared the proportion of normal cervical smears (Pap smears) that were positive for HPV DNA among 118 women in whom invasive cervical cancer developed an average of 5.6 years later (range, 0.5 month to 26.2 years) with the proportion of HPV DNA-positive smears from 118 women who remained healthy during a similar length of follow-up (controls). The control women were matched for age to the women with cancer, and they had had two normal Pap smears obtained at time points that were similar to the times of the base-line smear and the diagnosis of cancer confirmed by biopsy in the women with cancer. Results: At base line, 35 of the women with cancer (30 percent) and 3 of the control women (3 percent) were positive for HPV DNA (odds ratio, 16.4; 95 percent confidence interval, 4.4 to 75.1). At the time of diagnosis, 80 of the 104 women with cancer for whom tissue samples were available (77 percent) and 4 of the 104 matched control women (4 percent) were positive for HPV DNA. The HPV DNA type was the same in the base-line smear and the biopsy specimen in all of the women with cancer in whom HPV DNA was detected at base line. None of the control women had the same type of HPV in both smears. Conclusions: A single positive finding of HPV DNA in a Pap smear confers an increased risk of future invasive cervical cancer that is positive for the same type of virus. (N Engl J Med 1999;341:1633-8.) (C) 1999, Massachusetts Medical Society.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, S-17177 Stockholm, Sweden; Univ Hosp No Sweden, Ctr Oncol, Umea, Sweden; Univ Hosp No Sweden, Cytol Lab, Umea, Sweden; Univ Hosp No Sweden, Dept Pathol, Umea, Sweden; Univ Hosp No Sweden, Dept Oncol, Sect Gynecol, Umea, Sweden; Univ Hosp No Sweden, Dept Virol, Umea, Sweden; Univ Hosp No Sweden, Dept Publ Hlth & Clin Med, Med Bank, Umea, Sweden; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Karolinska Institutet; Umea University; Umea University; Umea University; Umea University; Umea University; Umea University; Tampere University	Wallin, KL (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, POB 280, S-17177 Stockholm, Sweden.							Chua KL, 1996, CANCER, V77, P121, DOI 10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO;2-6; CHUA KL, 1995, ANAL QUANT CYTOL, V17, P221; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; EVANDER M, 1992, J CLIN MICROBIOL, V30, P987, DOI 10.1128/JCM.30.4.987-992.1992; EVANDER M, 1991, ARCH VIROL, V116, P221, DOI 10.1007/BF01319244; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Jenkins D, 1996, INT J CANCER, V65, P768; MANOS MM, 1989, CANCER CEL, V7, P209; Meijer C J, 1992, IARC Sci Publ, P271; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; TANAKA H, 1993, CYTOPATHOLOGY, V4, P273, DOI 10.1111/j.1365-2303.1993.tb00102.x; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; WALBOOMERS JMM, 1995, J CLIN PATHOL, V48, P728, DOI 10.1136/jcp.48.8.728; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	16	391	408	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1633	1638		10.1056/NEJM199911253412201	http://dx.doi.org/10.1056/NEJM199911253412201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572150	Bronze			2022-12-24	WOS:000083847500001
J	Himsworth, RL; Goldacre, MJ				Himsworth, RL; Goldacre, MJ			Does time spent in hospital in the final 15 years of life increase with age at death? A population based study	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Cambridge; University of Oxford	Himsworth, RL (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.							GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HENDERSON J, 1990, BRIT MED J, V301, P17, DOI 10.1136/bmj.301.6742.17; vanWeel C, 1997, LANCET, V350, P1159, DOI 10.1016/S0140-6736(97)08312-8; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210	4	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1338	1339		10.1136/bmj.319.7221.1338	http://dx.doi.org/10.1136/bmj.319.7221.1338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567138	Green Published, Bronze			2022-12-24	WOS:000083930200025
J	White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM				White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM			Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1	SCIENCE			English	Article							MICROCOCCUS-RADIODURANS; ESCHERICHIA-COLI; RADIATION-RESISTANT; IONIZING-RADIATION; GENUS DEINOCOCCUS; DNA-REPAIR; PROTEIN; IDENTIFICATION; MUTATION; THERMUS	The complete genome sequence of the radiation-resistant bacterium Deinococcus radiodurans R1 is composed of two chromosomes (2,648,638 and 412,348 base pairs), a megaplasmid (172,466 base pairs), and a small plasmid (45,704 base pairs), yielding a total genome of 3,284,156 base pairs. Multiple components distributed on the chromosomes and megaplasmid that contribute to the ability of D. radiodurans to survive under conditions of starvation, oxidative stress, and high amounts of DNA damage were identified. Deinococcus radiodurans represents an organism in which all systems for DNA repair, DNA damage export, desiccation and starvation recovery, and genetic redundancy are present in one cell.	Inst Genome Res, Rockville, MD 20850 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Uniformed Services University of the Health Sciences - USA	Fraser, CM (corresponding author), Inst Genome Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Salzberg, Steven/Q-6514-2019; Nelson, William C/E-9263-2016; Eisen, Jonathan A./H-2706-2019; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Nelson, William C/0000-0002-1873-3929; Eisen, Jonathan A./0000-0002-0159-2197; Salzberg, Steven L/0000-0002-8859-7432; Aravind, L/0000-0003-0771-253X; Vamathevan, Jessica/0000-0003-2016-9754; Fraser, Claire/0000-0003-1462-2428; Heidelberg, John/0000-0003-0673-3224	NATIONAL CANCER INSTITUTE [R01CA077712] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agostini HJ, 1996, J BACTERIOL, V178, P6759, DOI 10.1128/jb.178.23.6759-6765.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOLING ME, 1966, BIOCHIM BIOPHYS ACTA, V123, P26, DOI 10.1016/0005-2787(66)90155-9; COUNSELL TJ, 1986, INT J SYST BACTERIOL, V36, P202, DOI 10.1099/00207713-36-2-202; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; Eisen JA, 1995, J MOL EVOL, V41, P1105; EISEN JA, 1999, THESIS STANFORD U ST; Ferreira AC, 1997, INT J SYST BACTERIOL, V47, P939, DOI 10.1099/00207713-47-4-939; Furuya K, 1998, FEMS MICROBIOL LETT, V168, P243, DOI 10.1111/j.1574-6968.1998.tb13280.x; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; HENSEL R, 1986, INT J SYST BACTERIOL, V36, P444, DOI 10.1099/00207713-36-3-444; Kitayama S, 1997, MUTAT RES-DNA REPAIR, V385, P151, DOI 10.1016/S0921-8777(97)00048-7; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lin CS, 1998, BIOCHEM MOL BIOL INT, V45, P651; Markillie LM, 1999, J BACTERIOL, V181, P666, DOI 10.1128/JB.181.2.666-669.1999; MASTERS CI, 1991, J GEN MICROBIOL, V137, P1459, DOI 10.1099/00221287-137-7-1459; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MITCHEL REJ, 1980, BIOCHIM BIOPHYS ACTA, V621, P138, DOI 10.1016/0005-2795(80)90069-0; MOSELEY BEB, 1983, J GEN MICROBIOL, V129, P2437; MUN C, 1994, RADIAT RES, V138, P282, DOI 10.2307/3578599; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; SETLOW JK, 1964, BIOCHIM BIOPHYS ACTA, V87, P664, DOI 10.1016/0926-6550(64)90284-1; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SWEET DM, 1976, MUTAT RES, V34, P175, DOI 10.1016/0027-5107(76)90122-6; Tanaka A, 1996, RADIAT ENVIRON BIOPH, V35, P95, DOI 10.1007/BF02434031; TEMPEST PR, 1980, MOL GEN GENET, V179, P191, DOI 10.1007/BF00268463; TIRGARI S, 1980, J GEN MICROBIOL, V119, P287; UDUPA KS, 1994, J BACTERIOL, V176, P7439, DOI 10.1128/JB.176.24.7439-7446.1994; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; Wolf YI, 1999, GENOME RES, V9, P17; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	41	757	1348	3	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1571	1577		10.1126/science.286.5444.1571	http://dx.doi.org/10.1126/science.286.5444.1571			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567266	Green Accepted			2022-12-24	WOS:000083768300062
J	Pianko, S; McHutchinson, J				Pianko, S; McHutchinson, J			Chronic hepatitis B: new therapies on the horizon?	LANCET			English	Editorial Material							LAMIVUDINE		Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, La Jolla, CA 92037 USA	Scripps Research Institute	Pianko, S (corresponding author), Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Couillin I, 1999, J INFECT DIS, V180, P15, DOI 10.1086/314828; Heathcote J, 1999, HEPATOLOGY, V30, P531, DOI 10.1002/hep.510300208; Kane MA, 1996, LANCET, V348, P696, DOI 10.1016/S0140-6736(05)65598-5; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221; Livingston BD, 1997, J IMMUNOL, V159, P1383; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Schiff E, 1998, HEPATOLOGY, V28, p388A; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	11	10	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1662	1663		10.1016/S0140-6736(99)00305-0	http://dx.doi.org/10.1016/S0140-6736(99)00305-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568564				2022-12-24	WOS:000083652800005
J	Dobson, A				Dobson, A			Is raised serum uric acid a cause of cardiovascular disease or death?	LANCET			English	Editorial Material							HEART-DISEASE; MORTALITY; RISK		Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia	University of Newcastle	Dobson, A (corresponding author), Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia.							Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEVYA F, 1997, EUR HEART J, V18, P858; Neter J., 1990, APPL LINEAR STAT MOD; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; ROSE BD, 1994, CLIN PHYSL ACID BASE; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1	11	35	36	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1578	1578		10.1016/S0140-6736(99)00260-3	http://dx.doi.org/10.1016/S0140-6736(99)00260-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560670				2022-12-24	WOS:000083551000007
J	O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S				O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S			Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling	SCIENCE			English	Article							HIPPOCAMPAL SYNAPSES; CALCIUM; PROTEIN; CHANNELS; INHIBITION; COMPLEX	Glutamatergic neurotransmission is controlled by presynaptic metabotropic glutamate receptors (mGluRs). A subdomain in the intracellular carboxyl-terminal tail of group III mGluRs binds calmodulin and heterotrimeric guanosine triphosphate-binding protein (G protein) beta gamma subunits in a mutually exclusive manner. Mutations interfering with calmodulin binding and calmodulin antagonists inhibit G protein-mediated modulation of ionic currents by mGluR 7. Calmodulin antagonists also prevent inhibition of excitatory neurotransmission via presynaptic mGluRs. These results reveal a novel mechanism of presynaptic modulation in which Ca2+-calmodulin is required to release G protein beta gamma subunits from the C-tail of group III mGluRs in order to mediate glutamatergic autoinhibition.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	Max Planck Society; University of Vienna; Max Planck Society	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.		Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Boehm S, 1997, J NEUROSCI, V17, P4066; Bradley SR, 1996, J NEUROSCI, V16, P2044; Bushell TJ, 1996, BRIT J PHARMACOL, V117, P1457, DOI 10.1111/j.1476-5381.1996.tb15306.x; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; ELFAR O, UNPUB; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LEUNG PC, 1984, J BIOL CHEM, V259, P2742; MINKAMI R, 1997, J BIOL CHEM, V272, P20291; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1995, MOL PHARMACOL, V48, P806; OCONNOR V, UNPUB; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Thomas NK, 1996, NEUROPHARMACOLOGY, V35, P637; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	30	134	136	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1180	1184		10.1126/science.286.5442.1180	http://dx.doi.org/10.1126/science.286.5442.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550060	Green Submitted			2022-12-24	WOS:000083534200050
J	Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM				Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM			Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis - A pilot study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; DISEASE; PREVALENCE; METABOLISM; OBESITY; STEATOSIS	Context The mechanisms that drive progression from fatty liver to steatohepatitis and cirrhosis are unknown. In animal models, obese mice with fatty livers are vulnerable to liver adenosine triphosphate (ATP) depletion and necrosis, suggesting that altered hepatic energy homeostasis may be involved. Objective To determine ii patients with fatty liver disease exhibit impaired recovery from hepatic ATP depletion. Design Laboratory analysis of liver ATP stores monitored by nuclear magnetic resonance spectroscopy before and after transient hepatic ATP depletion was induced by fructose injection. The study was conducted between July 15 and August 30, 1998. Setting University hospital. Patients Eight consecutive adults with biopsy-proven nonalcoholic steatohepatitis and 7 healthy age- and sex-matched controls. Main Outcome Measure Level of ATP 1 hour after fructose infusion in patients vs controls. Results In patients, serum aminotransferase levels were increased (P = .02 vs controls); albumin and bilirubin values were normal and clinical evidence of portal hypertension was absent in both groups. However, 2 patients had moderate fibrosis and 1 had cirrhosis on liver biopsy. Mean serum glucose, cholesterol, and triglyceride levels were similar between groups but patients weighed significantly more than controls (P = .02). Liver ATP levels were similar in the 2 groups before fructose infusion and decreased similarly in both after fructose infusion (P = .01 vs initial ATP levels). However, controls replenished their hepatic ATP stores during the 1-hour follow-up period (P<.02 vs minimum ATP) but patients did not. Hence, patients' hepatic ATP levels were lower than those of controls at the end of the study (P = .04), Body mass index (BMI) correlated inversely with ATP recovery, even in controls (R = -0.768; P = .07), Although BMI was greater in patients than controls (P = .02) and correlated strongly with fatty liver and serum aminotransferase elevations, neither of the latter 2 parameters nor the histologic severity of fibrosis strongly predicted hepatic ATP recovery. Conclusions These data suggest that recovery from hepatic ATP depletion becomes progressively less efficient as body mass increases in healthy controls and is severely impaired in patients with obesity-related nonalcoholic steatohepatitis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welchlink.welch.jhu.edu	Cortez-Pinto, Helena/A-3586-2012	Chatham, John/0000-0001-7180-9948				BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Boesch C, 1997, MAGN RESON IMAGING, V15, P1067, DOI 10.1016/S0730-725X(97)00163-X; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Czaja AJ, 1998, J HEPATOL, V29, P198, DOI 10.1016/S0168-8278(98)80004-4; ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774, DOI 10.1259/0007-1285-65-777-774; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; HODGSON M, 1991, BRIT J IND MED, V48, P690; ITURRIAGA H, 1988, AM J CLIN NUTR, V47, P235, DOI 10.1093/ajcn/47.2.235; LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9; LEE RG, 1995, HEPATOLOGY, V21, P1742, DOI 10.1002/hep.1840210636; Lonardo A, 1997, ITAL J GASTROENTEROL, V29, P351; LUDWIG J, 1980, MAYO CLIN PROC, V55, P347; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; OBERHAENSLI RD, 1986, BRIT J RADIOL, V59, P695, DOI 10.1259/0007-1285-59-703-695; OKOLO P, 1998, SLEISENGER FORDTRANS, P1215; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; TERRIER F, 1989, RADIOLOGY, V171, P557, DOI 10.1148/radiology.171.2.2704824; THALER H, 1975, CLIN GASTROENTEROL, V4, P273; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	28	362	374	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1659	1664		10.1001/jama.282.17.1659	http://dx.doi.org/10.1001/jama.282.17.1659			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553793	Bronze			2022-12-24	WOS:000083368400032
J	Watts, C; Kumaranayake, L				Watts, C; Kumaranayake, L			Thinking big: scaling-up HIV-1 interventions in sub-Saharan Africa	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Watts, C (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.							[Anonymous], 1997, CONFR AIDS PUBL PRIO; KUMARANAYAKE L, 1998, COSTING GUIDELINES H; Osborne C M, 1997, AIDS, V11 Suppl B, pS135; *UNICEF, 1999, PROGR NAT; *WHO, 1999, WHO REP 1999	5	13	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1492	1492		10.1016/S0140-6736(99)00365-7	http://dx.doi.org/10.1016/S0140-6736(99)00365-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551493				2022-12-24	WOS:000083411300007
J	Kobayashi, M; Furuya, H; Holland, PWH				Kobayashi, M; Furuya, H; Holland, PWH			Evolution - Dicyemids are higher animals	NATURE			English	Article							HOX		Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Kyoto Univ, Grad Sch Sci, Dept Zool, Kyoto 606, Japan; Osaka Univ, Dept Biol, Grad Sch Sci, Toyonaka, Osaka 560, Japan	University of Reading; Kyoto University; Osaka University	Kobayashi, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Bayascas JR, 1998, DEV GENES EVOL, V208, P467, DOI 10.1007/s004270050204; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; KATAYAMA T, 1995, BIOL BULL-US, V189, P81, DOI 10.2307/1542458; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; STUNKARD HW, 1954, Q REV BIOL, V29, P230, DOI 10.1086/400243; van Beneden E., 1876, B ACAD R BELG, V41, P1160	9	67	68	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					762	762		10.1038/44513	http://dx.doi.org/10.1038/44513			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548100	Bronze			2022-12-24	WOS:000083368700041
J	Ram, PT; Horvath, CM; Iyengar, R				Ram, PT; Horvath, CM; Iyengar, R			Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L G alpha(o) protein	SCIENCE			English	Article							MAP KINASE KINASE; PC12 CELLS; NEURITE OUTGROWTH; V-SRC; STAT3; ACTIVATION; DIFFERENTIATION; INTERLEUKIN-6; LOCALIZATION; ASSOCIATION	Expression of Q205L G alpha(o) (G alpha(o)*), an alpha subunit of heterotrimeric guanine nucleotide-binding proteins (G proteins) that lacks guanosine triphosphatase (GTPase) activity in NIH-3T3 cells, results in transformation. Expression of G alpha(o)* in NIH-3T3 cells activated signal transducer and activator of transcription 3 (Stat3) but not mitogen-activated protein (MAP) kinases 1 or 2, Coexpression of dominant negative Stat3 inhibited G alpha(o)*-induced transformation of NIH-3T3 cells and activation of endogenous Stat3, Furthermore, G alpha(o)* expression increased activity of the tyrosine kinase c-Src, and the G alpha(o)*-induced activation of Stat3 was blocked by expression of Csk (carboxyl-terminal Src kinase), which inactivates c-Src. The results indicate that Stat3 can function as a downstream effector for G alpha(o)* and mediate its biological effects.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Ram, PT (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	ramp01@doc.mssm.edu		Ram, Prahlad/0000-0003-4739-3166; Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [1F32 CA79134-01] Funding Source: Medline; NIDDK NIH HHS [DK-38671] Funding Source: Medline; NIGMS NIH HHS [GM-54508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA079134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1996, MOL CELL BIOCHEM, V127, P201; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nusse O, 1996, J CELL SCI, V109, P221; RAM P, UNPUB; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	25	89	89	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					142	144		10.1126/science.287.5450.142	http://dx.doi.org/10.1126/science.287.5450.142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615050				2022-12-24	WOS:000084578400055
J	Rees, G; Russell, C; Frith, CD; Driver, J				Rees, G; Russell, C; Frith, CD; Driver, J			Inattentional blindness versus inattentional amnesia for fixated but ignored words	SCIENCE			English	Article							SELECTIVE ATTENTION; PICTURES; PERCEPTION; HUMANS; LOAD; TASK	People often are unable to report the content of ignored in Formation, but it is unknown whether this reflects a complete failure to perceive it (inattentional blindness) or merely that it is rapidly forgotten (inattentional amnesia). Here functional imaging is used to address this issue by measuring brain activity for unattended words. When attention is fully engaged with other material, the brain no Longer differentiates between meaningful words and random letters, even when they are looked at directly. These results demonstrate true inattentional blindness for words and show that visual recognition wholly depends on attention even for highly familiar and meaningful stimuli at the center of gaze.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA; UCL, Dept Psychol, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; California Institute of Technology; University of London; University College London	Rees, G (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	geraint@klab.caltech.edu	Frith, Chris D/A-2171-2009; Driver, Jon/A-4779-2010; Rees, Geraint/C-1493-2008	Frith, Chris D/0000-0002-8665-0690; Rees, Geraint/0000-0002-9623-7007; Russell, Charlotte/0000-0002-8194-8033	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D. E., 1958, PERCEPTION COMMUNICA; Buchel C, 1998, NATURE, V394, P274, DOI 10.1038/28389; Cherry C., 1957, HUMAN COMMUNICATION, DOI [10.2307/1292231, DOI 10.2307/1292231]; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEUTSCH JA, 1963, PSYCHOL REV, V70, P80, DOI 10.1037/h0039515; DRIVER J, 1995, CURR OPIN NEUROBIOL, V5, P191, DOI 10.1016/0959-4388(95)80026-3; Fiez JA, 1998, P NATL ACAD SCI USA, V95, P914, DOI 10.1073/pnas.95.3.914; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; JOHNSTON WA, 1986, ANNU REV PSYCHOL, V37, P43, DOI 10.1146/annurev.ps.37.020186.000355; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, IN PRESS J EXP PSYCH; LEWIS JL, 1970, J EXP PSYCHOL, V85, P225, DOI 10.1037/h0029518; Luck SJ, 1996, NATURE, V383, P616, DOI 10.1038/383616a0; Mack A., 1998, INATTENTIONAL BLINDN; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Menard MT, 1996, NEUROPSYCHOLOGIA, V34, P185, DOI 10.1016/0028-3932(95)00099-2; Pashler HE, 1998, PSYCHOL ATTENTION; Posner M.I., 1978, CHRONOMETRIC EXPLORA; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1998, TRENDS COGN SCI, V2, P281, DOI 10.1016/S1364-6613(98)01201-7; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; ROCK I, 1981, J EXP PSYCHOL HUMAN, V7, P275, DOI 10.1037/0096-1523.7.2.275; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; TIPPER SP, 1988, MEM COGNITION, V16, P64, DOI 10.3758/BF03197746; TREISMAN A, 1974, MEM COGNITION, V2, P641, DOI 10.3758/BF03198133; Treisman A., 1996, ATTENTION PERFORM, VXVI, P15; TREISMAN AM, 1969, PSYCHOL REV, V76, P282, DOI 10.1037/h0027242; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; Vandenberghe R, 1996, NATURE, V383, P254, DOI 10.1038/383254a0; VANORDEN GC, 1988, J EXP PSYCHOL LEARN, V14, P371, DOI 10.1037/0278-7393.14.3.371; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; Wolfe JM, 1999, MIT BRAD COGN PSYCH, P71	37	185	190	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2504	2507		10.1126/science.286.5449.2504	http://dx.doi.org/10.1126/science.286.5449.2504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617465				2022-12-24	WOS:000084429700048
J	Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S				Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S			Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL ACTIVATION; HORMONE RECEPTORS; RETINOIC ACID; LIGAND; GENE; THIAZOLIDINEDIONES; IDENTIFICATION; PPAR-GAMMA-2	Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes(1). Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR gamma), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis(2). Here we report two different heterozygous mutations in the ligand-binding domain of PPAR gamma in three subjects with severe insulin resistance. In the PPAR gamma crystal structure, the mutations destabilize helix 12 which mediates transactivation. Consistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPAR gamma in a dominant negative manner. In addition to insulin resistance, all three subjects developed type 2 diabetes mellitus and hypertension at an unusually early age. Our findings represent the first germline loss-of-function mutations in PPAR gamma and provide compelling genetic evidence that this receptor is important in the control of insulin sensitivity, glucose homeostasis and blood pressure in man.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2QQ, England; Incyte Europe Ltd, Cambridge CB4 0WA, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Prince Philip Hosp, Llanelli SA14 8QF, Wales; Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Incyte; MRC Laboratory Molecular Biology	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	kkcl@mole.bio.cam.ac.uk; sorahill@hgmp.mrc.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Schwabe, John WR/A-9132-2008	O'Rahilly, Stephen/0000-0003-2199-4449; Schwabe, John WR/0000-0003-2865-4383; Barroso, Ines/0000-0001-5800-4520; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Maslen, Gareth/0000-0001-7318-3678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Beamer BA, 1998, DIABETES, V47, P1806, DOI 10.2337/diabetes.47.11.1806; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Doi K, 1998, CIRCULATION, V98, P39; FLIER JS, 1992, DIABETES, V41, P1207, DOI 10.2337/diabetes.41.9.1207; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Iijima K, 1998, BIOCHEM BIOPH RES CO, V247, P353, DOI 10.1006/bbrc.1998.8794; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIBBY P, 1999, ARTEROISCLER THROMB, V19, P546; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nakamura Y, 1998, BRIT J PHARMACOL, V123, P675, DOI 10.1038/sj.bjp.0701669; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Whitehead JP, 1998, DIABETES, V47, P837, DOI 10.2337/diabetes.47.5.837; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	30	1030	1082	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					880	883		10.1038/47254	http://dx.doi.org/10.1038/47254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622252				2022-12-24	WOS:000084482000034
J	Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ				Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ			p53 inhibition by the LANA protein of KSHV protects against cell death	NATURE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; DNA-SEQUENCES; NUCLEAR ANTIGEN; EXPRESSION; HUMAN-HERPESVIRUS-8; IDENTIFICATION; COACTIVATORS	Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, has been implicated in the development of Kaposi's sarcoma (KS) and several B-cen lymphoproliferative diseases(1-3) Most cells in lesions derived from these malignancies are latently infected, and different viral gene products have been identified in association with lytic or latent infection by KSHV4,5. The latency-associated nuclear antigen (LANA), encoded by open reading frame 73 of the KSHV genome, is a highly immunogenic protein that is expressed predominantly during viral latency, in most KS spindle cells and in cell lines established from body-cavity-based lymphomas(6,7). Antibodies to LANA can be detected in a high percentage of HIV-infected individuals who subsequently develop KS8,9, although its role in disease pathogenesis is not completely understood. p53 is a potent transcriptional regulator of cell growth whose induction leads either to cell-cycle arrest or apoptosis. Loss of p53 function correlates with cell transformation and oncogenesis(10,11), and several viral oncoproteins interact with p53 and modulate its biological activity(12-13). Here we show that LANA interacts with the tumour suppressor protein p53 and represses its transcriptional activity. This viral gene product further inhibits the ability of p53 to induce cell death. We propose that LANA contributes to viral persistence and oncogenesis in KS through its ability to promote cell survival by altering p53 function.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr,MSC 3005, Bethesda, MD 20892 USA.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JJ, 1997, AM J DERMATOPATH, V19, P373, DOI 10.1097/00000372-199708000-00009; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NOEL JC, 1997, AM J DERMATOPATH, V19, P322; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255	30	539	558	1	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					889	894		10.1038/47266	http://dx.doi.org/10.1038/47266			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622254				2022-12-24	WOS:000084482000036
J	Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y				Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y			Impaired immunoproteasome assembly and immune responses in PA28(-/-) mice	SCIENCE			English	Article							PROTEASOME REGULATOR PA28; REG-ALPHA; PEPTIDE; BETA; PA28-ALPHA; ACTIVATOR; COMPLEXES; CELLS	In vitro PA28 binds and activates proteasomes. It is shown here that mice with a disrupted PA28b gene Lack PA28a and PA28b polypeptides, demonstrating that PA28 functions as a hetero-oligomer in vivo. Processing of antigenic epitopes derived from exogenous or endogenous antigens is altered in PA28(-/-) mice. Cytotoxic T Lymphocyte responses are impaired, and assembly of immunoproteasomes is greatly inhibited in mice lacking PA28. These results show that PA28 is necessary for immunoproteasome assembly and is required for efficient antigen processing, thus demonstrating the importance of PA28-mediated proteasome function in immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Fruh, K (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.		Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045; winqvist, Ola/0000-0003-0842-4441; Fung-Leung, Wai-Ping/0000-0001-7013-8855; Angulo, Ana/0000-0002-5792-1164; Frueh, Klaus/0000-0001-8014-3877				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Borrow Persephone, 1997, P593; BUCHMEIER MJ, 1999, PERSISTENT VIRAL INF, P575; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Flad T, 1998, CANCER RES, V58, P5803; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Ho M., 1991, CYTOMEGALOVIRUS BIOL; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Li YH, 1999, IMMUNOGENETICS, V49, P149, DOI 10.1007/s002510050476; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; PRECKEL T, UNPUB; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Vitiello A, 1997, EUR J IMMUNOL, V27, P671, DOI 10.1002/eji.1830270315; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	26	143	147	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2162	2165		10.1126/science.286.5447.2162	http://dx.doi.org/10.1126/science.286.5447.2162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591649				2022-12-24	WOS:000084157300054
J	Hampson, RE; Simeral, JD; Deadwyler, SA				Hampson, RE; Simeral, JD; Deadwyler, SA			Distribution of spatial and nonspatial information in dorsal hippocampus	NATURE			English	Article							TO-SAMPLE PERFORMANCE; SHORT-TERM-MEMORY; ENSEMBLE ACTIVITY; PLACE CELLS; SEMANTIC MEMORY; AMPAKINE CX516; ORGANIZATION; NAVIGATION; BRAIN; RATS	The hippocampus in the mammalian brain is required for the encoding of current and the retention of past experience, Previous studies have shown that the hippocampus contains neurons that encode information required to perform spatial and nonspatial short-term memory tasks. A more detailed understanding of the functional anatomy of the hippocampus would provide important insight into how such encoding occurs. Here we show that hippocampal neurons in the rat are distributed anatomically in distinct segments along the length of the hippocampus. Each longitudinal segment contains clusters of neurons that become active when the animal performs a task with spatial attributes. Within these same segments are ordered arrangements of neurons that encode the nonspatial aspects of the task appropriate to those spatial features. Thus, anatomical segregation of spatial information, together with the interleaved representation of nonspatial information, represents a structural framework that may help to resolve conflicting views of hippocampal function.	Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Wake Forest University	Hampson, RE (corresponding author), Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.		Simeral, John/CCI-2624-2022					AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; Burgess N, 1996, HIPPOCAMPUS, V6, P749; Burwell RD, 1995, HIPPOCAMPUS, V5, P390, DOI 10.1002/hipo.450050503; Cohen N J, 1991, Hippocampus, V1, P265, DOI 10.1002/hipo.450010312; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; Colombo M, 1998, J NEUROPHYSIOL, V80, P1002, DOI 10.1152/jn.1998.80.2.1002; Deadwyler SA, 1996, J NEUROSCI, V16, P354; DEADWYLER SA, 1995, SCIENCE, V270, P1316, DOI 10.1126/science.270.5240.1316; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; EICHENBAUM H, 1993, SCIENCE, V261, P993, DOI 10.1126/science.8351525; Gabrieli JDE, 1998, NEUROBIOL LEARN MEM, V70, P275, DOI 10.1006/nlme.1998.3853; Gothard KM, 1996, J NEUROSCI, V16, P823; Hampson RE, 1996, P NATL ACAD SCI USA, V93, P13487, DOI 10.1073/pnas.93.24.13487; Hampson RE, 1996, HIPPOCAMPUS, V6, P281, DOI 10.1002/(SICI)1098-1063(1996)6:3<281::AID-HIPO6>3.0.CO;2-Q; Hampson RE, 1998, J NEUROSCI, V18, P2740; Hampson RE, 1998, J NEUROSCI, V18, P2748; Hampson RE, 1999, J NEUROSCI, V19, P1492; Hirsch JA, 1998, J NEUROSCI, V18, P9517; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Kohonen T, 1999, TRENDS NEUROSCI, V22, P135, DOI 10.1016/S0166-2236(98)01342-3; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; LI XM, 1994, POTENTIAL ANAL, V3, P339, DOI 10.1007/BF01049807; McClelland JL, 1998, ANN NY ACAD SCI, V843, P153, DOI 10.1111/j.1749-6632.1998.tb08212.x; MORRIS RG, 1997, PHIL T R SOC LOND B, V29, P1489; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Moser MB, 1998, J NEUROSCI, V18, P7535; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; Rawlins JNP, 1999, NATURE, V397, P561, DOI 10.1038/17481; RAWLINS JNP, 1982, BEHAV BRAIN RES, V5, P331, DOI 10.1016/0166-4328(82)90039-0; Samsonovich A, 1997, J NEUROSCI, V17, P5900; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Shapiro ML, 1997, HIPPOCAMPUS, V7, P624, DOI 10.1002/(SICI)1098-1063(1997)7:6<624::AID-HIPO5>3.3.CO;2-T; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Touretzky DS, 1996, HIPPOCAMPUS, V6, P247; Tulving E, 1997, CURR OPIN NEUROBIOL, V7, P209, DOI 10.1016/S0959-4388(97)80009-8; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wallenstein GV, 1998, TRENDS NEUROSCI, V21, P317, DOI 10.1016/S0166-2236(97)01220-4; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	48	234	240	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					610	614		10.1038/45154	http://dx.doi.org/10.1038/45154			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604466				2022-12-24	WOS:000084189800053
J	Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH				Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH			Evolution - Conservation of a sex-determining gene	NATURE			English	Article									Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Smith, CA (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia.		Sinclair, Andrew H/A-3598-2010	Sinclair, Andrew H/0000-0003-2741-7992; Smith, Craig/0000-0002-1670-5545; Western, Patrick/0000-0002-7587-8227				Bull J. J., 1983, EVOLUTION SEX DETERM; Flejter WL, 1998, AM J HUM GENET, V63, P794, DOI 10.1086/302016; Guioli S, 1998, AM J HUM GENET, V63, P905, DOI 10.1086/302017; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Nanda I, 1999, NAT GENET, V21, P258, DOI 10.1038/6769; Raymond CS, 1999, HUM MOL GENET, V8, P989, DOI 10.1093/hmg/8.6.989; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	8	304	332	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					601	602		10.1038/45130	http://dx.doi.org/10.1038/45130			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604464				2022-12-24	WOS:000084189800045
J	Kobe, B; Kemp, BE				Kobe, B; Kemp, BE			Active site-directed protein regulation	NATURE			English	Article							TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; BOVINE TRYPSINOGEN; KARYOPHERIN-ALPHA; INSULIN-RECEPTOR; DOMAIN; ACTIVATION; SRC; RESOLUTION; INSIGHTS	Regulation of protein function is vital for the control of cellular processes. Proteins are often regulated by allosteric mechanisms, in which effecters bind to regulatory sites distinct from the active sites and alter protein function. Intrasteric regulation, directed at the active site and thus the counterpart of allosteric control, is now emerging as an important regulatory mechanism.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Kobe, B (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Kobe, Bostjan/D-1292-2009; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kobe, Bostjan/0000-0001-9413-9166; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CIGNOLANI G, 1999, NATURE, V399, P221; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1994, PROTEIN KINASES, P30; Khan AR, 1998, PROTEIN SCI, V7, P815; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; Lin K, 1997, STRUCTURE, V5, P1511, DOI 10.1016/S0969-2126(97)00300-6; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG F, 1993, NATURE, V367, P704	46	163	166	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					373	376		10.1038/46478	http://dx.doi.org/10.1038/46478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586874				2022-12-24	WOS:000083913600045
J	Soltis, PS; Soltis, DE; Chase, MW				Soltis, PS; Soltis, DE; Chase, MW			Angiosperm phylogeny inferred from multiple genes as a tool for comparative biology	NATURE			English	Article							LARGE DATA SETS; COMPLEX PHYLOGENIES; SEQUENCES; EVOLUTION; PARSIMONY; ORIGIN; RBCL	Comparative biology requires a firm phylogenetic foundation to uncover and understand patterns of diversification and evaluate hypotheses of the processes responsible for these patterns. In the angiosperms, studies of diversification in floral form(1,2), stamen organization(3), reproductive biology(4), photosynthetic pathway(5), nitrogen-fixing symbioses(6) and life histories(7) have relied on either explicit or implied phylogenetic trees, Furthermore, to understand the evolution of specific genes and gene families, evaluate the extent of conservation of plant genomes and make proper sense of the huge volume of molecular genetic data available for model organisms(8) such as Arabidopsis, Antirrhinum, maize, rice and wheat, a phylogenetic perspective is necessary. Here we report the results of parsimony analyses of DNA sequences of the plastid genes rbcL and atpB and the nuclear 18S rDNA for 560 species of angiosperms and seven non-flowering seed plants and show a well-resolved and well-supported phylogenetic tree for the angiosperms for use in comparative biology.	Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	Washington State University; Royal Botanic Gardens, Kew	Soltis, PS (corresponding author), Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.	psoltis@wsu.edu	Chase, Mark W/A-6642-2011; Soltis, Pamela S/GNH-5557-2022; Soltis, Douglas/L-5957-2015; Soltis, Pamela S/L-5184-2015	Soltis, Pamela S/0000-0001-9310-8659; Chase, Mark/0000-0002-9927-4938				CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHASE MW, IN PRESS P MON 2 2 I, V2; Crepet WL, 1998, AM J BOT, V85, P1122, DOI 10.2307/2446345; CRONQUIST A., 1981, INTEGRATED SYSTEM CL; Cronquist A., 1988, EVOLUTION CLASSIFICA; Dodd ME, 1999, EVOLUTION, V53, P732, DOI [10.2307/2640713, 10.1111/j.1558-5646.1999.tb05367.x]; Donoghue MJ, 1998, TRENDS PLANT SCI, V3, P311, DOI 10.1016/S1360-1385(98)01278-3; DOYLE JA, 1994, ANN MO BOT GARD, V81, P419, DOI 10.2307/2399899; ENDRESS PK, 1994, PLANT SYST EVOL, V192, P79, DOI 10.1007/BF00985910; Farris JS, 1996, CLADISTICS, V12, P99, DOI 10.1111/j.1096-0031.1996.tb00196.x; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; KELLOGG EA, 1998, BIOL C4 PHOTOSYNTHES, P411; Kramer EM, 1998, GENETICS, V149, P765; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Rice KA, 1997, SYST BIOL, V46, P554, DOI 10.2307/2413696; RONSEDECRAENE LP, 1987, NORD J BOT, V7, P239; SAVOLAINEN V, IN PRESS SYST BIOL; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; SWOFFORD D.L., 2003, PAUP PHYLOGENETIC AN; Takhtajan A, 1991, EVOLUTIONARY TRENDS; Takhtajan A. L., 1997, DIVERSITY CLASSIFICA; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355	30	653	697	1	107	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					402	404		10.1038/46528	http://dx.doi.org/10.1038/46528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586878				2022-12-24	WOS:000083913600053
J	Hargreave, TB				Hargreave, TB			Understanding the Y chromosome	LANCET			English	Editorial Material							GENE; SPERMATOGENESIS; MICRODELETIONS; INTERVAL-6; DELETIONS; LOCUS; MEN		Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Hargreave, TB (corresponding author), Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland.							BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; Cooke HJ, 1998, FERTIL STERIL, V69, P989, DOI 10.1016/S0015-0282(98)00071-5; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; Kuroki Y, 1999, J HUM GENET, V44, P289, DOI 10.1007/s100380050162; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Short RV, 1997, ACTA PAEDIATR, V86, P3; Silber SJ, 1998, HUM REPROD, V13, P3332, DOI 10.1093/humrep/13.12.3332; Stuppia L, 1997, J MED GENET, V34, P881, DOI 10.1136/jmg.34.11.881	12	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1746	1747		10.1016/S0140-6736(99)00311-6	http://dx.doi.org/10.1016/S0140-6736(99)00311-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577631				2022-12-24	WOS:000083853000004
J	Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL				Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL			Kainate receptors are involved in synaptic plasticity	NATURE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; GLUR5 SUBTYPE; TRANSMISSION; ACTIVATION; AMPA; ACID; CA3; DESENSITIZATION; ANTAGONISTS	The ability of synapses to modify their synaptic strength in response to activity is a fundamental property of the nervous system and may be an essential component of learning and memory(1). There are three classes of ionotropic glutamate receptor, namely NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) and kainate receptors(2); critical roles in synaptic plasticity have been identified for two of these. Thus, at many synapses in the brain, transient activation of NMDA receptors leads to a persistent modification in the strength of synaptic transmission mediated by AMPA receptors(3,4). Here, to determine whether kainate receptors(5-7) are involved in synaptic plasticity, we have used a new antagonist, LY382884 ((3S, 4aR, 6S, 8aR)-6-( (4-carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid), which antagonizes kainate receptors at concentrations that do not affect AMPA or NMDA receptors. We find that LY382884 is a selective antagonist at neuronal kainate receptors containing the GluR5 subunit. it has no effect on long-term potentiation (LTP) that is dependent on NMDA receptors but prevents the induction of mossy fibre LTP, which is independent of NMDA receptors. Thus, kainate receptors can act as the induction trigger for longterm changes in synaptic transmission.	Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Free Univ Brussels, Inst Pharmaceut, Dept Pharmaceut Chem & Drug Anal, B-1090 Brussels, Belgium; Univ Montpellier 2, Lab Plasticite Cerebrale, CNRS, F-34095 Montpellier, France; Allelix Biopharmaceut, Mississauga, ON L4V 1V7, Canada; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	University of Bristol; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Eli Lilly	Bortolotto, ZA (corresponding author), Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England.		Collingridge, Graham L/C-4605-2015; Ornstein, Paul/E-4212-2016; Vignes, Michel/AAA-7693-2019; collingridge, graham/AAI-8362-2020; Smolders, Ilse J/J-9399-2013	Collingridge, Graham L/0000-0002-9572-5359; Ornstein, Paul/0000-0002-4335-1877; Vignes, Michel/0000-0003-0969-2966; Smolders, Ilse J/0000-0003-2140-0751; Clarke, Vernon/0000-0002-6154-6555				BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; Bleakman D, 1996, MOL PHARMACOL, V49, P581; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; Hebb D.O., 1949, ORG BEHAV; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Neill MJ, 1998, NEUROPHARMACOLOGY, V37, P1211, DOI 10.1016/S0028-3908(98)00134-8; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Procter MJ, 1998, NEUROPHARMACOLOGY, V37, P1287, DOI 10.1016/S0028-3908(98)00136-1; Simmons RMA, 1998, NEUROPHARMACOLOGY, V37, P25, DOI 10.1016/S0028-3908(97)00188-3; Vignes M, 1997, NEUROPHARMACOLOGY, V36, P1477, DOI 10.1016/S0028-3908(97)00158-5; Vignes M, 1998, NEUROPHARMACOLOGY, V37, P1269, DOI 10.1016/S0028-3908(98)00148-8; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180	30	259	264	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					297	301		10.1038/46290	http://dx.doi.org/10.1038/46290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580501				2022-12-24	WOS:000083813700051
J	Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM				Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM			Developmental biology - Variable cell number in nematodes	NATURE			English	Article							CAENORHABDITIS-ELEGANS; LINEAGES		Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Imperial College London; Yeshiva University; Albert Einstein College of Medicine	Cunha, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Azevedo, Ricardo/AAV-3963-2021	Azevedo, Ricardo/0000-0001-5402-7071				Ambros V., 1987, Development as an Evolutionary Process. MBL Lectures in Biology, vol.8, P139; AZEVEDO RBR, IN PRESS NEMATOLOGY; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Rusin L. Y., 1998, Doklady, Biological Sciences, V361, P331; SOMMER RJ, 1994, DEVELOPMENT, V120, P85; STERNBERG PW, 1982, DEV BIOL, V93, P181, DOI 10.1016/0012-1606(82)90251-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; van Cleave HJ, 1932, Q REV BIOL, V7, P59, DOI 10.1086/394396; Voronov DA, 1998, DEVELOPMENT, V125, P143	13	32	33	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					253	253		10.1038/46211	http://dx.doi.org/10.1038/46211			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580494	Bronze			2022-12-24	WOS:000083813700037
J	Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG				Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG			The p66(shc) adaptor protein controls oxidative stress response and life span in mammals	NATURE			English	Article							DROSOPHILA-MELANOGASTER; DIETARY RESTRICTION; PATHWAY; MICE; RESISTANCE; ACTIVATION; MUTATION; UV; EXPRESSION; EXTENSION	Gene mutations in invertebrates have been identified that extend Life span and enhance resistance to environmental stresses such as ultraviolet light or reactive oxygen species(1). In mammals, the mechanisms that regulate stress response are poorly understood and no genes are known to increase individual life span. Here we report that targeted mutation of the mouse p66(shc) gene induces stress resistance and prolongs life span. p66(shc) is a splice variant of p52(shc)/p46(shc) (ref. 2), a cytoplasmic signal transducer involved in the transmission of mitogenic signals from activated receptors to Ras(3). We show that: (1) p66(shc) is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) Or irradiation with ultraviolet light; (2) ablation of p66(shc) enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serine-phosphorylation defective mutant of p66(shc) cannot restore the normal stress response in p66(shc-/-) cells; (4) the p53 and p21 stress response is impaired in p66(shc-/-) cells; (5) p66(shc-/-) mice have increased resistance to paraquat and a 30% increase in life span. We propose that p66(shc) is part of a signal transduction pathway that regulates stress apoptotic responses and life span in mammals.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cell Biol Program, Sloan Kettering Inst, New York, NY 10021 USA; Univ Perugia, Ist Patol Med, I-06100 Perugia, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Perugia; University of Perugia	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Migliaccio, Enrica/AAQ-8880-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Franzeck, Fabian C/B-5055-2011; Giorgio, Marco/I-9425-2012; Reboldi, Gianpaolo/A-3444-2009; Pelicci, Giuliana/AAA-8921-2022	Lanfrancone, Luisa/0000-0002-4523-3815; Giorgio, Marco/0000-0002-5842-6042; Reboldi, Gianpaolo/0000-0002-9877-0702; Pelicci, Giuliana/0000-0003-0986-8255				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; LARSEN PL, 1995, GENETICS, V139, P1576; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lithgow GJ, 1996, SCIENCE, V273, P80, DOI 10.1126/science.273.5271.80; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Marubini E, 1995, ANAL SURVIVAL DATA C; Medawar P. B., 1952, MODERN Q, V1, P30; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Murakami S, 1996, GENETICS, V143, P1207; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Renzing J, 1996, J CELL SCI, V109, P1105; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEVENSON MA, 1994, CANCER RES, V54, P12; SUN JY, 1994, J BIOL CHEM, V269, P18638; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	30	1383	1453	1	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					309	313		10.1038/46311	http://dx.doi.org/10.1038/46311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580504				2022-12-24	WOS:000083813700054
J	Peterschmitt, MJ; Simmons, JR; Levy, HL				Peterschmitt, MJ; Simmons, JR; Levy, HL			Reduction of false negative results in screening of newborns for homocystinuria.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFICIENCY; SPECIMEN	Background: Mental retardation and other medical problems (including ectopia lentis, osteoporosis, and thromboembolism) in patients who have homocystinuria as a result of a deficiency of cystathionine beta-synthase can be prevented by the screening of newborns with measurement of blood methionine, followed by the early treatment of affected infants. Many infants with this disorder, however, are not identified by screening and have irreversible brain damage. Methods: We reviewed the results of neonatal screening for homocystinuria over a period of 32 years in New England. Additional specimens were requested for repeated analysis when blood methionine measurements were at or above the established cutoff level. Homocystinuria due to cystathionine beta-synthase deficiency was confirmed by quantitative amino acid analyses. Results: For the first 23.5 years of the review period, the blood methionine cutoff value was 2 mg per deciliter (134 micromol per liter). Among the 2.2 million infants screened during that period, 8 with homocystinuria were identified (1:275,000). In 1990, the cutoff value was reduced to 1 mg per deciliter (67 mu mol per liter). Among the 1.1 million infants screened in the subsequent 8.5 years, 7 with the disorder were identified (1:157,000). During the latter period, the specimens were collected from six of the seven infants when they were two days of age or less; five of the six had blood methionine concentrations below 2 mg per deciliter. Use of the reduced cutoff level increased the false positive rate from 0.006 percent to 0.03 percent. Conclusions: A cutoff level for blood methionine of 1 mg per deciliter in neonatal screening tests for homocystinuria should identify affected infants who have only slightly elevated concentrations of methionine and reduce the frequency of false negative results. (N Engl J Med 1999;341:1572-6.) (C) 1999, Massachusetts Medical Society.	Childrens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; State Lab Inst, New England Newborn Screening Program, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Levy, HL (corresponding author), Childrens Hosp, Div Genet, 300 Longwood Ave,IC-106, Boston, MA 02115 USA.	levy_h@al.tch.harvard.edu						BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CUNNINGHAM CG, 1995, EARLY HOSP DISCHARGE, P31; DOHERTY LB, 1991, PEDIATRICS, V87, P240; EFRON ML, 1964, NEW ENGL J MED, V270, P1378, DOI 10.1056/NEJM196406252702602; Gaustadnes M, 1999, NEW ENGL J MED, V340, P1513, DOI 10.1056/NEJM199905133401915; GUTHRIE R, 1968, Birth Defects Original Article Series, V4, P92; *IL DEP PUBL HLTH, 1996, NEWB SCREEN OV NEWB; Krans JP, 1998, EUR J PEDIATR, V157, pS50, DOI 10.1007/PL00014304; Levy H.L., 1971, INHERITED DISORDERS, P235; LEVY HL, 1970, LANCET, V2, P522; MORRISON AS, 1992, MONOGRAPHS EPIDEMIOL, V19; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Naughten ER, 1998, EUR J PEDIATR, V157, pS84, DOI 10.1007/PL00014310; Pang S, 1993, SCREENING, V2, P105, DOI 10.1016/0925-6164(93)90024-D; VERKERK PH, 1993, AM J PUBLIC HEALTH, V83, P868, DOI 10.2105/AJPH.83.6.868; WAGSTAFF J, 1991, J PEDIATR-US, V118, P569, DOI 10.1016/S0022-3476(05)83383-9; WALRAVEN C, 1995, SCREENING, V4, P1, DOI 10.1016/0925-6164(95)00110-8; Walter JH, 1998, EUR J PEDIATR, V157, pS71, DOI 10.1007/PL00014308; Watanabe Toshiyuki, 1997, Journal of Medical Investigation, V44, P95; WHITEMAN PD, 1979, ARCH DIS CHILD, V54, P593, DOI 10.1136/adc.54.8.593; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Yap S, 1998, J INHERIT METAB DIS, V21, P738, DOI 10.1023/A:1005445132327	22	37	43	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1572	1576		10.1056/NEJM199911183412103	http://dx.doi.org/10.1056/NEJM199911183412103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564686				2022-12-24	WOS:000083717000003
J	Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM				Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM			Mechanical unfolding intermediates in titin modules	NATURE			English	Article							IMMUNOGLOBULIN-LIKE MODULES; MOLECULAR-DYNAMICS; CARDIAC MYOCYTES; PROTEIN TITIN; ELASTICITY; DOMAINS; FORCE; EXTENSIBILITY; REGION	The modular protein titin, which is responsible for the passive elasticity of muscle, is subjected to stretching forces. Previous work on the experimental elongation of single titin molecules has suggested that force causes consecutive unfolding of each domain in an all-or-none fashion(1-6). To avoid problems associated with the heterogeneity of the modular, naturally occurring titin, we engineered single proteins to have multiple copies of single immunoglobulin domains of human cardiac titin(7). Here we report the elongation of these molecules using the atomic force microscope. We find an abrupt extension of each domain by similar to 7 Angstrom before the first unfolding event. This fast initial extension before a full unfolding event produces a reversible 'unfolding intermediate'. Steered molecular dynamics(8,9) simulations show that the rupture of a pair of hydrogen bonds near the amino terminus of the protein domain causes an extension of about 6 Angstrom, which is in good agreement with our observations. Disruption of these hydrogen bonds by site-directed mutagenesis eliminates the unfolding intermediate. The unfolding intermediate extends titin domains by similar to 15% of their slack length, and is, therefore a likely to be an important previously unrecognized component of titin elasticity.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA	Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.	fernandez-julio@mayo.edu	Lu, Hui/K-3264-2019; Li, Hongbin/G-2949-2012; Schulten, Klaus/D-5561-2009; Carrion-Vazquez, Mariano/Y-3741-2018	Li, Hongbin/0000-0001-7813-1332; Carrion-Vazquez, Mariano/0000-0001-7319-406X; Lu, Hui/0000-0001-8347-0830				BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Erickson HP, 1997, SCIENCE, V276, P1090, DOI 10.1126/science.276.5315.1090; Evans E, 1999, BIOPHYS J, V76, P2439, DOI 10.1016/S0006-3495(99)77399-6; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Granzier H, 1997, BIOPHYS J, V73, P2043, DOI 10.1016/S0006-3495(97)78234-1; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Improta S, 1998, J MOL BIOL, V284, P761, DOI 10.1006/jmbi.1998.2028; Izrailev S, 1997, BIOPHYS J, V72, P1568, DOI 10.1016/S0006-3495(97)78804-0; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 1998, J STRUCT BIOL, V122, P197, DOI 10.1006/jsbi.1998.3988; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Linke WA, 1998, J CELL SCI, V111, P1567; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	30	666	681	2	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					100	103		10.1038/47083	http://dx.doi.org/10.1038/47083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573426				2022-12-24	WOS:000083638600052
J	Rees, J				Rees, J			Understanding barrier function of the skin	LANCET			English	Editorial Material									Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Rees, J (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							BODDE H, 1996, J INVEST DERMATOL, V5, P1155; Hashimoto T, 1999, J DERMATOL SCI, V20, P81, DOI 10.1016/S0923-1811(99)00014-6; HILLIS WD, 1993, CURR BIOL, V3, P79; Schaefer H., 1996, SKIN BARRIER; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shuster S., 1978, DERMATOLOGY INTERNAL, P116; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; Williams M L, 1998, J Investig Dermatol Symp Proc, V3, P75	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1491	1492		10.1016/S0140-6736(99)00281-0	http://dx.doi.org/10.1016/S0140-6736(99)00281-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551492				2022-12-24	WOS:000083411300006
J	Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M				Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M		MHC Sequencing Consortium	Complete sequence and gene map of a human major histocompatibility complex	NATURE			English	Article							HUMAN MHC; DNA-REPLICATION; CLASS-II; REGION; LOCUS; END	Here we report the first complete sequence and gene map of a human major histocompatibility complex (MHC), a region on chromosome 6 which is essential to the immune system (reviewed in ref. 1). When it was discovered over 50 years ago the region was thought to specify histocompatibility genes, but their nature has been resolved only in the last two decades. Although many of the 224 identified gene loci (128 predicted to be expressed) are still of unknown function, we estimate that about 40% of the expressed genes have immune system function. Over 50% of the MHC has been sequenced twice, in different haplotypes, giving insight into the extraordinary polymorphism and evolution of this region. Several genes, particularly of the MHC class II and III regions, can be traced by sequence similarity and synteny to over 700 million years ago, dearly predating the emergence of the adaptive immune system some 400 million years ago. The sequence is expected to be invaluable for the identification of many common disease loci. In the past, the search for these loci has been hampered by the complexity of high gene density and linkage disequilibrium.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Sanger Ctr, Hinxton CB10 1SA, England; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 25911, Japan; Univ Washington, Seattle, WA 98195 USA; HGMP Resource Ctr, Hinxton CB10 1SB, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Ctr Rech Immunol & Hematol, Strasbourg, France; Fujiya Co Ltd, Biosci Res Lab, Kanagawa 257, Japan	Fred Hutchinson Cancer Center; Wellcome Trust Sanger Institute; Tokai University; University of Washington; University of Washington Seattle; University of Cambridge	Geraghty, D (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.		Ribas-Despuig, Gloria/M-6190-2017; Aguado, Begoña/R-4496-2019; Bahram, Seiamak/GZA-7150-2022; Ribas, Gloria/K-3379-2013	Ribas, Gloria/0000-0001-6883-4130; Tamiya, Gen/0000-0002-0597-415X; Bowcock, Anne/0000-0001-8691-9090; Shiina, Takashi/0000-0002-2067-6708; Bahram, Seiamak/0000-0002-6928-9952; Aguado, Begona/0000-0003-4043-6944	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FUKAGAWA T, 1995, GENOMICS, V25, P184, DOI 10.1016/0888-7543(95)80124-5; Gruen JR, 1997, BLOOD, V90, P4252; Guillaudeux T, 1998, P NATL ACAD SCI USA, V95, P9494, DOI 10.1073/pnas.95.16.9494; HAINO M, 1994, J BIOL CHEM, V269, P2619; HAMILIN JL, 1995, CURR OPIN GENE DEV, V5, P153; Horton R, 1998, J MOL BIOL, V282, P71, DOI 10.1006/jmbi.1998.2018; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; Klein J., 1986, NATURAL HIST MAJOR H; LIMM TM, 1993, HUM IMMUNOL, V38, P57, DOI 10.1016/0198-8859(93)90520-B; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; Satta Y, 1999, IMMUNOL REV, V167, P367, DOI 10.1111/j.1600-065X.1999.tb01405.x; Stephens R, 1999, J MOL BIOL, V291, P789, DOI 10.1006/jmbi.1999.3004; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Tiwari J.L., 1985, HLA DIS ASS; Trachtulec Z, 1997, GENOMICS, V44, P1, DOI 10.1006/geno.1997.4839; TROWSDALE J, 1997, IMMUNOL TODAY S, V18	20	823	850	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					921	923		10.1038/44853	http://dx.doi.org/10.1038/44853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553908				2022-12-24	WOS:000083464700060
J	Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR				Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR			Integrin cytoplasmic tyrosine motif is required for outside-in alpha IIb beta 3 signalling and platelet function	NATURE			English	Article							CELL-ADHESION; IIB-IIIA; PHOSPHORYLATION; PROTEIN; TRANSDUCTION; ACTIVATION; DOMAINS	Integrins not only bind adhesive ligands(1), they also act as signalling receptors(2), Both functions allow the integrin alpha IIb beta 3 to mediate platelet aggregation(3), Platelet agonists activate alpha IIb beta 3 (inside-out signalling) to allow the binding of soluble fibrinogen. Subsequent platelet aggregation leads to outside-in alpha IIb beta 3 signalling, which results in calcium mobilization(4), tyrosine phosphorylation of numerous proteins(5,6) including beta 3 itself(7) increased cytoskeletal reorganisations and further activation of alpha IIb beta 3 (ref, 2). Thus, outside-in signals enhance aggregation, although the mechanisms and functional consequences of specific signalling events remain unclear, Here we describe a mouse that expresses an alpha IIb beta 3 in which the tyrosines in the integrin cytoplasmic tyrosine motif have been mutated to phenylalanines. These mice are selectively impaired in outside-in alpha IIb beta 3 signalling, with defective aggregation and clot-retraction responses in vitro, and an in vivo bleeding defect which is characterized by a pronounced tendency to rebleed, These data provide evidence for an important role of outside-in signalling in platelet physiology, Furthermore, they identify the integrin cytoplasmic tyrosine motif as a key mediator of beta-integrin signals and a potential target for new therapeutic agents.	COR Therapeut Inc, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, S San Francisco, CA 94080 USA.			Heiser, Patrick/0000-0002-8831-4973; DeGuzman, Francis/0000-0002-4479-1129				Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; CHEN YP, 1994, BLOOD, V84, P1857; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1990, NEW ENGL J MED, V322, P32; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; Shattil S, 1998, BLOOD, V91, P1; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMAGUCHI K, 1993, AM J HEMATOL, V44, P106, DOI 10.1002/ajh.2830440207; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	23	256	264	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					808	811		10.1038/44599	http://dx.doi.org/10.1038/44599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548108				2022-12-24	WOS:000083368700057
J	Rogers, J				Rogers, J			Sequencing - Gels and genomes	SCIENCE			English	Article									Wellcome Trust, Sanger Ctr, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Rogers, J (corresponding author), Wellcome Trust, Sanger Ctr, Genome Campus, Cambridge CB10 1SA, England.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					429	429		10.1126/science.286.5439.429	http://dx.doi.org/10.1126/science.286.5439.429			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577205				2022-12-24	WOS:000083121200033
J	Davis, SJ; Vener, AV; Vierstra, RD				Davis, SJ; Vener, AV; Vierstra, RD			Bacteriophytochromes: Phytochrome-like photoreceptors from nonphotosynthetic eubacteria	SCIENCE			English	Article							DEINOCOCCUS-RADIODURANS	Phytochromes are a family of photoreceptors used by green plants to entrain their development to the light environment. The distribution of these chromoproteins has been expanded beyond photoautotrophs with the discovery of phytochrome-like proteins in the nonphotosynthetic eubacteria Deinococcus radiodurans and Pseudomonas aeruginosa. Like plant phytochromes, the D. radiodurans receptor covalently binds Linear tetrapyrroles autocatalytically to generate a photochromic holoprotein. However, the attachment site is distinct, using a histidine to potentially form a Schiff base Linkage. Sequence homology and mutational analysis suggest that D. radiodurans bacteriophytochrome functions as a Light-regulated histidine kinase, which helps protect the bacterium from visible Light.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vierstra, RD (corresponding author), Univ Wisconsin, Genet Lab, 1575 Linden Dr, Madison, WI 53706 USA.							Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Davis S.M, UNPUB; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gupta RS, 1998, J MOL EVOL, V46, P716, DOI 10.1007/PL00006352; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Lemee L, 1997, TETRAHEDRON, V53, P919, DOI 10.1016/S0040-4020(96)01036-8; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; VIERSTRA RD, 1983, BIOCHEMISTRY-US, V22, P2498, DOI 10.1021/bi00279a029; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	18	276	293	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2517	2520		10.1126/science.286.5449.2517	http://dx.doi.org/10.1126/science.286.5449.2517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617469				2022-12-24	WOS:000084429700052
J	Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K				Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K			Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells	CELL			English	Article							DROSOPHILA-MELANOGASTER; SONIC HEDGEHOG; TRANSDUCING HEDGEHOG; GENE-EXPRESSION; PATCHED HOMOLOG; EGF RECEPTOR; PATTERN; POLARITY; INDUCTION; MUTATIONS	Members of the Hedgehog (Hh) family of secreted signaling proteins function as potent short-range organizers in animal development. Their range of action is limited by a C-terminal cholesterol tether and the upregulation of Patched (Ptc) receptor levels. Here we identify a novel segment-polarity gene in Drosophila, dispatched (disp), and demonstrate that its product is required in sending cells for normal Hh function. In the absence of Disp, cholesterol-modified but not cholesterol-free Hh is retained in these cells, indicating that Disp functions to release cholesterol-anchored Hh. Despite their opposite roles, Disp and Ptc share structural homology in the form of a sterol-sensing domain, suggesting that release and sequestration of cholesterol-modified Hh may be based on related molecular pathways.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Senti, Kirsten-Andre/AAB-3036-2020; Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X; Burke, Richard/0000-0003-0086-0767; Senti, Kirsten-Andre/0000-0002-7208-7593; Basler, Konrad/0000-0003-3534-1529				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chou TB, 1996, GENETICS, V144, P1673; COUSO JP, 1994, DEVELOPMENT, V120, P621; Deak P, 1997, GENETICS, V147, P1697; FORBES AJ, 1993, DEVELOPMENT, P115; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Golembo M, 1996, DEVELOPMENT, V122, P3363; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Marigo V, 1996, DEVELOPMENT, V122, P1225; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; NEWSOME TP, 2000, IN PRESS DEVELOPMENT; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pignoni F, 1997, DEVELOPMENT, V124, P271; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SLUSARSKI DC, 1995, GENETICS, V139, P229; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	54	414	434	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					803	815		10.1016/S0092-8674(00)81677-3	http://dx.doi.org/10.1016/S0092-8674(00)81677-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619433	Bronze, Green Accepted			2022-12-24	WOS:000084488200013
J	Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P				Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P			CD46 is a cellular receptor for human herpesvirus 6	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COFACTOR PROTEIN CD46; ACCELERATING FACTOR CD55; MEASLES-VIRUS; MARROW TRANSPLANTATION; FATAL ENCEPHALITIS; EXANTHEM-SUBITUM; DOWN-REGULATION; VARIANT-A; INFECTION	Human herpesvirus 6 (HHV-6) is the etiologic agent of exanthema subitum, causes opportunistic infections in immunocompromised patients, and has been implicated in multiple sclerosis and in the progression of AIDS. Here, we show that the two major HHV-6 subgroups (A and B) use human CD46 as a cellular receptor. Downregulation of surface CD46 was documented during the course of HHV-6 infection. Both acute infection and cell fusion mediated by HHV-6 were specifically inhibited by a monoclonal antibody to CD46; fusion was also blocked by soluble CD46. Nonhuman cells that were resistant to HHV-6 fusion and entry became susceptible upon expression of recombinant human CD46. The use of a ubiquitous immunoregulatory receptor opens novel perspectives for understanding the tropism and pathogenicity of HHV-6.	San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy; Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy; NIAID, Viral Dis Lab, Bethesda, MD 20894 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lusso, P (corresponding author), San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy.		Malnati, Mauro/AAN-4207-2020	Malnati, mauro/0000-0001-5355-1680	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000733, ZIAAI000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; BRODER CC, 1993, J VIROL, V67, P913, DOI 10.1128/JVI.67.2.913-926.1993; Buckland R, 1997, VIRUS RES, V48, P1, DOI 10.1016/S0168-1702(96)01421-9; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; CORBELLINO M, 1993, LANCET, V342, P1242, DOI 10.1016/0140-6736(93)92226-J; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorig Ruth E., 1994, Trends in Microbiology, V2, P312, DOI 10.1016/0966-842X(94)90447-2; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905; Emery VC, 1999, J MED VIROL, V57, P278, DOI 10.1002/(SICI)1096-9071(199903)57:3&lt;278::AID-JMV11&gt;3.0.CO;2-3; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Ghali M, 1998, J NEUROVIROL, V4, P521, DOI 10.3109/13550289809113496; Gobbi A, 1999, J EXP MED, V189, P1953, DOI 10.1084/jem.189.12.1953; Hall CB, 1998, CLIN INFECT DIS, V26, P132, DOI 10.1086/516280; Hirano A, 1999, J VIROL, V73, P4776, DOI 10.1128/JVI.73.6.4776-4785.1999; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; JARVIS JN, 1995, J ACQ IMMUN DEF SYND, V9, P249; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KNOX KK, 1995, CLIN INFECT DIS, V20, P406, DOI 10.1093/clinids/20.2.406; KNOX KK, 1994, LANCET, V343, P577, DOI 10.1016/S0140-6736(94)91524-5; KNOX KK, 1995, J MED VIROL, V45, P288, DOI 10.1002/jmv.1890450309; Kositanont U, 1999, J INFECT DIS, V180, P50, DOI 10.1086/314826; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; LUSSO P, 1989, LANCET, V1, P730; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; QAVI HB, 1992, CURR EYE RES, V11, P315, DOI 10.3109/02713689209001785; Randhawa PS, 1997, AM J SURG PATHOL, V21, P847, DOI 10.1097/00000478-199707000-00014; Sakata H, 1998, BIOL PHARM BULL, V21, P1121; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SEYA T, 1995, MICROBIOL IMMUNOL, V39, P295, DOI 10.1111/j.1348-0421.1995.tb02205.x; Tsujimura A, 1998, BIOCHEM J, V330, P163, DOI 10.1042/bj3300163; Tufaro F, 1997, TRENDS MICROBIOL, V5, P257, DOI 10.1016/S0966-842X(97)01057-3; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; YAMANISHI K, 1988, LANCET, V1, P1065; YEFENOF E, 1976, INT J CANCER, V17, P693, DOI 10.1002/ijc.2910170602	60	394	413	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					817	827		10.1016/S0092-8674(00)81678-5	http://dx.doi.org/10.1016/S0092-8674(00)81678-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619434	Bronze			2022-12-24	WOS:000084488200014
J	Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH				Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH			Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							ARTHRITIS; SERODIAGNOSIS; FIBROMYALGIA; POPULATION; FEATURES; CHILDREN	Background: Previous follow-up studies of patients with Lyme disease suggest that disseminated infection may be associated with long-term neurologic and musculoskeletal morbidity. Objective: To determine clinical and functional outcomes in persons who were treated for Lyme disease in the late 1980s. Design: Population-based, retrospective cohort study. Setting: Nantucket Island, Massachusetts. Participants: 186 persons who had a history of Lyme disease (case-patients) and 167 persons who did not (controls). Measurements: Standardized medical history, physical examination, functional status measure (Medical Outcomes Study 36-item Short Form Health Survey [SF-36]), mood state assessment (Profile of Mood States), neurocognitive tests, and serologic examination. Results: The prevalence of Lyme disease among adults on Nantucket Island was estimated to be 14.3% (95% CI, 9.3% to 19.1%). In multivariate analyses, persons with previous Lyme disease (mean time from infection to study evaluation, 6.0 years) had more joint pain (odds ratio for having joint pain in any joint, 2.1 [CI, 1.2 to 3.5]; P = 0.007), more symptoms of memory impairment (odds ratio for having any memory problem, 1.9 [CI, 1.1 to 3.5]; P = 0.003), and poorer functional status due to pain (odds ratio for 1 point on the SF-36 scale, 1.02 [CI, 1.01 to 1.03]; P < 0.001) than persons without previous Lyme disease. However, on physical examination, case-patients and controls did not differ in musculoskeletal abnormalities, neurologic abnormalities, or neurocognitive performance. Persons with previous Lyme disease who had persistent symptoms after receiving treatment (n = 67) were more likely than those who had completely recovered to have had fever, headache, photosensitivity, or neck stiffness during their acute illness (87% compared with 13%; odds ratio, 2.4 [CI, 1.0 to 5.5]; P = 0.045); however, the performance of the two groups on neurocognitive tests did not significantly differ. Conclusions: Because persons with previous Lyme disease exhibited no sequelae on physical examination and neurocognitive tests a mean of 6.0 years after infection, musculoskeletal and neurocognitive outcomes seem to be favorable. However, long-term impairment of functional status can occur.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Univ Munich, Bavarian Publ Hlth Res Ctr, Sch Med, Munich, Germany; Univ Connecticut, Ctr Hlth, Farmington, CT USA; IMUGEN Inc, Norwood, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Rochester; University of Munich; University of Connecticut	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR36308] Funding Source: Medline; PHS HHS [02033] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*ACR GLOSS COMM, 1982, DICT RHEUM DIS, V1; [Anonymous], 1978, MAIL TELEPHONE SURVE; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; BROADBENT DE, 1992, BR J CLIN PSYCHOL, V21, P1; Bujak DI, 1996, J RHEUMATOL, V23, P1392; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DELIS D, 1988, PSYCHOL CORPORATION; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HERMAN D, 1988, CLIN NEUROPSYCHOL, V2, P102; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kaplan RF, 1997, SEMIN NEUROL, V17, P31, DOI 10.1055/s-2008-1040910; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; MCNAIR DM, 1996, MANUAL PROFILE MOOD; MILLER GL, 1992, 5 INT C LYM BORR ARL; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; *PURD RES FDN, 1948, EX MAN PURD PEGB; S.A.S. Institute, 1990, SAS STAT US GUID; Sangha O, 1998, ANN INTERN MED, V128, P346, DOI 10.7326/0003-4819-128-5-199803010-00002; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; *STAT CT DEP PUBL, 1995, CONNECTICUT EPIDEMIO, V15, P185; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; US Army, 1944, ARM IND TEST BATT MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; 1996, MMWR MORB MORTAL WKL, V45, P481; 1990, MMWR MORB MORTAL WKL, V39, P19	37	114	114	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					919	+		10.7326/0003-4819-131-12-199912210-00003	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610642				2022-12-24	WOS:000084374400002
J	Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS				Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS			Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta	SCIENCE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; TARGETED DISRUPTION; SERTOLI CELLS; MOUSE; GENE; EXPRESSION; HORMONE; DIFFERENTIATION; TESTIS; DIETHYLSTILBESTROL	Mice lacking estrogen receptors alpha and beta were generated to clarify the roles of each receptor in the physiology of estrogen target tissues. Both sexes of alpha beta estrogen receptor knockout (alpha beta ERKO) mutants exhibit normal reproductive tract development but are infertile. Ovaries of adult alpha beta ERKO females exhibit follicle transdifferentiation to structures resembling seminiferous tubules of the testis, including Sertoli-like cells and expression of Mullerian inhibiting substance, sulfated glycoprotein-2, and Sox9, Therefore, Loss of both receptors Leads to an ovarian phenotype that is distinct from that of the individual ERKO mutants, which indicates that both receptors are required for the maintenance of germ and somatic cells in the postnatal ovary.	NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell Biol, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Korach, KS (corresponding author), NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	korach@niehs.nih.gov	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Bunch, Donna/0000-0002-3638-0522; Korach, Kenneth/0000-0002-7765-418X				BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; FITZPATRICK L, 1990, ENDOCRINOLOGY, V140, P2581; Flaws JA, 1997, BIOL REPROD, V57, P1233, DOI 10.1095/biolreprod57.5.1233; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; GUERRIER D, 1990, J REPROD FERTIL, V88, P695; GURAYA SS, 1995, INT REV CYTOL, V160, P163, DOI 10.1016/S0074-7696(08)61555-7; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; JOST A, 1970, MAMMALIAN REPRODUCTI, P4; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KURODA T, 1991, ENDOCRINOLOGY, V129, P2985, DOI 10.1210/endo-129-6-2985; Lindzey J, 1998, ENDOCRINOLOGY, V139, P4092, DOI 10.1210/en.139.10.4092; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Robertson KM, 1999, P NATL ACAD SCI USA, V96, P7986, DOI 10.1073/pnas.96.14.7986; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; TAKETO T, 1991, ANN NY ACAD SCI, V637, P74, DOI 10.1111/j.1749-6632.1991.tb27302.x; VIGIER B, 1987, DEVELOPMENT, V100, P43; Visser JA, 1998, ENDOCRINOLOGY, V139, P4244, DOI 10.1210/en.139.10.4244; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WENIGER JP, 1990, J DEV PHYSIOL, V14, P303; Whitworth DJ, 1998, TRENDS ENDOCRIN MET, V9, P2, DOI 10.1016/S1043-2760(98)00002-2; WU TCJ, 1992, MOL REPROD DEV, V33, P407, DOI 10.1002/mrd.1080330406; WU TCJ, 1993, FERTIL STERIL, V59, P54; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	28	429	447	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2328	2331		10.1126/science.286.5448.2328	http://dx.doi.org/10.1126/science.286.5448.2328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600740	Green Submitted			2022-12-24	WOS:000084318500057
J	Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC				Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC			Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana	NATURE			English	Article							REPETITIVE DNA; MITOCHONDRIAL GENOME; REGIONS; LIBRARY; MAP; RNA; CONSTRUCTION; DUPLICATION; PREDICTION; CENTROMERE	Arabidopsis thaliana (Arabidopsis) is unique among plant model organisms in having a small genome (130-140 Mb), excellent physical and genetic maps, and little repetitive DNA. Here we report the sequence of chromosome 2 from the Columbia ecotype in two gap-free assemblies (contigs) of 3.6 and 16 megabases (Mb). The latter represents the longest published stretch of uninterrupted DNA sequence assembled from any organism to date. Chromosome 2 represents 15% of the genome and encodes 4,037 genes, 49% of which have no predicted function. Roughly 250 tandem gene duplications were found in addition to large-scale duplications of about 0.5 and 4.5 Mb between chromosomes 2 and 1 and between chromosomes 2 and 4, respectively. Sequencing of nearly 2 Mb within the genetically defined centromere revealed a low density of recognizable genes, and a high density and diverse range of vestigial and presumably inactive mobile elements. More unexpected is what appears to be a recent insertion of a continuous stretch of 75% of the mitochondrial genome into chromosome 2.	Inst Genom Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Venter, JC (corresponding author), Cereon Genom, 270 Albany St, Cambridge, MA 02139 USA.	jcventer@celera.com	Salzberg, Steven/Q-6514-2019; Copenhaver, Gregory/AAH-2031-2022; Eisen, Jonathan A./H-2706-2019; Copenhaver, Gregory P/A-7549-2014; Salzberg, Steven L/F-6162-2011; Somerville, Christopher R/A-4048-2009; Copenhaver, Gregory/AFL-9831-2022	Salzberg, Steven/0000-0002-8859-7432; Copenhaver, Gregory/0000-0002-7962-3862; Eisen, Jonathan A./0000-0002-0159-2197; Copenhaver, Gregory P/0000-0002-7962-3862; Salzberg, Steven L/0000-0002-8859-7432; Somerville, Christopher R/0000-0003-4647-0094; Copenhaver, Gregory/0000-0002-7962-3862; Fraser, Claire/0000-0003-1462-2428; Buell, C Robin/0000-0002-6727-4677				Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; BEVAN M, 1998, NATURE, V391, P485; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; COPENHAVER GP, 1995, PLANT J, V7, P273, DOI 10.1046/j.1365-313X.1995.7020273.x; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; COPENHAVER GP, IN PRESS SCIENCE; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; KLEIN M, 1994, PLANT J, V6, P447, DOI 10.1046/j.1365-313X.1994.06030447.x; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; LIU YG, 1995, PLANT J, V7, P351, DOI 10.1046/j.1365-313X.1995.7020351.x; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; Schweizer D, 1987, Results Probl Cell Differ, V14, P235; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Terryn N, 1999, FEBS LETT, V445, P237, DOI 10.1016/S0014-5793(99)00097-6; Thompson H, 1996, MOL GEN GENET, V253, P247, DOI 10.1007/s004380050319; Thompson HL, 1996, NUCLEIC ACIDS RES, V24, P3017, DOI 10.1093/nar/24.15.3017; Thompson HL, 1996, PLANT MOL BIOL, V32, P553, DOI 10.1007/BF00019109; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamada Y., 1990, SECONDARY PRODUCTS P, P227; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	50	535	3223	5	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					761	+		10.1038/45471	http://dx.doi.org/10.1038/45471			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617197	Bronze			2022-12-24	WOS:000084330500053
J	Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I				Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I		European Union Arabidopsis Genome; Washington Univ; PE Biosystems Arabidopsis Sequenci	Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana	NATURE			English	Article							FISSION YEAST; DNA-SEQUENCES; GENOMIC DNA; MODEL-PLANT; REGIONS; RFLP; RNA; RECOMBINATION; PREDICTION; TELOMERE	The higher plant Arabidopsis thaliana (Arabidopsis) is an important model for identifying plant genes and determining their function. To assist biological investigations and to define chromosome structure, a coordinated effort to sequence the Arabidopsis genome was initiated in late 1996, Here we report one of the first milestones of this project, the sequence of chromosome 4. Analysis of 17.38 megabases of unique sequence, representing about 17% of the genome, reveals 3,744 protein coding genes, 81 transfer RNAs and numerous repeat elements. Heterochromatic regions surrounding the putative centromere, which has not yet been completely sequenced, are characterized by an increased frequency of a variety of repeats, new repeats, reduced recombination, lowered gene density and lowered gene expression. Roughly 60% of the predicted protein-coding genes have been functionally characterized on the basis of their homology to known genes. Many genes encode predicted proteins that are homologous to human and Caenorhabditis elegans proteins.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequences, Max Planck Inst Biochem, D-82152 Munich, Germany; AGOWA GmbH, D-12489 Berlin, Germany; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; GATC GmbH, D-78467 Constance, Germany; QIAGEN GmbH, D-40724 Hilden, Germany; DLO, CPRO, NL-6700 AA Wageningen, Netherlands; SRD GmbH, D-61440 Oberursel, Germany; Univ Ghent, Dept Genet, B-3000 Louvain, Belgium; Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; GBF, D-38124 Braunschweig, Germany; Univ Amsterdam, Mol Biol Sect, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; MWG AG Biotech, D-85554 Ebersberg, Germany; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Naples Federico II, CEINGE, I-80131 Naples, Italy; MediGenomix GmbH, DNA Analyt & Genom, D-82152 Planegg Martinsried, Germany; Univ Grenoble 1, Lab Plastes & Differenciat Cellulaire, UMR5575, F-38041 Grenoble, France; CNRS, F-38041 Grenoble, France; Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Paris Sud, UMR CNRS 8618, Inst Biotechnol Plantes, F-91405 Orsay, France; Univ Perpignan, UMR CNRS 5545, Lab Physiol & Biol Mol Plantes, F-66860 Perpignan, France; CSIC, Inst Biol Mol Barcelona, Dept Mol Genet, Barcelona, Spain; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Microsynth GmbH, CH-9436 Balgach, Switzerland; Baseclear, Leiden, Netherlands; Fac Univ Sci Agronom, Microbiol Unit, B-5030 Gembloux, Belgium; Univ Valencia, Dept Genet, Valencia 46100, Spain; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Keygene NV, NL-6700 AE Wageningen, Netherlands; Deutsch Krebsforschungszentrum, Funct Genome Anal, D-69120 Heidelberg, Germany; Inst Plant Genet & Crop Plant Res IPK, D-06466 Gatersleben, Germany; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Lita Annenberg Hazen Genome Ctr, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Cold Spring Harbor Plant Biol Grp, Cold Spring Harbor, NY 11724 USA; Appl Biosyst Inc, Foster City, CA 94494 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; KU Leuven; QIAGEN GmbH; Ghent University; Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Helmholtz-Center for Infection Research; University of Amsterdam; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Vienna Biocenter (VBC); UDICE-French Research Universities; Universite Paris Saclay; Universite Perpignan Via Domitia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Durham University; University of Valencia; Universite Catholique Louvain; Keygene N.V.; Helmholtz Association; German Cancer Research Center (DKFZ); Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Washington University (WUSTL); Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Thermo Fisher Scientific; Applied Biosystems	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.	bevan@bbsrc.ac.uk	Frishman, Dmitrij/AAT-7815-2020; Marra, Marco A/B-5987-2008; Pérez-Alonso, Manuel/M-3333-2014; Ansorge, Wilhelm/AAN-8780-2020; Mayer, Klaus FX/M-7941-2015; Monfort, Amparo/K-1356-2015; Mardis, Elaine/W-2202-2019; Wilson, Richard K./AAF-4139-2019; Entian, Karl-Dieter/D-3080-2011; Terol, Javier/H-6401-2013; Quail, michael/ABE-6131-2020; Klein Lankhorst, René/HGD-0360-2022; Bancroft, Ian/AAH-3831-2020; Muendlein, Axel/AAS-5313-2021; Mewes, Hans-Werner/A-8204-2019	Marra, Marco A/0000-0001-7146-7175; Pérez-Alonso, Manuel/0000-0002-3266-0340; Mayer, Klaus FX/0000-0001-6484-1077; Monfort, Amparo/0000-0001-7106-7745; Wilson, Richard K./0000-0002-1992-1358; Terol, Javier/0000-0003-3345-0078; Bancroft, Ian/0000-0001-7707-1171; Muendlein, Axel/0000-0002-5582-4125; Benes, Vladimir/0000-0002-0352-2547; Sander, Peters/0000-0002-2663-5149; Argiriou, Anagnostis/0000-0002-9164-632X; Kay, Mike/0000-0002-3282-0834; Van den Daele, Hilde/0000-0002-4271-6694; Casacuberta, Elena/0000-0002-8203-8357; Boutry, Marc/0000-0002-2315-6900; Mewes, Hans-Werner/0000-0002-9713-6398; Schmidt, Wolfgang/0000-0002-6944-2443				ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; BEVAN M, 1998, NATURE, V391, P485; BORODOVSKY M, 1994, COMPUT CHEM, V18, P259, DOI 10.1016/0097-8485(94)85022-4; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; *C EL SEQ CONS, 1998, SCIENCE, V282, P2012; CHOI S, 1995, WEEDS WORLD, V2, P17; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Gamas P, 1996, MOL PLANT MICROBE IN, V9, P233, DOI 10.1094/MPMI-9-0233; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gerstein M, 1997, J MOL BIOL, V274, P562, DOI 10.1006/jmbi.1997.1412; Grewal SIS, 1997, GENETICS, V146, P1221; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Jensen RB, 1998, FEBS LETT, V436, P283, DOI 10.1016/S0014-5793(98)01143-0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Kotani H, 1997, DNA Res, V4, P291, DOI 10.1093/dnares/4.4.291; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 1999, NUCLEIC ACIDS RES, V27, P44, DOI 10.1093/nar/27.1.44; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mizutani M, 1998, PLANT MOL BIOL, V37, P39, DOI 10.1023/A:1005921406884; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Richards EJ, 1998, CURR OPIN PLANT BIOL, V1, P130, DOI 10.1016/S1369-5266(98)80014-9; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHAFFER AA, IN PRESS BIOINFORMAT; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Xu XJ, 1995, PLANT CELL, V7, P2151, DOI 10.1105/tpc.7.12.2151	50	291	2757	4	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					769	+		10.1038/47134	http://dx.doi.org/10.1038/47134			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617198				2022-12-24	WOS:000084330500054
J	Higashi, M; Takimoto, G; Yamamura, N				Higashi, M; Takimoto, G; Yamamura, N			Sympatric speciation by sexual selection	NATURE			English	Article							COSTLY MATE PREFERENCES; EVOLUTION; CHOICE; MODEL; DIVERSIFICATION; REINFORCEMENT; CICHLIDS		Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan	Kyoto University	Higashi, M (corresponding author), Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan.							Albertson RC, 1999, P NATL ACAD SCI USA, V96, P5107, DOI 10.1073/pnas.96.9.5107; BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; Deutsch JC, 1997, BIOL J LINN SOC, V62, P1; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI 10.1111/j.1558-5646.1991.tb02646.x; Kawecki TJ, 1997, EVOLUTION, V51, P1751, DOI 10.1111/j.1558-5646.1997.tb05099.x; KODRASHOV AS, 1999, NATURE, V400, P351; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, 1987, J THEOR BIOL, V128, P195, DOI 10.1016/S0022-5193(87)80169-8; Ritchie MG, 1998, ENDLESS FORMS, P291; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; SEGER J, 1985, EVOLUTION, V39, P1185, DOI 10.1111/j.1558-5646.1985.tb05685.x; Tauber C.A., 1989, P307; TAUBER CA, 1977, NATURE, V268, P702, DOI 10.1038/268702a0; Turner G.F., 1994, Advances in Limnology, V44, P139; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; WU GI, 1985, EVOLUTION, V39, P66	23	256	264	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					523	526		10.1038/990087	http://dx.doi.org/10.1038/990087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591210				2022-12-24	WOS:000084013200054
J	Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA				Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA			Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2	LANCET			English	Article							FAMILY HISTORY; MUTATION CARRIERS; AGE; DIFFERENTIATION; PATTERN; PARITY; WOMEN	Background Early age at first full-term pregnancy and increasing parity are associated with a reduced risk of breast cancer. However, whether pregnancy decreases the risk of early-onset hereditary breast cancer is unknown. There is concern that pregnancy may increase breast-cancer risk in carriers of BRCA1 and BRCA2 germline mutations. We aimed to establish whether pregnancy is a risk factor for hereditary breast cancer. Methods We did a matched case-control study of breast cancer in women who carry deleterious BRCA1 or BRCA2 mutations. Cases were carriers who developed breast cancer by age 40 years, and controls were carriers of the same age without breast cancer, or who were diagnosed with breast cancer after age 40 years. Women who had undergone preventive mastectomy, hysterectomy, or oophorectomy, or who were diagnosed with ovarian cancer before the age at which breast cancer was diagnosed in the matched case were excluded. Information about pregnancies and pregnancy outcome was derived from a questionnaire completed by women in the course of genetic counselling. Findings A higher proportion of cases than controls had had a full term pregnancy (173/236 vs 146/236; odds ratio 1.71 [95% CI 1.13-2.62], p=0.01). The mean number of births was also greater for cases than for controls (1.62 vs 1.38, p=0.04). The risk increased with the number of births and did not diminish with time since last pregnancy. There were no significant differences in age at first birth or age at last birth between cases and controls. Interpretation Carriers of the BRCA1 and BRCA2 mutations who have children are significantly more likely to develop breast cancer by age 40 than carriers who are nulliparous. Each pregnancy is associated with an increased cancer risk. An early first pregnancy does not confer protection for carriers of BRCA1 or BRCA2 mutations.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Ctr Hosp Univ Montreal, Epidemiol Res Unit, Res Ctr, Montreal, PQ, Canada; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Div Canc Epidemiol & Control, Boston, MA 02115 USA; Fox Chase Canc Ctr, Div Basic Sci & Populat Sci, Philadelphia, PA 19111 USA; Univ Chicago, Med Ctr, Canc Risk Clin, Sect Hematol & Oncol, Chicago, IL 60637 USA; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON, Canada; Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden	University of Toronto; University Toronto Affiliates; Womens College Hospital; Georgetown University; Universite de Montreal; Creighton University; University of Pennsylvania; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; University of Chicago; University of Chicago Medical Center; McGill University; McGill University; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Lund University; Skane University Hospital	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750, Toronto, ON M5G 1N8, Canada.	steven.narod@swchsc.on.ca	Narod, Steven A/AAA-6112-2022; Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651	NATIONAL CANCER INSTITUTE [R01CA057601, R01CA063678, R01CA063682] Funding Source: NIH RePORTER; NCI NIH HHS [CA63678, CA57601, R01 CA63682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassler R, 1970, Curr Top Pathol, V53, P1; BERAL V, 1993, LANCET, V341, P1102, DOI 10.1016/0140-6736(93)92469-A; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; DICKSON R, 1996, DIS BREAST, P15; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EASTON DF, 1995, AM J HUM GENET, V56, P265; Egan KM, 1998, CANCER EPIDEM BIOMAR, V7, P359; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Jernstrom H, 1998, BREAST, V7, P320, DOI 10.1016/S0960-9776(98)90074-1; Johannsson O, 1998, LANCET, V352, P1359, DOI 10.1016/S0140-6736(05)60750-7; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LYNCH HT, 1984, J MED GENET, V21, P96, DOI 10.1136/jmg.21.2.96; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Magnusson C, 1998, CANCER CAUSE CONTROL, V9, P259, DOI 10.1023/A:1008817018942; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCredie M, 1997, INT J CANCER, V73, P503, DOI 10.1002/(SICI)1097-0215(19971114)73:4<503::AID-IJC8>3.0.CO;2-3; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; Narod SA, 1995, INT J CANCER, V64, P394, DOI 10.1002/ijc.2910640608; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P219; RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Russo J, 1997, PROG CLIN BIOL RES, V396, P1; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	150	155	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1846	1850		10.1016/S0140-6736(99)04336-6	http://dx.doi.org/10.1016/S0140-6736(99)04336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584720				2022-12-24	WOS:000083909100009
J	Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW				Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW			Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONAL-AGE; IN-UTERO; INFANTS; INJURY; REPAIR; MODEL	Context Intrauterine closure of exposed spinal cord tissue prevents secondary neurologic injury in animals with a surgically created spinal defect; however, whether in utero repair of myelomeningocele improves neurologic outcome in infants with spina bifida is not known. Objective To determine whether intrauterine repair of myelomeningocele improves patient outcomes compared with standard care. Design Single-institution, nonrandomized observational study conducted between January 1990 and February 1999. Setting Tertiary care medical center. Participants A sample of 29 study patients with isolated fetal myelomeningocele referred for intrauterine repair that was performed between 24 and 30 gestational weeks and 23 controls matched to cases for diagnosis, level of lesion, practice parameters, and calendar time. All infants were followed up for a minimum of 6 months after delivery. Main Outcome Measures Requirement for ventriculoperitoneal shunt placement, obstetrical complications, gestational age at delivery, and birth weight for study vs control subjects. Results The requirement for ventriculoperitoneal shunt placement for decompression of hydrocephalus was significantly decreased among study infants (59% vs 91%, P =.01). The median age at shunt placement was also older among study infants (50 vs 5 days; P =.006). This may be explained by the reduced incidence of hindbrain herniation among study infants (38% vs 95%; P<.001), Following hysterotomy, study patients had an increased risk of oligohydramnios (48% vs 4%; P =.001) and admission to the hospital for preterm uterine contractions (50% vs 9%; P =.002). The estimated gestational age at delivery was earlier for study patients (33.2 vs 37.0 weeks; P<.001), and the birth weight of study neonates was less (2171 vs 3075 g; P<.001). Conclusions Our study suggests that intrauterine repair of myelomeningocele decreases the incidence of hindbrain herniation and shunt-dependent hydrocephalus in infants with spina bifida, but increases the incidence of premature delivery.	Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat Neurosurg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Obstet Anesthesia, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neonatol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA; New England Res Inst, Watertown, MA 02172 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; HealthCore, Inc	Bruner, JP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, B-1100 Med Ctr N, Nashville, TN 37232 USA.							BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; BABSON SG, 1976, J PEDIATR-US, V89, P814, DOI 10.1016/S0022-3476(76)80815-3; BEALER JF, 1995, J PEDIATR SURG, V30, P1150, DOI 10.1016/0022-3468(95)90009-8; BRUNER JP, IN PRESS AM J OBSTET; CANTOR AB, 1992, STAT MED, V11, P931, DOI 10.1002/sim.4780110710; FLETCHER JC, 1991, UNBORN PATIENT, P12; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HEFFEZ DS, 1993, NEUROSURGERY, V32, P1005, DOI 10.1227/00006123-199306000-00021; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; MEULI M, 1995, J PEDIATR SURG, V30, P1028, DOI 10.1016/0022-3468(95)90335-6; MICHEJDA M, 1984, Z KINDERCHIR, V39, P259; Ranzini AC, 1999, OBSTET GYNECOL, V93, P826, DOI 10.1016/S0029-7844(98)00423-2; Rekate H L, 1985, Clin Neurosurg, V32, P593; RUTHERFORD SE, 1987, J REPROD MED, V32, P587; SCHLIEVERT P, 1977, SEMIN PERINATOL, V1, P59; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SPOSTO R, 1992, BIOMETRICS, V48, P87, DOI 10.2307/2532741; STEINBOK P, 1992, CHILD NERV SYST, V8, P92, DOI 10.1007/BF00298448; Storrs BB, 1988, CONCEPTS PEDIAT NEUR, V8, P51; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WERNER EE, 1966, CHILD DEV, V37, P39, DOI 10.1111/j.1467-8624.1966.tb05367.x	22	296	300	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1819	1825		10.1001/jama.282.19.1819	http://dx.doi.org/10.1001/jama.282.19.1819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573272	Bronze			2022-12-24	WOS:000083615700024
J	Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J				Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J			Cost effectiveness analysis of antenatal HIV screening in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							TO-CHILD TRANSMISSION; ZIDOVUDINE; STRATEGIES; INFECTION; IMPACT; AIDS	Objective To assess the cost effectiveness of universal antenatal HIV screening compared with selective screening in the United Kingdom. Design Incremental cost effectiveness analysis relating additional costs of screening to life years gained. Maternal and paediatric costs and life years were combined. Setting United Kingdom. Main outcome measures Number of districts for which universal screening would be cost effective compared with selective screening under various conditions. Results On base case assumptions, a new diagnosis of a pregnant woman with HIV results in a gain of 6.392 life years and additional expenditure of pound 14 833. If decision makers are prepared to pay up to pound 10 000 for an additional life year, this would imply a net benefit of pound 49 090 (range pound 12 300-pound 59 000), which would be available to detect each additional infected woman in an antenatal screening programme. In London, universal antenatal screening would be cost effective compared with a selective screening under any reasonable assumptions about screening costs. Outside London, universal screening with uptake above 90% would be cost effective with a pound 0.60 HIV antibody test cost and up to 3.5 minutes for pretest discussion. Cost effectiveness of universal testing is lower if selective testing can achieve high uptake among those at higher risk. A universal strategy with only 50% uptake may not be less cost effective in low prevalence districts and may cost more and be less effective than a well run selective strategy. Conclusions Universal screening with pretest discussion should be adopted throughout the United Kingdom as part of routine antenatal care as long as test costs can be kept low and uptake high.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; York Univ, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of London; University College London; University of York - UK; Brunel University	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Ratcliffe, Julie/G-3169-2017	Ratcliffe, Julie/0000-0001-7365-1988; Gibb, Diana/0000-0002-9738-5490; Sculpher, Mark/0000-0003-3746-9913				Ades AE, 1999, AIDS, V13, P271, DOI 10.1097/00002030-199902040-00016; ADES AE, 25 BRUN U HLTH EC RE; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, REG COST EFF STUD 19; *DEP HLTH, 1999, 1999183 DEP HLTH; *DEP HLTH, 1994, PLCO945 DEP HLTH; *DEP HLTH, 1995, POL APPR HLTH; Ecker JL, 1996, AM J OBSTET GYNECOL, V174, P716, DOI 10.1016/S0002-9378(96)70455-6; GIBB D, 1998, GUIDELINES MANAGEMEN; Gibb DM, 1999, AIDS, V13, P1569, DOI 10.1097/00002030-199908200-00018; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; LEWIS R, 1995, AM J OBSTET GYNECOL, V173, P1329, DOI 10.1016/0002-9378(95)91381-5; Mauskopf JA, 1996, JAMA-J AM MED ASSOC, V276, P132, DOI 10.1001/jama.276.2.132; Parry J V, 1993, Clin Diagn Virol, V1, P167, DOI 10.1016/0928-0197(93)90011-S; Postma MJ, 1999, BMJ-BRIT MED J, V318, P1656, DOI 10.1136/bmj.318.7199.1656; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; Ratcliffe J, 1998, AIDS, V12, P1381, DOI 10.1097/00002030-199811000-00021; Sculpher MJ, 1998, AIDS, V12, P1371, DOI 10.1097/00002030-199811000-00020; SIMPSON WM, 1999, HLTH TECHNOLOGY ASSE, P3; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X9801800209; STOTO MA, 1998, REDUCING ODDS PREVEN, P397; Stringer JSA, 1999, JAMA-J AM MED ASSOC, V281, P1946, DOI 10.1001/jama.281.20.1946; Tookey PA, 1998, J MED SCREEN, V5, P133, DOI 10.1136/jms.5.3.133	26	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1230	1234		10.1136/bmj.319.7219.1230	http://dx.doi.org/10.1136/bmj.319.7219.1230			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550083	Bronze, Green Published			2022-12-24	WOS:000083625600022
J	Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB				Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB			Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens	LANCET			English	Article							QUALITY-OF-LIFE; DIABETES-MELLITUS; INJECTOR; KINETICS; THERAPY	Background Neutral protamine Hagedorn (NPH) insulin is one of the most commonly used insulins in insulin pens. NPH in pen cartridges is in a two-phase solution with either a solvent or a short-acting insulin, and needs adequate mixing for complete resuspension. We assessed whether NPH insulin is accurately resuspended by patients and the association of suspension errors with diabetes control. Methods 109 patients (39 with type 1 diabetes) who had received conventional diabetic education had the NPH content of their cartridges measured by an optical system; a control cartridge was designated as 100%. A questionnaire was used to assess clinical details and insulin suspension habits. After the information about residual insulin error was known, all 109 patients were instructed to resuspend their insulin by rolling and tipping the pen 20 times. 52 patients were randomly selected to have cartridges reanalysed 3 months or 6 months later and to complete another questionnaire. Findings Only 10 (9%) of 109 patients tipped and rolled their pen more than ten times. NPH insulin content ranged from 5% to 214% and varied by more than 20% in 71 (65%) of 109 cartridges. There was no relation between inadequate suspension and the frequency of hypoglycaemic episodes (r=0.2, p=0.08). For all patients, there was a correlation between the absolute error of NPH suspension and cycles of rolling and tipping the pen (r=-0.23, p<0.05). After education on resuspending the pen's contents, data were available from 44 of 52 patients; suspension errors decreased in 35 (80%), were unchanged in three (7%), and increased in six (13%). The 35 patients with improved NPH insulin suspension had fewer mean hypoglycaemic episodes per month compared with the previous period (0.4 [SD 0.1] vs 1.0 [0.3], p<0.05). Mean HbA(1c) values in patients with improved suspension quality did not differ from baseline (8.4% [0.3] vs 8.9% [0.4], p=0.07). Mixing of NPH insulin by a mechanical device showed that at least 20 cycles were necessary before complete resuspension was obtained. Interpretation Inadequate NPH insulin suspension is common. We recommended that patients tip pens that contain NPH insulin at least 20 times, since inadequate mixing may impair diabetes control.	Univ Hosp Ulm, Div Nephrol, Ulm, Germany; Univ Hosp Ulm, Div Endocrinol, Ulm, Germany; Univ Ulm, Isotope Div, Ulm, Germany	Ulm University; Ulm University; Ulm University	Jehle, PM (corresponding author), Univ Ulm, Dept Internal Med 2, Div Nephrol, Robert Koch Str 8, D-89081 Ulm, Germany.		Boehm, Bernhard Otto/F-8750-2015					*AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS72; Andersson PO, 1997, DIABETES RES CLIN PR, V36, P169, DOI 10.1016/S0168-8227(97)00048-X; BAK JF, 1987, DIABETES RES CLIN EX, V6, P155; BERGER M, 1982, DIABETES CARE, V5, P77, DOI 10.2337/diacare.5.2.77; BROGDEN RN, 1987, DRUGS, V34, P650; BUYSSCHAERT M, 1988, DIABETES METAB, V14, P75; BUYSSCHAERT M, 1989, LANCET, V1, P965; Chantelau E, 1997, PATIENT EDUC COUNS, V30, P167, DOI 10.1016/S0738-3991(96)00964-0; CHASE HP, 1991, J ADOLESCENT HEALTH, V12, P373, DOI 10.1016/0197-0070(91)90050-V; DINNEEN SF, 1991, IRISH J MED SCI, V160, P286, DOI 10.1007/BF02948414; FISKEN RA, 1989, DIABETES RES CLIN EX, V11, P195; GINSBERG BH, 1994, HORM METAB RES, V26, P584, DOI 10.1055/s-2007-1001764; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; JORGENSEN JOL, 1988, DIABETIC MED, V5, P574, DOI 10.1111/j.1464-5491.1988.tb01054.x; MURRAY DP, 1988, DIABETIC MED, V5, P750, DOI 10.1111/j.1464-5491.1988.tb01102.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKYLER JS, 1988, MED CLIN N AM, V72, P1337, DOI 10.1016/S0025-7125(16)30710-6; STEINEMANN MA, 1990, THER UMSCH, V47, P22; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; 1989, LANCET, V1, P307	21	119	128	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1604	1607		10.1016/S0140-6736(98)12459-5	http://dx.doi.org/10.1016/S0140-6736(98)12459-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560676				2022-12-24	WOS:000083551000013
J	Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP				Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP			The spread of the obesity epidemic in the United States, 1991-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTISTATE TELEPHONE SURVEY; WEIGHT; ADULTS; OVERWEIGHT; TRENDS; HEIGHT	Context The increasing prevalence of obesity is a major public health concern, since obesity is associated with several chronic diseases. Objective To monitor trends in state-specific data and to examine changes in the prevalence of obesity among adults. Design Cross-sectional random-digit telephone survey (Behavioral Risk Factor Surveillance System) of noninstitutionalized adults aged 18 years or older conducted by the Centers for Disease Control and Prevention and state health departments from 1991 to 1998. Setting States that participated in the Behavioral Risk Factor Surveillance System. Main Outcome Measures Body mass index calculated from self-reported weight and height. Results The prevalence of obesity (defined as a body mass index greater than or equal to 30 kg/m(2)) increased from 12.0% in 1991 to 17.9% in 1998. A steady increase was observed in all states; in both sexes; across age groups, races, educational levels; and occurred regardless of smoking status. The greatest magnitude of increase was found in the following groups: 18- to 29-year-olds (7.1% to 12.1%), those with some college education (10.6% to 17.8%), and those of Hispanic ethnicity (11.6% to 20.8%), The magnitude of the increased prevalence varied by region (ranging from 31.9% for mid Atlantic to 67.2% for South Atlantic, the area with the greatest increases) and by state (ranging from 11.3% for Delaware to 101.8% for Georgia, the state with the greatest increases). Conclusions Obesity continues to increase rapidly in the United States. To alter this trend, strategies and programs for weight maintenance as well as weight reduction must become a higher public health priority.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mokdad, AH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.	ahm1@cdc.gov						ADAY LA, 1989, DESIGNING CONDUCTING, P79; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BRAY GA, 1992, OBESITY, P301; CAPERSEN CJ, DEP HLTH HUMAN SERVI; CASPERSEN CJ, 1987, P 21 NAT M PUBL HLTH; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; NELSON DE, 1998, P SECT SURV METH AM; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SAS I INC, 1998, SAS SYST COMP PROGR; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; SHAH BV, 1997, SUDAN USERS MANUAL R; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHO. World Health Organization, 1995, TECHNICAL REPORT SER, V854; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; Wolf A M, 1996, Am J Clin Nutr, V63, p466S, DOI 10.1093/ajcn/63.3.466	19	1653	1699	3	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1519	1522		10.1001/jama.282.16.1519	http://dx.doi.org/10.1001/jama.282.16.1519			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248MB	10546690	Bronze			2022-12-24	WOS:000083277800018
J	Yanovski, JA; Yanovski, SZ				Yanovski, JA; Yanovski, SZ			Recent advances in basic obesity research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; LEPTIN RECEPTOR; FRAMESHIFT MUTATION; REARED APART; EARLY-ONSET; GENE; WEIGHT; MICE; PROTEIN; INTERVENTION		NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yanovski, JA (corresponding author), NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	jy15i@nih.gov		Yanovski, Jack/0000-0001-8542-1637	CENTER FOR INFORMATION TECHNOLOGY [ZIACT000268, Z01CT000268] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000641] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000641] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Allison DB, 1996, INT J OBESITY, V20, P501; [Anonymous], 1996, NUTRITION, V12, P397; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1999, CURR OPIN ENDOCRINOL, V6, P163; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GREENBERG AS, 1998, DIABETES S, V47, pLB16; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hill JO, 1997, PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH, P88; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; Klem ML, 1997, AM J CLIN NUTR, V66, P239, DOI 10.1093/ajcn/66.2.239; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Perusse L, 1999, OBES RES, V7, P111, DOI 10.1002/j.1550-8528.1999.tb00398.x; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; ROLLS BJ, 1995, AM J CLIN NUTR, V62, P1086; Sjostrom CD, 1997, OBES RES, V5, P519; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; World Health Organization, 1997, PROGR NUTR FAM REPR; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	63	66	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1504	1506		10.1001/jama.282.16.1504	http://dx.doi.org/10.1001/jama.282.16.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546681				2022-12-24	WOS:000083277800001
J	Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE				Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE			Improved clinical outcome after widespread use of coronary-artery stenting in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WAVE MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; BYPASS-SURGERY; ADMINISTRATIVE DATA; COMORBIDITY INDEX; FOLLOW-UP; DISEASE; PLACEMENT; THROMBOLYSIS	Background: The introduction and refinement of coronary-artery stenting dramatically changed the practice of percutaneous coronary revascularization in the mid-1990s. We analyzed one-year follow-up data for all percutaneous coronary interventions performed in a large, unselected population in Canada to determine whether the use of coronary stenting has been associated with improved outcomes. Methods: Prospectively collected data on all percutaneous coronary interventions performed on residents of British Columbia, Canada, between April 1994 and June 1997 were linked to province-wide health care data bases to provide the date of the following end points: subsequent target-vessel revascularization, myocardial infarction, and death. Base-line characteristics and procedural variables were identified and Kaplan-Meier survival curves were generated for 9594 procedures divided into seven groups, one for each sequential half-year period. Results: The overall burden of coexisting illnesses remained stable throughout the study period. A large increase in the rate of coronary stenting (from 14.2 percent in the period from April to June 1994 to 58.7 percent in the period from January to June 1997) was associated with a significant reduction in the rate of adverse cardiac events at one year (from 28.8 percent to 22.8 percent; adjusted relative risk, 0.79; 95 percent confidence interval, 0.69 to 0.90; P<0.001). This reduction in adverse events was exclusively due to a large reduction in subsequent target-vessel revascularization (from 24.4 percent to 17.0 percent; adjusted relative risk, 0.72; 95 percent confidence interval, 0.62 to 0.83; P<0.001) without significant changes in the overall rates of myocardial infarction (5.4 percent, P=0.28) or death (3.9 percent, P=0.65). Conclusions: The need for target-vessel revascularization during one year of follow-up after percutaneous coronary intervention decreased during the mid-1990s. The reduction was coincident with the introduction and subsequent widespread use of coronary stenting. (N Engl J Med 1999;341:1957-65.) (C)1999, Massachusetts Medical Society.	Vancouver Gen Hosp, Vancouver, BC, Canada; British Columbian Cardiac Registries, Vancouver, BC, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Royal Jubilee Hosp, Victoria, BC, Canada; Royal Columbian Hosp, New Westminster, BC, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Buller, CE (corresponding author), Intervent Cardiol Res, 865 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.		Spinelli, John J./B-6210-2013	Spinelli, John J./0000-0002-9119-3287				Alderman EL, 1996, NEW ENGL J MED, V335, P217; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Buller CE, 1999, CIRCULATION, V100, P236, DOI 10.1161/01.CIR.100.3.236; *BYP ANG REV INV I, 1996, NEW ENGL J MED, V336, P147; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Gruntzig A, 1980, G Ital Cardiol, V10, P261; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Landon B, 1996, INQUIRY-J HEALTH CAR, V33, P155; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Pitt B, 1998, CIRCULATION, V98, P636; *PRINC INV CASS TH, 1981, CIRCULATION S1, V63, P1; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys P, 1998, LANCET, V352, P1478; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; TERRIN ML, 1993, J AM COLL CARDIOL, V22, P1763, DOI 10.1016/0735-1097(93)90755-P; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 1998, NEW ENGL J MED, V339, P1702, DOI 10.1056/NEJM199812033392311; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Williams JI, 1996, 9603TR I CLIN EV SCI	37	102	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1957	1965		10.1056/NEJM199912233412602	http://dx.doi.org/10.1056/NEJM199912233412602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607812				2022-12-24	WOS:000084399400002
J	Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN				Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN			Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; STRAIN DIFFERENTIATION; TRANSMISSION; POLYMORPHISM; ELEMENT; IS6110; PROBE	Context Typing of Mycobacterium tuberculosis could provide a more sensitive means of identifying outbreaks than use of conventional surveillance techniques alone. Variants of the New York City W strain of M tuberculosis were identified in New Jersey. Objective To describe the spread of the W family of M tuberculosis strains in New Jersey identified by molecular typing and surveillance data. Design Population-based cross-sectional study. Setting and Subjects All incident culture-positive tuberculosis cases reported in New Jersey from January 1996 to September 1998, for which the W family was defined by insertion sequence (IS) IS6110 DNA fingerprinting, polymorph ic GC-rich repetitive sequence (PGRS) typing, spacer oligotyping (spoligotyping), and variable number tandem repeat (VNTR) analysis. Main Outcome Measure Identification and characterization of W family clones supplemented by surveillance data. Results Isolates from 1207 cases were analyzed, of which 68 isolates (6%) belonged to the W family based on IS6110 and spoligotype hybridization patterns. The IS6110 hybridization patterns or fingerprints revealed that 43 patients (designated group A) shared a unique banding motif not present in other W family isolates. Strains collected from the remaining 25 patients (designated group B), while related to W, displayed a variety of IS6110 patterns and did not share this motif, The PGRS and VNTR typing confirmed the division of the W family into groups A and B and again showed group A strains to be closely related and group B strains to be more diverse. The demographic characteristics of individuals from groups A and B were specific and defined. Group A patients were more likely than group B patients to be US born (91% vs 24%, P < .001), black (76% vs 16%, P < .001), human immunodeficiency virus positive (40% vs 0%, P = .007), and residents of urban northeast New Jersey counties (P < .001), Patients with group B strains were primarily non-US born, of Asian descent, and more dispersed throughout New Jersey. No outbreak had been detected using conventional surveillance alone. Conclusions The implementation of multiple molecular techniques in conjunction with surveillance data enabled us to identify a previously undetected outbreak in a defined geographical setting. The outbreak isolates comprise members of a distinct branch of the W family phylogenetic lineage. The use of molecular strain typing provides a proactive approach that may be used to initiate, and not just augment, traditional surveillance outbreak investigations.	Publ Hlth Res Inst City New York Inc, TB Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY USA; New Jersey Dept Hlth & Senior Serv, Div Communicable Dis, Trenton, NJ USA; Univ Washington, Dept Geog, Seattle, WA 98195 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Baylor Coll Med, Dept Pathol, Inst Study Human Bacterial Pathogenesis, Houston, TX 77030 USA	New York University; New York University; New Jersey Department of Health & Senior Services; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; Wadsworth Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Baylor College of Medicine	Kreiswirth, BN (corresponding author), Publ Hlth Res Inst City New York Inc, TB Ctr, 455 1st Ave, New York, NY 10016 USA.			Bifani, Pablo/0000-0001-9651-6439; Tempalski, Barbara/0000-0002-6128-2510; Mathema, Barun/0000-0003-2772-479X	NIAID NIH HHS [AI27742] Funding Source: Medline; NIDA NIH HHS [DA09238] Funding Source: Medline; PHS HHS [NL51517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; Frothingham R, 1998, MICROBIOL-UK, V144, P1189, DOI 10.1099/00221287-144-5-1189; GROENEN PMA, 1993, MOL MICROBIOL, V10, P1057, DOI 10.1111/j.1365-2958.1993.tb00976.x; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; KREISWIRTH BN, 1996, TUBERCULOSIS, P199; Kurepina N. E., 1998, Tubercle and Lung Disease, V79, P31, DOI 10.1054/tuld.1998.0003; LIN R, 1996, INT J INFECT DIS, V1, P18; Moss AR, 1997, INT J TUBERC LUNG D, V1, P115; Palittapongarnpim P, 1997, INT J TUBERC LUNG D, V1, P370; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; TORREA G, 1995, J CLIN MICROBIOL, V33, P1899, DOI 10.1128/JCM.33.7.1899-1904.1995; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991	27	138	151	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2321	2327		10.1001/jama.282.24.2321	http://dx.doi.org/10.1001/jama.282.24.2321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612319				2022-12-24	WOS:000084261700025
J	Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE				Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE			Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study	ANNALS OF INTERNAL MEDICINE			English	Article							STROKE PREVENTION; PHYSICIAN ATTITUDES; NATIONAL PATTERNS; COMMUNITY; PROPHYLAXIS; PREVALENCE; HOSPITALS; ASPIRIN	Background: Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied. Objective: To assess the rates and predictors of warfarin use in ambulatory patients with nonvalvular atrial fibrillation. Design: Cross-sectional study. Setting: Large health maintenance organization. Patients: 13428 patients with a confirmed ambulatory diagnosis of nonvalvular atrial fibrillation and known warfarin status between 1 July 1996 and 31 December 1997. Measurements: Data from automated pharmacy, laboratory, and clinical-administrative databases were used to determine the prevalence and determinants of warfarin use in the 3 months before or after the identified diagnosis of atrial fibrillation. Results: Of 11082 patients with nonvalvular atrial fibrillation and no known contraindications, 55% received warfarin. Warfarin use was substantially lower in patients who were younger than 55 years of age (44.3%) and those who were 85 years of age or older (35.4%). Only 59.3% of patients with one or more risk factors for stroke and no contraindications were receiving warfarin. Among a subset of "ideal" candidates to receive warfarin (persons 65 to 74 years of age who had no contraindications and had previous stroke, hypertension, or both), 62.1% had evidence of warfarin use. Among our entire cohort, the strongest predictors of receiving warfarin were previous stroke (adjusted odds ratio, 2.55 [95% CI, 2.23 to 2.92]), heart failure (odds ratio, 1.63 [CI, 1.51 to 1.77]), previous intracranial hemorrhage (odds ratio, 0.33 [CI, 0.21 to 0.52]), age 85 years or older (odds ratio, 0.35 [CI, 0.31 to 0.40]), and previous gastrointestinal hemorrhage (odds ratio, 0.47 [CI, 0.40 to 0.57]). Conclusions: In a large, contemporary cohort of ambulatory patients with atrial fibrillation who received care within a health maintenance organization, warfarin use was considerably higher than in other reported studies. Although the reasons why physicians did not prescribe warfarin could not be elucidated, many apparently eligible patients with atrial fibrillation and at least one additional risk factor for stroke, especially hypertension, did not receive anticoagulation. Interventions are needed to increase the use of warfarin for stroke prevention among appropriate candidates.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Kaiser Permanente; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Go, AS (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway St,12th Floor, Oakland, CA 94611 USA.	axg@dor.kaiser.org	Go, Alan S./AAE-7745-2019	Hylek, Elaine/0000-0001-8263-8304	NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; *AM SOC HLTH SYST, 1998, AM J HEALTH-SYST PH, V55, P376; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; Arnsten JH, 1997, AM J MED, V103, P11, DOI 10.1016/S0002-9343(97)90048-6; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; Blackshear JL, 1996, LANCET, V348, P633; Brass LM, 1998, ARCH INTERN MED, V158, P2093, DOI 10.1001/archinte.158.19.2093; Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382; Cleves M A, 1997, Jt Comm J Qual Improv, V23, P550; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Diggle PJ, 2002, ANAL LONGITUDINAL DA; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Flaker GC, 1999, AM HEART J, V137, P307, DOI 10.1053/hj.1999.v137.91403; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Greenberg MK, 1998, NEUROLOGY, V51, P671; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Gurwitz JH, 1997, ARCH INTERN MED, V157, P978, DOI 10.1001/archinte.157.9.978; Kerr C, 1996, EUR HEART J, V17, P48, DOI 10.1093/eurheartj/17.suppl_C.48; Kerr CR, 1998, AM J CARDIOL, V82, p82N, DOI 10.1016/S0002-9149(98)00589-X; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; Lackner T E, 1995, Arch Fam Med, V4, P1017, DOI 10.1001/archfami.4.12.1017; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; Munschauer FE, 1997, STROKE, V28, P72, DOI 10.1161/01.STR.28.1.72; PETERSEN P, 1989, LANCET, V1, P175; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Smith NL, 1999, ARCH INTERN MED, V159, P1574, DOI 10.1001/archinte.159.14.1574; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Teo K, 1998, CAN J CARDIOL, V14, P695; White RH, 1999, AM J MED, V106, P165, DOI 10.1016/S0002-9343(98)00389-1; Whittle J, 1997, ARCH INTERN MED, V157, P441, DOI 10.1001/archinte.157.4.441	48	495	508	2	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					927	+		10.7326/0003-4819-131-12-199912210-00004	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610643				2022-12-24	WOS:000084374400003
J	Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ				Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ			Possible ancient oceans on Mars: Evidence from Mars Orbiter Laser Altimeter data	SCIENCE			English	Article							TOPOGRAPHY; UTOPIA	High-resolution altimetric data define the detailed topography of the northern lowlands of Mars, and a range of data is consistent with the hypothesis that a Lowland-encircling geologic contact represents the ancient shoreline of a Large standing body of water present in middle Mars history. The contact altitude is close to an equipotential Line, the topography is smoother at all scales below the contact than above it, the volume enclosed by this contact is within the range of estimates of available water on Mars, and a series of extensive terraces parallel the contact in many places.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Russian Acad Sci, Vernadsky Inst, Moscow 117975, Russia; Kharkov State Univ, Kharkov Astron Observ, UA-310022 Kharkov, Ukraine	Brown University; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National University	Head, JW (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Kreslavsky, Mikhail/J-3425-2013; Thomson, Bradley/AAA-3496-2022	Thomson, Bradley/0000-0001-8635-8932; Kreslavsky, Mikhail/0000-0002-1900-826X; Ivanov, Mikhail/0000-0001-5696-8131				Aharonson O, 1998, GEOPHYS RES LETT, V25, P4413, DOI 10.1029/1998GL900057; Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; BANIN A., 2000, MARS, P594; BIRD EC, 1976, BEACH PROCESSES SEDI; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CLIFFORD SM, 1999, LUNAR PLANET SCI, V30, P1619; Garvin JB, 1999, GEOPHYS RES LETT, V26, P381, DOI 10.1029/1998GL900309; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1987, US GEOL SUR VMISC IN; HEARD JW, 1998, GEOPHYS RES LETT, V25, P4401; IVANOV MA, 1999, 5 INT C MARS; Kreslavsky MA, 1999, J GEOPHYS RES-PLANET, V104, P21911, DOI 10.1029/1999JE001051; KUZMIN RO, 1988, SOLAR SYST RES, V22, P195; LUCCHITTA BK, 1986, J GEOPHYS RES, V91, P166; Malin MC, 1999, GEOPHYS RES LETT, V26, P3049, DOI 10.1029/1999GL002342; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MCGILL GE, 1986, GEOPHYS RES LETT, V13, P705, DOI 10.1029/GL013i008p00705; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; McSween HY, 1999, J GEOPHYS RES-PLANET, V104, P8679, DOI 10.1029/98JE02551; MUTCH TA, 1976, SCIENCE, V194, P1277, DOI 10.1126/science.194.4271.1277; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; ROTTO S, 1995, US GEOL SURV MISC IN; SCOTT DH, 1992, P LUNAR PLANET SCI, V22, P53; SCOTT DH, 1995, US GEOL SURV MISC IN; SCOTT DH, 1986, US GEOL SURV MISC IN; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; Squyres S. W., 1992, MARS, P523; Tanaka KL, 1997, J GEOPHYS RES-PLANET, V102, P4131, DOI 10.1029/96JE02862; TANAKA KL, 1992, US GEOL SURV MISC IN; TANAKA KL, 1987, US GEOL SURV MISC IN; Thomas P., 1992, MARS, P767; THOMSON BJ, 1999, LUNAR PLANET SCI C, V30, P1894; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	41	292	294	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2134	2137		10.1126/science.286.5447.2134	http://dx.doi.org/10.1126/science.286.5447.2134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591640				2022-12-24	WOS:000084157300045
J	Jee, SH; Suh, I; Kim, IS; Appel, LJ				Jee, SH; Suh, I; Kim, IS; Appel, LJ			Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol - The Korea Medical Insurance Corporation Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CIGARETTE-SMOKING; RISK-FACTORS; JAPANESE MEN; MORTALITY; STROKE; FRAMINGHAM; HAWAII; DEATH	Context Few studies have examined the interactive effects of smoking and serum cholesterol level on morbidity and mortality from cardiovascular dieseases. In East Asia, where the prevalence of smoking is among the highest in the world, morbidity and mortality from ischemic heart disease (IHD) is rapidly escalating. Objectives To determine whether cigarette smoking is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the Republic of Korea (South Korea), a population that has relatively low levels of serum cholesterol, and to determine whether serum cholesterol levels modify the risk relationship between smoking and ASCVD, Design Prospective cohort study with a follow-up period of 6 years (1993-1998). Setting and Subjects A total of 106745 Korean men aged 35 to 59 years who received health insurance from the Korea Medical Insurance Corporation and who had biennial medical evaluations in 1990 and 1992. Main Outcome Measures Hospital admissions and deaths from IHD, cerebrovascular disease (CVD), and total ASCVD. Results At baseline, 61 389 (58%) were current cigarette smokers and 64 482 (60%) had a total cholesterol level of less than 5.17 mmol/L (200 mg/dL). Between 1993 and 1998, 1006 IHD events (176 per 100 000 person-years), 1364 CVD events (238 per 100 000 person-years), and 716 other ASCVD events (125 per 100 000 person-years) occurred. In multivariate Cox proportional hazard models controlling for age, hypertension, hypercholesterolemia, and diabetes, current smoking increased the risk of IHD (risk ratio [RR], 2.2; 95% confidence interval [CI], 1.8-2.8), CVD (RR, 1.6, 95% CI, 1.4-1.8), and total ASCVD (RR, 1.6, 95% CI, 1.5-1.8). For each outcome, there were significant dose-response relationships with amount and duration of smoking. Throughout the range of serum cholesterol levels, current smoking significantly increased the risk of IHD and CVD. In the lowest quartile of serum cholesterol levels (<4.42 mmol/L [171 mg/dL]), the RR from current smoking was 3.3 (95% CI, 1.7-6.2) for IHD and 1.6 (95% CI, 1.2-2.3) for CVD. There was no evidence of an interaction between smoking and serum cholesterol (P for interaction = .75, .87, and .92 for IHD, CVD, and total ASCVD, respectively). Conclusions This study demonstrates that in Korea smoking is a major independent risk factor for IHD, CVD, and ASCVD and that a low cholesterol level confers no protective benefit against smoking-related ASCVD.	Yonsei Univ, Grad Sch Hlth Sci & Management, Dept Epidemiol & Dis Control, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul, South Korea; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA	Yonsei University; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Appel, LJ (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.		Appel, Larry/GLT-2608-2022	Jee, Sun Ha/0000-0001-9519-3068; Suh, Il/0000-0002-9689-7849				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BRESLOW NE, 1980, IARC SCI PUBL, V32, P146; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; *GALL KOR, 1994, KOR GALL REP 1994; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOLDBERG RJ, 1992, PREVENTION CORONARY, P3; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; Jee SH, 1998, ANN EPIDEMIOL, V8, P14, DOI 10.1016/S1047-2797(97)00131-2; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; Kawane H, 1998, THORAX, V53, P328, DOI 10.1136/thx.53.4.328a; KIYOHARA Y, 1990, J HYPERTENS, V8, pS9; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; *NAT CHOL ED PROGR, 1994, NIH PUBL; *NAT STAT OFF, 1996, ANN REP CAUS DEATH S; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; *NIH, 1997, NIH PUBL; OKUMIYA N, 1985, AM J CARDIOL, V56, P62, DOI 10.1016/0002-9149(85)90567-3; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROBERTSON TL, 1977, AM J CARDIOL, V39, P244, DOI 10.1016/S0002-9149(77)80198-7; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SUH I, 1996, J HYPERTENS S1, V14, pS234; WIHELMSEN L, 1977, BRIT MED J, V39, P1179; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1988, AM J EPIDEMIOL, V127, P476, DOI 10.1093/oxfordjournals.aje.a114824; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646	27	155	158	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2149	2155		10.1001/jama.282.22.2149	http://dx.doi.org/10.1001/jama.282.22.2149			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591337	Bronze, Green Published			2022-12-24	WOS:000083971400034
J	Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA				Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA			Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, messenger; colorectal neoplasms; guanylate cyclase; neoplasm recurrence, local; lymph nodes	STABLE ENTEROTOXIN RECEPTORS; LYMPH-NODES; CARCINOEMBRYONIC ANTIGEN; ADJUVANT THERAPY; COLON-CANCER; OCCULT MICROMETASTASES; CARCINOMA; TUMORS; BREAST; FLUOROURACIL	Background: Patients with stage II colorectal cancer and no histologic evidence of lymph node invasion develop recurrent disease, presumably because of undetected micrometastases. Guanylyl cyclase C is expressed by intestinal and colorectal cancer cells but not by extraintestinal tissues or tumors. Objective: To examine the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer who did and did not have recurrent disease. Design: Case-control study. Setting: Tertiary care academic medical center. Patients: Paraffin-embedded lymph nodes were obtained from 21 patients with histologically confirmed node-negative colorectal cancer who had undergone resection. Controls included 11 patients without disease recurrence 6 or more yea rs after resection, a nd case-patients included 10 patients whose disease recurred up to 3 years after resection. Measurements: Sections of paraffin-embedded lymph nodes were obtained from each patient and were pooled, and their RNA was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Results: Guanylyl cyclase C mRNA was expressed in lymph nodes from all patients with recurrent disease but not in those from patients without recurrent disease (P = 0.004). Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1 of 10 patients with recurrent disease and those from 0 of 11 patients without recurrent disease. The odds ratio for death associated with expression of guanylyl cyclase C mRNA in regional lymph nodes was 15.0 (95% Cl, 1.1 to 756.7). Conclusions: Expression of guanylyl cyclase C mRNA in lymph nodes is associated with recurrence of colorectal cancer in patients with stage II disease. Analysis of guanylyl cyclase mRNA expression by RT-PCR may be useful for colorectal cancer staging.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg, Div Colorectal Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol & Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Div Gastroenterol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University	Waldman, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, 132 S 10th St,1170 Main, Philadelphia, PA 19107 USA.	scott.waldman@mail.tju.edu		Waldman, Scott/0000-0001-6619-175X; Park, Jason/0000-0001-6797-4000	NATIONAL CANCER INSTITUTE [R21CA079663, R01CA075123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008562] Funding Source: NIH RePORTER; NCI NIH HHS [CA79663, CA75123] Funding Source: Medline; NIGMS NIH HHS [5T32 GM08562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abati A, 1996, CANCER, V78, P1; ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; BEATTY JD, 1992, CANCER PHILA S5, V75, P1425; BORDES M, 1973, DIGESTION, V9, P106, DOI 10.1159/000197436; Bostick PJ, 1998, NEW ENGL J MED, V339, P1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; CARRITHERS SL, 1994, GASTROENTEROLOGY, V107, P1653, DOI 10.1016/0016-5085(94)90804-4; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; Carrithers SL, 1996, DIS COLON RECTUM, V39, P171, DOI 10.1007/BF02068072; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; CRESANTA JL, 1992, PRIMARY CARE, V19, P419; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUCHS CS, 1995, SEMIN ONCOL, V22, P472; Ghossein RA, 1998, NEW ENGL J MED, V339, P1642; GOLDENBERG DM, 1978, CANCER, V42, P1546, DOI 10.1002/1097-0142(197809)42:3+<1546::AID-CNCR2820420829>3.0.CO;2-D; Goldstein NS, 1996, AM J CLIN PATHOL, V106, P209; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; GREENWALD P, 1992, CANCER, V70, P1206, DOI 10.1002/1097-0142(19920901)70:3+<1206::AID-CNCR2820701504>3.0.CO;2-J; GUARINO A, 1987, DIGEST DIS SCI, V32, P1017, DOI 10.1007/BF01297193; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KROCZEK RA, 1993, J CHROMATOGR-BIOMED, V618, P133, DOI 10.1016/0378-4347(93)80031-X; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; Merrie AEH, 1998, NEW ENGL J MED, V339, P1642; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; RUBIO CA, 1977, SURG GYNECOL OBSTET, V145, P682; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLOANE JP, 1995, LANCET, V345, P1255, DOI 10.1016/S0140-6736(95)90921-4; Waldman SA, 1998, CANCER EPIDEM BIOMAR, V7, P505; Waldman SA, 1998, DIS COLON RECTUM, V41, P310, DOI 10.1007/BF02237484; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Zippelius A, 1997, J CLIN ONCOL, V15, P2701, DOI 10.1200/JCO.1997.15.7.2701	36	89	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					805	+		10.7326/0003-4819-131-11-199912070-00002	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610624				2022-12-24	WOS:000084053200001
J	Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A				Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A			Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity	SCIENCE			English	Article							CELL-DEATH; PROTEIN; FAMILY; MICE; ACTIVATION; THYMOCYTES; CASPASE-9; SURVIVAL; PATHWAYS; DELETION	Apoptosis can be triggered by members of the Bcl-2 protein family, such as Bim, that share only the BH3 domain with this family. Gene targeting in mice revealed important physiological lores for sim. Lymphoid and myeloid cells accumulated, T cell development was perturbed, and most older mice accumulated plasma cells and succumbed to autoimmune kidney disease. Lymphocytes were refractory to apoptotic stimuli such as cytokine deprivation, calcium ion flux, and microtubule perturbation but not to others. Thus, Bim is required for hematopoietic homeostasis and as a barrier to autoimmunity. Moreover, particular death stimuli appear to activate apoptosis through distinct BH3-only proteins.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013; Bouillet, Philippe/E-1241-2013; Huang, David C. S./C-7586-2013	Strasser, Andreas/0000-0002-5020-4891; Bouillet, Philippe/0000-0002-9012-6058; Huang, David C. S./0000-0002-3101-4873; Adams, Jerry/0000-0002-4360-8628; Tarlinton, David/0000-0001-9928-686X	NCI NIH HHS [CA80188, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080188, R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 1998, BIOTECHNIQUES, V25, P824, DOI 10.2144/98255st03; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pR151; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	1230	1274	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1735	1738		10.1126/science.286.5445.1735	http://dx.doi.org/10.1126/science.286.5445.1735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576740				2022-12-24	WOS:000083912200038
J	Zimmermann, S; Moelling, K				Zimmermann, S; Moelling, K			Phosphorylation and regulation of Raf by Akt (protein kinase B)	SCIENCE			English	Article							TRANSLOCATION; ACTIVATION; C-RAF-1	Activation of the protein kinase Raf can lead to opposing cellular responses such as proliferation, growth arrest, apoptosis, br differentiation. Akt (protein kinase B), a member of a different signaling pathway that also regulates these responses, interacted with Raf and phosphorylated this protein at a highly conserved serine residue in its regulatory domain in vivo. This phosphorylation of Raf by Akt inhibited activation of the Raf-MEK-ERK signaling pathway and shifted the cellular response in a human breast cancer cell line from cell cycle arrest to proliferation. These observations provide a molecular basis for cross talk between two signaling pathways at the level of Raf and Akt.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30-32, CH-8028 Zurich, Switzerland.							ALBAS J, 1998, ONCOGENE, V16, P131; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; GOSH S, 1996, J BIOL CHEM, V271, P8472; Hu E., 1996, SCIENCE, V274, P100; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322; ZIMMERMANN S, UNPUB	24	885	916	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1741	1744		10.1126/science.286.5445.1741	http://dx.doi.org/10.1126/science.286.5445.1741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576742				2022-12-24	WOS:000083912200040
J	Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM				Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM			Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR	SCIENCE			English	Article							GP120 ENVELOPE GLYCOPROTEIN; TYPE-5 FIBER PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; HIV; RESOLUTION; CD4	Binding of virus particles to specific host cell surface receptors is known to be an obligatory step in infection even though the molecular basis for these interactions is not well characterized. The crystal structure of the adenovirus fiber knob domain in complex with domain I of its human cellular receptor, coxsackie and adenovirus receptor (CAR), is presented here. Surface-exposed Loops on knob contact one face of CAR, forming a high-affinity complex. Topology mismatches between interacting surfaces create interfacial solvent-filled cavities and channels that may be targets for antiviral drug therapy. The structure identifies key determinants of binding specificity, which may suggest ways to modify the tropism of adenovirus-based gene therapy vectors.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Flanagan, JM (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.			bewley, maria/0000-0001-7097-0123	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1991, 4 DARS LAB SRC UK CO; FENDER P, 1995, VIROLOGY, V214, P110, DOI 10.1006/viro.1995.9949; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MUCKELBAUER JK, 1995, STRUCTURE, V3, P653, DOI 10.1016/S0969-2126(01)00201-5; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	23	349	360	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1579	1583		10.1126/science.286.5444.1579	http://dx.doi.org/10.1126/science.286.5444.1579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567268	Green Submitted			2022-12-24	WOS:000083768300064
J	Wessner, DR				Wessner, DR			Planning plasmids	SCIENCE			English	Software Review									Davidson Coll, Dept Biol, Davidson, NC 28036 USA	Davidson College	Wessner, DR (corresponding author), Davidson Coll, Dept Biol, POB 1719, Davidson, NC 28036 USA.								0	3	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1495	1496		10.1126/science.286.5444.1495	http://dx.doi.org/10.1126/science.286.5444.1495			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610552				2022-12-24	WOS:000083768300036
J	Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW				Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW			Energetic constraints on the diet of terrestrial carnivores	NATURE			English	Article							CONSUMPTION	Species in the mammalian order Carnivora exhibit a huge diversity of life histories with body sizes spanning more than three orders of magnitude. Despite this diversity, most terrestrial carnivores can be classified as either feeding on invertebrates and small vertebrates or on large vertebrates. Small carnivores feed predominantly on invertebrates probably because they are a superabundant: resource (sometimes 90% of animal biomass(1-3)); however, intake rates of invertebrate feeders are low, about one tenth of those of vertebrate feeders(4,5). Although small carnivores can subsist on this diet because of low absolute energy requirements, invertebrate feeding appears to be unsustainable for larger carnivores. Here we show, by reviewing the most common live prey in carnivore diets, that there is a striking transition from feeding on small prey (less than half of predator mass) to large prey (near predator mass), occurring at predator masses of 21.5-25kg. We test the hypothesis that this dichotomy is the consequence of mass-related energetic requirements and we determine the predicted maximum mass that an invertebrate diet can sustain. Using a simple energetic model and known invertebrate intake rates, we predict a maximum sustainable mass of 21.5 kg, which matches the point where predators shift from small to large prey.	Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Oxford OX1 3PS, England	Zoological Society of London; University of Oxford	Carbone, C (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Roberts, Craig/E-6919-2011; Mace, Georgina M/I-3072-2016	Roberts, Craig/0000-0002-9641-6101; Mace, Georgina M/0000-0001-8965-5211				BININDAEDMONDS ORP, 1994, BIOL REV, V74, P143; BININDAEMONDS ORP, 1998, THESIS U OXFORD; Estes RD., 1991, BEHAV GUIDE AFRICAN, P1; Gittleman J.L., 1989, P183; GITTLEMAN JL, 1995, OECOLOGIA, V67, P50; Gorman ML, 1998, NATURE, V391, P479, DOI 10.1038/35131; GRIFFITHS D, 1980, AM NAT, V116, P743, DOI 10.1086/283666; Joshi AR, 1997, J MAMMAL, V78, P584, DOI 10.2307/1382910; KAVANAU JL, 1975, AM NAT, V109, P391, DOI 10.1086/283009; Kingdon J, 1997, KINGDON FIELD GUIDE, P1; Kruuk H., 1989, SOCIAL BADGER; LAMPRECHT J, 1978, Z SAUGETIERKD, V43, P210; MACDONALD D. W., 1995, ENCY MAMMALS; MACDONALD DW, 1980, Z TIERPSYCHOL, V52, P171; MALCOLM JR, 1986, J ZOOL LOND, V208, P743; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; Nowak RM, 1991, WALKERS MAMMALS WORL; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; PURVIS A, IN PRESS CARNIVORE C; RICHARDSON PRK, 1987, Z SAUGETIERKD, V52, P307; ROOD J P, 1975, East African Wildlife Journal, V13, P89; Schaller G., 1972, SERENGETI LION STUDY, P1; SCHMIDTNIELSEN, 1984, SCALING WHY ANIMAL S, P1; Skinner J. D., 1990, MAMMALS SO AFRICAN S; TAYLOR CR, 1982, J EXP BIOL, V97, P1; WASER PM, 1980, AFR J ECOL, V18, P167, DOI 10.1111/j.1365-2028.1980.tb00640.x; Williams JB, 1997, ECOLOGY, V78, P2588; Wilson E.O., 1987, Conservation Biology, V1, P344, DOI 10.1111/j.1523-1739.1987.tb00055.x; Wilson E.O, 1990, SUCCESS DOMINANCE EC	29	410	426	3	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					286	288		10.1038/46266	http://dx.doi.org/10.1038/46266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580498				2022-12-24	WOS:000083813700047
J	Bhatt, RR; Ferrell, JE				Bhatt, RR; Ferrell, JE			The protein kinase p90 Rsk as an essential mediator of cytostatic factor activity	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; CELL-CYCLE; MOS; TRANSITION; MATURATION; METAPHASE; PREVENTS; OOCYTES	Persistent activation of p42 mitogen-activated protein kinase (p42 MAPK) during mitosis induces a "cytostatic factor" arrest, the arrest responsible for preventing the parthenogenetic activation of unfertilized eggs. The protein kinase p90 Rsk is a substrate of p42 MAPK; thus, the role of p90 Rsk in p42 MAPK-induced mitotic arrest was examined. Xenopus laevis egg extracts immunodepleted of Rsk lost their capacity to undergo mitotic arrest in response to activation of the Mos-MEK-1-p42 MAPK cascade of protein kinases. Replenishing Rsk-depleted extracts with catalytically competent Rsk protein restored the ability of the extracts to undergo mitotic arrest. Rsk appears to be essential for cytostatic factor arrest.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Abrieu A, 1996, J CELL SCI, V109, P239; Bhatt R., UNPUB; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chau ASS, 1998, BIOL CELL, V90, P565, DOI 10.1016/S0248-4900(99)80014-8; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; MALLER JL, 1995, TRENDS BIOCHEM SCI, V20, P524, DOI 10.1016/S0968-0004(00)89122-7; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	22	143	151	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1362	1365		10.1126/science.286.5443.1362	http://dx.doi.org/10.1126/science.286.5443.1362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558991				2022-12-24	WOS:000083675500043
J	Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D				Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D			Risk of cancer after use of fertility drugs with in-vitro fertilisation	LANCET			English	Article							EPITHELIAL OVARIAN-CANCER; INFERTILE WOMEN; BREAST-CANCER; COHORT; FERTILIZATION	Background We investigated the incidence of invasive cancer of the breast, ovary, and uterus in a cohort of patients who had undergone in-vitro-fertilisation (IVF) treatment and examined whether cause of infertility or exposure to fertility drugs to induce superovulation was associated with an increased cancer risk. Method Ten Australian IVF clinics provided data for women who had been referred far IVF before Jan 1, 1994. The frequencies of invasive breast, ovarian, and uterine cancer were assessed by record linkage to population-based cancer registries and the national death index. The observed number of cancers was compared with the expected number calculated by application of age-standardised general-population cancer rates to the cohort. Standardised incidence ratios (SIRs) were derived from the ratio of observed to expected cases. Findings The cohort consisted of 29 700 women: 20 656 were exposed to fertility drugs and 9044 were not, 143 breast cancers, 13 ovarian cancers, and 12 cancers of the uterus occurred among these women. For breast and ovarian cancer the incidence was no greater than expected (SIR 0.91 [95% CI 0.74-1.13] for breast cancer and 0.88 [0.42-1.84] for ovarian cancer in the exposed group and 0.95 [0.73-1.23] for breast cancer and 1.16 [0.52-2.59] for ovarian cancer in the unexposed group). The incidence of uterine cancer was no higher than expected in the exposed group (1.09 [0.45-2.61]) but was significantly higher in the unexposed group (2.47 [1.18-5.18]). Women with unexplained infertility had significantly more cancers of the ovary and uterus than expected (2.64 [1.10-6.35] and 4.59 [1.91-11.0], whole cohort). Analysis of cancer incidence within 12 months of exposure to fertility drugs with IVF showed that incidence was significantly higher than expected for breast and uterine cancer (1.96 [1.22-3.15] and 4.96 [1.24-19.8]). Interpretation Women who have been exposed to fertility drugs with IVF seem to have a transient increase in the risk of having breast or uterine cancer diagnosed in the first year after treatment, though the incidence overall is no greater than expected. Unexplained infertility was associated with an increased risk of a diagnosis of ovarian or uterine cancer.	La Trobe Univ, Ctr Study Mothers & Childrens Hlth, Carlton, Vic 3053, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Monash IVF, Richmond, Vic, Australia	La Trobe University; Monash University	Venn, A (corresponding author), La Trobe Univ, Ctr Study Mothers & Childrens Hlth, 251 Faraday St, Carlton, Vic 3053, Australia.		Venn, Alison J/J-2803-2013	Giles, Graham/0000-0003-4946-9099				Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; FRANCESCHI S, 1994, HUM REPROD, V9, P1673, DOI 10.1093/oxfordjournals.humrep.a138771; HARLOW BL, 1986, J NATL CANCER I, V76, P399; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; KVALE G, 1988, CANCER RES, V48, P6217; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1995, LANCET, V346, P1628; MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Mosgaard BJ, 1997, FERTIL STERIL, V67, P1005, DOI 10.1016/S0015-0282(97)81431-8; Potashnik G, 1999, FERTIL STERIL, V71, P853, DOI 10.1016/S0015-0282(99)00085-0; Ricci E, 1999, HUM REPROD, V14, P1653, DOI 10.1093/humrep/14.6.1653; ROSSING MA, 1995, LANCET, V346, P1627; Rossing MA, 1996, GYNECOL ONCOL, V60, P3, DOI 10.1006/gyno.1996.0002; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Sundstrom I, 1997, ACTA OBSTET GYN SCAN, V76, P238, DOI 10.1111/j.1600-0412.1997.tb07852.x; VENN A, 1995, LANCET, V346, P995, DOI 10.1016/S0140-6736(95)91687-3; VENN R, 1995, LANCET, V346, P1627; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	21	268	282	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1586	1590		10.1016/S0140-6736(99)05203-4	http://dx.doi.org/10.1016/S0140-6736(99)05203-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560672				2022-12-24	WOS:000083551000009
J	Marshall, J; Oberwinkler, J				Marshall, J; Oberwinkler, J			The colourful world of the mantis shrimp	NATURE			English	Article							STOMATOPOD CRUSTACEANS; COMPOUND EYES; OIL DROPLETS; PHOTORECEPTORS; COLOR; RETINA; VISION		Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia; Univ Groningen, Dept Neurobiophys, NL-9747 AG Groningen, Netherlands	University of Queensland; University of Groningen	Marshall, J (corresponding author), Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia.			Oberwinkler, Johannes/0000-0002-8541-3626; Marshall, Justin/0000-0001-9006-6713				Arikawa K, 1999, VISION RES, V39, P1, DOI 10.1016/S0042-6989(98)00070-4; CALDWELL RL, 1976, SCI AM, V234, P80, DOI 10.1038/scientificamerican0176-80; CRONIN TW, 1989, J COMP PHYSIOL A, V166, P261; CRONIN TW, 1994, VISION RES, V34, P2639, DOI 10.1016/0042-6989(94)90221-6; CRONIN TW, 1989, NATURE, V339, P137, DOI 10.1038/339137a0; HARDIE RC, 1986, TRENDS NEUROSCI, V9, P419, DOI 10.1016/0166-2236(86)90136-0; Hart NS, 1998, J EXP BIOL, V201, P1433; Marshall NJ, 1996, J COMP PHYSIOL A, V179, P473; MARSHALL NJ, 1991, PHILOS T ROY SOC B, V334, P33, DOI 10.1098/rstb.1991.0096; MARSHALL NJ, 1988, NATURE, V333, P557, DOI 10.1038/333557a0; NEUMEYER C, 1991, EVOLUTION EYE VISUAL, V2, P284; Osorio D, 1997, VISION RES, V37, P3299, DOI 10.1016/S0042-6989(97)00136-3; SELIGER HH, 1994, J COMP PHYSIOL A, V175, P475; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; TOVEE MJ, 1995, TRENDS ECOL EVOL, V10, P455, DOI 10.1016/S0169-5347(00)89179-X; Vorobyev M, 1998, J COMP PHYSIOL A, V183, P621, DOI 10.1007/s003590050286	16	87	90	10	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					873	874		10.1038/44751	http://dx.doi.org/10.1038/44751			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553902				2022-12-24	WOS:000083464700043
J	Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R				Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R			Inhibition of SNARE complex assembly differentially affects kinetic components of exocytosis	CELL			English	Article							ADRENAL CHROMAFFIN CELLS; MEMBRANE-FUSION; SYNAPTIC EXOCYTOSIS; NEUROTRANSMITTER RELEASE; FLASH-PHOTOLYSIS; CAGED CA2+; SECRETION; SYNTAXIN; VESICLES; PROTEINS	In chromaffin cells, an increase in intracellular Ca2+ leads to an exocytotic burst followed by sustained secretion. The burst can be further resolved into two kinetically distinct components, which suggests the presence of two separate pools of vesicles. To investigate how these components relate to SNARE complex formation, we introduced an antibody that blocks SNARE assembly but not disassembly. In the presence of the antibody, the sustained component was largely blocked, the burst was slightly reduced, and one of its kinetic components was eliminated. We conclude that SNARE complexes form before Ca2+-triggered membrane fusion and exist in a dynamic equilibrium between a loose and a tight state, both of which support exocytosis. Interaction of the antibody with preformed SNARE complexes favors the loose state.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Am Fassberg 2, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Oka, Yoshitaka/C-9670-2010; Neher, Erwin/A-2109-2013; Artalejo, Antonio R./H-4378-2015; Margittai, Martin/D-5039-2014; Artalejo, Antonio R./ABG-2009-2020	Oka, Yoshitaka/0000-0002-3482-3051; Artalejo, Antonio R./0000-0001-9720-9190; Margittai, Martin/0000-0003-1903-5927; Artalejo, Antonio R./0000-0001-9720-9190; Jahn, Reinhard/0000-0003-1542-3498				Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Bruns D, 1997, J NEUROSCI, V17, P1898; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gillis Kevin D., 1995, P155; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Ryan TA, 1998, NAT NEUROSCI, V1, P175, DOI 10.1038/621; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terrian DM, 1997, EUR J CELL BIOL, V73, P198; THEAN ET, 1989, ANAL BIOCHEM, V177, P256, DOI 10.1016/0003-2697(89)90048-1; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293	58	243	254	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					713	722		10.1016/S0092-8674(00)81669-4	http://dx.doi.org/10.1016/S0092-8674(00)81669-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619425	Bronze			2022-12-24	WOS:000084488200005
J	Collins, MW; Lovell, MR; Mckeag, DB				Collins, MW; Lovell, MR; Mckeag, DB			Current issues in managing sports-related concussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Henry Ford Hlth Syst, Div Neuropsychol, Detroit, MI 48202 USA; Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA	Henry Ford Health System; Henry Ford Hospital; Indiana University System; Indiana University-Purdue University Indianapolis	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, 1 Ford Pl 1E, Detroit, MI 48202 USA.	mcollin1@hfhs.org						CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 1999, P MIDW AM COLL SPORT; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, IN PRESS CLIN J SPOR; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCKEAG DB, 1999, P ANN M AM MED SOC S; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1; RICE SG, 1998, HEAD INJURED ATHLETE; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	15	87	89	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2283	2285		10.1001/jama.282.24.2283	http://dx.doi.org/10.1001/jama.282.24.2283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612307				2022-12-24	WOS:000084261700001
J	Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS				Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS			Deflection of the local interstellar dust flow by solar radiation pressure	SCIENCE			English	Article							INTER-STELLAR GRAINS; ULYSSES; GALILEO; PARTICLES; FORCES; SYSTEM; CLOUD; GAS	Interstellar dust grains intercepted by the dust detectors on the Ulysses and Galileo spacecrafts at heliocentric distances from 2 to 4 astronomical units show a deficit of grains with masses from 1 x 10(-17) to 3 x 10(-16) kilograms relative to grains intercepted outside 4 astronomical units. To divert grains out of the 2- to 4-astronomical unit region, the solar radiation pressure must be 1.4 to 1.8 times the force of solar gravity. These figures are consistent with the optical properties of spherical or elongated grains that consist of astronomical silicates or organic refractory material. Pure graphite grains with diameters of 0.2 to 0.4 micrometer experience a solar radiation pressure force as much as twice the force of solar gravity.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; ESA, European Space Operat Ctr, D-64293 Darmstadt, Germany; Royal Inst Technol, Dept Comp Sci & Syst, S-16440 Kista, Sweden; Stockholm Univ, S-16440 Kista, Sweden; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Univ Florida, Dept Astron, Gainesville, FL 32661 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; European Space Agency; Royal Institute of Technology; Stockholm University; Max Planck Society; State University System of Florida; University of Florida	Landgraf, M (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mailcode SN2, Houston, TX 77058 USA.	mlandgra@esoc.esa.de	Gustafson, Bo/B-9526-2011					Baguhl M, 1996, SPACE SCI REV, V78, P165, DOI 10.1007/BF00170803; BAGUHL M, 1995, SCIENCE, V268, P1016, DOI 10.1126/science.268.5213.1016; BEHANNON KW, 1989, J GEOPHYS RES-SPACE, V94, P1245, DOI 10.1029/JA094iA02p01245; BERTAUX JL, 1985, ASTRON ASTROPHYS, V150, P1; BERTAUX JL, 1976, NATURE, V262, P263, DOI 10.1038/262263a0; Bradley JP, 1999, SCIENCE, V285, P1716, DOI 10.1126/science.285.5434.1716; BREITSCHWERDT D, 1998, LECT NOTE PHYS, V506, P381; BROWNLEE DE, 1975, P LUNAR PLANET SCI C, P3409; BURNS JA, 1979, ICARUS, V40, P1, DOI 10.1016/0019-1035(79)90050-2; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; Frisch PC, 1999, ASTROPHYS J, V525, P492, DOI 10.1086/307869; GREENBERG JM, 1995, ASTROPHYS J, V455, pL177, DOI 10.1086/309834; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; Grun E, 1997, ICARUS, V129, P270, DOI 10.1006/icar.1997.5789; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, ASTRON ASTROPHYS SUP, V92, P411; GUSTAFSON BAS, 1994, ANNU REV EARTH PL SC, V22, P553, DOI 10.1146/annurev.ea.22.050194.003005; GUSTAFSON BAS, 1979, NATURE, V282, P276, DOI 10.1038/282276a0; Gustafson BAS, 1996, ASTR SOC P, V104, P35; JONES AP, 1994, ASTROPHYS J, V433, P797, DOI 10.1086/174689; LALLEMENT R, 1992, ASTRON ASTROPHYS, V266, P479; Landgraf M, 1999, PLANET SPACE SCI, V47, P1029, DOI 10.1016/S0032-0633(99)00031-8; LANDGRAF M, 1997, P IAU C, V166; LEVY EH, 1976, NATURE, V264, P423, DOI 10.1038/264423a0; Li AG, 1997, ASTRON ASTROPHYS, V323, P566; MCDONNELL JAM, 1975, SPACE RES, V15, P555; MORFILL GE, 1979, PLANET SPACE SCI, V27, P1283, DOI 10.1016/0032-0633(79)90106-5; MUKAI T, 1992, ASTRON ASTROPHYS, V262, P315; MUKAI T, 1981, ASTRON ASTROPHYS, V99, P1; WELLER CS, 1974, ASTROPHYS J, V193, P471, DOI 10.1086/153182; WITTE M, 1993, ADV SPACE RES-SERIES, V13, P121, DOI 10.1016/0273-1177(93)90401-V; Xu YL, 1999, ASTROPHYS J, V513, P894, DOI 10.1086/306892; Zook HA, 1996, SCIENCE, V274, P1501, DOI 10.1126/science.274.5292.1501; [No title captured]	36	65	66	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2319	2322		10.1126/science.286.5448.2319	http://dx.doi.org/10.1126/science.286.5448.2319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600737				2022-12-24	WOS:000084318500054
J	Watnick, RS; Gottesman, ME				Watnick, RS; Gottesman, ME			Binding of transcription termination protein nun to nascent RNA and template DNA	SCIENCE			English	Article							ESCHERICHIA-COLI; ANTITERMINATION; POLYMERASE	The amino-terminal arginine-rich motif of coliphage HK022 Nun binds phage lambda nascent transcript, whereas the carboxyl-terminal domain interacts with RNA polymerase (RNAP) and blocks transcription elongation. RNA binding is inhibited by zinc (Zn2+) and stimulated by Escherichia coli NusA, To study these interactions. the Nun carboxyl terminus was extended by a cysteine residue conjugated to a photochemical cross-linker. The carboxyl terminus contacted NusA and made Zn2+-dependent intramolecular contacts. When Nun was added to a paused transcription elongation complex, it cross-linked to the DNA template. Nun may arrest transcription by anchoring RNAP to DNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Columbia University; Columbia University	Gottesman, ME (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.							BULLARD JM, 1995, J MOL BIOL, V252, P572, DOI 10.1006/jmbi.1995.0521; Burova E, 1999, MOL MICROBIOL, V31, P1783, DOI 10.1046/j.1365-2958.1999.01315.x; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Hung SC, 1997, GENE DEV, V11, P2670, DOI 10.1101/gad.11.20.2670; HUNG SC, 1995, J MOL BIOL, V247, P428; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; WATNICK R, UNPUB; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546	12	24	24	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2337	2339		10.1126/science.286.5448.2337	http://dx.doi.org/10.1126/science.286.5448.2337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600743				2022-12-24	WOS:000084318500060
J	Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L				Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L			Implication of tubby proteins as transcription factors by structure-based functional analysis	SCIENCE			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; GENE FAMILY; MOLECULAR CHARACTERIZATION; ANOMALOUS DIFFRACTION; RETINAL DEGENERATION; MOUSE; MUTATIONS; TULP1; ACTIVATOR; SUGGESTS	Tubby-like proteins (TULPs) are found in a broad range of multicellular organisms. In mammals, genetic mutation of tubby or other TULPs can result in one dr more of three disease phenotypes: obesity (from which the name "tubby" is derived), retinal degeneration, and hearing loss. These disease phenotypes indicate a vital role for tubby proteins; however, no biochemical function has yet been ascribed to any member of this protein family. A structure-directed approach was employed to investigate the biological function of these proteins. The crystal structure of the core domain from mouse tubby was determined at a resolution of 1.9 angstroms. From primarily structural clues, experiments were devised, the results of which suggest that TULPs are a unique family of bipartite transcription factors.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Shapiro, L (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Berg OG, 1990, BIOL NONSPECIFIC DNA, P71; BRUGER AT, 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; *DNASTAR, 1996, MOL BIOTECHNOL, V5, P185; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goslin K., 1991, CULTURING NERVE CELL, P251; Gu SM, 1998, LANCET, V351, P1103, DOI 10.1016/S0140-6736(05)79384-3; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ikeda S, 1999, INVEST OPHTH VIS SCI, V40, P2706; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kim SH, 1998, NAT STRUCT BIOL, V5, P643, DOI 10.1038/1334; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis CA, 1999, INVEST OPHTH VIS SCI, V40, P2106; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishina PM, 1998, GENOMICS, V54, P215, DOI 10.1006/geno.1998.5567; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; Ohlemiller KK, 1997, AUDIOL NEURO-OTOL, V2, P175, DOI 10.1159/000259242; Ohlemiller KK, 1998, CELL TISSUE RES, V291, P489, DOI 10.1007/s004410051018; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; PORSCH P, 1993, ANAL BIOCHEM, V211, P133; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; Rost B, 1996, METHOD ENZYMOL, V266, P525; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shapiro L, 1998, STRUCTURE, V6, P265, DOI 10.1016/S0969-2126(98)00030-6; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Terwilliger TC, 1998, PROTEIN SCI, V7, P1851, DOI 10.1002/pro.5560070901; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	47	152	168	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2119	2125		10.1126/science.286.5447.2119	http://dx.doi.org/10.1126/science.286.5447.2119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591637				2022-12-24	WOS:000084157300042
J	Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P				Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P			Three-dimensional structures of the TAF(II)-containing complexes TFIID and TFTC	SCIENCE			English	Article							RNA-POLYMERASE-II; ACETYLASE COMPLEX; HISTONE OCTAMER; TRANSCRIPTION; DISTINCT; CORE; TAFS; MICROSCOPY; SIMILARITY; SUBUNITS	TBP (TATA-binding protein)-associated factors (TAF(II)s) are components of Large multiprotein complexes such as TFIID, TFTC, STAGA, PCAF/GCN5, and SAGA, which play a key role in the regulation of gene expression by RNA polymerase II. The structures of TFIID and TFTC have been determined at 3.5-nanometer resolution by electron microscopy and digital image analysis of single particles. Human TFIID resembles a macromolecular clamp that contains four globular domains organized around a solvent-accessible groove of a size suitable to bind DNA. TFTC is Larger and contains five domains, four of which are similar to TFIID.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schultz, P (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Boite Postale 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; schultz, patrick/0000-0002-7310-6186				Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; GANGLOFF YG, IN PRESS MOL CELL BI; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	31	102	106	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2151	2153		10.1126/science.286.5447.2151	http://dx.doi.org/10.1126/science.286.5447.2151			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591645				2022-12-24	WOS:000084157300050
J	Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF				Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF			Mouse tumor model for neurofibromatosis type 1	SCIENCE			English	Article							MICE DEFICIENT; NEURAL CREST; COLORECTAL-CANCER; GENE; RAS; P53; MUTATION; CELL; NF1; GAP	Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by increased incidence of benign and malignant tumors of neural crest origin. Mutations that activate the protooncogene ras, such as Loss of Nf1, cooperate with inactivating mutations at the p53 tumor suppressor gene during malignant transformation, One hundred percent of mice harboring null Nf1 and p53 alleles in cis synergize to develop soft tissue sarcomas between 3 and 7 months of age. These sarcomas exhibit Loss of heterozygosity at both gene loci and express phenotypic traits characteristic of neural crest derivatives and human NF1 malignancies.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.	parada@utsw.swmed.edu	Parada, luis F/B-9400-2014	Klesse, Laura/0000-0003-1323-7720	NINDS NIH HHS [NS34296, R01 NS034296-04, R01 NS034296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Bernardis V, 1999, DIGESTION, V60, P82, DOI 10.1159/000007594; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Halling KC, 1996, AM J CLIN PATHOL, V106, P282; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ISHIZAKI Y, 1992, SURGERY, V111, P706; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JHANWAR SC, 1994, CANCER GENET CYTOGEN, V78, P138, DOI 10.1016/0165-4608(94)90081-7; Kamijo T, 1999, CANCER RES, V59, P2217; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Orlow I, 1999, INT J ONCOL, V15, P17; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; RICCARDI VM, 1994, AM J PATHOL, V145, P994; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TANAKA M, 1994, J SURG ONCOL, V57, P57, DOI 10.1002/jso.2930570115; Vogel KS, 1998, MOL CELL NEUROSCI, V11, P19, DOI 10.1006/mcne.1998.0670; VOGEL KS, UNPUB; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	40	260	264	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2176	2179		10.1126/science.286.5447.2176	http://dx.doi.org/10.1126/science.286.5447.2176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591653	Green Accepted			2022-12-24	WOS:000084157300058
J	Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P				Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P			Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; CAMP-REGULATED PHOSPHOPROTEIN; PROTEIN-KINASE; INHIBITOR; SCAFFOLD; SUBUNIT; POTENT	The physiological state of the cell is controlled by signal transduction mechanisms which regulate the balance between protein kinase and protein phosphatase activities(1). Here we report that a single protein can, depending on which particular amino-acid residue is phosphorylated, function either as a kinase or phosphatase inhibitor. DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34 (refs 2, 3), We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5), Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells. Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Kurume Univ, Sch Med, Dept Physiol, Fukuoka 8300011, Japan; CNRS, Biol Stn, F-29682 Roscoff, France; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Coll France, INSERM, U114, F-75231 Paris 05, France; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Rockefeller University; Kurume University; Centre National de la Recherche Scientifique (CNRS); Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Howard Hughes Medical Institute; Johns Hopkins University; Cornell University; Cornell University	Greengard, P (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Nairn, Angus/0000-0002-7075-0195; , laurent/0000-0003-3511-4916	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CAPORASO G, IN PRESS NEUROPHARMA; Czernik A. J., 1997, REGULATORY PROTEIN M, V30, P219; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1989, J BIOL CHEM, V264, P7726; HORIUCHI A, 1990, J BIOL CHEM, V265, P9476; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; NICOLA SM, IN PRESS ANN REV NEU; Nishi A, 1997, J NEUROSCI, V17, P8147; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	23	460	481	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					669	671		10.1038/45251	http://dx.doi.org/10.1038/45251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604473				2022-12-24	WOS:000084189800067
J	Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G				Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G			Use of chemokine receptors by poxviruses	SCIENCE			English	Article							VACCINIA VIRUS-INFECTION; CC-CHEMOKINE; HIV-1 CORECEPTOR; T1/35KDA FAMILY; GROWTH-FACTOR; A27L PROTEIN; ANIMAL-CELLS; MYXOMA VIRUS; RESISTANCE; ALLELE	Chemokine receptors serve as portals of entry for certain intracellular pathogens, most notably human immunodeficiency virus (HIV). Myxoma virus is a member of the poxvirus family that induces a Lethal systemic disease in rabbits, but no poxvirus receptor has ever been defined. Rodent fibroblasts (3T3) that cannot be infected with myxoma virus could be made fully permissive for myxoma virus infection by expression of any one of several human chemokine receptors, including CCR1, CCR5, and CXCR4. Conversely, infection of 3T3-CCR5; cells can be inhibited by RANTES, anti-CCR5 polyclonal antibody, or herbimycin A but not by monoclonal antibodies that block HIV-1 infection or by pertussis toxin. These findings suggest that poxviruses, Like HIV, are able to use chemokine receptors to infect specific cell subtypes, notably migratory Leukocytes, but that their mechanisms of receptor interactions are distinct.	Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Immunol, London, ON N6G 2V4, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; New York University	McFadden, G (corresponding author), Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada.	mcfadden@rri.on.ca	Everett, Helen E/D-7123-2011	Everett, Helen/0000-0002-1233-4265				Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; CHANG W, 1995, J VIROL, V69, P517, DOI 10.1128/JVI.69.1.517-522.1995; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1990, J VIROL, V64, P4884, DOI 10.1128/JVI.64.10.4884-4892.1990; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; Fenner F., 1965, MYXOMATOSIS; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; GRIST NR, 1988, J INFECTION, V16, P117, DOI 10.1016/S0163-4453(88)93822-4; Hollinshead M, 1999, J VIROL, V73, P1503, DOI 10.1128/JVI.73.2.1503-1517.1999; Holmes Kathryn V., 1997, P35; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JANECZKO RA, 1987, ARCH VIROL, V92, P135, DOI 10.1007/BF01310068; Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lalani AS, 1997, J LEUKOCYTE BIOL, V62, P570, DOI 10.1002/jlb.62.5.570; LALANI AS, UNPUB; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MOSS B, 1996, REPLICATION POXVIRUS, P2637; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Smith GL, 1998, ADV EXP MED BIOL, V440, P395; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Trkola A, 1999, J VIROL, V73, P6370, DOI 10.1128/JVI.73.8.6370-6379.1999; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Vanderplasschen A, 1997, J VIROL, V71, P4032, DOI 10.1128/JVI.71.5.4032-4041.1997; Vanderplasschen A, 1998, J GEN VIROL, V79, P877, DOI 10.1099/0022-1317-79-4-877; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	50	124	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1968	1971		10.1126/science.286.5446.1968	http://dx.doi.org/10.1126/science.286.5446.1968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583963				2022-12-24	WOS:000084003400056
J	Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ				Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ			Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt	SCIENCE			English	Article							PROTEIN-KINASE CASCADE; PHOSPHATIDYLINOSITOL 3-KINASE; EXPRESSION; ACTIVATION; RECEPTOR; MYOGENESIS; TARGET; CELLS	Extracellular signals often result in simultaneous activation of both the Raf-MEK-ERK and PI3K-Akt pathways (where ERK is extracellular-regulated kinase, MEK is mitogen-activated protein kinase or ERK kinase, and PI3K is phosphatidylinositol 3-kinase). However, these two signaling pathways were shown to exert opposing effects on muscle cell hypertrophy. Furthermore, the PI3K-Akt pathway was shown to inhibit the Raf-MEK-ERK pathway: this cross-regulation depended on the differentiation state of the cell: Akt activation inhibited the Raf-MEK-ERK pathway in differentiated myotubes, but not in their myoblast precursors. The stage-specific inhibitory action of Akt correlated with its stage-specific ability to form a complex with Raf, suggesting the existence of differentially expressed mediators of an inhibitory Akt-Raf complex.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Regeneron; University of Zurich	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	31	652	677	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1738	1741		10.1126/science.286.5445.1738	http://dx.doi.org/10.1126/science.286.5445.1738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576741				2022-12-24	WOS:000083912200039
J	Holgate, ST				Holgate, ST			The epidemic of allergy and asthma	NATURE			English	Editorial Material								Allergic diseases, such as asthma, rhinitis, eczema and food allergies, are reaching epidemic proportions in both the developed and developing world. Key factors driving these rising trends are increased exposure to sensitizing allergens and reduced stimulation of the immune system during critical periods of development. In allergic disease, there is a polarization of T-lymphocyte responses, and enhanced secretion of cytokines involved in regulation of immunoglobulin E, mast cells, basophils and eosinophils, ultimately leading to inflammation and disease. A clear understanding of the cellular and molecular mechanisms of allergic disease and the complex interplay between genetic and environmental factors will undoubtedly create new opportunities for public health and therapeutic interventions.	Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Mail Point 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COHEN SG, 1992, CLASSICS ALLERGY; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies DE, 1999, ALLERGY, V54, P771; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; EVANS MJ, IN PRESS AM J RESP C; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOLGATE ST, 1998, 30 YEARS IGE, P91; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Lee SC, 1999, J IMMUNOL, V162, P6867; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; O'Byrne PM, 1999, CLIN EXP ALLERGY, V29, P27, DOI 10.1046/j.1365-2222.1999.00005.x-i2; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1111/j.1365-2222.1997.tb00667.x; Schulz O, 1999, CLIN EXP ALLERGY, V29, P439, DOI 10.1046/j.1365-2222.1999.00464.x; WALLS AF, IN PRESS ASTHMA RHIN; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	23	455	478	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B2	B4		10.1038/35037000	http://dx.doi.org/10.1038/35037000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586888				2022-12-24	WOS:000083913900002
J	Lima, CD; Wang, LK; Shuman, S				Lima, CD; Wang, LK; Shuman, S			Structure and mechanism of yeast RNA triphosphatase: An essential component of the mRNA capping apparatus	CELL			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; ENZYME BINDS; DNA-LIGASE; PROTEIN	RNA triphosphatase is an essential mRNA processing enzyme that catalyzes the first step in cap formation. The 2.05 Angstrom crystal structure of yeast RNA triphosphatase Cet1p reveals a novel active site fold whereby an eight-stranded beta barrel forms a topologically closed triphosphate tunnel. Interactions of a sulfate in the center of the tunnel with a divalent cation and basic amino acids projecting into the tunnel suggest a catalytic mechanism that is supported by mutational data. Discrete surface domains mediate Cet1p homodimerization and Cet1p binding to the guanylyltransferase component of the capping apparatus. The structure and mechanism of fungal RNA triphosphatases are completely different from those of mammalian mRNA capping enzymes. Hence, RNA triphosphatase presents an ideal target for structure-based antifungal drug discovery.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Lima, Christopher/0000-0002-9163-6092				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HO CK, 1999, IN PRESS NUCL ACIDS; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	42	108	109	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					533	543		10.1016/S0092-8674(00)81541-X	http://dx.doi.org/10.1016/S0092-8674(00)81541-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589681	Bronze			2022-12-24	WOS:000083986300012
J	Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD				Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD			Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis	LANCET			English	Article							DYNAMICS IN-VIVO; ACQUIRED IMMUNODEFICIENCY SYNDROME; INTERFERON-ALPHA; MONKEY MODEL; TURNOVER; INFECTION; THERAPY; TYPE-1; SYSTEM	Background In chronic HIV-1 infection, dynamic equilibrium exists between viral production and clearance. The half-life of free virions can be estimated by inhibiting virion production with antiretroviral agents and modelling the resulting decline in plasma HIV-1 RNA. To define HIV-1 and hepatitis C virus (HCV) dynamics, we used plasma apheresis to increase virion clearance temporarily while leaving Virion production unaffected. Methods Plasma virus loads were measured frequently before, during, and after apheresis in four HIV-1-infected patients, two of whom were also co-infected with HCV. Rates of virion clearance were derived by non-linear least-square fitting of plasma virus load to a model of Viral dynamics. Findings Virion clearance rate constants were 0.0063/min (9.1/day) to 0.025/min (36.0/day; half-life 28-110 min) for HIV-1 and 0.0038/min (5.5/day) to 0.0069/min (9.9/day; half-life 100-182 min) for HCV. These values provided estimates of daily particle production of 9.3 log(10)-10.2 log(10) particles for HIV-1 and 11.6 log(10)-13.0 log(10) particles for HCV. Interpretation Our findings confirm that HIV-1 and HCV are produced and cleared extremely rapidly. New estimates for HIV-1 clearance are up to ten times higher than previous ones, whereas HCV clearance is similar to previous estimates.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; ETH Zentrum NW, Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Los Alamos Natl Lab, Los Alamos, NM USA	Rockefeller University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Friedrich Miescher Institute for Biomedical Research; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@ADARC.org	Perelson, Alan S/Z-1959-2019; Bonhoeffer, Sebastian/A-2735-2008	Perelson, Alan S/0000-0002-2455-0002; Bonhoeffer, Sebastian/0000-0001-8052-3925	NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [AI40387, AI41534] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534, R01AI040387] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagnarelli P, 1997, J INFECT DIS, V176, P801, DOI 10.1086/517306; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BENDER BS, 1988, REV INFECT DIS, V10, P1142; BENDER BS, 1987, J CLIN INVEST, V79, P715, DOI 10.1172/JCI112876; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Mittler JE, 1999, AIDS, V13, P1415, DOI 10.1097/00002030-199907300-00023; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Taylor RP, 1997, J IMMUNOL, V158, P842; Taylor RP, 1997, CLIN IMMUNOL IMMUNOP, V82, P49, DOI 10.1006/clin.1996.4286; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zeuzem S, 1998, HEPATOLOGY, V28, P245, DOI 10.1002/hep.510280132; Zeuzem S, 1996, HEPATOLOGY, V23, P366; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999	20	375	377	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1782	1785		10.1016/S0140-6736(99)02035-8	http://dx.doi.org/10.1016/S0140-6736(99)02035-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577640				2022-12-24	WOS:000083853000013
J	Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI				Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI			Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa	SCIENCE			English	Article							LIPID-A; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; REGULATED GENES; PHOP-PHOQ; RESISTANCE; QUADRUPOLE; VIRULENCE; PEPTIDES; MUTANT	Cystic fibrosis (CF) patients develop chronic airway infections with Pseudomonas aeruginosa (PA), Pseudomonas aeruginosa synthesized lipopolysaccharide (LPS) with a variety of penta- and hexa-acylated lipid A structures under different environmental conditions. CF patient PA synthesized LPS with specific Lipid A structures indicating unique recognition of the CF airway environment. CF-specific Lipid A forms containing palmitate and aminoarabinose were associated with resistance to cationic antimicrobial peptides and increased inflammatory responses, indicating that they are likely to be involved in airway disease.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, SI (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	millersi@u.washingtan.edu		Ernst, Robert/0000-0001-5016-8694	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL048888] Funding Source: NIH RePORTER; NHLBI NIH HHS [R55 HL 48888] Funding Source: Medline; PHS HHS [R21 R13400] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM SOC MASS SPECT, 1998, P 46 ASMS C MASS SPE; [Anonymous], 1997, NIH Consens Statement, V15, P1; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELL A, 1989, J BACTERIOL, V171, P3211, DOI 10.1128/jb.171.6.3211-3217.1989; BHAT R, 1990, J BACTERIOL, V172, P6631, DOI 10.1128/jb.172.12.6631-6636.1990; BIER ME, 1997, ELECTROSPRAY IONIZAT, P235; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; DARVEAU RP, 1995, INFECT IMMUN, V63, P1311, DOI 10.1128/IAI.63.4.1311-1317.1995; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; ERNST RK, UNPUB; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Gunn JS, 1996, J BACTERIOL, V178, P6369, DOI 10.1128/jb.178.21.6369-6373.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; KARUNARATNE DN, 1992, ARCH BIOCHEM BIOPHYS, V299, P368, DOI 10.1016/0003-9861(92)90289-9; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Wong P.S., 1997, CURRENT SEPARATIONS, V16, P85; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; Yi E., UNPUB; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	34	387	399	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1561	1565		10.1126/science.286.5444.1561	http://dx.doi.org/10.1126/science.286.5444.1561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567263				2022-12-24	WOS:000083768300059
J	Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A				Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A		Multistate Evaluation Surveillance	Name-based surveillance and public health interventions for persons with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							PARTNER NOTIFICATION; EPIDEMIC	Name-based surveillance of HIV infection is the law in 31 U.S. states but remains controversial, This policy can be advocated solely to support surveillance of the epidemic, but a frequent argument is that it also provides a public health benefit by allowing follow-up of HIV-infected persons. These persons can then receive timely medical care and can be assisted with notifying sex and needle-sharing partners. Few comparative data are available to evaluate the outcomes of these interventions, In five states with name-based surveillance of HIV infection, the Multistate Evaluation of Surveillance for HIV Study Group surveyed a cross-sectional probability sample of persons with AIDS who tested positive for HIV before the date of their AIDS diagnosis, Health department follow-up of a reported HIV infection was not associated with more timely receipt of medical care after a positive HIV test result. Only 8.6% of persons who delayed medical care after their first positive HIV test result gave concern about being reported by name as a reason; no person gave it as the main reason. Persons who were tested anonymously and those who were tested confidentially did not differ in the mean number of sex and needle-sharing partners notified: Those tested anonymously reported personally notifying 3.85 sex and needle-sharing partners, and those tested confidentially reported notifying-personally and through the health department-3.80 partners. Many researchers and policymakers believe that name-based surveillance of HIV infection will have positive or negative effects on partner notification and access to health care, These results suggest that the potential for such effects has been exaggerated.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Osmond, DH (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Box 0866, San Francisco, CA 94143 USA.	dosmond@psg.ucsf.edu		Hecht, Frederick/0000-0002-5782-1171				ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Colfax GN, 1998, AM J PUBLIC HEALTH, V88, P876, DOI 10.2105/AJPH.88.6.876; *COUNC STAT TERR E, 1997, POSITION STATEMENT N; Cowan FM, 1996, GENITOURIN MED, V72, P247; FIUMARAN, 1957, NEW ENGL J MED, V256, P982; FRANCIS DP, 1993, J ACQ IMMUN DEF SYND, V6, P285; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; OXMAN AD, 1994, CAN J PUBLIC HEALTH, V85, pS41; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; POTTERAT JJ, 1977, AM J PUBLIC HEALTH, V67, P174, DOI 10.2105/AJPH.67.2.174; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1998, MMWR MORB MORTAL WKL, V47, P1086; 1992, MMWR MORB MORTAL WKL, V41, P247; 1998, MMWR MORB MORTAL WKL, V47, P309; 1998, MMWR MORB MORTAL WKL, V46, P1254	21	37	38	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					775	779		10.7326/0003-4819-131-10-199911160-00010	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255QC	10577302				2022-12-24	WOS:000083680100009
J	Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK				Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK			Tomographic 3D reconstruction of quick-frozen, Ca2+-activated contracting insect flight muscle	CELL			English	Article							RABBIT SKELETAL-MUSCLE; MYOSIN HEADS; CROSS-BRIDGES; LIGHT-CHAIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; FORCE GENERATION; FISH MUSCLE; ADP RELEASE; ACTIN	Motor actions of myosin were directly visualized by electron tomography of insect flight muscle quick-frozen during contraction. In 3D images, active crossbridges are usually single myosin heads, bound preferentially to actin target zones sited midway between troponins. Active attached bridges (similar to 30% of all heads) depart markedly in axial and azimuthal angles from Rayment's rigor acto-S1 model, one-third requiring motor domain (MD) tilting on actin, and two-thirds keeping rigor contact with actin while the light chain domain (LCD) tilts axially from similar to 105 degrees to similar to 70 degrees. The results suggest the MD tilts and slews on actin from weak to strong binding, followed by swinging of the LCD through an similar to 35 degrees axial angle, giving an similar to 13 nm interaction distance and an similar to 4-6 nm working stroke.	Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Max Planck Inst Med Forsch, Biophys Abt, D-69120 Heidelberg, Germany	State University System of Florida; Florida State University; University of Pennsylvania; MRC Laboratory Molecular Biology; Duke University; Max Planck Society	Taylor, KA (corresponding author), Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.			Edwards, Robert/0000-0003-4446-1194; Sasaki, Hiroyuki/0000-0002-5358-5853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR014317] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR014317] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adhikari B, 1997, P NATL ACAD SCI USA, V94, P9643, DOI 10.1073/pnas.94.18.9643; Bershitsky SY, 1997, NATURE, V388, P186, DOI 10.1038/40651; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Frank J, 1992, ELECT TOMOGRAPHY; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HEINRICH B, 1996, HTERMAL WARRIORS STR, P127; HIROSE K, 1993, J MUSCLE RES CELL M, V14, P432, DOI 10.1007/BF00121295; HIROSE K, 1994, J CELL BIOL, V127, P763, DOI 10.1083/jcb.127.3.763; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1996, CURR OPIN STRUC BIOL, V6, P781, DOI 10.1016/S0959-440X(96)80008-X; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Lenart TD, 1996, BIOPHYS J, V71, P2289, DOI 10.1016/S0006-3495(96)79464-X; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MORRIS EP, 1991, J STRUCT BIOL, V107, P237, DOI 10.1016/1047-8477(91)90049-3; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; REEDY MK, 1985, J MOL BIOL, V185, P145, DOI 10.1016/0022-2836(85)90188-3; REEDY MK, 1968, J MOL BIOL, V31, P155, DOI 10.1016/0022-2836(68)90437-3; REEDY MK, 1993, ADV EXP MED BIOL, V332, P33; Schmitz H, 1996, J MOL BIOL, V264, P279, DOI 10.1006/jmbi.1996.0641; Schmitz H, 1997, J CELL BIOL, V139, P695, DOI 10.1083/jcb.139.3.695; Taylor KA, 1997, J STRUCT BIOL, V120, P372, DOI 10.1006/jsbi.1997.3932; Tregear RT, 1998, BIOPHYS J, V74, P1439, DOI 10.1016/S0006-3495(98)77856-7; Tsaturyan AK, 1999, BIOPHYS J, V77, P354, DOI 10.1016/S0006-3495(99)76895-5; VARRIANOMARSTON E, 1984, J MUSCLE RES CELL M, V5, P363, DOI 10.1007/BF00818256; Walker M, 1999, P NATL ACAD SCI USA, V96, P465, DOI 10.1073/pnas.96.2.465; Wendt T, 1997, J STRUCT BIOL, V118, P1, DOI 10.1006/jsbi.1996.3834; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Winkler H, 1996, J MOL BIOL, V264, P302, DOI 10.1006/jmbi.1996.0642; Winkler H, 1996, ULTRAMICROSCOPY, V63, P125, DOI 10.1016/0304-3991(96)00024-1; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g	49	134	137	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					421	431		10.1016/S0092-8674(00)81528-7	http://dx.doi.org/10.1016/S0092-8674(00)81528-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571184	Bronze			2022-12-24	WOS:000083709300009
J	Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M				Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M			Lung transplantation and life extension in children with cystic fibrosis	LANCET			English	Article							HEART; SURVIVAL	Background Lung transplantation has been available as therapy for end-stage lung disease since the early 1980s, but survival after transplantation remains poor, with continued controversy as to the survival benefit from the procedure. We examined the effect of lung or heart-lung transplantation on the survival of a cohort of children with cystic fibrosis and severe lung disease. Methods Between May, 1988, and May, 1998, 124 children with cystic fibrosis were accepted for lung transplantation. 47 received transplants, 68 died while they awaited organs, and nine remained on the active waiting list. We constructed a proportional-hazards model that used variables of prognostic significance in this population. By including transplant status as a time-dependent covariate, we were able to calculate a hazard ratio for transplantation. Date of entry into the study was the dale when children were added to the list for transplantation, and measurements were taken at this time. Children were accepted for transplantation if they had a life expectancy of 2 years or less, a poor quality of life, and no contraindications to transplantation. Findings After 1 year, 35 (74%) children were still alive; after 5 years 12 (33%) children were alive. The univariate hazard ratio for transplantation was 0.41 (95% CI 0.23-0.74; p=0.003). Transplantation remained significantly associated with survival after correction for differences in age, sex, height-corrected forced expiratory volume in 1 s, minimum oxygen saturation during a 12 min walk, haemoglobin concentration, albumin concentration, and age-corrected resting heart rate (hazard ratio 0.31 [0.13-0.72]; p=0.007). Interpretation If centres follow our criteria for accepting patients for transplantation, and achieve similar survival after transplantation, they could expect a survival benefit for their patients in line with our results.	Great Ormond St Hosp Children NHS Trust, Cardioresp & Crit Care Directorate, London WC1N 3JH, England; Greenwich Hosp, Inst Child Hlth, London, England; Greenwich Hosp, Dept Paediat, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Aurora, P (corresponding author), Great Ormond St Hosp Children, Resp Unit, Cardiac Wing, Level 6, London WC1N 3JH, England.		Elliott, Martin J/E-9229-2010	Elliott, Martin J/0000-0002-3913-9099				Cox D. R., 1984, ANAL SURVIVAL DATA; Geertsma A, 1998, J HEART LUNG TRANSPL, V17, P511; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; Mankad Pankaj S., 1997, P167; Milla CE, 1998, CHEST, V113, P1230, DOI 10.1378/chest.113.5.1230; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; SHARPLES L, 1993, J HEART LUNG TRANSPL, V12, P669; TURNBULL BW, 1974, J AM STAT ASSOC, V69, P74, DOI 10.2307/2285502; WHITEHEAD BF, 1995, EUR J CARDIO-THORAC, V9, P1, DOI 10.1016/S1010-7940(05)80040-5	12	74	75	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1591	1593		10.1016/S0140-6736(99)03031-7	http://dx.doi.org/10.1016/S0140-6736(99)03031-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560673				2022-12-24	WOS:000083551000010
J	Tan, Y; Li, WH				Tan, Y; Li, WH			Vision - Trichromatic vision in prosimians	NATURE			English	Article							COLOR-VISION; BUSH-BABY; PIGMENTS; PHOTOPIGMENTS; MONKEY; GENE; RED		Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Tan, Y (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.			Li, Wen-Hsiung/0000-0003-1086-1456				ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Casagrande Vivien A., 1994, Cerebral Cortex, V10, P201; Deegan JF, 1996, AM J PRIMATOL, V40, P55, DOI 10.1002/(SICI)1098-2345(1996)40:1<55::AID-AJP4>3.0.CO;2-#; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; JACOBS GH, 1993, AM J PRIMATOL, V30, P243, DOI 10.1002/ajp.1350300307; Jacobs GH, 1996, NATURE, V382, P156, DOI 10.1038/382156a0; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Shyue SK, 1998, J MOL EVOL, V46, P697, DOI 10.1007/PL00006350; TRAVIS DS, 1988, VISION RES, V28, P481, DOI 10.1016/0042-6989(88)90170-8; Yamada ES, 1998, VISION RES, V38, P3345, DOI 10.1016/S0042-6989(97)00412-4; Zhou YH, 1997, J MOL EVOL, V45, P610, DOI 10.1007/PL00006265	13	130	130	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					36	36		10.1038/46947	http://dx.doi.org/10.1038/46947			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573416	Bronze			2022-12-24	WOS:000083638600033
J	Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H				Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H			Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer?	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, squamous cell; lymphoma, non-Hodgkin; colonic neoplasms; prostatic neoplasms; lung neoplasms; breast neoplasms	CYTOKINE DYSREGULATION; CARCINOMA; RISK; LYMPHOMA	Background: Nonmelanoma skin cancer is associated with increased occurrence of subsequent cancer and death from cancer, but it is not known whether a history of skin cancer is associated with poor prognosis after a second diagnosis of cancer. Objective: To determine whether history of squamous-cell skin cancer is a marker of poor prognosis in patients with cancer. Design: Population-based cohort study. Setting: Sweden, 1958 to 1996. Patients: All patients in the Swedish Cancer Registry with or without a first diagnosis of squamous-cell skin cancer and a subsequent or first diagnosis of non-Hodgkin lymphoma (including chronic lymphocytic leukemia) or cancer of the colon, breast, prostate, or lung. Measurements: Relative risk (RR) for death determined by using Cox proportional hazards regression analysis. Results: Patients with a history of squamous-cell skin cancer had a significantly greater risk for death than those with no such history after receiving a diagnosis of non-Hodgkin lymphoma (RR, 1.33). colon cancer (RR, 1.24), breast cancer (RR, 1.19), or prostate cancer (RR, 1.17). Patients with lung cancer and a history of squamous-cell skin cancer who survived for 1 year after diagnosis of lung cancer also had an increased risk for death (RR, 1.29). Conclusion: Patients with a registered history of squamous-cell skin cancer have a poor prognosis after diagnosis of subsequent cancer and warrant careful medical attention.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; State Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Harvard Sch Publ Hlth, Boston, MA USA; NCI, Viral Epidemiol Branch, Rockville, MD 20852 USA; Univ Uppsala Hosp, Uppsala, Sweden	Karolinska Institutet; Statens Serum Institut; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Askling, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	Johan.Askling@mep.ki.se	Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Sorensen, Per Soelberg/0000-0002-2818-3780				Adami HO, 1996, INT J CANCER, V67, P764, DOI 10.1002/(SICI)1097-0215(19960917)67:6<764::AID-IJC3>3.0.CO;2-P; ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; [Anonymous], 1996, ACTA ONCOL, V35, P47; Au WW, 1996, ENVIRON HEALTH PERSP, V104, P579, DOI 10.2307/3432826; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CLAYTON D, 1993, STAT METHODS EPIDEMI; Clerici M, 1998, J NATL CANCER I, V90, P261, DOI 10.1093/jnci/90.4.261; Dreyer L, 1997, APMIS, V105, P9; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; HARRIS NL, 1994, BLOOD, V84, P1361; HJALGRIM H, IN PRESS INT J CANC; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KINLEN LJ, 1992, IARC SCI PUBL, V116, P237; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; Levi F, 1997, AM J EPIDEMIOL, V146, P734; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Lunde A S, 1980, Vital Health Stat 2, P1; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; STENBECK M, 1995, ACTA ONCOL, V34, P881, DOI 10.3109/02841869509127200; Teppo L, 1999, ACTA ONCOL, V38, P283; TEPPO L, 1985, J NATL CANCER I, V75, P207; Wassberg C, 1999, INT J CANCER, V80, P511, DOI 10.1002/(SICI)1097-0215(19990209)80:4<511::AID-IJC5>3.3.CO;2-G; WEI QY, 1994, CANCER RES, V54, P437	26	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					655	+		10.7326/0003-4819-131-9-199911020-00004	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577327				2022-12-24	WOS:000083446200003
J	Walker, AJ; Cross, SS; Harrison, RF				Walker, AJ; Cross, SS; Harrison, RF			Visualisation of biomedical datasets by use of growing cell structure networks: a novel diagnostic classification technique	LANCET			English	Article								Background Medical research produces large multivariable datasets that are difficult to visualise and interpret intuitively. We describe a novel growing cell structure (GCS) technique that compresses multidimensional datasets into two dimensional maps with colour overlays that can be visually interpreted. Methods The two-dimensional map is self-discovered from the training set by distribution of cases to different nodes according to similarity between the cases at each node. Nodes are added to the map until there is no further significant reduction in error. The Parzen window method is used to estimate the probability distribution of the training cases, and this probability is converted to posterior class probabilities by use of Bayes' theorem. Classification performance can be assessed by means of receiver operating characteristic (ROC) curves. Colour maps of the Values of each input variable at each node are constructed, which illustrate the relation between each input variable and the overall distribution of cases in the network map. Findings From a dataset of 11 input variables from 692 fine-needle aspirate samples from breast lesions, a 32-node network produced an area under the ROC curve of 0.96, which was not significantly different from that for logistic regression (0.98, z=1.09, p>0.05). Colour maps of the input variables showed that some variables had discrete distributions over exclusively benign or malignant areas of the network, and were thus discriminant, whereas others, such as foamy macrophages, covered both benign and malignant regions. Interpretation This technique produces dimensional compression that allows multidimensional data to be displayed as two-dimensional colour images. This envisioning of information allows the highly developed visuospatial abilities of human observers to perceive subtle inter-relations in the dataset.	Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Sch Med, Dept Automat Control & Syst Engn, Sheffield, S Yorkshire, England; Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA	University of Sheffield; University of Sheffield; Princeton University	Cross, SS (corresponding author), Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England.	s.s.cross@sheffield.ac.uk	Harrison, Robert/B-9034-2008	Harrison, Robert/0000-0002-9323-8637; Cross, Simon/0000-0003-2044-1754				CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; FRITZKE B, 1994, NEURAL NETWORKS, V7, P1441, DOI 10.1016/0893-6080(94)90091-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hjalmarson A, 1999, LANCET, V353, P2001; KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288; PARZEN E, 1962, ANN MATH STAT, V33, P1065, DOI 10.1214/aoms/1177704472; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; WELLS CA, 1994, CYTOPATHOLOGY, V5, P316, DOI 10.1111/j.1365-2303.1994.tb00437.x; [No title captured]; [No title captured]; [No title captured]	12	31	32	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1518	1521		10.1016/S0140-6736(99)02186-8	http://dx.doi.org/10.1016/S0140-6736(99)02186-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551499				2022-12-24	WOS:000083411300013
J	Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J				Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J			Influence of environmental changes on degradation of chiral pollutants in soils	NATURE			English	Article							ENANTIOSELECTIVE DEGRADATION; HERBICIDE	Numerous anthropogenic chemicals of environmental concern-including some phenoxy acid herbicides, organophosphorus insecticides, polychlorinated biphenyls, phthalates, freon substitutes and some DDT derivatives-are chiral. Their potential biological effects, such as toxicity, mutagenicity, carcinogenicity, and endocrine disrupter activity, are generally enantiomer-selective, and different enantiomers are preferentially degraded (transformed) by micro-organisms in various environments(1-8). Here we use field and laboratory experiments to demonstrate that environmental changes in soils can alter these preferences, and to suggest that the preferences shift owing to different groups of related microbial genotypes being activated by different environmental changes. In Brazilian soils, almost all pasture samples preferentially transformed the non-herbicidal enantiomer of dichlorprop ((RS)-2-(2,4-dichlorophenoxy)propionic acid), while most forest samples either transformed the herbicidal enantiomer more readily or as rapidly as the non-herbicidal enantiomer. Organic nutrient enrichments shifted enantioselectivity for methyl dichlorprop ((RS)-methyl 2-(2,4-dichlorophenoxy)propionic acid) strongly towards preferentially removing the non-herbicidal enantiomer in soils from Brazil and North America, potentially increasing phytotoxicity of its residues relative to that of the racemate. Assessments of the risks chemical pollutants pose to public health and the environment need to take into account the chiral selectivity of microbial transformation processes and their alteration by environmental changes, especially for pesticides as up to 25 per cent are chiral(9).	US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA; Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02542 USA	United States Environmental Protection Agency; University System of Georgia; University of Georgia; Marine Biological Laboratory - Woods Hole	Lewis, DL (corresponding author), US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA.			Lewis, David/0000-0003-0777-2460				Aigner EJ, 1998, ENVIRON SCI TECHNOL, V32, P1162, DOI 10.1021/es970750h; AKKERMANS ADL, 1995, MOL MICROBIAL ECOLOG, P1; BUSER HP, 1997, CHIRAL SEPARATIONS, pCH5; FALCONER RL, 1995, ENVIRON SCI TECHNOL, V29, P1297, DOI 10.1021/es00005a023; Fulthorpe RR, 1998, APPL ENVIRON MICROB, V64, P1620; Garrison AW, 1996, ENVIRON SCI TECHNOL, V30, P2449, DOI 10.1021/es950552v; HOLLIBAUGH JT, 1979, ESTUAR COAST MAR SCI, V9, P215, DOI 10.1016/0302-3524(79)90116-6; JANTUNEN LM, 1996, GEOPHYS RES, V108, P28837; Kohler HPE, 1997, CHIMIA, V51, P947; Lewis DL, 1996, NATURE, V381, P731, DOI 10.1038/381731a0; Lukewille A, 1997, GLOB CHANGE BIOL, V3, P13, DOI 10.1046/j.1365-2486.1997.00088.x; MOYER CL, 1994, APPL ENVIRON MICROB, V60, P871, DOI 10.1128/AEM.60.3.871-879.1994; MULLER MD, 1995, ENVIRON SCI TECHNOL, V29, P2031, DOI 10.1021/es00008a023; PETERJOHN WT, 1994, ECOL APPL, V4, P617, DOI 10.2307/1941962; TETT VA, 1994, FEMS MICROBIOL ECOL, V14, P191, DOI 10.1111/j.1574-6941.1994.tb00105.x; Wiberg K, 1998, ANAL CHEM, V70, P3845, DOI 10.1021/ac980064g; Williams A, 1996, PESTIC SCI, V46, P3, DOI 10.1002/(SICI)1096-9063(199601)46:1&lt;3::AID-PS337&gt;3.0.CO;2-J; Zipper C, 1998, ENVIRON SCI TECHNOL, V32, P2070, DOI 10.1021/es970880q; 1998, CHEM ENG NEWS, V76, P83	19	331	361	8	218	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					898	901		10.1038/44801	http://dx.doi.org/10.1038/44801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553905				2022-12-24	WOS:000083464700053
J	Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H				Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H			Asynchronous replication of imprinted genes is established in the gametes and maintained during development	NATURE			English	Article							ALLELE-SPECIFIC REPLICATION; MOUSE; REGION; EXPRESSION; MECHANISMS; CELLS; H19; HYBRIDIZATION; METHYLATION; TRANSITION	Genomic imprinting is characterized by allele-specific expression of multiple genes within large chromosomal domains' that undergo DNA replication asynchronously during S phase(2,3). Here we show, using both fluorescence in situ hybridization analysis and S-phase fractionation techniques, that differential replication timing is associated with imprinted genes in a variety of fell types, and is already present in the pre-implantation embryo soon after fertilization. This pattern is erased before meiosis in the germ line, and parent-specific replication timing is then reset in late gametogenesis in both the male and female. Thus, asynchronous replication timing is established in the gametes and maintained throughout development, indicating that it may function as a primary epigenetic marker for distinguishing between the parental alleles.	Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Natl Inst Genet, Dept Evolut Genet, Mishima, Shizuoka 4118540, Japan; Hadassah Ein Kerem Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78228 USA	Hebrew University of Jerusalem; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Hebrew University of Jerusalem; Hadassah University Medical Center; Texas Biomedical Research Institute	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.			Simon, Itamar/0000-0002-8517-1903; Reubinoff, Benjamin/0000-0003-0353-1299				BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Gabriel JM, 1998, P NATL ACAD SCI USA, V95, P14857, DOI 10.1073/pnas.95.25.14857; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARPER JC, 1994, HUM REPROD, V9, P721, DOI 10.1093/oxfordjournals.humrep.a138577; Hogan B, 1994, MANIPULATING MOUSE E; KAWAME H, 1995, HUM MOL GENET, V4, P2287, DOI 10.1093/hmg/4.12.2287; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; MCCARREY JR, 1987, J EXP ZOOL, V242, P107, DOI 10.1002/jez.1402420116; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shemer R., 1996, Epigenetic mechanisms of gene regulation., P215; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Windham CQ, 1997, DEV GENET, V20, P29, DOI 10.1002/(SICI)1520-6408(1997)20:1<29::AID-DVG4>3.0.CO;2-B; Wines ME, 1998, GENOMICS, V51, P223, DOI 10.1006/geno.1998.5347	30	131	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					929	932		10.1038/44866	http://dx.doi.org/10.1038/44866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553911				2022-12-24	WOS:000083464700063
J	Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB				Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB			Annual deaths attributable to obesity in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; MORTALITY; WEIGHT; OVERWEIGHT; PREVALENCE; DISEASE; WOMEN	Context Obesity is a major health problem in the United States, but the number of obesity-attributable deaths has not been rigorously estimated. Objective To estimate the number of deaths, annually, attributable to obesity among US adults. Design Data from 5 prospective cohort studies (the Alameda Community Health Study, the Framingham Heart Study, the Tecumseh Community Hearth Study, the American Cancer Society Cancer Prevention Study I, and the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study) and 1 published study (the Nurses' Health Study) in conjunction with 1991 national statistic; on body mass index distributions, population size, and overall deaths. Subjects Adults, 18 years or older in 1991, classified by body mass index (kg/m(2)) as overweight (25-30), obese (30-35), and severely obese (>35), Main Outcome Measure Relative hazard ratio (HR) of death for obese or overweight persons. Results The estimated number of annual deaths attributable to obesity varied with the cohort used to calculate the HRs, but findings were consistent overall. More than 80% of the estimated obesity-attributable deaths occurred among individuals with a body mass index of more than 30 kg/m(2). When HRs were estimated for all eligible subjects from ail 6 studies, the mean estimate of deaths attributable to obesity in the United States was 280 184 (range, 236 111-341 153),Hazard ratios also were calculated from data for nonsmokers or never-smokers only. When these HRs were applied to the entire population (assuming the HR applied to all individuals), the mean estimate for obesity-attributable death was 324 940 (range, 262 541-383 410). Conclusions The estimated number of annual deaths attributable to obesity among US adults is approximately 280 000 based on HRs from all subjects and 325 000 based on HRs from only nonsmokers and never-smokers.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, New York, NY 10025 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med, Baltimore, MD USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Allison, DB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	dba8@columbia.edu	Kohn, Geoffrey P/A-9056-2009	Allison, David/0000-0003-3566-9399	NIDDK NIH HHS [P30DK26687, R01DK51716] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051716, P30DK026687] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison D B, 1995, Endocr Pract, V1, P353; Allison DB, 1999, ANN EPIDEMIOL, V9, P132, DOI 10.1016/S1047-2797(98)00039-8; Allison DB, 1997, AM J EPIDEMIOL, V146, P672; Allison DB, 1999, AM J PUBLIC HEALTH, V89, P1194, DOI 10.2105/AJPH.89.8.1194; Allison DB, 1999, OBES RES, V7, P342, DOI 10.1002/j.1550-8528.1999.tb00417.x; Amler RW, 1987, AM J PREV MED, V3, P181; BERKHAM LF, 1983, HLTH WAYS LIVING ALA; Cox C S, 1997, Vital Health Stat 1, P1; Cox D. R., 1984, ANAL SURVIVAL DATA; D'AGOSTINO R. B., 1988, NIH PUBLICATION, V88-2970; DAGOSTINO RB, 1989, P AM STAT ASS SESQ 1, P707; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; EPSTEIN FH, 1970, ARCH ENVIRON HEALTH, V21, P402, DOI 10.1080/00039896.1970.10667258; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine K., 1998, DIS MANAG HLTH OUT, V3, P61; FORSTER J, 1995, PATIENT CARE, V29, P152; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hill JO, 1998, PEDIATRICS, V101, P570, DOI 10.1542/peds.101.3.570; HOCHSTIM JR, 1970, COMMUNITY EPIDEMIOLO; ILIENFELD AM, 1980, FDN EPIDEMIOLOGY; *KNOLL PHARM CO, 1999, MER PAT SUPP PACK; KOLATA G, 1998, NY TIMES        0101, P2; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MEISOL P, 1998, BALTIMORE SUN   0723, P3; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P897; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P891; NAPIER JA, 1962, AM J PUBLIC HEALTH N, V52, P208, DOI 10.2105/AJPH.52.2.208; NAPIER JA, 1970, COMMUNITY EPIDEMIOLO; *NHANES, 1997, BOOK CD ROM; PETITTI D, 1994, META ANAL DECISION A; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; SEIDELL JC, 1998, HDB OBESITY, P79; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1999, AM J EPIDEMIOL, V150, P399, DOI 10.1093/oxfordjournals.aje.a010019; Troiano RP, 1996, INT J OBESITY, V20, P63; *US CENS BUR, 1998, 1990 US CENS DAT; WHO, 1998, WHO TECHN REP SER; Wilding J, 1998, NATURE, V391, P759, DOI 10.1038/35793; WILL GF, 1997, NEWSWEEK        0707, P82	47	1272	1312	2	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1530	1538		10.1001/jama.282.16.1530	http://dx.doi.org/10.1001/jama.282.16.1530			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546692	Bronze			2022-12-24	WOS:000083277800020
J	Galuska, DA; Will, JC; Serdula, MK; Ford, ES				Galuska, DA; Will, JC; Serdula, MK; Ford, ES			Are health care professionals advising obese patients to lose weight?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; PHYSICIAN ADVICE; PRACTITIONERS; PROMOTION; ATTITUDES; BEHAVIOR	Context Implementation of the National Institutes of Health's 1998 guidelines, which recommended that health care professionals advise obese patients to lose weight, required baseline data for evaluation. Objectives To describe the proportion and characteristics of obese persons advised to lose weight by their health care professional during the previous 12 months and to determine whether the advice was associated with reported attempts to lose weight. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting Population-based sample from 50 states and the District of Columbia. Participants A total of 22 835 adults, 18 years and older, classified as obese (body mass index greater than or equal to 30 kg/m(2)), who had visited their physician for a routine checkup during the previous 12 months. Main Outcome Measures Reported advice from a health care professional to lose weight, and reported attempts to lose weight. Results Forty-two percent of participants reported that their hearth care professional advised them to lose weight. Using multivariate logistic regression analysis, we found that the persons who were more likely to receive advice were female, middle aged, had higher levels of education, lived in the northeast, reported poorer perceived health, were more obese, and had diabetes mellitus. Persons who reported receiving advice to lose weight were significantly more likely to report trying to lose weight than those who did not (OR, 2.79; 95% CI, 2.53-3.08). Conclusions Less than half of obese adults report being advised to lose weight by health care professionals. Barriers to counseling need to be identified and addressed.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Galuska, DA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, 4770 Bufford Hwy,MS K26, Atlanta, GA 30341 USA.							[Anonymous], 1998, CLIN GUID ID EV TREA; CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine KR, 1998, ARCH FAM MED, V7, P381, DOI 10.1001/archfami.7.4.381; Ford ES, 1998, J CLIN EPIDEMIOL, V51, P55, DOI 10.1016/S0895-4356(97)00225-4; FRIEDMAN C, 1994, AM J PREV MED, V10, P367, DOI 10.1016/S0749-3797(18)30567-1; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JANES GR, 1995, US DEP HLTH HUMAN SE; KOTTKE TE, 1984, PREV MED, V13, P215; Kristeller JL, 1997, PREV MED, V26, P542, DOI 10.1006/pmed.1997.0171; KUSHNER RF, 1995, PREV MED, V24, P546, DOI 10.1006/pmed.1995.1087; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; NELSON DE, 1998, P SECT SURV METH AM; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PRICE JH, 1987, AM J PREV MED, V3, P339; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; Shah BV, 1997, SUDAAN USERS MANUAL; SWIWBURN BA, 1998, AM J PUBLIC HEALTH, V88, P288; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WOODWELL DA, 1997, ADV DATA VITAL HLTH, V295; Yeager KK, 1996, AM J PREV MED, V12, P238, DOI 10.1016/S0749-3797(18)30318-0	24	478	486	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1576	1578		10.1001/jama.282.16.1576	http://dx.doi.org/10.1001/jama.282.16.1576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546698	Bronze			2022-12-24	WOS:000083277800026
J	Bi, GQ; Poo, MM				Bi, GQ; Poo, MM			Distributed synaptic modification in neural networks induced by patterned stimulation	NATURE			English	Article							LONG-TERM POTENTIATION; PLASTICITY; DEPRESSION; HIPPOCAMPUS; NEURONS; COMPUTATION; INFORMATION; SIGNAL; TIME	Activity-dependent changes in synaptic efficacy or connectivity are critical for the development(1), signal processing(2) and learning and memory functions(3-6) of the nervous system. Repetitive correlated spiking of pre- and postsynaptic neurons can induce a persistent increase or decrease in synaptic strength, depending on the timing of the pre- and postsynaptic excitation(7-13). Previous studies on such synaptic modifications have focused on synapses made by the stimulated neuron. Here we examine, in networks of cultured hippocampal neurons, whether and how localized stimulation can modify synapses that are remote from the stimulated neuron. We found that repetitive paired-pulse stimulation of a single neuron for brief periods induces persistent strengthening or weakening of specific polysynaptic pathways in a manner that depends on the interpulse interval. These changes can be accounted for by correlated pre- and postsynaptic excitation at distant synaptic sites, resulting from different transmission delays along separate pathways. Thus, through such a 'delay-line' mechanism, temporal information coded in the timing of individual spikes(14-17) can be converted into and stored as spatially distributed patterns of persistent synaptic modifications in a neural network.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Bi, GQ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Bi, Guo-Qiang/E-5075-2013	Bi, Guo-Qiang/0000-0001-8735-3818				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Abeles M., 1991, CORTICONICS; Bell CC, 1997, NATURE, V387, P278, DOI 10.1038/387278a0; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buonomano DV, 1997, P NATL ACAD SCI USA, V94, P10403, DOI 10.1073/pnas.94.19.10403; BUZSAKI G, 1988, BRAIN RES, V455, P192, DOI 10.1016/0006-8993(88)90133-3; CARR CE, 1990, J NEUROSCI, V10, P3227; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; Goda Y, 1996, CURR BIOL, V6, P375, DOI 10.1016/S0960-9822(02)00499-2; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kristan WB, 1998, NAT NEUROSCI, V1, P643, DOI 10.1038/3640; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MILES R, 1987, NATURE, V329, P724, DOI 10.1038/329724a0; Moore JW, 1998, TIMING OF BEHAVIOR, P3; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; Squire L. R., 1987, MEMORY BRAIN; Strong SP, 1998, PHYS REV LETT, V80, P197, DOI 10.1103/PhysRevLett.80.197; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	30	183	190	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					792	796		10.1038/44573	http://dx.doi.org/10.1038/44573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548104				2022-12-24	WOS:000083368700053
J	Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N				Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N			Psychiatric illness and risk factors for suicide in Denmark	LANCET			English	Article							PREVENTING SUICIDE; ATTRIBUTABLE RISK; SWEDISH SUICIDE; UNEMPLOYMENT; MORTALITY	Background Several risk factors for suicide have been identified, We assessed the relative risks and population attributable risks of suicide associated with various socioeconomic factors and with previous mental illness that necessitated hospital admission. Our aim was to assist in the choice of potential strategies for preventing suicide in the general population. Methods We did a population-based nested case-control study based on register data. Data were collected on a random 5% sample of the Danish population aged 16-78 years during a 15-year period (1980-94) and analysed with conditional logistic regression. Findings 811 cases of suicide were found and 79 871 controls were chosen in this population. Unemployment, tow income, being single, and a history of mental illness necessitating hospital admission were associated With increased risk of suicide. However, in the multivariate analysis, the strongest risk factor was mental illness necessitating hospital admission; risk of suicide was especially high during admission (relative risk 62.6 [95% CI 41.1-95.4]) and during the year after discharge (6.51 [5.03-8.44]). The effect of socioeconomic variables decreased after adjustment for history of mental illness. The population attributable risk associated with mental illness necessitating admission to hospital was 44.6% (43.6-45.5); the attributable risks associated with the other factors were 3.0% (1.4-6.6) for unemployment and 10.3% (6.13-16.9) for being single. Interpretation Suicide prevention aimed at patients who are admitted to hospital with mental disorders and improved detection and treatment of mental disorders in the general population may be the most efficient strategy to decrease risk of suicide. Reports of high relative risk and attributable risk associated with unemployment and other socioeconomic risk factors may be confounded and overestimated owing to the lack of adjustment for the association with mental disorders.	Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Univ Aarhus, Ctr Labour Market & Social Res, Aarhus, Denmark	Aarhus University; Aarhus University	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark.		Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012	Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; Eriksson, Tor/0000-0001-9309-5499				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; BARNDORFFNIELSE.OE, 1989, ASYMPTOMATIC TECHNIQ; BARNERASMUSSEN P, 1986, ACTA PSYCHIAT SCAND, V73, P449, DOI 10.1111/j.1600-0447.1986.tb02710.x; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; FerradaNoli M, 1997, ACTA PSYCHIAT SCAND, V96, P108, DOI 10.1111/j.1600-0447.1997.tb09914.x; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldberg DP., 1992, COMMON MENTAL DISORD; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hills, 1993, STAT MODELS EPIDEMIO; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; Johansson LM, 1997, SOC PSYCH PSYCH EPID, V32, P165; KREITMAN N, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P73; KURITZ SJ, 1988, BIOMETRICS, V44, P355, DOI 10.2307/2531850; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Lewis G, 1997, BRIT J PSYCHIAT, V171, P351, DOI 10.1192/bjp.171.4.351; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Rosenman SJ, 1998, MED J AUSTRALIA, V169, P100, DOI 10.5694/j.1326-5377.1998.tb140193.x; *SUNDH, 1992, DODS 1990 CAUS DEATH; WESTERGARDNIELS.N, 1984, STUDIES LABOR MARKET, P267; *WHO, 1967, MAN INT CLASS DIS IC; WILKINSON G, 1994, BRIT MED J, V309, P860, DOI 10.1136/bmj.309.6958.860; World Health Organisation, 1993, ICD 10 CLASS MENT BE; 1993, LANCET, V342, P381	30	253	260	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					9	12		10.1016/S0140-6736(99)06376-X	http://dx.doi.org/10.1016/S0140-6736(99)06376-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279MU	10615884				2022-12-24	WOS:000085049200009
J	Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS				Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS			Underrepresentation of patients 65 years of age or older in cancer-treatment trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST-ONCOLOGY-GROUP; ACUTE MYELOID-LEUKEMIA; CLINICAL-TRIALS; BREAST-CANCER; WOMEN; CHEMOTHERAPY; REPRESENTATION; HEALTH	Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P < 0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P < 0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. (N Engl J Med 1999;341:2061-7.) (C)1999, Massachusetts Medical Society.	Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA; Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA; Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX 78284 USA; Loyola Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Maywood, IL 60153 USA	University of Arkansas System; University of Arkansas Medical Sciences; Fred Hutchinson Cancer Center; Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; Loyola University Chicago	Hutchins, LF (corresponding author), SW Oncol Grp, Operat Off, 4980 Omicron Dr, San Antonio, TX 78245 USA.		Unger, Joseph/O-7457-2019		NATIONAL CANCER INSTITUTE [U10CA032102, U10CA037981, U10CA038926] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102, CA37981, CA38926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P271, DOI 10.1056/NEJM199307223290409; Baquet C, 1986, Prog Clin Biol Res, V216, P215; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; BONADONNA G, 1992, CANCER RES, V52, P2127; Chamberlain RM, 1998, INT J RADIAT ONCOL, V40, P9, DOI 10.1016/S0360-3016(97)00833-X; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; COTTON P, 1993, JAMA-J AM MED ASSOC, V269, P2067; CRIVELLARI D, 1998, P AN M AM SOC CLIN, V17, pA102; DEES EC, 1998, P AN M AM SOC CLIN, V17, pA103; Dignam JJ, 1997, CANCER-AM CANCER SOC, V80, P80, DOI 10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B; FELDMAN EJ, 1995, SEMIN ONCOL, V22, P21; Food and Drug Administration, 1993, FED REG, V58, P39406; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GIOVANAZZIBANNON S, 1994, J CLIN ONCOL, V12, P2447, DOI 10.1200/JCO.1994.12.11.2447; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; Gotay C C, 1993, Oncology (Williston Park), V7, P67; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; HAYUNGA EG, 1997, APPL CLIN TRIALS, V6, P41; Hutchins L F, 1987, Clin Geriatr Med, V3, P483; JOHNSON PRE, 1993, BRIT J HAEMATOL, V83, P1, DOI 10.1111/j.1365-2141.1993.tb04622.x; Leith CP, 1997, BLOOD, V89, P3323; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MARLIN SM, 1996, CLIN INVEST MED S, V19, pA50; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P418, DOI 10.1001/jama.279.6.418; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; PINN VW, 1992, AM J PREV MED, V8, P399; RYAN DH, 1992, AM J CLIN ONCOL-CANC, V15, P69, DOI 10.1097/00000421-199202000-00013; SCHMUCKER DL, 1993, CLIN PHARMACOL THER, V54, P11, DOI 10.1038/clpt.1993.102; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; YANCIK R, 1986, AM J OBSTET GYNECOL, V154, P639, DOI 10.1016/0002-9378(86)90623-X	32	1677	1695	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2061	2067		10.1056/NEJM199912303412706	http://dx.doi.org/10.1056/NEJM199912303412706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615079				2022-12-24	WOS:000084573300006
J	Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J				Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J			Long-term follow-up of idiopathic chronic pericardial effusion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY CHYLOPERICARDIUM; CARDIAC-TAMPONADE; EXPERIENCE; SERIES	Background: A large idiopathic chronic pericardial effusion is a collection of pericardial fluid that persists for more than three months and has no apparent cause. We conducted a prospective study of the natural history and treatment of this disorder. Methods: Between 1977 and 1992, we prospectively evaluated and enrolled patients with large idiopathic chronic pericardial effusion. We performed pericardiocentesis in most of the patients. We performed pericardiectomy when large pericardial effusion reappeared after pericardiocentesis. Follow-up ranged from 18 months to 20 years (median, 7 years). Results: During the study period, we evaluated a total of 1108 patients with pericarditis, 461 of whom had large pericardial effusion. Twenty-eight of these patients (age range, 7 to 85 years; median, 61) had large idiopathic chronic effusion and were included in the study. The duration of effusion ranged from 6 months to 15 years (median, 3 years). At the initial evaluation, 13 patients were asymptomatic. Overt tamponade was found in eight patients (29 percent). Therapeutic pericardiocentesis, performed in 24 patients, was followed by the disappearance of or marked reduction in the effusion in 8. Five of the 24 patients underwent early pericardiectomy, and in 11 large pericardial effusion reappeared. Cardiac catheterization, performed in 16 patients, showed elevated intrapericardial pressure (mean [+/-SD], 4.75+/-3.79 mm Hg) and reduced transmural pressure (1.0+/-2.50 mm Hg) before pericardiocentesis. Both of these abnormalities in pressure improved significantly after pericardiocentesis. Pericardiectomy, performed in 20 patients, yielded excellent long-term results. At the end of the follow-up period, 10 patients had died, but none had died from pericardial disease. Conclusions: Large idiopathic chronic pericardial effusion is well tolerated for long periods in most patients, but severe tamponade can develop unexpectedly at any time. Pericardiocentesis alone frequently results in the resolution of large effusions, but recurrence is common and pericardiectomy should be considered whenever a large effusion recurs after pericardiocentesis. (N Engl J Med 1999;341:2054-9.) (C)1999, Massachusetts Medical Society.	Hosp Gen Univ Vall Dhebron, Serv Cardiol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Sagrista-Sauleda, J (corresponding author), Hosp Gen Univ Vall Dhebron, Serv Cardiol, Passeig Vall Dhebron 119-129, Barcelona 08035, Spain.							BARKER PS, 1950, CIRCULATION, V2, P134, DOI 10.1161/01.CIR.2.1.134; BEDFORD DE, 1964, BRIT HEART J, V26, P499; BENDAYAN P, 1991, ARCH MAL COEUR VAISS, V84, P127; BOUVRAIN Y, 1957, Sem Hop, V33, P3353; BROWN AK, 1966, BRIT HEART J, V28, P609; COLOMBO A, 1988, CLIN CARDIOL, V11, P389, DOI 10.1002/clc.4960110606; CONNOLLY DC, 1959, CIRCULATION, V20, P1095, DOI 10.1161/01.CIR.20.6.1095; CONTRO S, 1955, CIRCULATION, V11, P844, DOI 10.1161/01.CIR.11.6.844; DRESSLER W, 1966, J AMER MED ASSOC, V195, P1064, DOI 10.1001/jama.195.12.1064; DUNN RP, 1975, AM HEART J, V89, P369, DOI 10.1016/0002-8703(75)90088-5; FOWLER NO, 1985, PERICARDIUM HLTH DIS, P217; GHOSH SC, 1985, INT SURG, V70, P5; GONIN A, 1956, REV LYON MED, V5, P741; GUIDOTTI P L, 1954, Arch Mal Coeur Vaiss, V47, P1001; HOUSEHAM C, 1982, S AFR MED J, V62, P293; JAFFE RJ, 1959, ANN INTERN MED, V51, P363, DOI 10.7326/0003-4819-51-2-363; KANE G C, 1988, Chest, V93, P434, DOI 10.1378/chest.93.2.434; KLOPFENSTEIN HS, 1990, PERICARDIAL DIS NEW, P47; Loire R, 1996, ARCH MAL COEUR VAISS, V89, P835; MARION MMJ, 1979, BORDEAUX MED, V12, P1449; MASK WK, 1990, J THORAC CARDIOV SUR, V99, P569; MUSEMECHE CA, 1990, J PEDIATR SURG, V25, P840, DOI 10.1016/0022-3468(90)90187-E; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; PUIGMASSANA M, 1972, BRIT HEART J, V34, P431; REDDY PS, 1990, AM J CARDIOL, V66, P1487, DOI 10.1016/0002-9149(90)90540-H; RIVAS JJ, 1985, MED CLIN-BARCELONA, V84, P102; SAGRISTASAULEDA J, 1988, J AM COLL CARDIOL, V11, P724, DOI 10.1016/0735-1097(88)90203-3; SAGRISTASAULEDA J, 1982, CIRCULATION, V66, P895, DOI 10.1161/01.CIR.66.4.895; SAINTPIERRE A, 1966, ACTUAL CARDIOVASC, P300; SANCHEZ MAG, 1982, MONOCARDIO, V3, P24; SCHEUER J, 1960, CIRCULATION, V21, P41, DOI 10.1161/01.CIR.21.1.41; SHABETAI R, 1981, PERICARDIUM, P108; Soler-Soler J, 1990, PERICARDIAL DIS NEW, P217; SOULIE P, 1960, ARCH MAL COEUR, V53, P1248; Suzman S, 1943, BRIT HEART J, V5, P19; TAVARES S, 1981, MD STATE MED J, V30, P64; WEITZMAN LB, 1984, CIRCULATION, V69, P506, DOI 10.1161/01.CIR.69.3.506; WOOD P, 1968, WOODS DIS HEART CIRC, P762; YU PNG, 1953, ANN INTERN MED, V39, P928, DOI 10.7326/0003-4819-39-4-928; ZISKIND AA, 1993, J AM COLL CARDIOL, V21, P1, DOI 10.1016/0735-1097(93)90710-I	40	122	132	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2054	2059		10.1056/NEJM199912303412704	http://dx.doi.org/10.1056/NEJM199912303412704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615077				2022-12-24	WOS:000084573300004
J	Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR				Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR			Shaken, not stirred: bioanalytical study of the antioxidant activities of martinis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; RISK; ALCOHOL	Background Moderate consumption of alcoholic drinks seems to reduce the risks of developing cardiovascular disease, stroke, and cataracts, perhaps through antioxidant actions of their alcohol, flavonoid, ur polyphenol contents. "Shaken, not stirred" routinely identifies the way the famous secret agent James Bond requires his martinis. Objectives As Mr Bond is not afflicted by cataracts or cardiovascular disease, an investigation was conducted to determine whether the mode of preparing martinis has an influence on their antioxidant capacity. Design Stir-red and shaken martinis were assayed for their ability to quench luminescence by a luminescent procedure in which hydrogen peroxide reacts with luminol bound to albumin. Student's t test was used for statistical analysis. Results Shaken martinis were more effective in deactivating hydrogen peroxide than the stirred variety, and both were more effective than gin or vermouth alone (0.072% of peroxide control for shaken martini, 0.157% for stirred v 58.3% for gin and 1.90% for vermouth). The reason for this is not clear, but it may well not involve the facile oxidation of reactive martini components: control martinis through which either oxygen or nitrogen was bubbled did not differ in their ability to deactivate hydrogen peroxide (0.061% v 0.057%) and did not differ from the shaken martini. Moreover, preliminary experiments indicate that martinis are less well endowed with polyphenols than Sauvignon white wine or Scotch whisky (0.056 mmol/l (catechin equivalents) shaken, 0.060 mmol/l stirred v 0.0592 mmol/l wine, 0.575 mmol/l whisky). Conclusions 007's profound state of health may be due, at least in part, to compliant bartenders.	Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Trevithick, JR (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.	trevjohn@julian.uwo.ca		Chartrand, Michelle/0000-0003-3398-7246				CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SASAKI H, 1997, US JAP COOP CAT RES, P66; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Trevithick CC, 1999, REDOX REP, V4, P89, DOI 10.1179/135100099101534765; Trevithick JR, 1997, BIOCHEM MOL BIOL INT, V41, P695; TREVITHICK JR, 1994, BIOCHEM MOL BIOL INT, V33, P1179	13	11	11	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1600	1602		10.1136/bmj.319.7225.1600	http://dx.doi.org/10.1136/bmj.319.7225.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600955	Green Published, Bronze			2022-12-24	WOS:000084562600008
J	Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA				Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA			Evolution of shape complementarity and catalytic efficiency from a primordial antibody template	SCIENCE			English	Article							DIELS-ALDER REACTION; AUTOMATED DOCKING; RATE ACCELERATIONS; CROSS-REACTIVITY; PROTEINS; COMPLEXES; INSIGHTS; ENERGY	The crystal structure of an efficient Diels-Alder antibody catalyst at 1.9 angstrom resolution reveals almost perfect shape complementarity with its transition state analog. Comparison with highly related progesterone and Diels-Alderase antibodies that arose from the same primordial germ Line template shows the relatively subtle mutational steps that were able to evolve both structural complementarity and catalytic efficiency.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Swiss Fed Inst Technol, ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; Swiss Federal Institutes of Technology Domain; ETH Zurich	Xu, JA (corresponding author), Mol Simulat Inc, 9685 Scranton Rd, San Diego, CA 92121 USA.		Bartek, Jiri/G-5870-2014	Xu, Jian/0000-0002-4251-6895	NCI NIH HHS [CA27489] Funding Source: Medline; NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038273, R29GM038273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Badger J, 1999, PROTEINS, V35, P25, DOI 10.1002/(SICI)1097-0134(19990401)35:1<25::AID-PROT3>3.3.CO;2-M; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; Cossi M, 1996, CHEM PHYS LETT, V255, P327, DOI 10.1016/0009-2614(96)00349-1; Frisch M.J., GAUSSIAN; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1997, SCIENCE, V275, P1140; Haynes MR, 1996, ISRAEL J CHEM, V36, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Heine A, 1998, SCIENCE, V279, P1934, DOI 10.1126/science.279.5358.1934; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, 1999, TOP STEREOCHEM, V22, P83; Hollfelder F, 1996, NATURE, V383, P60, DOI 10.1038/383060a0; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES S, 1996, P NATL ACAD SCI USA, V93, P1320; Kabat EA, 1991, SEQUENCES PROTEINS I; Kikuchi K, 1996, J AM CHEM SOC, V118, P8184, DOI 10.1021/ja9617395; Laschat S, 1996, ANGEW CHEM INT EDIT, V35, P289, DOI 10.1002/anie.199602891; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; MEEKEL AAP, 1995, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39950000571; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PAULING L, 1948, Am Sci, V36, P51; PEARLMAN DA, 1995, AMBER 4 1; Pitt AR, 1996, ISRAEL J CHEM, V36, P171; Romesberg FE, 1999, BIOORG MED CHEM LETT, V9, P1741, DOI 10.1016/S0960-894X(99)00281-4; RORNESBERG FE, 1998, SCIENCE, V279, P1929; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seelig B, 1999, CHEM BIOL, V6, P167, DOI 10.1016/S1074-5521(99)89008-5; Stura E. A., 1993, IMMUNOMETHODS, V3, P164; Tarasow TM, 1997, NATURE, V389, P54, DOI 10.1038/37950; THORN SN, 1995, NATURE, V373, P228, DOI 10.1038/373228a0; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Warshel A, 1998, P NATL ACAD SCI USA, V95, P5950, DOI 10.1073/pnas.95.11.5950; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001	50	106	107	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2345	2348		10.1126/science.286.5448.2345	http://dx.doi.org/10.1126/science.286.5448.2345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600746				2022-12-24	WOS:000084318500063
J	Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G				Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G			T-cell co-stimulation through B7RP-1 and ICOS	NATURE			English	Article							CONTACT HYPERSENSITIVITY; MOLECULAR-CLONING; EFFICIENCY; EXPRESSION; RESPONSES; TOLERANCE; BLOCKADE; SYSTEM; MEMORY; CTLA-4	T-cell activation requires co-stimulation through receptors such as CD28 (refs 1-3) and antigen-specific signalling through the T-cell antigen receptor. Here we describe a new murine costimulatory receptor-ligand pair. The receptor, which is related to CD28 and is the homologue of the human protein ICOS4, is expressed on activated T cells and resting memory T cells. The ligand, which has homology to B7 molecules and is called B7-related protein-1 (B7RP-1), is expressed on B cells and macrophages. ICOS and B7RP-1 do not interact with proteins in the CD28-B7 pathway, and B7RP-1 co-stimulates T cells in vitro independently of CD28. Transgenic mice expressing a B7RP-1-Fc fusion protein show lymphoid hyperplasia in the spleen, lymph nodes and Peyer's patches. Presensitized mice treated with B7RP-1-Fc during antigen challenge show enhanced hypersensitivity. Therefore, B7RP-1 exhibits co-stimulatory activities in vitro and in vivo. ICOS and B7RP-1 define a new and distinct receptor-ligand pair that is structurally related to CD28-B7 and is involved in the adaptive immune response.	Amgen Inc, Thousand Oaks, CA 91320 USA; Amgen Inc, Res Inst, Toronto, ON M5G 2C1, Canada	Amgen	Yoshinaga, SK (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bajorath J, 1999, J MOL MODEL, V5, P169, DOI 10.1007/s008940050116; Beverley PCL, 1996, CURR OPIN IMMUNOL, V8, P327, DOI 10.1016/S0952-7915(96)80120-8; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Greene RME, 1998, EUR RADIOL, V8, P359, DOI 10.1007/s003300050394; GROSS JA, 1990, J IMMUNOL, V144, P3201; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; McHale JF, 1999, J IMMUNOL, V162, P1648; Schulte M, 1998, OXID MET, V49, P33, DOI 10.1023/A:1018818021754; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Tang AM, 1996, J IMMUNOL, V157, P117; Tang AM, 1997, EUR J IMMUNOL, V27, P3143, DOI 10.1002/eji.1830271210; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419	23	643	752	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					827	832		10.1038/45582	http://dx.doi.org/10.1038/45582			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617205				2022-12-24	WOS:000084330500069
J	Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L				Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L			Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; COST-EFFECTIVENESS; CARDIAC PROCEDURES; ELDERLY PATIENTS; CERVICAL-CANCER; HEALTH-CARE; OUTCOMES; MEDICINE; POLICY; ANGIOPLASTY	Context Expert panels and decision-analytic techniques are increasingly used to determine the appropriateness of medical interventions, but these 2 approaches use different methods to process evidence. Objective To compare expert panel appropriateness ratings of coronary angiography after myocardial infarction (from the time of hospital discharge to 12 weeks after infarction) with the health gains and cost-effectiveness predicted by a decision-analytic model. Design Comparison of the degree of importance of the clinical variables considered in expert panel appropriateness ratings vs a previously published decision-analytic model. Identification of 36 clinical scenarios from the expert panel that could be simulated by the decision-analytic model. Main Outcome Measures Appropriateness score and appropriateness classification (expert panel) vs gain in quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (decision-analytic model). Results The most important clinical variables were similar in the 2 approaches, with the exercise tolerance test result exerting the greatest leverage on strength of recommendation for angiography. Among the expert panel clinical scenarios considered to be appropriate for coronary angiography that could be simulated in the decision-analysis model, the median (interquartile range) health gain and incremental cost-effectiveness ratio were 0.59 (0.41-0.76) QALYs and $27 000 ($23 000-$35 000) per QALY gained, respectively. Among the clinical scenarios that expert panels considered inappropriate, the corresponding medians (interquartile ranges) were 0.24 (0.19-0.34) QALYs and $54 000 ($36 000-$58 000) per QALY gained. The Spearman rank correlation between appropriateness score and QALY gain was 0.58 (P<.001) and between appropriateness score and estimated incremental cost-effectiveness ratios was -0.66 (P<.001). Conclusions For the 36 expert panel scenarios that could be simulated by the decision; analytic model, there was moderate to good agreement between the appropriateness score and both the health gain and the incremental cost-effectiveness ratio of coronary angiography compared with no angiography in the convalescent phase of acute myocardial infarction, but several scenarios judged as inappropriate by the expert panel approach had cost-effectiveness ratios comparable with many generally recommended medical interventions. Formal synthesis of expert judgment and decision modeling is warranted in future efforts at guideline development.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA; Univ San Francisco, Sch Med, Dept Med, San Francisco, CA 94117 USA	Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of San Francisco	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA.				AHRQ HHS [R01-HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], CORONARY ANGIOGRAPHY; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; Bernstein SJ, 1997, INT J QUAL HEALTH C, V9, P255, DOI 10.1093/intqhc/9.4.255; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHURCHILL DN, 1984, MED DECIS MAKING, V4, P489, DOI 10.1177/0272989X8400400411; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Field MJ, 1990, CLIN PRACTICE GUIDEL; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Gold MR, 1996, COST EFFECTIVENESS H; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Hawkes AP, 1996, AM J PREV MED, V12, P342; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; Landrum MB, 1999, STAT MED, V18, P117, DOI 10.1002/(SICI)1097-0258(19990130)18:2<117::AID-SIM8>3.0.CO;2-7; LEAPE LL, 1990, QRB QUAL REV B, V16, P24; *NAT CTR HLTH STAT, 1991, MORTALITY A, V2; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Weinstein MC, 1980, CLIN DECISION ANAL; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	31	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2246	2251		10.1001/jama.282.23.2246	http://dx.doi.org/10.1001/jama.282.23.2246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605977				2022-12-24	WOS:000084138600033
J	Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH				Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH			The crystal structure of a T cell receptor in complex with peptide and MHC class II	SCIENCE			English	Review							TOXIC LYMPHOCYTES-T; BOUND SINGLE PEPTIDES; MYELIN BASIC-PROTEIN; TCR FAB FRAGMENT; ALPHA-CHAIN; ANTIGEN RECEPTOR; 3-DIMENSIONAL STRUCTURE; BETA-CHAIN; SUPERANTIGEN RECOGNITION; POSITIVE SELECTION	The crystal structure of a complex involving the D10 T cell receptor (TCR), 16-residue foreign peptide antigen, and the I-A(k) self major histocompatibility complex (MHC) class II molecule is reported at 3.2 angstrom resolution. The D10 TCR is oriented in an orthogonal mode relative to its peptide-MHC (pMHC) Ligand, necessitated by the amino-terminal extension of peptide residues projecting from the MHC class II antigen-binding groove as part of a mini beta sheet. Consequently, the disposition of D10 complementarity-determining region Loops is altered relative to that of most pMHCI-specific TCRs; the Latter TCRs assume a diagonal orientation, although with substantial variability. Peptide recognition, which involves P-1 to P8 residues, is dominated by the V alpha domain, which also binds to the class II MHC beta(1) helix. That docking is Limited to one segment of MHC-bound peptide offers an explanation for epitope recognition and altered peptide Ligand effects, suggests a structural basis for alloreactivity, and illustrates how bacterial superantigens can span the TCR-pMHCII surface.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Argonne National Laboratory	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu; jwang@red.dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037581, R01AI019807, R37AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA37581, AI19807] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUTO O, 1984, P NATL ACAD SCI-BIOL, V81, P3851, DOI 10.1073/pnas.81.12.3851; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDREANI M, 1994, INT J MULTIPHAS FLOW, V20, P1, DOI 10.1016/0301-9322(94)90069-8; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Benacerraf B, 1973, Harvey Lect, V67, P109; BENACERRAF B, 1978, J IMMUNOL, V120, P1809; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; Blackman MA, 1996, IMMUNOL RES, V15, P98, DOI 10.1007/BF02918500; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHAN SH, 1993, IMMUNOL REV, V135, P119, DOI 10.1111/j.1600-065X.1993.tb00646.x; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DALY K, 1995, J IMMUNOL, V155, P27; Daniel C, 1998, IMMUNITY, V8, P543, DOI 10.1016/S1074-7613(00)80559-2; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Donson D, 1997, J IMMUNOL, V158, P5229; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FABBI M, 1984, NATURE, V312, P269, DOI 10.1038/312269a0; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; Frelinger JA, 1996, IMMUNOL REV, V154, P45, DOI 10.1111/j.1600-065X.1996.tb00929.x; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; Hare BJ, 1999, NAT STRUCT BIOL, V6, P574; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Hong SC, 1997, J IMMUNOL, V159, P4395; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Koyasu S, 1997, INT IMMUNOL, V9, P1475, DOI 10.1093/intimm/9.10.1475; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; KRUISBEEK AM, 1993, CURR OPIN IMMUNOL, V5, P227, DOI 10.1016/0952-7915(93)90009-H; LABRECQUE N, 1994, J EXP MED, V180, P1921, DOI 10.1084/jem.180.5.1921; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEVELT CN, 1995, EUR J IMMUNOL, V25, P1257, DOI 10.1002/eji.1830250519; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; REAY PA, 1994, J IMMUNOL, V152, P3946; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REINHERZ EL, 1983, IMMUNOL REV, V74, P83, DOI 10.1111/j.1600-065X.1983.tb01085.x; REINHERZ EL, UNPUB; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SIM GK, 1984, NATURE, V312, P771; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEBB SR, 1994, CURR OPIN IMMUNOL, V6, P467, DOI 10.1016/0952-7915(94)90129-5; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Xu Y, 1996, P NATL ACAD SCI USA, V93, P2169, DOI 10.1073/pnas.93.5.2169; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	127	347	357	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1913	1921		10.1126/science.286.5446.1913	http://dx.doi.org/10.1126/science.286.5446.1913			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583947				2022-12-24	WOS:000084003400040
J	Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E				Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E			Bazooka provides an apical cue for Inscuteable localization in Drosophila neuroblasts	NATURE			English	Article							ASYMMETRIC CELL-DIVISION; CAENORHABDITIS-ELEGANS; DAUGHTER-CELL; PROSPERO; PROTEIN; STAUFEN; MIRANDA; GENE; SEGREGATION; POLARITY	Asymmetric cell division generates daughter cells with different developmental fates from progenitor cells that contain localized determinants. During this division, the asymmetric localization of cell-fate determinants and the orientation of the mitotic spindle must be precisely coordinated. In Drosophila neuroblasts, inscuteable controls both spindle orientation and the asymmetric localization of the cell-fate determinants Prospero and Numb(1). Inscuteable itself is localized in an apical cortical crescent and thus reflects the intrinsic asymmetry of the neuroblast(1,2). Here we show that localization of Inscuteable depends on Bazooka, a protein containing three PDZ domains with overall sequence similarity to Par-3 of Caenorhabditis elegans(3). Bazooka and Inscuteable form a complex that also contains Staufen, a protein responsible for the asymmetric localization of prospero messenger RNA. We propose that, after delamination of the neuroblast from the neuroepithelium, Bazooka provides an asymmetric cue in the apical cytocortex that is required to anchor Inscuteable, As Bazooka is also responsible for the maintenance of apical-basal polarity in epithelial tissues(4), it may be the missing link between epithelial polarity and neuroblast polarity.	Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Wodarz, A (corresponding author), Univ Dusseldorf, Inst Genet, Univ Str 1, D-40225 Dusseldorf, Germany.		Knust, Elisabeth/B-4338-2017; Wodarz, Andreas/D-4642-2013	Wodarz, Andreas/0000-0002-0007-6289				BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hung TJ, 1999, DEVELOPMENT, V126, P127; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089	27	359	363	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					544	547		10.1038/990128	http://dx.doi.org/10.1038/990128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591216				2022-12-24	WOS:000084013200060
J	Trewavas, A				Trewavas, A			Much food, many problems	NATURE			English	Editorial Material									Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	University of Edinburgh	Trewavas, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland.							Ames B. N., 1990, P NATL ACAD SCI USA, V87, P777; AVERY D, 1999, FEARING FOOD RISK HL, P3; BAUM M, 1992, ANNU REV PLANT PHYS, V43, P117, DOI 10.1146/annurev.pp.43.060192.001001; *BR MED ASS, 1999, IMP GEN MOD AGR FOOD; Chrispeels MJ, 1994, PLANTS GENES AGR; *CHRIST AID, 1999, SELL SUIC FARM FALS; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; de Maagd RA, 1999, TRENDS PLANT SCI, V4, P9, DOI 10.1016/S1360-1385(98)01356-9; Evans L.T, 1998, FEEDING 10 BILLION P; FITT GP, 1994, BIOCONTROL SCI TECHN, V4, P535, DOI 10.1080/09583159409355367; HOLLIDAY RJ, 1980, J APPL ECOL, V17, P779, DOI 10.2307/2402655; Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MacKenzie D, 1999, NEW SCI, V162, P4; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; RAYBOUD RF, 1999, TRENDS PLANT SCI, V4, P247; Richards A.J, 1997, PLANT BREEDING SYSTE; Schuler TH, 1999, NATURE, V400, P825, DOI 10.1038/23605; Tilman D, 1998, NATURE, V396, P211, DOI 10.1038/24254; *US FAO, 1992, WORLD FOOD SUPPL PRE	20	25	25	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					231	232		10.1038/46157	http://dx.doi.org/10.1038/46157			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580487				2022-12-24	WOS:000083813700021
J	Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E				Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E			Control of organ asymmetry in flowers of Antirrhinum	CELL			English	Article							BITHORAX COMPLEX; IDENTITY GENES; ABDOMINAL-B; MAJUS; DROSOPHILA; EXPRESSION; MERISTEM; BOUNDARY; ELEMENT; DOMAIN	Organ asymmetry is thought to have evolved many times independently in plants. In Antirrhinum, asymmetry of the flower and its component organs requires eye and dich gene activity. We show that, like eye, the dich gene encodes a product belonging to the TCP family of DNA-binding proteins that is first expressed in the dorsal domain of early floral meristems. However, whereas eye continues to be expressed throughout dorsal regions, expression of dich eventually becomes restricted to the most dorsal half of each dorsal petal. This correlates with the effects of dich mutations and ectopic eye expression on petal shape, providing an indication that plant organ asymmetry can reflect subdomains of gene activity. Taken together, the results indicate that plant organ asymmetry can arise through a series of steps during which early asymmetry in the developing meristem is progressively built upon.	John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Dept Genet, Colney Lane, Norwich NR4 7UH, Norfolk, England.							Almeida J, 1997, DEVELOPMENT, V124, P1387; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Charlton W.A., 1998, SYMMETRY PLANTS, P61; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Coen ES, 1996, EMBO J, V15, P6777, DOI 10.1002/j.1460-2075.1996.tb01069.x; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Mihaly J, 1997, DEVELOPMENT, V124, P1809; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SIMON J, 1992, DEVELOPMENT, V114, P493; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Wolpert L., 1998, PRINCIPLES DEV; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	26	302	353	4	66	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					367	376						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571179	Bronze			2022-12-24	WOS:000083709300004
J	Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R				Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R			Persistence of memory CD8 T cells in MHC class I-deficient mice	SCIENCE			English	Article							SURVIVAL; MATURE; MOLECULES; ANTIGEN; LYMPHOCYTES; SELECTION; NAIVE; VIVO; IMMUNOGLOBULIN; PROLIFERATION	An understanding of how T cell memory is maintained is crucial for the rational design of vaccines. Memory T tells were shown to persist indefinitely in major histocompatibility complex (MHC) class I-deficient mice and retained the ability to make rapid cytokine responses upon reencounter with antigen. In addition, memory CD8 T cells, unlike naive cells, divided without MHC-T cell receptor interactions. This "homeostatic" proliferation is Likely to be important in maintaining memory T cell numbers in the periphery. Thus, after naive CD8 T cells differentiate into memory cells, they evolve an MHC class I-independent "life-style" and do not require further stimulation with specific or cross-reactive antigen for their maintenance.	Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Pasteur Merieux Connaught Canada, N York, ON M2R 3TA, Canada; Inst Pasteur, Dept SIDA & Retrovirus, F-75724 Paris, France	Emory University; Emory University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ahmed, R (corresponding author), Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Sambhara, Suryaprakash/AAC-4428-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030048, R01AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30048] Funding Source: Medline; NINDS NIH HHS [NS21496] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; AHMED R, 1996, SCIENCE, V272, P55; Bachmann MF, 1999, J EXP MED, V189, P1521, DOI 10.1084/jem.189.10.1521; Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; Barthlott T, 1998, J IMMUNOL, V161, P3992; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; Boursalian TE, 1999, J IMMUNOL, V162, P3795; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Bruno L, 1996, EUR J IMMUNOL, V26, P3179, DOI 10.1002/eji.1830261251; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Kedl RM, 1998, J IMMUNOL, V161, P674; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; MCDONAGH M, 1995, IMMUNOLOGY, V84, P514; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nesic D, 1998, J IMMUNOL, V160, P3705; PEREIRA P, 1991, INT IMMUNOL, V3, P1077, DOI 10.1093/intimm/3.11.1077; Pestano GA, 1999, SCIENCE, V284, P1187, DOI 10.1126/science.284.5417.1187; Pihlgren M, 1996, J EXP MED, V184, P2141, DOI 10.1084/jem.184.6.2141; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRENT J, 1997, CURR OPIN IMMUNOL, V9, P37; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zimmermann C, 1999, EUR J IMMUNOL, V29, P284, DOI 10.1002/(SICI)1521-4141(199901)29:01<284::AID-IMMU284>3.0.CO;2-C; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P258, DOI 10.1016/S0167-5699(97)80017-5	50	613	636	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1377	1381		10.1126/science.286.5443.1377	http://dx.doi.org/10.1126/science.286.5443.1377			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558996				2022-12-24	WOS:000083675500048
J	Antman, KH; Heitjan, DF; Hortobagyi, GN				Antman, KH; Heitjan, DF; Hortobagyi, GN			High-dose chemotherapy for breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED TRIAL; CELL SUPPORT; FOLLOW-UP		Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Austin, TX USA	Columbia University; University of Texas System; University of Texas Austin; UTMD Anderson Cancer Center	Antman, KH (corresponding author), MHB 6N 435,177 Ft Washington Ave, New York, NY 10032 USA.		Heitjan, Daniel F./D-1116-2009	/0000-0002-1093-8356				Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BERGH J, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BEZWODA WR, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, pA115; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HORTOBAGYI GN, 1998, P AN M AM SOC CLIN, V17, P12; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LOTZ JP, 1999, P AN M AM SOC CLIN, V18, pA43; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; PETERS W, 1999, P AN M AM SOC CLIN, V18, pA1; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0	19	16	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1701	1703		10.1001/jama.282.18.1701	http://dx.doi.org/10.1001/jama.282.18.1701			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568629				2022-12-24	WOS:000083471400001
J	Johansen, HK; Gotzsche, PC				Johansen, HK; Gotzsche, PC			Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL AMPHOTERICIN-B; PREVENTING FUNGAL INFECTION; NEUTROPENIC PATIENTS; ACUTE-LEUKEMIA; HEMATOLOGICAL MALIGNANCIES; OROPHARYNGEAL CANDIDIASIS; GRANULOCYTOPENIC PATIENTS; REMISSION INDUCTION; FLUCONAZOLE; NYSTATIN	Meta-analyses may become biased if the reported data in the individual trials are biased and if overlap among trials cannot be identified. We describe the unanticipated problems we encountered in collecting data for a metaanalysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia. In 3 large trials that comprised 43% of the patients identified for the meta-analysis, results for amphotericin B were combined with results for nystatin in a "polyene" group. Because nystatin is recognized as an ineffective drug in these circumstances, this approach creates a bias in favor of fluconazole. Furthermore, 79% of the patients were randomized to receive oral amphotericin B, which is poorly absorbed and not an established treatment, in contrast to intravenous amphotericin B, which was administered in 4 of 5 placebo-controlled trials, or 86% of patients. It was unclear whether there was overlap among the "polyene" trials, and it is possible that results from single-center trials were included in multicenter trial reports. We were unable to obtain information to clarify these issues from the trial authors or the manufacturer of fluconazole. Two of 11 responding authors replied that the data were with the drug manufacturer and two indicated that they did not have access to their data because of change of affiliation. In the meta-analyses, fluconazole and amphotericin B (mostly given orally) had similar effects (13 trials), whereas nystatin was no better than placebo (3 trials). Since individual trials are rarely conclusive, investigators, institutions, and pharmaceutical companies should provide essential details about their work to ensure that meta-analyses can accurately reflect: the studies conducted and that patients will realize maximum benefits from treatments. We recommend that: investigators keep copies of their trial data to help facilitate accurate and unbiased meta-analyses.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark.							AKIYAMA H, 1993, MYCOSES, V36, P373, DOI 10.1111/j.1439-0507.1993.tb00725.x; Anaissie EJ, 1996, CLIN INFECT DIS, V23, P964, DOI 10.1093/clinids/23.5.964; BODEY GP, 1994, CANCER-AM CANCER SOC, V73, P2099, DOI 10.1002/1097-0142(19940415)73:8&lt;2099::AID-CNCR2820730814&gt;3.0.CO;2-N; BODEY GP, 1974, MEDICINE, V53, P209, DOI 10.1097/00005792-197405000-00004; BOW EJ, 1997, 37 INT C ANT AG CHEM; Brammer K W, 1990, Haematol Blood Transfus, V33, P546; BUCHANAN AG, 1985, CLIN INVEST MED, V8, P139; *COCHR COLL, 1998, REV MAN REVM COMP PR; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER T, 1995, SUPPORT CARE CANCER, V3, P139, DOI 10.1007/BF00365855; ELLIS ME, 1994, J ANTIMICROB CHEMOTH, V33, P1223, DOI 10.1093/jac/33.6.1223; ELLIS ME, 1994, EUR J CLIN MICROBIOL, V13, P3, DOI 10.1007/BF02026116; ELLIS ME, 1995, J INFECTION, V30, P141, DOI 10.1016/S0163-4453(95)80009-3; EPSTEIN JB, 1992, ORAL SURG ORAL MED O, V73, P682, DOI 10.1016/0030-4220(92)90009-F; Finke R, 1990, Mycoses, V33 Suppl 1, P42; FLYNN PM, 1995, J PEDIATR-US, V127, P322, DOI 10.1016/S0022-3476(95)70321-7; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; Gotzsche PC, 1997, BMJ-BRIT MED J, V314, P1238, DOI 10.1136/bmj.314.7089.1238; GOTZSCHE PC, 1998, COCHRANE REV CD ROM; Groll AH, 1997, J ANTIMICROB CHEMOTH, V40, P855, DOI 10.1093/jac/40.6.855; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; HOPPE JE, 1995, MYCOSES, V38, P41, DOI 10.1111/j.1439-0507.1995.tb00007.x; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; JOHANSEN HK, 1998, COCHRANE REV; Lake DE, 1996, CHEMOTHERAPY, V42, P308, DOI 10.1159/000239459; Lapierre V, 1992, 32 INT C ANT AG CHEM, P214; Lumbreras C, 1996, J INFECT DIS, V174, P583, DOI 10.1093/infdis/174.3.583; MARIE JP, 1993, CAH ONCOL, V2, P171; MENICHETTI F, 1994, ANN INTERN MED, V120, P913, DOI 10.7326/0003-4819-120-11-199406010-00003; MEUNIER F, 1991, DRUG INVEST, V3, P258, DOI 10.1007/BF03259575; NAKIELNY J, 1993, BRIT MED J, V306, P1125, DOI 10.1136/bmj.306.6885.1125-b; NINANE J, 1994, EUR J CLIN MICROBIOL, V13, P330, DOI 10.1007/BF01974614; PHILPOTTHOWARD JN, 1993, J ANTIMICROB CHEMOTH, V31, P973, DOI 10.1093/jac/31.6.973; Pons V, 1997, CLIN INFECT DIS, V24, P1204, DOI 10.1086/513664; Rogers TRF, 1995, J ANTIMICROB CHEMOTH, V36, P899, DOI 10.1093/jac/36.6.899; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SAVINO JA, 1994, J TRAUMA, V36, P20, DOI 10.1097/00005373-199401000-00004; Silling-Engelhardt G, 1994, BLOOD S, V10, p306a; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Teshima H, 1994, DRUG EVALUATION, V7, P535; Tian D, 1997, 20 INT C CHEM JUN 29, P87; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Viscoli C, 1996, EUR J CANCER, V32A, P814, DOI 10.1016/0959-8049(95)00619-2; VISCOLI C, 1995, 7 EUR C CLIN MICR IN; WILLIAMS C, 1977, MED PEDIATR ONCOL, V3, P275, DOI 10.1002/mpo.2950030309; WINSTON DJ, 1997, 20 INT C CHEM JUN 29	48	101	104	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1752	1759		10.1001/jama.282.18.1752	http://dx.doi.org/10.1001/jama.282.18.1752			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568648				2022-12-24	WOS:000083471400030
J	Shann, F				Shann, F			Haemophilus influenzae pneumonia: type b or non-type b?	LANCET			English	Editorial Material							PAPUA-NEW-GUINEA; CHILDREN; ETIOLOGY; PAKISTAN		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.		Shann, Frank/C-9510-2011					ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; GRATTEN M, 1991, PAPUA NEW GUINEA MED, V34, P185; MOXON ER, 1991, REV INFECT DIS, V13, pS518; MUSHER DM, 1982, ARCH INTERN MED, V142, P448, DOI 10.1001/archinte.142.3.632; SHANN F, 1984, LANCET, V2, P537; STGEME JW, 1993, INFECT AGENT DIS, V2, P1; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; Utsunomiya Y, 1998, J TROP PEDIATRICS, V44, P338, DOI 10.1093/tropej/44.6.338; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WEINBERG GA, 1990, REV INFECT DIS, V12, pS1017; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; WONG SN, 1991, J PAEDIATR CHILD H, V27, P113, DOI 10.1111/j.1440-1754.1991.tb00364.x	12	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1488	1490		10.1016/S0140-6736(99)00232-9	http://dx.doi.org/10.1016/S0140-6736(99)00232-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551490				2022-12-24	WOS:000083411300004
J	Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN				Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN			A molecular target for viral killer toxin: TOK1 potassium channels	CELL			English	Article							DOUBLE-STRANDED-RNA; RECTIFYING K+ CHANNEL; 2 PORE DOMAINS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; HANSENULA-ANOMALA; YEAST; PREPROTOXIN; EXPRESSION; GENE	Killer strains of S. cerevisiae harbor double-stranded RNA viruses and secrete protein toxins that kill virus-free cells. The K1 killer toxin acts on sensitive yeast cells to perturb potassium homeostasis and cause cell death. Here, the toxin is shown to activate the plasma membrane potassium channel of S. cerevisiae, TOK1. Genetic deletion of TOK1 confers toxin resistance; overexpression increases susceptibility. Cells expressing TOK1 exhibit toxin-induced potassium flux; those without the gene do not. K1 toxin acts in the absence of other viral or yeast products: toxin synthesized from a cDNA increases open probability of single TOK1 channels (via reversible destabilization of closed states) whether channels are studied in yeast cells or X. laevis oocytes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Pediat, New York, NY 10032 USA	Yale University; Yale University; Columbia University; Columbia University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 333 Cedar St, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Ahmed, Aamir/0000-0001-7405-5336				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ALAIDROOS K, 1978, CAN J MICROBIOL, V24, P228, DOI 10.1139/m78-041; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bertl A, 1998, J MEMBRANE BIOL, V162, P67, DOI 10.1007/s002329900343; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BOONE C, 1986, CELL, V46, P105, DOI 10.1016/0092-8674(86)90864-0; BOSTIAN KA, 1984, CELL, V36, P741, DOI 10.1016/0092-8674(84)90354-4; Brachmann CB, 1998, YEAST, V14, P115; BUSSEY H, 1979, J BACTERIOL, V140, P888, DOI 10.1128/JB.140.3.888-892.1979; BUSSEY H, 1981, ADV MICROB PHYSIOL, V22, P93, DOI 10.1016/S0065-2911(08)60326-4; BUSSEY H, 1976, ANTIMICROB AGENTS CH, V9, P352, DOI 10.1128/AAC.9.2.352; BUSSEY H, 1990, EXPERIENTIA, V46, P193, DOI 10.1007/BF02027313; BUSSEY H, 1973, J BACTERIOL, V113, P1193, DOI 10.1128/JB.113.3.1193-1197.1973; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; Colquhoun David, 1995, P483; DELAPENA P, 1980, BIOCHEM BIOPH RES CO, V96, P544, DOI 10.1016/0006-291X(80)91390-X; DELAPENA P, 1981, J BIOL CHEM, V256, P420; Fairman C, 1999, J MEMBRANE BIOL, V168, P149, DOI 10.1007/s002329900505; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; ICHO T, 1989, J BIOL CHEM, V264, P6716; Ilan N, 1999, BIOPHYS J, V76, pA411; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KURZWEILOVA H, 1993, FOLIA MICROBIOL, V38, P524, DOI 10.1007/BF02814408; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Magliani W, 1997, CLIN MICROBIOL REV, V10, P369, DOI 10.1128/CMR.10.3.369; Bevan E. A., 1963, Genetics today. Proceedings of the XI International Congress of Genetics, The Hague, The Netherlands, September 1963., V1, P202; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; McIntosh J M, 1999, Methods Enzymol, V294, P605; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; MURPHY N, 1986, LANCET, V1, P291; PALFREE RGE, 1979, EUR J BIOCHEM, V93, P487, DOI 10.1111/j.1432-1033.1979.tb12847.x; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; PETTOELLOMANTOVANI M, 1995, GASTROENTEROLOGY, V109, P1900, DOI 10.1016/0016-5085(95)90757-2; POLONELLI L, 1986, MYCOPATHOLOGIA, V96, P103, DOI 10.1007/BF00436668; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Schmitt MJ, 1995, ARCH MICROBIOL, V164, P435; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIPPER N, 1984, EMBO J, V3, P107, DOI 10.1002/j.1460-2075.1984.tb01769.x; SKIPPER N, 1977, J BACTERIOL, V129, P668, DOI 10.1128/JB.129.2.668-677.1977; STARMER WT, 1987, CAN J MICROBIOL, V33, P783, DOI 10.1139/m87-134; STURLEY SL, 1986, EMBO J, V5, P3381, DOI 10.1002/j.1460-2075.1986.tb04654.x; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; THIELE DJ, 1982, NUCLEIC ACIDS RES, V10, P6903, DOI 10.1093/nar/10.21.6903; VANVUUREN HJJ, 1992, AM J ENOL VITICULT, V43, P119; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; WICKNER RB, 1974, J BACTERIOL, V117, P1356, DOI 10.1128/JB.117.3.1356-1357.1974; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZHU H, 1991, MOL CELL BIOL, V11, P175, DOI 10.1128/MCB.11.1.175	56	70	72	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					283	291		10.1016/S0092-8674(00)81659-1	http://dx.doi.org/10.1016/S0092-8674(00)81659-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555144	hybrid			2022-12-24	WOS:000083440600006
J	He, TC; Chan, TA; Vogelstein, B; Kinzler, KW				He, TC; Chan, TA; Vogelstein, B; Kinzler, KW			PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs	CELL			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TUMOR-SUPPRESSOR PROTEIN; HUMAN COLORECTAL-CANCER; RETINOID-X-RECEPTOR; PEROXISOME-PROLIFERATOR; BETA-CATENIN; FATTY-ACIDS; COLON-CANCER; ANTIINFLAMMATORY DRUGS; ADENOMATOUS POLYPOSIS	PPAR delta was identified as a target of APC through the analysis of global gene expression profiles in human colorectal cancer (CRC) cells. PPAR delta expression was elevated in CRCs and repressed by APC in CRC cells. This repression was mediated by beta-catenin/Tcf-4-responsive elements in the PPAR delta promotor. The ability of PPARs to bind eicosanoids suggested that PPAR delta might be a target of chemopreventive nonsteroidal anti-inflammatory drugs (NSAIDs). Reporters containing PPAR delta-responsive elements were repressed by the NSAID sulindac. Furthermore, sulindac was able to disrupt the ability of PPAR delta to bind its recognition sequences. These findings suggest that NSAIDs inhibit tumorigenesis through inhibition of PPAR delta, the gene for which is normally regulated by APC.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	kinzlke@welchlink.welch.jhu.edu	Chan, Timothy A/ABD-5850-2021		NATIONAL CANCER INSTITUTE [P50CA062924, R37CA057345, R01CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, P50 CA062924, CA62924, R37 CA057345, R01 CA057345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Reddy BS, 1999, CANCER RES, V59, P3387; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SANO H, 1995, CANCER RES, V55, P3785; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thun MJ, 1997, ADV EXP MED BIOL, V400, P395; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	61	979	1028	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					335	345		10.1016/S0092-8674(00)81664-5	http://dx.doi.org/10.1016/S0092-8674(00)81664-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555149	Green Accepted, hybrid			2022-12-24	WOS:000083440600011
J	Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH				Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH			A mammalian H+ channel generated through alternative splicing of the NADPH oxidase homolog NOH-1	SCIENCE			English	Article							HYDROGEN-ION CURRENTS; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; INTRACELLULAR PH; PROTON CURRENT; MEMBRANE; CONDUCTANCE; LEUKOCYTES	Voltage-gated proton (H+) channels are found in many human and animal tissues and play an important role in cellular defense against acidic stress. However, a molecular identification of these unique ion conductances has so far not been achieved. A 191-amino acid protein is described that, upon heterologous expression, has properties indistinguishable from those of native H+ channels. This protein is generated through alternative splicing of messenger RNA derived from the gene NOH-1 (NADPH oxidase homolog 1, where NADPH is the reduced form of nicotinamide adenine dinucleotide phosphate).	Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Dept Geriatr, Biol Aging Lab, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Fdn Rech Med, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Semmelweis Univ, Dept Physiol, H-1444 Budapest 8, Hungary	University of Geneva; University of Geneva; University of Geneva; University of Geneva; Semmelweis University	Demaurex, N (corresponding author), Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Sinha, Bhanu/0000-0003-1634-0010; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; BANFI B, UNPUB; BERNHEIM L, 1993, J PHYSIOL-LONDON, V470, P313, DOI 10.1113/jphysiol.1993.sp019860; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DECOURSEY TE, 1994, J MEMBRANE BIOL, V141, P203; Decoursey Thomas E., 1998, Frontiers in Bioscience, V3, pD477; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Hille B., 1992, IONIC CHANNELS EXCIT; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Kuno M, 1997, J GEN PHYSIOL, V109, P731, DOI 10.1085/jgp.109.6.731; NANDA A, 1994, J BIOL CHEM, V269, P27280; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Roos D, 1986, Methods Enzymol, V132, P250; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	26	240	252	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					138	142		10.1126/science.287.5450.138	http://dx.doi.org/10.1126/science.287.5450.138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615049				2022-12-24	WOS:000084578400054
J	McCarron, P; Harvey, I; Brogan, R; Peters, TJ				McCarron, P; Harvey, I; Brogan, R; Peters, TJ			Self reported health of people in an area contaminated by chromium waste: interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY EXPOSURE; SITES	Objectives To compare the self reported health of a group of individuals living in an area contaminated by chromium (chromium group) wtih a group living in an uncontaminated area (control group), and to assess the effects of perception of risk from exposure to chromium ori health. Design Cross sectional study using the SF-36 validated quality of life questionnaire. Further questions were added to examine the relations between perceptions about living on or near land contaminated with chromium and the effects on self reported health. Setting An area contaminated with chromium (Cambuslang, Carmyle, and Rutherglen) and a control area (Barrmulloch and Pollok). Participants Residents of an area containing chromium landfill and residents of an uncontaminated control area. Main outcome measures Scores on SF-36. Results Little difference was found in health scores between the two groups, and only for general health was there a significantly higher score in the chromium group. Health scores for the chromium group were significantly worse across all dimensions for chose who believed that chromium adversely affected health. Most of the chromium group (68%) would prefer money to be spent on improving amenities rather than on chromium remediation. Conclusions Similar self reported health among residents of the chromium and control groups indicates that there is no evidence of harm to health from exposure to chromium in this setting. Noticeably lower scores in participants who believed chromium to be harmful to health point to the potential importance of perception and possible anxiety. Given the overall greater desire for better amenities rather than remedial action, policy makers and planners should discuss with residents how best to spend resources before instigating expensive cleaning up programmes.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich R4 7TJ, Norfolk, England; Greater Glasgow Hlth Board, Glasgow G3 8YZ, Lanark, Scotland	University of Bristol; University of East Anglia	McCarron, P (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	P.McCarron@bristol.ac.uk						ANDERSON RA, 1993, J TOXICOL ENV HEALTH, V40, P555, DOI 10.1080/15287399309531819; Barnhart J, 1997, REGUL TOXICOL PHARM, V26, pS3, DOI 10.1006/rtph.1997.1132; BIDSTRUP P L, 1956, Br J Ind Med, V13, P260; BIDSTRUP PL, 1951, BRIT J IND MED, V8, P302; BIDSTRUP PL, 1983, ENCY OCCUPATIONAL HL; Carstairs V., 1991, DEPRIVATION HLTH SCO; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; *DEP PUBL HLTH, 1991, ASS RISK HUM HLTH LA; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; EIZAGUIRRE D, 1993, USE ROUTINE HLTH DAT; EIZAGUIRRE D, 1996, THESIS U GLASGOW GLA; EIZAGUIRRE D, 1999, IN PRESS J PUBLIC HL; Fagliano JA, 1997, REGUL TOXICOL PHARM, V26, pS13, DOI 10.1006/rtph.1997.1134; HUGHES K, 1994, ENVIRON CARCIN ECO R, V12, P237; *INT AG RES CANC, 1990, IARC MON EV CARC RIS, V38, P49; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LANGARD S, 1975, HDB TOXICOLOGY METAL; PASTIDES H, 1994, AM J IND MED, V25, P663, DOI 10.1002/ajim.4700250506; *PUBL AN STRATHCL, 1989, SOILS RUTH SIT INV; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; SHUSTERMAN D, 1991, ENVIRON HEALTH PERSP, V94, P25, DOI 10.2307/3431288; SLOVIC P, 1997, ENV HLTH, V54, P22; Ware J., 1993, SF 36 HLTH SURVEY MA	23	30	30	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2000	320	7226					11	15		10.1136/bmj.320.7226.11	http://dx.doi.org/10.1136/bmj.320.7226.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617516	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000084621600013
J	Sgro, CM; Partridge, L				Sgro, CM; Partridge, L			A delayed wave of death from reproduction in Drosophila	SCIENCE			English	Article							MORTALITY-RATES; LIFE-HISTORY; MELANOGASTER; LONGEVITY; SENESCENCE; EVOLUTION; SELECTION; COST; EXPOSURE; MALES	Mortality rates typically increase rapidly at the onset of aging but can decelerate at Later ages. Reproduction increases the death rate in many organisms. To test the idea that a delayed impact of earlier reproduction contributes to both an increase in death rates and a Later deceleration in mortality, the timing of the surplus mortality produced by an increased Level of egg production was measured in female Drosophila. Reproduction produced a delayed wave of mortality, coincident with the sharp increase in death rates at the onset of aging and the subsequent deceleration of mortality. These results suggest that aging has evolved primarily because of the damaging effects of reproduction earlier in Life, rather than because of mutations that have detrimental effects only at Late ages.	UCL, Dept Biol, London NW1 2HE, England	University of London; University College London	Partridge, L (corresponding author), UCL, Dept Biol, 4 Stephenson Way, London NW1 2HE, England.	l.partridge@ucl.ac.uk	Partridge, Linda/E-7342-2015; Sgro, Carla M/G-5166-2010; Sgro, Carla/A-2495-2010; Partridge, Linda/A-5501-2010	Partridge, Linda/0000-0001-9615-0094; Sgro, Carla/0000-0001-7950-2246				Ashburner M., 1989, DROSOPHILA LAB HDB; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BROOKS A, 1994, SCIENCE, V263, P668, DOI 10.1126/science.8303273; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HOULE D, 1994, GENETICS, V138, P773; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; LAMB MJ, 1964, J INSECT PHYSIOL, V10, P487, DOI 10.1016/0022-1910(64)90072-1; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; Medawar P., 1952, UNSOLVED PROBLEM BIO; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; Miller R. G., 1981, SURVIVAL ANAL; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Partridge L, 1999, P ROY SOC B-BIOL SCI, V266, P255, DOI 10.1098/rspb.1999.0630; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; Pletcher SD, 1998, GENETICS, V148, P287; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROSE MR, 1981, GENETICS, V97, P187; SMITH JM, 1958, J EXP BIOL, V35, P832; TATAR M, 1993, EVOLUTION, V47, P1302, DOI [10.2307/2410149, 10.1111/j.1558-5646.1993.tb02156.x]; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.1111/j.1558-5646.1995.tb02301.x	33	197	205	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2521	2524		10.1126/science.286.5449.2521	http://dx.doi.org/10.1126/science.286.5449.2521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617470	Green Submitted			2022-12-24	WOS:000084429700053
J	Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A				Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A			EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; DIPHTHERIA-TOXIN RECEPTOR; KINASE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; SECRETION; DOMAIN; ALPHA; CELLS	Cross-communication between different signalling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. The transactivation of epidermal growth factor receptor (EGFR)-dependent signalling pathways upon stimulation of G-protein-coupled receptors (GPCRs), which are critical for the mitogenic activity of ligands such as lysophosphatidic acid, endothelin, thrombin, bombesin and carbachol, provides evidence for such an interconnected communication network(1-4). Here we show that EGFR transactivation upon GPCR stimulation involves proHB-EGF and a metalloproteinase activity that is rapidly induced upon GPCR-ligand interaction. We show that inhibition of proHB-EGF processing blocks GPCR-induced EGFR transactivation and downstream signals, The pathophysiological significance of this mechanism is demonstrated by inhibition of constitutive EGFR activity upon treatment of PC3 prostate carcinoma cells with the metalloproteinase inhibitor batimastat. Together, our results establish a new mechanistic concept for cross-communication among different signalling systems.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	Ullrich@biochem.mpg.de						BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHING KZ, 1993, MOL CELL BIOCHEM, V126, P151, DOI 10.1007/BF00925693; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; GOLSHI K, 1995, MOL BIOL CELL, V6, P967; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	29	1445	1492	2	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					884	888		10.1038/47260	http://dx.doi.org/10.1038/47260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622253				2022-12-24	WOS:000084482000035
J	Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ				Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ			Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut	SCIENCE			English	Article							ENCEPHALITIS	West Nile (WN) virus, a mosquito-transmitted virus native to Africa. Asia. and Europe, was isolated from two species of mosquitoes, Culex pipiens and Aedes vexans, and from brain tissues of 28 American crows, Corvus brachyrhynchos, and one Cooper's hawk, Accipiter cooperii, in Connecticut. A portion of the genome of virus isolates from four different hosts was sequenced and analyzed by comparative phylogenetic analysis. Our isolates from Connecticut were similar to one another and most closely related to two WN isolates from Romania (2.8 and 3.6 percent difference). If established in North America, WN virus will likely have severe effects on human health and on the health of populations of birds.	Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA; Connecticut Agr Expt Stn, Dept Soil & Water, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06512 USA; Univ Connecticut, Dept Pathobiol, Storrs, CT 06269 USA	Connecticut Agricultural Experiment Station; Connecticut Agricultural Experiment Station; Yale University; University of Connecticut	Anderson, JF (corresponding author), Connecticut Agr Expt Stn, Dept Entomol, POB 1106, New Haven, CT 06504 USA.	john.f.anderson@po.state.ct.us; theodore.andreadis@po.state.ct.us; charles.vossbrinck@po.state.ct.us			NIAID NIH HHS [P01-AI-30548] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030548] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreadis TG, 1998, J MED ENTOMOL, V35, P296, DOI 10.1093/jmedent/35.3.296; ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P845; CHAYES CG, 1989, ARBOVIRUSES EPIDEMIO, V5, pCH49; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; KITAOKA MASAMI, 1950, JAPANESE MED JOUR, V3, P77; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Philip CB, 1943, P SOC EXP BIOL MED, V53, P49, DOI 10.3181/00379727-53-14180; Savage HM, 1999, AM J TROP MED HYG, V61, P600, DOI 10.4269/ajtmh.1999.61.600; Sibley CG., 1990, DISTRIBUTION TAXONOM; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872; WORK TH, 1953, P SOC EXP BIOL MED, V84, P719, DOI 10.3181/00379727-84-20764	19	267	299	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2331	2333		10.1126/science.286.5448.2331	http://dx.doi.org/10.1126/science.286.5448.2331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600741				2022-12-24	WOS:000084318500058
J	Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD				Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD			Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons	SCIENCE			English	Article							NERVE GROWTH-FACTOR; C-FOS; BCL-2; DEATH; PHOSPHORYLATION; MECHANISM; PROTEIN	Nerve growth factor (NGF) and other neurotrophins support survival of neurons through processes that are incompletely understood. The transcription factor CREB is a critical mediator of NGF-dependent gene expression, but whether CREB family transcription factors regulate expression of genes that contribute to NGF-dependent survival of sympathetic neurons is unknown. CREB-mediated gene expression was both necessary for NGF-dependent survival and sufficient on its own to promote survival of sympathetic neurons, Moreover, expression of Bcl-2 was activated by NGF and other neurotrophins by a CREB-dependent transcriptional mechanism. Overexpression of Bcl-2 reduced the death-promoting effects of CREB inhibition. Together, these data support a model in which neurotrophins promote survival of neurons, in part through a mechanism involving CREB family transcription factor-dependent expression of genes encoding prosurvival factors.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA	Johns Hopkins University; University of Pennsylvania	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Davenport, Christopher/0000-0003-2639-6392	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034814, R37NS034814, R29NS034814] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34814-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Lanahan A, 1997, J NEUROSCI, V17, P2876; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RICCIO A, UNPUB; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	23	663	682	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2358	2361		10.1126/science.286.5448.2358	http://dx.doi.org/10.1126/science.286.5448.2358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600750				2022-12-24	WOS:000084318500067
J	Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E				Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E			Functional characterization of a potassium-selective prokaryotic glutamate receptor	NATURE			English	Article							ACID-BINDING PROTEINS; AMPA RECEPTORS; EXPRESSION; CHANNELS; FAMILY; DESENSITIZATION; CONDUCTION; SEQUENCE; MUTATION; KAINATE	Ion channels are molecular pores that facilitate the passage of ions across cell membranes and participate in a range of biological processes, from excitatory signal transmission in the mammalian nervous system to the modulation of swimming behaviour in the protozoan Paramecium(1). Two particularly important families of ion channels are ionotropic glutamate receptors (GluRs)(2) and potassium channels(3,4). GluRs are permeable to Na+, K+ and Ca2+ are gated by glutamate, and have previously been found only in eukaryotes(2), In contrast, potassium channels are selective for K+, are gated by a range of stimuli, and are found in both prokaryotes and eukaryotes(3,4). Here we report the discovery and functional characterization of GluR0 from Synechocystis PCC 6803, which is the first GluR found in a prokaryote. GluR0 binds glutamate, forms potassium-selective channels and is related in amino-acid sequence to both eukaryotic GluRs and potassium channels. On the basis of amino-acid sequence and functional relationships between GluR0 and eukaryotic GluRs, we propose that a prokaryotic GluR was the precursor to eukaryotic GluRs. GluR0 provides evidence for the missing link between potassium channels and GluRs, and we suggest that their ion channels have a similar architecture, that GluRs are tetramers and that the gating mechanisms of GluRs and potassium channels have some essential features in common.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; NICHHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019; Mayer, Mark/AAE-7356-2019; Mayer, Mark L/H-5500-2013	Gouaux, Eric/0000-0002-8549-2360; Mayer, Mark/0000-0003-4378-8451; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Baro DJ, 1996, GENE, V170, P267, DOI 10.1016/0378-1119(95)00876-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Kaneko T, 1996, DNA Res, V3, P109; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEINANEN K, 1994, BIO-TECHNOL, V12, P802, DOI 10.1038/nbt0894-802; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lam HM, 1998, NATURE, V396, P125, DOI 10.1038/24066; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	30	269	282	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					817	821		10.1038/45568	http://dx.doi.org/10.1038/45568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617203				2022-12-24	WOS:000084330500067
J	Zorio, DAR; Blumenthal, T				Zorio, DAR; Blumenthal, T			Both subunits of U2AF recognize the 3 ' splice site in Caenorhabditis elegans	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; FUNCTIONAL-ANALYSIS; RNA; CLONING; DOMAIN; GENE	Introns are defined by sequences that bind components of the splicing machinery. The branchpoint consensus, polypyrimidine (poly(Y)) tract, and AG at the splice boundary comprise the mammalian 3' splice site(1), Although the AG is crucial for the recognition of introns with relatively short poly(Y) tracts, which are termed 'AG-dependent introns'(2), the molecule responsible for AG recognition has never been identified. A key player in 3' splice site definition is the essential heterodimeric splicing factor U2AF, which facilitates the interaction of the U2 small nuclear ribonucleoprotein particle with the branch point. The U2AF subunit with a relative molecular mass (M-r 65K) of 65,000 (U2AF(65)) binds to the poly(Y) tract(3-7), whereas the role of the 35K subunit (U2AF(35))(8) has not been clearly defined. It is not required for splicing in vitro(4) but it plays a critical role in vivo(9,10) Caenorhabiditis elegans introns have a highly conserved U(4)CAG/R at their 3' splice sites instead of branch-point and poly(Y) consensus sequences(11). Nevertheless, C. elegans has U2AF (refs 10, 12). Here we show that both U2AF subunits crosslink to the 3' splice site. Our results suggest that the U2AF(65)-U2AF(35) complex identifies the U(4)CAG/R, with U2AF35 being responsible for recognition of the canonical AG.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Indiana University System; Indiana University Bloomington	Blumenthal, T (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.							BLUMENTHAL T, 1997, C ELEGANS, V2, P117; CONRAD R, 1993, NUCLEIC ACIDS RES, V21, P913, DOI 10.1093/nar/21.4.913; JONES D, 1986, J BIOL CHEM, V261, P2006; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MacMorris MA, 1999, P NATL ACAD SCI USA, V96, P3813, DOI 10.1073/pnas.96.7.3813; Moore M., 1993, RNA WORLD, P303; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; Rudner DZ, 1998, MOL CELL BIOL, V18, P4004, DOI 10.1128/MCB.18.7.4004; RUSKIN B, 1988, CELL, V52, P201; STROEHER VL, 1994, DEV BIOL, V163, P367, DOI 10.1006/dbio.1994.1155; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAMORE PD, 1991, EMBO J, V10, P210; Zhang HB, 1996, RNA, V2, P380; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1997, MOL CELL BIOL, V17, P946, DOI 10.1128/MCB.17.2.946; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225	20	195	221	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					835	838		10.1038/45597	http://dx.doi.org/10.1038/45597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617207				2022-12-24	WOS:000084330500071
J	Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM				Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM			Control of early viral and bacterial distribution and disease by natural antibodies	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CELL-DEFICIENT MICE; B-CELLS; ANTIVIRAL PROTECTION; IMMUNE-RESPONSE; CRUCIAL ROLE; COMPLEMENT; INFECTION; MEMORY	Natural antibodies are often dismissed from immunological analysis as "background," but they may play an important role in conferring immunity against infections. In antibody-free mice infected with various viruses or with Listeria monocytogenes, viral or bacterial titers in peripheral organs, including the kidney and brain, were 10 to 100 times greater than in antibody-competent mice (and enhanced their susceptibility to some infections), and titers in secondary Lymphoid organs were 10 to 100 times lower than in antibody-competent mice. Thus, natural antibodies play a crucial role by preventing pathogen dissemination to vital organs and by improving immunogenicity through enhanced antigen-trapping in secondary Lymphoid organs.	Univ Hosp Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Max Planck Inst Immunobiol, Freiburg, Germany; Univ Zurich, Inst Virol, CH-8006 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	University of Zurich; University Zurich Hospital; Max Planck Society; University of Zurich; University of Cape Town	Ochsenbein, AF (corresponding author), Univ Hosp Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Fehr, Thomas/AFQ-9308-2022	Fehr, Thomas/0000-0003-1668-1800; Ochsenbein, Adrian/0000-0003-1773-5436				AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COUTINHO A, 1989, IMMUNOL REV, V110, P63, DOI 10.1111/j.1600-065X.1989.tb00027.x; DIETZSCHOLD B, 1995, VIROLOGY, P1137; Ehrenstein MR, 1998, P NATL ACAD SCI USA, V95, P10089, DOI 10.1073/pnas.95.17.10089; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; Fehr T, 1998, J EXP MED, V188, P145, DOI 10.1084/jem.188.1.145; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; FREI PC, 1968, J IMMUNOL, V101, P605; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; GOBET R, 1988, EXP CELL BIOL, V56, P175; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LAMERS MC, 1981, EUR J IMMUNOL, V11, P764, DOI 10.1002/eji.1830111006; Lutz C, 1998, NATURE, V393, P797, DOI 10.1038/31716; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Reid RR, 1997, J IMMUNOL, V159, P970; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; Thomsen AR, 1996, J IMMUNOL, V157, P3074; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; THORNTON BP, 1994, J IMMUNOL, V152, P1727; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; WAGNER RR, 1987, RHABDOVIRUSES; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WILSON GS, 1961, PRINCIPLES BACTERIOL, P1223	39	701	738	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2156	2159		10.1126/science.286.5447.2156	http://dx.doi.org/10.1126/science.286.5447.2156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591647				2022-12-24	WOS:000084157300052
J	Friedlander, AM; Pittman, PR; Parker, GW				Friedlander, AM; Pittman, PR; Parker, GW			Anthrax vaccine - Evidence for safety and efficacy against inhalational anthrax	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROTECTIVE ANTIGEN; GUINEA-PIGS; SPORE CHALLENGE; ADJUVANTS		USA, Med Res Inst Infect Dis, Ft Detrick, Frederick, MD 21702 USA		Friedlander, AM (corresponding author), USA, Med Res Inst Infect Dis, Ft Detrick, 1425 Porter St, Frederick, MD 21702 USA.	friedlan@ncifcrf.gov	Pittman, Phillip/S-3203-2019; Pittman, Phillip/ADI-6097-2022	Pittman, Phillip/0000-0003-1787-759X; 				AUERBACH S, 1955, J IMMUNOL, V75, P129; Brachman P. S., 1999, VACCINES, P629; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; FELLOWS PF, 1998, 3 INT C ANTHR SEPT P; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; FRITZ DL, 1995, LAB INVEST, V73, P691; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Ivins B, 1995, VACCINE, V13, P1779, DOI 10.1016/0264-410X(95)00139-R; Ivins B.E., 1996, SALISBURY MED B, V87, P125; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; Ivins BE, 1998, VACCINE, V16, P1141, DOI 10.1016/S0264-410X(98)80112-6; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; IVINS BE, 1999, COMMUNICATION    JUL; LITTLE SF, 1986, INFECT IMMUN, V52, P509, DOI 10.1128/IAI.52.2.509-512.1986; PITT ML, 1999, COMMUNICATION    JUL; Pitt MLM, 1999, J APPL MICROBIOL, V87, P304, DOI 10.1046/j.1365-2672.1999.00897.x; PITT MLM, 1996, SALISBURY MED B S, V87, P130; PITTMAN PR, 1999, COMMUNICATION    JUL; STRAWDER G, 1999, COMMUNICATION    AUG; TURNBULL PCB, 1986, INFECT IMMUN, V52, P356, DOI 10.1128/IAI.52.2.356-363.1986; 1985, FED REG, V50, P51058	21	131	137	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2104	2106		10.1001/jama.282.22.2104	http://dx.doi.org/10.1001/jama.282.22.2104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591317				2022-12-24	WOS:000083971400002
J	Lissauer, JJ				Lissauer, JJ			How common are habitable planets?	NATURE			English	Article							IMPACTS; ASTEROIDS; SYSTEMS; COMETS; EARTH	The Earth is teeming with life, which occupies a diverse array of environments; other bodies in our Solar System offer fewer, if any, niches that are habitable by life as we know it. Nonetheless, astronomical studies suggest that many habitable planets may be present within our Galaxy.	NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lissauer, JJ (corresponding author), NASA, Ames Res Ctr, Div Space Sci, MS 245-3, Moffett Field, CA 94035 USA.							CHAPMAN CR, 1994, NATURE, V367, P33, DOI 10.1038/367033a0; Joshi MM, 1997, ICARUS, V129, P450, DOI 10.1006/icar.1997.5793; LEWIS JS, 1998, WORLDS END EXPLORATI; Lissauer JJ, 1999, REV MOD PHYS, V71, P835, DOI 10.1103/RevModPhys.71.835; LISSAUER JJ, 1995, ICARUS, V114, P217, DOI 10.1006/icar.1995.1057; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; SAFRONOV VS, 1972, PUBLICATION NASA; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Toon OB, 1997, REV GEOPHYS, V35, P41, DOI 10.1029/96RG03038; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; WETHERILL GW, 1994, ASTROPHYS SPACE SCI, V212, P23, DOI 10.1007/BF00984505	12	17	18	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C11	C14		10.1038/35011503	http://dx.doi.org/10.1038/35011503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591221	Green Submitted			2022-12-24	WOS:000084014100002
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP			Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							FETAL GROWTH; CARDIOVASCULAR-DISEASE; ADULT LIFE; IN-UTERO; MEN; COHORT; DEATH; SIZE; VALIDITY; FINLAND	Objective To examine whether women who develop coronary heart disease have different patterns of fetal and childhood growth from men in the same cohort who develop the disease. Design Follow up study of women whose body size at birth was recorded and who had an average of 10 measurements of height and weight during childhood. Setting Helsinki, Finland. Subjects 3447 women who were born in Helsinki University Central Hospital during 1924-33 and who went to school in Helsinki. Main outcome measures Hazard ratios for hospital admission for or death from coronary heart disease. Results Coronary heart disease among women was associated with low birth weight (P = 0.08 after adjustment for gestation, P = 0.007 after adjustment for placental weight) and was more strongly associated with short body length at birth (P = 0.001 and P < 0.0001, respectively). The hazard ratio for women developing coronary heart disease increased by 10.2% (95% confidence interval 4.3 to 15.7) for each rm decrease in length at birth. The effect of short length at birth was greatest in women whose height "caught up" after birth so that as girls they were tall. Such girls tended to have tall mothers. In contrast, men in the same cohort who developed the disease were thin at birth rather than short, showed "catch up" growth in weight rather than height, and their mothers tended to be overweight rather than tall. Conclusion Coronary heart disease among both women and men reflects poor prenatal nutrition and consequent small body size at birth combined with improved postnatal nutrition and "catch up" growth in childhood. The disease is associated with reductions in those aspects of body proportions at birth that distinguish die two sexes-short body length in women and thinness in men.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.			Osmond, Clive/0000-0002-9054-4655				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; Barker DJP, 1998, MOTHERS BABIES HLTH; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; GARN SM, 1974, AM J PHYS ANTHROPOL, V41, P353, DOI 10.1002/ajpa.1330410302; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Mahonen M, 1997, EUR J EPIDEMIOL, V13, P403, DOI 10.1023/A:1007306110822; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; PEDERSEN JF, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253; PITTS GC, 1986, GROWTH, V50, P419; Rapola JM, 1997, EUR J EPIDEMIOL, V13, P133, DOI 10.1023/A:1007380408729; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; TANNER JM, 1989, FOETUS MAN; WIDDOWSON EM, 1963, PROC R SOC SER B-BIO, V158, P329, DOI 10.1098/rspb.1963.0051	25	333	334	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1403	1407		10.1136/bmj.319.7222.1403	http://dx.doi.org/10.1136/bmj.319.7222.1403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574856	Green Published, Bronze			2022-12-24	WOS:000083995200027
J	Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A				Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A			Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Aldemoor Hlth Ctr, Acad Dept Primary Med Care, Southampton SO9 5NH, Hants, England; Univ Southampton, Southampton Gen Hosp, Dept Med Stat, Southampton SO9 5NH, Hants, England; Queen Alexandra Hosp, Postgrad Med Sch, Portsmouth PO6 3LY, Hants, England; Sch Nursing, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	George, S (corresponding author), Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	pluto@soton.ac.uk	Smith, Helen E/M-2449-2016; Moore, Michael/C-3447-2011	Smith, Helen E/0000-0003-1883-6124; Moore, Michael/0000-0002-5127-4509; Turnbull, Joanne/0000-0002-5006-4438				Brogan C, 1998, BRIT MED J, V316, P524, DOI 10.1136/bmj.316.7130.524; *COLL HLTH, 1998, DEV NHS DIR; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054	4	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1408	1408		10.1136/bmj.319.7222.1408	http://dx.doi.org/10.1136/bmj.319.7222.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574857	Green Published, Green Accepted, Bronze			2022-12-24	WOS:000083995200028
J	Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G				Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G			Development - Ubiquitin tag for sperm mitochondria	NATURE			English	Article							DNA; INHERITANCE; FATE		Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell Dev Biol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Obstet Gynecol, Beaverton, OR 97006 USA; Int Ctr Canc Res & Dev Biol, Santiago, Chile; Univ Coimbra, Dept Zool, Ctr Neurosci, Coimbra, Portugal	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Universidade de Coimbra	Sutovsky, P (corresponding author), Oregon Reg Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	schatten@ohsu.edu	Moreno, Ricardo R/C-6802-2011; Santos, João/HHZ-5595-2022; Ramalho-Santos, João/F-8641-2012; simerly, Calvin/AAC-9564-2021; Schatten, Gerald/B-3253-2009	Ramalho-Santos, João/0000-0002-1172-4018; Schatten, Gerald/0000-0001-5206-7782; Moreno, Ricardo/0000-0002-7499-5501; Sutovsky, Peter/0000-0002-9231-2823				BARRIT J, 1999, FERTIL STERIL, V72, P31; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HUTCHINSON SA, 1974, NATURE, V251, P536; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; PERREAULT SD, 1984, DEV BIOL, V101, P160, DOI 10.1016/0012-1606(84)90126-X; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Sutovsky P, 1996, BIOL REPROD, V55, P1195, DOI 10.1095/biolreprod55.6.1195; SZOLLOSI D, 1965, J EXP ZOOL, V159, P367, DOI 10.1002/jez.1401590309	14	446	474	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					371	372		10.1038/46466	http://dx.doi.org/10.1038/46466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586873				2022-12-24	WOS:000083913600042
J	Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA				Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA			p27(Xic1), a cdk inhibitor, promotes the determination of glial cells in Xenopus retina	CELL			English	Article							DEPENDENT-KINASE INHIBITOR; PROGENITOR CELLS; RAT RETINA; ROD PHOTORECEPTORS; NERVOUS-SYSTEM; PROTEIN-KINASE; MOUSE RETINA; MICE LACKING; CYCLIN-A; P27(KIP1)	p27(Xic1), a member of the Cip/Kip family of Cdk inhibitors, besides its known function of inhibiting cell division, induces Muller glia from retinoblasts. This novel gliogenic function of p27(Xic1) is mediated by part of the N-terminal domain near but distinct from the region that inhibits cyclin-dependent kinases. Cotransfections with dominant-negative and constitutively active Delta and Notch constructs indicate that the gliogenic effects of p27(Xic1) work within the context of an active Notch pathway. The gradual increase of p27(Xic1) in the developing retina thus not only limits the number of retinal cells but also increasingly favors the fate of the last cell type to be born in the retina, the Muller glia.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Ohnuma, Shin-ichi/0000-0002-3305-5126; Philpott, Anna/0000-0003-3789-2463; Holt, Christine Elizabeth/0000-0003-2829-121X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Bohner AP, 1997, DEVELOPMENT, V124, P915; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chang WS, 1998, J NEUROBIOL, V35, P227; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; Dowling J. E., 1987, RETINA APPROACHABLE; DRAGER UC, 1984, J NEUROSCI, V4, P2025; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARPER JW, 1993, CELL, V75, P805; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Jensen AM, 1997, DEV BIOL, V188, P267, DOI 10.1006/dbio.1997.8645; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; McFarlane S, 1998, DEVELOPMENT, V125, P3967; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1997, J NEUROSCI, V17, P8975; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Raff MC, 1998, INT J DEV BIOL, V42, P263; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Tikoo R, 1998, J NEUROBIOL, V36, P431, DOI 10.1002/(SICI)1097-4695(19980905)36:3<431::AID-NEU10>3.3.CO;2-N; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; Welcker M, 1998, CANCER RES, V58, P5053; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao SL, 1996, BRAIN RES, V723, P169, DOI 10.1016/0006-8993(96)00237-5; Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7	62	189	189	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					499	510		10.1016/S0092-8674(00)81538-X	http://dx.doi.org/10.1016/S0092-8674(00)81538-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589678	Bronze			2022-12-24	WOS:000083986300009
J	Murphy, PC; Duckett, SG; Sillito, AM				Murphy, PC; Duckett, SG; Sillito, AM			Feedback connections to the lateral geniculate nucleus and cortical response properties	SCIENCE			English	Article							CAT VISUAL-CORTEX; CORTICOFUGAL FEEDBACK; NEURONS; PATHWAY; CELLS; AREA-17; HYPOTHESIS; MORPHOLOGY	The cerebral cortex receives sensory input from the periphery by means of thalamic relay nuclei, but the flow of information goes both ways. Each cortical area sends a reciprocal projection back to the thalamus. In the visual system, the synaptic relations that govern the influence of thalamic afferents on orientation selectivity in the cortex have been studied extensively. It now appears that the connectivity of the corticofugal feedback pathway is also fundamentally linked to the orientation preference of the cortical cells involved.	Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England	St Georges University London; University of London; University College London	Murphy, PC (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England.	p.murphy@sghms.ac.uk						AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALBUS K, 1975, EXP BRAIN RES, V24, P181, DOI 10.1007/BF00234062; ANDOLINA IM, UNPUB; Cudeiro J, 1996, J PHYSIOL-LONDON, V490, P481, DOI 10.1113/jphysiol.1996.sp021159; Das A, 1999, NATURE, V399, P655, DOI 10.1038/21371; DAVIES OL, 1984, STAT METHODS RES PRO, P208; Erisir A, 1997, P NATL ACAD SCI USA, V94, P1517, DOI 10.1073/pnas.94.4.1517; GRIEVE KL, 1995, J NEUROSCI, V15, P4868; HARVEY AR, 1980, J PHYSIOL-LONDON, V302, P507; HENRY GH, 1994, PROG NEUROBIOL, V43, P381, DOI 10.1016/0301-0082(94)90061-2; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KATZ LC, 1987, J NEUROSCI, V7, P1223; KOCH C, 1987, NEUROSCIENCE, V23, P399, DOI 10.1016/0306-4522(87)90064-9; Maldonado PE, 1996, VISUAL NEUROSCI, V13, P509, DOI 10.1017/S095252380000818X; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; MONTERO VM, 1991, EXP BRAIN RES, V86, P257; MURPHY PC, 1987, NATURE, V329, P727, DOI 10.1038/329727a0; Murphy PC, 1996, J NEUROSCI, V16, P1180; Murphy PC, 1996, J PHYSIOL-LONDON, V494P, pP17; Pinault D, 1996, J NEUROSCI METH, V65, P113, DOI 10.1016/0165-0270(95)00144-1; SANDERUD A, 1971, Scandinavian Journal of Thoracic and Cardiovascular Surgery, V5, P143, DOI 10.3109/14017437109135546; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; Usrey WM, 1999, ANNU REV PHYSIOL, V61, P435, DOI 10.1146/annurev.physiol.61.1.435; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	28	114	116	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1552	1554		10.1126/science.286.5444.1552	http://dx.doi.org/10.1126/science.286.5444.1552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567260				2022-12-24	WOS:000083768300056
J	Arango, NA; Lovell-Badge, R; Behringer, RR				Arango, NA; Lovell-Badge, R; Behringer, RR			Targeted mutagenesis of the endogenous mouse Mis gene promoter: In vivo definition of genetic pathways of vertebrate sexual development	CELL			English	Article							MULLERIAN-INHIBITING SUBSTANCE; STEROIDOGENIC FACTOR-I; SRY-RELATED GENE; NUCLEAR RECEPTOR SF-1; CAMPOMELIC DYSPLASIA; GONADAL DEVELOPMENT; HORMONE-RECEPTOR; TRANSGENIC MICE; SOX9 EXPRESSION; DIFFERENTIATION	Mutations were introduced into conserved steroidogenic factor 1 (SF1)- and SOX9-binding sites within the endogenous mouse Mullerian inhibiting substance (Mis) promoter. Male mice homozygous for the mutant SF1-binding site correctly initiated Mis transcription in fetal testes, although at significantly reduced levels. Surprisingly, sufficient MIS was produced to eliminate the Mullerian ducts. In contrast, males homozygous for the mutant SOX9-binding site did not initiate Mis transcription, resulting in pseudohermaphrodites. These studies suggest an essential role for SOX9 in the initiation of Mis transcription, whereas SF1 appears to act as a quantitative regulator of Mis transcript levels, perhaps for influencing non-Mullerian duct tissues. Comparative studies of Mis expression in vertebrates indicate that the Mis promoter receives transcriptional inputs that vary between species but result in the same functional readout.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Inst Med Res, Div Dev Genet, London NW7 1AA, England	University of Texas System; UTMD Anderson Cancer Center; MRC National Institute for Medical Research	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; NCI NIH HHS [CA09299] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD030284, R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baroiller JF, 1999, CELL MOL LIFE SCI, V55, P910, DOI 10.1007/s000180050344; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARREEUSEBE D, 1996, J BIOL CHEM, V271, P4798; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DRESSER DW, 1995, HUM MOL GENET, V4, P1613, DOI 10.1093/hmg/4.9.1613; ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Giuili G, 1997, DEVELOPMENT, V124, P1799; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Kent J, 1996, DEVELOPMENT, V122, P2813; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Koopman P, 1993, ESSENTIAL DEV BIOL P, P233; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lee MM, 1999, ENDOCRINOLOGY, V140, P2819, DOI 10.1210/en.140.6.2819; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYET L, 1995, BIOL REPROD, V52, P444, DOI 10.1095/biolreprod52.2.444; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1995, MOL ENDOCRINOL, V9, P1337, DOI 10.1210/me.9.10.1337; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meier C, 1998, CAN J ZOOL, V76, P1188, DOI 10.1139/cjz-76-6-1188; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Neeper M, 1996, GENE, V176, P203, DOI 10.1016/0378-1119(96)00248-X; Oreal E, 1998, DEV DYNAM, V212, P522, DOI 10.1002/(SICI)1097-0177(199808)212:4<522::AID-AJA5>3.0.CO;2-J; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; Pieau Claude, 1994, P433; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Smith CA, 1999, GEN COMP ENDOCR, V113, P187, DOI 10.1006/gcen.1998.7214; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Viger RS, 1998, DEVELOPMENT, V125, P2665; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Western PS, 1999, DEV DYNAM, V214, P171, DOI 10.1002/(SICI)1097-0177(199903)214:3<171::AID-AJA1>3.0.CO;2-S; WIBBELS T, 1992, J EXP ZOOL, V262, P454, DOI 10.1002/jez.1402620413; Wibbels T, 1998, J EXP ZOOL, V281, P409, DOI 10.1002/(SICI)1097-010X(19980801)281:5<409::AID-JEZ6>3.0.CO;2-S; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	66	356	364	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					409	419		10.1016/S0092-8674(00)81527-5	http://dx.doi.org/10.1016/S0092-8674(00)81527-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571183	Bronze			2022-12-24	WOS:000083709300008
J	Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL				Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL			Induction of metaphase arrest in cleaving Xenopus embryos in by the protein kinase p90(Rsk)	SCIENCE			English	Article							OOCYTE MATURATION; MAP KINASE; MOS; PHOSPHORYLATION; DOMAINS; ACTIVATION; PP90(RSK); CELLS	Before fertilization, vertebrate eggs are arrested in metaphase of meiosis II by cytostatic factor (CSF), an activity that requires activation of the mitogen-activated protein kinase (MAPK) pathway. To investigate whether CSF arrest is mediated by the protein kinase p90(Rsk), which is phosphorylated and activated by MAPK, a constitutively activated (CA) form of Rsk was expressed in Xenopus embryos. Expression of CA Rsk resulted in cleavage arrest, and cytological analysis showed that arrested blastomeres were in M phase with prominent spindles characteristic of meiotic metaphase. Thus, Rsk appears to be the mediator of MAPK-dependent CSF arrest in vertebrate unfertilized eggs.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.			Gross, Stefan/0000-0002-5645-7304	NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MOLLER DE, 1994, AM J PHYSIOL, V266, P351; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	20	133	141	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1365	1367		10.1126/science.286.5443.1365	http://dx.doi.org/10.1126/science.286.5443.1365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558992				2022-12-24	WOS:000083675500044
J	Jonas, EA; Buchanan, J; Kaczmarek, LK				Jonas, EA; Buchanan, J; Kaczmarek, LK			Prolonged activation of mitochondrial conductances during synaptic transmission	SCIENCE			English	Article							SQUID GIANT SYNAPSE; PERMEABILITY TRANSITION PORE; DIVALENT-CATIONS; OUTER-MEMBRANE; POSTTETANIC POTENTIATION; TRANSMITTER RELEASE; CHANNEL ACTIVITY; CA2+ TRANSIENTS; CALCIUM; MODULATION	Although ion channels have been detected in mitochondria, scientists have not been able to record ion transport in mitochondria of intact cells. A Variation of the patch clamp technique was used to record ion channel activity from intracellular organelles in the presynaptic terminal of the squid. Electron microscopy indicated that mitochondria are numerous in this terminal and are the only organelles compatible with the tips of the pipettes. Before synaptic stimulation, channel activity was infrequent and its conductance was small, although Large conductances (similar to 0.5 to 2.5 nanosiemens) could be detected occasionally. During a train of action potentials, the conductance of the mitochondrial membrane increased up to 60-fold, The conductance increased after a delay of several hundred milliseconds and continued to increase after stimulation had stopped. Recovery occurred over tens of seconds.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Yale University; Stanford University	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.	leonard.kaczmarek@yale.edu						ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; ANTONENKO YN, 1994, BBA-BIOMEMBRANES, V1194, P247, DOI 10.1016/0005-2736(94)90306-9; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CHARLTON MP, 1978, J GEN PHYSIOL, V72, P471, DOI 10.1085/jgp.72.4.471; Colombini M, 1996, Ion Channels, V4, P169; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Dresbach T, 1998, J NEUROSCI, V18, P2923; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jonas EA, 1997, NEURON, V19, P7, DOI 10.1016/S0896-6273(00)80343-8; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KINNALLY KW, 1994, MOL BIOL MITOCHONDRI, P169; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LEHNINGE.AL, 1970, BIOCHEM J, V119, P128; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Peng YY, 1998, J NEUROPHYSIOL, V80, P186, DOI 10.1152/jn.1998.80.1.186; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Pivovarova NB, 1998, J GEN PHYSIOL, V112, p39A; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SZABO I, 1992, J BIOL CHEM, V267, P2940; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9	45	76	77	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1347	1350		10.1126/science.286.5443.1347	http://dx.doi.org/10.1126/science.286.5443.1347			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558987				2022-12-24	WOS:000083675500039
J	Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM				Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM			Activation of PPAR gamma coactivator-1 through transcription factor docking	SCIENCE			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; ONCOPROTEIN; BINDING; SRC-1; E1A	Transcriptional coactivators have been viewed as constitutively active components, using transcription factors mainly to Localize their functions. Here, it is shown that PPAR gamma coactivator-1 (PGC-1) promotes transcription through the assembly of a complex that includes the histone acetyltransferases steroid receptor coactivator-1 (SRC-1) and CREB binding protein (CBP)/p300. PGC-1 has a Low inherent transcriptional activity when it is not bound to a transcription factor. The docking of PGC-1 to peroxisome proliferator-activated receptor gamma (PPAR gamma) stimulates an apparent conformational change in PGC-1 that permits binding of SRC-1 and CBP/p300, resulting in a Large increase in transcriptional activity. Thus, transcription factor docking switches on the activity of a coactivator protein.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77040 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Baylor College of Medicine	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, R56DK054477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZU Z, 1999, CELL, V98, P115	21	465	489	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1368	1371		10.1126/science.286.5443.1368	http://dx.doi.org/10.1126/science.286.5443.1368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558993				2022-12-24	WOS:000083675500045
J	Buschbeck, E; Ehmer, B; Hoy, R				Buschbeck, E; Ehmer, B; Hoy, R			Chunk versus point sampling: Visual imaging in a small insect	SCIENCE			English	Article							SPIDER CUPIENNIUS-SALEI; ONE BRAIN; EYES; SYSTEMS	The eyes of strepsipteran insects are very unusual among living insects. In their anatomical organization they may form a modern counterpart to the structural plan proposed for the eyes of some trilobites. Externally they differ from the usual "insect plan" by presenting far fewer but much larger lenses. Beneath each lens is its own independent retina. Anatomical and optical measurements indicate that each of these units is image-forming, so that the visual field is subdivided into and represented by "chunks," unlike the conventional insect compound eye that decomposes the visual image in a pointwise manner. This results in profound changes In the neural centers for vision and implies major evolutionary changes.	Cornell Univ, Ithaca, NY 14853 USA	Cornell University	Ehmer, B (corresponding author), Cornell Univ, Mudd Hall, Ithaca, NY 14853 USA.							BRUNO MS, 1977, J COMP PHYSIOL, V120, P123, DOI 10.1007/BF00619310; DUELLI P, 1994, CELL TISSUE RES, V187, P417; FORDYCE D, 1993, PALEOBIOLOGY, V19, P288, DOI 10.1017/S0094837300000282; GILBERT C, 1994, ANNU REV ENTOMOL, V39, P23; HORRIDGE GA, 1977, ENDEAVOUR, V1, P7, DOI 10.1016/0160-9327(77)90004-7; Kinzelbach R., 1971, Handb Zool Berl, V4, P1; Land M.F., 1981, HDB SENSORY PHYSL, P471, DOI DOI 10.1007/978-3-642-66907-14; LAND MF, 1969, J EXP BIOL, V51, P443; MACCARTHY H R, 1991, Journal of the Entomological Society of British Columbia, V88, P27; MEIXNER J, 1936, HDB ZOOLOGIE, P1349; Nilsson D.-E., 1989, P30; Paulus H.F., 1979, P299; ROSCH P, 1913, Z NATURWISS, V50, P97; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SNYDER AW, 1977, J COMP PHYSIOL, V116, P161, DOI 10.1007/BF00605401; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P63, DOI 10.1002/cne.903280105; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P43, DOI 10.1002/cne.903280104; Strohm Karl, 1910, Zoologischer Anzeiger Leipzig, V36; TOH Y, 1994, CELL TISSUE RES, V278, P125, DOI 10.1007/BF00305784; WACHMANN E, 1972, Z ZELLFORSCH MIK ANA, V123, P411, DOI 10.1007/BF00335640; WARRANT EJ, 1993, PROG NEUROBIOL, V40, P413, DOI 10.1016/0301-0082(93)90017-M; WILSON M, 1978, J COMP PHYSIOL, V124, P297, DOI 10.1007/BF00661380	22	54	56	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1178	1180		10.1126/science.286.5442.1178	http://dx.doi.org/10.1126/science.286.5442.1178			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550059				2022-12-24	WOS:000083534200049
J	Gibson, JR; Beierlein, M; Connors, BW				Gibson, JR; Beierlein, M; Connors, BW			Two networks of electrically coupled inhibitory neurons in neocortex	NATURE			English	Article							INTRINSIC FIRING PATTERNS; RAT FRONTAL-CORTEX; BARREL CORTEX; IN-VITRO; SOMATOSENSORY CORTEX; CIRCUIT FORMATION; GAP-JUNCTIONS; SYNCHRONIZATION; INTERNEURONS; EXCITATION	Inhibitory interneurons are critical to sensory transformations, plasticity and synchronous activity in the neocortex(1,2). There are many types of inhibitory neurons, but their synaptic organization is poorly understood. Here we describe two functionally distinct inhibitory networks comprising either fast-spiking (FS) or low-threshold spiking (LTS) neurons. Paired-cell recordings showed that inhibitory neurons of the same type were strongly interconnected by electrical synapses, but electrical synapses between different inhibitory cell types were rare. The electrical synapses;were strong enough to synchronize spikes in coupled interneurons. Inhibitory chemical synapses were also common between FS cells, and between FS and LTS cells, but LTS cells rarely inhibited one another. Thalamocortical synapses, which convey sensory information to the cortex, specifically and strongly excited only the FS cell network. The electrical and chemical synaptic connections of different types of inhibitory neurons are specific, and may allow each inhibitory network to function independently.	Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157; Beierlein, Michael/0000-0003-2210-3118				AGMON A, 1992, J NEUROSCI, V12, P319; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; Bennett M., 1977, HDB PHYSL          1, P357; BozhilovaPastirova A, 1995, NEUROSCI LETT, V201, P265, DOI 10.1016/0304-3940(95)12193-5; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; CHRISTIE MJ, 1989, J NEUROSCI, V9, P3584; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1983, J NEUROSCI, V3, P773; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Gil Z, 1999, NEURON, V23, P385, DOI 10.1016/S0896-6273(00)80788-6; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689, DOI 10.1152/physrev.1995.75.4.689; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; JOHNSTON MF, 1980, NATURE, V286, P498, DOI 10.1038/286498a0; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Mann-Metzer P, 1999, J NEUROSCI, V19, P3298; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; Nadarajah B, 1997, J NEUROSCI, V17, P3096; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; SIMONS DJ, 1984, J COMP NEUROL, V230, P119, DOI 10.1002/cne.902300111; SLOPER JJ, 1978, PROC R SOC SER B-BIO, V203, P39, DOI 10.1098/rspb.1978.0089; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Staiger JF, 1996, EUR J NEUROSCI, V8, P2273, DOI 10.1111/j.1460-9568.1996.tb01191.x; Swadlow HA, 1998, J NEUROPHYSIOL, V79, P567, DOI 10.1152/jn.1998.79.2.567; Thomson AM, 1997, CEREB CORTEX, V7, P510, DOI 10.1093/cercor/7.6.510; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985	30	1088	1106	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					75	79		10.1038/47035	http://dx.doi.org/10.1038/47035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573419				2022-12-24	WOS:000083638600045
J	Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T				Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T			Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; DEPENDENT NEURITE RETRACTION; CAPILLARY-TUBE FORMATION; FIBROBLAST GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; ANGIOGENESIS INVITRO; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-CLONING; RHO	Vascular endothelial cells undergo morphogenesis into capillary networks in response to angiogenic factors. We show here that sphingosine-1-phosphate (SPP), a platelet-derived bioactive lipid, activates the EDG-1 and -3 subtypes of G protein-coupled receptors on endothelial cells to regulate angiogenesis. SPP induces the G(i)/mitogen-activated protein kinase/cell survival pathway and the smalt GTPase Rho- and Rac-coupled adherens junction assembly. Both EDG-1- and EDG-3-regulated signaling pathways are required for endothelial cell morphogenesis into capillary-like networks. Indeed, SPP synergized with polypeptide angiogenic growth factors in the formation of mature neovessels in vivo. These data define SPP as a novel regulator of angiogenesis.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NCI NIH HHS [CA64436] Funding Source: Medline; NHLBI NIH HHS [HL54710] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064436, R01CA064436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; ANDELLIN N, 1999, J BIOL CHEM, V274, P18997; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Esser S, 1998, J CELL SCI, V111, P1853; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Ilan N, 1998, J CELL SCI, V111, P3621; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Satake S, 1998, BIOCHEM BIOPH RES CO, V244, P642, DOI 10.1006/bbrc.1998.8313; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yatomi Y, 1997, J BIOCHEM, V121, P969	49	827	854	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					301	312		10.1016/S0092-8674(00)81661-X	http://dx.doi.org/10.1016/S0092-8674(00)81661-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555146	Bronze			2022-12-24	WOS:000083440600008
J	Okano, M; Bell, DW; Haber, DA; Li, E				Okano, M; Bell, DW; Haber, DA; Li, E			DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development	CELL			English	Article							EMBRYONIC STEM-CELLS; ICF SYNDROME; MOUSE CELLS; GERM-LINE; CYTOSINE-5 METHYLTRANSFERASES; DENOVO METHYLATION; RETROVIRAL GENOMES; DE-NOVO; GENE; EXPRESSION	The establishment of DNA methylation patterns requires de novo methylation that occurs predominantly during early development and gametogenesis in mice. Here we demonstrate that two recently identified DNA methyltransferases, Dnmt3a and Dnmt3b, are essential for de novo methylation and for mouse development. inactivation of both genes by gene targeting blocks de novo methylation in ES cells and early embryos, but it has no effect on maintenance of imprinted methylation patterns. Dnmt3a and Dnmt3b also exhibit nonoverlapping functions in development, with Dnmt3b specifically required for methylation of centromeric minor satellite repeats. Mutations of human DNMT3B are found in ICF syndrome, a developmental defect characterized by hypomethylation of pericentromeric repeats. Our results indicate that both Dnmt3a and Dnmt3b function as de novo methyltransferases that play important roles in normal development and disease.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Li, E (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	en@cvrc.mgh.harvard.edu			NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BROCKDORFF N, 1997, GENOMIC IMPRINTING, P191; CARPENTER NJ, 1988, J PEDIATR-US, V112, P757, DOI 10.1016/S0022-3476(88)80698-X; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; EHRLICH M, 1999, DNA ALTERATIONS CANC; FEIL R, 1994, DEVELOPMENT, V120, P2933; Hasties ND, 1989, GENETIC VARIANTS STR, P559; Hogan B, 1994, MANIPULATING MOUSE E; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E., 1997, V18, P1; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; MONK M, 1987, DEVELOPMENT, V99, P371; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SMEETS DFCM, 1994, HUM GENET, V94, P240; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	47	4198	4400	16	379	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					247	257		10.1016/S0092-8674(00)81656-6	http://dx.doi.org/10.1016/S0092-8674(00)81656-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555141	Bronze			2022-12-24	WOS:000083440600003
J	Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK				Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK			The mechanism of membrane insertion for a cholesterol-dependent cytolysin: A novel paradigm for pore-forming toxins	CELL			English	Article							PERFRINGOLYSIN-O; PROTECTIVE ANTIGEN; THETA-TOXIN; BINDING; IDENTIFICATION; HEMOLYSIN; BILAYERS; DOMAIN	Perfringolysin O (PFO), a water-soluble monomeric cytolysin secreted by pathogenic Clostridium perfringens, oligomerizes and forms large pores upon encountering cholesterol-containing membranes. Whereas all pore-forming bacterial toxins examined previously have been shown to penetrate the membrane using a single amphipathic beta hairpin per polypeptide, cysteine-scanning mutagenesis and multiple independent fluorescence techniques here reveal that each PFO monomer contains a second domain involved in pore formation, and that each of the two amphipathic a hairpins completely spans the membrane. In the soluble monomer, these transmembrane segments are folded into six alpha helices. The insertion of two transmembrane hairpins per toxin monomer and the major change in secondary structure are striking and define a novel paradigm far the mechanism of membrane insertion by a cytolytic toxin.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Vincents Inst Med Res, Ian Potter Fdn, Prot Crystallog Lab, Fitzroy, Vic 3065, Australia	Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St. Vincent's Institute of Medical Research	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Johnson, Arthur E/G-3457-2012; Parker, Michael W/F-9069-2013; Rossjohn, Jamie/F-9032-2013	Parker, Michael W/0000-0002-3101-1138; Rossjohn, Jamie/0000-0002-2020-7522	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37657, R01 AI037657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207	16	288	292	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					293	299		10.1016/S0092-8674(00)81660-8	http://dx.doi.org/10.1016/S0092-8674(00)81660-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555145	Bronze			2022-12-24	WOS:000083440600007
J	Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J				Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J			Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex	NATURE			English	Article							S-PHASE PROGRESSION; CELL-CYCLE; RETINOBLASTOMA-PROTEIN; MITOTIC CYCLINS; PROTEOLYSIS; MITOSIS; ACTIVATION; FAMILY; UBIQUITIN; YEAST	In mammalian somatic-cell cycles, progression through the G1-phase restriction point and initiation of DNA replication are controlled by the ability of the retinoblastoma tumour-suppressor protein (pRb) family to regulate the E2F/DP transcription factors(1,2). Continuing transcription of E2F target genes beyond the G1/S transition is required for coordinating S-phase progression with cell division(3-5), a process driven by cyclin-B-dependent kinase(6,7) and anaphase-promoting complex (APC)-mediated proteolysis(8). How E2F-dependent events at G1/S transition are orchestrated with cyclin B and APC activity remains unknown. Here, using an in vivo assay to measure protein stability in real time during the cell cycle, we show that repression of E2F activity or inhibition of cyclin-A-dependent kinase in S phase triggers the destruction of cyclin B1 through the re-assembly of APC, the ubiquitin ligase that is essential for mitotic cyclin proteolysis(9), with its activatory subunit Cdh1 (refs 10-13). Phosphorylation-deficient mutant Cdh1 or immunodepletion of cyclin A resulted in assembly of active Cdh1-APC even in S-phase cells. These results implicate an E2F-dependent, cyclin A/Cdk2-mediated phosphorylation of Cdh1 in the timely accumulation of cyclin B1 and the coordination of cell-cycle progression during the post-restriction point period.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Res Inst Mol Pathol, A-1030 Vienna, Austria	Danish Cancer Society; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020; Kramer, Edgar/A-9288-2012	Santoni-Rugiu, Eric/0000-0002-2283-3535; Kramer, Edgar/0000-0002-4882-4143; Lukas, Claudia/0000-0001-7169-6883; Sorensen, Claus/0000-0001-6022-9710				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; IOWNSLEY FM, 1998, TRENDS CELL BIOL, V8, P238; Irniger S, 1997, J CELL SCI, V110, P1523; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	249	255	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					815	818		10.1038/44611	http://dx.doi.org/10.1038/44611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548110				2022-12-24	WOS:000083368700059
J	Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE				Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE			Structure of a transiently phosphorylated switch in bacterial signal transduction	NATURE			English	Article							RESPONSE REGULATOR; 3-DIMENSIONAL STRUCTURE; RECEIVER DOMAIN; NMR STRUCTURE; PROTEIN CHEY; CHEMOTAXIS; ACTIVATION; CONFORMATION; MECHANISM; DYNAMICS	Receiver domains are the dominant molecular switches in bacterial signalling(1,2), Although several structures of non-phosphorylated receiver domains have been reported(3-8), a detailed structural understanding of the activation arising from phosphorylation has been impeded by the very short half-lives of the aspartyl-phosphate linkages. Here we present the first structure of a receiver domain in its active state, the phosphorylated receiver domain of the bacterial enhancer-binding protein NtrC (nitrogen regulatory protein C), Nuclear magnetic resonance spectra were taken during steady-state autophosphorylation/dephosphorylation, and three-dimensional spectra from multiple samples were combined. Phosphorylation induces a large conformational change involving a displacement of beta-strands 4 and 5 and alpha-helices 3 and 4 away from the active site, a register shift and an axial rotation in helix 4, This creates an exposed hydrophobic surface that is likely to transmit the signal to the transcriptional activation domain.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Sci, Berkeley, CA 94720 USA	Brandeis University; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kern, D (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.		Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; Hwang I, 1999, P NATL ACAD SCI USA, V96, P4880, DOI 10.1073/pnas.96.9.4880; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Nohaile M, 1997, J MOL BIOL, V273, P299, DOI 10.1006/jmbi.1997.1296; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMBEL L, 1998, COLD SPRING HARB SYM, P157; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANTORO J, 1995, J MOL BIOL, V247, P717, DOI 10.1006/jmbi.1995.0175; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001	29	174	177	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					894	898		10.1038/47273	http://dx.doi.org/10.1038/47273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622255				2022-12-24	WOS:000084482000037
J	Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A				Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A		Swiss HIV Cohort Study	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; COMBINATION; DISEASE; HAART; RECOVERY; COUNT	Context Acquired immunodeficiency syndrome-related opportunistic illnesses (Ols) continue to occur after initiation of potent antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection, Risk factors for clinical progression to Ols during potent therapy are not well defined, Objective To examine the incidence of and risk factors for Ols among patients treated with potent antiretroviral therapy in a population-based study, Design The Swiss HIV Cohort Study, a prospective cohort study of adult HIV-infected persons. Setting Seven study centers throughout Switzerland. Patients A total of 2410 cohort study participants with a potential follow-up of at least 15 months after starting potent therapy between September 1995 and December 1997. Main Outcome Measures Disease-specific incidence of Ols during the 6 months preceding potent antiretroviral therapy and at 3 intervals after initiating therapy; risk factors for development of Ols during therapy. Results Of the 2410 participants, 143 developed 186 Ols after initiation of potent antiretroviral therapy, Incidence of any OI decreased from 15.1 per 100 person-years in the 6 months before therapy to 7.7 in the first 3 months after starting treatment, 2.6 in the following 6 months, and 2.2 per 100 person-years between 9 and 15 months. Reductions in incidence ranged from 38% per month for Kaposi sarcoma (P<.001) to 5% per month for non-Hodgkin lymphoma (P =.31). Baseline CD4 cell count continued to predict the risk of disease progression after initiating potent therapy, Compared with CD4 cell counts above 200 x 10(6)/L, the hazard ratio for developing Ols was 2.5 (95% confidence interval [CI], 1.4-4.5) for counts between 51 and 200 x 10(6)/L and 5.8 (95% CI, 3.2-10.5) for counts below 51 x 10(6)/L at baseline, Independent of baseline CD4 cell count, a rise in CD4 cell count by 50 x 10(6)/L or more and undetectable HIV-1 RNA in plasma (<400 copies/mL) by 6 months reduced risk of subsequent events, with hazard ratios of 0.32 (95% CI, 0.20-0.52) and 0.39 (0.24-0.65), respectively, Conclusions Our data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy, Baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy. Individuals with CD4 cell counts of 50 x 10(6)/L or below may need close clinical surveillance after initiation of potent therapy.	Univ Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Hosp, Div Infect Dis, Lausanne, Switzerland; Univ Hosp, Div Infect Dis, Geneva, Switzerland; Univ Bern, Inselspital, Med Policlin, CH-3010 Bern, Switzerland; Univ Basel, Cantonal Hosp, Med Policlin, Basel, Switzerland; Cantonal Hosp, Internal Med Clin A, St Gall, Switzerland; Reg Hosp, Infect Dis Ambulatorium, Lugano, Switzerland	University of Zurich; University Zurich Hospital; University of Bristol; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Bern; University Hospital of Bern; University of Basel	Telenti, A (corresponding author), CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Telenti, Amalio/AAY-1674-2021; Weber, Rainer/D-5175-2012; Ledergerber, Bruno/B-5656-2009; Furrer, Hansjakob/G-6768-2013	Ledergerber, Bruno/0000-0002-6881-4401; Furrer, Hansjakob/0000-0002-1375-3146; Egger, Matthias/0000-0001-7462-5132				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114; Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1997, LANCET, V350, P589, DOI 10.1016/S0140-6736(05)63175-3; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Feinberg J, 1999, LANCET, V353, P1287, DOI 10.1016/S0140-6736(99)00123-3; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Furrer H, 1999, AM J MED, V106, P371, DOI 10.1016/S0002-9343(99)00015-7; Hengge UR, 1998, AIDS, V12, pF225, DOI 10.1097/00002030-199817000-00003; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Perry CM, 1998, DRUGS, V55, P461, DOI 10.2165/00003495-199855030-00014; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2	32	374	385	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2220	2226		10.1001/jama.282.23.2220	http://dx.doi.org/10.1001/jama.282.23.2220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605973				2022-12-24	WOS:000084138600029
J	Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC				Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC			Relationship between modifiable health risks and short-term health care charges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; LIFE-STYLE; COST; DISEASE; MORTALITY; DATABASE; SMOKING; MEMBERS; IMPACT; MEN	Context If physical inactivity, obesity, and smoking status prove to contribute significantly to increased health care charges within a short period of time, health plans and payers may wish to invest in strategies to modify these risk factors. However, few data are available to guide such resource allocation decisions. Objective To examine the relationship of modifiable health risks to subsequent health care charges after controlling for age, race, sex, and chronic conditions. Design, Setting, and Participants Cohort study of a stratified random sample of 5689 adults (75.5% of total sample of 7535) aged 40 years or older who were enrolled in a Minnesota health plan and completed a 60-item questionnaire. Main Outcome Measure Resource use as measured by billed health care charges from July 1, 1995, to December 31, 1996, compared by health risk (physical activity, body mass index [BMI], and smoking status). Results The mean annual per patient charge in the total study population was $3570 (median, $600), and 15% of patients had no charges during the study period. After adjustment for age, race, sex,and chronic disease status, physical activity (4.7% lower health care charges per active day per week), BMI (1.9% higher charges per BMI unit), current smoking status (18% higher charges), and history of tobacco use (25.8% higher charges) were prospectively related to health care charges over 18 months. Never-smokers with a BMI of 25 kg/m(2) and who participated in physical activity 3 days per week had mean annual health care charges that were approximately 49% lower than physically inactive smokers with a BMI of 27.5 kg/m(2), Conclusions Our data suggest that adverse health risks translate into significantly higher health care charges within 18 months. Health plans or payers seeking to minimize health care charges may wish to consider strategic investments in interventions that effectively modify adverse health risks.	Healthpartners Res Fdn, Minneapolis, MN 55440 USA; Healthpartners Ctr Hlth Promot, Minneapolis, MN USA	HealthPartners Institute for Education & Research	O'Connor, PJ (corresponding author), Healthpartners Res Fdn, 8100 34th Ave S, Minneapolis, MN 55440 USA.	Patrick.J.Oconnor@HealthPartners.com	Martinson, Brian C/AAX-2860-2020; O'Connor, Patrick/HII-2987-2022	Martinson, Brian C/0000-0002-4255-5595; O'Connor, Patrick/0000-0002-2324-6228				Ainsworth B., 1992, MED EXERCISE NUTR HL, V1, P75; BAUM WP, 1986, J OCCUP MED, V28, P18; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Boyle RG, 1998, AM J HEALTH PROMOT, V12, P170, DOI 10.4278/0890-1171-12.3.170; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Edington DW, 1997, J OCCUP ENVIRON MED, V39, P1037, DOI 10.1097/00043764-199711000-00004; GILMER T, 1998, MINN HLTH SERV RES C; Gilmer TG, 1998, DIABETES, V47, pA190; Goetzel RZ, 1998, J OCCUP ENVIRON MED, V40, P843, DOI 10.1097/00043764-199810000-00003; Goetzel RZ, 1996, AM J HEALTH PROMOT, V10, P340, DOI 10.4278/0890-1171-10.5.340; Hornbrook MC, 1996, HEALTH SERV RES, V31, P283; HORNBROOK MC, 1995, INQUIRY-J HEALTH CAR, V32, P56; HOSMER D, 1989, WILEY SERIES PROBABI, V13, P307; KAMAN RL, 1995, WORKSITE HLTH PROMOT; KEELER EB, 1989, AM J PUBLIC HEALTH, V79, P975, DOI 10.2105/AJPH.79.8.975; Kortt MA, 1998, CLIN THER, V20, P772, DOI 10.1016/S0149-2918(98)80140-9; MANNING W, 1991, COSTS POOR HLTH HABI, P223; O'Connor P J, 1996, HMO Pract, V10, P17; O'Connor P J, 1997, Fam Med, V29, P424; O'Connor PJ, 1998, AM J MANAG CARE, V4, P335; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pelletier KR, 1997, J OCCUP ENVIRON MED, V39, P1154, DOI 10.1097/00043764-199712000-00009; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; PRONK N, IN PRESS MED SCI SPO; Pronk N P, 1997, J Ambul Care Manage, V20, P24; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; SHEPHARD RJ, 1992, AM J HLTH PROMOT, V17, P475; STEIN AD, 1993, AM J PUBLIC HEALTH, V83, P1768, DOI 10.2105/AJPH.83.12.1768; VELICER WF, 1993, TOB CONTROL, V2, P95	33	202	204	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2235	2239		10.1001/jama.282.23.2235	http://dx.doi.org/10.1001/jama.282.23.2235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605975	Bronze			2022-12-24	WOS:000084138600031
J	Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA				Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA			Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand	NATURE			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAIN; INHIBITORY RECEPTOR; 3-DIMENSIONAL STRUCTURE; LY-49A RECOGNIZES; H-2D(D); PEPTIDE; COMPLEX; SPECIFICITY; MOLECULES	Natural killer (NK) cell function is regulated by NK receptors that interact with MHC class I (MHC-I) molecules on target cells. The murine NK receptor Ly49A inhibits NK cell activity by interacting with H-2D(d) through its G-type-lectin-like NK receptor domain. Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d), The Ly49A dimer interacts extensively with two H-2D(d) molecules at distinct sites, At one interface, a single Ly49A subunit contacts one side of the MHC-I peptide-binding platform, presenting an open cavity towards the conserved glycosylation site on the H-2D(d) alpha 2 domain, At a second, larger interface, the Ly49A dimer binds in a region overlapping the CD8-binding site. The smaller interface probably represents the interaction between Ly49A on the NK cell and MHC-I on the target cell, whereas the larger one suggests an interaction between Ly49A and MHC-I on the NK cell itself. Both Ly49A binding sites on MHC-I are spatially distinct from that of the T-cell receptor.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; NIAID, Mol Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Marluzza, RA (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9,600 Gudelsky Dr, Rockville, MD 20850 USA.	dhm@nih.gov; mariuzza@carb.nist.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000394, Z01AI000394] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; Andersson M, 1998, J IMMUNOL, V161, P6475; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CS, 1998, J IMMUNOL, V160, P4367; Chung Y, 1999, J IMMUNOL, V163, P3692; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Franksson L, 1999, EUR J IMMUNOL, V29, P2748, DOI 10.1002/(SICI)1521-4141(199909)29:09<2748::AID-IMMU2748>3.0.CO;2-C; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kase A, 1998, J IMMUNOL, V161, P6133; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; Lian RH, 1998, J IMMUNOL, V161, P2301; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Orihuela M, 1996, P NATL ACAD SCI USA, V93, P11792, DOI 10.1073/pnas.93.21.11792; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Sundback J, 1998, J IMMUNOL, V160, P5971; Vales-Gomez M, 1999, EMBO J, V18, P4250, DOI 10.1093/emboj/18.15.4250; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Yokoyama W. M., 1999, FUNDAMENTAL IMMUNOLO, P575	49	231	238	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					623	631		10.1038/45170	http://dx.doi.org/10.1038/45170			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604468				2022-12-24	WOS:000084189800055
J	Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J				Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J		CESDI SUDI Res Grp	Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome	BRITISH MEDICAL JOURNAL			English	Article							HONG-KONG; COT DEATH	Objective To investigate the risks of the sudden infant death syndrome and factors that may contribute to unsafe sleeping environments. Design Three year, population based case-control study. Parental interviews were conducted for each sudden infant death and for four controls matched for age, locality, and time of sleep. Setting Fire regions in England with a total population of over 17 million people. Subjects 325 babies who died and 1300 control infants. Results In die multivariate analysis infants who shared their parents' bed and were then put back in their own cot had no increased risk (odds ratio 0.67; 95% confidence interval 0.22 to 2.00). There was an increased risk for infants who shared the bed for the whole sleep or were taken to and found in the parental bed (9.78; 4.02 to 23.83), infants who slept in a separate room from their parents (10.49; 4.26 to 25.81), and infants who shared a sofa (48.99; 5.04 to 475.60). The risk associated with being found in the parental bed was not significant for older infants (> 14 weeks) or for infants of parents who did not smoke and became non-significant after adjustment for recent maternal alcohol consumption(> 2 units), use of duvets ( > 4 togs), parental tiredness (infant slept less than or equal to 4 hours for longest sleep in previous 24 hours), and overcrowded housing conditions (> 2 people per room of the house). Conclusions There are certain circumstances when bed sharing should be avoided, particularly for infants under four months old. Parents sleeping on a sofa Midi infants should always be avoided. There is no evidence that bed sharing is hazardous for infants of parents who do not smoke.	Royal Hosp Sick Children, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Nuffield Inst Hlth Serv, Leeds LS2 9PL, W Yorkshire, England; Royal Victoria Infirm, Newcastle Neonatal Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Newcastle University - UK	Blair, PS (corresponding author), Royal Hosp Sick Children, Inst Child Hlth, St Michaels Hill, Bristol BS2 8BJ, Avon, England.		Platt, Martin Ward/D-4008-2014; Young, Jeanine/G-2528-2010; Fleming, Peter J/A-9081-2010; Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019	Platt, Martin Ward/0000-0003-0536-5749; Young, Jeanine/0000-0003-3849-3392; Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				Anderson G C, 1991, J Perinatol, V11, P216; BALL HL, IN PRESS AM ANTHR; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI I, 1994, BMJ-BRIT MED J, V308, P204, DOI 10.1136/bmj.308.6922.204b; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; Gantley M, 1993, BMJ-BRIT MED J, V16, P263; HOFFMAN HJ, 1988, SUDDEN INFANT DEATH, P153; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; LEACH CEA, IN PRESS PEDIATRICS; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; Ludington-Hoe S M, 1991, J Perinatol, V11, P19; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MCKENNA J, 1994, EARLY HUM DEV, V38, P187, DOI 10.1016/0378-3782(94)90211-9; McKenna JJ, 1996, ANNU REV ANTHROPOL, V25, P201, DOI 10.1146/annurev.anthro.25.1.201; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; MITCHELL EA, 1992, NJ PAEDIAT CHILD HLT, V28, pS3; Mitchell EA, 1995, SUDDEN INFANT DEATH; MOSKO S, 1993, J BEHAV MED, V16, P589, DOI 10.1007/BF00844721; Nelson EAS, 1996, NEW ZEAL MED J, V109, P144; RINTAHAKA RJ, 1986, FORENSIC SCI INT, V30, P219, DOI 10.1016/0379-0738(86)90017-4; *SAS I, 1992, P229 SAS I; TAKEDA K, 1987, Journal of Kyoto Prefectural University of Medicine, V96, P965; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664	25	217	224	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1457	1461		10.1136/bmj.319.7223.1457	http://dx.doi.org/10.1136/bmj.319.7223.1457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582925	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000084129200016
J	Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME				Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME			An essential role for BLNK in human B cell development	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ADAPTER PROTEIN SLP-76; TYROSINE KINASE; INTERLEUKIN-2 PRODUCTION; DEFICIENT MICE; T-CELLS; MUTATIONS; RECEPTOR; EXPRESSION; GENE	The signal transduction events that control the progenitor B cell (pro-B cell) to precursor B cell (pre-B cell) transition have not been well delineated. In evaluating patients with absent B cells, a male with a homozygous splice defect in the cytoplasmic adapter protein BLNK (B cell Linker protein) was identified. Although this patient had normal numbers of pro-B cells, he had no pre-B cells or mature B cells, indicating that BLNK plays a critical role in orchestrating the pro-B cell to pre-B cell transition. The immune system and overall growth and development were otherwise normal in this patient, suggesting that BLNK function is highly specific.	St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Johns Hopkins Hosp, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21287 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med,Div Rheumatol,Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, St Louis, MO 63110 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center	Conley, ME (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025129, R37AI025129, R01AI042787] Funding Source: NIH RePORTER; NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI25129, AI42787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; COOPER DN, 1994, HUMAN GENE MUTATION, P239; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KENNY RA, 1995, CARDIOL ELDER, V3, P301; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	32	251	258	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1954	1957		10.1126/science.286.5446.1954	http://dx.doi.org/10.1126/science.286.5446.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583958				2022-12-24	WOS:000084003400051
J	Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D				Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D			The dynamics of chromosome evolution in birds and mammals	NATURE			English	Article							RATES; TREE	Comparative mapping, which compares the location of homologous genes in different species, is a powerful tool for studying genome evolution(1). Comparative maps suggest that rates of chromosomal change in mammals can vary from one to ten rearrangements per million years(1-4). On the basis of these rates we would expect 84 to 600 conserved segments in a chicken comparison with human or mouse. Here we build comparative maps between these species and estimate that numbers of conserved segments are in the lower part of this range. We conclude that the organization of the human genome is closer to that of the chicken than the mouse and by adding comparative mapping results from a range of vertebrates, we identify three possible phases of chromosome evolution. The relative stability of genomes such as those of the chicken and human will enable the reconstruction of maps of ancestral vertebrates.	Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; TUM, Lehrstuhl Tierzucht, D-85350 Munich, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Technical University of Munich	Burt, DW (corresponding author), Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland.	Dave-Burt@bbsrc.ac.uk	Smith, Jacqueline/C-7719-2013; Burt, David W/C-7802-2013; Sazanov, Alexei/A-6980-2014; Dunn, Ian/C-7689-2013	Smith, Jacqueline/0000-0002-2813-7872; Burt, David W/0000-0002-9991-1028; Sazanov, Alexei/0000-0002-5273-5397; Dunn, Ian/0000-0003-3630-0120				Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; Burt David W., 1998, ILAR J, V39, P229; BUSH GL, 1977, P NATL ACAD SCI USA, V74, P3942, DOI 10.1073/pnas.74.9.3942; Davisson Muriel T., 1998, ILAR J, V39, P96; de Jong WW, 1998, TRENDS ECOL EVOL, V13, P270, DOI 10.1016/S0169-5347(98)01335-4; Hastie TJ., 1990, GEN ADDITIVE MODELS; Hurvich CM, 1998, J ROY STAT SOC B, V60, P271, DOI 10.1111/1467-9868.00125; Kosambi DD, 1943, ANN EUGENIC, V12, P172, DOI 10.1111/j.1469-1809.1943.tb02321.x; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; Morizot D. C., 1994, Animal Biotechnology, V5, P113, DOI 10.1080/10495399409525812; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; OBrien SJ, 1997, TRENDS GENET, V13, P393, DOI 10.1016/S0168-9525(97)01297-3; OHTA T, 1993, P NATL ACAD SCI USA, V90, P10676, DOI 10.1073/pnas.90.22.10676; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; WADDINGTON D, IN PRESS GENETICS; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; Wienberg Johannes, 1998, ILAR J, V39, P77; [No title captured]	22	229	233	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					411	413		10.1038/46555	http://dx.doi.org/10.1038/46555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586880				2022-12-24	WOS:000083913600056
J	Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW				Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW			Accretion of low-metallicity gas by the Milky Way	NATURE			English	Article							HIGH-VELOCITY CLOUDS; H-II REGIONS; ABUNDANCES; GALAXIES; LINE; ORIGIN; HALO	Models of the chemical evolution of the Milky Way suggest that: the observed abundances of elements heavier than helium ('metals') require a continuous infall of gas with metallicity (metal abundance) about 0.1 times the solar value. An infall rate integrated over the entire disk of the Milky Way of similar to 1 solar mass per year can solve the 'G-dwarf problem'-the observational fact that the metallicities of most long-lived stars near the Sun lie in a relatively narrow range(1-3). This infall dilutes the enrichment arising from the production of heavy elements in stars, and thereby prevents the metallicity of the interstellar medium from increasing steadily with time. However, in other spiral galaxies, the low-metallicity gas needed to provide this infall has been observed only in associated dwarf galaxies(4) and in the extreme outer disk of the Milky Way(5,6). In the distant Universe, low-metallicity hydrogen clouds (known as 'damped Ly alpha absorbers') are sometimes seen near galaxies(7,8). Here we report a metallicity of 0.09 times solar for a massive cloud that is falling into the disk of the Milky Way. The mass now associated with this cloud represents an infall per unit area of about the theoretically expected rate, and similar to 0.1-0.2 times the amount required for the whole Galaxy.	Univ Wisconsin, Dept Astron, Madison, WI 53706 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands; Lewis & Clark Coll, Dept Phys, Portland, OR 97219 USA; Univ Nijmegen, NL-6500 GL Nijmegen, Netherlands; Univ Durham, Dept Phys, Durham DH1 3LE, England; Univ Bonn, Inst Radioastron, D-53121 Bonn, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; University of Groningen; Radboud University Nijmegen; Durham University; University of Bonn	Wakker, BP (corresponding author), Univ Wisconsin, Dept Astron, Madison, WI 53706 USA.		Howk, Jay/D-2577-2013; Peletier, Reynier F/B-9633-2012	Howk, J. Christopher/0000-0002-2591-3792; Kalberla, Peter/0000-0002-8381-7889; Peletier, Reynier/0000-0001-7621-947X				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; Ferguson AMN, 1998, ASTRON J, V116, P673, DOI 10.1086/300456; Gardiner LT, 1996, MON NOT R ASTRON SOC, V278, P191, DOI 10.1093/mnras/278.1.191; GIOVAGNOLI A, 1995, MON NOT R ASTRON SOC, V273, P499, DOI 10.1093/mnras/273.2.499; Haffner LM, 1999, ASTROPHYS J, V523, P223, DOI 10.1086/307734; Hartmann D., 1997, ATLAS GALACTIC NEUTR; Lu LM, 1998, ASTRON J, V115, P55, DOI 10.1086/300180; Lu LM, 1998, ASTRON J, V115, P162, DOI 10.1086/300181; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; Pagel B.E.J., 1997, NUCLEOSYNTHESIS CHEM; Pettini M, 1999, ASTROPHYS J, V510, P576, DOI 10.1086/306635; Reynolds RJ, 1998, PUBL ASTRON SOC AUST, V15, P14, DOI 10.1071/AS98014; Rudolph AL, 1997, ASTROPHYS J, V489, P94, DOI 10.1086/304758; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Skillman ED, 1997, ASTROPHYS J, V474, P205, DOI 10.1086/303464; Snowden SL, 1998, ASTROPHYS J, V493, P715, DOI 10.1086/305135; van Woerden H, 1999, ASTR SOC P, V166, P1; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; VANDENBERGH S, 1962, ASTRON J, V67, P486, DOI 10.1086/108757; VERNER DA, 1994, ASTRON ASTROPHYS SUP, V108, P287; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; Wakker BP, 1997, ANNU REV ASTRON ASTR, V35, P217, DOI 10.1146/annurev.astro.35.1.217; Wakker BP, 1999, ASTR SOC P, V166, P26; Wakker BP, 1996, ASTRON ASTROPHYS, V306, pL25; WOLFIRE MG, 1995, ASTROPHYS J, V453, P673, DOI 10.1086/176429; YANNY B, 1992, ASTROPHYS J, V391, P569, DOI 10.1086/171371; Zwaan MA, 1997, ASTROPHYS J, V490, P173, DOI 10.1086/304872	29	180	181	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					388	390		10.1038/46498	http://dx.doi.org/10.1038/46498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586877				2022-12-24	WOS:000083913600048
J	Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T				Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T			Reversible molecular adsorption based on multiple-point interaction by shrinkable gels	SCIENCE			English	Article							N-ISOPROPYLACRYLAMIDE	A general approach is presented for creating polymer-gels that can recognize and capture a target molecule by multiple-point interaction and that can reversibly change their affinity to the target by more than one order of magnitude. The polymers consist of majority monomers that make the gel reversibly swell and shrink and minority monomers that constitute multiple-point adsorption centers for the target molecule, Multiple-point interaction is experimentally proven by power Laws found between the affinity and the concentration of the adsorbing monomers within the gels.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, George R Harrison Spect Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oya, T (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Takeoka, Yukikazu/I-6785-2014; Grosberg, Alexander Y/O-2122-2015; Grosberg, Alexander/AAD-9614-2019; yilmaz, yasar/D-6190-2014; Takeoka, Yukikazu/W-9627-2019	Takeoka, Yukikazu/0000-0002-1406-0704; Grosberg, Alexander Y/0000-0002-4230-8690; Grosberg, Alexander/0000-0002-4230-8690; yilmaz, yasar/0000-0003-2352-4723; Takeoka, Yukikazu/0000-0002-1406-0704				HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; RICKA J, 1985, MACROMOLECULES, V18, P83, DOI 10.1021/ma00143a013; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Tanaka T, 1995, FARADAY DISCUSS, V101, P201, DOI 10.1039/fd9950100201; YAMATO M, 1999, CONNECT TISSUE, V31, P13	5	179	186	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1543	1545		10.1126/science.286.5444.1543	http://dx.doi.org/10.1126/science.286.5444.1543			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567256				2022-12-24	WOS:000083768300052
J	Rastogi, VK; Girvin, ME				Rastogi, VK; Girvin, ME			Structural changes linked to proton translocation by subunit c of the ATP synthase	NATURE			English	Article							PROTEIN-STRUCTURE DETERMINATION; ESCHERICHIA-COLI; CHEMICAL-SHIFTS; CROSS-LINKING; DIRECT REFINEMENT; NMR; F1-ATPASE; ROTATION; F-0; SECTOR	F1F0 ATP synthases use a transmembrane proton gradient to drive the synthesis of cellular ATP. The structure of the cytosolic F-1 portion of the enzyme and the basic mechanism of ATP hydrolysis by F-1 are now well established, but how proton translocation through the transmembrane F-0 portion drives these catalytic changes is less clear. Here we describe the structural changes in the proton-translocating F-0 subunit c that are induced by deprotonating the specific aspartic acid involved in proton transport. conformational changes between the protonated and deprotonated forms of subunit c provide the structural basis for an explicit mechanism to explain coupling of proton translocation by F-0 to the rotation of subunits within the core of F-1. Rotation of these subunits within F-1 causes the catalytic conformational changes in the active sites of F-1 that result in ATP synthesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Girvin, ME (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	girvin@aecom.yu.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSZEWSKI J, 1995, J MAGN RESON SER B, V107, P293, DOI 10.1006/jmrb.1995.1093; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORWOOD TJ, 1992, BIOCHEMISTRY-US, V31, P6285, DOI 10.1021/bi00142a017; Rastogi VK, 1999, J BIOMOL NMR, V13, P91, DOI 10.1023/A:1008379624478; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIGRISTNELSON K, 1979, J BIOL CHEM, V254, P4470; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	50	381	387	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					263	268		10.1038/46224	http://dx.doi.org/10.1038/46224			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580496				2022-12-24	WOS:000083813700040
J	Rogers, J; Joyce, GF				Rogers, J; Joyce, GF			A ribozyme that lacks cytidine	NATURE			English	Article							IN-VITRO EVOLUTION; RNA; SEQUENCES	The RNA-world hypothesis proposes that, before the advent of DNA and protein, life was based on RNA, with RNA serving as both the repository of genetic information and the chief agent of catalytic function(1). An argument against an RNA world is that the components of RNA lack the chemical diversity necessary to sustain life. Unlike proteins, which contain 20 different aminoacid subunits, nucleic acids are composed of only four subunits which have very similar chemical properties. Yet RNA is capable of a broad range of catalytic functions(2-7). Here we show that even three nucleic-acid subunits are sufficient to provide a substantial increase in the catalytic rate. Starting from a molecule that contained roughly equal proportions of all four nucleosides, we used in vitro evolution to obtain an RNA ligase ribozyme that lacks cytidine. This ribozyme folds into a defined structure and has a catalytic rate that is about 10(5)-fold faster than the uncatalysed rate of template-directed RNA ligation.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Joyce, GF (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gjoyce@scripps.edu						Atkins J.F, 1999, RNA WORLD; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; Rohatgi R, 1996, J AM CHEM SOC, V118, P3332, DOI 10.1021/ja953712b; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; STERN S, 1988, METHOD ENZYMOL, V164, P481; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; Vartanian JP, 1996, NUCLEIC ACIDS RES, V24, P2627, DOI 10.1093/nar/24.14.2627; Wright MC, 1997, SCIENCE, V276, P614, DOI 10.1126/science.276.5312.614; YOSHIDA H, 1994, NUCLEIC ACIDS RES, V22, P41, DOI 10.1093/nar/22.1.41; Zhang BL, 1998, CHEM BIOL, V5, P539, DOI 10.1016/S1074-5521(98)90113-2	20	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					323	325		10.1038/46335	http://dx.doi.org/10.1038/46335			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580507				2022-12-24	WOS:000083813700057
J	Swain, SL; Hu, H; Huston, G				Swain, SL; Hu, H; Huston, G			Class II-independent generation of CD4 memory T cells from effecters	SCIENCE			English	Article							ANTIGEN; SURVIVAL; RECEPTOR; NAIVE; MOLECULES; REQUIREMENTS; LYMPHOCYTES; MICE; TH1	The factors required for the generation of memory CD4 T cells remain unclear, and whether there is a continuing requirement for antigen stimulation is critical to design of vaccine strategies. CD4 effecters generated in vitro from naive CD4 T cells of mice efficiently gave rise to small resting memory cells after transfer to class II-deficient hosts, indicating no requirement for further antigen or class ii recognition.	Trudeau Inst Inc, Biomed Res Labs, Saranac Lake, NY 12983 USA	Trudeau Institute	Swain, SL (corresponding author), Trudeau Inst Inc, Biomed Res Labs, 100 Algonquin Ave, Saranac Lake, NY 12983 USA.							Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; DECKER G, UNPUB; Dubey C, 1996, J IMMUNOL, V157, P3280; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Nesic D, 1998, J IMMUNOL, V160, P3705; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; Rogers PR, 1998, J IMMUNOL, V161, P3844; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SWAIN SL, UNPUB; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	22	345	354	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1381	1383		10.1126/science.286.5443.1381	http://dx.doi.org/10.1126/science.286.5443.1381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558997				2022-12-24	WOS:000083675500049
J	Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D			A combined algorithm for genome-wide prediction of protein function	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COLON-CANCER; GENES; YEAST; DATABASE; INTERACT; MUTATION; HOMOLOG; MSH6	The availability of over 20 fully sequenced genomes has driven the development of new methods to find protein function and interactions. Here we group proteins by correlated evolution(1), correlated messenger RNA expression patterns(2) and patterns of domain fusion(3) to determine functional relationships among the 6,217 proteins of the yeast Saccharomyces cervisiae. Using these methods, we discover over 93,000 pairwise links between functionally related yeast proteins. Links between characterized and uncharacterized proteins allow a general function to be assigned to more than half of the 2,557 previously uncharacterized yeast proteins. Examples of functional links are given for a protein family of previously unknown function, a protein whose human homologues are implicated in colon cancer and the yeast prion Sup35.	Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, POB 951570, Los Angeles, CA 90095 USA.			Pellegrini, Matteo/0000-0001-9355-9564; Thompson, Michael/0000-0002-2914-1080; Marcotte, Edward/0000-0001-8808-180X; Yeates, Todd/0000-0001-5709-9839				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BARDOSI A, 1990, ACTA NEUROPATHOL, V79, P387, DOI 10.1007/BF00308714; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Karp PD, 1998, NUCLEIC ACIDS RES, V26, P50, DOI 10.1093/nar/26.1.50; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Lynch HT, 1997, ANN NY ACAD SCI, V833, P1, DOI 10.1111/j.1749-6632.1997.tb48588.x; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mewes HW, 1998, NUCLEIC ACIDS RES, V26, P33, DOI 10.1093/nar/26.1.33; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; 1997, NATURE S, V387, P1	26	681	723	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					83	86		10.1038/47048	http://dx.doi.org/10.1038/47048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573421				2022-12-24	WOS:000083638600047
J	Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB				Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB			Trans-gender induction of hair follicles	NATURE			English	Article							DERMAL PAPILLA CELLS; GROWTH		Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Durham University; Newcastle University - UK; Columbia University; Columbia University	Reynolds, AJ (corresponding author), Univ Durham, Dept Biol Sci, South Rd, Durham DH1 3LE, England.	c.a.b.jahoda@durham.ac.uk		Jahoda, Colin/0000-0002-1762-1220				CHONG SS, 1993, HUM MOL GENET, V2, P1187, DOI 10.1093/hmg/2.8.1187; FABRE JW, 1987, TRANSPLANT P, V19, P45; GIBSON WT, 1991, ANN NY ACAD SCI, V642, P291; Halloran P F, 1993, Transpl Immunol, V1, P3, DOI 10.1016/0966-3274(93)90055-D; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; IBRAHIM MAA, 1995, IMMUNOL TODAY, V16, P181, DOI 10.1016/0167-5699(95)80118-9; JAHODA CAB, 1993, J INVEST DERMATOL, V101, P584, DOI 10.1111/1523-1747.ep12366039; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158	10	173	198	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					33	34		10.1038/46938	http://dx.doi.org/10.1038/46938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573414				2022-12-24	WOS:000083638600030
J	Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH				Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH			Placental abruption and adverse perinatal outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; RISK; ASPIRIN; COCAINE; MODELS; RATIO; RACE	Context Pregnancies complicated by abruption result in increased frequency of perinatal death and decreased fetal size and gestational duration, yet the extent of placental separation and its effect on these adverse outcomes is unknown. Objective To assess the contribution of placental abruption and extent of placental separation to stillbirth, preterm delivery, and fetal growth restriction. Design Hospital-based, retrospective cohort study. Setting Mount Sinai Hospital, New York City, NY. Participants A total of 53 371 pregnancies occurring in 40 789 women who were delivered of singleton births between 1986 and 1996. Main Outcome Measures Risks and relative risks for stillbirth (>20 weeks), preterm delivery (<37 weeks), and fetal growth restriction (birth weight below 10th percentile for gestational age) in relation to abruption. Results The incidence of abruption was 1% (n = 530), Abruption was associated with an 8.9-fold (95% confidence interval [CI], 6.0-13.0) adjusted relative risk (aRR) of stillbirth. Preterm birth proportions among women with and without abruption were 39.6% and 9.1%, respectively, yielding an aRR of 3.9 (95% CI, 3.5-4.4). In the abruption group, 14.3% of neonates were growth restricted, compared with 8.1% among all other births (aRR, 2.0; 95% CI, 1.5-2.4). Extent of placental separation had a profound effect on stillbirth (aRR for 75% separation, 31.5; 95% CI, 17.0-58.4), although evident only among those with at least 50% separation. However, the risk of preterm delivery was substantially increased even for mild abruptions (aRR for 25% separation, 5.5; 95% CI, 4.2-7.3). Conclusions In this cohort, placental abruption had a profound impact on stillbirth, preterm delivery, and fetal growth restriction. The risk of stillbirth was dramatically increased for severe placental separation, but preterm delivery was common even among women with lesser degrees of placental separation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, New Brunswick, NJ 08901 USA; Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA; Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill	Ananth, CV (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, 125 Paterson St, New Brunswick, NJ 08901 USA.		Savitz, David A/I-2211-2014	Ananth, Cande/0000-0002-0410-2595				Ananth CV, 1999, OBSTET GYNECOL, V93, P622, DOI 10.1016/S0029-7844(98)00408-6; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FLEMING AD, 1991, CRIT CARE CLIN, V7, P865, DOI 10.1016/S0749-0704(18)30285-9; FUCHS F, 1993, PRETERM BIRTH, P217; HARRIS BA, 1985, OBSTET GYNECOL, V66, P774; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; HIBBARD BM, 1966, OBSTET GYNECOL, V27, P155; HURD WW, 1983, OBSTET GYNECOL, V61, P467; Kistin N, 1996, PAEDIATR PERINAT EP, V10, P269, DOI 10.1111/j.1365-3016.1996.tb00050.x; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; KNAB DR, 1978, OBSTET GYNECOL, V52, P625; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; NAEYE RL, 1980, OBSTET GYNECOL, V55, P701; NISWANDER KR, 1966, AM J OBSTET GYNECOL, V95, P838, DOI 10.1016/0002-9378(66)90088-3; SAFTLAS AF, 1991, OBSTET GYNECOL, V78, P1081; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; WOLF EJ, 1992, J MATERN FETAL MED, V14, P206; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZHANG J, 1995, OBSTET GYNECOL, V86, P200, DOI 10.1016/0029-7844(95)00142-E	23	224	230	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1646	1651		10.1001/jama.282.17.1646	http://dx.doi.org/10.1001/jama.282.17.1646			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553791	Bronze			2022-12-24	WOS:000083368400030
J	Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF				Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF			Prenatal origin of acute lymphoblastic leukaemia in children	LANCET			English	Article							CHILDHOOD LEUKEMIA; INFANT LEUKEMIAS; IDENTICAL-TWINS; BLOOD SPOTS; FUSION; CANCER; GENE; DETERMINANTS; MALIGNANCY; ETIOLOGY	Background There is little current insight into the natural history of childhood leukaemia or the timing of relevant mutational events. TEL-AML1 gene fusion due to chromosomal translocation is frequently-seen in the common form of childhood acute lymphoblastic leukaemia. We investigated whether this abnormality arises prenatally. Methods We identified, by reverse-transcriptase PCR screening of blood or bone marrow, TEL-AML1 fusion in 12 children, plus a pair of identical twins, aged 2-5 years from Italy and the UK, who had newly diagnosed acute lymphoblastic leukaemia. We amplified and sequenced the genomic TEL-AMLI fusion gene with a long-distance inverse PCR method. Primers were designed that could be used in short-range PCR to screen for patient-specific, leukaemia clone-specific TEL-AMLI genomic fusion sequences in neonatal blood spots from each child. Findings We initially identified TEL-AMLI fusion sequences in blood spots from the identical twins, diagnosed with concordant acute lymphoblastic leukaemia at age 4 years, who shared a single or clonotypic TEL-AMLI sequence that suggested prenatal origin in one twin. Three children were excluded because control genes could not be amplified. Of the other nine patients, six had positive blood spots. Blood spots that were classified as negative were uninformative. Interpretation Our findings showed that childhood acute lymphoblastic leukaemia is frequently initiated by a chromosome translocation event in utero. Studies in identical twins show however that such an event is insufficient for clinical leukaemia and that a postnatal promotional event is also required.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Univ Milan, Osped San Gerardo, Ctr Ric Tettamanti, Pediat Clin, Milan, Italy; Christie Hosp NHS Trust, Acad Unit Paediat Oncol, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Clin Biochem, Manchester M27 1HA, Lancs, England; Royal London Hosp, Dept Paediat Haematol & Oncol, London E1 1BB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; San Gerardo Hospital; University of Milan; Christie NHS Foundation Trust; Christie Hospital; Royal Manchester Children's Hospital; Barts Health NHS Trust; Royal London Hospital	Greaves, MF (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England.		Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016; Cazzaniga, Giovanni/K-6338-2016	Biondi, Andrea/0000-0002-6757-6173; Saha, Vaskar/0000-0002-2916-9649; Cazzaniga, Giovanni/0000-0003-2955-4528				Alexander FE, 1998, BRIT J CANCER, V77, P818, DOI 10.1038/bjc.1998.133; BHATIA S, 1999, CHILDHOOD LEUKEMIAS, P38; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Buckley JD, 1996, MED PEDIATR ONCOL, V26, P223, DOI 10.1002/(SICI)1096-911X(199604)26:4<223::AID-MPO1>3.0.CO;2-L; CHESSELLS JM, 1977, LANCET, V2, P1307; COMEAU AM, 1993, J PEDIATR-US, V123, P252, DOI 10.1016/S0022-3476(05)81697-X; *COMM MED ASP RAD, 1996, INC CANC LEUK YOUNG; DRAPER GJ, 1974, 11 INT CANC C, P150; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford AM, 1997, BLOOD, V89, P281, DOI 10.1182/blood.V89.1.281.281_281_285; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X; GREAVES M, 1993, BLOOD, V82, P1043; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1985, LEUKEMIA RES, V9, P715, DOI 10.1016/0145-2126(85)90281-4; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; Kersey JH, 1997, BLOOD, V90, P4243, DOI 10.1182/blood.V90.11.4243.4243_4243_4251; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MAKOWSKI GS, 1995, NUCLEIC ACIDS RES, V23, P3788, DOI 10.1093/nar/23.18.3788; OCHS J, 1996, LEUKEMIA, P419; Parkin DM, 1998, IARC SCI PUBLICATION, V144; PUI CH, 1995, LEUKEMIA, V9, P762; RAIMONDI SC, 1993, BLOOD, V81, P2237; Raskin S, 1992, PCR Methods Appl, V2, P154; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; RODVALL Y, 1990, INT J CANCER, V46, P362, DOI 10.1002/ijc.2910460304; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SAHA V, 1993, ARCH DIS CHILD, V68, P771, DOI 10.1136/adc.68.6.771; Smith MA, 1997, J NATL CANCER I, V89, P1542, DOI 10.1093/jnci/89.20.1542; Taylor GM, 1996, LEUKEMIA, P210; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, CANCER RES, V59, P4075	39	451	459	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1499	1503		10.1016/S0140-6736(99)09403-9	http://dx.doi.org/10.1016/S0140-6736(99)09403-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551495				2022-12-24	WOS:000083411300009
J	Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP				Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP			Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; C2 DOMAIN; PHOSPHOLIPID-BINDING; CYTOSOLIC PHOSPHOLIPASE-A2; GLIOMA-CELLS; SYNAPTOTAGMIN; GENE; RECOGNITION; CANCER; DELTA	The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Sloan Kettering Div, Dept Pharmacol, New York, NY 10021 USA; Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Michigan System; University of Michigan; Princeton University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	nikola@xray2.mskcc.org	di cristofano, antonio/AAJ-3796-2020; Di Cristofano, Antonio/B-4148-2016; Lee, Jie-Oh/C-1581-2011; Maehama, Tomohiko/HGB-4896-2022; Lee, Jie-Oh/AAG-4302-2020; Georgescu, Maria-Magdalena/AAJ-6359-2020; Maehama, Tomohiko/AAX-8926-2020	di cristofano, antonio/0000-0003-2537-3228; Maehama, Tomohiko/0000-0002-9685-2317; Lee, Jie-Oh/0000-0001-6519-6049; Shi, Yigong/0000-0003-2030-168X	NCI NIH HHS [CA09673] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	42	821	859	7	107	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					323	334		10.1016/S0092-8674(00)81663-3	http://dx.doi.org/10.1016/S0092-8674(00)81663-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555148	Bronze			2022-12-24	WOS:000083440600010
J	Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H				Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H			Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes	NATURE			English	Article							ANTI-ANXIETY AGENTS; SINGLE HISTIDINE; DIAZEPAM; PHARMACOLOGY; SUBUNITS; ETHANOL; MOUSE	GABA(A) (gamma-aminobutyric acid(A)) receptors are molecular substrates for the regulation of vigilance, anxiety, muscle tension, epileptogenic activity and memory functions, which is evident from the spectrum of actions elicited by clinically effective drugs acting at their modulatory benzodiazepine-binding site. Here we show, by introducing a histidine-to-arginine point mutation at position 101 of the murine alpha 1-subunit gene, that alpha 1-type GABA(A) receptors, which are mainly expressed in cortical areas and thalamus(1), are rendered insensitive to allosteric modulation by benzodiazepine-site ligands, whilst regulation by the physiological neurotransmitter gamma-aminobutyric acid is preserved. alpha 1(H101R) mice failed to show the sedative, amnesic and partly the anticonvulsant action of diazepam. In contrast, the anxiolytic-like, myorelaxant, motor-impairing and ethanol-potentiating effects were fully retained, and are attributed to the nonmutated GABA(A) receptors found in the limbic system (alpha 2, alpha 5), in monoaminergic neurons (alpha 3) and in motoneurons (alpha 2, alpha 5)(1). Thus, benzodiazepine-induced behavioural responses are mediated by specific GABA(A) receptor subtypes in distinct neuronal circuits, which is of interest for drug design.	Univ Zurich, Inst Pharmacol, CH-8057 Zurich, Switzerland; ETH Zurich, CH-8057 Zurich, Switzerland; Ciba Geigy AG, Div Pharma, Preclin Res, CH-4002 Basel, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol, Winterthurestr 190, CH-8057 Zurich, Switzerland.			Fritschy, Jean-Marc/0000-0002-8552-3702				Barnard EA, 1998, PHARMACOL REV, V50, P291; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; BERNARD F, 1996, ZOLPIDEM UPDATE ITS, P21; BEUZEN A, 1995, PHYSIOL BEHAV, V58, P111, DOI 10.1016/0031-9384(95)00013-9; BONETTI EP, 1988, PHARMACOL BIOCHEM BE, V31, P733, DOI 10.1016/0091-3057(88)90259-6; BONETTI EP, 1982, PSYCHOPHARMACOLOGY, V78, P8, DOI 10.1007/BF00470579; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; KLEINGOOR C, 1993, NEUROREPORT, V4, P187, DOI 10.1097/00001756-199302000-00018; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; MELCHIOR CL, 1992, PHARMACOL BIOCHEM BE, V42, P605, DOI 10.1016/0091-3057(92)90005-Z; MISSLIN R, 1989, BEHAV PROCESS, V18, P119, DOI 10.1016/S0376-6357(89)80010-5; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	19	944	972	1	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					796	800		10.1038/44579	http://dx.doi.org/10.1038/44579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548105				2022-12-24	WOS:000083368700054
J	Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP				Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP			Evidence of a chronic systemic cause of instability of atherosclerotic plaques	LANCET			English	Article							CAROTID STENOSIS; 1001 ANGIOGRAMS; ULCERATION; REPRODUCIBILITY; INFARCTION; MECHANISMS; DISEASE; LINK	Background Major thrombotic and embolic complications of atherosclerosis are closely associated with irregularity and rupture of atheromatous plaques in both the carotid and coronary arteries. Plaque instability is partly determined by local factors, but systemic factors, such as infection, autoimmunity, or genes, may also be important. If plaque stability is influenced by systemic factors that are present in only a proportion of patients, some individuals should be more prone to rupture of plaques than others-ie, irregular plaques should occur in multiple vascular beds in some individuals more frequently than would be expected by chance alone. Methods We studied 5393 carotid bifurcation angiograms from 3007 patients with a recently symptomatic carotid stenosis. We assessed the extent to which plaque-surface irregularity at the symptomatic carotid artery was associated with irregularity at a distant site, the contralateral carotid artery, and the extent to which plaque irregularity at these sites was associated with previous myocardial infarction or subsequent non-stroke vascular death (due mainly to coronary-artery disease). Findings Patients with plaque-surface irregularity (n=1897) in the symptomatic carotid artery were more likely than those with smooth plaque (n=110) to have irregularity in the contralateral carotid artery (odds ratio 2.21 [95% CI 1.62-3.01], p<0.001). Patients with irregular plaques in both arteries were more likely to have had a previous myocardial infarction than patients with smooth plaques (hazard ratio 1.82 [1.23-2.64], p<0.001), and were more likely to have a non-stroke vascular death on follow-up (hazard ratio 1.67 [1.15-2.44], p=0.007). However, there was no difference in the risk of non-vascular death (hazard ratio 0.92 [0.57-1.45], p=0.5). These associations were not explicable on the basis of differences in traditional vascular risk factors. Interpretation These data suggest that some individuals have a systemic predisposition to irregularity and rupture of atherosclerotic plaques that is independent of traditional vascular risk factors. This finding supports the hypothesis that other systemic factors are important in the cause of plaque instability.	Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Radcliffe Infirmary; University of Edinburgh	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020; Donders, A.R.T./L-4277-2015	Rothwell, Peter/0000-0001-9739-9211; Donders, A.R.T./0000-0002-0484-1419				Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EIKELBOOM BC, 1983, STROKE, V14, P882, DOI 10.1161/01.STR.14.6.882; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; EPSTEIN SE, 1996, LANCET S, V348, P13; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER M, 1987, ANGIOLOGY, V38, P116, DOI 10.1177/000331978703800204; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; JULIAN OC, 1963, ARCH SURG-CHICAGO, V86, P131; Lammie GA, 1999, STROKE, V30, P1319, DOI 10.1161/01.STR.30.7.1319; LIBBY P, 1996, LANCET, V348, P4; RICHARDSON PD, 1989, LANCET, V2, P941; ROSS R, 1992, OXFORD TXB PATHOLOGY; Rothwell P. M., 1996, CEREBROVASC DIS, V6, P1; ROTHWELL PM, 1994, STROKE, V25, P2440, DOI 10.1161/01.STR.25.12.2440; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; Rothwell PM, 1998, CLIN RADIOL, V53, P439, DOI 10.1016/S0009-9260(98)80273-0; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SITZER M, 1995, STROKE, V26, P1231, DOI 10.1161/01.STR.26.7.1231; STREIFLER JY, 1994, STROKE, V25, P1130, DOI 10.1161/01.STR.25.6.1130; THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5; TOUBOUL PJ, 1994, CEREBROVASC DIS, V4, P8, DOI 10.1159/000108544; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X	23	179	184	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					19	24		10.1016/S0140-6736(99)04470-0	http://dx.doi.org/10.1016/S0140-6736(99)04470-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615886				2022-12-24	WOS:000085049200011
J	Wu, SP; Romfo, CM; Nilsen, TW; Green, MR				Wu, SP; Romfo, CM; Nilsen, TW; Green, MR			Functional recognition of the 3 ' splice site AG by the splicing factor U2AF(35)	NATURE			English	Article							PRE-MESSENGER-RNA; SMALL-SUBUNIT; BRANCH POINT; IDENTIFICATION; U2AF(65); PROTEIN; DROSOPHILA; SEQUENCES	In metazoans, spliceosome assembly is initiated through recognition of the 5' splice site by U1 snRNP and the polypyrimidine tract by the U2 small nuclear ribonucleoprotein particle (snRNP) auxiliary factor, U2AF (refs 1, 2), U2AF is a heterodimer comprising a large subunit, U2AF(65), and a small subunit, U2AF(35) (ref. 3). U2AF65 directly contacts the polypyrimidine tract and is required for splicing in vitro(4). In comparison, the role of U2AF35 has been puzzling: U2AF(35) is highly conserved(5-7) and is required for viabilit(6,7), but can be dispensed with for splicing in vitro(4,8,9). Here we use sire-specific crosslinking to show that very early during spliceosome assembly U2AF directly contacts the 3' splice site. Mutational analysis and in vitro genetic selection indicate that U2AF35 has a sequence-specific RNA-binding activity that recognizes the 3'-splice-site consensus, AG/G. We show that for introns with weak polypyrimidine tracts, the U2AF(35)-3'-splice-site interaction is critical for U2AF binding and splicing. Our results demonstrate a new biochemical activity of U2AF(35) identify the factor that initially recognizes the 3' splice site, and explain why the AG dinucleotide is required for the first step of splicing for some but not all introns.	Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, 373 Plantat St, Worcester, MA 01605 USA.	michael.green@umassmed.edu						Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NILSEN TW, 1997, TRANSSPLICING EUKARY, P310; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, SPLICEOSOME ASSEMBLY, P103; Romfo CM, 1997, NUCLEIC ACIDS RES, V25, P4658, DOI 10.1093/nar/25.22.4658; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	21	322	331	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					832	835		10.1038/45590	http://dx.doi.org/10.1038/45590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617206				2022-12-24	WOS:000084330500070
J	Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F				Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F			More than 200 meters of lake ice above subglacial lake Vostok, Antarctica	SCIENCE			English	Article							CENTRAL EAST-ANTARCTICA; ISOTOPIC COMPOSITION; AIR CONTENT; DELTA-O-18; WATER	Isotope studies show that the Vostok ice core consists of ice refrozen from Lake Vostok water, from 3539 meters below the surface of the Antarctic ice sheet to its bottom at about 3750 meters. Additional evidence comes from the total gas content, crystal size, and electrical conductivity of the ice. The Vostok site is a likely place for water freezing at the Lake-ice interface, because this interface occurs at a higher Level here than anywhere else above the Lake. Isotopic data suggest that subglacial Lake Vostok is an open system with an efficient circulation of water that was formed during periods that were slightly warmer than those of the past 420,000 years. Lake ice recovered by deep drilling is of interest for preliminary investigations of Lake chemistry and bedrock properties and for the search for indigenous lake microorganisms. This latter aspect is of potential importance for the exploration of icy planets and moons.	CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France; Lab Glaciol & Geophys Environm, CNRS, F-38402 St Martin Dheres, France; Free Univ Brussels, Fac Sci, Dept Sci Terre, B-1050 Brussels, Belgium; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia; St Petersburg Min Inst, St Petersburg 199026, Russia	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Arctic & Antarctic Research Institute; Saint Petersburg Mining University	Jouzel, J (corresponding author), CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France.		Vasilyev, Nikolay I./AAS-2261-2020; Raynaud, Dominique/H-9626-2016; raynaud, dominique/ABG-4718-2020; Lipenkov, Vladimir Y/Q-8262-2016	Vasilyev, Nikolay I./0000-0002-2279-699X; Lipenkov, Vladimir Y/0000-0003-4221-5440				CARSEY F, 1998, NAT SCI FDN WORKSH L, P21; CRAIG H, 1961, SCIENCE, V133, P1702, DOI 10.1126/science.133.3465.1702; JOUZEL J, 1982, J GLACIOL, V28, P35, DOI 10.3189/S0022143000011771; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; KERN RG, 1998, NAT SCI FDN WORKSH L, P24; LIPENKOV V, 1995, J GLACIOL, V41, P423, DOI 10.3189/S0022143000016294; LIPENKOV V, 1998, P INT WORKSH LAK VOS, P31; MARTINERIE P, 1994, J GEOPHYS RES-ATMOS, V99, P10565, DOI 10.1029/93JD03223; Paillard D, 1998, NATURE, V391, P378, DOI 10.1038/34891; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; SALAMATIN A, 1998, DATA GLACIOL STUD, V85, P233; Siegert MJ, 1998, J GEOPHYS RES-SOL EA, V103, P10195, DOI 10.1029/98JB00390; SOUCHEZ R, 1987, GEOPHYS RES LETT, V14, P599, DOI 10.1029/GL014i006p00599; SOUCHEZ RA, 1984, J GLACIOL, V30, P369, DOI 10.3189/S0022143000006249; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TIEDJIE JM, 1998, NAT SCI FDN WORKSH L, P19; Vimeux F, 1999, NATURE, V398, P410, DOI 10.1038/18860; WHITE DC, 1998, NAT SCI FDN WORKSH L, P22; 1998, NAT SCI FDN WORKSH L	21	139	144	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2138	2141		10.1126/science.286.5447.2138	http://dx.doi.org/10.1126/science.286.5447.2138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591641				2022-12-24	WOS:000084157300046
J	Tonks, NK; Myers, MP				Tonks, NK; Myers, MP			Cancer - Structural assets of a tumor suppressor	SCIENCE			English	Editorial Material							PHOSPHATASE; PTEN; GENE		Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.							Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; FUNARI FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292	11	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2096	2097		10.1126/science.286.5447.2096	http://dx.doi.org/10.1126/science.286.5447.2096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617421				2022-12-24	WOS:000084157300037
J	Holland, PWH				Holland, PWH			The future of evolutionary developmental biology	NATURE			English	Article							HOX GENES; DROSOPHILA; ULTRABITHORAX; ANTENNAPEDIA; COMPLEXES; SEQUENCE; PLAN	Combining fields as diverse as comparative embryology, palaeontology, molecular phylogenetics and genome analysis, the new discipline of evolutionary developmental biology aims at explaining how developmental processes and mechanisms become modified during evolution, and how these modifications produce changes in animal morphology and body plans. In the next century this should give us far greater mechanistic insight into how evolution has produced the vast diversity of living organisms, past and present.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Holland, PWH (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aldridge RJ, 1996, TRENDS ECOL EVOL, V11, P463, DOI 10.1016/0169-5347(96)10048-3; Aparicio S, 1997, NAT GENET, V16, P79, DOI 10.1038/ng0597-79; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Budd GE, 1999, BIOESSAYS, V21, P326, DOI 10.1002/(SICI)1521-1878(199904)21:4<326::AID-BIES9>3.0.CO;2-0; BURKE AC, 1995, DEVELOPMENT, V121, P333; COATES MI, 1994, DEVELOPMENT, P169; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Darwin C., 1859, ORIGIN SPECIES MEANS; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Force A, 1999, GENETICS, V151, P1531; Gaunt SJ, 1999, MECH DEVELOP, V82, P109, DOI 10.1016/S0925-4773(99)00018-0; HAECKEL E, 1903, PEDIGREE MAN OTHER E; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Mackay TFC, 1996, BIOESSAYS, V18, P113, DOI 10.1002/bies.950180207; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, GENETICS, V137, P607; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; Mouchel-Vielh E, 1998, MOL PHYLOGENET EVOL, V9, P382, DOI 10.1006/mpev.1998.0498; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; Shashikant CS, 1998, P NATL ACAD SCI USA, V95, P15446, DOI 10.1073/pnas.95.26.15446; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Willmer P, 1990, INVERTEBRATE RELATIO	29	56	59	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C41	C44		10.1038/35011536	http://dx.doi.org/10.1038/35011536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591224	Bronze			2022-12-24	WOS:000084014100006
J	Saxena, D; Flores, S; Stotzky, G				Saxena, D; Flores, S; Stotzky, G			Transgenic plants - Insecticidal toxin in root exudates from Bt corn	NATURE			English	Article							THURINGIENSIS SUBSP KURSTAKI; BACILLUS-THURINGIENSIS; SOIL; TENEBRIONIS		NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA; Inst Venezolano Invest Cient, Caracas 1020A, Venezuela	New York University; Venezuelan Institute Science Research	Saxena, D (corresponding author), NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA.	gs5@is2.nyu.edu	Saxena, Deepak/K-1864-2019					BENIZRI E, 1995, SOIL BIOL BIOCHEM, V27, P71, DOI 10.1016/0038-0717(94)00131-J; Crecchio C, 1998, SOIL BIOL BIOCHEM, V30, P463, DOI 10.1016/S0038-0717(97)00147-8; Hilbeck A, 1998, ENVIRON ENTOMOL, V27, P480, DOI 10.1093/ee/27.2.480; Koskella J, 1997, APPL ENVIRON MICROB, V63, P3561, DOI 10.1128/AEM.63.9.3561-3568.1997; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; LOWRY OH, 1951, J BIOL CHEM, V193, P265; TAPP H, 1994, SOIL BIOL BIOCHEM, V26, P663, DOI 10.1016/0038-0717(94)90258-5; Tapp H, 1998, SOIL BIOL BIOCHEM, V30, P471, DOI 10.1016/S0038-0717(97)00148-X; TAPP H, 1995, APPL ENVIRON MICROB, V61, P1786, DOI 10.1128/AEM.61.5.1786-1790.1995; Wadman M, 1999, NATURE, V397, P639, DOI 10.1038/17655	10	282	391	0	93	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					480	480		10.1038/44997	http://dx.doi.org/10.1038/44997			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591205	Bronze			2022-12-24	WOS:000084013200041
J	Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ				Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ			Regulation of lineage commitment distinct from positive selection	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; THYMIC SELECTION; INTERMEDIATE STEPS; CD8 LINEAGE; THYMOCYTES; MICE; MODEL; GENERATION; EXPRESSION	Developing alpha beta T cells diverge into the CD4 and CD8 Lineages as they mature in the thymus. It is unclear whether Lineage commitment is mechanistically distinct from the process that selects for the survival of T cells with useful T cell receptor (TCR) specificities (positive selection). In HD mice, which Lack mature CD4(+) T cells, major histocompatibility complex (MHC) class II-restricted T cells are redirected to the CD8 lineage independent of MHC class I expression. However, neither TCR-mediated signaling nor positive selection is impaired. Thus, the HD mutation provides genetic evidence that lineage commitment may be mechanistically distinct from positive selection.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kappes, DJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Wiest, David/0000-0002-0792-3188	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA074620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034472] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA74620] Funding Source: Medline; NIAID NIH HHS [AI34472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN D, UNPUB; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Dave VP, 1998, P NATL ACAD SCI USA, V95, P8187, DOI 10.1073/pnas.95.14.8187; DAVE VP, UNPUB; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAPPES DJ, UNPUB; KAYE J, 1992, J IMMUNOL, V148, P3342; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KEEFE R, UNPUB; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KYDD R, 1995, J IMMUNOL, V155, P3806; LUCAS B, 1994, J IMMUNOL, V153, P53; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; LUNDBERG K, 1995, J EXP MED, V181, P1643, DOI 10.1084/jem.181.5.1643; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; Punt JA, 1996, J EXP MED, V184, P2091, DOI 10.1084/jem.184.6.2091; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1980, J IMMUNOL, V124, P2845; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139	33	86	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1149	1153		10.1126/science.286.5442.1149	http://dx.doi.org/10.1126/science.286.5442.1149			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550051				2022-12-24	WOS:000083534200041
J	Kroger, N; Deutzmann, R; Sumper, M				Kroger, N; Deutzmann, R; Sumper, M			Polycationic peptides from diatom biosilica that direct silica nanosphere formation	SCIENCE			English	Article							CELL-WALLS; PROTEIN; MORPHOGENESIS; ACID	Diatom cell walls are regarded as a paradigm for controlled production of nanostructured silica, but the mechanisms allowing biosilicification to proceed at ambient temperature at high rates have remained enigmatic. A set of polycationic peptides (called silaffins) isolated from diatom cell walls were shown to generate networks of silica nanospheres within seconds when added to a solution of silicic acid. Silaffins contain covalently modified Lysine-Lysine elements. The first Lysine bears a polyamine consisting of 6 to 11 repeats of the N-methyl-propylamine unit. The second Lysine was identified as epsilon-N,N-dimethyl-lysine. These modifications drastically influence the silica-precipitating activity of silaffins.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Kroger, N (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany.	nils.kroeger@vkl.uni-regensburg.de						BOROWITZKA MA, 1978, J PHYCOL, V14, P10; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; CHIAPPINO ML, 1977, PROTOPLASMA, V93, P205, DOI 10.1007/BF01275654; GORDON R, 1994, INT REV CYTOL, V150, P243; HECKY RE, 1973, MAR BIOL, V19, P323, DOI 10.1007/BF00348902; Iler R. K, 1979, CHEM SILICA; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; LINDQUIST GM, 1976, J COLLOID INTERF SCI, V55, P45, DOI 10.1016/0021-9797(76)90007-2; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Mann S., 1989, BIOMINERALIZATION CH; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; NAKAJIMA T, 1969, SCIENCE, V164, P1400, DOI 10.1126/science.164.3886.1400; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Pickett-Heaps J., 1990, PROGR PHYCOLOGICAL R, V7, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID AMM, 1979, PROTOPLASMA, V100, P267, DOI 10.1007/BF01279316; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWIFT DM, 1992, J PHYCOL, V28, P202, DOI 10.1111/j.0022-3646.1992.00202.x; Volcani B., 1981, SILICON SILICEOUS ST, P157; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	23	1129	1180	14	330	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1129	1132		10.1126/science.286.5442.1129	http://dx.doi.org/10.1126/science.286.5442.1129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550045				2022-12-24	WOS:000083534200035
J	Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS				Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS			Environmental toxins - Exposure to bisphenol A advances puberty	NATURE			English	Article									Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Zool, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Howdeshell, KL (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	vomsaalf@missouri.edu						COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; GRAY LE, 1992, ADV MOD ENV, V21, P203; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; SAAL FSV, 1989, J ANIM SCI, V67, P1824; TAKAO Y, 1999, J HEALTH SCI, V45, P39; VANDENBERGH JG, 1969, ENDOCRINOLOGY, V84, P658, DOI 10.1210/endo-84-3-658; VOMSAAL FS, 1981, J REPROD FERTIL, V62, P633, DOI [10.1530/jrf.0.0620633, 10.1530/jrf.0.0620033]; VOMSAAL FS, 1998, FORUM APPL RES PUBLI, V13, P11	14	657	688	5	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					763	764		10.1038/44517	http://dx.doi.org/10.1038/44517			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548101				2022-12-24	WOS:000083368700043
J	Kinra, S; Okasha, M				Kinra, S; Okasha, M			Unsafe sax: cohort study of the impact of too much sax on the mortality of famous jazz musicians	BRITISH MEDICAL JOURNAL			English	Article									S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England	University of Bristol	Kinra, S (corresponding author), S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England.							CARR I, 1998, JAZZ ROUGH GUIDE; COOK R, 1994, PENGUIN GUIDE JAZZ; FORDHAM J, 1993, ANATOMY INSTRUMENTS, P60	3	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1612	1613		10.1136/bmj.319.7225.1612	http://dx.doi.org/10.1136/bmj.319.7225.1612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600961	Green Published, Bronze			2022-12-24	WOS:000084562600015
J	Zhou, JM; Levine, M				Zhou, JM; Levine, M			A novel cis-regulatory element, the PTS, mediates an anti-insulator activity in the Drosophila embryo	CELL			English	Article							CHROMATIN DOMAIN BOUNDARY; BITHORAX COMPLEX; ABDOMINAL-B; MOLECULAR ANALYSIS; GENE-EXPRESSION; MELANOGASTER; ENHANCER; REPRESSION; PROTEIN; FAB-7	The Abd-B Hox gene contains an extended 3' cis-regulatory region that is subdivided into a series of separate lab domains. The iab-7 domain activates Abd-B in parasegment 12 (ps12), whereas iab-8 controls expression in ps13. iab-7 is flanked by two insulators, Fab-7 and Fab-8, which are thought to prevent regulatory factors, such as Polycomb silencers, from influencing neighboring iab domains. This organization poses a potential paradox, since insulator DNAs can work in a dominant fashion to block enhancer-promoter interactions over long distances. Here, we present evidence for a novel cia-regulatory sequence located within iab-7, the promoter targeting sequence (PTS), which permits distal enhancers to overcome the blocking effects of Fab-8 and the heterologous su(Hw) insulator. We propose that the PTS converts dominant, long-range insulators into local regulatory elements that separate neighboring iab domains.	Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA.	mlevine@uclink4.berkeley.edu		Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM 34431, GM 19329] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARGES S, 2000, IN PRESS DEVELOPMENT; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BOULET AM, 1991, DEVELOPMENT, V111, P393; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Busturia A, 1997, DEVELOPMENT, V124, P4343; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CASTRILLON DH, 1993, GENETICS, V135, P489; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; DORSETT D, 1993, GENETICS, V134, P1135; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; HENDRICKSON JE, 1995, GENETICS, V139, P835; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; HOPMANN R, 1995, GENETICS, V139, P815; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; Mallin DR, 1998, GENETICS, V148, P331; MCCALL K, 1994, GENETICS, V138, P387; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; PARO R, 1998, NOVART FDN SYMP, V214, P61; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SCHIER AF, 1993, P NATL ACAD SCI USA, V90, P1450, DOI 10.1073/pnas.90.4.1450; Sipos L, 1998, GENETICS, V149, P1031; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; Wu XL, 1998, DEVELOPMENT, V125, P3765; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; Zhou JM, 1999, DEVELOPMENT, V126, P3057	56	105	107	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					567	575		10.1016/S0092-8674(00)81546-9	http://dx.doi.org/10.1016/S0092-8674(00)81546-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612393	Bronze			2022-12-24	WOS:000084278700004
J	Le Feuvre, Y; Fenelon, VS; Meyrand, P				Le Feuvre, Y; Fenelon, VS; Meyrand, P			Central inputs mask multiple adult neural networks within a single embryonic network	NATURE			English	Article							LOBSTER STOMATOGASTRIC GANGLION; CENTRAL PATTERN GENERATOR; LONG-TERM POTENTIATION; MUSCARINIC MODULATION; GASTRIC RHYTHM; NERVOUS-SYSTEM; MOTOR PATTERN; NEURONS; CIRCUIT; CONSTRUCTION	It is usually assumed that, after construction of basic network architecture in embryos(1), immature networks undergo progressive maturation to acquire their adult properties(2-4), We examine this assumption in the context of the lobster stomatogastric nervous system. In the lobster, the neuronal population(5) that will form this system is at first organized into a single embryonic network that generates a single rhythmic pattern(6). The system then splits into different functional adult networks(6) controlled by central descending systems(7,8); these adult networks produce multiple motor programmes, distinctively different from the single output of the embryonic network. We show here that the single embryonic network can produce multiple adult-like programmes. This occurs after the embryonic network is silenced by removal of central inputs, then pharmacologically stimulated to restore rhythmicity, Furthermore, restoration of the flow of descending information reversed the adult-like pattern to an embryonic pattern. This indicates that the embryonic network possesses the ability to express adult-like network characteristics, but descending information prevents it from doing so. Functional adult networks may therefore not necessarily be derived from progressive ontogenetic changes in networks themselves, but may result from maturation of descending systems that unmask preexisting adult networks in an embryonic system.	CNRS, Lab Neurobiol Reseaux, F-33405 Talence, France; Univ Bordeaux 1, UMR 5816, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Meyrand, P (corresponding author), CNRS, Lab Neurobiol Reseaux, Batiment B2,Ave Fac, F-33405 Talence, France.			Fenelon, Valerie/0000-0001-8023-0049; Le Feuvre, Yves/0000-0002-2646-4028				Angulo MC, 1999, J NEUROSCI, V19, P1566; BAL T, 1994, J NEUROSCI, V14, P3019; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; CASASNOVAS B, 1995, J NEUROSCI, V15, P5703; Clemens S, 1998, J NEUROSCI, V18, P2788; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ELSON RC, 1992, J NEUROPHYSIOL, V68, P890, DOI 10.1152/jn.1992.68.3.890; Faumont S, 1998, J NEUROPHYSIOL, V80, P2776, DOI 10.1152/jn.1998.80.5.2776; Fenelon VS, 1999, J COMP NEUROL, V408, P335, DOI 10.1002/(SICI)1096-9861(19990607)408:3<335::AID-CNE3>3.0.CO;2-W; Fenelon VS, 1998, CURR OPIN NEUROBIOL, V8, P705, DOI 10.1016/S0959-4388(98)80111-6; Fenelon VS, 1998, J COMP NEUROL, V399, P289, DOI 10.1002/(SICI)1096-9861(19980928)399:3<289::AID-CNE1>3.0.CO;2-X; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P847, DOI 10.1152/jn.1986.55.5.847; Harris -Warrick R.M., 1992, DYNAMIC BIOL NETWORK; HOOPER SL, 1984, BRAIN RES, V305, P186, DOI 10.1016/0006-8993(84)91138-7; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kilman V, 1999, J COMP NEUROL, V408, P318, DOI 10.1002/(SICI)1096-9861(19990607)408:3<318::AID-CNE2>3.0.CO;2-S; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MASABUAU JC, 1996, J NEUROSCI, V16, P3950; MCCORMICK DA, 1995, J NEUROSCI, V15, P2739; MEYRAND P, 1991, NATURE, V351, P60, DOI 10.1038/351060a0; MOULINS M, 1982, J NEUROBIOL, V5, P447; Nick TA, 1996, J NEUROSCI, V16, P7583; ROBERTSON RM, 1984, J COMP PHYSIOL, V154, P473, DOI 10.1007/BF00610162; Sillar Keith T., 1994, Current Opinion in Neurobiology, V4, P101, DOI 10.1016/0959-4388(94)90038-8; SPITZER NC, 1994, PROG BRAIN RES, V102, P169; Sun QQ, 1998, J PHYSIOL-LONDON, V507, P257, DOI 10.1111/j.1469-7793.1998.257bu.x; TURRIGIANO GG, 1989, J NEUROSCI, V9, P2486; Warren RA, 1997, J NEUROSCI, V17, P277, DOI 10.1523/JNEUROSCI.17-01-00277.1997	28	41	41	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					660	664		10.1038/45238	http://dx.doi.org/10.1038/45238			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604471				2022-12-24	WOS:000084189800065
J	Mitchell, JR; Wood, E; Collins, K				Mitchell, JR; Wood, E; Collins, K			A telomerase component is defective in the human disease dyskeratosis congenita	NATURE			English	Article							SMALL NUCLEOLAR RNAS; EPSTEIN-BARR-VIRUS; RIBOSOMAL-RNA; PSEUDOURIDINE SYNTHASE; FIBROBLASTS; PROTEIN; CELLS; CBF5P	The X-linked form of the human disease dyskeratosis congenita (DKC) is caused by mutations in the gene encoding dyskerin(1). Sufferers have defects in highly regenerative tissues such as skin and bone marrow, chromosome instability and a predisposition to develop certain types of malignancy. Dyskerin is a putative pseudouridine synthase, and it has been suggested that DKC may be caused by a defect in ribosomal RNA processing. Here we show that dyskerin is associated not only with H/ACA small nucleolar RNAs2, but also with human telomerase RNA, which contains an H/ACA RNA motif(3). Telomerase adds simple sequence repeats to chromosome ends using an internal region of its RNA as a template(4), and is required for the indefinite proliferation of primary human cells(5). We find that primary fibroblasts and lymphoblasts from DKC-affected males are not detectably deficient in conventional H/ACA small nucleolar RNA accumulation or function; however, DKC cells have a lower level of telomerase RNA, produce lower levels of telomerase activity and have shorter telomeres than matched normal cells. The pathology of DKC is consistent with compromised telomerase function leading to a defect in telomere maintenance, which may limit the proliferative capacity of human somatic cells in epithelia and blood.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Mitchell, JR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dokal I, 1996, BRIT J HAEMATOL, V92, P775, DOI 10.1046/j.1365-2141.1996.355881.x; DOKAL I, 1992, BLOOD, V80, P3090; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; MARSH JCW, 1992, BLOOD, V79, P3138; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SIRINAVIN C, 1975, J MED GENET, V12, P339, DOI 10.1136/jmg.12.4.339; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TROWBRIDGE AA, 1977, AM J HEMATOL, V3, P143, DOI 10.1002/ajh.2830030205; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	27	848	886	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					551	555		10.1038/990141	http://dx.doi.org/10.1038/990141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591218				2022-12-24	WOS:000084013200062
J	Malek, AM; Alper, SL; Izumo, S				Malek, AM; Alper, SL; Izumo, S			Hemodynamic shear stress and its role in atherosclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY DISEASE; CANINE CAROTID-ARTERY; WHO-ISFC PBDAY; WALL SHEAR; BLOOD-FLOW; IN-VIVO; GENE-EXPRESSION; SMOOTH-MUSCLE	Atherosclerosis, the leading cause of death in the developed world and nearly the leading cause in the developing world, is associated with systemic risk factors including hypertension, smoking, hyperlipidemia, and diabetes mellitus, among others, Nonetheless, atherosclerosis remains a geometrically focal disease, preferentially affecting the outer edges of vessel bifurcations. In these predisposed areas, hemodynamic shear stress, the frictional force acting on the endothelial cell surface as a result of blood flow, is weaker than in protected regions, Studies have identified hemodynamic shear stress as an important determinant of endothelial function and phenotype, Arterial-level shear stress (>15 dyne/cm(2)) induces endothelial quiescence and an atheroprotective gene expression profile, while low shear stress (<4 dyne/cm(2)), which is prevalent at atherosclerosis-prone sites, stimulates an atherogenic phenotype, The functional regulation of the endothelium by local hemodynamic shear stress provides a model for understanding the focal propensity of atherosclerosis in the setting of systemic factors and may help guide future therapeutic strategies.	Brigham & Womens Hosp, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA USA; Univ Calif San Francisco, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Francisco	Malek, AM (corresponding author), Brigham & Womens Hosp, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	ammalek@bics.bwh.harvard.edu			NHLBI NIH HHS [HL15175] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando J, 1996, BIOCHEM BIOPH RES CO, V225, P347, DOI 10.1006/bbrc.1996.1178; ANDO J, 1994, AM J PHYSIOL, V267, pC679, DOI 10.1152/ajpcell.1994.267.3.C679; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; Aschoff L, 1912, BEITR PATHOL ANAT AL, V52, P0205; BASSIOUNY HS, 1994, J VASC SURG, V19, P426, DOI 10.1016/S0741-5214(94)70069-9; BEERE PA, 1992, ARTERIOSCLER THROMB, V12, P1245, DOI 10.1161/01.ATV.12.11.1245; BenDriss A, 1997, AM J PHYSIOL-HEART C, V272, pH851, DOI 10.1152/ajpheart.1997.272.2.H851; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BHARADVAJ BK, 1982, J BIOMECH, V15, P349, DOI 10.1016/0021-9290(82)90057-4; Busse R., 1994, Arzneimittel-Forschung, V44, P392; BUTTERFIELD AB, 1977, ATHEROSCLEROSIS, V26, P215, DOI 10.1016/0021-9150(77)90104-6; CARO CG, 1971, PROC R SOC SER B-BIO, V177, P109, DOI 10.1098/rspb.1971.0019; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1998, J BIOMECH ENG-T ASME, V120, P2, DOI 10.1115/1.2834303; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; Chun TH, 1997, HYPERTENSION, V29, P1296, DOI 10.1161/01.HYP.29.6.1296; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; FRIEDMAN MH, 1993, ATHEROSCLEROSIS, V98, P193, DOI 10.1016/0021-9150(93)90128-H; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; Fung Y. C., 1997, BIOMECHANICS CIRCULA; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; Girerd X, 1996, HYPERTENSION, V27, P799, DOI 10.1161/01.HYP.27.3.799; Gnasso A, 1997, STROKE, V28, P993, DOI 10.1161/01.STR.28.5.993; Gnasso A, 1996, CIRCULATION, V94, P3257, DOI 10.1161/01.CIR.94.12.3257; Grabowski EF, 1995, J VASC INTERV RADIOL, V6, pS25, DOI 10.1016/S1051-0443(95)71245-3; Guzman RJ, 1997, SURGERY, V122, P273, DOI 10.1016/S0039-6060(97)90018-0; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; HISHIKAWA K, 1995, HYPERTENSION, V25, P449, DOI 10.1161/01.HYP.25.3.449; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Inoue N, 1996, CIRC RES, V79, P32, DOI 10.1161/01.RES.79.1.32; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; Jou LD, 1996, MAGN RESON MED, V35, P577, DOI 10.1002/mrm.1910350418; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; Kawai Y, 1996, BLOOD, V87, P2314, DOI 10.1182/blood.V87.6.2314.bloodjournal8762314; Kerber CW, 1996, AM J NEURORADIOL, V17, P1417; Kingwell BA, 1997, AM J PHYSIOL-HEART C, V272, pH1070, DOI 10.1152/ajpheart.1997.272.3.H1070; KJAERNES M, 1981, ACTA PATH MICRO IM A, V89, P35; Kolpakov V, 1996, ATHEROSCLEROSIS, V122, P173, DOI 10.1016/0021-9150(95)05735-8; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; Kosaki K, 1998, CIRC RES, V82, P794, DOI 10.1161/01.RES.82.7.794; KRAISS LW, 1991, ARTERIOSCLER THROMB, V11, P1844, DOI 10.1161/01.ATV.11.6.1844; Kraiss LW, 1996, CIRC RES, V79, P45, DOI 10.1161/01.RES.79.1.45; LABARBERA M, 1990, SCIENCE, V249, P992, DOI 10.1126/science.2396104; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Laurila A, 1997, ARTERIOSCL THROM VAS, V17, P2910, DOI 10.1161/01.ATV.17.11.2910; LEVESQUE MJ, 1990, BIOMATERIALS, V11, P702, DOI 10.1016/0142-9612(90)90031-K; Lynch J, 1997, CIRCULATION, V96, P302; MALEK A, 1992, AM J PHYSIOL, V263, pC389, DOI 10.1152/ajpcell.1992.263.2.C389; MALEK AM, 1994, CIRC RES, V74, P852, DOI 10.1161/01.RES.74.5.852; MALEK AM, 1994, J HYPERTENS, V12, P989; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; Masatsugu K, 1998, J CARDIOVASC PHARM, V31, pS42, DOI 10.1097/00005344-199800001-00014; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812, DOI 10.1161/01.ATV.9.6.812; Mattsson EJR, 1997, ARTERIOSCL THROM VAS, V17, P2245, DOI 10.1161/01.ATV.17.10.2245; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MELKUMYANTS AM, 1989, CARDIOVASC RES, V23, P741, DOI 10.1093/cvr/23.9.741; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; MOTOMIYA M, 1984, STROKE, V15, P50, DOI 10.1161/01.STR.15.1.50; Murata M, 1997, CIRCULATION, V96, P3281; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; Nerem RM, 1998, AM J MED SCI, V316, P169, DOI 10.1097/00000441-199809000-00004; Nicholson AC, 1998, ARTERIOSCL THROM VAS, V18, P339, DOI 10.1161/01.ATV.18.3.339; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OKAHARA K, 1995, FEBS LETT, V373, P108, DOI 10.1016/0014-5793(95)01027-C; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; Oshinski JN, 1995, JMRI-J MAGN RESON IM, V5, P640; Oyre S, 1997, EUR J VASC ENDOVASC, V13, P263, DOI 10.1016/S1078-5884(97)80097-4; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; Pedersen EM, 1997, EUR J VASC ENDOVASC, V13, P443, DOI 10.1016/S1078-5884(97)80171-2; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; Ravensbergen J, 1998, ARTERIOSCL THROM VAS, V18, P708, DOI 10.1161/01.ATV.18.5.708; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; RODBARD S, 1975, CARDIOLOGY, V60, P4, DOI 10.1159/000169701; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossitti S, 1995, ACTA NEUROCHIR, V137, P138, DOI 10.1007/BF02187185; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; SAWCHUK AP, 1994, J VASC SURG, V19, P58, DOI 10.1016/S0741-5214(94)70120-2; SHAREFKIN JB, 1991, J VASC SURG, V14, P1; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Sloop GD, 1996, MED HYPOTHESES, V47, P321, DOI 10.1016/S0306-9877(96)90073-0; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P429; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P2, DOI 10.1161/01.ATV.15.1.2; WALPOLA PL, 1993, AM J PATHOL, V142, P1392; WATERS D, 1995, CIRCULATION, V92, P2404, DOI 10.1161/01.CIR.92.9.2404; WEBER G, 1993, CLIN EXP HYPERTENS, V15, P31; ZAMIR M, 1976, J GEN PHYSIOL, V67, P213, DOI 10.1085/jgp.67.2.213; ZARINS CK, 1987, J VASC SURG, V5, P413, DOI 10.1067/mva.1987.avs0050413; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	113	2418	2580	18	300	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2035	2042		10.1001/jama.282.21.2035	http://dx.doi.org/10.1001/jama.282.21.2035			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591386				2022-12-24	WOS:000083908700023
J	Fetscher, S				Fetscher, S			An entirely benign disorder	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Fetscher, S (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	fetscher@mml1.ukl.uni-freiburg.de							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					786	788		10.7326/0003-4819-131-10-199911160-00014	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577305				2022-12-24	WOS:000083680100012
J	Kim, L; Liu, JC; Kimmel, AR				Kim, L; Liu, JC; Kimmel, AR			The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASES; DICTYOSTELIUM-DISCOIDEUM; AXIS SPECIFICATION; RECEPTOR; XENOPUS; PHOSPHORYLATION; IDENTIFICATION; DIFFERENTIATION; CLASSIFICATION	Inhibition of GSK3 by 7-TM Wnt/wg receptor signaling is critical for specifying embryonic cell fate patterns. In Dictyostelium, the 7-TM cAMP receptors regulate GSK3 by parallel, antagonistic pathways to establish a developmental body plan. We describe here a novel tyrosine kinase, ZAK1, downstream of 7-TM cAMP receptor signaling that is required for GSK3 activation during development, zak1-nulls have reduced GSK3 activity and are defective in GSK3-regulated developmental pathways. Moreover, recombinant ZAK1 phosphorylates and activates GSK3 in vitro. We propose that ZAK1 is a positive regulator of GSK3 activity required for cell pattern formation in Dictyostelium and speculate that similar mechanisms exist to antagonize Wnt/wg signaling for metazoan cell fate specification.	NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kimmel, AR (corresponding author), NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.	ark1@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams Douglas, 1979, HITCHHIKERS GUIDE GA; Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Baldauf SL, 1997, P NATL ACAD SCI USA, V94, P12007, DOI 10.1073/pnas.94.22.12007; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; Ginsburg GT, 1997, GENE DEV, V11, P2112, DOI 10.1101/gad.11.16.2112; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KAY RR, 1987, METHOD CELL BIOL, V28, P433; KIM L, 1995, MOL CELL BIOL, V15, P4553; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LOUIS JM, 1994, GENE DEV, V8, P2086, DOI 10.1101/gad.8.17.2086; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Plyte SE, 1999, DEVELOPMENT, V126, P325; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; ROGERS KC, 1997, DICTYOSTELIUM MODEL, P163; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Verkerke-Van Wijk I, 1998, MOL CELL BIOL, V18, P5744, DOI 10.1128/MCB.18.10.5744; WANG QM, 1994, J BIOL CHEM, V269, P14566	38	136	141	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					399	408		10.1016/S0092-8674(00)81526-3	http://dx.doi.org/10.1016/S0092-8674(00)81526-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571182	Bronze			2022-12-24	WOS:000083709300007
J	Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA				Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA			Solution structure of anti-HIV-1 and anti-tumor protein MAP30: Structural insights into its multiple functions	CELL			English	Article							RIBOSOME-INACTIVATING PROTEINS; POKEWEED ANTIVIRAL PROTEIN; ADENOSINE GLYCOSIDASE ACTIVITY; RICIN A-CHAIN; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; BACKBONE DYNAMICS; STRANDED-DNA; J-COUPLINGS; NMR	We present the solution structure of MAP30, a plant protein with anti-HIV and anti-tumor activities. Structural analysis and subsequent biochemical assays lead to several novel discoveries. First, MAP30 acts like a DNA glycosylase/apurinic (ap) lyase, an additional activity distinct from its known RNA N-glycosidase activity toward the 28S rRNA. Glycosylase/ap lyase activity explains MAP30's apparent inhibition of the HIV-1 integrase, MAP30's ability to irreversibly relax supercoiled DNA, and may be an alternative cytotoxic pathway that contributes to MAP30's anti-HIV/anti-tumor activities. Second, two distinct, but contiguous, subsites are responsible for MAP30's glycosylase/ap lyase activity. Third, Mn2+ and Zn2+ interact with negatively charged surfaces next to the catalytic sites, facilitating DNA substrate binding instead of directly participating in catalysis.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Mol Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMSD, Prot Express Lab, NIH, Bethesda, MD 20892 USA; Amer BioSci, New York, NY 10021 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee-Huang, S (corresponding author), NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.			Huang, Paul/0000-0002-5436-8658; Lee-Huang, Sylvia/0000-0003-3302-241X; Wingfield, Paul/0000-0002-9515-4752	NIAID NIH HHS [R01 AI-31343] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041115, ZIAAR041115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000687] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; HUANG PL, 1992, BIOFACTORS, V4, P37; HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5; IRVIN JD, 1992, PHARMACOL THERAPEUT, V55, P279, DOI 10.1016/0163-7258(92)90053-3; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEEHUANG S, 1991, FEBS LETT, V291, P139, DOI 10.1016/0014-5793(91)81122-O; LEEHUANG S, 1995, GENE, V161, P151, DOI 10.1016/0378-1119(95)00186-A; LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P3865; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MLSNA D, 1993, PROTEIN SCI, V2, P429; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Ottiger M, 1999, J BIOMOL NMR, V13, P187, DOI 10.1023/A:1008395916985; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; Sawa R., 1995, NATURE, V373, P487; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang YX, 1998, J AM CHEM SOC, V120, P7385, DOI 10.1021/ja980862o; Wang YX, 1999, J BIOMOL NMR, V14, P181, DOI 10.1023/A:1008346517302; WANG YX, 1999, IN PRESS PROTEIN SCI; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Xiong JP, 1997, CHINESE J CHEM, V15, P265; Yamazaki T, 1996, PROTEIN SCI, V5, P495; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	63	66	79	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					433	442		10.1016/S0092-8674(00)81529-9	http://dx.doi.org/10.1016/S0092-8674(00)81529-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571185	Bronze			2022-12-24	WOS:000083709300010
J	Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L				Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L			Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study	LANCET			English	Article							COMPLICATIONS; MICROEMBOLI; RISK; DSA	Background Cerebral angiography is associated with a small but definite risk of neurological complications with an unknown incidence of clinically silent embolism. We assessed the neurological complication rate compared with the frequency of silent embolism after angiography Methods We used diffusion-weighted magnetic resonance imaging (MRI) before and after angiography to assess embolic events. 100 consecutive angiographies (66 diagnostic and 34 interventional procedures) were done on 91 patients. Patients underwent neurological assessment before, immediately after, and 1 day after angiography. Findings Before angiography, no abnormalities were seen on diffusion-weighted MRI. Diffusion-weighted MRI showed 42 bright lesions in 23 patients after 23 procedures (17 diagnostic, six interventional) in a pattern consistent with embolic events. There was no new neurological deficit after any angiographic procedure. After diagnostic angiography in patients with a history of vasculopathy, the frequency of lesions was significantly higher than in patients without vascular risk factors (12 [44%] of 27 vs five [13%] of 39 patients, p=0.03), in diagnostic angiography, the appearance of lesions was significantly correlated with whether Vessels were difficult to probe (p=0.01), amount of contrast medium needed (p<0.01), fluoroscopy time (p<0.01), and use of additional catheters (p=0.02). Interpretation After diagnostic and interventional cerebral angiography, embolic events are more frequent than the apparent neurological complication rate. In diagnostic procedures, the incidence of embolism is closely related to a vascular risk profile.	Univ Wurzburg, Dept Neuroradiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Bendszus, M (corresponding author), Univ Wurzburg, Dept Neuroradiol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.		Koltzenburg, Martin/C-1349-2008; Solymosi, László/E-6449-2018	Koltzenburg, Martin/0000-0001-9181-5966; Solymosi, László/0000-0001-9647-8647				DAGIRMANJIAN A, 1993, AM J ROENTGENOL, V161, P1037, DOI 10.2214/ajr.161.5.7903842; DAVIES KN, 1993, J NEUROL NEUROSUR PS, V56, P967, DOI 10.1136/jnnp.56.9.967; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247; GRZYSKA U, 1990, NEURORADIOLOGY, V32, P296, DOI 10.1007/BF00593048; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Horowitz MB, 1998, INTERV NEURORADIOL, V4, P27, DOI 10.1177/159101999800400103; MARKUS H, 1993, LANCET, V341, P784, DOI 10.1016/0140-6736(93)90561-T; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P432; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; Woolfenden AR, 1997, STROKE, V28, P2311, DOI 10.1161/01.STR.28.11.2311	13	370	385	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1594	1597		10.1016/S0140-6736(99)07083-X	http://dx.doi.org/10.1016/S0140-6736(99)07083-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560674				2022-12-24	WOS:000083551000011
J	Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J				Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J			Cross sectional survey of patients' satisfaction with information about cancer	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; Heriot Watt Univ, Dept Comp Sci, Edinburgh EH14 4AS, Midlothian, Scotland	University of Glasgow; Beatson Oncology Centre; Heriot Watt University	Jones, R (corresponding author), Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland.							Carstairs V., 1991, DEPRIVATION HLTH SCO; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; National Cancer Alliance, 1996, PAT CTR CANC SERV WH; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1247	1248		10.1136/bmj.319.7219.1247	http://dx.doi.org/10.1136/bmj.319.7219.1247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550091	Green Published, Bronze			2022-12-24	WOS:000083625600027
J	Brown, ME; Calvin, WM				Brown, ME; Calvin, WM			Evidence for crystalline water and ammonia ices on Pluto's satellite Charon	SCIENCE			English	Article							SURFACE-COMPOSITION; SPECTROSCOPY; IRRADIATION; VOLCANISM; SYSTEM; FLOW	Observations have resolved the satellite Charon from its parent planet Pluto, giving separate spectra of the two objects from 1.0 to 2.5 micrometers. The spectrum of Charon is found to be different from that of Pluto, with water ice in crystalline form covering most of the surface of the satellite. In addition, an absorption feature in Charon's spectrum suggests the presence of ammonia ices. Ammonia ice-water ice mixtures have been proposed as the cause of flowlike features observed on the surfaces of many icy satellites. The existence of such ices on Charon may indicate geological activity in the satellite's past.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Nevada, Dept Geol Sci, Reno, NV 89557 USA	California Institute of Technology; Nevada System of Higher Education (NSHE); University of Nevada Reno	Brown, ME (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.			Brown, Michael E./0000-0002-8255-0545				BROWN RH, 1988, ICARUS, V74, P262, DOI 10.1016/0019-1035(88)90041-3; BULE MW, 1987, NATURE, V329, P522; CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; CHRISTY JW, 1978, IAU CIRC, V3241, P1; CROFT SK, 1997, URANUS, P561; Cruikshank D.P., 1997, PLUTO CHARON, P221; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; DURHAM WB, 1993, J GEOPHYS RES-SOL EA, V98, P17667, DOI 10.1029/93JB01564; Fanale FP, 1999, ICARUS, V139, P179, DOI 10.1006/icar.1999.6117; FINK U, 1982, COMETS, P172; Grundy WM, 1998, J GEOPHYS RES-PLANET, V103, P25809, DOI 10.1029/98JE00738; GRUNDY WM, IN PRESS ICARUS; HAPKE B, 1981, J GEOPHYS RES, V86, P3039, DOI 10.1029/JB086iB04p03039; KARGEL JS, 1991, ICARUS, V89, P93, DOI 10.1016/0019-1035(91)90090-G; KHARE BN, 1989, ICARUS, V79, P350, DOI 10.1016/0019-1035(89)90082-1; KOUCHI A, 1990, NATURE, V344, P134, DOI 10.1038/344134a0; LANCON A, 1992, ASTRON ASTROPHYS SUP, V96, P593; LANZEROTTI LJ, 1984, NATURE, V312, P139, DOI 10.1038/312139a0; LEWIS JS, 1971, ICARUS, V15, P174, DOI 10.1016/0019-1035(71)90072-8; LIDE DR, 1996, CRC HDB CHEM PHYSICS, P77; MARCIALIS RL, 1987, SCIENCE, V237, P1349, DOI 10.1126/science.237.4820.1349; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; ROUSH TL, 1994, ICARUS, V108, P243, DOI 10.1006/icar.1994.1059; Roush TL, 1996, ICARUS, V119, P214, DOI 10.1006/icar.1996.0014; SCHENK PM, 1991, J GEOPHYS RES-SOLID, V96, P1887, DOI 10.1029/90JB01604; Schmitt B, 1998, ASTROPHYS SPACE SC L, V227, P199, DOI 10.1007/978-94-011-5252-5_9; STEVENSON DJ, 1982, NATURE, V298, P142, DOI 10.1038/298142a0	27	149	150	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					107	109		10.1126/science.287.5450.107	http://dx.doi.org/10.1126/science.287.5450.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615040				2022-12-24	WOS:000084578400045
J	Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ				Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ			Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Maternal-Fetal Medicine	JAN 18-23, 1999	SAN FRANCISCO, CALIFORNIA	Soc Maternal Fetal Med			ALPHA-FETOPROTEIN; FETAL GROWTH; 2ND-TRIMESTER; HCG; PREECLAMPSIA; MANAGEMENT	Background: Maternal serum chorionic gonadotropin is measured to screen for fetal chromosomal abnormalities. Whether the results can also be used to predict the risk of complications or an adverse outcome of pregnancy is not known. Methods: We reviewed the medical records of 28,743 girls and women in whom chorionic gonadotropin was measured during the second trimester of pregnancy (between July 1, 1995, and January 31, 1997), seeking information about the complications and outcome of their pregnancies. We excluded girls and women who had preexisting risk factors for complications or an adverse outcome of pregnancy. Results: Higher serum chorionic gonadotropin concentrations were associated with higher rates of stillbirth (odds ratio for every increase in chorionic gonadotropin of 1 multiple of the median, 1.4; 95 percent confidence interval, 1.1 to 1.9). There was no relation between higher serum chorionic gonadotropin concentrations and the risk of gestational diabetes, premature rupture of membranes, or intrauterine growth retardation or small size for gestational age (odds ratio, 1.1; 95 percent confidence interval, 0.9 to 1.2). Higher serum chorionic gonadotropin concentrations were associated with a risk of placental abnormalities (odds ratio, 1.5; 95 percent confidence interval, 1.3 to 1.7), pregnancy-induced hypertension (odds ratio, 1.4; 95 percent confidence interval, 1.3 to 1.5), and preterm delivery without pregnancy-induced hypertension (odds ratio, 1.1; 95 percent confidence interval, 1.0 to 1.2). Inclusion in certain racial or ethnic categories (black, Filipino or Pacific Islander, unknown race or ethnic group, and "other,'' which included those of Middle Eastern descent and Native Americans) was a better predictor of the risk of an adverse outcome than serum chorionic gonadotropin values. Conclusions: Measurements of serum chorionic gonadotropin are of little clinical value for predicting the risk of complications and the outcome of pregnancy. (N Engl J Med 1999;341:2033-8.) (C) 1999, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Dept Obstet, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Schoen, EJ (corresponding author), Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, 280 W MacArthur Blvd, Oakland, CA 94611 USA.			Walton, David/0000-0002-8461-2551				ABUELO DN, 1991, PRENATAL DIAG, V11, P381, DOI 10.1002/pd.1970110607; Ashour AMN, 1997, AM J OBSTET GYNECOL, V176, P438, DOI 10.1016/S0002-9378(97)70512-X; Benn PA, 1996, OBSTET GYNECOL, V87, P217, DOI 10.1016/0029-7844(95)00390-8; Bodegard G, 1983, Acta Paediatr Scand Suppl, V304, P1; Chalmers I, 1989, EFFECTIVE CARE PREGN; FREEMAN RK, 1982, AM J OBSTET GYNECOL, V143, P771, DOI 10.1016/0002-9378(82)90008-4; GANT NF, 1994, SEMIN PERINATOL, V18, P94; GLANTZ JC, 1993, CLIN OBSTET GYNECOL, V36, P279, DOI 10.1097/00003081-199306000-00009; GONEN R, 1992, OBSTET GYNECOL, V80, P83; GRAVETT CP, 1992, AM J MED GENET, V44, P485, DOI 10.1002/ajmg.1320440420; Heinonen S, 1996, AM J PERINAT, V13, P437, DOI 10.1055/s-2007-994384; *INT CLASS DIS, 1997, ICD9CM; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; MORSSINK LP, 1995, PRENATAL DIAG, V15, P1041, DOI 10.1002/pd.1970151109; Onderoglu LS, 1997, INT J GYNECOL OBSTET, V56, P245, DOI 10.1016/S0020-7292(96)02830-5; SORENSEN TK, 1993, AM J OBSTET GYNECOL, V169, P834, DOI 10.1016/0002-9378(93)90013-9; TANAKA M, 1993, OBSTET GYNECOL, V81, P341; VASILENKO P, 1995, 43 ACOG ANN M SAN FR; VORHERR H, 1975, AM J OBSTET GYNECOL, V123, P67, DOI 10.1016/0002-9378(75)90951-5; Wilkins-Haug L, 1998, CURR OPIN OBSTET GYN, V10, P469, DOI 10.1097/00001703-199812000-00007; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624	22	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2033	2038		10.1056/NEJM199912303412701	http://dx.doi.org/10.1056/NEJM199912303412701			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615074				2022-12-24	WOS:000084573300001
J	Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD				Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD			Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study	LANCET			English	Article							DIAGNOSIS; EPIDEMIOLOGY; ULTRASOUND; MOTILITY; OLIVE	Background In February, 1999, a local US health department identified a cluster of pertussis cases among neonates born at a community hospital and recommended oral erythromycin for post-exposure prophylaxis for about 200 neonates born at that hospital between Feb 1 and Feb 24, 1999, We investigated a cluster of seven cases of infantile hypertrophic pyloric stenosis (IHPS) that occurred the following month among the neonates who had received erythromycin. Methods We obtained a masked, independent review of the IHPS ultrasonography diagnoses, calculated the monthly IHPS incidence, and compared index and historical (1998-99) IHPS cases with respect to several characteristics including erythromycin exposure. We used a retrospective cohort of infants born in January and February, 1999, to investigate further erythromycin exposure and development of IHPS. Findings An independent review confirmed the ultrasonographic diagnoses of all seven index IHPS cases. All index cases versus none of the historical IHPS cases had been given erythromycin for pertussis prophylaxis. The IHPS rate for infants born in the hospital in February, 1999, was 323 per 1000 liveborn infants, representing nearly a seven-fold increase over 1997-98 (relative risk 6.8 [95% CI 3.0-15.7]). Among infants born in January and February, 1999, erythromycin was associated with IHPS (absolute risk 4.5%, relative risk infinity [1.7-infinity]). Interpretation Neonates receiving oral erythromycin may have an increased risk of IHPS. The risks and benefits of erythromycin for neonatal pertussis prophylaxis should be re-evaluated, and caution should be used in defining risk groups for prophylaxis.	Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Knox Cty Hlth Dept, Knoxville, TN USA; Johns Hopkins Sch Med, Baltimore, MD USA; E Tennessee Childrens Hosp, Knoxville, TN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Medicine	Honein, MA (corresponding author), Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, MS F-45,4770 Buford Highway NE, Atlanta, GA 30341 USA.							Abbas AE, 1999, AM SURGEON, V65, P73; Ali KI, 1996, EUR J PEDIATR SURG, V6, P233, DOI 10.1055/s-2008-1066516; APPLEGATE MS, 1995, ARCH PEDIAT ADOL MED, V149, P1123, DOI 10.1001/archpedi.1995.02170230077011; Boiron M, 1997, ARCH PHYSIOL BIOCHEM, V105, P591, DOI 10.1076/apab.105.6.591.3281; Coulie B, 1998, GUT, V43, P395, DOI 10.1136/gut.43.3.395; DILORENZO C, 1994, DIGEST DIS SCI, V39, P1399; Godbole P, 1996, ARCH DIS CHILD, V75, P335, DOI 10.1136/adc.75.4.335; HERNANZSCHULMAN M, 1994, RADIOLOGY, V193, P771, DOI 10.1148/radiology.193.3.7972822; HITCHCOCK NE, 1987, ARCH DIS CHILD, V62, P512, DOI 10.1136/adc.62.5.512; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Jadcherla SR, 1997, PEDIATR RES, V42, P365, DOI 10.1203/00006450-199709000-00018; Misra D, 1997, EUR J PEDIATR SURG, V7, P328, DOI 10.1055/s-2008-1071185; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; PERITI P, 1993, DRUG SAFETY, V9, P346, DOI 10.2165/00002018-199309050-00004; PETER G, 1997, 1997 RED BOOK REPORT, P397; Poon TSC, 1996, J PEDIATR SURG, V31, P1611, DOI 10.1016/S0022-3468(96)90032-9; RASMUSSEN L, 1989, INT J EPIDEMIOL, V18, P413, DOI 10.1093/ije/18.2.413; Rohrschneider WK, 1998, PEDIATR RADIOL, V28, P429, DOI 10.1007/s002470050377; ROLLINS MD, 1989, ARCH DIS CHILD, V64, P138, DOI 10.1136/adc.64.1.138; SANFILIPPO JA, 1976, J PEDIATR SURG, V11, P177; Schechter R, 1997, PAEDIATR PERINAT EP, V11, P407, DOI 10.1046/j.1365-3016.1997.d01-32.x; SCHWARTZ MZ, 1998, PEDIAT SURG, P1111; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STANG H, 1986, MINN MED, V69, P669; STANG H, 1986, MINN MED, V69, P682; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; TEELE RL, 1977, NEW ENGL J MED, V296, P1149, DOI 10.1056/NEJM197705192962006; White MC, 1998, J PEDIATR SURG, V33, P913, DOI 10.1016/S0022-3468(98)90673-X; ZEIDAN B, 1988, ARCH DIS CHILD, V63, P1060, DOI 10.1136/adc.63.9.1060	29	118	124	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2101	2105		10.1016/S0140-6736(99)10073-4	http://dx.doi.org/10.1016/S0140-6736(99)10073-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609814				2022-12-24	WOS:000084318200010
J	Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT				Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT			Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study	LANCET			English	Article							HORMONE-BINDING GLOBULIN; EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; ISOFLAVONOID PHYTOESTROGENS; CARDIOVASCULAR RISK; LIPID-PEROXIDATION; PHYTO-ESTROGENS; BREAST-CANCER	Background The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been implicated in protection against cancer. We investigated the association of serum enterolactone concentration with the risk of acute coronary events in a prospective nested case-control study in middle-aged men from eastern Finland. Methods Enterolactone was measured by time-resolved fluoroimmunoassay in serum from 167 men who had an average 7.7 years of follow-up to an acute coronary event and from 167 control men. Both cases and controls were from a cohort of 2005 men who had no clinical coronary heart disease (CHD) at baseline. The controls were matched for age, examination year, and residence. Acute coronary events were registered prospectively. Findings The mean baseline serum enterolactone concentration was lower among the cases than the controls (18.2 [SD 21.1] vs 23.5 [18.2] nmol/L, p=0.001). The men in the highest quarter of the enterolactone distribution (>30.1 nmol/L) had a 58.8% (95% CI 24.1-77.6, p=0.005) lower risk of acute coronary events than men in the lowest quarter. After adjustment for the nine most strongly predictive risk factors, men in the highest enterolactone quarter had a 65.3% (11.9-86.3, p=0.03) lower risk than men in the lowest quarter. Interpretation Healthy men with high serum concentrations of enterolactone had a lower risk of acute coronary events than men with lower concentrations. These findings support the hypothesis that plant-dominated fibre-rich food lowers the risk of CHD.	Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Univ Helsinki, Folkhalsan Res Ctr, Inst Prevent Med Nutr & Canc, Helsinki, Finland; Univ Helsinki, Dept Clin Chem, Helsinki, Finland	University of Eastern Finland; University of Eastern Finland; Folkhalsan Research Center; University of Helsinki; University of Helsinki	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, PO 1627, FIN-70211 Kuopio, Finland.			Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL 44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; Adlercreutz H, 1998, ANAL BIOCHEM, V265, P208, DOI 10.1006/abio.1998.2886; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; Haffner SM, 1996, J CLIN ENDOCR METAB, V81, P3697, DOI 10.1210/jc.81.10.3697; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; KUMAR KV, 1993, FREE RADICAL RES COM, V19, P59, DOI 10.3109/10715769309056499; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAPIDUS L, 1986, CLIN CHEM, V32, P146; Martin M E, 1996, Life Sci, V58, P429; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PUGEAT M, 1995, J STEROID BIOCHEM, V53, P567, DOI 10.1016/0960-0760(95)00102-6; PUHAKAINEN EVJ, 1987, CLIN CHIM ACTA, V170, P255, DOI 10.1016/0009-8981(87)90135-5; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; Steinberg FM, 1998, AM J CLIN NUTR, V68, P319, DOI 10.1093/ajcn/68.2.319; TOUMILEHTO J, 1992, EUR HEART J, V13, P577; Zeleniuch-Jacquotte A, 1998, CANCER EPIDEM BIOMAR, V7, P885	30	185	190	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2112	2115		10.1016/S0140-6736(99)05031-X	http://dx.doi.org/10.1016/S0140-6736(99)05031-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609816				2022-12-24	WOS:000084318200012
J	Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S				Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S			Requirement of yeast SGS1 and SRS2 genes for replication and transcription	SCIENCE			English	Article							WERNER-SYNDROME PROTEIN; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; BLOOMS-SYNDROME; HOMOLOG; PRODUCT; PURIFICATION; EXONUCLEASE; INTERACTS	The SGS1 gene of the yeast Saccharomyces cerevisiae encodes a DNA helicase with homology to the human Bloom's syndrome gene BLM and the Werner's syndrome gene WRN. The SRS2 gene of yeast also encodes a DNA helicase. Simultaneous deletion of SGS1 and SRS2 is Lethal in yeast. Here, using a conditional mutation of SGS1, it is shown that DNA replication and RNA polymerase I transcription are drastically inhibited in the srs2 Delta sgs1-ts strain at the restrictive temperature. Thus, SGS1 and SRS2 function in DNA replication and RNA polymerase I transcription. These functions may contribute to the various defects observed in Werner's and Bloom's syndromes.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA80882] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; Lee S. A., UNPUB; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	28	121	121	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2339	2342		10.1126/science.286.5448.2339	http://dx.doi.org/10.1126/science.286.5448.2339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600744				2022-12-24	WOS:000084318500061
J	Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K				Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K			Ghrelin is a growth-hormone-releasing acylated peptide from stomach	NATURE			English	Article							NATRIURETIC PEPTIDE; RECEPTOR; PITUITARY; RAT; SECRETAGOGUE; BRAIN; NEUROPEPTIDES	Small synthetic molecules called growth-hormone secretagogues (GHSs)(1-3) stimulate the release of growth hormone (GH) from the pituitary(4,5). They act through GHS-R, a G-protein-coupled receptor for which the ligand is unknown. Recent cloning of GHS-R-6,R-7 strongly suggests that an endogenous ligand for the receptor does exist and that there is a mechanism for regulating GH release that is distinct from its regulation by hypothalamic growth-hormone-releasing hormone (GHRH)(4,5). We now report the purification and identification in rat stomach of an endogenous ligand specific for GHS-R. The purified ligand is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated. The acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation at serine 3 is essential for the activity. We designate the GH-releasing peptide 'ghrelin' (ghre is the Proto-Indo-European root of the word 'grow'). Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin.	Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan; Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	Kangawa, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan.							AKMAN MS, 1993, ENDOCRINOLOGY, V132, P1286, DOI 10.1210/en.132.3.1286; ALONSO G, 1988, BRAIN RES, V453, P191, DOI 10.1016/0006-8993(88)90158-8; BERGHE GV, 1999, J CLIN ENDOCR METAB, V84, P1311; Bisi G, 1999, J ENDOCRINOL INVEST, V22, P266, DOI 10.1007/BF03343555; Bowers CY, 1998, CELL MOL LIFE SCI, V54, P1316, DOI 10.1007/s000180050257; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Date Y, 1999, ENDOCRINOLOGY, V140, P2398, DOI 10.1210/en.140.5.2398; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; JONATHAN NB, 1983, METHOD ENZYMOL, V103, P249; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KOJIMA M, 1994, J BIOL CHEM, V269, P13136; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; Smith GD, 1997, EUR HEART J, V18, P6; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0	27	6578	7085	9	332	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					656	660		10.1038/45230	http://dx.doi.org/10.1038/45230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604470				2022-12-24	WOS:000084189800064
J	Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT				Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT			The RCAF complex mediates chromatin assembly during DNA replication and repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; II TRANSCRIPTION; YEAST; PROTEIN; GENES; IDENTIFICATION; ACETYLATION; REPRESSION; TELOMERES; INVITRO	Chromatin assembly is a fundamental biological process that is essential for the replication and maintenance of the eukaryotic genome(1-4). In dividing cells, newly synthesized DNA is rapidly assembled into chromatin by the deposition of a tetramer of the histone proteins H3 and H4, followed by the deposition of two dimers of histones H2A and H2B to complete the nucleosome-the fundamental repeating unit of chromatin(5). Here we describe the identification, purification, cloning, and characterization of replication-coupling assembly factor (RCAF), a novel protein complex that facilitates the assembly of nucleosomes onto newly replicated DNA in vitro. RCAF comprises the Drosophila homologue of anti-silencing function 1 protein ASF1(6) and histones H3 and H4. The specific acetylation pattern of H3 and H4 in RCAF is identical to that of newly synthesized histones. Genetic analyses in Saccharomyces cerevisiae demonstrate that ASF1 is essential for normal fell cycle progression, and suggest that RCAF mediates chromatin assembly after DNA replication and the repair of double-strand DNA damage in vivo.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; NICHD, NIH, Bethesda, MD 20892 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Cold Spring Harbor Laboratory	Tyler, JK (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Tyler, Jessica/0000-0001-9765-1659	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008731] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Singer MS, 1998, GENETICS, V150, P613; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4	28	438	445	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					555	560		10.1038/990147	http://dx.doi.org/10.1038/990147			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591219				2022-12-24	WOS:000084013200063
J	Henney, JE				Henney, JE			Parkinson treatment approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-24	WOS:000083908700006
J	Lin, RCY; Wang, WYS; Morris, BJ				Lin, RCY; Wang, WYS; Morris, BJ			High penetrance, overweight and glucocorticoid receptor variant: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENE		Univ Sydney, Dept Physiol, Gene Lab, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Morris, BJ (corresponding author), Univ Sydney, Dept Physiol, Gene Lab, Bldg F13, Sydney, NSW 2006, Australia.	brianm@physiol.usyd.edu.au	Wang, William/E-7862-2013; Lin, Ruby CY/A-1636-2009	Wang, William/0000-0002-5369-5446; Lin, Ruby CY/0000-0003-4163-511X				Clement K, 1996, INT J OBESITY, V20, P507; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; Meirhaeghe A, 1999, LANCET, V353, P896, DOI 10.1016/S0140-6736(99)00251-2; Takami S, 1999, AM J PHYSIOL-HEART C, V276, pH1379, DOI 10.1152/ajpheart.1999.276.4.H1379	5	84	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1999	319	7221					1337	1338		10.1136/bmj.319.7221.1337	http://dx.doi.org/10.1136/bmj.319.7221.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567137	Green Published, Bronze			2022-12-24	WOS:000083930200024
J	Gross, R				Gross, R			Leg lengthening	LANCET			English	Editorial Material							LIMB		Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA	Medical University of South Carolina	Gross, R (corresponding author), Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA.							Aldegheri R, 1999, J BONE JOINT SURG AM, V81A, P624, DOI 10.2106/00004623-199905000-00004; ANDERSON WV, 1967, MODERN TRENDS ORTHOP, P1; Cheng JCY, 1998, J BONE JOINT SURG BR, V80B, P772, DOI 10.1302/0301-620X.80B5.8475; Codivilla A., 1905, J BONE JOINT SURG, Vs2, P353; DEBASTIANI G, 1987, J PEDIATR ORTHOPED, V7, P129; GROSS RH, 1971, J BONE JOINT SURG AM, VA 53, P693, DOI 10.2106/00004623-197153040-00008; ILIZAROV GA, 1990, CLIN ORTHOP RELAT R, P8; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; MOSCA V, 1986, ORTHOP T, V10, P462; Sharma M, 1996, J PEDIATR ORTHOPED, V16, P438, DOI 10.1097/01241398-199607000-00004; SOFIELD HA, 1958, J BONE JOINT SURG AM, V40, P311, DOI 10.2106/00004623-195840020-00006; WAGNER H, 1978, CLIN ORTHOP RELAT R, P125; 1988, LANCET, V1, P1032	13	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1574	1575		10.1016/S0140-6736(99)00221-4	http://dx.doi.org/10.1016/S0140-6736(99)00221-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560667				2022-12-24	WOS:000083551000004
J	Cox, JS; Chen, B; McNeil, M; Jacobs, WR				Cox, JS; Chen, B; McNeil, M; Jacobs, WR			Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice	NATURE			English	Article							MYCOCEROSIC ACID SYNTHASE; BOVIS BCG; TRANSPOSON MUTAGENESIS; VIRULENCE GENES; COENZYME-A; IDENTIFICATION; ADJACENT	Tuberculosis is the leading cause of death in the world resulting from a single bacterial infection(1). Despite its enormous burden on world health, little is known about the molecular mechanisms of pathogenesis of Mycobacterium tuberculosis. Bacterial multiplication and concomitant tissue damage within an infected host, including experimentally infected mice, occurs primarily in the lungs-the favoured niche of M. tuberculosis(2). Although it has been proposed that the distinctive cell wall of M. tuberculosis is important for virulence, rigorous genetic proof has been lacking. Here, using signature-tagged mutagenesis, we isolated three attenuated M. tuberculosis mutants that cannot synthesize or transport a complex, cell wall-associated lipid called phthiocerol dimycocerosate (PDIM) which is found only in pathogenic mycobacteria(3,4), Two mutants have transposon insertions affecting genes implicated in PDIM synthesis; the third has a disruption in a gene encoding a large transmembrane protein required for proper subcellular localization of PDIM. Synthesis and transport of this complex lipid is only required for growth in the lung; all three mutants are unaffected for growth in the liver and spleen. This clearly shows that a lipid is required for M. tuberculosis virulence.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Colorado State University	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		McNeil, Michael/G-3325-2019	Jacobs, William/0000-0003-3321-3080				[Anonymous], 1999, WORLD HLTH REPORT 19; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Bystrykh LV, 1996, J BACTERIOL, V178, P2238, DOI 10.1128/jb.178.8.2238-2244.1996; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fitzmaurice AM, 1997, J BACTERIOL, V179, P2608, DOI 10.1128/jb.179.8.2608-2615.1997; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garay S, 1996, TUBERCULOSIS, P373; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HUNTER SW, 1983, J BIOL CHEM, V258, P7556; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MCADAM RA, 1995, INFECT IMMUN, V63, P1004, DOI 10.1128/IAI.63.3.1004-1012.1995; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; MIDDLEBROOK G, 1947, J EXP MED, V86, P175, DOI 10.1084/jem.86.2.175; OCHMAN H, 1988, GENETICS, V120, P621; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P667; RAINWATER DL, 1983, J BIOL CHEM, V258, P2979	23	586	614	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					79	83		10.1038/47042	http://dx.doi.org/10.1038/47042			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573420				2022-12-24	WOS:000083638600046
J	Henney, JE				Henney, JE			Infections from endoscopes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P557	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-24	WOS:000083368400008
J	Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR				Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR			Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy	CELL			English	Article							HEART-FAILURE; CARDIAC-HYPERTROPHY; MYOCARDIAL-CONTRACTILITY; VENTRICULAR MYOCYTES; TRANSGENIC MICE; GENE-EXPRESSION; PROTEIN; KINASE; MOUSE; PHOSPHORYLATION	Dilated cardiomyopathy and end-stage heart failure result in multiple defects in cardiac excitation-contraction coupling. Via complementation of a genetically based mouse model of dilated cardiomyopathy, we now provide evidence that progressive chamber dilation and heart failure are dependent on a Ca2+ cycling defect in the cardiac sarcoplasmic reticulum. The ablation of a muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban, rescued the spectrum of phenotypes that resemble human heart failure. Inhibition of phospholamban-SERCA2a interaction via in vivo expression of a phospholamban point mutant dominantly activated the contractility of ventricular muscle cells. Thus, interfering with phospholamban-SERCA2a interaction may provide a novel therapeutic approach for preventing the progression of dilated cardiomyopathy.	Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Calgary, Sch Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; University of Calgary	Chien, KR (corresponding author), Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA.			Wang, Yibin/0000-0003-0852-0767; Minamisawa, Susumu/0000-0003-4728-2116	NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL52318, HL26057] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P50HL052318, R37HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CHIEN KR, 1999, MOL BASIS CARDIOVASC, P211; CHRISTENSEN G, 1999, IN PRESS CIRCULATION; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Lindner M, 1998, J MOL CELL CARDIOL, V30, P743, DOI 10.1006/jmcc.1997.0626; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Martone ME, 1999, J NEUROSCI, V19, P1988; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PIESKE B, 1995, CIRCULATION, V92, P1169, DOI 10.1161/01.CIR.92.5.1169; Qi M, 1997, AM J PHYSIOL-HEART C, V272, pH2416, DOI 10.1152/ajpheart.1997.272.5.H2416; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Santana LF, 1998, J GEN PHYSIOL, V112, p11A; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SORDAHL LA, 1973, AM J PHYSIOL, V224, P497, DOI 10.1152/ajplegacy.1973.224.3.497; Tada M, 1998, TRENDS CARDIOVAS MED, V8, P330, DOI 10.1016/S1050-1738(98)00032-2; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Ward CA, 1997, J PHYSIOL-LONDON, V500, P631, DOI 10.1113/jphysiol.1997.sp022048; WHITMER JT, 1988, CIRC RES, V62, P81, DOI 10.1161/01.RES.62.1.81	52	397	406	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					313	322		10.1016/S0092-8674(00)81662-1	http://dx.doi.org/10.1016/S0092-8674(00)81662-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555147	Bronze			2022-12-24	WOS:000083440600009
J	Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A				Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A			The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens	NATURE			English	Article							DROSOPHILA HOST-DEFENSE; GENE; FAMILY; MYD88; LIPOPOLYSACCHARIDE; 18-WHEELER; EXPRESSION; ADAPTER; COMPLEX; MICE	Macrophages orchestrate innate immunity by phagocytosing pathogens and coordinating inflammatory responses(1). Effective defence requires the host to discriminate between different pathogens. The specificity of innate immune recognition in Drosophila is mediated by the Toll family of receptors(2,3); Toll mediates anti-fungal responses, whereas 18-wheeler mediates anti-bacterial defence(4-6). A large number of Toll homologues have been identified in mammals, and Toll-like receptor 4 is critical in responses to Gram-negative bacteria(7-11). Here we show that Toll-like receptor 2 is recruited specifically to macrophage phagosomes containing yeast, and that a point mutation in the receptor abrogates inflammatory responses to yeast and Gram-positive bacteria, but not to Gram-negative bacteria. Thus, during the phagocytosis of pathogens, two classes of innate immune receptors cooperate to mediate host defence: phagocytic receptors, such as the mannose receptor, signal particle internalization, and the Toll-like receptors sample the contents of the vacuole and trigger an inflammatory response appropriate to defence against the specific organism.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Aderem, A (corresponding author), Univ Washington, Dept Immunol, Box 357650, Seattle, WA 98195 USA.	aaderem@u.washington.edu	Bassetti, Matteo/L-3081-2019; UNDERHILL, DAVID/ABE-2185-2021	Underhill, David/0000-0002-2989-658X; Hajjar, Adeline/0000-0002-4838-8070				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; ELDON E, 1994, DEVELOPMENT, V120, P885; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heine H, 1999, J IMMUNOL, V162, P6971; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Medzhitov R, 1998, P NATL ACAD SCI USA, V95, P429, DOI 10.1073/pnas.95.2.429; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	27	1148	1209	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					811	815		10.1038/44605	http://dx.doi.org/10.1038/44605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548109				2022-12-24	WOS:000083368700058
J	Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E				Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E			Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal	BRITISH MEDICAL JOURNAL			English	Article								Objective To find out whether taking images of the male and female genitals during coitus is feasible and to find out whether former and current ideas about the anatomy during sexual intercourse and during female sexual arousal are based on assumptions or on facts. Design Observational study Setting University hospital in the Netherlands. Methods Magnetic resonance imaging was used to study are female sexual response and the male and female genitals during coitus. Thirteen experiments were performed with eight couples and three single women. Results The images obtained showed that during intercourse in the "missionary position" the penis has the shape of a boomerang and 1/3 of its length consists of the root of the penis. During female sexual arousal without intercourse the uterus was raised and the anterior vaginal wall lengthened. The size of the uterus did not increase during sexual arousal. Conclusion Taking magnetic resonance images of the male and female genitals during coitus is feasible and contributes to understanding of anatomy.	Univ Groningen Hosp, Dept Gynaecol, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Lab Cell Biol & Electron Microscopy, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Dept Radiol, NL-9700 RB Groningen, Netherlands; Dept Business Anthropol VU, NL-1081 HV Amsterdam, Netherlands	University of Groningen; University of Groningen; University of Groningen	Schultz, WW (corresponding author), Univ Groningen Hosp, Dept Gynaecol, POB 30 001, NL-9700 RB Groningen, Netherlands.	w.c.m.weymar.schultz@oprit.rug.nl	Sabelis, Ida/F-8893-2013; Sabelis, Ida/G-4830-2013	Sabelis, Ida/0000-0003-0109-0127; Sabelis, Ida/0000-0003-0109-0127				ALZATE H, 1984, J SEX MARITAL THER, V10, P49, DOI 10.1080/00926238408405789; CHIANCHI M, 1998, LEONARDO ANATOMY, P56; Clark K, 1968, CATALOGUE DRAWINGS L, V2nd; Dickinson RL, 1949, HUMAN SEX ANATOMY TO, P84; FLECK L, 1979, GENESIS DEV SCI FACT, P35; HILLIGES M, 1995, ACTA ANAT, V153, P119; HOCH Z, 1986, ACTA OBSTET GYN SCAN, V65, P767, DOI 10.3109/00016348609161498; Johnson Virginia E., 1964, MANUAL CONTRACEPTIVE, P138; KRANTZ KE, 1958, OBSTET GYNECOL, V12, P382; LEVIN RJ, 1998, INT J IMPOT RES S1, V10, P14; Masters WH., 1966, HUMAN SEXUAL RESPONS; MINH MH, 1981, CAHIERS SEXUOL CLIN, V7, P169; O'Connell HE, 1998, J UROLOGY, V159, P1892, DOI 10.1016/S0022-5347(01)63188-4; RILEY AJ, 1992, INT CONGR SER, P29; SCHULTZ WCMW, 1989, ARCH SEX BEHAV, V18, P87, DOI 10.1007/BF01543115; SOHN MH, 1991, IMPOTENCE RES, V3, P36; VANANDEL P, 1994, BRIT J PHILOS SCI, V45, P631	17	74	75	6	87	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1596	1600		10.1136/bmj.319.7225.1596	http://dx.doi.org/10.1136/bmj.319.7225.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600954	Bronze, Green Published			2022-12-24	WOS:000084562600007
J	DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ				DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ			Transport-dependent proteolysis of SREBP: Relocation of Site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi	CELL			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; BOUND TRANSCRIPTION FACTOR; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; STEROL RESISTANCE; MEMBRANE-PROTEIN; BREFELDIN-A; IDENTIFICATION; SECRETION	Cholesterol homeostasis in animal cells is achieved by regulated cleavage of membrane-bound transcription factors, designated SREBPs. Proteolytic release of the active domains of SREBPs from membranes requires a sterol-sensing protein, SCAP, which forms a complex with SREBPs. In sterol-depleted cells, SCAP escorts SREBPs from ER to Golgi, where SREBPs are cleaved by Site-1 protease (S1P). Sterols block this transport and abolish cleavage. Relocating active S1P from Golgi to ER by treating cells with brefeldin A or by fusing the ER retention signal KDEL to S1P obviates the SCAP requirement and renders cleavage insensitive to sterols. Transport-dependent proteolysis may be a common mechanism to regulate the processing of membrane proteins.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Nohturfft, Axel/0000-0001-9484-3209	NHLBI NIH HHS [HL-20948, HL-09993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL009993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLLAG DM, 1991, PROTEIN METHODS, P1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Harlow E., 1999, USING ANTIBODIES LAB, P1; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KOMFELD R, 1985, ANNU REV BIOCHEM, V54, P631; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PELHAM HRB, 1992, P ROY SOC B-BIOL SCI, V250, P1, DOI 10.1098/rspb.1992.0123; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	37	244	250	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					703	712		10.1016/S0092-8674(00)81668-2	http://dx.doi.org/10.1016/S0092-8674(00)81668-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619424	Bronze			2022-12-24	WOS:000084488200004
J	Foley, D				Foley, D			Sorting out sleep in patients with Alzheimer's disease	LANCET			English	Editorial Material									NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Foley, D (corresponding author), NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA.							ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; Bliwise DL, 1996, J AM GERIATR SOC, V44, P1407; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Foley DJ, 1999, J AM GERIATR SOC, V47, P524, DOI 10.1111/j.1532-5415.1999.tb02564.x; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; McCurry SM, 1999, J GERIATR PSYCH NEUR, V12, P53, DOI 10.1177/089198879901200203; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; Redline S, 1998, SLEEP, V21, P759; Taylor, 1997, Semin Clin Neuropsychiatry, V2, P113; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; VITIELLO MV, 1992, NEUROLOGY, V42, P83; Wilcox S, 1999, J GERONTOL B-PSYCHOL, V54, pP189, DOI 10.1093/geronb/54B.3.P189	12	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2098	2099		10.1016/S0140-6736(99)00413-4	http://dx.doi.org/10.1016/S0140-6736(99)00413-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609812				2022-12-24	WOS:000084318200006
J	Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD				Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD			A structural change in the kinesin motor protein that drives motility	NATURE			English	Article							CRYSTAL-STRUCTURE; DIMERIC KINESIN; MYOSIN MOTOR; CRYOELECTRON MICROSCOPY; ATP HYDROLYSIS; MICROTUBULE; DOMAIN; MECHANISM; COMPLEX; NCD	Kinesin motors power many motile processes by converting ATP energy into unidirectional motion along microtubules, The force-generating and enzymatic properties of conventional kinesin have been extensively studied; however, the structural basis of movement is unknown. Here we have detected and visualized a large conformational change of a similar to 15-amino-acid region (the neck linker) in kinesin using electron paramagnetic resonance, fluorescence resonance energy transfer, pre-steady state kinetics and cryo-electron microscopy, This region becomes immobilized and extended towards the microtubule 'plus' end when kinesin binds microtubules and ATP, and reverts to a more mobile conformation when gamma-phosphate is released after nucleotide hydrolysis, This conformational change explains both the direction of kinesin motion and processive movement by the kinesin dimer.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Washington State Univ, Dept Pure & Appl Math, Pullman, WA 99164 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute; University of Pennsylvania; University of Illinois System; University of Illinois Urbana-Champaign; University of Chicago; Washington State University	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.uscf.edu	Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Carragher, Bridget/0000-0002-0624-5020				AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BARNETT VA, 1986, BIOPHYS J, V49, P144, DOI 10.1016/S0006-3495(86)83628-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; HOENGER A, 1998, CURR BIOL, V8, P191; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Marx A, 1998, EUR BIOPHYS J BIOPHY, V27, P455, DOI 10.1007/s002490050156; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 1997, BIOCHEMISTRY-US, V36, P9681, DOI 10.1021/bi9706881; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Safer D, 1999, J STRUCT BIOL, V127, P101, DOI 10.1006/jsbi.1999.4110; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; THOMAS DD, 1995, BIOPHYS J, V68, pS135; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	50	618	642	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					778	784		10.1038/45483	http://dx.doi.org/10.1038/45483			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617199				2022-12-24	WOS:000084330500055
J	Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR				Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR			The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder	CELL			English	Article							FIELD GEL-ELECTROPHORESIS; ACTIVATED PROTEIN-KINASE; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; HUMAN FIBROBLASTS; HUMAN MRE11; CELLS; YEAST; IDENTIFICATION	We show that hypomorphic mutations in hMRE11, but not in ATM, are present in certain individuals with an ataxia-telangiectasia-like disorder (ATLD). The cellular features resulting from these hMRE11 mutations are similar to those seen in A-T as well as NBS and include hypersensitivity to ionizing radiation, radioresistant DNA synthesis, and abrogation of ATM-dependent events, such as the activation of Jun kinase following exposure to gamma irradiation. Although the mutant hMre11 proteins retain some ability to interact with hRad50 and Nbs1, formation of ionizing radiation-induced hMre11 and Nbs1 fool was absent in hMRE11 mutant cells. These data demonstrate that ATM and the hMre11/h Rad50/Nbs1 protein complex act in the same DNA damage response pathway and link hMre11 to the complex pathology of A-T.	Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Wisconsin, Sch Med, Madison, WI 53706 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of Birmingham; University of Wisconsin System; University of Wisconsin Madison; Erasmus University Rotterdam	Taylor, AMR (corresponding author), Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	jpetrini@facstaff.wisc.edu; a.m.r.taylor@bham.ac.uk	Maser, Richard/B-2970-2012	Stankovic, Tatjana/0000-0002-3780-274X; Stewart, Grant/0000-0002-0960-3241	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056888, R01GM059413, R37GM059413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59413, GM56888] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGER DD, 1990, INT J RADIAT BIOL, V58, P249, DOI 10.1080/09553009014551601; AJIMURA M, 1993, GENETICS, V133, P51; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel F, 1989, MOL REPROD DEV, V1, P146; Bressan DA, 1998, GENETICS, V150, P591; BRESSAN DA, 1999, IN PRESS MOL CELL BI; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; JASPERS NGJ, 1982, CANCER RES, V42, P335; Jorgensen TJ, 1996, INT J RADIAT BIOL, V69, P527, DOI 10.1080/095530096145535; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLEIJER WJ, 1994, INT J RADIAT BIOL, V66, pS167, DOI 10.1080/09553009414552001; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McConville CM, 1996, AM J HUM GENET, V59, P320; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; NOVE J, 1986, MUTAT RES, V163, P255, DOI 10.1016/0027-5107(86)90023-0; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; RYDBERG B, 1994, RADIAT RES, V139, P133, DOI 10.2307/3578657; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Taylor A. M. R., 1996, P138; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamazaki V, 1998, CANCER RES, V58, P2316; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	46	777	793	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					577	587		10.1016/S0092-8674(00)81547-0	http://dx.doi.org/10.1016/S0092-8674(00)81547-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612394	Bronze			2022-12-24	WOS:000084278700005
J	Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I				Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I			A prospective study of weight change and health-related quality of life in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; SYMPTOMATIC GALLSTONES; DIABETES-MELLITUS; OLDER WOMEN; RISK FACTOR; OF-LIFE; QUESTIONNAIRE; OBESE; ASSOCIATION; MORTALITY	Context The mean body weight of US adults increased by 3.6 kg (7.6 lb) during the past 15 years, but few studies exist that examine the impact of such weight change on functional health status. Objective To investigate, prospectively, the association between weight change and health-related quality of life in women. Design and Setting Nurses' Health Study, a 4-year prospective observational study from 1992 to 1996, using the Medical Outcomes Study Short-Form 36 Health Status Survey (a self-administered 36-item questionnaire) to measure quality of life. Participants A cohort of 40 098 women (from 46-71 years old in 1992) grouped according to 3 patterns of weight change over the 4-year period: women whose weight remained within 2.25 kg (5 lb) of their baseline weight, women who lost 2.25 kg (5 lb) or more, and women who gained 2.25 kg (5 lb) or more. Main Outcome Measures Change in scores on 7 health-related quality-of-life dimensions: physical functioning, vitality, bodily pain, limitations in role functioning due to emotional or physical problems, social functioning, and mental health, measured by the Short-Form 36 Health Status Survey, Results A total of 15 602 women (39%) maintained their weight, 15 160 (38%) gained between 2.25 and 9.0 kg (5-20 lb), and 6667 (17%) lost between 2.25 and 9.0 kg (5-20 Ib), Weight gain was associated with decreased physical function and vitality, and increased bodily pain regardless of baseline weight. For example, the odds ratio for developing role limitations due to physical problems was 2.05 (95% confidence interval, 1.69-2.49) for the leanest women who gained 9.0 kg (20 lb) or more. Weight loss in overweight women was associated with improved physical function and vitality as well as decreased bodily pain. Weight change was more strongly associated with physical rather than mental health. The impact of weight change, especially weight gain, was just as strong in women 65 years and older as in women younger than 65 years. Conclusions These longitudinal data support current US guidelines for women of all body mass index levels to avoid weight gain. Weight maintenance and, in cases of overweight, weight loss are desirable and likely to be beneficial for physical function, vitality, and bodily pain.	Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Kawachi, I (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	ichiro.kawachi@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012806] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIA NIH HHS [AG 12806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Coakley EH, 1998, INT J OBESITY, V22, P958, DOI 10.1038/sj.ijo.0800698; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; Fontaine KR, 1996, J FAM PRACTICE, V43, P265; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; KOLOTKIN RL, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00120.x; KRAL JG, 1992, AM J CLIN NUTR, V55, P611, DOI 10.1093/ajcn/55.2.611s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MARTON KI, 1981, ANN INTERN MED, V95, P568, DOI 10.7326/0003-4819-95-5-568; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RUMPEL C, 1994, INT J OBESITY, V18, P179; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J.E., 1993, LINC RI QUAL METR IN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	30	294	300	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2136	2142		10.1001/jama.282.22.2136	http://dx.doi.org/10.1001/jama.282.22.2136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591335	Bronze			2022-12-24	WOS:000083971400032
J	Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R				Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R			Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY; ACCIDENT		Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Epidemiol & Biostat, Montreal, PQ H3H 1P3, Canada; Univ Southampton, Wessex Inst Hlth Res & Dev, Biomed Serv, Southampton SO16 7PX, Hants, England	St Georges University London; McGill University; McGill University; University of Southampton	Lord, J (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.		Ducharme, Francine/N-8332-2013; Lord, Joanne/H-1417-2011	Ducharme, Francine/0000-0001-5096-0614; Lord, Joanne/0000-0003-1086-1624; Churchill, Rachel/0000-0002-1751-0512				BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Lord J, 1999, HEALTH ECON, V8, P323, DOI 10.1002/(SICI)1099-1050(199906)8:4<323::AID-HEC431>3.0.CO;2-0; Partridge MR, 1997, J ACCID EMERG MED, V14, P16; Plotnick LH, 1998, BMJ-BRIT MED J, V317, P971, DOI 10.1136/bmj.317.7164.971; Stell IM, 1996, J ACCID EMERG MED, V13, P392	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1470	1471		10.1136/bmj.319.7223.1470	http://dx.doi.org/10.1136/bmj.319.7223.1470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582930	Green Published, Bronze			2022-12-24	WOS:000084129200022
J	Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B				Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B			Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; HEART-FAILURE; ORGANIZATION; LOCUS; DEFICIENCY; FREQUENCY; LINKAGE; CDNA	Background: Inherited mutations cause approximately 35 percent of cases of dilated cardiomyopathy; however, few genes associated with this disease have been identified. Previously, we located a gene defect that was responsible for autosomal dominant dilated cardiomyopathy and conduction-system disease on chromosome 1p1-q21, where nuclear-envelope proteins lamin A and lamin C are encoded by the LMNA (lamin A/C) gene. Mutations in the head or tail domain of this gene cause Emery-Dreifuss muscular dystrophy, a childhood-onset disease characterized by joint contractures and in some cases by abnormalities of cardiac conduction during adulthood. Methods: We evaluated 11 families with autosomal dominant dilated cardiomyopathy and conduction-system disease. Sequences of the lamin A/C exons were determined in probands from each family, and variants were confirmed by restriction-enzyme digestion. The genotypes of the family members were ascertained. Results: Five novel missense mutations were identified: four in the (alpha)-helical rod domain of the lamin A/C gene, and one in the lamin C tail domain. Each mutation caused heritable, progressive conduction-system disease (sinus bradycardia, atrioventricular conduction block, or atrial arrhythmias) and dilated cardiomyopathy. Heart failure and sudden death occurred frequently within these families. No family members with mutations had either joint contractures or skeletal myopathy. Serum creatine kinase levels were normal in family members with mutations of the lamin rod but mildly elevated in some family members with a defect in the tail domain of lamin C. Conclusions: Genetic defects in distinct domains of the nuclear-envelope proteins lamin A and lamin C selectively cause dilated cardiomyopathy with conduction-system disease or autosomal dominant Emery-Dreifuss muscular dystrophy. Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and indicate that this intermediate filament protein has an important role in cardiac conduction and contractility. (N Engl J Med 1999;341:1715-24.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Wisconsin, Div Cardiovasc, Madison, WI USA; Hosp G Brotzu, Div Cardiovasc, Cagliari, Italy; Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales; Royal Brisbane Hosp, Dept Cardiol, Brisbane, Qld 4029, Australia; Marshfield Clin Fdn Med Res & Educ, Div Cardiovasc, Marshfield, WI USA; Hammersmith Hosp, London, England	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; Cardiff University; Royal Brisbane & Women's Hospital; Marshfield Clinic; Imperial College London	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Alpert Rm 533,200 Longwood Ave, Boston, MA 02115 USA.	cseidman@rascal.med.harvard.edu	Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				Barresi R, 1997, ACTA NEUROPATHOL, V94, P28, DOI 10.1007/s004010050668; BHARATI S, 1992, PACE, V15, P1720, DOI 10.1111/j.1540-8159.1992.tb02960.x; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Cohn JN, 1997, CIRCULATION, V95, P766; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; EMERY AEH, 1987, CLIN GENET, V32, P360; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Jung M, 1998, CIRCULATION, V98, P246; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KEELING PJ, 1995, BRIT HEART J, V73, P417; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Manilal S, 1999, HUM MOL GENET, V8, P353, DOI 10.1093/hmg/8.2.353; MAWATARI S, 1973, ARCH NEUROL-CHICAGO, V28, P55, DOI 10.1001/archneur.1973.00490190073010; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; VOIT T, 1988, NEUROPEDIATRICS, V19, P62, DOI 10.1055/s-2008-1052404; WATERS DD, 1975, NEW ENGL J MED, V293, P1017, DOI 10.1056/NEJM197511132932004; Wydner KL, 1996, GENOMICS, V32, P474, DOI 10.1006/geno.1996.0146; Yates JRW, 1999, NEUROMUSCULAR DISORD, V9, P199, DOI 10.1016/S0960-8966(98)00095-9	40	950	983	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1715	1724		10.1056/NEJM199912023412302	http://dx.doi.org/10.1056/NEJM199912023412302			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580070				2022-12-24	WOS:000083955800002
J	Nichols, MJ; Newsome, WT				Nichols, MJ; Newsome, WT			The neurobiology of cognition	NATURE			English	Article							HUMAN BRAIN; STIMULATION; PERCEPTION; CORTEX; SIGNAL; REWARD	Perhaps the deepest mysteries facing the natural sciences concern the higher functions of the central nervous system. Understanding how the brain gives rise to mental experiences looms as one of the central challenges for science in the new millennium.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Nichols, MJ (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019					Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Fuster JM, 1995, MEMORY CEREBRAL CORT; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GEORGE JS, 1995, J CLIN NEUROPHYSIOL, V12, P406, DOI 10.1097/00004691-199509010-00002; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Hubel David H, 1995, EYE BRAIN VISION, P6; Hubener M, 1997, J NEUROSCI, V17, P9270; JACKSON F, 1982, PHILOS QUART, V32, P127, DOI 10.2307/2960077; MARTINEZ, 1999, NATURE NEUROSCI, V2, P364; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Parker AJ, 1998, ANNU REV NEUROSCI, V21, P227, DOI 10.1146/annurev.neuro.21.1.227; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Posner MI, 1998, P NATL ACAD SCI USA, V95, P763, DOI 10.1073/pnas.95.3.763; Romo R, 1999, CURR OPIN NEUROBIOL, V9, P487, DOI 10.1016/S0959-4388(99)80073-7; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Svoboda K, 1999, NAT NEUROSCI, V2, P65, DOI 10.1038/4569; Tanaka K, 1992, Curr Opin Neurobiol, V2, P502, DOI 10.1016/0959-4388(92)90187-P; THOMPSON E, 1992, PHILOS STUD, V68, P321, DOI 10.1007/BF00694850; Wandell BA, 1999, ANNU REV NEUROSCI, V22, P145, DOI 10.1146/annurev.neuro.22.1.145; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1	28	42	43	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C35	C38		10.1038/35011531	http://dx.doi.org/10.1038/35011531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	261MZ	10591223	Bronze			2022-12-24	WOS:000084014100005
J	Dano, S; Sorensen, PG; Hynne, F				Dano, S; Sorensen, PG; Hynne, F			Sustained oscillations in living cells	NATURE			English	Article							BELOUSOV-ZHABOTINSKY REACTION; BRIGGS-RAUSCHER REACTION; METABOLIC OSCILLATIONS; GLYCOLYTIC OSCILLATIONS; HOPF-BIFURCATION; HEART-CELLS; YEAST-CELLS; BETA-CELLS; MAKE-UP; MUSCLE	Glycolytic oscillations in yeast have been studied for many years simply by adding a glucose pulse to a suspension of cells and measuring the resulting transient oscillations of NADH(1-12). Here we show, using a suspension of yeast cells, that living cells can be kept ia a well defined oscillating state indefinitely when starved cells, glucose and cyanide are pumped into a cuvette with outflow of surplus liquid. Our results show that the transitions between stationary and oscillatory behaviour are uniquely described mathematically by the Hopf bifurcation(13). This result characterizes the dynamical properties close to the transition point. Our perturbation experiments show that the cells remain strongly coupled very close to the transition. Therefore, the transition takes place in each of the cells and is not a desynchronization phenomenon. With these two observations, a study of the kinetic details of glycolysis, as it actually takes place in a living cell, is possible using experiments designed in the framework of nonlinear dynamics. Acetaldehyde is known to synchronize the oscillations(10). Our results show that glucose is another messenger substance, as long as the glucose transporter is not saturated.	Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, DK-2100 Copenhagen, Denmark	University of Copenhagen	Dano, S (corresponding author), Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, Univ Pk 5, DK-2100 Copenhagen, Denmark.							ALDRIDGE J, 1976, NATURE, V259, P670, DOI 10.1038/259670a0; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; Civelek VN, 1997, DIABETES, V46, P51, DOI 10.2337/diabetes.46.1.51; DUYSENS LNM, 1957, BIOCHIM BIOPHYS ACTA, V24, P19, DOI 10.1016/0006-3002(57)90141-5; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GHOSH AK, 1971, ARCH BIOCHEM BIOPHYS, V145, P319, DOI 10.1016/0003-9861(71)90042-7; GOLDBETER A, 1996, BIOCH OSCILLATIONS C, P6; HESS B, 1968, H-S Z PHYSIOL CHEM, V349, P1567, DOI 10.1515/bchm2.1968.349.2.1567; HYNNE F, 1993, J CHEM PHYS, V98, P219, DOI 10.1063/1.464667; HYNNE F, 1990, J CHEM PHYS, V92, P1747, DOI 10.1063/1.458056; KOSEK J, 1994, J PHYS CHEM-US, V98, P6128, DOI 10.1021/j100075a015; KREUZBERG KH, 1979, J INTERDISCIPL CYCLE, V10, P41; MATTHEWS PC, 1991, PHYSICA D, V52, P293, DOI 10.1016/0167-2789(91)90129-W; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; OROURKE B, 1995, ADV EXP MED BIOL, V382, P165; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; Richard P, 1996, YEAST, V12, P731; Richard P, 1996, EUR J BIOCHEM, V235, P238, DOI 10.1111/j.1432-1033.1996.00238.x; RICHARD P, 1994, FEBS LETT, V341, P223, DOI 10.1016/0014-5793(94)80461-3; RICHARD P, 1993, FEBS LETT, V318, P80, DOI 10.1016/0014-5793(93)81332-T; Siegel G, 1997, INT J MICROCIRC, V17, P360, DOI 10.1159/000179252; Teusink B, 1996, J BIOL CHEM, V271, P24442, DOI 10.1074/jbc.271.40.24442; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; VUKOJEVIC V, 1993, J PHYS CHEM-US, V97, P4091, DOI 10.1021/j100118a027; Vukojevic V, 1996, J PHYS CHEM-US, V100, P17175, DOI 10.1021/jp960785o; WINFREE AT, 1972, ARCH BIOCHEM BIOPHYS, V149, P388, DOI 10.1016/0003-9861(72)90337-2	28	208	210	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					320	322		10.1038/46329	http://dx.doi.org/10.1038/46329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580506				2022-12-24	WOS:000083813700056
J	Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L				Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L			Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL DENSITY; RHEUMATOID-ARTHRITIS; WOMEN; ALLELES; CALCIUM; GENOTYPE; DISEASE; RATES; LOCUS	Background: Bone loss is a frequent complication after liver transplantation. Objective: To investigate whether vitamin D receptor gene polymorphism influences bone loss in men after liver transplantation. Design: Prospective cohort study. Setting: University hospital. Patients: 55 male candidates for liver transplantation. Measurements: Lumbar spine bone mineral density was measured before and 3, 6, 12, and 24 months after liver transplantation. Vitamin D receptor genotype was determined by restriction endonuclease Bsml. Results: Vitamin D receptor genotypes were significantly associated with post-transplantation changes in bone mineral density (P = 0.028). Within 3 months after transplantation, patients with the genotypes Bb or BE showed a vertebral bone loss substantially greater than that in patients with the bb genotype (between-group difference in the percentage change with respect to baseline bone mineral density, 3.7% [95% CI, 0.6% to 6.9%]). In 3 to 24 months after transplantation, bone mineral density increased steadily in the three allelic groups. Conclusions: Vitamin D receptor gene polymorphism influences bone loss after liver transplantation. Patients with the bb genotype are, to some extent, protected against post-transplantation bone loss.	Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gastroenterol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Rheumatol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gen Surg, Barcelona 08907, Spain; NIDDKD, Liver Unit, NIH, Bethesda, MD 20892 USA	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Guardiola, J (corresponding author), Hosp Comarcal LAlt Penedes, Gastroenterol Unit, Espriall S-N, Barcelona 08720, Spain.			Xiol, Xavier/0000-0002-4461-4704; Guardiola, Jordi/0000-0002-0464-241X				AN SF, 1991, J CLIN PATHOL, V44, P924, DOI 10.1136/jcp.44.11.924; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DIAMOND TH, 1989, GASTROENTEROLOGY, V96, P213, DOI 10.1016/0016-5085(89)90783-X; EASTELL R, 1991, HEPATOLOGY, V14, P296, DOI 10.1002/hep.1840140215; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Gough A, 1998, J RHEUMATOL, V25, P864; HAY JE, 1993, GASTROENTEROL CLIN N, V22, P337; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; Jorgensen HL, 1996, BRIT MED J, V313, P586, DOI 10.1136/bmj.313.7057.586; KRALL EA, 1995, J BONE MINER RES, V10, P978; MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1002/hep.1840140407; MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002-9343(94)90324-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; RIGGS BL, 1995, J BONE MINER RES, V10, P991; Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	20	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					752	755		10.7326/0003-4819-131-10-199911160-00006	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577298				2022-12-24	WOS:000083680100005
J	Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J				Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J			Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data	BRITISH MEDICAL JOURNAL			English	Article							ZIDOVUDINE PROPHYLAXIS; CESAREAN-SECTION	Objective To estimate and interpret time trends in vertical transmission rates for HIV using data from national obstetric and paediatric surveillance registers. Design Prospective study of HIV infected women reported through obstetric surveillance. HIV infection status of the child and onset of AIDS were reported through paediatric surveillance. Rates of Vertical transmission and progression to AIDS rate were estimated by methods that take account of incomplete follow up of children with indeterminate infection status and delay in AIDS reporting. Setting British Isles. Subjects Pregnant women infected with HIV whose infection was diagnosed before delivery, and their babies. Main outcome measures Mother to child transmission of infection and progression to AIDS in children. Results By January 1999, 800 children born to diagnosed HN infected women who had not breast fed had been reported. Vertical transmission rates rose to 19.6% (95% confidence interval 8.0% to 32.5%) in 1993 before falling to 2.2% (0% to 7.8%) in 1998, Between 1995 and 1998 use of antiretroviral treatment increased significantly each year, reaching 97% of live births in 1998. The rate of elective caesarean section remained constant, at around 40%, up to 1997 but increased to 62% in 1998, Caesarean section and antiretroviral treatment together were estimated to reduce risk of transmission from 31.6% (13.6% to 52.2%) to 4.2% (0.8% to 8.5%). The proportion of infected children developing AIDS in the first 6 months fell from 17.7% (6.8% to 30.8%) before 1994 to 7.2% (0% to 15.7%) after, coinciding with increased use of prophylaxis against Pneumocystis carinii pneumonia. Conclusions In the British Isles both HIV related morbidity and vertical transmission are being reduced through increased use of interventions.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Med Res Ctr, Clin Trials Unit, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; Medical Research Council Clinical Trials Unit	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CIRIA LM, 1998, 12 WORLD AIDS C GEN; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dempster A. P., 1977, JRSSSB, V39, P1; Dunn DT, 1996, J AM STAT ASSOC, V91, P935, DOI 10.2307/2291712; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; *EUR MOD DEL COLL, 1999, MANDET, V353, P1035; FISCUS S, 1998, 12 WORLD AIDS C GEN; GALVAAO NO, 1998, 12 WORLD AIDS C GEN; GIBB DM, 1993, GUIDELINES MANAGEMEN, P1; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; LINDEGREN ML, 1999, 6 C RETR OPP INF CHI; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Maguire A, 1997, AIDS, V11, P1851, DOI 10.1097/00002030-199715000-00010; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Newell ML, 1996, AIDS, V10, P1675; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; RAKUSAN TA, 1998, 12 WORLD AIDS C GEN; ROSENBERG PS, 1990, J ACQ IMMUN DEF SYND, V3, P49; *US PUBL HLTH SERV, 1995, MMWR-MORBID MORTAL W, V44, P1	21	58	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1227	1229		10.1136/bmj.319.7219.1227	http://dx.doi.org/10.1136/bmj.319.7219.1227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550082	Bronze, Green Published			2022-12-24	WOS:000083625600021
J	Hu, X; Lazar, MA				Hu, X; Lazar, MA			The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors	NATURE			English	Article							RETINOID-X-RECEPTOR; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LIGAND-BINDING; CO-REPRESSOR; ACTIVATION; DOMAINS; SPECIFICITY; COMPLEX; BETA	N-CoR1 and SMRT2 are transcriptional corepressors that associate with nuclear hormone receptors (NRs) in the absence of ligand. This interaction is the molecular target of differentiation therapy for acute promyelocytic leukaemia, wherein retinoic acid dissociates corepressor from leukaemogenic receptor fusion pioteins(3,4). Binding of ligand to NRs induces a conformation that attracts coactivator proteins containing an Leu-x-x-Leu-Leu motif (the 'NR box')(5,6). Here we show that N-CoR and SMRT contain sequences that are similar to the NR pox and are repeated in each of two NR interaction domains(7-10). We show that this CoRNR ('corner') box is required for NR interaction, and that CoRNR box peptides specifically block corepressor interaction in vitro and repression in vivo. Sequences flanking the CoRNR box determine NR specificity. Thus, the key feature of hormone action, differential recognition of unliganded and liganded NRs by coactivators and corepressors, is due to very subtle differences between CoRNR and NR boxes. The molecular mechanisms of repression and activation by NRs are thus linked in an unexpected manner.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019					CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	29	501	510	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					93	96		10.1038/47069	http://dx.doi.org/10.1038/47069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573424				2022-12-24	WOS:000083638600050
J	Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A				Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A			Neurotrophin-evoked rapid excitation through TrkB receptors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; BRAIN; BDNF; RAT; LOCALIZATION; PLASTICITY; RELEASE; POTENTIATION	Neurotrophins are a family of structurally related proteins that regulate the survival, differentiation and maintenance of function of different populations of peripheral and central neurons(1-3). They are also essential for modulating activity-dependent neuronal plasticity(4-7). Here we show that neurotrophins elicit action potentials in central neurons. Even at low concentrations, brain-derived neurotrophic factor (BDNF) excited neurons in the hippocampus, cortex and cerebellum. We found that BDNF and neurotrophin-4/5 depolarized neurons just as rapidly as the neurotransmitter glutamate, even at a more than thousand-fold lower concentration. Neurotrophin-3 produced much smaller responses, and nerve growth factor was ineffective. The neurotrophin-induced depolarization resulted from the activation of a sodium ion conductance which was reversibly blocked by K-252a, a protein kinase blocker which prefers tyrosine kinase Trk receptors(8). Our results demonstrate a very rapid excitatory action of neurotrophins, placing them among the most potent endogenous neuro-excitants in the mammalian central nervous system described so far.	Tech Univ Munich, Inst Physiol, D-80802 Munich, Germany; Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	Technical University of Munich; Saarland University; Max Planck Society	Konnerth, A (corresponding author), Tech Univ Munich, Inst Physiol, Biedersteinerstr 29, D-80802 Munich, Germany.							BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BERNAL I, 1993, STRUCT CHEM, V4, P131, DOI 10.1007/BF00677373; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; Cellerino A, 1996, PROG NEUROBIOL, V50, P333; Cellerino A, 1996, PROG NEUROBIOL, V49, P53, DOI 10.1016/0301-0082(96)00008-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; IP NY, 1993, J NEUROSCI, V13, P3394; KAHLE P, 1994, J NEUROSCI RES, V38, P599, DOI 10.1002/jnr.490380512; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; LESSMANN V, 1994, NEUROREPORT, V6, P21; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Yan Q, 1997, J COMP NEUROL, V382, P546; Yan Q, 1997, J COMP NEUROL, V378, P135; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	32	455	464	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					918	921		10.1038/44847	http://dx.doi.org/10.1038/44847			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553907				2022-12-24	WOS:000083464700059
J	Pagel, M				Pagel, M			Inferring the historical patterns of biological evolution	NATURE			English	Review							PHYLOGENETICALLY INDEPENDENT CONTRASTS; CORRELATED EVOLUTION; MOLECULAR EVIDENCE; METAZOAN PHYLA; PHYLOGENIES; CHARACTERS; SEQUENCES; RECONSTRUCTION; RATES; BIRDS	Phylogenetic trees describe the pattern of descent amongst a group of species. With the rapid accumulation of DNA sequence data, more and more phylogenies are being constructed based upon sequence comparisons. The combination of these phylogenies with powerful new statistical approaches for the analysis of biological evolution is challenging widely held beliefs about the history and evolution of life on Earth.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Pagel, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.		Rohlf, F J/A-8710-2008					Arnason U, 1998, J MOL EVOL, V47, P718, DOI 10.1007/PL00006431; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; BOWLER PJ, 1991, C DARWIN MAN HIS INF; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bull JJ, 1997, GENETICS, V147, P1497; COLLINS TM, 1994, SYST BIOL, V43, P482, DOI 10.2307/2413547; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Crandall KA, 1999, MOL BIOL EVOL, V16, P372, DOI 10.1093/oxfordjournals.molbev.a026118; Darwin Charles, 1888, ORIGIN SPECIES MEANS, VSixth; Durham WH., 1991, COEVOLUTION GENES CU; EDWARDS Anthony William Fairbank, 1972, LIKELIHOOD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Fortey R., 1997, LIFE UNAUTHORISED BI; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Harvey PH, 1998, P ROY SOC B-BIOL SCI, V265, P1691, DOI 10.1098/rspb.1998.0490; Healy SD, 1996, BRAIN BEHAV EVOLUT, V47, P195, DOI 10.1159/000113239; Hecht M.K., 1986, Oxford Surveys in Evolutionary Biology, V3, P1; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; Hillis DM, 1996, MOL SYSTEMATICS; Holden C, 1997, HUM BIOL, V69, P605; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Johnston J., 1963, ECONOMETRIC METHODS; Kerr RA, 1999, SCIENCE, V284, P412; Koshi JM, 1996, J MOL EVOL, V42, P313, DOI 10.1007/BF02198858; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Li W-H, 1997, MOL EVOLUTION; MADDISON DR, 1994, ANNU REV ENTOMOL, V39, P267, DOI 10.1146/annurev.en.39.010194.001411; MADDISON WP, 1990, EVOLUTION, V44, P539, DOI 10.1111/j.1558-5646.1990.tb05937.x; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; MARTINS EP, 1991, EVOLUTION, V45, P534, DOI [10.2307/2409910, 10.1111/j.1558-5646.1991.tb04328.x]; Martins EP, 1997, AM NAT, V149, P646, DOI 10.1086/286013; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Mooers AO, 1999, SYST BIOL, V48, P623, DOI 10.1080/106351599260193; Mooers AO, 1999, AM NAT, V154, P249, DOI 10.1086/303226; Omland KE, 1997, EVOLUTION, V51, P1381, DOI 10.2307/2411190; OMLAND KE, 1994, SYST BIOL, V43, P369, DOI 10.2307/2413674; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pagel M, 1999, SYST BIOL, V48, P612, DOI 10.1080/106351599260184; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; PAGEL M, 1993, J THEOR BIOL, V164, P191, DOI 10.1006/jtbi.1993.1148; PAGEL MD, 1989, SCIENCE, V244, P1589, DOI 10.1126/science.2740904; PAGEL MD, 1992, J THEOR BIOL, V156, P431, DOI 10.1016/S0022-5193(05)80637-X; Price T, 1997, PHILOS T ROY SOC B, V352, P519, DOI 10.1098/rstb.1997.0036; PURVIS A, 1994, J THEOR BIOL, V167, P293, DOI 10.1006/jtbi.1994.1071; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; Rambaut A, 1998, MOL BIOL EVOL, V15, P442, DOI 10.1093/oxfordjournals.molbev.a025940; RAUP DM, 1991, MASS EXTINCTIONS BAD; Ricklefs RE, 1996, OIKOS, V77, P167, DOI 10.2307/3545598; RIDLEY M, 1981, EXPLANATION ORGANIC; Rolland C, 1998, AM NAT, V151, P514, DOI 10.1086/286137; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Schluter D, 1997, EVOLUTION, V51, P1699, DOI 10.1111/j.1558-5646.1997.tb05095.x; SCHLUTER D, 1995, NATURE, V377, P108, DOI 10.1038/377108a0; Strauss E, 1999, SCIENCE, V283, P1435, DOI 10.1126/science.283.5407.1435; Tuffley C, 1997, B MATH BIOL, V59, P581, DOI 10.1016/S0092-8240(97)00001-3; URSING BM, 1998, P R SOC LOND B, V265, P2252; Valentine JW, 1996, DEV BIOL, V173, P373, DOI 10.1006/dbio.1996.0033; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; Williams G. C., 1992, NATURAL SELECTION; Wilson IJ, 1998, GENETICS, V150, P499; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; YANG ZH, 1995, GENETICS, V141, P1641; Yeager M, 1999, IMMUNOL REV, V167, P45, DOI 10.1111/j.1600-065X.1999.tb01381.x	77	3202	3237	23	589	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					877	884		10.1038/44766	http://dx.doi.org/10.1038/44766			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553904				2022-12-24	WOS:000083464700048
J	Blau, J; Young, MW				Blau, J; Young, MW			Cycling vrille expression is required for a functional Drosophila clock	CELL			English	Article							NERVOUS-SYSTEM; CIRCADIAN-RHYTHMS; TRANSCRIPTION FACTORS; GENE-PRODUCT; BZIP FAMILY; DOUBLE-TIME; PERIOD; MELANOGASTER; PROTEIN; CRYPTOCHROME	We identified a novel regulatory loop within Drosophila's circadian clock. A screen for clock-controlled genes recovered vrille (vri), a transcription factor essential for embryonic development. vri iss expressed in circadian pacemaker cells in larval and adult brains. vri RNA levels oscillate with a circadian rhythm. Cycling is directly regulated by the transcription factors dCLOCK and CYCLE, which are also required for oscillations of period and timeless RNA. Eliminating the normal vri cycle suppresses period and timeless expression and causes long-period behavioral rhythms and arrhythmicity, indicating that cycling vri is required for a functional Drosophila clock. We also show that dCLOCK and VRI independently regulate levels of a neuropeptide, pigment dispersing factor, which appears to regulate overt behavior.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA	Rockefeller University	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cheng YZ, 1998, J NEUROSCI, V18, P741; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; George H, 1997, GENETICS, V146, P1345; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; NEWBY LM, 1993, GENETICS, V135, P1077; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	45	332	340	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					661	671		10.1016/S0092-8674(00)81554-8	http://dx.doi.org/10.1016/S0092-8674(00)81554-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612401	Bronze			2022-12-24	WOS:000084278700012
J	Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B				Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B			An auxin-dependent distal organizer of pattern and polarity in the Arabidopsis root	CELL			English	Article							CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; RESPONSE ELEMENTS; AUX/IAA PROTEINS; FLORAL MERISTEM; GENE MONOPTEROS; THALIANA; ENCODES; EMBRYO	Root formation in plants involves the continuous interpretation of positional cues. Physiological studies have linked root formation to auxins. An auxin response element displays a maximum in the Arabidopsis root and we investigate its developmental significance. Auxin response mutants reduce the maximum or its perception, and interfere with distal root patterning. Polar auxin transport mutants affect its localization and distal pattern. Polar auxin transport inhibitors cause dramatic relocalization of the maximum, and associated changes in pattern and polarity. Auxin application and laser ablations correlate root pattern with a maximum adjacent to the vascular bundle. Our data indicate that an auxin maximum at a vascular boundary establishes a distal organizer in the root.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; NYU, Dept Biol, New York, NY 10003 USA; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; INRA, Ctr Versailles, Lab Genet & Ameliorat Plantes, F-78026 Versailles, France	Utrecht University; University of Missouri System; University of Missouri Columbia; New York University; University of York - UK; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Scheres, B (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	b.scheres@bio.uu.nl	Leyser, Ottoline/AAC-5577-2019	Scheres, Ben/0000-0001-5400-9578; SABATINI, Sabrina/0000-0002-9691-6595; Beis, Dimitris/0000-0003-2579-7848; Leyser, Ottoline/0000-0003-2161-3829				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BERLETH T, 1993, DEVELOPMENT, V118, P575; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Davies P. J, 1995, PLANT HORMONES; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOLAN L, 1993, DEVELOPMENT, V119, P71; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HOBBIE L, 1995, PLANT J, V7, P211, DOI 10.1046/j.1365-313X.1995.7020211.x; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KELLY MO, 1986, PLANT PHYSIOL, V82, P713, DOI 10.1104/pp.82.3.713; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Malamy JE, 1997, DEVELOPMENT, V124, P33; Malamy JE, 1997, PLANT J, V12, P957, DOI 10.1046/j.1365-313X.1997.12040957.x; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Mattsson J, 1999, DEVELOPMENT, V126, P2979; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; SACHS T, 1991, DEVELOPMENT, P83; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Sessions A, 1997, DEVELOPMENT, V124, P4481; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STJOHNSTON D, 1992, CELL, V68, P201; Tian Q, 1999, DEVELOPMENT, V126, P711; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; Ulmasov T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/pnas.96.10.5844; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Willemsen V, 1998, DEVELOPMENT, V125, P521	50	1011	1053	9	162	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					463	472		10.1016/S0092-8674(00)81535-4	http://dx.doi.org/10.1016/S0092-8674(00)81535-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589675	Bronze, Green Published			2022-12-24	WOS:000083986300006
J	Bartsch, P				Bartsch, P			Platelet activation with exercise and risk of cardiac events	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; STRENUOUS EXERCISE; PHYSICAL EXERTION; FIBRINOLYSIS; COAGULATION; MODERATE; DEATH; MEN		Univ Heidelberg, Div Sports Med, Dept Internal Med, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bartsch, P (corresponding author), Univ Heidelberg, Div Sports Med, Dept Internal Med, Bergheimer Str 58, D-69115 Heidelberg, Germany.							DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; KESTIN AS, 1993, CIRCULATION, V88, P1502, DOI 10.1161/01.CIR.88.4.1502; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; STREIFF M, 1994, SEMIN HEMATOL, V31, P155; Wallen NH, 1999, CLIN SCI, V97, P27, DOI 10.1042/CS19990013; WANG JS, 1994, CIRCULATION, V90, P2877, DOI 10.1161/01.CIR.90.6.2877; WANG JS, 1995, ARTERIOSCL THROM VAS, V15, P1668, DOI 10.1161/01.ATV.15.10.1668; Weiss C, 1998, MED SCI SPORT EXER, V30, P246, DOI 10.1097/00005768-199802000-00012; Weiss C, 1998, AM J CARDIOL, V81, P672, DOI 10.1016/S0002-9149(97)01026-6; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WINDER WW, 1978, J APPL PHYSIOL, V45, P370, DOI 10.1152/jappl.1978.45.3.370	13	42	43	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1747	1748		10.1016/S0140-6736(99)90259-3	http://dx.doi.org/10.1016/S0140-6736(99)90259-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577632				2022-12-24	WOS:000083853000005
J	Russell, DF; Wilkens, LA; Moss, F				Russell, DF; Wilkens, LA; Moss, F			Use of behavioural stochastic resonance by paddle fish for feeding	NATURE			English	Article							NOISE; MECHANORECEPTORS; CRAYFISH; SYSTEM	Stochastic resonance is the phenomenon whereby the addition of an optimal level of noise to a weak information-carrying input to certain nonlinear systems can enhance the information content at their outputs(1-4). Computer analysis of spike trains has been needed to reveal stochastic resonance in the responses of sensory receptors(5-7) except for one study on human psychophysics(8). But is an animal aware of, and can it make use of, the enhanced sensory information from stochastic resonance? Here, we show that stochastic resonance enhances the normal feeding behaviour of paddlefish (Polyodon spathula)(9,10), which use passive electroreceptors(11,12) to detect electrical signals from planktonic prey(13). We demonstrate significant broadening of the spatial range for the detection of plankton when a noisy electric field of optimal amplitude is applied in the water. We also show that swarms of Daphnia plankton are a natural source of electrical noise. Our demonstration of stochastic resonance at the level of a vital animal behaviour, feeding, which has probably evolved for functional success, provides evidence that stochastic resonance in sensory nervous systems is an evolutionary adaptation(14).			Russell, DF (corresponding author), Univ Missouri, Ctr Neurodynam, St Louis, MO 63121 USA.							Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BOUCHERLE MM, 1976, OHIO J SCI, V56, P90; Bullock T.H., 1986, P651; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; BURGGREN WW, 1992, PHYSIOL ZOOL, V65, P515, DOI 10.1086/physzool.65.3.30157967; Collins JJ, 1996, J NEUROPHYSIOL, V76, P642, DOI 10.1152/jn.1996.76.1.642; Collins JJ, 1996, NATURE, V383, P770, DOI 10.1038/383770a0; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; GIBBONS JD, 1976, NONPARAMETRIC METHOD, P223; Gluckman BJ, 1996, PHYS REV LETT, V77, P4098, DOI 10.1103/PhysRevLett.77.4098; Jaramillo F, 1998, NAT NEUROSCI, V1, P384, DOI 10.1038/1597; JORGENSEN JM, 1972, Z ZELLFORSCH MIK ANA, V130, P362; Laming PR, 1981, BRAIN MECHANISMS BEH, P203; Levin JE, 1996, NATURE, V380, P165, DOI 10.1038/380165a0; MARASCUILO LA, 1977, NONPARAMETRIC DISTRI, P290; NEW JG, 1985, BRAIN RES, V336, P89, DOI 10.1016/0006-8993(85)90419-6; POUGH FH, 1996, VERTEBRATE LIFE, P258; Robbins Trevor W., 1995, P703; RUELLE R, 1977, T AM FISH SOC, V106, P609, DOI 10.1577/1548-8659(1977)106<609:PPS>2.0.CO;2; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; TEETER JH, 1980, J COMP PHYSIOL, V138, P213, DOI 10.1007/BF00657039; Tricas TC, 1998, J COMP PHYSIOL A, V182, P89; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; Wilkens LA, 1997, P ROY SOC B-BIOL SCI, V264, P1723, DOI 10.1098/rspb.1997.0239	26	388	397	1	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					291	294		10.1038/46279	http://dx.doi.org/10.1038/46279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580499				2022-12-24	WOS:000083813700049
J	Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ				Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ			Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms	SCIENCE			English	Article							ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; TYROSINE PHOSPHORYLATION; PDS1P; INHIBITOR; DESTRUCTION; TRANSITION; METAPHASE	In response to DNA damage, cells activate checkpoint pathways that prevent cell cycle progression. In fission yeast and mammals, mitotic arrest in response to DNA damage requires inhibitory Cdk phosphorylation regulated by Chk1. This study indicates that Chk1 is required for function of the DNA damage checkpoint in Saccharomyces cerevisiae but acts through a distinct mechanism maintaining the abundance of Pds1, an anaphase inhibitor. Unlike other checkpoint mutants, chk1 mutants were only mildly sensitive to DNA damage, indicating that checkpoint functions besides cell cycle arrest influence damage sensitivity. Another kinase, Rad53, was required to both maintain active cyclin-dependent kinase 1, Cdk1(Cdc28), and prevent anaphase entry after checkpoint activation. Evidence suggests that Rad53 exerts its role in checkpoint control through regulation of the Polo kinase Cdc5. These results support a model in which Chk1 and Rad53 function in parallel through Pds1 and Cdc5, respectively, to prevent anaphase entry and mitotic exit after DNA damage. This model provides a possible explanation for the role of Cdc5 in DNA damage checkpoint adaptation.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.		Sanchez, Yolanda/L-2847-2014	Sanchez, Yolanda/0000-0002-7650-9319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANCHEZ Y, UNPUB; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1993, GENETICS, V134, P63; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	28	445	454	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1166	1171		10.1126/science.286.5442.1166	http://dx.doi.org/10.1126/science.286.5442.1166			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550056				2022-12-24	WOS:000083534200046
J	Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC				Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC			An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GYRA GENE; SEROVAR TYPHIMURIUM; PRODUCTION ANIMALS; PHAGE TYPES; HUMANS; MUTATIONS; DENMARK	Background Food-borne salmonella infections have become a major problem in industrialized countries. The strain of Salmonella enterica serotype typhimurium known as definitive phage type 104 (DT104) is usually resistant to five drugs: ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline. An increasing proportion of DT104 isolates also have reduced susceptibility to fluoroquinolones. Methods The Danish salmonella surveillance program determines the phage types of all typhimurium strains from the food chain, and in the case of suspected outbreaks, five-drug-resistant strains are characterized by molecular methods. All patients infected with five-drug-resistant typhimurium are interviewed to obtain clinical and epidemiologic data. In 1998, an outbreak of salmonella occurred, in which the strain of typhimurium DT104 was new to Denmark. We investigated this outbreak and report our findings here. Results Until 1997, DT104 infections made up less than 1 percent of all human salmonella infections. The strain isolated from patients in the first community outbreak of DT104 in Denmark, in 1998, was resistant to nalidixic acid and had reduced susceptibility to fluoroquinolones. The outbreak included 25 culture-confirmed cases. Eleven patients were hospitalized, and two died. The molecular epidemiology and data from patients indicated that the primary source was a Danish swine herd. Furthermore, the investigation suggested reduced clinical effectiveness of treatment with fluoroquinolones. Conclusions Our investigation of an outbreak of DT104 documented the spread of quinolone-resistant bacteria from food animals to humans; this spread was associated with infections that were difficult to treat. Because of the increase in quinolone resistance in salmonella, the use of fluoroquinolones in food animals should be restricted. (N Engl J Med 1999;341:1420-5.) (C)1999, Massachusetts Medical Society.	Statens Serum Inst, DK-2300 Copenhagen S, Denmark; Danish Vet Lab, Copenhagen, Denmark; Danish Food & Vet Adm, Copenhagen, Denmark; Danish Zoonosis Ctr, Copenhagen, Denmark	Statens Serum Institut	Molbak, K (corresponding author), Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark.			Petersen, Andreas Munk/0000-0003-0531-0553; Wegener, Henrik Caspar/0000-0002-6888-2121; Aarestrup, Frank/0000-0002-7116-2723; Molbak, Kare/0000-0002-3100-4990; Engberg, Jorgen/0000-0001-9042-1631				ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; Anglim Anne M., 1995, P1525; BAGGESEN DL, 1994, ACTA VET SCAND, V35, P349; CALLOW B R, 1959, J Hyg (Lond), V57, P346; *DIV EM OTH COMM D, 1997, P WHO M BERL GERM 13; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Griggs DJ, 1996, ANTIMICROB AGENTS CH, V40, P1009, DOI 10.1128/AAC.40.4.1009; HALD T, 1998, ANN REPORT ZOONOSES; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; OLSEN JE, 1994, J MED MICROBIOL, V40, P15, DOI 10.1099/00222615-40-1-15; Ouabdesselam S, 1996, MICROB DRUG RESIST, V2, P299, DOI 10.1089/mdr.1996.2.299; Piddock LJV, 1998, J ANTIMICROB CHEMOTH, V41, P635, DOI 10.1093/jac/41.6.635; Ridley A, 1998, MICROB DRUG RESIST, V4, P113, DOI 10.1089/mdr.1998.4.113; Ruiz J, 1997, J MED MICROBIOL, V46, P623, DOI 10.1099/00222615-46-7-623; Seyfarth AM, 1997, J ANTIMICROB CHEMOTH, V40, P67, DOI 10.1093/jac/40.1.67; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; Vasallo FJ, 1998, CLIN INFECT DIS, V26, P535, DOI 10.1086/517087; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; WEGENER HC, 1994, APMIS, V102, P521, DOI 10.1111/j.1699-0463.1994.tb05200.x; WISTROM J, 1995, J ANTIMICROB CHEMOTH, V36, P23, DOI 10.1093/jac/36.1.23; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	22	347	360	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1420	1425		10.1056/NEJM199911043411902	http://dx.doi.org/10.1056/NEJM199911043411902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547404	Bronze			2022-12-24	WOS:000083472100002
J	Page, CC; Moser, CC; Chen, XX; Dutton, PL				Page, CC; Moser, CC; Chen, XX; Dutton, PL			Natural engineering principles of electron tunnelling in biological oxidation-reduction	NATURE			English	Article							PHOTOSYNTHETIC REACTION-CENTER; DELTA-G-DEGREES; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-SPHAEROIDES; DESULFOVIBRIO-GIGAS; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; NIFE HYDROGENASE; TEMPERATURE; OXIDASE	We have surveyed proteins with known atomic structure whose function involves electron transfer; in these, electrons can travel up to 14 Angstrom between redox centres through the protein medium. Transfer over longer distances always involves a chain of cofactors. This redox centre proximity alone is sufficient to allow tunnelling of electrons at rates far faster than the substrate redox reactions it supports. Consequently, there has been no necessity for proteins to evolve optimized routes between redox centres. Instead, simple geometry enables rapid tunnelling to high-energy intermediate states. This greatly simplifies any analysis of redox protein mechanisms and challenges the need to postulate mechanisms of superexchange through redox centres or the maintenance of,charge neutrality when investigating electron-transfer reactions. Such tunnelling also allows sequential electron transfer in catalytic sites to surmount radical transition states without involving the movement of hydride ions, as is generally assumed. The 14 Angstrom or less spacing of redox centres provides highly robust engineering for electron transfer, and may reflect selection against designs that have proved more vulnerable to mutations during the course of evolution.	Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA	University of Pennsylvania	Dutton, PL (corresponding author), Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.	dutton@mail.med.upenn.edu	Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568; Chen, Xiaoxi/0000-0002-1049-3537				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; Allen JP, 1998, PHOTOSYNTH RES, V55, P227, DOI 10.1023/A:1005977901937; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; Darwin C., 1872, ORIGIN SPECIES MEANS, V144, P971; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DOHSE B, 1995, BIOCHEMISTRY-US, V34, P11335, DOI 10.1021/bi00036a006; DUTTON PL, 1998, BIOL ELECT TRANSFER, P3; EBERSON L, 1987, ELECT TRANSFER REACT, P1; EHRENBERG A, 1998, 3 INT S BIOL PHYS, V1, P1; FARRINGTON JA, 1980, BIOCHIM BIOPHYS ACTA, V590, P273, DOI 10.1016/0005-2728(80)90031-6; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Gunner M.R., 1982, FUNCTION QUINONES EN, P265; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1993, J BIOL CHEM, V268, P18685; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; Li JL, 1998, BIOCHEMISTRY-US, V37, P2818, DOI 10.1021/bi971699x; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1991, STRUCT BOND, V75, P159; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; MICHAELIS L, 1951, ENZYMES, P1; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Ortega JM, 1999, PHOTOSYNTH RES, V59, P147, DOI 10.1023/A:1006149621029; POWELL MF, 1984, J AM CHEM SOC, V106, P3850, DOI 10.1021/ja00325a024; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PROSS A, 1985, ACCOUNTS CHEM RES, V18, P212, DOI 10.1021/ar00115a004; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; SMALLEY JF, 1995, J PHYS CHEM-US, V99, P13141, DOI 10.1021/j100035a016; SOGABE S, 1992, PHOTOSYNTH RES, V34, P154; Spee JH, 1998, FEBS LETT, V432, P55, DOI 10.1016/S0014-5793(98)00827-8; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; Venturoli G, 1998, BIOPHYS J, V74, P3226, DOI 10.1016/S0006-3495(98)78029-4; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4; Zinth W, 1996, BER BUNSEN PHYS CHEM, V100, P1962, DOI 10.1002/bbpc.19961001206	50	1436	1455	9	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					47	52		10.1038/46972	http://dx.doi.org/10.1038/46972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573417				2022-12-24	WOS:000083638600036
J	Ricchetti, M; Fairhead, C; Dujon, B				Ricchetti, M; Fairhead, C; Dujon, B			Mitochondrial DNA repairs double-strand breaks in yeast chromosomes	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NONHOMOLOGOUS RECOMBINATION; NUCLEUS; GENOME; ESCAPE; GENES; INTEGRATION; MIGRATION; DELETIONS; SEQUENCE	The endosymbiotic theory for the origin of eukaryotic cells' proposes that genetic information can be transferred from mitochondria to the nucleus of a cell, and genes that are probably of mitochondrial origin have been found in nuclear chromosomes(2). Occasionally, short or rearranged sequences homologous to mitochondrial DNA are seen in the chromosomes of different organisms including yeast, plants and humans(3). Here we report a mechanism by which fragments of mitochondrial DNA, in single or tandem array, are transferred to yeast chromosomes under natural conditions during the repair of double-strand breaks in haploid mitotic cells. These repair insertions originate from noncontiguous regions of the mitochondrial genome. Our analysis of the Saccharomyces cerevisiae mitochondrial genome(4) indicates that the yeast nuclear genome does indeed contain several short sequences of mitochondrial origin which are similar in size and composition to those that repair double-strand breaks. These sequences are located predominantly in non-coding regions of the chromosomes, frequently in the vicinity of retrotransposon long terminal repeats, and appear as recent integration events. Thus, colonization of the yeast genome by mitochondrial DNA is an ongoing process.	Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, F-75724 Paris 15, France; Univ Paris 06, Inst Pasteur, UFR 927, CNRS,URA1300,Unite Genet Mol Levures, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite	Ricchetti, M (corresponding author), Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.	mricch@pasteur.fr	Dujon, Bernard A/F-4971-2010; Fairhead, Cecile/D-9011-2014	Fairhead, Cecile/0000-0002-0456-0377				Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Blanchard JL, 1996, MOL BIOL EVOL, V13, P537, DOI 10.1093/oxfordjournals.molbev.a025614; Byers B, 1981, MOL BIOL YEAST SACCH, P59; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; Fairhead C, 1998, GENE, V223, P33, DOI 10.1016/S0378-1119(98)00171-1; Fairhead C, 1996, YEAST, V12, P1439; FAIRHEAD C, 1993, MOL GEN GENET, V240, P170, DOI 10.1007/BF00277054; FARRELLY F, 1983, NATURE, V301, P296, DOI 10.1038/301296a0; Feuermann M, 1997, YEAST, V13, P861, DOI 10.1002/(SICI)1097-0061(199707)13:9<861::AID-YEA125>3.3.CO;2-0; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LOUIS EJ, 1991, CURR GENET, V20, P411, DOI 10.1007/BF00317070; MARGULIS L, 1970, P349; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Perna NT, 1996, CURR BIOL, V6, P128, DOI 10.1016/S0960-9822(02)00441-4; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SCHIESTL RH, 1993, MOL CELL BIOL, V13, P2697, DOI 10.1128/MCB.13.5.2697; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Thorsness PE, 1996, INT REV CYTOL, V165, P207, DOI 10.1016/S0074-7696(08)62223-8; THORSNESS PE, 1993, GENETICS, V134, P21; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	30	185	192	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					96	100		10.1038/47076	http://dx.doi.org/10.1038/47076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573425				2022-12-24	WOS:000083638600051
J	Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA				Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA			Early beta-blocker therapy for acute myocardial infarction in elderly patients	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; age factors; adrenergic beta-antagonists; time factors; outcome assessment (health care)	COOPERATIVE CARDIOVASCULAR PROJECT; MEDICARE PATIENTS; GUIDELINES; MORTALITY; QUALITY; CARE	Background: Despite the evidence supporting the importance of early beta-blocker therapy, this intervention has received little attention as an indicator of quality of care. Objectives: To determine how often beta-blockers are administered as early treatment of acute myocardial infarction in patients 65 years of age or older, to identify predictors of the decision to use beta-blockers, and to evaluate the association between the early use of beta-blockers and in-hospital mortality. Design: Observational study. Setting: Nongovernment, acute care hospitals in the United States. Patients: Medicare beneficiaries who were 65 years of age or older, were hospitalized with an acute myocardial infarction in 1994 and 1995, and did not have a contraindication to beta-blocker therapy. Measurements: Medical chart review to obtain information about the use of beta-blockers, contraindications to these drugs, patient demographics, and clinical factors. Results: Of the 58 165 patients (from a total of 4414 hospitals), 28 256 (49%) received early beta-blocker therapy. Patients with the highest risk for in-hospital death were the least likely to receive therapy. Patients who received beta-blockers had a lower in-hospital mortality rate than patients who did not receive beta-blockers (odds ratio, 0.81 [95% CI, 0.75 to 0.87]), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Early beta-blocker therapy was not used for 51% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to this therapy. Increasing the early use of beta-blockers for these patients would provide an excellent opportunity to improve their care and outcomes.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA; US Hlth Care Financing Adm, Baltimore, MD 21244 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Room IE-61 SHM, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				[Anonymous], 1986, LANCET, V2, P57; Berger AK, 1998, AM HEART J, V135, P349, DOI 10.1016/S0002-8703(98)70104-8; *BUR CENS, 1991, STAT METR AR DAT BOO; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; HJALMARSON A, 1985, AM J CARDIOL, V56, pG15; HOSMER DW, 1988, BIOMETRICAL J, V30, P911, DOI 10.1002/bimj.4710300805; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; *NAT COMM QUAL ASS, 1997, HLTH PLAN EMPL DAT I; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SEDERHOLM M, 1984, NEW ENGL J MED, V310, P9; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	78	81	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					648	+		10.7326/0003-4819-131-9-199911020-00003	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577326				2022-12-24	WOS:000083446200002
J	Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP				Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP			P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A	NATURE			English	Article							BRAIN CA2+ CHANNELS; GENE-EXPRESSION; TRANSCRIPTION; NEURONS; PROTEIN; CREB; PHOSPHORYLATION; IDENTIFICATION; COMPLEX; FORMS	Spatial and temporal changes in intracellular calcium concentrations are critical for controlling gene expression in neurons(1-5). In many neurons, activity-dependent calcium influx through L-type channels stimulates transcription that depends on the transcription factor CREB by activating a calmodulin-dependent pathway(6-11). Here we show that selective influx of calcium through P/Q-type channels(12-14) is responsible for activating expression of syntaxin-1A, a presynaptic protein that mediates vesicle docking, fusion and neurotransmitter release. The initial P/Q-type calcium signal is amplified by release of calcium from intracellular stores and acts through phosphorylation that is dependent on the calmodulin-dependent kinase CaM K II/IV, protein kinase A and mitogen-activated protein kinase kinase, Initiation of syntaxin-1A expression is rapid and short-lived, with syntaxin-1A ultimately interacting with the P/Q-type calcium channel to decrease channel availability. Our results define an activity-dependent feedback pathway that may regulate synaptic efficacy and function in the nervous system.	Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Snutch, TP (corresponding author), Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada.	snutch@zoology.ubc.ca	Snutch, Terrance P/L-3464-2019; Murphy, Timothy/AAW-1975-2021; Murphy, Timothy H/I-4982-2014	Snutch, Terrance P/0000-0001-5182-1296; Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Betz A, 1997, J BIOL CHEM, V272, P2520; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Daly C, 1997, J NEUROSCI, V17, P2365; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HONER WG, 1993, BRAIN RES, V609, P9, DOI 10.1016/0006-8993(93)90848-H; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694	30	101	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					800	804		10.1038/44586	http://dx.doi.org/10.1038/44586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548106				2022-12-24	WOS:000083368700055
J	Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G				Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G			Assessment of impact on health of residents living near the Nant-y-Gwyddon landfill site: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objectives To compare indices of health in a population living near a landfill site with a population matched for socioeconomic status and to review environmental monitoring data. Design Ecological study with small area statistics and environmental reports. Setting Electoral wards in valleys of South Wales. Subjects Populations in the five wards near the landfill site who had formally complained of odours (exposed population), and comparison populations in 22 wards in the same unitary authority within the same fifth of Townsend score. Outcome measures Mortality, rates of hospital admission, measures of reproductive health (proportion of all births and stillbirths of infants weighing < 2500 g; rates of admissions for spontaneous abortion; rates of all reported congenital malformations). Environmental data on site emissions. Results There were no consistent differences in mortality, rates of hospital admissions, or proportion of low birthweight infants between the two populations. There was an increased maternal risk of having a baby with a congenital abnormality in residents near the site, both before its opening (relative risk 1.9; 95% confidence interval 1.3 to 2.85; P < 0.001) and after (1.9; 1.23 to 2.95; P = 0.003). Environmental monitoring showed that hydrogen sulphide from the site was probably responsible for odours. Conclusions The area surrounding the landfill site has an increased rate of reported congenital malformations,which predated the opening of the landfill, although the cluster of cases of gastroschisis postdated its opening. Several chemicals emitted from the site, including hydrogen sulphide and benzene, were found in air samples in the nearby community. Further studies of the reproductive risk in such communities are needed to examine the safety of waste disposal sites.	Univ Wales Coll Med, Div Publ Hlth, Cardiff CF14 4XN, S Glam, Wales; Bro Taf Hlth Author, Temple Peace & Hlth, Dept Informat, Cardiff CF1 3NW, S Glam, Wales; Univ Wales Inst, WHO, Collaborating Ctr Chem Incidents, Cardiff CG5 2YB, S Glam, Wales	Cardiff University; World Health Organization	Fielder, HMP (corresponding author), Welsh Combined Ctr Publ Hlth, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.							*AG TOX SUBST DIS, 1994, ENV NEED PUBL HLTH A; BOTTING B, 1998, POP TRENDS, V3, P19; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; GARDNER MJ, 1992, CONFIDENCE INTERVAL; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; GOLDBERG MS, 1995, ENVIRON RES, V69, P37, DOI 10.1006/enrs.1995.1023; HADDOW JE, 1993, TERATOLOGY, V47, P225, DOI 10.1002/tera.1420470306; HERTZMAN C, 1987, ENVIRON HEALTH PERSP, V75, P173, DOI 10.2307/3430589; NEAVE HR, 1989, ELEMENTARY STAT TABL; RAMSEY TL, 1994, MANAGING HAZARDOUS I, V3; SCOTT PE, 1998, INVESTIGATION ODOUR; Tan KH, 1996, BRIT MED J, V313, P903; *WORK GROUP REG GE, 1995, 43 OFF POP CENS SURV	13	69	72	2	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					19	22		10.1136/bmj.320.7226.19	http://dx.doi.org/10.1136/bmj.320.7226.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617518	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000084621600016
J	Brondello, JM; Pouyssegur, J; McKenzie, FR				Brondello, JM; Pouyssegur, J; McKenzie, FR			Reduced MAP kinase phosphatase-1 degradation after p42/p44(MAPK)-dependent phosphorylation	SCIENCE			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-TYROSINE-PHOSPHATASE; FIBROBLAST PROLIFERATION; SUBSTRATE RECOGNITION; C-JUN; EXPRESSION; CELLS; IDENTIFICATION; PATHWAY; TRANSDUCTION	The mitogen-activated protein (MAP) kinase cascade is inactivated at the level of MAP kinase by members of the MAP kinase phosphatase (MKP) family, including MKP-1. MKP-1 was a labile protein in CCL39 hamster fibroblasts; its degradation was attenuated by inhibitors of the ubiquitin-directed proteasome complex; MKP-1 was a target in vivo and in vitro for p42(MAPK) or p44(MAPK), which phosphorylates MKP-1 on two carboxyl-terminal serine residues, Serine 359 and Serine 364. This phosphorylation did not modify MKP-1's intrinsic ability to dephosphorylate p44(MAPK) but led to stabilization of the protein. These results illustrate the importance of regulated protein degradation in the control of mitogenic signaling.	Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	McKenzie, FR (corresponding author), Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026939] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26939] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRONDELLO JM, 1991, NATURE, V350, P359; CHARLES CH, 1992, ONCOGENE, V7, P197; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SEGER R, 1992, J BIOL CHEM, V267, P14373; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	38	353	365	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2514	2517		10.1126/science.286.5449.2514	http://dx.doi.org/10.1126/science.286.5449.2514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617468				2022-12-24	WOS:000084429700051
J	Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH				Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH			A pdf neuropeptide gene mutation and ablation of PDF neurons each cause severe abnormalities of behavioral circadian rhythms in Drosophila	CELL			English	Article							HORMONE-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; SUPRACHIASMATIC NUCLEUS; VISUAL-SYSTEM; DARK CYCLES; CLOCK GENE; MELANOGASTER; PERIOD; MUTANTS; CELLS	The mechanisms by which circadian pacemaker systems transmit timing information to control behavior are largely unknown. Here, we define two critical features of that mechanism in Drosophila. We first describe animals mutant for the pdf neuropeptide gene, which is expressed by most of the candidate pacemakers (LN, neurons). Next, we describe animals in which pdf neurons were selectively ablated. Both sets of animals produced similar behavioral phenotypes. Both sets entrained to light, but both were largely arrhythmic under constant conditions. A minority of each pdf variant exhibited weak to moderate free-running rhythmicity. These results confirm the assignment of LN, neurons as the principal circadian pacemakers controlling daily locomotion in Drosophila. They also implicate PDF as the principal circadian transmitter.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Natl Sci Fdn Biol Timing, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Washington University (WUSTL); Brandeis University; Brandeis University; National Science Foundation (NSF); Brandeis University; Howard Hughes Medical Institute	Taghert, PH (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.			Park, Jae/0000-0002-4846-2197	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33205] Funding Source: Medline; NIMH NIH HHS [F32MH-1196] Funding Source: Medline; NINDS NIH HHS [NS-21749] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; Benveniste RJ, 1999, J NEUROBIOL, V38, P507, DOI 10.1002/(SICI)1097-4695(199903)38:4<507::AID-NEU7>3.0.CO;2-X; Boer GJ, 1999, NEUROSCIENCE, V89, P375, DOI 10.1016/S0306-4522(98)00300-5; BRAND A, 1993, DEVELOPMENT, V118, P410; CASSONE VM, 1984, J EXP ZOOL, V232, P539, DOI 10.1002/jez.1402320321; CASSONE VM, 1983, BRAIN RES, V272, P311, DOI 10.1016/0006-8993(83)90578-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DIRCKSEN H, 1987, CELL TISSUE RES, V250, P377; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; DUSHAY MS, 1990, GENETICS, V125, P557; Elekes K, 1999, CELL TISSUE RES, V295, P339, DOI 10.1007/s004410051240; Hamblen MJ, 1998, GENETICS, V149, P165; HAMBLEN MJ, 1966, J NEUROGENET, V3, P249; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Harrington ME, 1999, J NEUROSCI, V19, P6637; Helfrich-Forster C, 1998, CHRONOBIOL INT, V15, P567, DOI 10.3109/07420529808993195; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HOMBERG U, 1991, CELL TISSUE RES, V266, P343, DOI 10.1007/BF00318190; Inouye SIT, 1996, PROG BRAIN RES, V111, P75, DOI 10.1016/S0079-6123(08)60401-X; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Li XD, 1998, CURR OPIN NEUROBIOL, V8, P648, DOI 10.1016/S0959-4388(98)80094-9; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Loros JJ, 1998, CURR OPIN MICROBIOL, V1, P698, DOI 10.1016/S1369-5274(98)80118-5; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; MENAKER M, 1976, AM ZOOL, V16, P45; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; NASSEL DR, 1991, CELL TISSUE RES, V266, P511, DOI 10.1007/BF00318593; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Pyza E, 1996, J COMP PHYSIOL A, V178, P33, DOI 10.1007/BF00189588; RAO KR, 1993, ANN NY ACAD SCI, V680, P78, DOI 10.1111/j.1749-6632.1993.tb19676.x; SCHNEIDER LE, 1993, NEURON, V10, P279, DOI 10.1016/0896-6273(93)90318-L; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	45	830	837	1	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					791	802		10.1016/S0092-8674(00)81676-1	http://dx.doi.org/10.1016/S0092-8674(00)81676-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619432	Bronze			2022-12-24	WOS:000084488200012
J	Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D				Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D			An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing	CELL			English	Article							MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; POLY(ADP-RIBOSE) POLYMERASE; TELOMERIC HETEROCHROMATIN; ESCHERICHIA-COLI; ADP-RIBOSYLATION; BINDING-PROTEIN; COMPLEX; DNA; TRANSCRIPTION	Despite its conservation in organisms from bacteria to human and its general requirement for transcriptional silencing in yeast, the function of the Sir2 protein is unknown. Here we show that Sir:! can transfer labeled phosphate from nicotinamide adenine dinucleotide to itself and histones in vitro. A modified form of Sir2, which results from its automodification activity, is specifically recognized by anti-mono-ADP-ribose antibodies, suggesting that Sir2 is an ADP-ribosyltransferase. Mutation of a phylogenetically invariant histidine residue in Sir2 abolishes both its enzymatic activity in vitro and its silencing functions in vivo. However, the mutant protein is associated with chromatin and other silencing factors in a manner similar to wild-type Sir2. These findings suggest that Sir2 contains an ADP-ribosyltransferase activity that is essential for its silencing function.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Molekularbiol, D-20246 Hamburg, Germany	Harvard University; Harvard Medical School; University of Hamburg	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BISERCIC M, 1991, J BACTERIOL, V173, P3894; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GOLDERER G, 1991, BIOCHEM J, V277, P607, DOI 10.1042/bj2770607; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Holmes SG, 1997, GENETICS, V145, P605; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KLAR AJS, 1979, GENETICS, V93, P37; KUN E, 1976, P NATL ACAD SCI USA, V73, P3131, DOI 10.1073/pnas.73.9.3131; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; RINE J, 1987, GENETICS, V116, P9; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; SPRAGUE G F JR, 1991, P77; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73	41	330	347	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					735	745		10.1016/S0092-8674(00)81671-2	http://dx.doi.org/10.1016/S0092-8674(00)81671-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619427	Bronze			2022-12-24	WOS:000084488200007
J	Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F				Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F			Atomic scale movement of the voltage-sensing region in a potassium channel measured via spectroscopy	NATURE			English	Article							SHAKER K+ CHANNEL; RESONANCE ENERGY-TRANSFER; SODIUM-CHANNELS; FLUORESCENCE; S4; ACTIVATION; CURRENTS; SEQUENCE; CHELATE	Voltage-gated ion channels are transmembrane proteins that are essential for nerve impulses and regulate ion flow across cell membranes in response to changes in membrane potential. They are made up of four homologous domains or subunits, each of which contains six transmembrane segments(1,2). Studies of potassium channels have shown that the second (S2) and fourth (S4) segments contain several charged residues, which sense changes in voltage and form part of the voltage sensor(3-5). Although these regions clearly undergo conformational changes in response to voltage(6-10), little is known about the nature of these changes because voltage-dependent distance changes have not been measured. Here we use lanthanide-based resonance energy transfer(11,12) to measure distances between Shaker potassium channel subunits at specific residues. Voltage-dependent distance changes of up to 3.2 Angstrom were measured at several sites near the S4 segment. These movements directly correlated with electrical measurements of the voltage sensor, establishing the link between physical changes and electrical charge movement. Measured distance changes suggest that the region associated with the S4 segment undergoes a rotation and possible tilt, rather than a large transmembrane movement, in response to voltage. These results demonstrate the first in situ measurement of atomic scale movement in a transmembrane protein.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Anesthesiol, Sch Med, Los Angeles, CA 90095 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bezanilla, F (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.							Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; BEZANILLA F, IN PRESS PHYSL REV; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen JY, 1999, BIOCONJUGATE CHEM, V10, P311, DOI 10.1021/bc980113w; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURRELL SR, 1992, BIOPHYS J, V62, P238; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Scholz F, 1998, J SOLID STATE ELECTR, V2, P1, DOI 10.1007/s100080050056; SCOH SA, 1996, NEURON, V16, P1159; Selvin PR, 1996, INORG CHEM, V35, P700, DOI 10.1021/ic950840s; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Xiao M, 1998, P NATL ACAD SCI USA, V95, P15309, DOI 10.1073/pnas.95.26.15309; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	25	426	443	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					809	813		10.1038/45552	http://dx.doi.org/10.1038/45552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617201	Bronze			2022-12-24	WOS:000084330500065
J	Parsonnet, J; Shmuely, H; Haggerty, T				Parsonnet, J; Shmuely, H; Haggerty, T			Fecal and oral shedding of Helicobacter pylori from healthy infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNOMAGNETIC SEPARATION; GASTRIC BIOPSY; DENTAL PLAQUE; TRANSMISSION; SALIVA; FECES; PCR; DNA; SPECIMENS; SEQUENCE	Context Helicobacter pylori commonly infects humans; however, its mode of transmission remains unknown. Objective To determine how humans-the primary host for H pylori-shed the organism into the environment. Design Controlled clinical experimental study conducted from February through December 1998. Setting Clinical research unit of a hospital in northern California. Patients Sixteen asymptomatic H pylori-infected and 10 uninfected adults. Intervention A cathartic (sodium phosphate) and an emetic (ipecac) were given to all infected subjects and an emetic was given to 1 uninfected subject. Main Outcome Measure Confirmed H pylori isolates cultured from stool, air, or saliva before and after catharsis and emesis and from vomitus during emesis. Isolates were fingerprinted using repetitive extragenic palindromic (REP) polymerase chain reaction and species identity was confirmed by sequencing the 16s ribosomal RNA gene. Results All vomitus samples from infected subjects grew H pylori, often in high quantities. Air sampled during vomiting grew H pylori from 6 (37.5%) of the 16 subjects. Saliva before and after emesis grew low quantities of H pylori in 3 (18.8%) and 9 (56.3%) subjects, respectively. No normal stools and only 22 (21.8%) of 101 induced stools grew the organism, although 7 (50.0%) of 14 subjects had at least 1 positive culture (2 stool culture samples were contaminated by fungus and were not included). Fingerprints of isolates within subjects were identical to one another but differed among subjects. No samples from uninfected subjects yielded H pylori. Conclusions Helicobacter pylori can be cultivated uniformly from vomitus and, occasionally, from saliva and cathartic stools. The organism is potentially transmissible during episodes of gastrointestinal tract illness, particularly with vomiting.	Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Parsonnet, J (corresponding author), Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, HRP Bldg,Room T225, Stanford, CA 94305 USA.	parsonnt@leland.stanford.edu		Parsonnet, Julie/0000-0001-7342-5366	NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NIDDK NIH HHS [R01 DK053689, R01 DK/CA53689] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053689] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axon ATR, 1996, EUR J GASTROEN HEPAT, V8, P1, DOI 10.1097/00042737-199601000-00001; Black Robert E., 1995, P13; *BOARD DIR AM SOC, 1997, AM HOSP FORM SERV DR; CAUL EO, 1994, LANCET, V343, P1240, DOI 10.1016/S0140-6736(94)92146-6; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P505; ENROTH H, 1995, J CLIN MICROBIOL, V33, P2162, DOI 10.1128/JCM.33.8.2162-2165.1995; FERGUSON DA, 1993, J CLIN MICROBIOL, V31, P2802, DOI 10.1128/JCM.31.10.2802-2804.1993; Figura N, 1996, LANCET, V347, P1342, DOI 10.1016/S0140-6736(96)90996-4; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Georgopoulos SD, 1996, GUT, V39, P634, DOI 10.1136/gut.39.5.634; GO MF, 1995, SCAND J GASTROENTERO, V30, P640, DOI 10.3109/00365529509096306; Grove DI, 1998, PATHOLOGY, V30, P183, DOI 10.1080/00313029800169206; KELLY SM, 1994, GASTROENTEROLOGY, V107, P1671, DOI 10.1016/0016-5085(94)90806-0; KRAJDEN S, 1989, J CLIN MICROBIOL, V27, P1397, DOI 10.1128/JCM.27.6.1397-1398.1989; Lau D, 1998, GASTROENTEROLOGY, V114, pA196, DOI 10.1016/S0016-5085(98)80798-1; Li CF, 1996, DIGEST DIS SCI, V41, P2142, DOI 10.1007/BF02071393; LOFFELD RJLF, 1991, J PATHOL, V165, P69, DOI 10.1002/path.1711650111; LUDWIG W, 1994, FEMS MICROBIOL REV, V15, P155, DOI 10.1111/j.1574-6976.1994.tb00132.x; Luman W, 1996, EUR J GASTROEN HEPAT, V8, P11, DOI 10.1097/00042737-199601000-00004; Madinier IM, 1997, J PERIODONTOL, V68, P2, DOI 10.1902/jop.1997.68.1.2; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, AM J GASTROENTEROL, V87, P1728; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; MEGRAUD F, 1995, ALIMENT PHARM THERAP, V9, P85; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; Parsonnet J, 1998, GUT, V43, pS6, DOI 10.1136/gut.43.2008.S6; PEREZPEREZ GI, 1991, J CLIN MICROBIOL, V29, P642, DOI 10.1128/JCM.29.3.642-644.1991; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; Tauxe Robert V., 1995, P37; Taylor David N., 1995, P551; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; Watanabe T, 1998, SCAND J GASTROENTERO, V33, P1140, DOI 10.1080/00365529850172476; WEISS J, 1994, J CLIN MICROBIOL, V32, P1663, DOI 10.1128/JCM.32.7.1663-1668.1994; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685	38	244	260	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2240	2245		10.1001/jama.282.23.2240	http://dx.doi.org/10.1001/jama.282.23.2240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605976	Bronze			2022-12-24	WOS:000084138600032
J	Schober, M; Schaefer, M; Knoblich, JA				Schober, M; Schaefer, M; Knoblich, JA			Bazooka recruits Inscuteable to orient asymmetric cell divisions in Drosophila neuroblasts	NATURE			English	Article							CAENORHABDITIS-ELEGANS; POLARITY; PROSPERO; PROTEIN; YEAST; NUMB; LOCALIZATION; MECHANISMS; MITOSIS; GENE	Asymmetric cell divisions can be generated by the segregation of determinants into one of the two daughter cells(1-4). In Drosophila, neuroblasts divide asymmetrically along the apical-basal axis shortly after their delamination from the neuroectodermal epithelium. Several proteins, including Numb and Miranda, segregate into the basal daughter cell and are needed for the determination of its correct cell fate(5-10). Both the apical-basal orientation of the mitotic spindle and the localization of Numb and Miranda to the basal cell cortex are directed by Inscuteable, a protein that localizes to the apical cell cortex before and during neuroblast mitosis(11,12). Here we show that the apical localization of Inscuteable requires Bazooka, a protein containing a PDZ domain that is essential for apical-basal polarity in epithelial cells(13,14). Bazooka localizes with Inscuteable in neuroblasts and binds to the Inscuteable localization domain in vitro and in vivo. In embryos lacking both maternal and zygotic bazooka function, Inscuteable no longer localizes asymmetrically in neuroblasts and is instead uniformly distributed in the cytoplasm. Mitotic spindles in neuroblasts are misoriented in these embryos, and the proteins Numb and Miranda fail to localize asymmetrically in metaphase. Our results suggest that direct binding to Bazooka mediates the asymmetric localization of Inscuteable and connects the asymmetric division of neuroblasts to the axis of epithelial apical-basal polarity.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Knoblich, JA (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Matthias, Schaefer Ronald/E-9157-2015; Knoblich, Juergen A/C-2974-2015	Matthias, Schaefer Ronald/0000-0003-1952-8115; Knoblich, Juergen A/0000-0002-6751-3404				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; McKim KS, 1996, GENETICS, V144, P215; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; WADDLE JA, 1994, DEVELOPMENT, V120, P2317	25	297	301	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					548	551		10.1038/990135	http://dx.doi.org/10.1038/990135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591217				2022-12-24	WOS:000084013200061
J	Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V				Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V			Purification and cloning of amyloid precursor protein beta-secretase from human brain	NATURE			English	Article							ALZHEIMERS-DISEASE; INHIBITOR; MUTATION; TERMINUS	Proteolytic processing of the amyloid precursor protein (APP) generates amyloid beta (A beta) peptide, which is thought to be causal for the pathology and subsequent cognitive decline in Alzheimer's disease. Cleavage by beta-secretase at the amino terminus of the A beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP(1), and a corresponding cell-associated carboxy-terminal fragment. Cleavage of the C-terminal fragment by gamma-secretase(s) leads to the formation of A beta. The pathogenic mutation K670M671 --> N670L671 at the beta-secretase cleavage site in APP(2), which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased beta-secretase cleavage of the mutant substrate(3). Here we describe a membrane-bound enzyme activity that cleaves full-length APP at the beta-secretase cleavage site, and find it to be the predominant beta-cleavage activity in human brain. We have purified this enzyme activity to homogeneity from human brain using a new substrate analogue inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for beta-secretase. Cloning and expression of the enzyme reveals that human brain beta-secretase is a new membrane-bound aspartic proteinase.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Sinha, S (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KNOPS J, 1991, J BIOL CHEM, V266, P7285; Lin J H, 1998, Pharm Biotechnol, V11, P233; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Narutaki S, 1999, J BIOCHEM, V125, P75, DOI 10.1093/oxfordjournals.jbchem.a022271; Rich D. H., 1986, PROTEINASE INHIBITOR; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; VALDES F, 1977, BRAIN RES, V122, P95, DOI 10.1016/0006-8993(77)90665-5; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	12	1413	1554	0	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					537	540		10.1038/990114	http://dx.doi.org/10.1038/990114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591214				2022-12-24	WOS:000084013200058
J	Henney, JE				Henney, JE			Complications related to vascular hemostasis devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-24	WOS:000083908700004
J	Matsumoto, I; Staub, A; Benoist, C; Mathis, D				Matsumoto, I; Staub, A; Benoist, C; Mathis, D			Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme	SCIENCE			English	Article							RHEUMATOID-ARTHRITIS; AUTOIMMUNITY; COLLAGEN; MODEL	The hallmark of rheumatoid arthritis (RA) is specific destruction of the synovial joints. In a mouse line that spontaneously develops a disorder with many of the features of human RA, disease is initiated by T cell recognition of a ubiquitously expressed self-antigen; once initiated, pathology is driven almost entirely by immunoglobulins. In this study, the target of both the initiating T cells and pathogenic immunoglobulins was identified as glucose-6-phosphate isomerase, a glycolytic enzyme, Thus, some forms of RA or related arthritides may develop by a mechanism fundamentally different from the currently popular paradigm of a joint-specific T cell response.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Benoist, C (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.							Amigorena S, 1998, CURR OPIN IMMUNOL, V10, P88, DOI 10.1016/S0952-7915(98)80037-X; Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; HALLBOOK F, 1989, J NEUROSCI RES, V23, P142, DOI 10.1002/jnr.490230204; Kalden JR, 1998, ARTHRITIS RHEUM, V41, P191, DOI 10.1002/1529-0131(199802)41:2<191::AID-ART2>3.3.CO;2-3; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; MANGIALAIO S, IN PRESS ARTHRITIS R; MATSUMOTO I, UNPUB; NAPORSTECK Y, 1993, ANNU REV IMMUNOL, V11, P79; NERI B, 1983, ONCOLOGY, V40, P332, DOI 10.1159/000225756; OHNO O, 1978, ARTHRITIS RHEUM, V21, P516, DOI 10.1002/art.1780210505; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; Thomas R, 1996, ARTHRITIS RHEUM, V39, P183, DOI 10.1002/art.1780390202; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WARNER CM, 1985, GERONTOLOGY, V31, P315, DOI 10.1159/000212715; WEST JD, 1990, GENET RES, V56, P223, DOI 10.1017/S0016672300035321; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	20	462	488	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1732	1735		10.1126/science.286.5445.1732	http://dx.doi.org/10.1126/science.286.5445.1732			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576739				2022-12-24	WOS:000083912200037
J	Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J				Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J			Subtle chromosomal rearrangements in children with unexplained mental retardation	LANCET			English	Article							WOLF-HIRSCHHORN-SYNDROME; FRAGILE-X-SYNDROME; MOLECULAR CHARACTERIZATION; TRANSLOCATION; HYBRIDIZATION; RECURRENCE; TELOMERES; DELETIONS; ETIOLOGY; BORN	Background No explanation for moderate to severe mental retardation is apparent in about 40% of cases. Although small chromosomal rearrangements may account for some undiagnosed cases, a lack of genome-wide screening methods has made it impossible to ascertain the frequency of such abnormalities. Methods A fluorescence in-situ hybridisation (FISH) test was used to examine the integrity of chromosome ends in 284 children with unexplained moderate to severe retardation, and in 182 children with unexplained mild retardation. 75 normal men were also tested. When a chromosomal rearrangement was found, its size was estimated, and members of the child's family were investigated. Findings Subtle chromosomal abnormalities occurred with a frequency of 7.4% in the children with moderate to severe mental retardation, and of 0.5% in the children with mild retardation. The abnormalities had an estimated population prevalence of 2.1 per 10000, and were familial in almost half of cases. Interpretation Once recognisable syndromes have been excluded, abnormalities that include the ends of chromosomes are the commonest cause of mental retardation in children with undiagnosed moderate to severe mental retardation. Owing to the high prevalence of familial cases, screening for subtle chromosomal rearrangements is warranted in children with unexplained moderate to severe mental retardation.	John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England; Univ London, Inst Child Hlth, Mothercare Unit Paediat Genet & Fetal Med, London WC1N 1EH, England; Univ Cambridge, Dept Psychiat, Dev Psychiat Sect, Cambridge, England; Univ London St Georges Hosp, Dept Genet, London, England	University of Oxford; University of London; University College London; University of Cambridge; St Georges University London	Flint, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England.			Flint, Jonathan/0000-0002-9427-4429; Knight, Samantha/0000-0002-6047-3462	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTHERR MR, 1991, AM J HUM GENET, V49, P1235; Altherr MR, 1997, AM J MED GENET, V71, P47, DOI 10.1002/(SICI)1096-8628(19970711)71:1<47::AID-AJMG9>3.0.CO;2-N; Birch HG, 1970, MENTAL SUBNORMALITY; Broman S., 1987, RETARDATION YOUNG CH; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; BUNDEY S, 1989, J MED GENET, V26, P260, DOI 10.1136/jmg.26.4.260; CASSIMAN JJ, 1975, HUMANGENETIK, V28, P43, DOI 10.1007/BF00272481; CURTIS A, 1991, AM J HUM GENET, V49, P299; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EINFELD SL, 1984, J MENT DEFIC RES, V28, P129; ELWOOD JH, 1981, J MENT DEFIC RES, V25, P147; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Giraudeau F, 1997, J MED GENET, V34, P314, DOI 10.1136/jmg.34.4.314; GOODSHIP J, 1992, J MED GENET, V29, P451; GRAHAM SM, 1993, J PAEDIATR CHILD H, V29, P360, DOI 10.1111/j.1440-1754.1993.tb00535.x; GRIPENBERG U, 1980, HEREDITAS, V92, P223; GUSTAVSON KH, 1977, NEUROPADIATRIE, V8, P293, DOI 10.1055/s-0028-1091525; JACOBS PA, 1993, J MED GENET, V30, P454, DOI 10.1136/jmg.30.6.454; JACOBS PA, 1978, CLIN GENET, V13, P37; Knight SJL, 1997, EUR J HUM GENET, V5, P1; LAMB J, 1989, LANCET, V2, P819; LAMONT MA, 1988, ARCH DIS CHILD, V63, P1032, DOI 10.1136/adc.63.9.1032; Law CJ, 1998, J MED GENET, V35, P685, DOI 10.1136/jmg.35.8.685; LAXOVA R, 1977, AM J MED GENET, V1, P75, DOI 10.1002/ajmg.1320010109; MCDONALD AD, 1973, AM J MENT DEF, V78, P205; Morton JE, 1997, J MED GENET, V34, P1, DOI 10.1136/jmg.34.1.1; Moser HW, 1971, NERVOUS SYSTEM, P117; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; Ning Y, 1996, NAT GENET, V14, P86, DOI 10.1038/ng0996-86; Opitz J M, 1978, Birth Defects Orig Artic Ser, V14, P1; Rosenberg M, 1997, GENOME RES, V7, P917, DOI 10.1101/gr.7.9.917; Rutter M., 1970, ED HLTH BEHAV; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SLANEY SF, 1995, ARCH DIS CHILD, V72, P33, DOI 10.1136/adc.72.1.33; Strathdee G, 1997, AM J HUM GENET, V60, P860; SUTHERLAND GR, 1976, HUM GENET, V36, P231	36	354	417	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1676	1681		10.1016/S0140-6736(99)03070-6	http://dx.doi.org/10.1016/S0140-6736(99)03070-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568569				2022-12-24	WOS:000083652800010
J	Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S				Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S			Evidence for autoregulation of cystathionine gamma-synthase mRNA stability in Arabidopsis	SCIENCE			English	Article							STORAGE PROTEIN GENE; METHIONINE BIOSYNTHESIS; THALIANA MUTANT; MOSAIC-VIRUS; GUS FUSIONS; EXPRESSION; PLANTS; MULTIPLICATION; PROTOPLASTS; PROMOTER	Control of messenger RNA (mRNA) stability serves as an important mechanism, for regulating gene expression. Analysis of Arabidopsis mutants that overaccumulate soluble methionine (Met) revealed that the gene for cystathionine gamma-synthase (CCS), the key enzyme in Met biosynthesis, is regulated at the Level of mRNA stability, Transfection experiments with wild-type and mutant forms of the CCS gene suggest that an amino acid sequence encoded by the first exon of CCS acts in cis to destabilize its own mRNA in a process that is activated by Met or one of its metabolites.	Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan; AFRC, Inst Arable Crops Res, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England; Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA	Hokkaido University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Rutgers State University New Brunswick	Naito, S (corresponding author), Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	naito@abs.agr.hokudai.ac.jp	Chiba, Yukako/AAA-9238-2019; Chiba, Yukako/B-7057-2009; Nambara, Eiji/E-5533-2012	Chiba, Yukako/0000-0002-7329-2775				ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHIBA Y, UNPUB; DATKO AH, 1978, PLANT PHYSIOL, V62, P629, DOI 10.1104/pp.62.4.629; FUJIWARA T, 1991, PLANT CELL REP, V9, P602, DOI 10.1007/BF00231797; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; GUZMAN P, 1988, NUCLEIC ACIDS RES, V16, P11091, DOI 10.1093/nar/16.23.11091; HIRAI MY, 1994, PLANT CELL PHYSIOL, V35, P927; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; ISHIKAWA M, 1993, J VIROL, V67, P5328, DOI 10.1128/JVI.67.9.5328-5338.1993; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kim J., 1999, Plant Physiology, V120, P635; Kim JS, 1996, PLANT MOL BIOL, V32, P1117, DOI 10.1007/BF00041395; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; Matthews BF, 1999, BOOK SOIL P, P205; NAITO S, 1994, PLANT PHYSIOL, V104, P497, DOI 10.1104/pp.104.2.497; NEWMAN TC, 1993, PLANT CELL, V5, P701, DOI 10.1105/tpc.5.6.701; Ravanel S, 1998, BIOCHEM J, V331, P639, DOI 10.1042/bj3310639; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Rogers EE, 1997, PLANT CELL, V9, P305, DOI 10.1105/tpc.9.3.305; ROGNES SE, 1986, PLANT SCI, V43, P45, DOI 10.1016/0168-9452(86)90106-8; Rose AB, 1997, PLANT J, V11, P455, DOI 10.1046/j.1365-313X.1997.11030455.x; SAKATA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P2104, DOI 10.1271/bbb.58.2104; Sambrook JFE, 1989, MOL CLONING LAB MANU; THOMPSON GA, 1982, PLANT PHYSIOL, V69, P1077, DOI 10.1104/pp.69.5.1077; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLSGROVE RM, 1983, PLANT PHYSIOL, V71, P780, DOI 10.1104/pp.71.4.780; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Yoshii M, 1998, J VIROL, V72, P8731, DOI 10.1128/JVI.72.11.8731-8737.1998	31	145	156	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1371	1374		10.1126/science.286.5443.1371	http://dx.doi.org/10.1126/science.286.5443.1371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558994				2022-12-24	WOS:000083675500046
J	Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD				Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD			Novel functions of nanos in downregulating mitosis and transcription during the development of the Drosophila germline	CELL			English	Article							POSTERIOR MORPHOGEN NANOS; SYNCYTIAL EMBRYOS; SEX DETERMINATION; CELL-DEVELOPMENT; GENE-EXPRESSION; BODY PATTERN; OSKAR; POLE; MIGRATION; RNA	It has previously been shown that germ cells in embryos derived from nos mutant mothers do not migrate to the primitive gonad and prematurely express several germline-specific markers. In the studies reported here, we have traced these defects back to the syncytial blastoderm stage. We show that pole cells in nos(-) embryos fail to establish/maintain transcriptional quiescence; the sex determination gene Sex-lethal (Sxl) and the segmentation genes fushi tarazu and even-skipped are ectopically activated in nos- germ cells. We show that nos- germ cells are unable to attenuate the cell cycle and instead continue dividing. Unexpectedly, removal of the Sxl gene in the zygote mitigates both the migration and mitotic defects of nos(-) germ cells. Supporting the conclusion that Sri is an important target for nos repression, ectopic, premature expression of Sxl protein in germ cells disrupts migration and stimulates mitotic activity.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Deshpande, G (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Yanowitz, Judith L/AGJ-8504-2022	Yanowitz, Judith L/0000-0001-6886-8787				Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CHOU TB, 1992, GENETICS, V131, P643; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAHMUS ME, 1996, J BIOL CHEM, V265, P19185; DALBY B, 1992, DEVELOPMENT, V115, P989; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FOE VE, 1983, J CELL SCI, V61, P31; Forbes A, 1998, DEVELOPMENT, V125, P679; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, CELL, V18, P577; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILMENSEE K, 1976, DEV BIOL, V49, P40; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; Su TT, 1998, DEV BIOL, V196, P160, DOI 10.1006/dbio.1998.8855; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Van Doren M, 1998, CURR BIOL, V8, P243; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; Wei Y, 1998, TRENDS CELL BIOL, V8, P266; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	37	123	130	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					271	281		10.1016/S0092-8674(00)81658-X	http://dx.doi.org/10.1016/S0092-8674(00)81658-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555143	Bronze			2022-12-24	WOS:000083440600005
J	Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH				Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH			The disease burden associated with overweight and obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	North-American-Association-for-the-Study-of-Obesity Meeting	NOV 10, 1997	CANCUN, MEXICO	N Amer Assoc Study Obesity			BODY-MASS INDEX; CORONARY HEART-DISEASE; FAT DISTRIBUTION; WOMEN; MORTALITY; RISK; PREVALENCE; WEIGHT; POPULATION; PREDICTORS	Context Overweight and obesity are increasing dramatically in the United States and most likely contribute substantially to the burden of chronic health conditions. Objective To describe the relationship between weight status and prevalence of health conditions by severity of overweight and obesity in the US population. Design and Setting Nationally representative cross-sectional survey using data from the Third National Health and Nutrition Examination Survey (NHANES III), which was conducted in 2 phases from 1988 to 1994. Participants A total of 16 884 adults, 25 years and older, classified as overweight and obese (body mass index [BMI] greater than or equal to 25 kg/m(2)) based on National Institutes of Health recommended guidelines. Main Outcome Measures Prevalence of type 2 diabetes mellitus, gallbladder disease, coronary heart disease, high blood cholesterol level, high blood pressure, or osteoarthritis, Results Sixty-three percent of men and 55% of women had a body mass index of 25 kg/m(2) or greater. A graded increase in the prevalence ratio (PR) was observed with increasing severity of overweight and obesity for all of the health outcomes except for coronary heart disease in men and high blood cholesterol level in both men and women. With normal-weight individuals as the reference, for individuals with BMIs of at least 40 kg/m(2) and who were younger than 55 years, PRs were highest for type 2 diabetes for men (PR, 18.1; 95% confidence interval [CI], 6.7-46.8) and women (PR, 12.9; 95% CI, 5.7-28.1) and gallbladder disease for men (PR, 21.1; 95% CI, 4.1-84.2) and women (PR, 5.2; 95% CI, 2.9-8.9). Prevalence ratios generally were greater in younger than in older adults. The prevalence of having 2 or more health conditions increased with weight status category across all racial and ethnic subgroups. Conclusions Based on these results, more than half of all US adults are considered overweight or obese. The prevalence of obesity-related comorbidities emphasizes the need for concerted efforts to prevent and treat obesity rather than just its associated comorbidities.	Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA; Tufts Univ, USDA, Human Nutr Res Ctr, Medford, MA 02155 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Tufts Univ New England Med Ctr, Dept Pediat Gastroenterol & Nutr, Boston, MA USA; Ctr Dis Control & Prevent, Ctr Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA USA	Tufts University; Tufts University; United States Department of Agriculture (USDA); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Tufts Medical Center; Centers for Disease Control & Prevention - USA	Must, A (corresponding author), Tufts Univ, Sch Med, Dept Family Med & Community Hlth, 136 Harrison Ave, Boston, MA 02111 USA.	amust@hnrc.tufts.edu	Colditz, Graham/A-3963-2009; Field, Alison/AAA-4508-2021; Kohn, Geoffrey P/A-9056-2009	Colditz, Graham/0000-0002-7307-0291; 				ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; [Anonymous], 1994, VITAL HLTH STAT, V1, P1, DOI DOI 10.1136/BMJ.L42; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; BURTON BT, 1985, INT J OBESITY, V9, P155; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Drewnowski A, 1997, NUTR REV, V55, P31, DOI 10.1111/j.1753-4887.1997.tb01593.x; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; FORBES GB, 1970, METABOLIS, V19, P653, DOI 10.1016/0026-0495(70)90062-4; HANSEN RG, 1995, J IND ECON, V43, P261, DOI 10.2307/2950579; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEE J, 1984, AM J PUBLIC HEALTH, V74, P376, DOI 10.2105/AJPH.74.4.376; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G, 1982, CARDIOVASCULAR SURVE; SAVAGE P J, 1991, Ethnicity and Disease, V1, P200; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Shah BV, 1997, SOFTWARE STAT ANAL C; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; Sundquist J, 1999, AM J PUBLIC HEALTH, V89, P723, DOI 10.2105/AJPH.89.5.723; *US DEP HHS, 1996, LAB PROD US NHANES, V3; *USDA, 1995, HOM GARD B, V232; WHO, 1997, OBESITY PREVENTING M; *WHO MONICA PROJ, 1989, INT J EPIDEMIOL S1, V18, pS46; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Winkleby MA, 1999, JAMA-J AM MED ASSOC, V281, P1006, DOI 10.1001/jama.281.11.1006; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZILLIKENS MC, 1990, AM J CLIN NUTR, V52, P45, DOI 10.1093/ajcn/52.1.45; [No title captured]	39	3209	3307	10	380	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1523	1529		10.1001/jama.282.16.1523	http://dx.doi.org/10.1001/jama.282.16.1523			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	248MB	10546691				2022-12-24	WOS:000083277800019
J	Firth-Cozens, J; Midgley, SJ; Burges, C				Firth-Cozens, J; Midgley, SJ; Burges, C			Questionnaire survey of post-traumatic stress disorder in doctors involved in the Omagh bombing	BRITISH MEDICAL JOURNAL			English	Article									Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Erne Hosp, Sperrin Lake Hlth & Social Care Trust, Enniskillen, North Ireland	Northumbria University	Firth-Cozens, J (corresponding author), Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England.							Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Bamber M, 1994, Nurs Times, V90, P32; FIRTHCOZENS J, 1995, YORKSHIRE MED, V7, P10; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353	5	35	35	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1609	1609		10.1136/bmj.319.7225.1609	http://dx.doi.org/10.1136/bmj.319.7225.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600958	Bronze, Green Published			2022-12-24	WOS:000084562600012
J	Diede, SJ; Gottschling, DE				Diede, SJ; Gottschling, DE			Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta	CELL			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; SINGLE-STRANDED-DNA; LENGTH REGULATION; BINDING PROTEIN; REPLICATION FORK; GENE DISRUPTION; YEAST KU; ATAXIA-TELANGIECTASIA; REVERSE-TRANSCRIPTASE; EST GENES	To better understand the requirements for telomerase-mediated telomere addition in vivo, we developed an assay in S. cerevisiae that creates a chromosome end immediately adjacent to a short telomeric DNA tract. The de novo end acts as a telomere: it is protected from degradation in a CDC13-dependent manner, telomeric sequences are added efficiently, and addition occurs at a faster rate in mutant strains that have long telomeres. Telomere addition was detected in M phase arrested cells, which permitted us to determine that the essential DNA polymerases alpha and delta and DNA primase were required. This indicates that telomeric DNA synthesis by telomerase is tightly coregulated with the production of the opposite strand. Such coordination prevents telomerase from generating excessively long single-stranded tails, which may be deleterious to chromosome stability in S. cerevisiae.	Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Fred Hutchinson Cancer Center; University of Chicago	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA.		Diede, Scott/G-2288-2012	Diede, Scott/0000-0001-5422-549X	NIGMS NIH HHS [GM43893, GM07281] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AK, 1996, MOL CELL BIOL, V16, P4614; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Brachmann CB, 1998, YEAST, V14, P115; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHATTOO BB, 1979, GENETICS, V93, P51; CONRAD MN, 1983, MOL CELL BIOL, V3, P1000, DOI 10.1128/MCB.3.6.1000; Dionne I, 1998, NUCLEIC ACIDS RES, V26, P5365, DOI 10.1093/nar/26.23.5365; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; Formosa T, 1999, GENETICS, V151, P1459; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARTWELL LH, 1985, GENETICS, V110, P381; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1991, P132; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Maniatis T., 1982, MOL CLONING LAB MANU; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Marcand S, 1997, CIBA F SYMP, V211, P76; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Price CM, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1216; Ray A, 1999, MOL CELL BIOL, V19, P31; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	85	313	317	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					723	733		10.1016/S0092-8674(00)81670-0	http://dx.doi.org/10.1016/S0092-8674(00)81670-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619426	Bronze			2022-12-24	WOS:000084488200006
J	Cogoni, C; Macino, G				Cogoni, C; Macino, G			Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase	SCIENCE			English	Article							TRANSGENIC PLANTS; BLOOMS-SYNDROME; TOPOISOMERASE; RNA; SUPPRESSION; SENSITIVITY; INDUCTION; CRASSA	The phenomenon of posttranscriptional gene silencing (PTGS), which occurs when a transgene is introduced into a cell, is poorly understood. Here, the qde-3 gene, which is required for the activation and maintenance of gene silencing in the fungus Neurospora crassa, was isolated. Sequence analysis revealed that the qde-3 gene belongs to the RecQ DNA helicase family. The QDE3 protein may function in the DNA-DNA interaction between introduced transgenes or with an endogenous gene required for gene-silencing activation. In animals, genes that are homologous to RecQ protein, such as the human genes for Bloom's syndrome and Werner's syndrome, may also function in PTGS.	Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy	Sapienza University Rome	Cogoni, C (corresponding author), Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Viale Regina Elena 324, I-00161 Rome, Italy.							Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Duguet M, 1997, J CELL SCI, V110, P1345; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; INOUE H, 1981, MUTAT RES, V80, P27, DOI 10.1016/0027-5107(81)90175-5; ISHII C, 1991, MOL GEN GENET, V228, P33, DOI 10.1007/BF00282444; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Matzke MA, 1998, CELL MOL LIFE SCI, V54, P94, DOI 10.1007/s000180050128; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; PICKFORD A, UNPUB; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; YU EE, 1996, SCIENCE, V272, P258	25	203	244	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2342	2344		10.1126/science.286.5448.2342	http://dx.doi.org/10.1126/science.286.5448.2342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600745				2022-12-24	WOS:000084318500062
J	Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A				Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A			Cognitive modularity and genetic disorders	SCIENCE			English	Article							INFANT; NEUROPSYCHOLOGY	This study challenges the use of adult neuropsychological models for explaining developmental disorders of genetic origin. When uneven cognitive profiles are found in childhood or adulthood, it is assumed that such phenotypic outcomes characterize infant starting states, and it has been claimed that modules subserving these abilities start out either intact or impaired. Findings from two experiments with infants with Williams syndrome (a phenotype selected to bolster innate modularity claims) indicate a within-syndrome double dissociation: For numerosity judgments, they do well in infancy but poorly in adulthood, whereas for Language, they perform poorly in infancy but well in adulthood. The theoretical and clinical implications of these results could Lead to a shift in focus for studies of genetic disorders.	UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England; Univ London Univ Coll, Dept Psychol, London WC1E 6BT, England; Birkbeck Coll, Ctr Brain & Cognit Dev, London WC1E 7JL, England	University of London; University College London; University of London; University College London; University of London; Birkbeck University London	Karmiloff-Smith, A (corresponding author), UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England.	a.karmiloff-smith@ich.ucl.ac.uk	Karmiloff-Smith, Annette/N-4535-2014	Karmiloff-Smith, Annette/0000-0002-2470-5609; Johnson, Mark/0000-0003-4229-2585				BARONCOHEN S, 1998, HDB MENTAL RETARDATI, P335; Bayley N., 1993, BAYLEY SCALES INFANT; Bellugi U., 1994, ATYPICAL COGNITIVE D, P23; Bishop DVM, 1997, Q J EXP PSYCHOL-A, V50, P899, DOI 10.1080/027249897391946; Clearfield MW, 1999, PSYCHOL SCI, V10, P408, DOI 10.1111/1467-9280.00177; Elman JL, 1996, RETHINKING INNATENES; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GOLINKOFF RM, 1987, J CHILD LANG, V14, P23, DOI 10.1017/S030500090001271X; HAAF RA, 1989, INFANT BEHAV DEV, V12, P211, DOI 10.1016/0163-6383(89)90007-6; Karmiloff-Smith A, 1998, TRENDS COGN SCI, V2, P389, DOI 10.1016/S1364-6613(98)01230-3; KINNEAR PR, 1999, SPSS WINDOWS MADE SI, P98; Leslie A.M., 1992, CURRENT DIRECTIONS P, V1, P18, DOI DOI 10.1111/1467-8721; ONEILL JM, 1994, INFANT BEHAV DEV, V17, P465, DOI 10.1016/0163-6383(94)90039-6; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Schafer G, 1998, CHILD DEV, V69, P309, DOI 10.2307/1132166; Singh Gurinder, 2014, J MENT HEALTH, V22, P522, DOI [10.3109/10717544.2014.885616, DOI 10.3109/09638237.2014.954693, 10.3109/08039481003777484]; STARKEY P, 1990, COGNITION, V36, P97, DOI 10.1016/0010-0277(90)90001-Z; STRAUSS MS, 1981, CHILD DEV, V52, P1146, DOI 10.2307/1129500; Tassabehji M, 1999, AM J HUM GENET, V64, P118, DOI 10.1086/302214; Temple CM, 1997, J CHILD PSYCHOL PSYC, V38, P27, DOI 10.1111/j.1469-7610.1997.tb01504.x	21	187	188	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2355	2358		10.1126/science.286.5448.2355	http://dx.doi.org/10.1126/science.286.5448.2355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	266UK	10600749				2022-12-24	WOS:000084318500066
J	Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA				Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA			CNS myelin and Sertoli cell tight junction strands are absent in Osp/Claudin-11 null mice	CELL			English	Article							OLIGODENDROCYTE-SPECIFIC PROTEIN; ZONULA OCCLUDENS; NERVOUS-SYSTEM; EXPRESSION; GENE; BARRIER; TESTIS; PERMEABILITY; ARCHITECTURE; MUTATION	Oligodendrocyte-specific protein (OSP)/claudin-11 is a recently identified transmembrane protein found in CNS myelin and testis with unknown function. Herein we demonstrate that Osp null mice exhibit both neurological and reproductive deficits: CNS nerve conduction is slowed, hindlimb weakness is conspicuous, and males are sterile. Freeze fracture reveals that tight junction intramembranous strands are absent in CNS myelin and between Sertoli cells of mutant mice. Our results demonstrate that OSP is the mediator of parallel-array tight junction strands and distinguishes this protein from other intrinsic membrane proteins in tight junctions. These novel results provide direct evidence of the pivotal role of the claudin family in generating the paracellular physical barrier of tight junctions necessary for spermatogenesis and normal CNS function.	CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Dept Ophthalmol, New York, NY 10029 USA; NICHHD, Sect Struct Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lazzarini, RA (corresponding author), CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.			gow, alexander/0000-0001-7446-8990	NATIONAL EYE INSTITUTE [K08EY000390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033165, K08NS001596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000002, ZIADC000002] Funding Source: NIH RePORTER; NEI NIH HHS [1K08 EY 00390-01A1] Funding Source: Medline; NINDS NIH HHS [NS01596, NS33165] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUMULLER G, 1986, INT J ANDROL, V9, P99, DOI 10.1111/j.1365-2605.1986.tb00872.x; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BLAKEMORE WF, 1969, J ULTRA MOL STRUCT R, V29, P496, DOI 10.1016/S0022-5320(69)90069-0; Bronstein JM, 1996, NEUROLOGY, V47, P772, DOI 10.1212/WNL.47.3.772; Bronstein JM, 1997, J NEUROSCI RES, V50, P713, DOI 10.1002/(SICI)1097-4547(19971201)50:5<713::AID-JNR8>3.3.CO;2-Q; Dym M, 1970, Biology Reprod., V3, P308; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FANNON AM, 1995, J CELL BIOL, V129, P189, DOI 10.1083/jcb.129.1.189; FRIEDRICH VL, 1981, HDB NEUROANATOMICAL, P345; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; GILULA NB, 1976, DEV BIOL, V50, P142, DOI 10.1016/0012-1606(76)90074-9; Gondre M, 1998, J CELL BIOL, V141, P493, DOI 10.1083/jcb.141.2.493; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Gow A, 1998, J CELL BIOL, V140, P925, DOI 10.1083/jcb.140.4.925; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRIFFITHS IR, 1995, NEUROPATH APPL NEURO, V21, P97, DOI 10.1111/j.1365-2990.1995.tb01035.x; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HILDEBRAND C, 1971, ACTA PHYSIOL SCAND, P43; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Mori Seiji, 1998, American Journal of Physiology, V274, pC1708; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; MUGNAINI E, 1974, NATURE, V251, P725, DOI 10.1038/251725a0; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; PLYMATE S, 1994, ENDOCRIN METAB CLIN, V23, P749, DOI 10.1016/S0889-8529(18)30065-3; Ruio-Hortega, 1928, MEM REL SOC ESPAN HI, V14, P5; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Scherer SS, 1995, J NEUROSCI, V15, P8281; SCHNAPP B, 1978, PHYSL PATHOBIOLOGY A, P83; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STRAIN GM, 1993, BRAIN RES BULL, V32, P57, DOI 10.1016/0361-9230(93)90319-7; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; TABIRA T, 1978, J NEUROCYTOL, V7, P489, DOI 10.1007/BF01173993; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; YULE TD, 1990, J REPROD IMMUNOL, V18, P89, DOI 10.1016/0165-0378(90)90026-3	47	551	561	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					649	659		10.1016/S0092-8674(00)81553-6	http://dx.doi.org/10.1016/S0092-8674(00)81553-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612400	Bronze			2022-12-24	WOS:000084278700011
J	Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A				Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A			Systemic amyloidosis presenting with angina pectoris	ANNALS OF INTERNAL MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; CARDIAC AMYLOIDOSIS; CHEST PAIN; CORONARY; ARTERIES	Background: Manifestations of cardiac amyloidosis may include congestive heart failure and sudden cardiac death. Although vascular involvement in patients with amyloidosis is common, systemic amyloidosis presenting with angina is rare. Objectives: To report on patients with systemic amyloidosis presenting with angina pectoris. Design: Case series. Setting: Academic medical center. Patients: Five patients who presented with angina pectoris and normal coronary angiogram as the initial manifestation of systemic amyloidosis. Measurements: Endothelial-dependent and endothelialin-dependent coronary flow reserve. Results: All patients had coronary flow reserve abnormalities and subsequently developed congestive heart failure and systemic manifestations of amyloidosis. Histologic evaluation revealed amyloid deposition in the intramyocardial coronary vessels. Conclusions: Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormalities despite normal coronary angiograms. This finding may have major therapeutic and prognostic implications in this patient population.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA; NHLBI, NIH, Cardiol Branch, Bethesda, MD 20892 USA	Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lerman.amir@mayo.edu	Gertz, Morie/K-2873-2019	al suwaidi, MB, ChB, FACC, FESC, FSCAI, jassim/0000-0002-5299-9106				BRANDT K, 1968, AM J MED, V44, P955, DOI 10.1016/0002-9343(68)90095-8; BUJA LM, 1970, AM J CARDIOL, V26, P394, DOI 10.1016/0002-9149(70)90736-8; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CROTTY TB, 1994, CARDIOVASC PATHOL, V5, P39; CUETOGARCIA L, 1985, AM J CARDIOL, V55, P606, DOI 10.1016/0002-9149(85)90268-1; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; Hasdai D, 1998, MAYO CLIN PROC, V73, P1133, DOI 10.4065/73.12.1133; Hasdai D, 1997, CIRCULATION, V96, P3390; LICHTLEN PR, 1995, J AM COLL CARDIOL, V25, P1013, DOI 10.1016/0735-1097(94)00519-V; NARANG R, 1993, CARDIOLOGY, V82, P294, DOI 10.1159/000175878; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SAFFITZ JE, 1983, AM J CARDIOL, V51, P1234, DOI 10.1016/0002-9149(83)90379-X; Schafer S, 1996, CIRCULATION, V94, P3376, DOI 10.1161/01.CIR.94.12.3376; SMITH RRL, 1979, AM J CARDIOL, V44, P413, DOI 10.1016/0002-9149(79)90389-8; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; THIBAULT GE, 1992, NEW ENGL J MED, V327, P714, DOI 10.1056/NEJM199209033271008; WRIGHT JR, 1981, MEDICINE, V60, P429, DOI 10.1097/00005792-198111000-00004	18	55	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					838	841		10.7326/0003-4819-131-11-199912070-00007	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610629				2022-12-24	WOS:000084053200006
J	Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A				Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A			Organogenic role of B lymphocytes in mucosal immunity	SCIENCE			English	Article							MAMMARY-TUMOR VIRUS; SCANNING ELECTRON-MICROSCOPY; PEYERS PATCH LYMPHOCYTES; CELL-DEFICIENT MICE; T-CELLS; NECROSIS-FACTOR; LECTIN-BINDING; CD40 LIGAND; MOUSE; INFECTION	Follicle-associated epithelium (FAE) in the intestinal Peyer's patches contains M cells that deliver pathogens to organized Lymphoid tissue. Development of Peyer's patches, FAE, and M cells was found to be impaired in mice that had no B cells. Transgenic expression of membrane-bound immunoglobulin M restored B cells and FAE development. The Lack of M cells abrogated infection with a milk-borne retrovirus. Thus, in addition to secretion of antibodies and presentation of antigens, B cells are important for organogenesis of the mucosal immune barriers.	Jackson Lab, Bar Harbor, ME 04609 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA	Jackson Laboratory; Yale University; Yale University	Chervonsky, A (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959; Chervonsky, Alexander/0000-0001-7547-871X	NATIONAL CANCER INSTITUTE [P30CA034196, R29CA065795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053561] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196, CA65795] Funding Source: Medline; NIDDK NIH HHS [DK53561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; BEUTNER U, 1994, J EXP MED, V179, P1457, DOI 10.1084/jem.179.5.1457; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; Buggiano V, 1999, SCAND J IMMUNOL, V49, P269; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHERVONSKY A, UNPUB; CHERVONSKY AV, 1995, IMMUNITY, V3, P139, DOI 10.1016/1074-7613(95)90166-3; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CLARK MA, 1993, J HISTOCHEM CYTOCHEM, V41, P1679, DOI 10.1177/41.11.7691933; Culkin SJ, 1997, J IMMUNOL, V158, P3277; Debard N, 1999, SEMIN IMMUNOL, V11, P183, DOI 10.1006/smim.1999.0174; Fu YX, 1998, J EXP MED, V187, P1009, DOI 10.1084/jem.187.7.1009; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KARAPETIAN O, 1994, J EXP MED, V180, P1511, DOI 10.1084/jem.180.4.1511; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LIN RH, 1991, J EXP MED, V173, P1433, DOI 10.1084/jem.173.6.1433; MALICK LE, 1975, STAIN TECHNOL, V50, P265, DOI 10.3109/10520297509117069; MALICK LE, 1975, SCANNING ELECT MICRO, P256; Marcotte H, 1996, J INFECT DIS, V173, P1034, DOI 10.1093/infdis/173.4.1034; Matsuzaki G, 1999, CELL IMMUNOL, V194, P178, DOI 10.1006/cimm.1999.1503; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811; Neutra MR, 1999, SEMIN IMMUNOL, V11, P171, DOI 10.1006/smim.1999.0173; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; Owen RL, 1999, SEMIN IMMUNOL, V11, P157, DOI 10.1006/smim.1999.0171; OWEN RL, 1977, GASTROENTEROLOGY, V72, P440; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Sansonetti PJ, 1999, SEMIN IMMUNOL, V11, P193, DOI 10.1006/smim.1999.0175; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Teitelbaum R, 1999, IMMUNITY, V10, P641, DOI 10.1016/S1074-7613(00)80063-1; Velin D, 1997, J EXP MED, V185, P1871, DOI 10.1084/jem.185.10.1871; Vordermeier HM, 1996, CLIN EXP IMMUNOL, V106, P312, DOI 10.1046/j.1365-2249.1996.d01-845.x; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643	45	194	197	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1965	1968		10.1126/science.286.5446.1965	http://dx.doi.org/10.1126/science.286.5446.1965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583962				2022-12-24	WOS:000084003400055
J	Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T				Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T			A pair of related genes with antagonistic roles in mediating flowering signals	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; TIME; ARCHITECTURE; ACTIVATION; INITIATION; ENCODES; PLANTS	Flowering in Arabidopsis is promoted via several interacting pathways. A photoperiod-dependent pathway relays signals from photoreceptors to a transcription factor gene, CONSTANS (CO), which activates downstream meristem identity genes such as LEAFY (LFY). FT, together with LFY, promotes flowering and is positively regulated by CO. Loss of FT causes delay in flowering, whereas overexpression of FT results in precocious flowering independent of CO or photoperiod. FT acts in part downstream of CO and mediates signals for flowering in an antagonistic manner with its homologous gene, TERMINAL FLOWER1 (TFL1).	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Araki, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.	taraqui@gr.bot.kyoto-u.ac.jp	Araki, Takashi/G-1760-2013; Rosa, Bruce/F-6393-2010	Araki, Takashi/0000-0002-3616-1493; Kaya, Hidetaka/0000-0003-4711-8236				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; IGENO MI, COMMUNICATION; KOBAYASHI Y, UNPUB; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; KYOZUKA J, COMMUNICATION; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	23	971	1084	5	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1960	1962		10.1126/science.286.5446.1960	http://dx.doi.org/10.1126/science.286.5446.1960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583960				2022-12-24	WOS:000084003400053
J	Schopfer, CR; Nasrallah, ME; Nasrallah, JB				Schopfer, CR; Nasrallah, ME; Nasrallah, JB			The male determinant of self-incompatibility in Brassica	SCIENCE			English	Article							POLLEN COAT PROTEIN; S-LOCUS GENE; ANTIMICROBIAL PEPTIDES; OLERACEA; CAMPESTRIS; EVOLUTION; SEQUENCES; PLANTS	In the S locus-controlled self-incompatibility system of Brassica, recognition of self-related pollen at the surface of stigma epidermal cells leads to inhibition of pollen tube development. The female (stigmatic) determinant of this recognition reaction is a polymorphic transmembrane receptor protein kinase encoded at the 5 Locus. Another highly polymorphic, anther-expressed gene, SCR, also encoded at the 5 locus, fulfills the requirements for the hypothesized pollen determinant. Loss-of-function and gain-of-function studies prove that the SCR gene product is necessary and sufficient for determining pollen self-incompatibility specificity, possibly by acting as a Ligand for the stigmatic receptor.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	Nasrallah, JB (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.		Swaibu, Ramadhani A/H-3164-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyes DC, 1997, PLANT CELL, V9, P237, DOI 10.1105/tpc.9.2.237; BOYES DC, 1995, PLANT CELL, V7, P1283, DOI 10.1105/tpc.7.8.1283; BOYES DC, 1991, GENETICS, V127, P221; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CASSELMAN AL, UNPUB; Conner JA, 1998, PLANT CELL, V10, P801, DOI 10.1105/tpc.10.5.801; DIXIT R, UNPUB; Doughty J, 1998, PLANT CELL, V10, P1333, DOI 10.1105/tpc.10.8.1333; DWYER KG, 1991, PLANT MOL BIOL, V16, P481, DOI 10.1007/BF00024000; KHO YO, 1968, EUPHYTICA, V17, P298; Kusaba M, 1997, P NATL ACAD SCI USA, V94, P7673, DOI 10.1073/pnas.94.14.7673; Nasrallah JB, 1997, P NATL ACAD SCI USA, V94, P9516, DOI 10.1073/pnas.94.18.9516; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NASRALLAH JB, IN PRESS ANN BOT; Stanchev BS, 1996, PLANT J, V10, P303, DOI 10.1046/j.1365-313X.1996.10020303.x; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Suzuki G, 1999, GENETICS, V153, P391; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TORIYAMA K, 1991, THEOR APPL GENET, V81, P769, DOI 10.1007/BF00224988; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yu KF, 1996, PLANT CELL, V8, P2369, DOI 10.1105/tpc.8.12.2369	23	563	641	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1697	1700		10.1126/science.286.5445.1697	http://dx.doi.org/10.1126/science.286.5445.1697			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576728				2022-12-24	WOS:000083912200026
J	Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM				Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM			The effect of patients' preferences on racial differences in access to renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVASCULARIZATION PROCEDURES; SURGICAL-PROCEDURES; HEART-DISEASE; RACE; WOMEN; ENDARTERECTOMY; ANGIOGRAPHY; DIALYSIS; QUALITY; SURGERY	Background: In the United States, black patients undergo renal transplantation less often than white patients, but few studies have directly assessed the association between race and patients' preferences with respect to transplantation. Methods: To assess preferences with respect to transplantation and experiences with medical care, we interviewed 1392 (82.9 percent) of 1679 eligible patients with end-stage renal disease (age range, 18 to 54 years) approximately 10 months after they had begun maintenance treatment with dialysis. Participants were selected from a stratified random sample of patients undergoing dialysis in four regions of the United States (Alabama, southern California, Michigan, and the mid-Atlantic region of Maryland, Virginia, and the District of Columbia) in 1996 and 1997. Patients were followed until March 1999. Results: The interviews were conducted with 384 black women, 354 white women, 337 black men, and 317 white men. Black patients were less likely than white patients to want a transplant (76.3 percent of black women reported such a preference, vs. 79.3 percent of white women, and 80.7 percent of black men vs. 85.5 percent of white men), and they were less likely to be very certain about this preference (58.3 percent vs. 65.3 percent and 64.1 percent vs. 75.7 percent, respectively; P<0.01 for each comparison with both sexes combined). However, much larger differences were evident in rates of referral for evaluation at a transplantation center (50.4 percent for black women vs. 70.5 percent for white women, and 53.9 percent for black men vs. 76.2 percent for white men; P<0.001 for each comparison) and placement on a waiting list or transplantation within 18 months after the start of dialysis therapy (31.3 percent for black women vs. 56.5 percent for white women, and 35.3 percent for black men vs. 60.6 percent for white men; P<0.001). These racial differences remained significant after adjustment for patients' preferences and expectations about transplantation, sociodemographic characteristics, the type of dialysis facility, perceptions of care, health status, the cause of renal failure, and the presence or absence of coexisting illnesses. Conclusions: In the United States, the preferences and expectations with respect to renal transplantation among patients with end-stage renal disease differ according to race. These differences, however, explain only a small fraction of the substantial racial differences in access to transplantation. Physicians should ensure that black patients who desire renal transplantation are fully informed about it and are referred for evaluation. (N Engl J Med 1999;341:1661-9.) (C) 1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019					Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P656, DOI 10.1056/NEJM199308263290912; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELIXHAUSER A, 1994, AHCPR PUBLICATION; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HORNER RD, 1995, MILBANK Q, V73, P443, DOI 10.2307/3350374; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LEVY DR, 1985, PEDIATRICS, V75, P639; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; McCauley J, 1997, AM J KIDNEY DIS, V30, P739, DOI 10.1016/S0272-6386(97)90077-9; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; ODDONE EZ, 1993, ARCH INTERN MED, V153, P2781, DOI 10.1001/archinte.153.24.2781; Oddone EZ, 1998, J NATL MED ASSOC, V90, P25; Ozminkowski RJ, 1997, AM J KIDNEY DIS, V30, P749, DOI 10.1016/S0272-6386(97)90078-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; *REN DAT SYST, 1998, USRDS 1998 ANN DAT R; Saha S., 1999, JGIM, V14, P67; Satcher D, 1973, JAMA, V223, P1498; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1007/s11606-006-5062-0; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	41	493	493	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1661	1669		10.1056/NEJM199911253412206	http://dx.doi.org/10.1056/NEJM199911253412206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258PL	10572155				2022-12-24	WOS:000083847500006
J	Berghammer, AJ; Klingler, M; Wimmer, EA				Berghammer, AJ; Klingler, M; Wimmer, EA			Genetic techniques - A universal marker for transgenic insects	NATURE			English	Article							YELLOW-FEVER MOSQUITO; TRANSPOSABLE ELEMENT; AEDES-AEGYPTI; TRANSFORMATION; DROSOPHILA; MARINER; FLY		Univ Munich, Inst Zool, D-80333 Munich, Germany; Univ Bayreuth, Lehrstuhl Genet, D-95447 Bayreuth, Germany	University of Munich; University of Bayreuth	Berghammer, AJ (corresponding author), Univ Munich, Inst Zool, Luisenstr 14, D-80333 Munich, Germany.		Klingler, Martin/J-8383-2013	Klingler, Martin/0000-0001-8859-1965; Wimmer, Ernst A./0000-0002-2480-2804				Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Handler AM, 1998, P NATL ACAD SCI USA, V95, P7520, DOI 10.1073/pnas.95.13.7520; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MEDHORA MM, 1988, EMBO J, V7, P2185, DOI 10.1002/j.1460-2075.1988.tb03057.x; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WARREN WD, 1994, GENET RES, V64, P87, DOI 10.1017/S0016672300032699	12	263	280	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					370	371		10.1038/46463	http://dx.doi.org/10.1038/46463			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586872				2022-12-24	WOS:000083913600041
J	Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN				Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN			Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFRINGENS; LINCOSAMIDE; MACROLIDE; OUTBREAK; TETRACYCLINE; RESTRICTION; PLASMIDS; SEQUENCE; COLITIS; GENES	Background: Large outbreaks of diarrhea caused by a newly recognized strain of Clostridium difficile occurred in four hospitals located in different parts of the United States between 1989 and 1992. Since frequent use of clindamycin was associated with the outbreak in one of the hospitals, we examined the resistance genes of the epidemic-strain isolates and studied the role of clindamycin use in these outbreaks. Methods: Case-control studies were performed at three of the four hospitals to assess the relation of the use of clindamycin to C. difficile-associated diarrhea. All isolates of the epidemic strain and representative isolates of other strains identified during each outbreak were tested for susceptibility to clindamycin. Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance -- the erythromycin ribosomal methylase B (ermB) gene -- found in C. perfringens and C. difficile. Results: In a stratified analysis of the case-control studies with pooling of the results according to the Mantel-Haenszel method, we found that the use of clindamycin was significantly increased among patients with diarrhea due to the epidemic strain of C. difficile, as compared with patients whose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval, 2.02 to 9.38; P<0.001). Exposure to other types of antibiotics or hospitalization in a surgical ward was not significantly associated with the risk of C. difficile-associated diarrhea due to the epidemic strain. All epidemic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 microg per milliliter). DNA hybridization and PCR analysis showed that all these isolates had an ermB gene, which encodes a 23S ribosomal RNA methylase that mediates resistance to macrolide, lincosamide, and streptogramin antibiotics. Only 15 percent of the nonepidemic strains were resistant to clindamycin. Conclusions: A strain of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarrhea in four hospitals in different states. The use of clindamycin is a specific risk factor for diarrhea due to this strain. Resistance to clindamycin further increases the risk of C. difficile-associated diarrhea, an established complication of antimicrobial use. (N Engl J Med 1999;341:1645-51.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Ctr Dis Control & Prevent, Atlanta, GA USA; Stratton Vet Affairs Med Ctr, Albany, NY USA; Albany Med Coll, Albany, NY 12208 USA; Vet Affairs Med Ctr, Tucson, AZ USA	Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Monash University; Centers for Disease Control & Prevention - USA; Albany Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Johnson, S (corresponding author), Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, 333 E Huron, Chicago, IL 60611 USA.	stu-johnson@nwu.edu	Rood, Julian I/A-4858-2008	Rood, Julian I/0000-0003-2126-7209; Johnson, Stuart/0000-0001-9548-229X; Lyras, Dena/0000-0003-2345-9271				ABRAHAM LJ, 1985, J BACTERIOL, V161, P636, DOI 10.1128/JB.161.2.636-640.1985; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BERRYMAN DI, 1995, ANTIMICROB AGENTS CH, V39, P1830, DOI 10.1128/AAC.39.8.1830; BERRYMAN DI, 1994, ANTIMICROB AGENTS CH, V38, P1041, DOI 10.1128/AAC.38.5.1041; Brazier JS, 1998, J ANTIMICROB CHEMOTH, V41, P47, DOI 10.1093/jac/41.suppl_3.47; BREFORT G, 1977, PLASMID, V1, P52, DOI 10.1016/0147-619X(77)90008-7; CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1991, 31 INT C ANT AG CHEM, P352; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KILLGORE GE, 1994, J CLIN MICROBIOL, V32, P1591, DOI 10.1128/JCM.32.6.1591-1593.1994; LYRAS D, 1997, CLOSTRIDIA MOL BIOL, P73; MEKONEN E, 1996, INFECT CONTROL HOS S, V17, pP32; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; *NAT COMM CLIN LAB, 1997, M11A4 NCCLS; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P88; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P366; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; Rafferty ME, 1998, J CLIN MICROBIOL, V36, P2957, DOI 10.1128/JCM.36.10.2957-2963.1998; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P270; Samore M, 1997, J INFECT DIS, V176, P1233, DOI 10.1086/514117; SAMORE MH, 1994, J INFECT DIS, V170, P615, DOI 10.1093/infdis/170.3.615; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; SMITH CJ, 1981, ANTIMICROB AGENTS CH, V19, P997, DOI 10.1128/AAC.19.6.997; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; WUST J, 1983, ANTIMICROB AGENTS CH, V23, P784, DOI 10.1128/AAC.23.5.784	29	253	261	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1645	1651		10.1056/NEJM199911253412203	http://dx.doi.org/10.1056/NEJM199911253412203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572152				2022-12-24	WOS:000083847500003
J	Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P				Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P			Crystal structures of the membrane-binding C2 domain of human coagulation factor V	NATURE			English	Article							FACTOR-VIII; PROTHROMBIN ACTIVATION; PHOSPHOLIPID-VESICLES; PHOSPHATIDYLSERINE; COMPLEX; PROTEIN; ASSOCIATION; INSIGHTS; COFACTOR; MODELS	Rapid and controlled clot formation is achieved through sequential activation of circulating serine proteinase precursors on phosphatidylserine-rich procoagulant membranes of activated platelets and endothelial cells(1). The homologous complexes Xase and prothrombinase, each consisting of an active proteinase and a non-enzymatic cofactor, perform critical steps within this coagulation cascade. The activated cofactors VIIIa and Va, highly specific for their cognate proteinases, are each derived from precursors with the same A1-A2-B-A3-C1-C2 architecture(2). Membrane binding is mediated by the C2 domains of both cofactors, Here we report two crystal structures of the C2 domain of human factor Va. The conserved beta-barrel framework provides a scaffold for three protruding loops, one of which adopts markedly different conformations in the two crystal forms. We propose a mechanism of calcium-independent, stereospecific binding of factors Va and VIIIa to phospholipid membranes(3,4), on the basis of (1) immersion of hydrophobic residues at the apices of these loops in the apolar membrane core; (2) specific interactions with phosphatidylserine head groups in the groove enclosed by these loops; and (3) favourable electrostatic contacts of basic side chains with negatively charged membrane phosphate groups.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; DESY, MPG ASMB, Prot Dynam Grp, Max Planck Res Unit Struct Mol Biol, D-22603 Hamburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany	Max Planck Society; Duke University; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Philipps University Marburg	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	bode@biochem.mpg.de	Macedo-Ribeiro, Sandra/D-9258-2011; Bourenkov, Gleb P/C-7794-2017; Stubbs, Milton/ABC-7585-2020	Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bourenkov, Gleb P/0000-0002-2617-5920; Stubbs, Milton/0000-0003-1278-9013; Fuentes-Prior, Pablo/0000-0002-6618-3204				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Cutsforth GA, 1996, BIOPHYS J, V70, P2938, DOI 10.1016/S0006-3495(96)79864-8; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KANE WH, 1988, BLOOD, V71, P539; KIM SW, IN PRESS BIOCHEMISTR; KNIGHT S, 1989, THESIS SWEDISH U AGR; Koppaka V, 1997, BIOPHYS J, V73, P2638, DOI 10.1016/S0006-3495(97)78293-6; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORTEL TL, 1994, J BIOL CHEM, V269, P15898; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Ortel TL, 1998, BLOOD, V91, P4188, DOI 10.1182/blood.V91.11.4188.411k33_4188_4196; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1993, J BIOL CHEM, V268, P21130; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Villoutreix BO, 1998, J MOL MODEL, V4, P268, DOI 10.1007/s008940050084; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	30	210	220	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					434	439		10.1038/46594	http://dx.doi.org/10.1038/46594			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586886				2022-12-24	WOS:000083913600062
J	Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D				Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D			LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITIES; AXOSPINOUS SYNAPSES; PYRAMIDAL CELLS; POTENTIATION; CA1; RAT; SYNAPTOGENESIS; TRANSMISSION; HIPPOCAMPUS	Structural remodelling of synapses(1-4) and formation of new synaptic contacts(5-8) has been postulated as a possible mechanism underlying the late phase of long-term potentiation (LTP), a form of plasticity which is involved in learning and memory(9). Here we use electron microscopy to analyse the morphology of synapses activated by high-frequency stimulation and identified by accumulated calcium in dendritic spines. LTP induction resulted in a sequence of morphological changes consisting of a transient remodelling of the postsynaptic membrane followed by a marked increase in the proportion of axon terminals contacting two or more dendritic spines. Three-dimensional reconstruction revealed that these spines arose from the same dendrite. As pharmacological blockade of LTP prevented these morphological changes, we conclude that LTP is associated with the formation of new, mature and probably functional synapses contacting the same presynaptic terminal and thereby duplicating activated synapses.	Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland; Univ Bern, Inst Anat, CH-3000 Bern, Switzerland	University of Geneva; University of Bern	Muller, D (corresponding author), Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland.		Toni, Nicolas/M-2057-2014	Toni, Nicolas/0000-0001-5585-268X				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; BUCHS PA, 1994, J NEUROSCI METH, V54, P83, DOI 10.1016/0165-0270(94)90162-7; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; CALVERLEY RKS, 1990, BRAIN RES REV, V15, P215, DOI 10.1016/0165-0173(90)90002-6; CARLIN RK, 1983, P NATL ACAD SCI-BIOL, V80, P3517, DOI 10.1073/pnas.80.11.3517; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GEINISMAN Y, 1993, HIPPOCAMPUS, V3, P435, DOI 10.1002/hipo.450030405; Geinisman Y, 1996, J COMP NEUROL, V368, P413; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kleim JA, 1997, J NEUROSCI, V17, P717; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; NIETOSAMPEDRO M, 1982, P NATL ACAD SCI-BIOL, V79, P5718, DOI 10.1073/pnas.79.18.5718; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sorra KE, 1998, J COMP NEUROL, V398, P225; SORRA KE, 1993, J NEUROSCI, V13, P3736; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Trommald M, 1997, J COMP NEUROL, V377, P15, DOI 10.1002/(SICI)1096-9861(19970106)377:1<15::AID-CNE3>3.0.CO;2-M; Woolley CS, 1996, J COMP NEUROL, V373, P108; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	28	751	761	2	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					421	425		10.1038/46574	http://dx.doi.org/10.1038/46574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586883				2022-12-24	WOS:000083913600059
J	Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME				Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME			Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha	SCIENCE			English	Article							LIGHT-CHAIN PHOSPHATASE; VASCULAR SMOOTH-MUSCLE; DNA-BINDING DOMAIN; LEUCINE-ZIPPER; SIGNAL-TRANSDUCTION; TARGETING SUBUNITS; GMP; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Contraction and relaxation of smooth muscle are regulated by myosin light-chain kinase and myosin phosphatase through phosphorylation and dephosphorylation of myosin light chains. Cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (cGKI alpha) mediates physiologic relaxation of vascular smooth muscle in response to nitric oxide and cGMP. It is shown here that cGKI alpha is targeted to the smooth muscle cell contractile apparatus py a Leucine zipper interaction with the myosin-binding subunit (MBS) of myosin phosphatase. Uncoupling of the cGKI alpha-MBS interaction prevents cGMP-dependent dephosphorylation of myosin light chain, demonstrating that this interaction is essential to the regulation of vascular smooth muscle cell tone.	Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Div Cardiol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 514, Japan; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	Tufts University; Tufts University; Tufts Medical Center; National Center for Global Health & Medicine - Japan; Mie University; University of Alabama System; University of Alabama Birmingham	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA.	mmendelsohn@lfespan.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09330, HL55309] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOI KY, 1994, CELL, V78, P499; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FILO RS, 1965, SCIENCE, V147, P1581, DOI 10.1126/science.147.3665.1581; GLATZ RHD, 1992, NUCLEIC ACIDS RES, V20, P1425; GONG MC, 1992, J BIOL CHEM, V267, P21492; GUTFREUND H, 1971, ENZYMES PHYSICAL PRI, P67; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln T.M., 1994, CYCLIC GMP BIOCH PHY, P97; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTTJD, 1996, TRENDS BIOCHEM SCI, V21, P312; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SURKS HK, UNPUB; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460	53	401	419	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1583	1587		10.1126/science.286.5444.1583	http://dx.doi.org/10.1126/science.286.5444.1583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567269				2022-12-24	WOS:000083768300065
J	Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT				Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT			Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; RHESUS MACAQUES; VAGINAL TRANSMISSION; VIRAL REPLICATION; TYPE-1 INFECTION; IN-VITRO; CYCLE; LYMPHOCYTES	In sexual transmission of simian immunodeficiency virus, and early and later stages of human immunodeficiency virus-type 1 (HIV-1) infection, both viruses were found to replicate predominantly in CD4(+) T cells at the portal of entry and in Lymphoid tissues, infection was propagated not only in activated and proliferating T cells but also, surprisingly, in resting T cells. The infected proliferating cells correspond to the short-lived population that produces the bulk of HIV-1. Most of the HIV-1-infected resting T cells persisted after antiretroviral therapy. Latently and chronically infected cells that may be derived from this population pose challenges to eradicating infection and developing an effective vaccine.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Harvard Univ, Beth Israel Hosp, Div Viral Pathogenesis, Boston, MA 02215 USA; Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Amsterdam, Acad Med Ctr, Acad Hosp, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Northwestern Univ, Sch Med, Div Infect Dis, Chicago, IL 60611 USA; San Diego VA Hlth Care Syst, La Jolla, CA 92093 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; Bernhard Nocht Institut fur Tropenmedizin; Northwestern University	Haase, AT (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Little, Susan/AAA-6116-2019; Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028246, R01AI138565, R01AI038565] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00168] Funding Source: Medline; NIAID NIH HHS [AI 28246, AI 38565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Benoist C, 1997, SCIENCE, V276, P2000, DOI 10.1126/science.276.5321.2000; BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKRINSKY MI, 1991, SCIENCE, V254, P423; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chou CS, 1997, P NATL ACAD SCI USA, V94, P1361, DOI 10.1073/pnas.94.4.1361; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Freitas AA, 1997, SCIENCE, V277, P1950, DOI 10.1126/science.277.5334.1950; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Miller C. J., 1992, Laboratory Investigation, V68, P129; Miller CJ, 1998, J VIROL, V72, P3248, DOI 10.1128/JVI.72.4.3248-3258.1998; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; *NAT RES COUNC, 1996, GUID CAR US LAB; Orendi JM, 1998, J INFECT DIS, V178, P1279, DOI 10.1086/314451; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANG SB, 1995, J VIROL, V69, P5659, DOI 10.1128/JVI.69.9.5659-5665.1995; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	41	699	710	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1353	1357		10.1126/science.286.5443.1353	http://dx.doi.org/10.1126/science.286.5443.1353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558989				2022-12-24	WOS:000083675500041
J	Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA				Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA			Protein interaction maps for complete genomes based on gene fusion events	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENZYMES	A large-scale effort to measure, detect and analyse protein-protein interactions using experimental methods is under way(1,2). These include biochemistry such as co-immunoprecipitation or crosslinking, molecular biology such as the two-hybrid system or phage display, and genetics such as unlinked noncomplementing mutant detection). Using the two-hybrid system(4), an international effort to analyse the complete yeast genome is in progress'. Evidently, all these approaches are tedious, labour intensive and inaccurate(6). From a computational perspective, the question is how can we predict that two proteins interact from structure or sequence alone. Here we present a method that identifies gene-fusion events in complete genomes, solely based on sequence comparison. Because there must be selective pressure for certain genes to be fused over the course of evolution, we are able to predict functional associations of proteins. We show that 215 genes or proteins in the complete genomes of Escherichia coli, Haemophilus influenzae and Methanococcus jannaschii are involved in 64 unique fusion events. The approach is general, and can be applied even to genes of unknown function.	EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England; Integrated Genom Inc, Chicago, IL 60612 USA	European Molecular Biology Laboratory (EMBL)	Ouzounis, CA (corresponding author), EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England.	ouzounis@ebi.ac.uk	Enright, Anton/F-3094-2011; Ouzounis, Christos A/G-2302-2010; Kyrpides, Nikos C./A-6305-2014	Enright, Anton/0000-0002-6090-3100; Ouzounis, Christos A/0000-0002-0086-8657; Kyrpides, Nikos C./0000-0002-6131-0462				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Bulow L, 1990, Biochem Soc Symp, V57, P123; BURNS DM, 1990, J BIOL CHEM, V265, P2060; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DENISDUPHIL M, 1989, BIOCHEM CELL BIOL, V67, P612, DOI 10.1139/o89-094; DUNCAN K, 1988, FEBS LETT, V241, P83, DOI 10.1016/0014-5793(88)81036-6; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lakey JH, 1998, CURR OPIN STRUC BIOL, V8, P119, DOI 10.1016/S0959-440X(98)80019-5; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lecrenier N, 1998, BIOESSAYS, V20, P1; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Ouzounis CA, 1997, J MOL EVOL, V45, P708, DOI 10.1007/PL00013145; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tamames J, 1997, J MOL EVOL, V44, P66, DOI 10.1007/PL00006122; WALES ME, 1991, METHOD ENZYMOL, V202, P687; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193	27	789	842	5	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					86	90		10.1038/47056	http://dx.doi.org/10.1038/47056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573422				2022-12-24	WOS:000083638600048
J	Molinari, M; Helenius, A				Molinari, M; Helenius, A			Glycoproteins form mixed disulphides with oxidoreductases during folding in living cells	NATURE			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM	The formation of intra- and interchain disulphide bonds constitutes an integral part of the maturation of most secretory and membrane-bound proteins in the endoplasmic reticulum(1,2). Evidence indicates that members of the protein disulphide isomerase (PDI) superfamily are part of the machinery needed for proper oxidation and isomerization of disulphide bonds(3-6). Models based on in vitro studies predict that the formation of mixed disulphide bonds between oxidoreductase and substrate is intermediate in the generation of the native intrachain disulphide bond in the substrate polypeptide(7). Whether this is how thiol oxidoreductases work inside the endoplasmic reticulum is not clear. Nor has it been established which of the many members of the PDI superfamily interacts directly with newly synthesized substrate proteins, because transient mixed disulphides have never been observed in the mammalian endoplasmic reticulum during oxidative protein folding(7,8). Here we describe the mechanisms involved in co- and post-translational protein oxidation in vivo. We show that the endoplasmic-reticulum-resident oxidoreductases PDI and ERp57 are directly involved in disulphide oxidation and isomerization, and, together with the lectins calnexin and calreticulin, are central in glycoprotein folding in the endoplasmic reticulum of mammalian cells.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	ari.helenius@bc.biol.ethz.ch	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; KRIJNSELOCKER J, 1999, J CELL BIOL, V144, P267; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946, DOI 10.1073/pnas.71.10.3946; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	19	263	268	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					90	93		10.1038/47062	http://dx.doi.org/10.1038/47062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573423				2022-12-24	WOS:000083638600049
J	Grammatopoulos, DK; Hillhouse, EW				Grammatopoulos, DK; Hillhouse, EW			Role of corticotropin-releasing hormone in onset of labour	LANCET			English	Article							HUMAN-FETAL MEMBRANES; HUMAN MYOMETRIUM; BINDING PROTEIN; LOCAL STIMULATION; HUMAN PARTURITION; HUMAN-PREGNANCY; FACTOR CRF; RECEPTOR; PROGESTERONE; EXPRESSION	Corticotropin-releasing hormone (CRH) derived from the placenta is secreted into the maternal circulation in Targe amounts during the third trimester of human pregnancy and may have an important role in the onset of labour. Although the biological role of CRH remains enigmatic, the presence of functional CRH receptors in the myometrium suggests that CRH may modulate myometrial contractility and hence parturition. CRH action is mediated via multiple receptor subtypes and pregnancy results in differential receptor expression. These receptors are primarily linked to the adenylate cyclase second messenger system, which would help the Intracellular microenvironment to maintain the required myometrial quiescence. CRH can exert further actions such as inhibition of prostaglandin production to prevent contractions. At term under the influence of oxytocin there is a modification in the coupling mechanisms that leads to a decrease in the biological activity of the CRH receptor and in the generation of cyclic adenosine monophosphate which favours myometrial contractions. CRH, via distinct receptor subtypes, is then able to enhance the contractile response of the myometrium. This hypothesis places CRH in a central role in coordinating the smooth transition from a state of relaxation to one of contraction.	Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England	University of Warwick	Grammatopoulos, DK (corresponding author), Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England.			grammatopoulos, dimitris/0000-0002-6296-8290	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; BENEDETTO C, 1994, AM J OBSTET GYNECOL, V171, P126, DOI 10.1016/0002-9378(94)90457-X; CAMBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054; Clifton VL, 1998, J CLIN ENDOCR METAB, V83, P3716, DOI 10.1210/jc.83.10.3716; CLIFTON VL, 1994, J CLIN ENDOCR METAB, V79, P666, DOI 10.1210/jc.79.2.666; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GOLAND RS, 1995, PLACENTA, V16, P375, DOI 10.1016/0143-4004(95)90095-0; GRAMMATOPOULOS D, 1995, J CLIN ENDOCR METAB, V80, P2388, DOI 10.1210/jc.80.8.2388; Grammatopoulos D, 1998, J CLIN ENDOCR METAB, V83, P2539, DOI 10.1210/jc.83.7.2539; Grammatopoulos D, 1996, J CLIN ENDOCR METAB, V81, P745, DOI 10.1210/jc.81.2.745; GRAMMATOPOULOS D, 1994, MOL CELL ENDOCRINOL, V99, P245, DOI 10.1016/0303-7207(94)90014-0; Grammatopoulos DK, 1999, J CLIN ENDOCR METAB, V84, P2204, DOI 10.1210/jc.84.6.2204; Grammatopoulos DK, 1999, ENDOCRINOLOGY, V140, P585, DOI 10.1210/en.140.2.585; HILLHOUSE EW, 1993, J CLIN ENDOCR METAB, V76, P736, DOI 10.1210/jc.76.3.736; JONES SA, 1989, BIOCHEM BIOPH RES CO, V159, P192, DOI 10.1016/0006-291X(89)92422-4; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; LINTON EA, 1990, J CLIN ENDOCR METAB, V70, P1574, DOI 10.1210/jcem-70-6-1574; LINTON EA, 1993, J CLIN ENDOCR METAB, V76, P260, DOI 10.1210/jc.76.1.260; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; MITCHELL BF, 1993, AM J OBSTET GYNECOL, V168, P1377, DOI 10.1016/S0002-9378(11)90768-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P852, DOI 10.1210/jc.81.2.852; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; QUARTERO HWP, 1989, PLACENTA, V10, P439, DOI 10.1016/0143-4004(89)90054-4; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; Rodriguez-Linares B, 1998, J ENDOCRINOL, V156, P15, DOI 10.1677/joe.0.1560015; Stevens MY, 1998, J CLIN ENDOCR METAB, V83, P4107, DOI 10.1210/jc.83.11.4107; Wallace EM, 1999, LANCET, V353, P1404, DOI 10.1016/S0140-6736(98)08229-4; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; ZUO J, 1994, J CLIN ENDOCR METAB, V79, P894, DOI 10.1210/jc.79.3.894	32	127	131	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1546	1549		10.1016/S0140-6736(99)03418-2	http://dx.doi.org/10.1016/S0140-6736(99)03418-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551516				2022-12-24	WOS:000083411300042
J	Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM				Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM			High-resolution X-ray structure of an early intermediate in the bacteriorhodopsin photocycle	NATURE			English	Article							LIPIDIC CUBIC PHASES; ANGSTROM RESOLUTION; MEMBRANE-PROTEINS; PURPLE MEMBRANE; DIFFRACTION; CRYSTALLOGRAPHY; CRYSTALLIZATION; MODEL	Bacteriorhodopsin is the simplest known photon-driven proton pump(1) and as such provides a model for the study of a basic function in bioenergetics. Its seven transmembrane helices' encompass a proton translocation pathway containing the chromophore, a retinal molecule covalently bound to lysine 216 through a protonated Schiff base, and a series of proton donors and accepters. Photoisomerization of the all-trans retinal to the) 13-cis configuration initiates the vectorial translocation of a proton from the Schiff base, the primary proton donor, to the extracellular side, followed by reprotonation of the Schiff base from the cytoplasm. Here we describe the high-resolution X-ray structure of an early intermediate in the photocycle of bacteriorhodopsin, which is formed directly after photoexcitation. A key water molecule is dislocated, allowing the primary proton acceptor, Asp 85, to move. Movement of the main-chain Lys 216 locally disrupts the hydrogen-bonding network of helix G, facilitating structural changes later in the photocycle.	Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4056 Basel, Switzerland; Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble 2, France	University of Basel; Uppsala University; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Landau, EM (corresponding author), Univ Basel, Biozentrum, Dept Mol Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	neutze@xray.bmc.uu.se; landau@ubaclu.unibas.ch	Neutze, Richard/A-7573-2010; Royant, Antoine/G-3684-2012	Neutze, Richard/0000-0003-0986-6153; Royant, Antoine/0000-0002-1919-8649				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulllough PA, 1999, J MOL BIOL, V286, P1663, DOI 10.1006/jmbi.1999.2570; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASATO K, 1991, FEBS LETT, V292, P75; Nollert P, 1998, BIOCHEM SOC T, V26, P709, DOI 10.1042/bst0260709; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SONG IK, 1991, KOREAN J CHEM ENG, V8, P33, DOI 10.1007/BF02697695; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TAKEI H, 1994, J BIOL CHEM, V269, P7387; Ursby T, 1997, ACTA CRYSTALLOGR A, V53, P564, DOI 10.1107/S0108767397004522; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; XIE A, 1990, BIOPHYS J, V58, P1127, DOI 10.1016/S0006-3495(90)82455-3; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	32	292	301	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					822	826		10.1038/44623	http://dx.doi.org/10.1038/44623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548112				2022-12-24	WOS:000083368700061
J	Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY				Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY			Spectroscopic mapping of voltage sensor movement in the Shaker potassium channel	NATURE			English	Article							K+ CHANNEL; SODIUM-CHANNELS; ENERGY-TRANSFER; MOLECULAR-BASIS; S4 SEGMENT; CONFORMATIONS; FLUORESCENCE; CHARGE	Voltage-gated ion channels underlie the generation of action potentials and trigger neurosecretion and muscle contraction. These channels consist of an inner pore-forming domain, which contains the ion permeation pathway and elements of its gates, together with four voltage-sensing domains, which regulate the gates(1-6). To understand the mechanism of voltage sensing it is necessary to define the structure and motion of the S4 segment, the portion of each voltage-sensing domain that moves charged residues across the membrane in response to voltage change(7-14) We have addressed this problem by using fluorescence resonance energy transfer as a spectroscopic ruler(15-17) to determine distances between S4s in the Shaker K+ channel in different gating states. Here we provide evidence consistent with S4 being a tilted helix that twists during activation. We propose that helical twist contributes to the movement of charged side chains across the membrane electric field and that it is involved in coupling voltage sensing to gating.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 271 Life Sci Addit, Berkeley, CA 94720 USA.		isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; FRETCH GC, 1989, NATURE, V340, P642; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jovin T.M, 1989, CELL STRUCT FUNCT, P99; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	26	243	255	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					813	817		10.1038/45561	http://dx.doi.org/10.1038/45561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617202				2022-12-24	WOS:000084330500066
J	Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC				Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC			Global transposon mutagenesis and a minimal mycoplasma genome	SCIENCE			English	Article							SEQUENCE; GENITALIUM; SPIROCHETE; PNEUMONIAE; ARCHAEON; COPIES; IS256	Mycoplasma genitalium with 517 genes has the smallest gene complement of any independently replicating cell so far identified. Global transposon mutagenesis was used to identify nonessential genes in an effort to Learn whether the naturally occurring gene complement is a true minimal genome under Laboratory growth conditions. The positions of 2209 transposon insertions in the completely sequenced genomes of M. genitalium and its close relative M. pneumoniae were determined by sequencing across the junction of the transposon and the genomic DNA. These junctions defined 1354 distinct sites of insertion that were not Lethal. The analysis suggests that 265 to 350 of the 480 protein-coding genes of M. genitalium are essential under Laboratory growth conditions, including about 100 genes of unknown function.	Inst Gen Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Venter, JC (corresponding author), Celera Gen, 45 W Gude Dr, Rockville, MD 20850 USA.			Fraser, Claire/0000-0003-1462-2428				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cho MK, 1999, SCIENCE, V286, P2087, DOI 10.1126/science.286.5447.2087; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; DYKE KGH, 1992, PLASMID, V28, P235, DOI 10.1016/0147-619X(92)90055-F; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOFFEAU A, 1997, NATURE, V387; Himmelreich R, 1997, NUCLEIC ACIDS RES, V25, P701, DOI 10.1093/nar/25.4.701; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; Kaneko T, 1996, DNA Res, V3, P109; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNUDTSON KL, 1993, GENE, V137, P217, DOI 10.1016/0378-1119(93)90009-R; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P128, DOI 10.1016/S0968-0004(96)80165-4; Krause DC, 1996, MOL MICROBIOL, V20, P247, DOI 10.1111/j.1365-2958.1996.tb02613.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MOROWITZ HJ, 1984, ISRAEL J MED SCI, V20, P750; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Reddy SP, 1996, FEMS IMMUNOL MED MIC, V15, P199, DOI 10.1016/0928-8244(96)00060-0; RICE LB, 1995, ANTIMICROB AGENTS CH, V39, P1147, DOI 10.1128/AAC.39.5.1147; Romero-Arroyo CE, 1999, J BACTERIOL, V181, P1079, DOI 10.1128/JB.181.4.1079-1087.1999; Saurin W, 1996, MOL MICROBIOL, V22, P389; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	29	662	710	3	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2165	2169		10.1126/science.286.5447.2165	http://dx.doi.org/10.1126/science.286.5447.2165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591650				2022-12-24	WOS:000084157300055
J	Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J				Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J			Golgi membranes are absorbed into and reemerge from the ER during mitosis	CELL			English	Article							ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; LIVING CELLS; BREFELDIN-A; HELA-CELLS; MATRIX PROTEIN; APPARATUS; FRAGMENTATION; DYNAMICS; COMPLEX	Quantitative imaging and photobleaching were used to measure ER/Golgi recycling of GFP-tagged Golgi proteins in interphase cells and to monitor the dissolution and reformation of the Golgi during mitosis. In interphase, recycling occurred every 1.5 hr, and blocking ER egress trapped cycling Golgi enzymes in the ER with loss of Golgi structure. In mitosis, when ER export stops, Golgi proteins redistributed into the ER as shown by quantitative imaging in vivo and immuno-EM. Comparison of the mobilities of Golgi proteins and lipids ruled out the persistence of a separate mitotic Golgi vesicle population and supported the idea that all Golgi components are absorbed into the ER. Moreover, reassembly of the Golgi complex after mitosis failed to occur when ER export was blocked. These results demonstrate that in mitosis the Golgi disperses and reforms through the intermediary of the ER, exploiting constitutive recycling pathways. They thus define a novel paradigm for Golgi genesis and inheritance.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; BioInformat Serv, Rockville, MD 20854 USA; NINCDS, Light Imaging Facil, NIH, Bethesda, MD 20892 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Mol Neurobiol Lab, I-66030 Santa Maria Imbaro, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.		Ward, Theresa H./E-9650-2013; Hirschberg, Koret/AAF-4566-2019; Ellenberg, Jan/I-4688-2014	Ward, Theresa H./0000-0002-9881-8649; Ellenberg, Jan/0000-0001-5909-701X; Polishchuk, Roman/0000-0002-7698-1955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059018] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59018-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Edidin M., 1994, MOBILITY PROXIMITY B, P109; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Farmaki T, 1999, J CELL SCI, V112, P589; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FOSTER DM, 1994, BMES BULL, V18, P19; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACQUEZ JA, 1996, COMPARTMENTAL ANAL B; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1992, J CELL SCI, V103, P875; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Polishchuk RS, 1999, EUR J CELL BIOL, V78, P170, DOI 10.1016/S0171-9335(99)80096-X; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; WADSWORTH P, 1983, J CELL BIOL, V97, P1249, DOI 10.1083/jcb.97.4.1249; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	48	265	274	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					589	601		10.1016/S0092-8674(00)81548-2	http://dx.doi.org/10.1016/S0092-8674(00)81548-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612395	Bronze			2022-12-24	WOS:000084278700006
J	Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR				Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR			A novel nuclear export activity in HIV-1 matrix protein required for viral replication	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INTRACELLULAR-TRANSPORT; LOCALIZATION SIGNAL; NONDIVIDING CELLS; RNA DIMERIZATION; MESSENGER-RNA; LEPTOMYCIN-B; INFECTION; CRM1; ENCAPSIDATION	An important aspect of the pathophysiology of human immunodeficiency virus type-1 (HIV-1) infection is the ability of the virus to replicate in non-dividing cells(1-3). HIV-1 matrix (MA), the amino-terminal domain of the Pr55 gag polyprotein (Pr55), bears a nuclear localization signal that promotes localization of the viral preintegration complex to the nucleus of non-dividing cells following virus entry(3-5). However, late during infection, MA, as part of Pr55, directs unspliced viral RNA to the plasma membrane(6), the site of virus assembly. How MA can mediate these two opposing targeting functions is not understood. Here we demonstrate that MA has a previously undescribed nuclear export activity. Although MA lacks the canonical leucine-rich nuclear export signal, nuclear export is mediated through the conserved Crmlp pathway and functions in both mammalian cells and yeast. A mutation that disrupts the MA nuclear export signal (MA-M4) mislocalizes Pr55 and genomic viral RNA to the nucleus, thereby severely impairing viral replication. Furthermore, we show that MA-M4 can act in a dominant-negative fashion to mislocalize genomic viral RNA even in the presence of wild-type MA, We conclude that the MA nuclear export signal is required to counteract the MA nuclear localization signal, thus ensuring the cytoplasmic availability of the components required for virion assembly.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Fornerod M, 1997, CELL, V90, P1051; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Krausslich HG, 1996, CURR TOP MICROBIOL, V214, P25; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Sakuragi J, 1997, J VIROL, V71, P3250, DOI 10.1128/JVI.71.4.3250-3254.1997; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	26	102	105	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					681	685		10.1038/45272	http://dx.doi.org/10.1038/45272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604476				2022-12-24	WOS:000084189800070
J	Thommes, EW; Duncan, MJ; Levison, HF				Thommes, EW; Duncan, MJ; Levison, HF			The formation of Uranus and Neptune in the Jupiter-Saturn region of the Solar System	NATURE			English	Article							GIANT PLANETS; FAMILY COMETS; KUIPER BELT; ORIGIN; ACCRETION	Planets are believed to have formed through the accumulation of a large number of small bodies(1-4). In the case of the gas-giant planets Jupiter and Saturn, they accreted a significant amount of gas directly from the protosolar nebula after accumulating solid cores of about 5-15 Earth masses(5,6). Such models, however, have been unable to produce the smaller ice giants(7,8) Uranus and Neptune at their present locations, because in that region of the Solar System the small planetary bodies will have been more widely spaced, and less tightly bound gravitationally to the Sun. When applied to the current Jupiter-Saturn zone, a recent theory predicts that, in addition to the solid cores of Jupiter and Saturn, two or three other solid bodies of comparable mass are likely to have formed(9). Here we report the results of model calculations that demonstrate that such cores will have been gravitationally scattered outwards as Jupiter, and perhaps Saturn, accreted nebular gas. The orbits of these cores then evolve into orbits that resemble those of Uranus and Neptune, as a result of gravitational interactions with the small bodies in the outer disk of the protosolar nebula.	Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada; SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA	Queens University - Canada	Duncan, MJ (corresponding author), Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				Agnor CB, 1999, ICARUS, V142, P219, DOI 10.1006/icar.1999.6201; BODENHEIMER P, 1986, ICARUS, V67, P391, DOI 10.1016/0019-1035(86)90122-3; Chambers JE, 1998, ICARUS, V136, P304, DOI 10.1006/icar.1998.6007; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Duncan MJ, 1998, ASTRON J, V116, P2067, DOI 10.1086/300541; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Kokubo E, 1998, ICARUS, V131, P171, DOI 10.1006/icar.1997.5840; Levison HF, 1998, ASTRON J, V116, P1998, DOI 10.1086/300557; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; Lin DNC, 1997, ASTROPHYS J, V477, P781, DOI 10.1086/303738; LISSAUER JJ, 1996, NEPTUNE TRITON, P37; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; Morbidelli A, 1998, ASTR SOC P, V149, P83; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Safronov V S., 1969, EVOLUTION PROTOPLANE; STEWART G, 1998, P LUN PLAN SCI C 29; Weidenschilling SJ, 1996, NATURE, V384, P619, DOI 10.1038/384619a0; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E	21	207	210	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					635	638		10.1038/45185	http://dx.doi.org/10.1038/45185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604469				2022-12-24	WOS:000084189800057
J	Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB				Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB			Elevated C-reactive protein levels in overweight and obese adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; NATIONAL-HEALTH; ADIPOSE-TISSUE; US ADULTS; RISK; INTERLEUKIN-6; MEN; ASSOCIATION	Context Human adipose tissue expresses and releases the proinflammatory cytokine interleukin 6, potentially inducing low-grade systemic inflammation in persons with excess body fat. Objective To test whether overweight and obesity are associated with low-grade systemic inflammation as measured by serum C-reactive protein (CRP) level. Design and Setting The Third National Health and Nutrition Examination Survey, representative of the US population from 1988 to 1994, Participants A total of 16 616 men and nonpregnant women aged 17 years or older Main Outcome Measures Elevated CRP level of 0.22 mg/dL or more and a more stringent clinically raised CRP level of more than 1.00 mg/dL. Results Elevated CRP levels and clinically raised CRP levels were present in 27.6% and 6.7% of the population, respectively. Both overweight (body mass index [BMI], 25-29.9 kg/m(2)) and obese (BMI, greater than or equal to 30 kg/m(2)) persons were more likely to have elevated CRP levels than their normal-weight counterparts (BMI, <25 kg/m(2)). After adjustment for potential confounders, including smoking and health status, the odds ratio (OR) for elevated CRP was 2.13 (95% confidence interval [CI], 1.56-2.91) for obese men and 6.21 (95% CI, 4.94-7.81) for obese women. In addition, BMI was associated with clinically raised CRP levels in women, with an OR of 4.76 (95% CI, 3.42-6.61) for obese women. Waist-to-hip ratio was positively associated with both elevated and clinically raised CRP levels, independent of BMI. Restricting the analyses to young adults (aged 17-39 years) and excluding smokers, persons with inflammatory disease, cardiovascular disease, or diabetes mellitus and estrogen users did not change the main findings. Conclusion Higher BMI is associated with higher CRP concentrations, even among young adults aged 17 to 39 years. These findings suggest a state of low-grade systemic inflammation in overweight and obese persons.	Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; NIA, Epidemiol Demog & Biometry Program, NIH, Bethesda, MD USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Visser, M (corresponding author), Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Visser, Marjolein/AAP-3224-2020; Wener, Mark/ABE-4491-2021	Bouter, Lex/0000-0002-2659-5482; Visser, Marjolein/0000-0002-5136-298X				[Anonymous], 1998, CLIN GUID ID EV TREA; Anzai T, 1997, CIRCULATION, V96, P778; BANKS RE, 1995, CLIN EXP IMMUNOL, V102, P217; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; Blackburn Jr W.D., 1994, J RHEUMATOL S, V42, P9; CASSANO PA, 1992, AM J EPIDEMIOL, V136, P1474, DOI 10.1093/oxfordjournals.aje.a116468; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Clark LW, 1997, CLIN CHEM, V43, P52; *CTR DIS CONTR PRE, 1996, 3 NAT HLTH NUTR EX S; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Folsom AR, 1998, AM J EPIDEMIOL, V148, P1187, DOI 10.1093/oxfordjournals.aje.a009608; Franzini C, 1998, CLIN CHEM LAB MED, V36, P131, DOI 10.1515/CCLM.1998.024; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gavin JR, 1997, DIABETES CARE, V20, P1183; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lohman TG, 1988, ANTHROPOMETRIC STAND; Mendall MA, 1996, BRIT MED J, V312, P1061; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G, 1982, CARDIOVASCULAR SURVE; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; Sebastian-Gambaro MA, 1997, EUR J CLIN CHEM CLIN, V35, P845; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; VOIGT LF, 1994, EPIDEMIOLOGY, V5, P525; WENER MH, 1997, MANUAL CLIN LAB IMMU; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	45	1721	1782	0	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2131	2135		10.1001/jama.282.22.2131	http://dx.doi.org/10.1001/jama.282.22.2131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591334	Bronze			2022-12-24	WOS:000083971400031
J	Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G				Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G			Stimulation of bone formation in vitro and in rodents by statins	SCIENCE			English	Article							GROWTH-FACTOR-BETA; NORMAL MICE; CONTAINING BISPHOSPHONATES; IN-VITRO; INTERLEUKIN-1; OSTEOBLASTS; CHOLESTEROL; RESORPTION; TURNOVER; INVITRO	Osteoporosis and other diseases of bone Loss are a major public health problem. Here it is shown that the statins, drugs widely used for Lowering serum cholesterol, also enhance new bone formation in vitro and in rodents. This effect was associated with increased expression of the bone morphogenetic protein-2 (BMP-2) gene in bone cells. Lovastatin and simvastatin increased bone formation when injected subcutaneously over the calvaria of mice and increased cancellous bone volume when orally administered to rats. Thus, in appropriate doses, statins may have therapeutic applications for the treatment of osteoporosis.	OsteoScreen, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Mundy, G (corresponding author), OsteoScreen, 2040 Babcock Rd, San Antonio, TX 78229 USA.	mundy@uthscsa.edu	Chan, Jeannie/B-5060-2013					Bauer DC, 1999, J BONE MINER RES, V14, pS179; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DUNSTAN CR, IN PRESS J BONE MINE; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GARRETT IR, UNPUB; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GOWEN M, 1986, J IMMUNOL, V136, P2478; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MELTON LJ, 1995, J BONE MINER RES, V10, P175; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; ROGERS MJ, 1995, MOL PHARMACOL, V47, P398; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406	22	1402	1628	5	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1946	1949		10.1126/science.286.5446.1946	http://dx.doi.org/10.1126/science.286.5446.1946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583956				2022-12-24	WOS:000084003400049
J	Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE				Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE			Similarity of the C-elegans developmental timing protein LIN-42 to circadian rhythm proteins	SCIENCE			English	Article							MINDED GENE ENCODES; CAENORHABDITIS-ELEGANS; SECONDARY STRUCTURE; NUCLEAR-PROTEIN; TIMELESS; PERIOD; CLOCK; TRANSCRIPTION; LOOP; EXPRESSION	The Caenorhabditis elegans heterochronic genes control the relative timing and sequence of many events during postembryonic development, including the terminal differentiation of the Lateral hypodermis, which occurs during the final (fourth) molt. Inactivation of the heterochronic gene lin-42 causes hypodermal terminal differentiation to occur precociously, during the third molt. LIN-42 most closely resembles the Period family of proteins from Drosophila and other organisms, proteins that function in another type of biological timing mechanism: the timing of circadian rhythms. Per mRNA Levels oscillate with an approximately 24-hour periodicity. lin-42 mRNA Levels also oscillate, but with a faster rhythm; the oscillation occurs relative to the approximately 6-hour molting cycles of postembryonic development.	Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Rougvie, AE (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA.				NICHD NIH HHS [HD007480] Funding Source: Medline; NIGMS NIH HHS [GM50227] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050227] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahante JE, 1998, GENETICS, V149, P1335; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1997, C ELEGANS, V2, P501; Bettinger JC, 1996, DEVELOPMENT, V122, P2517; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EVANS MMS, 1994, DEVELOPMENT, V120, P1971; FIRE A, COMMUNICATION; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; JEON M, UNPUB; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LIU Z, 1990, THESIS HARVARD U; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; POETHIG RS, 1988, GENETICS, V119, P959; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Telfer A, 1998, DEVELOPMENT, V125, P1889; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	33	137	144	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1141	1146		10.1126/science.286.5442.1141	http://dx.doi.org/10.1126/science.286.5442.1141			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550049				2022-12-24	WOS:000083534200039
J	Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG				Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG			Structural basis of Smad2 recognition by the Smad anchor for receptor activation	SCIENCE			English	Article							TGF-BETA RECEPTOR; PROTEINS; COMPLEX; SPECIFICITY	The Smad proteins mediate transforming growth factor-beta (TGF beta) signaling from the transmembrane serine-threonine receptor kinases to the nucleus. The Smad anchor for receptor activation (SARA) recruits Smad2 to the TGF beta receptors for phosphorylation. The crystal structure of a Smad2 MH2 domain in complex with the Smad-binding domain (SBD) of SARA has been determined at 2.2 angstrom resolution. SARA SBD, in an extended conformation comprising a rigid coil, an alpha helix, and a beta strand, interacts with the beta sheet and the three-helix bundle of Smad2 Recognition between the SARA rigid coil and the Smad2 beta sheet is essential for specificity, whereas interactions between the SARA beta strand and the Smad2 three-helix bundle contribute significantly to binding affinity. Comparison of the structures between Smad2 and a comediator Smad suggests a model for how receptor-regulated Smads are recognized by the type I receptors.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst,Dept Med Genet & Microb, Program Mol Biol & Microbiol, Toronto, ON M5G 1X5, Canada	Princeton University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu	Wrana, Jeffrey/F-8857-2013	Shi, Yigong/0000-0003-2030-168X; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA85171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA085171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Liu B, 1999, MOL CELL BIOL, V19, P424; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	19	225	249	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					92	97		10.1126/science.287.5450.92	http://dx.doi.org/10.1126/science.287.5450.92			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615055				2022-12-24	WOS:000084578400041
J	Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A				Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A			Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; INFECTION; MENINGITIS; STRATEGIES	Background: Group B streptococcal infections are a leading cause of neonatal mortality, and they also affect pregnant women and the elderly. Many cases of the disease in newborns can be prevented by the administration of prophylactic intrapartum antibiotics. In the 1990s, prevention efforts increased. In 1996, consensus guidelines recommended use of either a risk-based or a screening-based approach to identify candidates for intrapartum antibiotics. To assess the effects of the preventive efforts, we analyzed trends in the incidence of group B streptococcal disease from 1993 to 1998. Methods: Active, population-based surveillance was conducted in selected counties of eight states. A case was defined by the isolation of group B streptococci from a normally sterile site. Census and live-birth data were used to calculate the race-specific incidence of disease; national projections were adjusted for race. Results: Disease in infants less than seven days old accounted for 20 percent of all 7867 group B streptococcal infections. The incidence of early-onset neonatal infections decreased by 65 percent, from 1.7 per 1000 live births in 1993 to 0.6 per 1000 in 1998. The excess incidence of early-onset disease in black infants, as compared with white infants, decreased by 75 percent. Projecting our findings to the entire United States, we estimate that 3900 early-onset infections and 200 neonatal deaths were prevented in 1998 by the use of intrapartum antibiotics. Among pregnant girls and women, the incidence of invasive group B streptococcal disease declined by 21 percent. The incidence among nonpregnant adults did not decline. Conclusions: Over a six-year period, there has been a substantial decline in the incidence of group B streptococcal disease in newborns, including a major reduction in the excess incidence of these infections in black infants. These improvements coincide with the efforts to prevent perinatal disease by the wider use of prophylactic intrapartum antibiotics. (N Engl J Med 2000;342:15-20.).	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Serv, Atlanta, GA USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Johns Hopkins Sch Hyg & Publ Hlth, Baltimore, MD USA; Vanderbilt Med Ctr, Nashville, TN USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Minnesota Dept Hlth, Minneapolis, MN USA; Dept Human Resources, Portland, OR USA	Centers for Disease Control & Prevention - USA; Emory University; University of California System; University of California Berkeley; Johns Hopkins University; Vanderbilt University; Minnesota Department of Health (MHD)	Schrag, SJ (corresponding author), Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, MS-C23,1600 clifton Rd, Atlanta, GA 30333 USA.							Baker CJ, 1999, J INFECT DIS, V179, P142, DOI 10.1086/314574; BAKER CJ, 1973, J PEDIATR-US, V82, P724, DOI 10.1016/S0022-3476(73)80606-7; BARTON LL, 1973, J PEDIATR-US, V82, P719, DOI 10.1016/S0022-3476(73)80605-5; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P679; *COMM OBST PRACT, 173 ACOG COMM OBST P; *DEP HLTH HUM SERV, IN PRESS HLTH PEOPL; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; Fernandez M, 1998, ANTIMICROB AGENTS CH, V42, P1517, DOI 10.1128/AAC.42.6.1517; FRANCIOSI RA, 1973, J PEDIATR-US, V82, P707, DOI 10.1016/S0022-3476(73)80604-3; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Krohn MA, 1999, J INFECT DIS, V179, P1410, DOI 10.1086/314756; Locksmith GJ, 1999, AM J OBSTET GYNECOL, V180, P416, DOI 10.1016/S0002-9378(99)70225-5; MCCRACKEN GH, 1973, J PEDIATR-US, V82, P703, DOI 10.1016/S0022-3476(73)80603-1; Mohle-Boetani JC, 1999, PEDIATRICS, V103, P703, DOI 10.1542/peds.103.4.703; MOHLEBOETANI JC, 1993, JAMA-J AM MED ASSOC, V270, P1442, DOI 10.1001/jama.270.12.1442; Pearlman MD, 1998, OBSTET GYNECOL, V92, P258, DOI 10.1016/S0029-7844(98)00155-0; ROBBINS JB, 1995, ANN NY ACAD SCI, V754, P68, DOI 10.1111/j.1749-6632.1995.tb44439.x; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; Towers CV, 1998, AM J OBSTET GYNECOL, V179, P879, DOI 10.1016/S0002-9378(98)70182-6; YANCEY MK, 1994, OBSTET GYNECOL, V83, P367; YANCEY MK, 1994, OBSTET GYNECOL, V84, P816; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1996, MMWR MORB MORTAL WKL, V45, P1; 1997, MMWR MORB MORTAL WKL, V46, P473; 1998, MMWR MORB MORTAL WKL, V47, P665	28	700	730	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					15	20		10.1056/NEJM200001063420103	http://dx.doi.org/10.1056/NEJM200001063420103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620644				2022-12-24	WOS:000084575600003
J	Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT				Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT			Enhanced morphine analgesia in mice lacking beta-arrestin 2	SCIENCE			English	Article							ADRENERGIC-RECEPTOR KINASE; OPIOID-RECEPTOR; OPIATE RECEPTOR; MU-RECEPTOR; HOT-PLATE; DESENSITIZATION; GENE; INTERNALIZATION; STIMULATION; MECHANISMS	The ability of morphine to alleviate pain is mediated through a heterotrimeric guanine nucleotide binding protein (G protein)-coupled heptahelical receptor (GPCR), the mu opioid receptor (mu OR). The efficiency of GPCR signaling is tightly regulated and ultimately Limited by the coordinated phosphorylation of the receptors by specific GPCR kinases and the subsequent interaction of the phosphorylated receptors with beta-arrestin 1 and beta-arrestin 2. Functional deletion of the beta-arrestin 2 gene in mice resulted in remarkable potentiation and prolongation of the analgesic effect of morphine, suggesting that mu OR desensitization was impaired. These results provide evidence in vivo for the physiological importance of beta-arrestin 2 in regulating the function of a specific GPCR, the mu OR. Moreover, they suggest that inhibition of beta-arrestin 2 function might lead to enhanced analgesic effectiveness of morphine and provide potential new avenues for the study and treatment of pain, narcotic tolerance, and dependence.	Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu; caron002@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021; Bohn, Laura M/A-7483-2014; Bohn, Laura/A-4412-2008; Gainetdinov, Raul R/G-5875-2011	Bohn, Laura M/0000-0002-6474-8179; Gainetdinov, Raul R/0000-0003-2951-6038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA006023] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDA NIH HHS [F32 DA006023] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELKNAP JK, 1989, PHYSIOL BEHAV, V46, P69, DOI 10.1016/0031-9384(89)90324-7; BOHN LM, UNPUB; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Conner DA, 1997, CIRC RES, V81, P1021; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; Elmer GI, 1998, PAIN, V75, P129, DOI 10.1016/S0304-3959(97)00215-7; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GAINETDINOV RR, UNPUB; Gardmark M, 1998, PHARMACOL TOXICOL, V83, P252, DOI 10.1111/j.1600-0773.1998.tb01478.x; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LIN FC, UNPUB; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MAYER DJ, 1976, PAIN, V2, P379, DOI 10.1016/0304-3959(76)90080-4; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PORTOGHESE PS, 1990, J MED CHEM, V33, P1547, DOI 10.1021/jm00168a004; PORTOGHESE PS, 1993, HDB EXPT PHARM OPIOI, V1, P279; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; SMITH DJ, 1988, EUR J PHARMACOL, V156, P47, DOI 10.1016/0014-2999(88)90145-8; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Walker JKL, 1999, AM J PHYSIOL-REG I, V276, pR1214, DOI 10.1152/ajpregu.1999.276.4.R1214; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YAKSH TL, 1988, PROG BRAIN RES, V77, P371; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	39	751	770	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2495	2498		10.1126/science.286.5449.2495	http://dx.doi.org/10.1126/science.286.5449.2495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617462				2022-12-24	WOS:000084429700045
J	Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F				Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F			Pharmacological rescue of mutant p53 conformation and function	SCIENCE			English	Article							DNA-BINDING; CELL-LINES; WILD-TYPE; PROTEIN; MUTATIONS; INVITRO; DOMAIN	Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.	Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Groton, CT 06340 USA	Pfizer	Rastinejad, F (corresponding author), Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Eastern Point Rd, Groton, CT 06340 USA.							BARTEK J, 1990, ONCOGENE, V5, P893; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DANIELS DA, 1994, J MOL BIOL, V243, P639, DOI 10.1016/0022-2836(94)90038-8; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEGROS Y, 1994, ONCOGENE, V9, P3689; MILNER J, 1990, ONCOGENE, V5, P1683; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Nielsen LL, 1997, CANCER GENE THER, V4, P129; OConnor PM, 1997, CANCER RES, V57, P4285; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRUSINER SB, 1997, SCIENCE, V278, P243; ROSENFELD MR, 1995, NEUROLOGY, V45, P1533, DOI 10.1212/WNL.45.8.1533; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	24	652	690	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2507	2510		10.1126/science.286.5449.2507	http://dx.doi.org/10.1126/science.286.5449.2507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617466				2022-12-24	WOS:000084429700049
J	Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM				Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM			Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; ANGIOGENESIS; SKIN; INFLAMMATION; VENULES; TIE2	Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) are endothelial cell-specific growth factors. Direct comparison of transgenic mice overexpressing these factors in the skin revealed that the VEGF-induced blood vessels were Leaky, whereas those induced by Ang1 were nonleaky. Moreover, vessels in Ang1-overexpressing mice were resistant to Leaks caused by inflammatory agents. Coexpression of Ang1 and VEGF had an additive effect on angiogenesis but resulted in Leakage-resistant vessels typical of Ang1. Ang1 therefore may be useful for reducing microvascular Leakage in diseases in which the Leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Regeneron	Thurston, G (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.			Thurston, Gavin/0000-0002-4105-5919	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136, HL-59157] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baluk P, 1999, BRIT J PHARMACOL, V126, P522, DOI 10.1038/sj.bjp.0702323; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BERGMAN RK, 1975, J ALLERGY CLIN IMMUN, V55, P378, DOI 10.1016/0091-6749(75)90076-7; Cunha-Vaz J, 1998, EUR J OPHTHALMOL, V8, P127, DOI 10.1177/112067219800800301; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Erjefalt JS, 1998, CLIN EXP ALLERGY, V28, P1013; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FUJII E, 1994, N-S ARCH PHARMACOL, V350, P361; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Inoue H, 1997, EUR J PHARMACOL, V333, P231, DOI 10.1016/S0014-2999(97)01040-6; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P607, DOI 10.1083/jcb.11.3.607; MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; OHRUI T, 1992, J ALLERGY CLIN IMMUN, V89, P933, DOI 10.1016/0091-6749(92)90215-N; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Schainfeld RM, 1999, ANN INTERN MED, V130, P442, DOI 10.7326/0003-4819-130-5-199903020-00017; Shiels IA, 1998, MED HYPOTHESES, V50, P113, DOI 10.1016/S0306-9877(98)90195-5; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; SVENSJO E, 1986, FASEB J, V45, P89; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; WADSWORTH JDF, 1993, BIOCHEM J, V295, P537, DOI 10.1042/bj2950537; ZWEIFACH BW, 1973, ANNU REV PHYSIOL, V35, P117, DOI 10.1146/annurev.ph.35.030173.001001	31	1087	1167	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2511	2514		10.1126/science.286.5449.2511	http://dx.doi.org/10.1126/science.286.5449.2511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617467				2022-12-24	WOS:000084429700050
J	Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B				Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B			Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic	SCIENCE			English	Article							C-TERMINAL PART; ANTIMICROBIAL PEPTIDE; BACTERIAL-MEMBRANES; NISIN; TRANSLOCATION; VANCOMYCIN; VESICLES; BILAYERS	Resistance to antibiotics is increasing in some groups of clinically important pathogens. For instance, high vancomycin resistance has emerged in enterococci. Promising alternative antibiotics are the peptide antibiotics, abundant in host defense systems, which kill their targets by permeabilizing the plasma membrane, These peptides generally do not act via specific receptors and are active in the micromolar range. Here it is shown that vancomycin and the antibacterial peptide nisin Z use the same target: the membrane-anchored cell wall precursor Lipid II, Nisin combines high affinity for Lipid II with its pore-forming ability, thus causing the peptide to be highly active (in the nanomolar range).	Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53105 Bonn, Germany; NIZO, Food Res Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	Utrecht University; University of Bonn; NIZO Food Research; University of Groningen	Breukink, E (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	e.j.breukink@chem.uu.nl	Kuipers, Oscar/B-6752-2009; Breukink, Eefjan/I-3039-2016	Kuipers, Oscar/0000-0001-5596-7735; Breukink, Eefjan/0000-0002-7311-0660				Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STONE KJ, 1973, J BIOL CHEM, V249, P1823; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VanKraaij C, 1997, EUR J BIOCHEM, V247, P114; WILLIAMS DH, 1988, BIOCHEM PHARMACOL, V37, P133, DOI 10.1016/0006-2952(88)90765-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	17	614	634	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2361	2364		10.1126/science.286.5448.2361	http://dx.doi.org/10.1126/science.286.5448.2361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600751	Green Submitted			2022-12-24	WOS:000084318500068
J	Apfeld, J; Kenyon, C				Apfeld, J; Kenyon, C			Regulation of lifespan by sensory perception in Caenorhabditis elegans	NATURE			English	Article							NUCLEOTIDE-GATED CHANNEL; DAUER LARVA FORMATION; C-ELEGANS; NERVOUS-SYSTEM; LONGEVITY; DAF-2; GENES; SPAN; DIAPAUSE; PATHWAY	Caenorhabditis elegans senses environmental signals through ciliated sensory neurons located primarily in sensory organs in the head and tail. Cilia function as sensory receptors, and mutants with defective sensory cilia have impaired sensory perception(1,2) Cilia are membrane-bound microtubule-based structures and in C. elegans are only found at the dendritic endings of sensory neurons(3). Here we show that mutations that cause defects in sensory cilia or their support cells, or in sensory signal transduction, extend lifespan. Our findings imply that sensory perception regulates the lifespan of this animal, and suggest that in nature, its Lifespan may be regulated by environmental cues.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu		Apfeld, Javier/0000-0001-9897-5671				Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Coburn CM, 1998, DEVELOPMENT, V125, P249; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Collet J, 1998, GENETICS, V148, P187; DORMAN JB, 1995, GENETICS, V141, P1399; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Komatsu H, 1999, BRAIN RES, V821, P160, DOI 10.1016/S0006-8993(99)01111-7; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; LARSEN PL, 1995, GENETICS, V139, P1567; LAWLESS JF, 1982, MODELS METHODS LIFET; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Peckol EL, 1999, DEVELOPMENT, V126, P1891; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	27	394	438	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					804	809		10.1038/45544	http://dx.doi.org/10.1038/45544			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617200				2022-12-24	WOS:000084330500064
J	Forbes, RB; Lees, A; Waugh, N; Swingler, RJ				Forbes, RB; Lees, A; Waugh, N; Swingler, RJ			Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; GUIDELINES; CARE	Objective To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. Design Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey Local and published costs were used. Effectiveness was modelled using data on relative risk reductions from a randomised trial of interferon beta-lb. Setting Tayside region, 1993-5. Subjects 132 ambulatory people with secondary; progressive multiple sclerosis. Main outcome measures Cost per quality adjusted life lear (QALY) gained. Rate of relapse and proportion becoming wheelchair dependent ol:er three years. Results The number needed to treat for 30 months to delay time to wheelchair dependence in one per-son by nine months was 18 (95% confidence interval 5 to 26), For every 18 people treated for 30 months, sh relapses would be prevented, gaining 0.397 discounted QALYs. The cost per QALY gained was pound 1 024 667 (pound 276 466 to pound 1 485 499). If treatment was restricted to patients attending neurology services, the number needed to treat was 14 (cost per QALY gained pound 833 514 (pound 161 358 to infinity)). The cost per QALY gained was not sensitive to changes in cost which took account of a societal perspective. Conclusions The cost per QALY; gained from interferon beta is high because of the high drug cost and modest clinical effect Resources could be used more efficiently elsewhere.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurol, Dundee DD1 9SY, Scotland; Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland; Scottish Hlth Purchasing Informat Ctr, Aberdeen AB15 6RE, Scotland	University of Dundee	Forbes, RB (corresponding author), Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland.	raeburn.forbes@royalhospitals.n-i-nhs.uk		Forbes, Raeburn/0000-0002-1444-7909				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Auty A, 1998, CAN J NEUROL SCI, V25, P23; Blumhardt L., 1996, BR J MED EC, V10, P99; *BRIT MED ASS, 1995, BRIT NAT FORM; BROWN MG, 1996, THERAPEUTIC EC ASSES; Busch MP, 1997, TRANSFUSION, V37, P1003, DOI 10.1046/j.1537-2995.1997.371098016437.x; Carton H, 1998, J NEUROL NEUROSUR PS, V64, P444, DOI 10.1136/jnnp.64.4.444; Dolan P, 1995, SOCIAL TARIFF EUROQO; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Forbes RB, 1999, AM J EPIDEMIOL, V149, P1016; FREEMAN J, 1997, STANDARDS HEALTHCARE; Gardner MJ, 1989, STAT CONFIDENCE, P28; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; Goodkin DE, 1998, LANCET, V352, P1486, DOI 10.1016/S0140-6736(98)00057-9; Graham B, 1997, BRIT J GEN PRACT, V47, P170; Holmes J, 1997, BRIT MED J, V314, P601; HOLMES J, 1998, J NEUROL NEUROSUR PS, V64, P420; Holmes J., 1995, BR J MED EC, V8, P181; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MCALPINE D, 1952, Q J MED, V21, P135; MOONEY C, 1992, EC MED HLTH CARE, P5; OBRIEN B, 1997, MULT SCLER, V47, P170; PARKIN D, 1998, HLTH TECHNOL ASSESSM, V2; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Richards RG, 1996, BRIT MED J, V313, P1159, DOI 10.1136/bmj.313.7066.1159; SACKETT DL, 1996, PRACTICE TEACH EVIDE; Stolp-Smith KA, 1998, NEUROLOGY, V50, P1594, DOI 10.1212/WNL.50.6.1594; Tolley KH, 1997, PHARMACOECONOMICS, V11, P210, DOI 10.2165/00019053-199711030-00002; Tremlett HL, 1998, J NEUROL NEUROSUR PS, V65, P362, DOI 10.1136/jnnp.65.3.362; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; Vickrey BG, 1997, J CLIN EPIDEMIOL, V50, P557, DOI 10.1016/S0895-4356(97)00001-2; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1998, MS MATTERS       NOV	39	69	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1529	1533		10.1136/bmj.319.7224.1529	http://dx.doi.org/10.1136/bmj.319.7224.1529			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591710	Green Published, Bronze			2022-12-24	WOS:000084245600020
J	Stopfer, M; Laurent, G				Stopfer, M; Laurent, G			Short-term memory in olfactory network dynamics	NATURE			English	Article							OSCILLATING NEURAL ASSEMBLIES; VISUAL-CORTEX; INFORMATION; SYNCHRONIZATION; INSECTS; BULB; CAT	Neural assemblies in a number of animal species display self-organized, synchronized oscillations in response to sensory stimuli in a variety of brain areas.(1-5). In the olfactory system of insects, odour-evoked oscillatory synchronization of antennal lobe projection neurons (PNs) is superimposed on slower and stimulus-specific temporal activity patterns. Hence, each odour activates a specific and dynamic projection neuron assembly whose evolution during a stimulus is locked to the oscillation clock(6,7). Here we examine, using locusts, the changes in population dynamics of projection-neuron assemblies over repeated odour stimulations, as would occur when an animal first encounters and then repeatedly samples an odour for identification or localization. We find that the responses of these assemblies rapidly decrease in intensity, while they show a marked increase in spike time precision and inter-neuronal oscillatory coherence. Once established, this enhanced precision in the representation endures for several minutes. This change is stimulus-specific, and depends on events within the antennal lobe circuits, independent of olfactory receptor adaptation: it may thus constitute a form of sensory memory. Our results suggest that this progressive change in olfactory network dynamics serves to converge, over repeated odour samplings, on a more precise and readily classifiable odour representation, using relational information contained across neural assemblies.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.		Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1978, ELECTROEN CLIN NEURO, V44, P586, DOI 10.1016/0013-4694(78)90126-8; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Kay S. M., 1988, MODERN SPECTRAL ESTI; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; LAWLESS H, 1997, TASTING SMELLING; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; MASSON C, 1990, PHYSIOL REV, V70, P199, DOI 10.1152/physrev.1990.70.1.199; Mellon D, 1997, J COMP PHYSIOL A, V180, P553, DOI 10.1007/s003590050072; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; PRECHTL JC, 1994, P NATL ACAD SCI USA, V91, P12467, DOI 10.1073/pnas.91.26.12467; SLIFER EH, 1965, J MORPHOL, V114, P393; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WEHT M, 1999, J NEUROSCI, V19, P381	21	191	193	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					664	668		10.1038/45244	http://dx.doi.org/10.1038/45244			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604472				2022-12-24	WOS:000084189800066
J	Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM				Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM			The temporal requirement for endothelin receptor-B signalling during neural crest development	NATURE			English	Article							GENE-EXPRESSION; TRANSGENIC MICE; ENTERIC NEURONS; MAMMALIAN-CELLS; MOUSE EMBRYO; PIGMENTATION; MELANOCYTES; MUTATIONS; PROLIFERATION; DROSOPHILA	Endothelin receptor B (EDNRB) is a G-protein-coupled receptor with seven transmembrane domains which is required for the development of melanocytes and enteric neurons. Mice that are homozygous for a null mutation in the Ednrb gene are almost completely white and die as juveniles from megacolon, To determine when EDNRB signalling is required during embryogenesis, we have exploited the tetracycline-inducible system to generate strains of mice in which the endogenous Ednrb locus is under the control of the tetracycline-dependant transactivators tTa or rtTA. By using this system to express Ednrb at different stages of embryogenesis, we have determined that EDNRB is required during a restricted period of neural crest development between embryonic days 10 and 12.5. Moreover, our results imply that EDNRB is required for the migration of both melanoblasts and enteric neuroblasts.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hearn CJ, 1998, DEV BIOL, V197, P93, DOI 10.1006/dbio.1998.8876; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; KAPUR RP, 1995, DEVELOPMENT, V121, P3787; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Le Douarin N.M., 1982, NEURAL CREST; Leibl MA, 1999, GUT, V44, P246, DOI 10.1136/gut.44.2.246; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Newgreen DF, 1995, ACTA ANAT, V154, P243; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Reid K, 1996, DEVELOPMENT, V122, P3911; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STEEL KP, 1992, DEVELOPMENT, V115, P1111; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu JJ, 1999, DEVELOPMENT, V126, P1161; Yoshida H, 1996, DEVELOPMENT, V122, P1207	44	262	267	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					496	501		10.1038/990040	http://dx.doi.org/10.1038/990040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591209				2022-12-24	WOS:000084013200046
J	Sloan, FA; Taylor, DH				Sloan, FA; Taylor, DH			Private and public choices in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRENDS		Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA	Duke University	Sloan, FA (corresponding author), Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA.							COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Gramelspacher GP, 1997, J GEN INTERN MED, V12, P346, DOI 10.1007/s11606-006-5082-9; *I MED, 1997, APPR DEATH IMPR CAR; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	8	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2078	2078		10.1001/jama.282.21.2078	http://dx.doi.org/10.1001/jama.282.21.2078			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591394	hybrid			2022-12-24	WOS:000083908700031
J	Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL				Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL			Structure of the C2 domain of human factor VIII at 1.5 angstrom resolution	NATURE			English	Article							COAGULATION FACTOR-V; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; BINDING; PHOSPHATIDYLSERINE; INACTIVATION; MECHANISM; INHIBITOR; PEPTIDE; MODELS	Human factor VIII is a plasma glycoprotein that has a Critical role in blood Coagulation(1,2). Factor VIII circulates as a complex with von Willebrand factor(3). After cleavage by thrombin, factor VIIIa associates with factor IXa at the surface of activated platelets or endothelial cells(4,5). This complex activates factor X (refs 6, 7), which in turn converts prothrombin to thrombin in the presence of factor Va (refs 8, 9). The carboxyl-terminal C2 domain of factor VIII contains sites that are essential for its binding to von Willebrand factor and to negatively charged phospholipid surfaces(4,10,11). Here we report the structure of human factor VIII C2 domain at 1.5 Angstrom resolution. The structure reveals a beta-sandwich core, from which two beta-turns and a loop display a group of solvent-exposed hydrophobic residues. Behind the hydrophobic surface lies a ring. of positively charged residues. This motif suggests a mechanism for membrane binding involving both hydrophobic and electrostatic interactions. The structure explains, in part, mutations in the C2 region of factor VIII that lead to bleeding disorders in haemophilia A.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, Seattle, WA 98109 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, 1100 Fairview Ave N A3-023, Seattle, WA 98109 USA.	bstoddar@fhcrc.org	Pratt, Kathleen P/E-9489-2019	Pratt, Kathleen/0000-0001-6837-6133				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; *IMP COLL MED SCH, HAEM MUT DAT; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; Kuwabara I, 1999, J IMMUNOL METHODS, V224, P89, DOI 10.1016/S0022-1759(99)00012-5; LAFORTELLE E, 1997, CRYSTALLOGRAPHIC COM, V7, P100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANN KG, 1990, BLOOD, V76, P1; NIEH YP, IN PRESS ACTA CRYS D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TAKESHMA K, UNPUB J BIOL CHEM; VANDERBEEKEN Y, 1981, AM J REPROD IMMUNOL, V1, P236, DOI 10.1111/j.1600-0897.1981.tb00047.x; Veeraraghavan S, 1998, BIOCHEM J, V332, P549, DOI 10.1042/bj3320549; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030	30	270	288	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					439	442		10.1038/46601	http://dx.doi.org/10.1038/46601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586887				2022-12-24	WOS:000083913600063
J	Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D				Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D			CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid	NATURE			English	Article							TRANSPORT VESICLES; COATED VESICLES; PROTEIN; DYNAMIN	Membrane fission is essential in intracellular transport. Acyl-coenzyme As (acyl-CoAs) are important in lipid remodelling and are required for fission of COPI-coated vesicles(1). Here we show that CtBP/BARS, a protein that functions in the dynamics of Golgi tubules(2), is an essential component of the fission machinery operating at Golgi tubular networks, including Golgi compartments involved in protein transport and sorting. CtBP/BARS-induced fission was preceded by the formation of constricted sites in Golgi tubules, whose extreme curvature is likely to involve local changes in the membrane lipid composition. We find that CtBP/BARS uses acyl-CoA to selectively catalyse the acylation of lysophosphatidic acid to phosphatidic acid both in pure lipidic systems and in Golgi membranes, and that this reaction is essential for fission. Our results indicate a key role for lipid metabolic pathways in membrane fission.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Ist Ric Farmacol Mario Negri, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Ist Dermopat Immacolata, Lab Vasc Pathol, Rome, Italy; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Utrecht University	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy.	luini@cmns.mnegri.it; corda@cmns.mnegri.it	salmona, mario/ABI-4066-2020; Facchiano, Francesco/K-8716-2016; salmona, mario/AAA-7116-2020; Corda, Daniela/K-6385-2016; Spanò, Stefania/F-4951-2011; Colanzi, Antonino/D-6821-2012	Facchiano, Francesco/0000-0003-4313-0617; salmona, mario/0000-0002-9098-9873; Corda, Daniela/0000-0002-3614-751X; Spanò, Stefania/0000-0001-9154-7463; Colanzi, Antonino/0000-0002-5643-0216	Telethon [E.0982, E.1105] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; Buccione R, 1996, J BIOL CHEM, V271, P3523; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CLUETT EB, 1992, J CELL SCI, V103, P773; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Rambourg A., 1997, GOLGI APPARATUS, P37; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3	23	259	269	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					429	433		10.1038/46587	http://dx.doi.org/10.1038/46587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586885				2022-12-24	WOS:000083913600061
J	Schutzer, SE; Coyle, PK; Reid, P; Holland, B				Schutzer, SE; Coyle, PK; Reid, P; Holland, B			Borrelia burgdorferi-specific immune complexes in acute Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURFACE PROTEIN-A; CEREBROSPINAL-FLUID; OSPA; DIAGNOSIS; ANTIBODY; VACCINE	Context Diagnosis of infection with Borrelia burgdorferi, the cause of Lyme disease (LD), has been impeded by the lack of effective assays to detect active infection. Objective To determine whether B burgdorferi-specific immune complexes are detectable during active infection in LD. Design, Setting, and Patients Cross-sectional analysis of serum samples from 168 patients fulfilling Centers for Disease Control and Prevention surveillance criteria for LD and 145 healthy and other disease controls conducted over 8 years. Tests were performed blinded. Main Outcome Measure Detection of B burgdorferi immune complexes by enzyme-linked immunosorbent assay and Western blot. Results The B burgdorferi immune complexes were found in 25 of 26 patients with early seronegative erythema migrans (EM) LD; 105 of 107 patients with seropositive EM LD; 6 of 10 patients who were seronegative with culture-positive EM; 0 of 12 patients who were treated and recovered from LD; and 13 of 13 patients with neurologic LD without EM. Among 147 controls, B burgdorferi immune complex was found in 0 of 50 healthy individuals; 0 of 40 patients with persistent fatigue; 0 of 7 individuals with frequent tick exposure; and 2 of 50 patients with other diseases. Conclusion These data suggest that B burgdorferi immune complex formation is a common process in active LD. Analysis of the B burgdorferi immune complexes by a simple technique has the potential to support or exclude a diagnosis of early as well as active LD infection.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med, Newark, NJ 07103 USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schutzer, SE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, 1855 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034092] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31561] Funding Source: Medline; NIAMS NIH HHS [AR41518] Funding Source: Medline; NINDS NIH HHS [NS34092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P531; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC), 1995, MMWR MORB MORTAL WKL, V44, P590; COYLE PK, 1990, ANN NEUROL, V28, P739, DOI 10.1002/ana.410280603; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DIGEON M, 1977, J IMMUNOL METHODS, V16, P165, DOI 10.1016/0022-1759(77)90051-5; DOBSON SRM, 1988, J INFECT DIS, V158, P940, DOI 10.1093/infdis/158.5.940; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; FIKRIG E, 1992, J INFECT DIS, V165, P1127, DOI 10.1093/infdis/165.6.1127; INMAN RD, 1982, J CLIN INVEST, V70, P271, DOI 10.1172/JCI110614; JONES VE, 1981, J IMMUNOL METHODS, V44, P249, DOI 10.1016/0022-1759(81)90045-4; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RYS PN, 1993, J CLIN MICROBIOL, V31, P2356, DOI 10.1128/JCM.31.9.2356-2360.1993; Schutzer SE, 1997, J CLIN INVEST, V100, P763, DOI 10.1172/JCI119589; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SCHUTZER SE, 1994, J CLIN INVEST, V94, P454, DOI 10.1172/JCI117346; Schutzer SE, 1997, NEW ENGL J MED, V337, P794, DOI 10.1056/NEJM199709113371118; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; THEOFILOPOULOS AN, 1980, AM J PATHOL, V100, P529	24	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1942	1946		10.1001/jama.282.20.1942	http://dx.doi.org/10.1001/jama.282.20.1942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580460				2022-12-24	WOS:000083763400029
J	Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA				Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA			Mesenchymal to epithelial conversion in rat metanephros is induced by LIF	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; ADHESION MOLECULE UVOMORULIN; IL-6 SIGNAL TRANSDUCER; GROWTH-FACTOR; EMBRYONIC KIDNEY; MOUSE KIDNEY; TARGETED DISRUPTION; TYROSINE KINASE; NERVOUS-SYSTEM; ORGAN-CULTURE	Inductive signals cause conversion of mesenchyme into epithelia during the formation of many organs. Yet a century of study has not revealed the inducing molecules. Using a standard model of induction, we found that ureteric bud cells secrete factors that convert kidney mesenchyme to epithelia that, remarkably, then form nephrons. Purification and sequencing of one such factor identified it as leukemia inhibitory factor (LIF). LIF acted on epithelial precursors that we identified by the expression of Pax2 and Wnt4. Other IL-6 type cytokines acted like LIF, and deletion of their shared receptor reduced nephron development. In situ, the ureteric bud expressed LIF, and metanephric mesenchyme expressed its receptors. The data suggest that IL-6 cytokines are candidate regulators of mesenchymal to epithelial conversion during kidney development.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; Tokyo Med & Dent Univ, Dept Mol Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan; Osaka Univ, Dept Mol Immunol, Suita, Osaka 5650871, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Columbia University; Columbia University; University of Washington; University of Washington Seattle; Tokyo Medical & Dental University (TMDU); Osaka University; Memorial Sloan Kettering Cancer Center	Barasch, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; Malach, Stephen/0000-0002-2771-4957				ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; AVNER ED, 1985, IN VITRO CELL DEV B, V21, P297; Barasch J, 1997, AM J PHYSIOL-RENAL, V273, pF757, DOI 10.1152/ajprenal.1997.273.5.F757; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; BARD JBL, 1991, DEVELOPMENT, V113, P193; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Boyden EA, 1927, P SOC EXP BIOL MED, V24, P572; Cho EA, 1998, DEVELOPMENT, V125, P803; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; EKBLOM P, 1981, J CELL BIOL, V89, P276, DOI 10.1083/jcb.89.2.276; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; EKBLOM P, 1983, P NATL ACAD SCI-BIOL, V80, P2651, DOI 10.1073/pnas.80.9.2651; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gilbert T, 1996, KIDNEY INT, V50, P783, DOI 10.1038/ki.1996.377; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; Gruenwald P, 1943, ANAT REC, V86, P321, DOI 10.1002/ar.1090860303; Hara T, 1998, DEV BIOL, V201, P144, DOI 10.1006/dbio.1998.8990; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOLTHOFER H, 1984, LAB INVEST, V50, P552; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLEIN G, 1988, DEVELOPMENT, V102, P749; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; LEHTONEN E, 1985, DEV BIOL, V108, P481, DOI 10.1016/0012-1606(85)90051-X; LEVINE E, 1994, DEVELOPMENT, V120, P901; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MAYER M, 1994, DEVELOPMENT, V120, P143; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; METCALF D, 1988, LEUKEMIA, V2, P216; MURPHY M, 1993, DEVELOPMENT, V117, P1173; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NORDLING S, 1971, J EMBRYOL EXP MORPH, V26, P231; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REUTER R, 1993, DEVELOPMENT, V119, P1135; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TEPASS U, 1994, DEVELOPMENT, V120, P579; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	71	212	222	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					377	386		10.1016/S0092-8674(00)81524-X	http://dx.doi.org/10.1016/S0092-8674(00)81524-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571180	hybrid			2022-12-24	WOS:000083709300005
J	Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP				Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP			Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade	SCIENCE			English	Article							ANGELMAN-SYNDROME; PROTEIN; E6-AP; P53; EXPRESSION; CLONING; UBE3A; UBCH7	The E6AP ubiquitin-protein Ligase (E3) mediates the human papillomavirus-induced degradation of the p53 tumor suppressor in cervical cancer and is mutated in Angelman syndrome, a neurological disorder. The crystal structure of the catalytic hect domain of E6AP reveals a bilobal structure with a broad catalytic cleft at the junction of the two Lobes. The cleft consists of conserved residues whose mutation interferes with ubiquitin-thioester bond formation and is the site of Angelman syndrome mutations. The crystal structure of the E6AP hect domain bound to the UbcH7 ubiquitin-conjugating enzyme (E2) reveals the determinants of E2-E3 specificity and provides insights into the transfer of ubiquitin from the E2 to the E3.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick; Harvard University; Harvard Medical School	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		高, 雨莉/HGU-8187-2022	Howley, Peter/0000-0002-8668-9579				Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Malzac P, 1998, AM J HUM GENET, V62, P1353, DOI 10.1086/301877; MAYER RJ, 1998, UBIQUITIN BIOL CELL, P429; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439	17	421	451	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1321	1326		10.1126/science.286.5443.1321	http://dx.doi.org/10.1126/science.286.5443.1321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558980				2022-12-24	WOS:000083675500032
J	Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE				Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE			Olfaction - The world smells different to each nostril	NATURE			English	Article							NASAL CYCLE; ODORANTS; NOSE; FLOW		Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Minist Environm Protect, IL-72100 Ramle, Israel	Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Neurosci Program, Stanford, CA 94305 USA.		Sullivan, Edith V/ABD-5684-2021; Gabrieli, John/AAJ-2869-2020	Sullivan, Edith V/0000-0001-6739-3716; Sobel, Noam/0000-0002-3232-9391				BOJSENMOLLER F, 1971, J ANAT, V110, P25; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; Frye RE, 1995, NEUROL DIS, P471; GILBERT AN, 1987, ACTA OTO-LARYNGOL, V104, P180, DOI 10.3109/00016488709109065; HASEGAWA M, 1977, MAYO CLIN PROC, V52, P28; Kayser R., 1895, ARCH LARYNGOL RHINOL, V8, P101; Mirza N, 1997, LARYNGOSCOPE, V107, P62, DOI 10.1097/00005537-199701000-00014; MOZELL MM, 1973, SCIENCE, V181, P1247, DOI 10.1126/science.181.4106.1247; MOZELL MM, 1991, CHEM SENSES, V16, P631, DOI 10.1093/chemse/16.6.631; PRINCIPATO JJ, 1970, ARCHIV OTOLARYNGOL, V91, P71	10	98	100	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					35	35		10.1038/46944	http://dx.doi.org/10.1038/46944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573415				2022-12-24	WOS:000083638600032
J	Henney, JE				Henney, JE			First antibacterial for VREF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-24	WOS:000083368400007
J	Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW				Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW			NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BACULOVIRUS INHIBITOR; CELL-DEATH; MACROMOLECULES; GENE; IAP; COUPLINGS; CASPASES; FAMILY; SURVIVIN	The inhibitor-of-apoptosis (IAP) family of proteins, originally identified in baculoviruses(1), regulate programmed cell death in a variety of organisms(2-6), IAPs inhibit specific enzymes (caspases) in the death cascade(7-11) and contain one to three modules of a common 70-amino-acid motif called the BIR domain(12). Here we describe the nuclear magnetic resonance structure of a region encompassing the second BIR domain (BIR2) of a human IAP family member, XIAP (also called hILP or MIHA). The structure of the BIR domain consists of a three-stranded antiparallel beta-sheet and four alpha-helices and resembles a classical zinc finger(13). Unexpectedly, conserved amino acids within the linker region between the BIR1 and BIR2 domains were found to be critical for inhibiting caspase-3. The absence or presence of these residues may explain the differences in caspase inhibition observed for different truncated and full-length IAPs(10,11). Our data further indicate that these residues may bind to the active site and that the BIR domain may interact with an adjacent site on the enzyme.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BRUNGER AT, 1992, XPLOR 3 1 ANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rance M, 1999, J MAGN RESON, V136, P92, DOI 10.1006/jmre.1998.1626; RORUNDA I, 1996, NAT STRUCT BIOL, V3, P619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024	30	288	322	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					818	822		10.1038/44617	http://dx.doi.org/10.1038/44617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548111				2022-12-24	WOS:000083368700060
J	Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA				Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA			Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; PROTEIN-KINASE; HUMAN CANCERS; CELL-CYCLE; S-PHASE; ANTICANCER AGENTS; MISMATCH REPAIR; P53 MUTATIONS; PATHWAY	The hCHK2 gene encodes the human homolog of the yeast Cds1 and Rad53 G(2) checkpoint kinases, whose activation in response to DNA damage prevents cellular entry into mitosis. Here, it is shown that heterozygous germ Line mutations in hCHK2 occur in Li-Fraumeni syndrome, a highly penetrant Familiar cancer phenotype usually associated with inherited mutations in the TP53 gene. These observations suggest that hCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and they also provide a link between the central role of p53 inactivation in human cancer and the well-defined G(2) checkpoint in yeast.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA; Paterson Inst Canc Res, Canc Res Campaign, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Harvard Univ, Sch Med, Boston, MA 02114 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02114 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; Royal Manchester Childrens Hosp, Canc Res Campaign, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England	Harvard University; Massachusetts General Hospital; Harvard University; Paterson Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Manchester Children's Hospital	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Bldg 149, Charlestown, MA 02139 USA.	Haber@helix.mgh.harvard.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; BIRCH JM, 1994, CANCER RES, V54, P1298; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eng C, 1997, CANCER EPIDEM BIOMAR, V6, P379; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GARBER JE, 1991, CANCER RES, V51, P6094; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OConnor PM, 1997, CANCER RES, V57, P4285; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prives C, 1999, J PATHOL, V187, P112; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1909, TRENDS BIOCHEM SCI, V23, P399; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P261; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	55	695	713	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2528	2531		10.1126/science.286.5449.2528	http://dx.doi.org/10.1126/science.286.5449.2528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617473				2022-12-24	WOS:000084429700056
J	Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ				Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ			Photic induction of mPer1 and mPer2 in Cry-deficient mice lacking a biological clock	SCIENCE			English	Article							BLUE-LIGHT PHOTORECEPTORS; HUMAN PHOTOLYASE HOMOLOG; DROSOPHILA PERIOD GENE; CIRCADIAN CLOCK; EXPRESSION; SIMILARITY; ORTHOLOG; MAMMALS; RHYTHMS; OPSIN	Mice Lacking mCry1 and mCry2 are behaviorally arrhythmic. As shown here, cyclic expression of the clock genes mPer1 and mPer2 (mammalian Period genes 1 and 2) in the suprachiasmatic nucleus and peripheral tissues is abolished and mPer1 and mPer2 mRNA Levels are constitutively high. These findings indicate that the biological clock is eliminated in the absence of both mCRY1 and mCRY2 (mammalian cryptochromes 1 and 2) and support the idea that mammalian CRY proteins act in the negative Limb of the circadian feedback Loop. The mCry double-mutant mice retain the ability to have mPer1 and mPer2 expression induced by a brief Light stimulus known to phase-shift the biological clock in wild-type animals. Thus, mCRY1 and mCRY2 are dispensable for Light-induced phase shifting of the biological clock.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands	Kobe University; Tohoku University; Erasmus University Rotterdam	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	van der Horst, Gijsbertus TJ/E-3661-2015; Hoeijmakers, Jan/AAX-6972-2021; Jansen, Heiko T./A-5770-2008	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; KURNE K, 1999, CELL, V98, P193; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Soni BG, 1997, FEBS LETT, V406, P279, DOI 10.1016/S0014-5793(97)00287-1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; YAMAGUCHI S, UNPUB; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	35	307	319	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2531	2534		10.1126/science.286.5449.2531	http://dx.doi.org/10.1126/science.286.5449.2531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617474				2022-12-24	WOS:000084429700057
J	Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW				Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW			Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-DOSE METHOTREXATE; CULDOCENTESIS; DIAGNOSIS	Background: The use of methotrexate for the treatment of women with tubal ectopic pregnancies is now common practice. However, the clinical and hormonal determinants of the success of this treatment are not known. Methods: We studied 350 women with tubal ectopic pregnancies who were treated with methotrexate intramuscularly according to a single-dose protocol. Pretreatment serum concentrations of human chorionic gonadotropin and progesterone, the size and volume of the gestational mass, fetal cardiac activity, and the presence of fluid (presumably blood) in the peritoneal cavity were correlated with the efficacy of therapy, as defined by resolution of the ectopic pregnancy without the need for surgical intervention. Results: There was no relation between the women's age or parity, the size or volume of the conceptus, or the presence of fluid in the peritoneal cavity and the efficacy of treatment. Among the 320 women in whom treatment was successful (91 percent), the mean (+/-SD) serum chorionic gonadotropin and progesterone concentrations were 4019+/-6362 mIU per milliliter and 6.9+/-6.7 ng per milliliter (21.9+/-21.3 nmol per liter), respectively, as compared with 13,420+/-16,590 mIU per milliliter and 10.2+/-5.5 ng per milliliter (32.4+/-17.5 nmol per liter) (P<0.001 and P=0.02) in the 30 women in whom treatment was not successful. Fetal cardiac activity was present in 12 percent of the successfully treated cases and 30 percent of those in which treatment was not successful (P=0.01). Regression analysis revealed the pretreatment serum chorionic gonadotropin concentration to be the only factor that contributed to the failure rate. Conclusions: Among women with tubal ectopic pregnancies, a high serum chorionic gonadotropin concentration is the most important factor associated with failure of treatment with a single-dose methotrexate protocol. (N Engl J Med 1999;341:1974-8.) (C)1999, Massachusetts Medical Society.	Univ Tennessee, Div Gynecol, Dept Obstet & Gynecol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lipscomb, GH (corresponding author), Rm E102,853 Jefferson Ave, Memphis, TN 38103 USA.							CARTWRIGHT PS, 1984, J REPROD MED, V29, P88; CORSAN GH, 1995, HUM REPROD, V10, P2719, DOI 10.1093/oxfordjournals.humrep.a135774; FERNANDEZ H, 1995, FERTIL STERIL, V63, P25, DOI 10.1016/S0015-0282(16)57291-4; GLOCK JL, 1994, FERTIL STERIL, V62, P716; Kooi S, 1992, Obstet Gynecol Surv, V47, P739, DOI 10.1097/00006254-199211000-00001; Lipscomb GH, 1998, AM J OBSTET GYNECOL, V178, P1354, DOI 10.1016/S0002-9378(98)70343-6; RANSOM MX, 1994, OBSTET GYNECOL, V83, P1033, DOI 10.1097/00006250-199406000-00026; ROMERO R, 1985, OBSTET GYNECOL, V65, P519; SHALEV E, 1995, FERTIL STERIL, V63, P20, DOI 10.1016/S0015-0282(16)57290-2; Stika CS, 1996, AM J OBSTET GYNECOL, V174, P1840, DOI 10.1016/S0002-9378(96)70219-3; STORRING PL, 1980, J ENDOCRINOL, V84, P295, DOI 10.1677/joe.0.0840295; STOVALL TG, 1991, OBSTET GYNECOL, V77, P754; STOVALL TG, 1990, FERTIL STERIL, V54, P537; VERMESH M, 1990, AM J OBSTET GYNECOL, V162, P411, DOI 10.1016/0002-9378(90)90397-P	14	216	230	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1974	1978		10.1056/NEJM199912233412604	http://dx.doi.org/10.1056/NEJM199912233412604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607814				2022-12-24	WOS:000084399400004
J	Aithal, GP; Rawlins, MD; Day, CP				Aithal, GP; Rawlins, MD; Day, CP			Accuracy of hepatic adverse drug reaction reporting in one English health region	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Day, CP (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Day, Christopher/Z-3305-2019	Aithal, Guruprasad/0000-0003-3924-4830				Aithal PG, 1999, GUT, V44, P731, DOI 10.1136/gut.44.5.731; BENICHOU C, 1990, J HEPATOL, V11, P272; DANAN G, 1988, J HEPATOL, V7, P132, DOI 10.1016/S0168-8278(88)80517-8; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1053/jhep.1997.v26.pm0009303497; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41	5	94	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1541	1541		10.1136/bmj.319.7224.1541	http://dx.doi.org/10.1136/bmj.319.7224.1541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591713	Green Published, Bronze			2022-12-24	WOS:000084245600024
J	Hadfield, SJ; Axton, JM				Hadfield, SJ; Axton, JM			Reproduction - Germ cells colonized by endosymbiotic bacteria	NATURE			English	Article							DROSOPHILA; PLASM		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Hadfield, SJ (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Axton, Myles/AAZ-4093-2020	Axton, Myles/0000-0002-8042-4131				BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CALLAINI G, 1994, J CELL SCI, V107, P673; GLOVER DM, 1990, NATURE, V348, P117, DOI 10.1038/348117a0; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; HOLDEN PR, 1993, MOL GEN GENET, V240, P213, DOI 10.1007/BF00277059; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587	11	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					482	482		10.1038/45002	http://dx.doi.org/10.1038/45002			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591206				2022-12-24	WOS:000084013200043
J	He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK				He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK			Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; LOWER BLOOD-PRESSURE; NATIONAL-HEALTH; OBSERVATIONAL DATA; SALT INTAKE; WEIGHT-LOSS; MORTALITY; STROKE; HYPERTENSION; POTASSIUM	Context Dietary sodium is positively associated with blood pressure, and ecological and animal studies both have suggested that high dietary sodium intake increases stroke mortality. Objective To examine the risk of cardiovascular disease associated with dietary sodium intake in overweight and nonoverweight persons. Design Prospective cohort study. Setting The first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, conducted in 1982-1984, 1986, 1987, and 1992. Participants Of those aged 25 to 74 years when the survey was conducted in 1971-1975 (14 407 participants), a total of 2688 overweight and 6797 nonoverweight persons were included in the analysis. Main outcome Measures Dietary sodium and energy intake were estimated at baseline using a single 24-hour dietary recall method. Incidence and mortality data for cardiovascular disease were obtained from medical records and death certificates. Results For overweight and nonoverweight persons, over an average of 19 years of follow-up, the total number of documented cases were as follows: 680 stroke events (210 fatal), 1727 coronary heart disease events (614 fatal), 895 cardiovascular disease deaths, and 2486 deaths from all causes. Among overweight persons with an average energy intake of 7452 kJ, a 100 mmol higher sodium intake was associated with a 32% increase (relative risk [RR], 1.32; 95% confidence interval [CI], 1.07-1.64; P = .01) in stroke incidence, 89% increase (RR, 1.89; 95% CI, 1.31-2.74; P<.001) in stroke mortality, 44% increase (RR, 1.44; 95% CI, 1.14-1.81; P = .002) in coronary heart disease mortality, 61% increase (RR, 1.61; 95% CI, 1.32-1.96; P<.001) in cardiovascular disease mortality, and 39% increase (RR, 1.39; 95% CI, 1.23-1.58; P<.001) in mortality from all causes. Dietary sodium intake was not significantly associated with cardiovascular disease risk in nonoverweight persons. Conclusions Our analysis indicates that high sodium intake is strongly and independently associated with an increased risk of cardiovascular disease and all-cause mortality in overweight persons.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Tulane University; Tulane University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	He, JA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL 18, New Orleans, LA 70112 USA.	jhe@mailhost.tcs.tulane.edu			NHLBI NIH HHS [R03 HL61954, R01 HL60300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL061954, R01HL060300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; ALTSCHUL AM, 1981, INT J OBESITY, V5, P27; *AM HEART ASS, 1998, 1998 HEART STROK STA; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Black HR, 1998, ARCH INTERN MED, V158, P573; Briefel RR, 1997, AM J CLIN NUTR, V65, P1203; Chen J, 1997, EXP MOL PATHOL, V64, P173, DOI 10.1006/exmp.1997.2218; COHEN JS, 1987, TRADITION, V22, P1; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; COOK NR, 1995, HYPERTENSION, V25, P1153, DOI 10.1161/01.HYP.25.6.1153; Cox C S, 1997, Vital Health Stat 1, P1; COX CS, 1992, VITAL HLTH STAT, V27, P1; COX DR, 1972, J R STAT SOC B, V34, P187; COYLE P, 1988, HYPERTENSION, V12, P96, DOI 10.1161/01.HYP.12.2.96; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; Elliot P, 1997, BMJ-BRIT MED J, V315, P458; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Engel A, 1978, Vital Health Stat 1, P1; Finucane F, 1990, VITAL HLTH STAT 1, V25, P1; FREGLY MJ, 1983, ANN INTERN MED, V98, P792, DOI 10.7326/0003-4819-98-5-792; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; Hall JE, 1997, AM J HYPERTENS, V10, pS49, DOI 10.1016/S0895-7061(97)00075-7; HE J, 1994, CIRCULATION, V90, P503; He J, 1997, CURR OPIN CARDIOL, V12, P202, DOI 10.1097/00001573-199703000-00018; IKEDA M, 1986, PREV MED, V15, P46, DOI 10.1016/0091-7435(86)90035-6; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KLESGES RC, 1995, J CONSULT CLIN PSYCH, V63, P438; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; Luft FC, 1997, AM J CLIN NUTR, V65, P612; MACGREGOR GA, 1997, CAN J CARDIOL SB, V13, pB272; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HW, 1973, VITAL HLTH STAT 1 A, V10, P1; Najjar M F, 1987, Vital Health Stat 11, P1; PERRY IJ, 1992, J HUM HYPERTENS, V6, P23; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; SASAKI S, 1995, STROKE, V26, P783, DOI 10.1161/01.STR.26.5.783; TARONE RE, 1975, BIOMETRIKA, V62, P679; TOBIAN L, 1990, HYPERTENSION, V15, P900, DOI 10.1161/01.HYP.15.6.900; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P2330; UMES WP, 1987, LANCET, V1, P426; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; *WHO, 1996, WORLD HLTH STAT ANN; YANG J, 1997, CAN J CARDIOL, V13, P448; [No title captured]	54	344	350	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2027	2034		10.1001/jama.282.21.2027	http://dx.doi.org/10.1001/jama.282.21.2027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591385	Bronze			2022-12-24	WOS:000083908700022
J	Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM				Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM			Building neural representations of habits	SCIENCE			English	Article							OBSESSIVE-COMPULSIVE DISORDER; BASAL GANGLIA; CAUDATE-NUCLEUS; DORSOLATERAL STRIATUM; TRIPLE DISSOCIATION; FUNCTIONAL-ANATOMY; SYSTEMATIC CHANGES; ACTION REPERTOIRES; NEURONAL-ACTIVITY; CORTEX	Memories for habits and skills ("implicit or procedural memory") and memories for facts ("explicit or episodic memory") are built up in different brain systems and are vulnerable to different neurodegenerative disorders in humans. So that the striatum-based mechanisms underlying habit formation could be studied, chronic recordings from ensembles of striatal neurons were made with multiple tetrodes as rats learned a T-maze procedural task. Large and widely distributed changes in the neuronal activity patterns occurred in the sensorimotor striatum during behavioral acquisition, culminating in task-related activity emphasizing the beginning and end of the automatized procedure. The new ensemble patterns remained stable during weeks of subsequent performance of the same task. These results suggest that the encoding of action in the sensorimotor striatum undergoes dynamic reorganization as habit learning proceeds.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; London Hlth Sci Ctr, London, ON N6A 5A5, Canada; SRI Int, Menlo Park, CA 94025 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Massachusetts Institute of Technology (MIT); London Health Sciences Centre; SRI International; Karolinska Institutet	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.			Graybiel, Ann/0000-0002-4326-7720	NIMH NIH HHS [R03 MH57878] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH057878] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AOSAKI T, 1994, J NEUROSCI, V14, P3969; Apicella P, 1998, J NEUROPHYSIOL, V80, P3341, DOI 10.1152/jn.1998.80.6.3341; BENECKE R, 1987, BRAIN, V110, P361, DOI 10.1093/brain/110.2.361; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Carelli RM, 1997, J NEUROSCI, V17, P1804; CARELLI RM, 1991, J COMP NEUROL, V309, P231, DOI 10.1002/cne.903090205; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Denny-Brown D, 1976, Res Publ Assoc Res Nerv Ment Dis, V55, P115; Donoghue JP, 1995, CURR OPIN NEUROBIOL, V5, P749, DOI 10.1016/0959-4388(95)80102-2; EICHENBAUM H, 1998, NEURONAL ENSEMBLES S; Gerloff C, 1998, BRAIN, V121, P1513, DOI 10.1093/brain/121.8.1513; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; James W., 1890, PRINCIPLES PSYCHOL; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Kawagoe R, 1998, NAT NEUROSCI, V1, P411, DOI 10.1038/1625; KESNER RP, 1993, EXP BRAIN RES, V93, P462; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kubota Y., 1999, Society for Neuroscience Abstracts, V25, P1384; Kubota Y., UNPUB; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; Miyachi S, 1997, EXP BRAIN RES, V115, P1, DOI 10.1007/PL00005669; Nakamura K, 1998, J NEUROPHYSIOL, V80, P2671, DOI 10.1152/jn.1998.80.5.2671; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Picard N, 1997, J NEUROPHYSIOL, V77, P2197, DOI 10.1152/jn.1997.77.4.2197; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROLLS ET, 1983, BEHAV BRAIN RES, V7, P179, DOI 10.1016/0166-4328(83)90191-2; Sakai K, 1998, J NEUROSCI, V18, P1827; SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHWAB RS, 1954, AMA ARCH NEUROL PSY, V72, P591, DOI 10.1001/archneurpsyc.1954.02330050061010; Schwartz JM, 1996, ARCH GEN PSYCHIAT, V53, P109; Shadmehr R, 1997, SCIENCE, V277, P821, DOI 10.1126/science.277.5327.821; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964, DOI 10.1152/jn.1998.80.2.964; WEST MO, 1990, J NEUROPHYSIOL, V64, P1233, DOI 10.1152/jn.1990.64.4.1233; White NM, 1997, CURR OPIN NEUROBIOL, V7, P164, DOI 10.1016/S0959-4388(97)80004-9; Wilson C.J., 1998, SYNAPTIC ORG BRAIN, P329; WILSON MA, 1993, SCIENCE, V261, P10552; Wise SP, 1998, EXP BRAIN RES, V121, P285, DOI 10.1007/s002210050462; [No title captured]	54	601	612	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1745	1749		10.1126/science.286.5445.1745	http://dx.doi.org/10.1126/science.286.5445.1745			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576743				2022-12-24	WOS:000083912200041
J	Stock, D; Leslie, AGW; Walker, JE				Stock, D; Leslie, AGW; Walker, JE			Molecular architecture of the rotary motor in ATP synthase	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; C-SUBUNIT OLIGOMER; EPSILON-SUBUNIT; GAMMA-SUBUNIT; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; MEMBRANE DOMAIN; CROSS-LINKING; F1F0 ATPASE	Adenosine triphosphate (ATP) synthase contains a rotary motor involved in biological energy conversion. Its membrane-embedded F-0 sector has a rotation generator fueled by the proton-motive force, which provides the energy required for the synthesis of ATP by the F-1 domain. An electron density map obtained from crystals of a subcomplex of yeast mitochondrial ATP synthase shows a ring of 10 c subunits. Each c subunit forms an alpha-helical hairpin. The interhelical loops of six to seven of the c subunits are in close contact with the gamma and delta subunits of the central stalk. The extensive contact between the c ring and the stalk suggests that they may rotate as an ensemble during catalysis.	MRC, Dunn Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk		Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Bateson M, 1996, ANAL BIOCHEM, V238, P14, DOI 10.1006/abio.1996.0242; Berry S, 1996, BBA-BIOENERGETICS, V1276, P51, DOI 10.1016/0005-2728(96)00031-X; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHAYEN NE, 1992, J CRYST GROWTH, V122, P176, DOI 10.1016/0022-0248(92)90241-A; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COX GB, 1993, J MOL BIOL, V229, P1159, DOI 10.1006/jmbi.1993.1113; DEVENISH RJ, 1992, ANN NY ACAD SCI, V671, P403, DOI 10.1111/j.1749-6632.1992.tb43814.x; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FILLINGAME RH, 1992, BIOCHIM BIOPHYS ACTA, V1101, P240, DOI 10.1016/0005-2728(92)90235-T; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Groth G, 1998, J MOL BIOL, V281, P49, DOI 10.1006/jmbi.1998.1936; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Orriss GL, 1996, BIOCHEM J, V314, P695, DOI 10.1042/bj3140695; Panke O, 1999, BBA-BIOENERGETICS, V1412, P118, DOI 10.1016/S0005-2728(99)00059-6; Prescott M, 1997, FEBS LETT, V411, P97, DOI 10.1016/S0014-5793(97)00670-4; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sawada K, 1997, ARCH BIOCHEM BIOPHYS, V348, P183, DOI 10.1006/abbi.1997.0397; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SCHEMIDT RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P423, DOI 10.1006/abbi.1995.0063; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; TURK D, 1992, THESIS TU MUNCHEN MU; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WETZEL CM, 1993, PLANT PHYSIOL, V102, P241, DOI 10.1104/pp.102.1.241; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	72	1042	1075	7	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1700	1705		10.1126/science.286.5445.1700	http://dx.doi.org/10.1126/science.286.5445.1700			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576729				2022-12-24	WOS:000083912200027
J	Reddy, MM; Light, MJ; Quinton, PM				Reddy, MM; Light, MJ; Quinton, PM			Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; PROTEIN-KINASE; TRANSPORT; CULTURES; BINDING; GLANDS; CELLS	It is increasingly being recognized that cells coordinate the activity Of separate ion channels that allow electrolytes into the cell. However, a perplexing problem in channel regulation has arisen in the fatal genetic disease cystic fibrosis, which results fi om the loss of a specific Cl- channel (the CFTR channel) in epithelial cell membranes(1). Although this defect clearly inhibits the absorption of Na+ in sweat gands(2,3), it is widely accepted that Na+ absorption is abnormally elevated in defective airways in cystic fibrosis(4,5). The only frequently cited explanation for this hypertransport is that the activity of an epithelial Na+ channel (ENaC) is inversely related to the activity of the CFTR Cl- channel(5-7). However we report here that, in freshly isolated normal sweat ducts, ENaC activity is dependent on, and increases with, CFTR activity. Surprisingly, we also find that the primary defect in Cl- permeability in cystic fibrosis(8) is accompanied secondarily by a Na+ conductance in this tissue that cannot: be activated. Thus, reduced salt absorption in cystic fibrosis is due not only to poor Cl- conductance but also to poor Na+ conductance.	Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Quinton, PM (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA.							BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Ecke D, 1996, PFLUG ARCH EUR J PHY, V431, P984, DOI 10.1007/s004240050095; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; LETZ, 1997, AM J PHYSL, V272, pC657; PANAH MR, 1998, AM J PHYSIOL-CELL PH, V274, pC310; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REDDY MM, 1994, J MEMBRANE BIOL, V140, P57; REDDY MM, 1998, PED PULMONOL S, V14, pR46; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	28	178	182	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					301	304		10.1038/46297	http://dx.doi.org/10.1038/46297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580502				2022-12-24	WOS:000083813700052
J	Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME				Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME			Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms	SCIENCE			English	Article							CEREBELLAR GRANULE NEURONS; PROTEIN-KINASE AKT; GENE-EXPRESSION; BINDING PROTEIN; BCL-2 FAMILY; PHOSPHORYLATION; APOPTOSIS; DEATH; CREB; CAMP	A mechanism by which the Ras-mitogen-activated protein kinase (MAPK) signaling pathway mediates growth factor-dependent cell survival was characterized. The MAPK-activated kinases, the Rsks, catalyzed the phosphorylation of the pro-apoptotic protein BAD at serine 112 both in vitro and in vivo. The Rsk-induced phosphorylation of BAD at serine 112 suppressed BAD-mediated apoptosis in neurons. Rsks also are known to phosphorylate the transcription factor CREB (cAMP response element-binding protein) at serine 133. Activated CREB promoted cell survival, and inhibition of CREB phosphorylation at serine 133 triggered apoptosis. These findings suggest that the MAPK signaling pathway promotes cell survival by a dual mechanism comprising the posttranslational modification and inactivation of a component of the cell death machinery and the increased transcription of pro-survival genes.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Datta, Sandeep/0000-0002-8068-3862	NICHD NIH HHS [P01 HD 24926, NIHP30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1997, CAN J NEUROL SCI, V24, P272, DOI 10.1017/S0317167100032935; BONNI A, UNPUB; BORASIO GD, 1989, NEURON, V2, P1087; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HENGARTNER MO, 1994, CURR OPIN GENE DEV, V4, P481; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; RICCIO A, 1996, MOL CELL BIOL, V16, P5546; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHIMAMURA A, UNPUB; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; XING J, UNPUB; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	54	1591	1674	6	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1358	1362		10.1126/science.286.5443.1358	http://dx.doi.org/10.1126/science.286.5443.1358			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558990				2022-12-24	WOS:000083675500042
J	Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J				Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J			Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE SELECTION; PATHWAYS; TYROSINE; INSULIN; DIFFERENTIATION; ACTIVATION; CASCADE	The p42 and p44 mitogen-activated protein kinases (MAPKs), also called Erk2 and Erk1, respectively, have been implicated in proliferation as well as in differentiation programs. The specific role of the p44 MAPK isoform in the whole animal was evaluated by generation of p44 MAPK-deficient mice by homologous recombination in embryonic stem cells. The p44 MAPK(-/-) mice were viable, fertile, and of normal size. Thus, p44 MAPK is apparently dispensable and p42 MAPK (Erk2) may compensate for its Loss. However, in p44 MAPK(-/-) mice, thymocyte maturation beyond the CD4(+)CD8(+) stage was reduced by half, with a similar diminution in the thymocyte subpopulation expressing high Levels of T cell receptor (CD3(high)). In p44 MAPK(-/-) thymocytes, proliferation in response to activation with a monoclonal antibody to the T cell receptor in the presence of phorbol myristate acetate was severely reduced even though activation of p42 MAPK was more sustained in these cells. The p44 MAPK apparently has a specific role in thymocyte development.	Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France; Fac Med, INSERM, U364, F-06107 Nice, France; Fac Med, CJF 96 05, F-06107 Nice, France; Ctr Genome Res, Edinburgh, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Pages, G (corresponding author), Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valornbrose, F-06189 Nice, France.		Bonino, Ferruccio/B-7522-2013; Pages, Gilles/N-7135-2017; Anjuere-Casile, Fabienne/O-5779-2016; AUBERGER, Patrick/G-1491-2013	Anjuere-Casile, Fabienne/0000-0003-3144-8652; AUBERGER, Patrick/0000-0002-2481-8275; Smith, Austin/0000-0002-3029-4682				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKENZIE F, IN PRESS BIOCH BIOPH; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAGES G, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x	25	455	467	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1374	1377		10.1126/science.286.5443.1374	http://dx.doi.org/10.1126/science.286.5443.1374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558995				2022-12-24	WOS:000083675500047
J	Golan, L; Birkmeyer, JD; Welch, HG				Golan, L; Birkmeyer, JD; Welch, HG			The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; diabetes mellitus, non-insulin-dependent; angiotensin-converting enzyme inhibitors; outcome and process assessment (health care); diabetic nephropathies	NEPHROPATHY; QUALITY; RECOMMENDATIONS; MELLITUS; OUTCOMES	Background: Although guidelines recommend angiotensin-converting enzyme inhibitors for diabetic patients with microalbuminuria, this strategy requires that providers adhere to screening recommendations. In addition, the benefit of angiotensin-converting enzyme inhibitors in normoalbuminuric patients was recently demonstrated. Objective: To evaluate the cost-effectiveness of treating all patients with type 2 diabetes. Design: Markov model simulating the progression of diabetic nephropathy. Data Sources: Randomized trials estimating the progression of diabetic nephropathy with and without angiotensin-converting enzyme inhibitors. Target Population: Patients 50 years of age with newly diagnosed type 2 diabetes (fasting plasma glucose level greater than or equal to 7.8 mmol/L [140 mg/dL]). Time Horizon: Lifetime. Perspective: Societal. Interventions: Patients received angiotensin-converting enzyme inhibitors, screening for microalbuminuria, or screening for gross proteinuria. Outcome Measures: Lifetime cost, quality-adjusted life expectancy, and marginal cost-effectiveness. Results of Base-Case Analysis: Screening for gross proteinuria had the highest cost and the lowest benefit. Compared with screening for microalbuminuria, treating all patients was more expensive ($15 240 and $14 940 per patient) but was associated with increased quality-adjusted life expectancy (11.82 and 11.78 quality-adjusted life-years). The marginal cost-effectiveness ratio was $7500 per quality-adjusted life-year gained. Results of Sensitivity Analysis: Results were sensitive to the cost, effectiveness, and quality of life associated with angiotensin-converting enzyme inhibitor therapy, as well as age at diagnosis. The model was relatively insensitive to adherence with screening and costs of treating end-stage renal disease. Conclusions: Treating all middle-aged diabetic patients with angiotensin-converting enzyme inhibitors is a simple strategy that provides additional benefit at modest additional cost. The strategy assumes that patients meet the older diagnostic criteria for diabetes and makes sense only for those who are not bothered by treatment.	Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA		Welch, HG (corresponding author), Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA.		Golan, Lubor/O-2359-2017	Golan, Lubor/0000-0003-1705-1157				BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; DONOHOE JF, 1988, AM J MED, V85, P31, DOI 10.1016/0002-9343(88)90347-6; Frank E, 1997, J CLIN PSYCHIAT, V58, P11; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gaster B, 1998, ARCH INTERN MED, V158, P134, DOI 10.1001/archinte.158.2.134; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Kraft SK, 1999, J GEN INTERN MED, V14, P88, DOI 10.1046/j.1525-1497.1999.00292.x; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LOVELL HG, 1998, COCHRANE DATABASE SY, V3; Miller N H, 1997, Am J Med, V102, P43; Miller NH, 1997, CIRCULATION, V95, P1085; Niskanen LK, 1996, DIABETES CARE, V19, P486, DOI 10.2337/diacare.19.5.486; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; PARVING HH, 1994, KIDNEY INT, V45, pS165; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; *REP EXP COMM DIAG, 1997, DAIB CAR, V20, P183; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; RUDD P, 1995, AM HEART J, V130, P572, DOI 10.1016/0002-8703(95)90368-2; Schwartz L M, 1999, Eff Clin Pract, V2, P76; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; 1998, AM J KIDNEY, V32, pS69; 1996, NAT CTR HLTH STAT; 1996, LIFE EXPECTANCY	26	127	131	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					660	+		10.7326/0003-4819-131-9-199911020-00005	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577328				2022-12-24	WOS:000083446200004
J	Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS				Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS			AIDS - Re-emergence of HIV after stopping therapy	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; INDINAVIR		NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Chun, Tae-Wook/W-9187-2019	Chun, Tae-Wook/0000-0001-5153-7340				Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; CHUN TW, 1999, NAT MED, V5, P615; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; DAVEY RT, IN PRESS P NATL ACAD; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	10	329	333	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					874	875		10.1038/44755	http://dx.doi.org/10.1038/44755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553903				2022-12-24	WOS:000083464700044
J	Freeland, SJ; Knight, RD; Landweber, LF				Freeland, SJ; Knight, RD; Landweber, LF			Molecular evolution - Do proteins predate DNA?	SCIENCE			English	Editorial Material							GENETIC-CODE; RNA WORLD; RIBONUCLEOTIDE REDUCTASES; ERROR MINIMIZATION; ORIGIN		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Freeland, SJ (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	freeland@rnaworld.prince-ton.edu; rdknight@princeton.edu; lfl@princeton.edu		Knight, Rob/0000-0002-0975-9019				ALBERTS B, 1994, MOL BIOL CELL, pCH9; Ardell DH, 1998, J MOL EVOL, V47, P1, DOI 10.1007/PL00006356; Atkins J.F, 1999, RNA WORLD; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Freeland SJ, 1998, P ROY SOC B-BIOL SCI, V265, P2111, DOI 10.1098/rspb.1998.0547; Freeland SJ, 1998, J MOL EVOL, V47, P238, DOI 10.1007/PL00006381; HAIG D, 1991, J MOL EVOL, V33, P412, DOI 10.1007/BF02103132; HIRAO I, 1995, CURR BIOL, V5, P1017, DOI 10.1016/S0960-9822(95)00205-3; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lazcano A, 1996, CELL, V85, P793, DOI 10.1016/S0092-8674(00)81263-5; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Leon PE, 1998, J MOL EVOL, V47, P122, DOI 10.1007/PL00006368; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Olsen GJ, 1996, TRENDS GENET, V12, P377, DOI 10.1016/0168-9525(96)30092-9; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Smith J. M., 1995, MAJOR TRANSITIONS EV; Szathmary E, 1999, TRENDS GENET, V15, P223, DOI 10.1016/S0168-9525(99)01730-8; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; WOESE CR, 1967, GENETIC CODE; WONG JTF, 1979, J MOL EVOL, V13, P115, DOI 10.1007/BF01732867	24	67	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					690	692		10.1126/science.286.5440.690	http://dx.doi.org/10.1126/science.286.5440.690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10577226				2022-12-24	WOS:000083303200033
J	Wang, H; Tessier-Lavigne, M				Wang, H; Tessier-Lavigne, M			En passant neurotrophic action of an intermediate axonal target in the developing mammalian CNS	NATURE			English	Article							SENSORY NEURONS; COMMISSURAL AXONS; NERVOUS-SYSTEM; SPINAL-CORD; SURVIVAL; PROMOTE; DEATH; GUIDANCE; NETRINS	During development, neurons extend axons to their targets, then become dependent for their survival on trophic substances secreted by their target cells. Competition for limiting amounts of these substances is thought to account for much of the extensive naturally-occurring cell death that is seen throughout the nervous system. Here we show that spinal commissural neurons, a group of long projection neurons in the central nervous system (CNS), are also dependent for their survival on trophic support from one of their intermediate targets, the floor plate of the spinal cord. This dependence occurs during a several-day-long period when their axons extend along the floor plate, following which they develop additional trophic requirements. A dependence of neurons on trophic support derived en passant from their intermediate axonal targets provides a mechanism for rapidly eliminating misprojecting neurons, which may help to prevent the formation of aberrant neuronal circuits during the development of the nervous system.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; COMPENOT RB, 1982, DEV BIOL, V93, P1; COWAN W, 1984, S CEL HARV MED SCH B, P643; Davies AM, 1997, CURR OPIN NEUROBIOL, V7, P110, DOI 10.1016/S0959-4388(97)80128-6; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; Huang EJ, 1999, DEVELOPMENT, V126, P2191; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Liebl DJ, 1997, J NEUROSCI, V17, P9113; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PURVES D, 1985, PRINCIPLES NEURAL DE; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Wilkinson GA, 1996, J NEUROSCI, V16, P7661; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7	21	53	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					765	769		10.1038/44521	http://dx.doi.org/10.1038/44521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548102				2022-12-24	WOS:000083368700045
J	Chiswick, ML				Chiswick, ML			Assessment of pain in neonates	LANCET			English	Editorial Material							SKIN		St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England		Chiswick, ML (corresponding author), St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England.							ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; Andrews K, 1999, DEV MED CHILD NEUROL, V41, P696, DOI 10.1017/S0012162299001425; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; CONSTANTINOU J, 1994, NEUROREPORT, V5, P2281, DOI 10.1097/00001756-199411000-00019; Johnston CC, 1996, PEDIATRICS, V98, P925; Porter FL, 1998, PEDIATRICS, V102, P1383, DOI 10.1542/peds.102.6.1383; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0	10	18	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					6	8		10.1016/S0140-6736(99)00392-X	http://dx.doi.org/10.1016/S0140-6736(99)00392-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615882				2022-12-24	WOS:000085049200007
J	Garrow, J				Garrow, J			Christmas factor and snacking	LANCET			English	Editorial Material							WEIGHT; WOMEN		Dial House, Rickmansworth WD3 2DQ, England		Garrow, J (corresponding author), Dial House, Rickmansworth WD3 2DQ, England.							ANDERSSON I, 1992, INT J OBESITY, V16, P1013; Friedman JM, 1999, PROG OBES R, P307; Marmonier C, 1999, AM J CLIN NUTR, V70, P854; RODIN J, 1977, J COMP PHYSIOL PSYCH, V91, P586, DOI 10.1037/h0077354; SMITH S, 1855, LADY HOLLAND MEMOIR, P376; Stock M, 1982, OBESITY LEANNESS BAS; Tuomisto T, 1998, APPETITE, V30, P211, DOI 10.1006/appe.1997.0142; VANSTAVEREN WA, 1986, INT J OBESITY, V10, P133; WOOLEY OW, 1972, J COMP PHYSIOL PSYCH, V80, P250, DOI 10.1037/h0033069; ZAHORSKAMARKIEWICZ B, 1980, INT J OBESITY, V4, P139	10	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2000	355	9197					8	8		10.1016/S0140-6736(99)90449-X	http://dx.doi.org/10.1016/S0140-6736(99)90449-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615883				2022-12-24	WOS:000085049200008
J	Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E				Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E			Three-dimensional structure of the human TFIID-IIA-IIB complex	SCIENCE			English	Article							RNA-POLYMERASE-II; TATA-BINDING-PROTEIN; MEDIATE TRANSCRIPTIONAL ACTIVATION; YEAST TFIIA/TBP/DNA COMPLEX; CRYSTAL-STRUCTURE; PROMOTER SELECTIVITY; IN-VITRO; COACTIVATOR; INITIATION; DROSOPHILA	The multisubunit transcription factor IID (TFIID) is an essential component of the eukaryotic RNA polymerase II machinery that works in concert with TFIIA (IIA) and TFIIB (IIB) to assemble initiation complexes at core eukaryotic promoters. Here the structures of human TFIID and the TFIID-IIA-IIB complex that were obtained by electron microscopy and image analysis to 35 angstrom resolution are presented. TFIID is a trilobed, horseshoe-shaped structure, with TFIIA and TFIIB bound on opposite Lobes and flanking a central cavity. Antibody studies Locate the TATA-binding protein (TBP) between TFIIA and TFIIB at the top of the cavity that most Likely encompasses the TATA DNA binding region of the supramolecular complex.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	enogales@lbl.gov		Ladurner, Andreas/0000-0003-3835-232X				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ANDEL F, UNPUB; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen JL, 1996, METHOD ENZYMOL, V273, P208; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HARAUZ G, 1986, OPTIK, V73, P146; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	47	110	112	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2153	2156		10.1126/science.286.5447.2153	http://dx.doi.org/10.1126/science.286.5447.2153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591646				2022-12-24	WOS:000084157300051
J	Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T				Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T			Mouse models of tumor development in neurofibromatosis type 1	SCIENCE			English	Article							NF1 GENE; SUPPRESSOR GENE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CELLS; MUTATIONS; DELETIONS; SCHWANN; PRODUCT; ALLELES; CANCER	Neurofibromatosis type 1 (NF1) is a prevalent familiar cancer syndrome resulting from germ Line mutations in the NF1 tumor suppressor gene. Hallmark features of the disease are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress to malignancy. Unlike humans, mice that are heterozygous for a mutation in Nf1 do not develop neurofibromas. However, as described here, chimeric mice composed in part of Nf1(-/-) cells do, which demonstrates that loss of the wild-type Nf1 allele is rate-limiting in tumor formation. In addition, mice that carry Linked germ line mutations in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperative and causal role for p53 mutations in MPNST development. These two mouse models provide the means to address fundamental aspects of disease development and to test: therapeutic strategies.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Merck & Company; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Tufts University; Tufts University	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu	Reilly, Karlyne/V-4475-2019	Reilly, Karlyne/0000-0001-9109-4409				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BADER JL, 1986, ANN NY ACAD SCI, V486, P57, DOI 10.1111/j.1749-6632.1986.tb48062.x; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1992, MAMM GENOME, V3, pS162, DOI 10.1007/BF00648429; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; Daschner K, 1997, BIOCHEM BIOPH RES CO, V234, P346, DOI 10.1006/bbrc.1997.6645; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hope D G, 1981, Adv Neurol, V29, P33; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOTHE RA, 1995, J NEUROPATH EXP NEUR, V54, P65, DOI 10.1097/00005072-199501000-00008; LUONGO C, 1994, CANCER RES, V54, P5947; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STARK M, 1995, HUM GENET, V96, P619; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WICK MR, 1987, AM J CLIN PATHOL, V87, P425, DOI 10.1093/ajcp/87.4.425; WOODRUFF JM, 1996, SOFT TISSUE TUMORS; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	42	322	329	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2172	2176		10.1126/science.286.5447.2172	http://dx.doi.org/10.1126/science.286.5447.2172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591652				2022-12-24	WOS:000084157300057
J	Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD				Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD			The role of CCR7 in T(H)1 and T(H)2 cell localization and delivery of B cell help in vivo	SCIENCE			English	Article							INDUCER LYMPHOCYTES-T; CHEMOKINE RECEPTOR; LYMPHOID-TISSUES; PERTUSSIS TOXIN; DENDRITIC CELLS; EXPRESSION; MIGRATION; RESPONSES; SUBSETS; CLONES	Subsets of murine CD4(+) T cells Localize to different areas of the spleen after adoptive transfer. Naive and T helper 1 (T(H)1) cells, which express the chemokine receptor CCR7, are home to the periarteriolar Lymphoid sheath, whereas activated T(H)2 cells, which lack CCR7, form rings at the periphery of the T cell zones near B cell follicles. Retroviral transduction of T(H)2 cells with CCR7 forces them to localize in a T(H)1-like pattern and inhibits their participation in B cell help in vivo but not in vitro. Thus, differential expression of chemokine receptors results in unique cellular migration patterns that are important for effective Immune responses.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Chaplin, DD (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.			Chaplin, David/0000-0002-1354-3069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034580, U01AI034580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34580] Funding Source: Medline; NIGMS NIH HHS [T32 GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas A K, 1993, Semin Immunol, V5, P441, DOI 10.1006/smim.1993.1050; ABBAS AK, 1990, J IMMUNOL, V144, P2031; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; DELPRETE GF, 1991, J EXP MED, V174, P809, DOI 10.1084/jem.174.4.809; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KILLAR L, 1987, J IMMUNOL, V138, P1674; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PABST R, 1991, SCANNING MICROSCOPY, V5, P1075; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pulendran B, 1997, J IMMUNOL, V159, P2222; RANDOLPH D, UNPUB; Randolph DA, 1999, J IMMUNOL, V162, P2375; Ranganath S, 1998, J IMMUNOL, V161, P3822; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; van den Eertwegh A J, 1994, Semin Immunol, V6, P327, DOI 10.1006/smim.1994.1041; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WILLFUHR KU, 1990, EUR J IMMUNOL, V20, P903, DOI 10.1002/eji.1830200428; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	40	153	160	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2159	2162		10.1126/science.286.5447.2159	http://dx.doi.org/10.1126/science.286.5447.2159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591648				2022-12-24	WOS:000084157300053
J	White, KP; Rifkin, SA; Hurban, P; Hogness, DS				White, KP; Rifkin, SA; Hurban, P; Hogness, DS			Microarray analysis of Drosophila development during metamorphosis	SCIENCE			English	Article							STEROID-RECEPTOR SUPERFAMILY; GENE-EXPRESSION PATTERNS; ECDYSONE-INDUCIBLE GENE; CELL-DEATH; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHATASE; DNA MICROARRAY; EARLY PUFF; ENCODES 2; MELANOGASTER	Metamorphosis is an integrated set of developmental processes controlled by a transcriptional hierarchy that coordinates the action of hundreds of genes. In order to identify and analyze the expression of these genes, high-density DNA microarrays containing several thousand Drosophila melanogaster gene sequences were constructed. Many differentially expressed genes can be assigned to developmental pathways known to be active during metamorphosis, whereas others can be assigned to pathways not previously associated with metamorphosis. Additionally, many genes of unknown function were identified that may be involved in the control and execution of metamorphosis. The utility of this genome-based approach is demonstrated for studying a set of complex biological processes in a multicellular organism.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	White, KP (corresponding author), Stanford Univ, Med Ctr, Beckman Ctr B400, Dept Biochem, Stanford, CA 94305 USA.			Rifkin, Scott/0000-0001-8476-3256				Allard JD, 1996, DEVELOPMENT, V122, P1137; Artero R, 1998, DEV BIOL, V195, P131, DOI 10.1006/dbio.1997.8833; Ashburner M, 1999, GENETICS, V153, P179; BARNETT SW, 1990, DEV BIOL, V140, P362, DOI 10.1016/0012-1606(90)90086-X; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; BODMER R, 1993, DEVELOPMENT, V118, P719; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FINELLI L, 1995, GENETICS, V141, P271; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; GARBE JC, 1993, DEVELOPMENT, V119, P1237; GUILD GM, 1984, J MOL BIOL, V179, P289, DOI 10.1016/0022-2836(84)90067-6; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MARONI G, 1983, DROS INFORM SERV, V59, P142; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MURTHA MT, 1989, DEV BIOL, V135, P66, DOI 10.1016/0012-1606(89)90158-9; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROGULSKI KR, 1995, J MOL BIOL, V249, P298, DOI 10.1006/jmbi.1995.0298; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Speicher S, 1998, NEURON, V20, P221, DOI 10.1016/S0896-6273(00)80451-1; Stryer L., 1988, BIOCHEMISTRY-US; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Truman James W., 1993, P1245; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; Weaver TA, 1995, DEVELOPMENT, V121, P4149; WHITE K, UNPUB; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; Wright LG, 1996, J MOL BIOL, V255, P387, DOI 10.1006/jmbi.1996.0032	54	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2179	2184		10.1126/science.286.5447.2179	http://dx.doi.org/10.1126/science.286.5447.2179			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591654				2022-12-24	WOS:000084157300059
J	Mangus, RS; Dipiero, A; Hawkins, CE				Mangus, RS; Dipiero, A; Hawkins, CE			Medical students' attitudes toward physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUTHANASIA	Context In November 1994, Oregon became the first US state to legalize physician-assisted suicide (PAS) as an option for end-of-life care. Objective This study compares the attitudes and experiences of medical students in Oregon regarding PAS to those of fourth-year medical students in the United States outside Oregon. Design A survey of all students at the Oregon Health Sciences University and fourth-year medical students at 3 non-Oregonian US medical schools. Participants Oregon medical students returned 227 questionnaires (58%), and 113 were returned from control schools (33%). Results A similar percentage of both study groups favored the legalization of PAS (64% vs 66%; P=.74). If the practice were legal, 55% of the total surveyed reported they "might be willing to write a lethal prescription," (50% Oregon students vs 60% control; P=.13 and 44% fourth-year Oregon students vs 60% control; P=.04). Among fourth-year students, 20% reported a request by a patient to the student or a preceptor for a lethal prescription in the past year (26% vs 16%; P=.09). Conclusions This study demonstrates support for and willingness by many medical students to participate in PAS. Some medical students reported observation of PAS during their training experience. Fourth-year Oregon students reported significantly less willingness than other students to provide a patient with a lethal prescription, perhaps indicating hesitancy to include PAS in clinical practice.	Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Mangus, RS (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.		Mangus, Richard S/M-1446-2018	Mangus, Richard S/0000-0003-4300-2594				Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Muller MT, 1996, MED EDUC, V30, P428, DOI 10.1111/j.1365-2923.1996.tb00863.x; *MULTN COUNT EL DI, 1994, OR VOT PAMPHL BALL M, V16; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P967, DOI 10.1001/jama.278.12.967; Steinberg MA, 1997, MED J AUSTRALIA, V166, P131, DOI 10.5694/j.1326-5377.1997.tb140042.x; Verhoef MJ, 1996, CAN MED ASSOC J, V155, P885	10	20	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2080	2081		10.1001/jama.282.21.2080	http://dx.doi.org/10.1001/jama.282.21.2080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591396	hybrid			2022-12-24	WOS:000083908700033
J	Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S				Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S			Global trade and access to medicines: AIDS treatments in Thailand	LANCET			English	Editorial Material									Med Sans Frontieres, Bangkok 10240, Thailand		Wilson, D (corresponding author), Med Sans Frontieres, 311 Ladprao 101, Bangkok 10240, Thailand.							AONGSONWANG S, 1999, NGO M COMP LIC ESS M; Correa CM, 1997, URUGUAY ROUND DRUGS; *EC INT UN, 1999, THAIL COUNTR REP; Hemachudha T, 1999, CLIN INFECT DIS, V28, P143, DOI 10.1086/517179; KUNANUSONT C, 1996, HIV AIDS THAILAND 19, P82; LOMAR A, 1999, CUSTOS DIRECTOS TRAT; McGregor A, 1999, LANCET, V353, P1165, DOI 10.1016/S0140-6736(05)74394-4; *SAT S 21, 1995, P 3 INT C AIDS AS PA, P88; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; Suwanjandee J, 1999, LANCET, V354, P343, DOI 10.1016/S0140-6736(05)75255-7; *THAI FDA, 1995, THAI DRUG SYST SIT A; *THAI MIN PUBL HLT, 1997, GUID CLIN MAN HIV IN; UNDP (United Nations Development Programme), 1994, UNDP NIG 2016 ANN RE; *WHO, 1997, WHODAP989 TRIPS; World Health Organization, 1999, 52 WORLD HLTH ASS 52 WORLD HLTH ASS	16	20	20	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1893	1895		10.1016/S0140-6736(99)06114-0	http://dx.doi.org/10.1016/S0140-6736(99)06114-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584741				2022-12-24	WOS:000083909100043
J	Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M				Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M			Mechanical rotation of the c subunit oligomer in ATP synthase (F0F1): Direct observation	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; CARBOXYL-TERMINAL REGION; GAMMA-SUBUNIT; H+-ATPASE; ENERGY TRANSDUCTION; BETA-SUBUNIT; F-TYPE; CATALYSIS; F-1-ATPASE; MUTATIONS	F0F1, found in mitochondria or bacterial membranes, synthesizes adenosine 5'-triphosphate (ATP) coupling with an electrochemical proton gradient and also reversibly hydrolyzes ATP to form the gradient. An actin filament connected to a c subunit oligomer of F-0 was able to rotate by using the energy of ATP hydrolysis. The rotary torque produced by the c subunit oligomer reached about 40 piconewton-nanometers, which is similar to that generated by the gamma subunit in the F-1 motor. These results suggest that the gamma and c subunits rotate together during ATP hydrolysis and synthesis. Thus, coupled rotation may be essential for energy coupling between proton transport through F-0 and ATP hydrolysis or synthesis in F-1.	Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Biol, Tokyo 1538902, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	OMOTE, Hiroshi/B-1635-2011; Yanagida, Toshio/D-1919-2009					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PERLIN DS, 1985, BIOCHIM BIOPHYS ACTA, V807, P238, DOI 10.1016/0005-2728(85)90254-3; SHIN K, 1992, J BIOL CHEM, V267, P20835; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	33	393	400	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1722	1724		10.1126/science.286.5445.1722	http://dx.doi.org/10.1126/science.286.5445.1722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576736				2022-12-24	WOS:000083912200034
J	Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M				Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M			Large-scale analysis of the yeast genome by transposon tagging and gene disruption	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN LOCALIZATION; EXPRESSION; RECOMBINATION; BINDS	Economical methods by which gene function maybe analysed on a genomic scale are relatively scarce. To fill this need, we have developed a transposon-tagging strategy for the genome-wide analysis of disruption phenotypes, gene expression and protein localization, and have applied this method to the large-scale analysis of gene function in the budding yeast Saccharomyces cerevisiae. Here we present the largest collection of defined yeast mutants ever generated within a single genetic background-a collection of over 11,000 strains, each carrying a transposon inserted within a region of the genome expressed during vegetative growth and/or sporulation. These insertions affect nearly 2,000 annotated genes, representing about one-third of the 6,200 predicted genes in the yeast genome(1,2). We have used this collection to determine disruption phenotypes for nearly 8,000 strains using 20 different growth conditions; the resulting data sets were clustered to identify groups of functionally related genes. We have also identified over 300 previously non-annotated open reading frames and analysed by indirect immunofluorescence over 1,300 transposon-tagged proteins. In total, our study encompasses over 260,000 data points, constituting the largest functional analysis of the yeast genome ever undertaken.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, Ctr Med Informat, New Haven, CT 06510 USA; Yale Univ, Keck Fdn, Biotechnol Resource Lab, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.			Kumar, Anuj/0000-0002-8923-297X; Snyder, Michael/0000-0003-0784-7987				Adams A, 1997, METHODS YEAST GENETI; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Evangelista CC, 1996, GENETICS, V142, P1083; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Kaufman L., 2009, FINDING GROUPS DATA; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LODI T, 1995, MICROBIOL-SGM, V141, P2201, DOI 10.1099/13500872-141-9-2201; Lussier M, 1997, GENETICS, V147, P435; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; PAGE BD, 1992, GENE DEV, V6, P1414, DOI 10.1101/gad.6.8.1414; RossMacdonald P, 1995, METHOD MOL CELL BIOL, V5, P298; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STEARNS T, 1990, GENETICS, V124, P251; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White WH, 1997, GENETICS, V147, P43	30	403	430	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					413	418		10.1038/46558	http://dx.doi.org/10.1038/46558			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586881				2022-12-24	WOS:000083913600057
J	Schrag, A; Ben-Shlomo, Y; Quinn, NP				Schrag, A; Ben-Shlomo, Y; Quinn, NP			Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study	LANCET			English	Article							RICHARDSON-OLSZEWSKI-SYNDROME; TO-DOOR SURVEY; PARKINSONS-DISEASE; NATURAL-HISTORY; EPIDEMIOLOGY; POPULATION; DIAGNOSIS; COUNTY	Background The prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. Methods We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. Findings The participation rate was 84%. The age-adjusted prevalence for PSP was 6.4 per 100 000 (five probable and one possible case [95% CI 2.3-10.6]) and for MSA 4.4 per 100 000 (two probable and two possible cases [1.2-7.6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Interpretation Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.	Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of London; University College London; University of Bristol	Quinn, NP (corresponding author), Inst Neurol, Dept Clin Neurol, Queen Sq, London WC1N 3BG, England.		Ben-Shlomo, Yoav/ABD-2004-2021; Schrag, Anette/AAA-9344-2020; Schrag, Anette E/B-4181-2011	Ben-Shlomo, Yoav/0000-0001-6648-3007; Schrag, Anette/0000-0002-9872-6680; Schrag, Anette E/0000-0002-9872-6680				Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; Chio A, 1998, MOVEMENT DISORD, V13, P400, DOI 10.1002/mds.870130305; Cockerell OC, 1996, NEUROEPIDEMIOLOGY, V15, P73, DOI 10.1159/000109892; COCKERELL OC, 1993, J NEUROL NEUROSUR PS, V56, P735, DOI 10.1136/jnnp.56.7.735; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; HUGHES AJ, 1992, NEUROLOGY, V42, P142; Litvan I, 1996, J NEUROL NEUROSUR PS, V60, P615, DOI 10.1136/jnnp.60.6.615; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Maraganore DM, 1998, NEUROLOGY, V50, pA98; MASTAGLIA F L, 1973, Proceedings of the Australian Association of Neurologists, V10, P35; MORGANTE L, 1992, NEUROLOGY, V42, P1901; *OFF NAT STAT, 1997, EUR DAT SHOP; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P159, DOI 10.1159/000110150; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; RYBICKI BA, 1995, NEUROEPIDEMIOLOGY, V14, P72, DOI 10.1159/000109781; Smith P., 1987, CANC INCIDENCE 5 CON, V88, P790; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; TISON F, 1994, ACTA NEUROL SCAND, V90, P111; TRENKWALDER C, 1995, ARCH NEUROL-CHICAGO, V52, P1017, DOI 10.1001/archneur.1995.00540340109020; WENNING GK, 1995, J NEUROL NEUROSUR PS, V58, P160, DOI 10.1136/jnnp.58.2.160; WENNING GK, 1994, BRAIN, V117, P835, DOI 10.1093/brain/117.4.835; Wermuth L, 1997, NEUROLOGY, V49, P426, DOI 10.1212/WNL.49.2.426	27	389	406	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1771	1775		10.1016/S0140-6736(99)04137-9	http://dx.doi.org/10.1016/S0140-6736(99)04137-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577638				2022-12-24	WOS:000083853000011
J	Francis, D; Diorio, J; Liu, D; Meaney, MJ				Francis, D; Diorio, J; Liu, D; Meaney, MJ			Nongenomic transmission across generations of maternal behavior and stress responses in the rat	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; INTERGENERATIONAL TRANSMISSION; CARE	In the rat, variations in maternal care appear to influence the development of behavioral and endocrine responses to stress in the offspring. The results of cross-fostering studies reported here provide evidence for (i) a causal relationship between maternal behavior and stress reactivity in the offspring and (ii) the transmission of such individual differences in maternal behavior from one generation of females to the next. Moreover, an environmental manipulation imposed during early development that alters maternal behavior can then affect the pattern of transmission in subsequent generations. Taken together, these findings indicate that variations in maternal care can serve as the basis for a nongenomic behavioral transmission of individual differences in stress reactivity across generations.	McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Neurol & Neurosurg, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Meaney, MJ (corresponding author), McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada.	mdmm@musica.mcgill.ca	Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9; [Anonymous], 1994, SEMIN NEUROSCI; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BOWLBY J, 1951, MATERNAL CARE MENT H; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; Caldji C, 1998, P NATL ACAD SCI USA, V95, P5335, DOI 10.1073/pnas.95.9.5335; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; DENENBERG VH, 1967, NATURE, V216, P549, DOI 10.1038/216549a0; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; EISENBERG L, 1990, MAMMALIAN PARENTING; Fairbanks LA., 1996, ADV STUDY BEHAV VOL, V25, P579, DOI [10.1016/S0065-3454(08)60343-5, DOI 10.1016/S0065-3454(08)60343-5]; Field T, 1998, PREV MED, V27, P200, DOI 10.1006/pmed.1998.0293; FLEMING AS, 1988, PSYCHONEUROENDOCRINO, V13, P189, DOI 10.1016/0306-4530(88)90014-5; FRANCIS D, UNPUB; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GROSSMAN KE, 1993, ATTACHMENT LIFE CYCL; HARLOW HF, 1958, AM PSYCHOL, V13, P673, DOI 10.1037/h0047884; HENNESSY MB, 1982, PHYSIOL PSYCHOL, V10, P153; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEVINE S, 1967, PHYSIOL BEHAV, V2, P55, DOI 10.1016/0031-9384(67)90011-X; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS; LEVINE S, 1970, POSTNATAL DEV PHENOT; LIGHTMAN SL, 1994, CIBA F SYMP, V172, P173; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MACCARI S, 1995, J NEUROSCI, V15, P110; MALIZIA AL, 1995, GABAA RECEPTORS ANXI; McCarty Richard, 1996, Physiology and Behavior, V59, P71, DOI 10.1016/0031-9384(95)02034-9; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; Miller L, 1997, J AM ACAD CHILD PSY, V36, P1134, DOI 10.1097/00004583-199708000-00022; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; Noone R. J., 1995, FAMILY SYSTEMS, V2, P116; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paxinos G., 2004, J CHEM INF MODEL, V5th; Plomin R., 1997, BEHAV GENET; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; ROSENBLATT JS, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13259.x; RoyByrne P, 1996, AM J PSYCHIAT, V153, P1444; Rutter ML, 1997, AM PSYCHOL, V52, P390; SCHULKIN J, 1994, NEUROSCI BIOBEHAV R, V18, P385, DOI 10.1016/0149-7634(94)90051-5; Smotherman W.P., 1980, MATERNAL INFLUENCES; Stern JM, 1997, DEV PSYCHOBIOL, V31, P19, DOI 10.1002/(SICI)1098-2302(199707)31:1<19::AID-DEV3>3.0.CO;2-X; Suomi SJ, 1997, BRIT MED BULL, V53, P170; Vallee M, 1997, J NEUROSCI, V17, P2626; VAN IJZENDOORN MH, 1992, DEV REV, V12, P76, DOI 10.1016/0273-2297(92)90004-L; ZARROW MX, 1973, P SOC EXP BIOL MED, V356, P141; ZARROW WD, 1973, PHYSIOL BEHAV, V356, P141	51	1322	1349	4	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1155	1158		10.1126/science.286.5442.1155	http://dx.doi.org/10.1126/science.286.5442.1155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	253AJ	10550053				2022-12-24	WOS:000083534200043
J	Henney, JE				Henney, JE			Continuing shortage of IGIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P159	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-24	WOS:000083368400006
J	Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS				Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS			Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy	LANCET			English	Article							HEPATIC METASTASES; LIVER METASTASES; COLON-CANCER; FLUOROURACIL; THERAPY; FLOW; SONOGRAPHY; CARCINOMA; TUMOR	Background As yet there is no established method of accurately identifying patients with colorectal cancer who, despite undergoing apparently curative resection, are at high risk of recurrence. We assessed whether the doppler perfusion index (DPI; ratio of hepatic arterial to total liver blood flow) could be used to select patients who should receive adjuvant chemotherapy. Methods We studied 120 patients undergoing curative surgery for colorectal cancer. DPI was measured before surgery with colour duplex doppler ultrasonography. A DPI value of at least 0.3 was defined as abnormal. All patients were followed up until death or for at least 5 years. Results At 5 years, patients with Dukes' stage A or B tumours (n=61) had recurrence-free survival of 57% and overall survival of 64%, compared with 39% and 42% for patients with Dukes' stage C tumours (n=59; p=0.016 and p=0.008, respectively). 47 patients had normal DPI values and 73 patients had abnormal values. Patients with normal DPI had recurrence-free survival of 89% and overall survival of 91%, compared with 22% and 29% for those with abnormal DPI values (both p<0.0001). Conclusions DPI can be used to identify patients with colorectal cancer at high risk of recurrence who are in need of adjuvant treatment. However, further studies with larger numbers of patients are needed to confirm these findings.	Royal Infirm, Dept Radiol, Glasgow G31 2ER, Lanark, Scotland; Hairmyres Hosp, Dept Surg, E Kilbride, Lanark, Scotland; Royal Infirm, Univ Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Royal Infirmary of Edinburgh; University Hospital Hairmyres; Royal Infirmary of Edinburgh; University of Glasgow	Leen, E (corresponding author), Royal Infirm, Dept Radiol, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							CARTER R, 1994, BRIT J CANCER, V69, P1025, DOI 10.1038/bjc.1994.201; FINLAY IG, 1986, BRIT J SURG, V73, P732, DOI 10.1002/bjs.1800730918; GILBERT JM, 1984, BRIT J SURG, V71, P203, DOI 10.1002/bjs.1800710311; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; LABIANCA R, 1995, LANCET, V345, P939; LEEN E, 1993, GUT, V34, P554, DOI 10.1136/gut.34.4.554; LEEN E, 1991, ANN SURG, V214, P599, DOI 10.1097/00000658-199111000-00010; LEEN E, 1994, ANN SURG, V220, P663, DOI 10.1097/00000658-199411000-00010; LEEN E, 1995, RADIOLOGY, V195, P113, DOI 10.1148/radiology.195.1.7892449; LEEN E, 1991, BRIT J CANCER, V63, P323, DOI 10.1038/bjc.1991.76; LEVESON SH, 1985, BRIT J SURG, V72, P128, DOI 10.1002/bjs.1800720220; MCARDLE CS, 1990, BRIT J SURG, V77, P206; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; OBRIEN MJ, 1988, BR J MED SCI, V157, P5; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Oppo K, 1998, RADIOLOGY, V208, P453, DOI 10.1148/radiology.208.2.9680575; RIDGE JA, 1987, CANCER, V59, P1547, DOI 10.1002/1097-0142(19870501)59:9<1547::AID-CNCR2820590903>3.0.CO;2-6; Warren HW, 1993, BRIT J SURG, V80, P1461	18	66	71	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					34	37		10.1016/S0140-6736(99)06322-9	http://dx.doi.org/10.1016/S0140-6736(99)06322-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615889				2022-12-24	WOS:000085049200014
J	St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D				St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D			Changes in the scope of care provided by primary care physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES; MANAGED-CARE; CONSULTATION	Background: Strategies to control medical costs and improve the quality of care often translate into decisions affecting the range of services primary care physicians provide to patients, which patients are referred for specialty care, and the points in disease processes at which referrals are made. This study focused on physicians' assessments of changes in the scope of care provided by primary care physicians and their assessments of the appropriateness of the scope of the care that primary care physicians are expected to provide. Methods: We analyzed data from the 1996-1997 Community Tracking Study Physician Survey. Telephone interviews were conducted with 12,385 physicians (reflecting a response rate of 65 percent) who were drawn from a representative random sample of physicians providing direct patient care in the continental United States and not employed by the federal government. The analysis was based on responses from the 7015 primary care physicians and 5092 specialists who had been in practice for at least two years. Results: Thirty percent of the primary care physicians and 50 percent of the specialists reported that the scope of care provided by primary care physicians had increased during the previous two years. Twenty-four percent of the primary care physicians and 38 percent of the specialists reported that the scope of care expected to be provided by primary care physicians was greater than it should be. According to multivariate analysis, primary care physicians other than general or family practitioners (i.e., pediatricians and general internists), those who were in one- or two-physician practices, those who received revenues from capitation, and those who served as gatekeepers for their patients' care were significantly more likely to report that the scope of care they were expected to provide was greater than it should be. Conclusions: The finding that nearly one in four primary care physicians reported that the scope of care they were expected to provide was greater than it should be arouses concern about the potential impact of changes in the delivery of health care. The associations we found between financial and administrative aspects of managed care and physicians' concern about the scope of care they provide to their patients deserve careful consideration. (N Engl J Med 1999;341:1980-5.) (C)1999, Massachusetts Medical Society.	Kansas Hlth Inst, Topeka, KS 66612 USA; Ctr Study Hlth Syst Change, Washington, DC USA; Massachusetts Gen Hosp, Partners Healthcare Syst, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	St Peter, RF (corresponding author), Kansas Hlth Inst, 100 SE 9th St,3rd Fl, Topeka, KS 66612 USA.							EISENBERG J, 1986, DOCTORS DECISIONS CO; Grembowski DE, 1998, MED CARE RES REV, V55, P3, DOI 10.1177/107755879805500101; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; Hirth RA, 1996, MED CARE, V34, P1199, DOI 10.1097/00005650-199612000-00005; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1535; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; KEIL L, 1998, TECHNICAL PUBLICATIO, V9; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuo D, 1998, JAMA-J AM MED ASSOC, V280, P905, DOI 10.1001/jama.280.10.905; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; METCALF CE, 1996, TECHNICAL PUBLICATIO, V1; RESCHOVSKY JD, 1998, TECHNICAL PUBLICATIO, V10; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Rosser WW, 1996, J FAM PRACTICE, V42, P139; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136	20	92	94	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1980	1985		10.1056/NEJM199912233412606	http://dx.doi.org/10.1056/NEJM199912233412606			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607816				2022-12-24	WOS:000084399400006
J	Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC				Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC			Crystal structure of the vinculin tail suggests a pathway for activation	CELL			English	Article							F-ACTIN-BINDING; CYTOSKELETAL PROTEIN VINCULIN; INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; TALIN-BINDING; ALPHA-ACTININ; DOMAIN; SITE; MEMBRANE; SEQUENCE	Vinculin plays a dynamic role in the assembly of the actin cytoskeleton. A strong interaction between its head and tail domains that regulates binding to other cytoskeletal components is disrupted by acidic phospholipids. Here, we present the crystal structure of the vinculin tail, residues 879-1066. Five amphipathic helices form an antiparallel bundle that resembles exchangeable apolipoproteins. A C-terminal arm wraps across the base of the bundle and emerges as a hydrophobic hairpin surrounded by a collar of basic residues, adjacent to the N terminus. We show that the C-terminal arm is required for binding to acidic phospholipids but not to actin, and that binding either ligand induces conformational changes that may represent the first step in activation.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham-inst.org	Bagshaw, Clive R./L-5484-2019; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	Bagshaw, Clive R./0000-0002-5396-153X; de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739; Bakolitsa, Constantina/0000-0002-6980-9831				Adams PD, 1999, ACTA CRYSTALLOGR D, V55, P181, DOI 10.1107/S0907444998006635; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1992, J CELL SCI, V103, P719; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Goldmann WH, 1998, EUR J BIOCHEM, V254, P413, DOI 10.1046/j.1432-1327.1998.2540413.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hemmings L, 1996, J CELL SCI, V109, P2715; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls A., 1992, GRASP GRAPHICAL REPR; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WELLER PA, 1990, P NATL ACAD SCI USA, V87, P5667, DOI 10.1073/pnas.87.15.5667; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327	60	153	156	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					603	613		10.1016/S0092-8674(00)81549-4	http://dx.doi.org/10.1016/S0092-8674(00)81549-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612396	Bronze			2022-12-24	WOS:000084278700007
J	Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA				Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA			Functional human corneal equivalents constructed from cell lines	SCIENCE			English	Article							HUMAN EPITHELIAL-CELLS; GROWTH-FACTOR; FIBROBLAST GROWTH; IMMORTALIZATION; EXPRESSION; CULTURE; GENE; EYE	Human corneal equivalents comprising the three main Layers of the cornea (epithelium, stroma, and endothelium) were constructed. Each cellular layer was fabricated from immortalized human corneal cells that were screened for use on the basis of morphological, biochemical, and electrophysiological similarity to their natural counterparts. The resulting corneal equivalents mimicked human corneas in key physical and physiological functions, including morphology, biochemical marker expression, transparency, ion and fluid transport, and gene expression. Morphological and functional equivalents to human corneas that can be produced in vitro have immediate applications in toxicity and drug efficacy testing, and form the basis for future development of implantable tissues.	Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Hosp, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Procter & Gamble Co, Miami Valley Labs, Div Human & Environm Safety, Cincinnati, OH 45253 USA; Ctr Hosp Univ Quebec, Biomat Inst Quebec, Quebec City, PQ G1L 3L5, Canada; Univ Tennessee, Coll Med, Dept Physiol, Memphis, TN 38163 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Procter & Gamble; Laval University; University of Tennessee System; University of Tennessee Health Science Center	Griffith, M (corresponding author), Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada.		Mantovani, Diego/J-2457-2012	Mantovani, Diego/0000-0001-9672-895X; Griffith, May/0000-0003-1222-6720; Watsky, Mitchell/0000-0003-2079-9887				Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bockman CS, 1998, INVEST OPHTH VIS SCI, V39, P1143; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; DOILLON CJ, 1987, BIOMATERIALS, V8, P195, DOI 10.1016/0142-9612(87)90063-9; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Gause WC, 1995, PCR PRIMER LAB MANUA; Germain L, 1999, PATHOBIOLOGY, V67, P140, DOI 10.1159/000028064; GEROSKI DH, 1984, CURR EYE RES, V3, P331, DOI 10.3109/02713688408997217; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH JF, 1980, TOXICOL APPL PHARM, V55, P501, DOI 10.1016/0041-008X(80)90052-6; Griffith M., UNPUB; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; *INT LIF SCI I, 1996, J TOXICOL CUTANEOUS, V15, P211; JAGER MJ, 1995, EYE, V9, P241, DOI 10.1038/eye.1995.47; Janvier R, 1997, ANTICANCER RES, V17, P1551; KAHN CR, 1993, INVEST OPHTH VIS SCI, V34, P1983; KAO WWY, 1975, BIOCHIM BIOPHYS ACTA, V411, P202, DOI 10.1016/0304-4165(75)90300-1; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; MINAMI Y, 1993, INVEST OPHTH VIS SCI, V34, P2316; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; Okada Y, 1998, GRAEF ARCH CLIN EXP, V236, P853, DOI 10.1007/s004170050170; Pettenati MJ, 1997, HUM GENET, V101, P26, DOI 10.1007/s004390050580; PITTS DG, 1994, ENV VISION, pCH6; POWER WJ, 1995, CURR EYE RES, V14, P879, DOI 10.3109/02713689508995127; Priest D., 1998, IOVS, V39, pS352; QUINLAN MP, 1994, ONCOGENE, V9, P2639; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Shoichet M. S., 1998, POLYM TISSUE ENG; Sotozono C, 1997, CURR EYE RES, V16, P670, DOI 10.1076/ceyr.16.7.670.5057; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WATSKY MA, 1995, DUANES FDN CLIN OPHT, V2, pCH4; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	37	377	451	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2169	2172		10.1126/science.286.5447.2169	http://dx.doi.org/10.1126/science.286.5447.2169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591651				2022-12-24	WOS:000084157300056
J	Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH				Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH			Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; NEURONAL-SPECIFIC ACTIVATOR; GLYCOGEN-SYNTHASE KINASE-3; DIRECTED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; TAU-PROTEIN; ALZHEIMERS-DISEASE; REGULATORY SUBUNIT; CEREBRAL-CORTEX	Cyclin-dependent kinase 5 (Cdk5) is required for proper development of the mammalian central nervous system. To be activated, Cdk5 has to associate with its regulatory subunit, p35, We have found that p25, a truncated form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease. This accumulation correlates with an increase in Cdk5 kinase activity. Unlike p35, p25 is not readily degraded, and binding of p25 to Cdk5 constitutively activates Cdk5, changes its cellular location and alters its substrate specificity, In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules, Moreover, expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis, These findings indicate that cleavage of p35, followed by accumulation of p25, may be involved in the pathogenesis of cytoskeletal abnormalities and neuronal death in neurodegenerative diseases.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp E, Ctr Canc, Charlestown, MA 02119 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306				Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gilmore EC, 1998, J NEUROSCI, V18, P6370; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Guidato S, 1996, J NEUROCHEM, V66, P1698; Henchcliffe C, 1997, NEUROSCI LETT, V230, P41, DOI 10.1016/S0304-3940(97)00472-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANAKA T, 1995, FEBS LETT, V360, P5, DOI 10.1016/0014-5793(95)00061-D; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	49	1246	1335	0	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					615	622		10.1038/45159	http://dx.doi.org/10.1038/45159			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604467				2022-12-24	WOS:000084189800054
J	Goto, A; Reich, MR; Aitken, I				Goto, A; Reich, MR; Aitken, I			Oral contraceptives and women's health in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-CONTROL	Japan approved the use of low-dose oral contraceptives (OCs) in June 1999, after more than 35 years of debate, The debate leaves a legacy of misinformation about and various sources of resistance to OCs. Benefits are expected to include greater control for women over their fertility and a reduction in the high rates of unplanned pregnancies and abortions, Successful implementation of the new policy will require a new emphasis on women's health, including the provision of accurate information about OCs and their associated adverse effects, a women-centered approach to gynecological practice, and the promotion of condoms as protection from sexually transmitted diseases, rather than as contraception alone.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Goto, A (corresponding author), Yamagata Univ, Sch Med, Dept Publ Hlth, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Goto, Aya/0000-0002-7927-7648				*A GUTTM I, 1999, SHAR RESP; Arakawa O, 1999, Nihon Koshu Eisei Zasshi, V46, P204; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; COLEMAN S, 1981, STUD FAMILY PLANN, V12, P28, DOI 10.2307/1965861; COLEMAN S, 1991, FAMILY PLANNING JAPA; *HLTH WELF STAT AS, 1998, TRENDS NAT HLTH; *JAP SOC OBST GYN, 1999, GUID US LOW DOS OR C; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; Kihara M, 1997, J ACQ IMMUN DEF SYND, V14, pS3, DOI 10.1097/00042560-199700002-00002; KITAMURA K, 1997, SHINRYO KENKYU, V334, P5; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P37; KOROKU M, 1994, SEX TRANSM DIS, V21, P329, DOI 10.1097/00007435-199411000-00006; Maruyama H, 1996, NATURE, V379, P579, DOI 10.1038/379579a0; MATSUMOTO S, 1988, CURR THER RES CLIN E, V44, P165; MATSUMOTO S, 1991, JAPAN FAMILY PLANNIN, V6, P2; *MIN HLTH WELF, 1998, ANN REP HLTH WELF; *MIN HLTH WELF MIN, 1995, EUG PROT STAT REP; Munakata T, 1996, AIDS EDUC PREV, V8, P115; Nagata C, 1997, PREV MED, V26, P565, DOI 10.1006/pmed.1997.0176; *NHK HO BUNK KENK, 1998, MIND MOD JAP; Norgren T, 1998, J JPN STUD, V24, P59, DOI 10.2307/132939; Oddens BJ, 1998, CONTRACEPTION, V58, P13, DOI 10.1016/S0010-7824(98)00056-0; *OFF NAT STAT, 1994, 1994 AB STAT; OGINO M, 1993, REPROD HEALTH MATTER, V1, P78; *POP PROBL RES COU, 1998, 24 NAT SURV FAM PLAN; *POP PROBL RES COU, 1996, 23 NAT SURV FAM PLAN; *PRIM MIN OFF, 1997, PRES STAT PLANS NAT; TAKAHASHI S, 1999, JINKO MONDAI KENKYUS, V46, P3; TANAKA T, 1990, KOSEI NO SHIHYO, V37, P21; Uchino H, 1997, Nihon Koshu Eisei Zasshi, V44, P499; *WHO, 1998, WHO TECHN REP SER, V877; World Health Organisation [WHO, 1996, WHO TECHN REP SER, V866; Yamamoto T, 1999, Nihon Koshu Eisei Zasshi, V46, P304; YAMAUCHI M, 1991, BRIT MED J, V303, P1157	34	27	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2173	2177		10.1001/jama.282.22.2173	http://dx.doi.org/10.1001/jama.282.22.2173			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	260UG	10591342				2022-12-24	WOS:000083971400040
J	Conway, G; Toenniessen, G				Conway, G; Toenniessen, G			Feeding the world in the twenty-first century	NATURE			English	Article								The gains in food production provided by the Green Revolution have reached their ceiling while world population continues to rise. To ensure that the world's poorest people do not still go hungry in the twenty-first century, advances in plant biotechnology must be deployed for their benefit by a strong public-sector agricultural research effort.	Rockefeller Fdn, New York, NY 10018 USA		Conway, G (corresponding author), Rockefeller Fdn, New York, NY 10018 USA.							Cassman KG, 1999, P NATL ACAD SCI USA, V96, P5952, DOI 10.1073/pnas.96.11.5952; Conway G, 1999, DOUBLY GREEN REVOLUT; LEONARD HJ, 1989, ENV POOR DEV STRATEG, P3; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; Mann CC, 1999, SCIENCE, V283, P314, DOI 10.1126/science.283.5400.314; May R. M., 1999, GENETICALLY MODIFIED; *NUFF COUNC BIOETH, 1999, GEN MOD CROPS ETH SO; PARDEY PG, 1996, SUMMARY PRODUCTIVE P; PRETTY J, IN PRESS BIOCHEMIST; Rissler J, 1996, ECOLOGICAL RISKS ENG; *ROYSL SOC LONDON, 1998, GEN MOD PLANTS FOOD; SOMER A, 1966, VITAMIN A DEFICIENCY; *UN FAO, 1996, 61 FAO WHO; UNICEF, 1998, STAT WORLDS CHILDR 1; YE XD, UNPUB SCIENCE; [No title captured]	16	155	166	3	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C55	C58		10.1038/35011545	http://dx.doi.org/10.1038/35011545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591226				2022-12-24	WOS:000084014100008
J	Diesmann, M; Gewaltig, MO; Aertsen, A				Diesmann, M; Gewaltig, MO; Aertsen, A			Stable propagation of synchronous spiking in cortical neural networks	NATURE			English	Article							COINCIDENCE DETECTOR; ONGOING ACTIVITY; NEURONS; SYNCHRONIZATION; INTEGRATOR; PATTERNS; CORTEX; INPUTS; MODEL	The classical view of neural coding has emphasized the importance of information carried by the rate at which neurons discharge action potentials. More recent proposals that information may be carried by precise spike timing(1-5) have been challenged by the assumption that these neurons operate in a noisy fashion-presumably reflecting fluctuations in synaptic input(6)-and, thus, incapable of transmitting signals with millisecond fidelity. Here we show that precisely synchronized action potentials can propagate within a model of cortical network activity that recapitulates many of the features of biological systems. An attractor, yielding a stable spiking precision in the (sub)millisecond range, governs the dynamics of synchronization. Our results indicate that a combinatorial neural code, based on rapid associations of groups of neurons co-ordinating their activity at the single spike level, is possible within a cortical-like network.	Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, D-79104 Freiburg, Germany	University of Freiburg	Aertsen, A (corresponding author), Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, Schanzlestr 1, D-79104 Freiburg, Germany.	aertsen@biologie.uni-freiburg.de	Diesmann, Markus/H-3722-2013	Diesmann, Markus/0000-0002-2308-5727				ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1991, CORTICONICS; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Arnoldi HMR, 1996, BIOL CYBERN, V74, P209, DOI 10.1007/BF00652222; BERNANDER O, 1994, NEURAL COMPUT, V6, P622, DOI 10.1162/neco.1994.6.4.622; BIENENSTOCK E, 1995, NETWORK-COMP NEURAL, V6, P179, DOI 10.1088/0954-898X/6/2/004; Braitenberg V, 1991, ANATOMY CORTEX; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; DIESMAN M, 1995, SYNOD ENV NEURAL SYS; DIESMANN M, 1997, MEMBRANE MIND, P62; DIESMANN M, 1996, TRENDS RES 1995, P59; FETZ E, 1991, CEREB CORTEX, V9, P1; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GRIFFITH JS, 1963, BIOPHYS J, V3, P299, DOI 10.1016/S0006-3495(63)86822-8; HERRMANN M, 1995, NETWORK-COMP NEURAL, V6, P403, DOI 10.1088/0954-898X/6/3/006; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Marsalek PR, 1997, P NATL ACAD SCI USA, V94, P735, DOI 10.1073/pnas.94.2.735; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; Prut Y, 1998, J NEUROPHYSIOL, V79, P2857, DOI 10.1152/jn.1998.79.6.2857; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Tuckwell H.C., 1988, INTRO THEORETICAL NE, DOI [10.1017/CBO9780511623202, DOI 10.1017/CBO9780511623202]; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	30	669	675	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					529	533		10.1038/990101	http://dx.doi.org/10.1038/990101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591212				2022-12-24	WOS:000084013200056
J	Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA				Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA			Chromosomal landscape of nucleosome-dependent gene expression and silencing in yeast	NATURE			English	Article							ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; CHROMATIN STRUCTURE; TRANSCRIPTION; GENOME; RAP1; DEPLETION; PROMOTER; FAMILY	Eukaryotic genomes are packaged into nucleosomes, which are thought to repress gene expression generally(1-3), Repression is particularly evident at yeast telomeres, where genes within the telomeric heterochromatin appear to be silenced by the histone-binding silent information regulator (SIR) complex (Sir2, Sir3, Sir4) and Rap1 (refs 4-10). Here, to investigate how nucleosomes and silencing factors influence global gene expression, we use high-density arrays to study the effects of depleting nucleosomal histones and silencing factors in yeast. Reducing nucleosome content by depleting histone H4 caused increased expression of 15% of genes and reduced expression of 10% of genes, hut it had little effect on expression of the majority (75%) of yeast genes, Telomere-proximal genes were found to be de-repressed over regions extending 20 kilobases from the telomeres, well beyond the extent of Sir protein binding(11,12) and the effects of loss of Sir function, These results indicate that histones make Sir-independent contributions to telomeric silencing, and that the role of histones located elsewhere in chromosomes is gene specific rather than generally repressive.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Geneva; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Young, RA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Holstege, Frank/AAM-9944-2021; Shore, David/F-6240-2015; Young, Richard A/F-6495-2012	Shore, David/0000-0002-9859-143X; Young, Richard A/0000-0001-8855-8647; Causton, Helen/0000-0003-4630-6569				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RINE J, 1987, GENETICS, V116, P9; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	30	316	319	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					418	421		10.1038/46567	http://dx.doi.org/10.1038/46567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586882				2022-12-24	WOS:000083913600058
J	Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I				Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I			A low-temperature origin for the planetesimals that formed Jupiter	NATURE			English	Article							SOLAR NEBULA; WAVELENGTHS; CHEMISTRY; MODELS	The four giant planets in the Solar System have abundances of 'metals' (elements heavier than helium), relative to hydrogen, that are much higher than observed in the Sun. In order to explain this, all models for the formation of these planets rely on an influx of solid planetesimals(17). It is generally assumed that these planetesimals were similar, if not identical, to the comets from the Oort cloud that we see today. Comets that formed in the region of the giant planets should not have contained much neon, argon and nitrogen, because the temperatures were too high for these volatile gases to be trapped effectively in ice. This means that the abundances of those elements on the giant planets should be approximately solar. Here we show that argon, krypton and xenon in Jupiter's atmosphere are enriched to the same extent as the other heavy elements, which suggests that the planetesimals carrying these elements must have formed at temperatures lower than predicted by present models of giant-planet formation.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, Goddard Space Flight Ctr, Atmospheres Lab, Greenbelt, MD 20771 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Dept Geophys & Planetary Sci, IL-69978 Tel Aviv, Israel; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; Tel Aviv University; University of California System; University of California Berkeley	Owen, T (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	owen@ifa.hawaii.edu	Mahaffy, Paul/E-4609-2012	Mahaffy, Paul/0000-0003-1896-1726				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ATREYA SK, IN PRESS PLANET SPAC; ATREYA SK, 1997, 3 GALILEOS MAN SPACE, P289; BARNUN A, 1988, PHYS REV B, V38, P7749, DOI 10.1103/PhysRevB.38.7749; CASSEN P, 1994, ICARUS, V112, P405, DOI 10.1006/icar.1994.1195; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GEISS J, 1988, REV MOD ASTRON, V1, P1; JOINER J, 1991, J GEOPHYS RES-PLANET, V96, P17463, DOI 10.1029/91JE01740; KRANKOWSKY D, 1991, ASTROPHYS SPACE SC L, V167, P855; LINKE RA, 1983, ASTROPHYS J, V271, pL85, DOI 10.1086/184100; Mahaffy P. R., 1998, B AM ASTRON SOC, V30, P1066; MAHAFFY PR, 1998, PRIMORDIAL NUCL THEI, P239; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen TC, 1997, THREE GALILEOS: THE MAN, THE SPACECRAFT, THE TELESCOPE, P289; POLKNER WM, 1998, J GEOPHYS RES, V103, P22847; ROMANI PN, 1995, B AM ASTRON SOC, V27, P81; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; Showman AP, 1998, ICARUS, V132, P205, DOI 10.1006/icar.1998.5898; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WOMACK M, 1992, ASTROPHYS J, V401, P728, DOI 10.1086/172100; WYCKOFF S, 1991, ASTROPHYS J, V367, P641, DOI 10.1086/169659	24	225	226	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					269	270		10.1038/46232	http://dx.doi.org/10.1038/46232			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580497	Green Published			2022-12-24	WOS:000083813700041
J	Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M				Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M			Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling	NATURE			English	Article							LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; PROTEIN; SRC; NUCLEATION; CORTACTIN; PATHOGENS; DOMAINS; NCK	Studies of the actin-based motility of the intracellular pathogens Listeria monocytogenes and Shigella flexneri have provided important insight into the events occurring at the leading edges of motile cells(1-5). Like the bacteria Listeria and Shigella, vaccinia virus, a relative of the causative agent of smallpox, uses actin-based motility to spread between cells(6). In contrast to Listeria or Shigella, the actin-based motility of vaccinia is dependent on an unknown phosphotyrosine protein, but the underlying mechanism remains obscure(7). Here we show that phosphorylation of tyrosine 112 in the viral protein A36R by Src-family kinases is essential for the actin-based motility of vaccinia. Tyrosine phosphorylation of A36R results in a direct interaction with the adaptor protein Nck(8) and the recruitment of the Ena/VASP family member N-WASP(9) to the site of actin assembly. We also show that Nck and N-WASP are essential for the actin-based motility of vaccinia virus. We suggest that vaccinia virus spreads by mimicking the signalling pathways that are normally involved in actin polymerization at the plasma membrane.	European Mol Biol Lab, Cell Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Way, M (corresponding author), European Mol Biol Lab, Cell Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768; Frischknecht, Friedrich/0000-0002-8332-6668; GONFLONI, STEFANIA/0000-0002-9392-4258; Moreau, Violaine/0000-0002-4513-7022; Way, Michael/0000-0001-7207-2722				Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottger S, 1999, J VIROL, V73, P2863; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 1998, J GEN VIROL, V79, P1415, DOI 10.1099/0022-1317-79-6-1415; Sanderson CM, 1998, J VIROL, V72, P9924, DOI 10.1128/JVI.72.12.9924-9933.1998; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; SONG MY, 1995, SUPERCOND SCI TECH, V8, P20, DOI 10.1088/0953-2048/8/1/004; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	27	333	342	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					926	929		10.1038/44860	http://dx.doi.org/10.1038/44860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553910				2022-12-24	WOS:000083464700062
J	Lohr, F				Lohr, F			On losing your molecular privacy	BRITISH MEDICAL JOURNAL			English	Editorial Material													Lohr, Frank/AAC-2528-2022	Lohr, Frank/0000-0003-1014-5556					0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1651	1652		10.1136/bmj.319.7225.1651	http://dx.doi.org/10.1136/bmj.319.7225.1651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600984	Green Published			2022-12-24	WOS:000084562600035
J	Ross, SE				Ross, SE			"Memes" as infectious agents in psychosomatic illness	ANNALS OF INTERNAL MEDICINE			English	Article							ANOREXIA-NERVOSA; CHRONIC FATIGUE; FIBROMYALGIA; EPIDEMIC; DISORDERS; NEURASTHENIA; LABEL		Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ross, SE (corresponding author), Univ Colorado, Hlth Sci Ctr, Box F414,4200 E 9th Ave, Denver, CO 80262 USA.	steve.ross@uchsc.edu						ACOCELLA J, 1998, POLITICS HYSTERIA, P64; ANGELL M, 1996, CLASH MED EVIDENCE L; [Anonymous], 1999, LANCET, V354, P173; ARONOWITZ RA, 1992, STUDIES CULTURAL HIS; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; BARSKY AJ, 1979, ANN INTERN MED, V91, P63, DOI 10.7326/0003-4819-91-1-63; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; Boss LP, 1997, EPIDEMIOL REV, V19, P233, DOI 10.1093/oxfordjournals.epirev.a017955; BRODSKY CM, 1988, OCCUP MED, V3, P653; BRUMBERG JJ, 1988, EMERGENCE ANOREXIA N; CHEW P K, 1976, SMJ Singapore Medical Journal, V17, P10; CLELAND LG, 1987, MED J AUSTRALIA, V147, P236, DOI 10.5694/j.1326-5377.1987.tb133417.x; COLLIGAN M, 1982, MASS PSYCHOGENIC ILL; Dawkins R, 1976, SELFISH GENE; FAVA M, 1989, AM J PSYCHIAT, V146, P963; GOTHE CJ, 1995, PSYCHOSOMATICS, V36, P1; GREENBERG DB, 1990, PSYCHOSOMATICS, V31, P129, DOI 10.1016/S0033-3182(90)72185-8; HADLER NM, 1990, J OCCUP ENVIRON MED, V32, P38; Hadler NM, 1997, POSTGRAD MED, V102, P161, DOI 10.3810/pgm.1997.08.284; Hadler NM, 1996, CLEV CLIN J MED, V63, P85, DOI 10.3949/ccjm.63.2.85; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; HALL W, 1988, SOC SCI MED, V27, P645, DOI 10.1016/0277-9536(88)90013-5; Mehler PS, 1996, HOSP PRACT, V31, P109; Nemery B, 1999, LANCET, V354, P77, DOI 10.1016/S0140-6736(05)75348-4; Osterweis M., 1987, PAIN DISABILITY CLIN; Riley JL, 1998, PAIN, V74, P181, DOI 10.1016/S0304-3959(97)00199-1; Showalter E., 1997, HYSTORIES; SIROIS F, 1982, MASS PSYCHOGENIC ILL; WELCH MS, 1971, LADIES HOME J    NOV, P98; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; Wilke WS, 1996, CLEV CLIN J MED, V63, P87, DOI 10.3949/ccjm.63.2.87; YAGER J, 1974, NEW ENGL J MED, V291, P907, DOI 10.1056/NEJM197410242911713; YASSI A, 1989, CAN MED ASSOC J, V140, P816; 1981, AM HER DICT ENGLISH, P834; 1990, MMWR MORB MORTAL WKL, V39, P301; 1996, MMWR MORB MORTAL WKL, V45, P6	36	16	16	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					867	871		10.7326/0003-4819-131-11-199912070-00019	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262ET	10610639				2022-12-24	WOS:000084053200018
J	Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S				Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S			Domain movement in gelsolin: A calcium-activated switch	SCIENCE			English	Article							PLASMA GELSOLIN; BINDING-SITE; ACTIN; COMPLEX; IDENTIFICATION; FILAMENT	The actin-binding protein gelsolin is involved in remodeling the actin cytoskeleton during growth-factor signaling, apoptosis, cytokinesis, and cell movement. Calcium-activated gelsolin severs and caps actin filaments, The 3.4 angstrom x-ray structure of the carboxyl-terminal half of gelsolin (G4-G6) in complex with actin reveals the basis for gelsolin activation. Calcium binding induces a conformational rearrangement in which domain G6 is flipped over and translated by about 40 angstroms relative to G4 and G5. The structural reorganization tears apart the continuous beta sheet core of G4 and G6. This exposes the actin-binding site on G4, enabling severing and capping of actin filaments to proceed.	Salk Inst Biol Studies, Struct Biol Lab, San Diego, CA 92186 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Salk Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of British Columbia	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, POB 85800, San Diego, CA 92186 USA.		Robinson, Robert/G-9702-2011	Robinson, Robert/0000-0001-6367-6903				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; 1994, ACTA CRYSTALLOGR D, V55, P760	18	134	139	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1939	1942		10.1126/science.286.5446.1939	http://dx.doi.org/10.1126/science.286.5446.1939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583954				2022-12-24	WOS:000084003400047
J	Olson, ES				Olson, ES			Direct measurement of intra-cochlear pressure waves	NATURE			English	Article							BASILAR-MEMBRANE; MECHANICS; POSITION; BASE	The cochlear travelling wave is fundamental to the ability of the mammalian auditory system to resolve frequency. The seashell-shaped outer bone of the cochlea (the auditory inner ear) contains a spiral of cochlear fluid and the sensory tissue known as the cochlear partition. Sound travels down the ear canal to the eardrum, causing its flexible tympanic membrane to vibrate. This vibration is transmitted to the cochlea via the ossicles. Motion of the stapes (the stirrup ossicle) sets the cochlear fluid in motion, which in turn sets the cochlear partition near the stapes in motion. The motion of the cochlear partition ripples down the cochlear spiral as a travelling wave, stimulating the cochlea's sensory hair cells. The wave peaks near the base (the stapes end) of the cochlea for high frequency tones and near the apex for low frequencies'. The fundamental elements of the cochlear travelling wave are fluid pressure and motion and partition forces and motion. However, the wave's direct experimental study has to date relied almost solely on measurements of the partition motion. Here I report finely spaced measurements of intracochlear pressure close to the partition, which reveal the fluid component of the cochlear wave. The penetration depth of the wave is very limited, similar to 15 mu m. Over a range of frequencies at least an octave wide, the depth is independent of frequency.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University	Olson, ES (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.				NIDCD NIH HHS [R29 DC003130] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003130] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BROWNELL WE, 1985, SCIENCE, V227, P195; COOPER NP, 1992, HEARING RES, V63, P163, DOI 10.1016/0378-5955(92)90083-Y; DANCER A, 1980, HEARING RES, V2, P191, DOI 10.1016/0378-5955(80)90057-X; DEBOER E, 1984, PHYS REP, V105, P141, DOI 10.1016/0370-1573(84)90108-X; LIBERMAN MC, 1984, HEARING RES, V16, P55, DOI 10.1016/0378-5955(84)90025-X; LIGHTHILL J, 1981, J FLUID MECH, V106, P149, DOI 10.1017/S0022112081001560; Muller M, 1996, HEARING RES, V94, P148, DOI 10.1016/0378-5955(95)00230-8; Olson ES, 1998, J ACOUST SOC AM, V103, P3445, DOI 10.1121/1.423083; PLASSMANN W, 1987, BRAIN BEHAV EVOLUT, V30, P82, DOI 10.1159/000118639; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; Ruggero MA, 1997, J ACOUST SOC AM, V101, P2151, DOI 10.1121/1.418265; SELLICK PM, 1983, HEARING RES, V10, P101, DOI 10.1016/0378-5955(83)90020-5; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; STEELE CR, 1979, J ACOUST SOC AM, V65, P1007, DOI 10.1121/1.382570; von Bekesy G, 1960, EXPT HEARING; XUE SW, 1995, J ACOUST SOC AM, V97, P3030, DOI 10.1121/1.413103	16	95	96	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					526	529		10.1038/990092	http://dx.doi.org/10.1038/990092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591211				2022-12-24	WOS:000084013200055
J	Stone, SL; Arnoldo, M; Goring, DR				Stone, SL; Arnoldo, M; Goring, DR			A breakdown of Brassica self-incompatibility in ARC1 antisense transgenic plants	SCIENCE			English	Article							LOCUS RECEPTOR KINASE; PROTEIN PHOSPHATASE; STIGMA PAPILLAE; GENE; OLERACEA; PHENOTYPE; DOMAIN; SLG	Self-incompatibility, the rejection of self pollen, is the most widespread mechanism by which flowering plants prevent inbreeding. In Brassica, the S receptor kinase (SRK) has been implicated in the self-incompatibility response, but the molecular mechanisms involving SRK are unknown. One putative downstream effector for SRK is ARC1, a protein that binds to the SRK kinase domain. Here it is shown that suppression of ARC1 messenger RNA levels in the self-incompatible Brassica napus W1 line is correlated with a partial breakdown of self-incompatibility, resulting in seed production. This provides strong evidence that ARC1 is a positive effector of the Brassica self-incompatibility response.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Canola Res Stn, Pioneer Hi Bred Prod, Georgetown, ON L7G 4S7, Canada	York University - Canada	Goring, DR (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.			Stone, Sophia/0000-0003-2140-6037; Goring, Daphne/0000-0001-5295-4744				Becraft PW, 1998, TRENDS PLANT SCI, V3, P384, DOI 10.1016/S1360-1385(98)01301-6; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; Cabrillac D, 1999, PLANT CELL, V11, P971, DOI 10.1105/tpc.11.5.971; DELORME V, 1995, PLANT J, V7, P429, DOI 10.1046/j.1365-313X.1995.7030429.x; DENATTANCOURT D, 1997, SEX PLANT REPROD, V10, P185; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; Franklin TM, 1996, SEX PLANT REPROD, V9, P203, DOI 10.1007/BF02173099; GAUDE T, 1995, PLANT MOL BIOL, V27, P1003, DOI 10.1007/BF00037027; GORING DR, 1992, MOL GEN GENET, V234, P185, DOI 10.1007/BF00283838; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1996, SIGNAL TRANSDUCTION; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hiscock SJ, 1996, TRENDS CELL BIOL, V6, P421, DOI 10.1016/S0962-8924(96)10037-4; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; MATTON DP, 1994, P NATL ACAD SCI USA, V91, P1992, DOI 10.1073/pnas.91.6.1992; NASRALLAH JB, 1994, SCIENCE, V266, P1506; NASRALLAH JB, 1985, NATURE, V318, P236; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217; Sulaman W, 1997, PLANTA, V203, P327, DOI 10.1007/s004250050198; Williams RW, 1997, P NATL ACAD SCI USA, V94, P10467, DOI 10.1073/pnas.94.19.10467	24	180	223	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1729	1731		10.1126/science.286.5445.1729	http://dx.doi.org/10.1126/science.286.5445.1729			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576738				2022-12-24	WOS:000083912200036
J	Blass, JP				Blass, JP			Immunologic treatment of Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA	Cornell University	Blass, JP (corresponding author), Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA.							BLASS JP, 1995, CLIN DIAGNOSIS MANAG, P17; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Seabrook GR, 1999, NEUROPHARMACOLOGY, V38, P349, DOI 10.1016/S0028-3908(98)00204-4	5	11	27	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1694	1695		10.1056/NEJM199911253412213	http://dx.doi.org/10.1056/NEJM199911253412213			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572162				2022-12-24	WOS:000083847500013
J	Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG				Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG			Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; CONSUMPTION; BEVERAGES; COFFEE	Background: Whether the consumption of caffeine during pregnancy increases the risk of spontaneous abortion is controversial. Prior studies have determined caffeine consumption by questionnaire. We used a biologic marker, serum paraxanthine, a metabolite of caffeine, to measure the dose of caffeine. Methods: In a nested case-control study, we measured serum paraxanthine in 591 women who had spontaneous abortions at less than 140 days' gestation and in 2558 matched women from the same clinic who gave birth to live infants at 28 weeks' gestation or later and who had serum drawn on the same day of gestation as the women who had abortions. The women were enrolled in the Collaborative Perinatal Project during the period from 1959 to 1966, and serum paraxanthine was measured over 30 years later. Results: A total of 487 women who had spontaneous abortions (82 percent) and 2087 controls (82 percent) had quantifiable serum paraxanthine concentrations. However, the mean serum paraxanthine concentration was higher in the women who had spontaneous abortions than in the controls (752 vs. 583 ng per milliliter, P<0.001). The odds ratio for spontaneous abortion was not significantly elevated in the women who had serum paraxanthine concentrations of 1845 ng per milliliter or lower, corresponding to the 95th percentile of the matched women. However, the adjusted odds ratio for spontaneous abortion among women with serum paraxanthine concentrations higher than 1845 ng per milliliter, as compared with women who had concentrations below 50 ng per milliliter, was 1.9 (95 percent confidence interval, 1.2 to 2.8). Conclusions: Only extremely high serum paraxanthine concentrations are associated with spontaneous abortion. This suggests that moderate consumption of caffeine is unlikely to increase the risk of spontaneous abortion. (N Engl J Med 1999;341:1639-44.) (C) 1999, Massachusetts Medical Society.	NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; Univ Utah, Ctr Human Toxicol, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utah System of Higher Education; University of Utah	Klebanoff, MA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, 6100 Bldg,Rm 7B03,MSC 7510, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073262, Z01HD000373] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-7-3262] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310; ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P19, DOI 10.3109/00016348909087683; Dlugosz L, 1996, EPIDEMIOLOGY, V7, P250, DOI 10.1097/00001648-199605000-00006; ESKENAZI B, 1993, JAMA-J AM MED ASSOC, V270, P2973, DOI 10.1001/jama.270.24.2973; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; Fenster L, 1997, EPIDEMIOLOGY, V8, P515, DOI 10.1097/00001648-199709000-00008; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; INFANTERIVARD C, 1993, JAMA-J AM MED ASSOC, V270, P2940, DOI 10.1001/jama.270.24.2940; Klebanoff MA, 1998, ANN EPIDEMIOL, V8, P107, DOI 10.1016/S1047-2797(97)00125-7; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10; MILLS JL, 1993, JAMA-J AM MED ASSOC, V269, P593, DOI 10.1001/jama.269.5.593; Niswander K.R., 1972, WOMEN THEIR PREGNANC; *SAS I INC, 1992, P229 SAS I INC, P433; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; STEIN H, 1991, ANN ONCOL, V2, P163, DOI 10.1093/annonc/2.suppl_2.163; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; Yesair D W, 1984, Prog Clin Biol Res, V158, P215	20	90	92	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1639	1644		10.1056/NEJM199911253412202	http://dx.doi.org/10.1056/NEJM199911253412202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572151				2022-12-24	WOS:000083847500002
J	Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY				Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY			Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; ENCEPHALOMYELITIS; INFECTIONS; EPIDEMIC; EDEMA	Background In Taiwan, from April to July, 1998, an epidemic of hand, foot, and mouth disease associated with enterovirus 71 (EV71) occurred with fatal complications. We did a clinical study of EV71-related diseases in Taiwan. Methods We studied 154 children with virus-culture-confirmed EV71 infection. Children were divided into three groups: 11 patients with pulmonary oedema; 38 patients with central nervous system (CNS) involvement and no pulmonary oedema; and 105 children without complications. We compared the clinical features, laboratory findings, risk factors, and outcome among these three groups. Findings Nine children with pulmonary oedema had hand, foot, and mouth disease, one had herpangina, and one had febrile illness with eight children with limb weakness and one with limb hypesthesia. All children had had sudden onset of tachycardia, tachypnoea, and cyanosis 1-3 days after onset of the disease. Nine of 11 children died within 12 h of intubation; one child was braindead within 15 h and died 17 days after intubation; one child was in deep coma and died 3 months later. In children with CNS complication and no pulmonary oedema, one child died of pneumonia after 4 months of ventilator support and four children had sequelae. All 105 children without complications recovered. There was a significant association between CNS involvement and pulmonary oedema (odds ratio 12 4 [95% CI 2.6-60.1], p = 0.001). Risk factors for pulmonary oedema after CNS involvement were hyperglycaemia, leucocytosis, and limb weakness. Hyperglycaemia was tbe most significant prognostic factor for pulmonary oedema (odds ratio 21.5 [3-159], p = 0.003). Interpretation EV71 can cause hand. foot, and mouth disease, CNS involvement with severe sequelae, and fatal pulmonary oedema. Hyperglycaemia is the most important prognostic factor.	Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Neurol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Cardiol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pathol, Tao Yuan, Taiwan; Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; Chang Gung Univ, Sch Med Technol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Clin Virol Lab, Tao Yuan, Taiwan; Chang Gung Univ, Dept Hlth Care Management, Tao Yuan, Taiwan; Chang Gung Univ, Lab Epidemiol, Tao Yuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University	Lin, TY (corresponding author), Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, 5 Fu Hsing St, Tao Yuan, Taiwan.	pidlin@adm.cgmh.com.tw	Shih, Shin-Ru/M-9711-2016	Hsueh, Chuen/0000-0001-7860-5964; CHANG, LUAN-YIN/0000-0003-2632-1956; Shih, Shin-Ru/0000-0003-4874-401X; Hsu, Kuang-Hung/0000-0003-2642-7689; LEE, CHIN-YUN/0000-0002-3938-377X				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; BLOMBERG J, 1974, LANCET, V2, P112; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHEN HI, 1980, CIRC RES, V47, P366, DOI 10.1161/01.RES.47.3.366; CHUMAKOV M, 1979, ARCH VIROL, V60, P329, DOI 10.1007/BF01317504; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; GRANDIEN M, 1989, DIAGNOSTIC PROCEDURE, P513; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; KENNETT ML, 1974, B WORLD HEALTH ORGAN, V51, P609; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MATSUNAGA H, 1989, ENDOCRINOLOGY, V124, P1259, DOI 10.1210/endo-124-3-1259; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; NAGAI K, 1983, AM J PHYSIOL, V245, pE14, DOI 10.1152/ajpendo.1983.245.1.E14; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; RICHARDSON HB, 1965, J PEDIATR-US, V67, P6, DOI 10.1016/S0022-3476(65)80297-9; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321	23	322	395	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1682	1686		10.1016/S0140-6736(99)04434-7	http://dx.doi.org/10.1016/S0140-6736(99)04434-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568570				2022-12-24	WOS:000083652800011
J	Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V				Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V			Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules	LANCET			English	Article							NATURAL-KILLER-CELLS; RECEPTORS; PHENOTYPE	Background Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to complex criteria, but the underlying cause is rarely identified. We present evidence for a new aetiology for chronic granulomatous lesions associated with a recessive genetic defect, which is linked to the human leucocyte antigen (HLA) locus. Methods Five adults with necrotising granulomatous lesions in the upper respiratory tract and skin, associated with recurrent bacterial respiratory infections and skin vasculitis, were identified. A diagnosis of Wegener's granulomatosis was considered in all of them, but abandoned because of an incompatible disease course and resistance to immunosuppressive treatments. Peripheral-blood samples were taken and analysed by immunohistochemistry and fluorescent-activated-cell-sorter analysis. Since all five patients were homozygous for the HLA locus, we looked for genetic defects located within the HLA-locus with PCR and restriction fragment length polymorphism. Findings A severe decrease in cell-surface expression of HLA class-I molecule was seen in all patients. Defective expression of the transporter associated with antigen presentation (TAP) genes was responsible for the HLA class-I down-regulation, and in two patients we identified a mutation in the TAP2 gene responsible for the defective expression of the TAP complex. We showed the presence of autoreactive natural killer (NK) cells and gamma delta T lymphocytes in the peripheral blood cells of two patients. Correction of the genetic defect in vitro restored normal expression of HLA class-I molecules and prevented self-reactivity in the patients' cells. Histology of granulomatous lesions showed the presence of a large proportion of activated NK cells. Interpretation Our findings define the cause and pathogenesis of a new syndrome that affects patients with a defective surface expression of HLA class-I molecules. The syndrome resembles Wegener's granulomatosis both clinically and histologically. Patients have chronic necrotising granulomatous lesions in the upper respiratory tract and skin, recurrent infections of the respiratory tract, and skin vasculitis. A predominant NK population within the granulomatous lesions suggests that the pathophysiology of the skin lesions may relate to the inability of HLA class-I molecules to turn off NK cell responses. Accurate genetic analysis of a defined syndrome can provide a better understanding of the cause and pathogenesis of a disease.	Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England; Univ Lubeck, Rheumaklin Bad Bramstedt, D-2400 Lubeck, Germany; Basel Inst Immunol, Basel, Switzerland; CRC, Inst Canc Studies, Birmingham, W Midlands, England; Istanbul Fac Med, Dept Dermatol, Istanbul, Turkey; Univ Basel, Dept Dermatol, CH-4003 Basel, Switzerland; Univ Birmingham, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Div Cellular Sci, Oxford, England; Univ Ziekenhuis Antwerpen, Dept Dermatol, Edegem, Belgium; Dept Dermatol, Brussels, Belgium; Hop St Louis, INSERM, U0396, F-75010 Paris, France	University of Oxford; University of Lubeck; University of Birmingham; Istanbul University; University of Basel; University of Birmingham; University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cerundolo, V (corresponding author), Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England.	vcerundo@worf.molbiol.ox.ac.uk	Cella, Marina/G-8850-2011; Cella, Marina/ABA-8564-2020; Moins-Teisserenc, helene/AAL-1566-2021; Dunbar, Rod/C-2570-2012; Jones, Margaret/B-4083-2009	Moins-Teisserenc, helene/0000-0003-1602-7534; Dunbar, Rod/0000-0001-9626-2600; Cella, Marina/0000-0003-1230-1313; Colonna, Marco/0000-0001-5222-4987; Cerundolo, Vincenzo/0000-0003-0040-3793; Exley, Andrew/0000-0002-2628-6129				CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Furukawa H, 1999, J CLIN INVEST, V103, P755, DOI 10.1172/JCI5335; Furukawa H, 1999, HUM IMMUNOL, V60, P32, DOI 10.1016/S0198-8859(98)00097-4; GROSS WL, 1998, OXFORD TXB RHEUMATOL, V2, P1331; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Orange JS, 1996, J IMMUNOL, V156, P4746; Plebani A, 1996, J AM ACAD DERMATOL, V35, P814, DOI 10.1016/S0190-9622(96)90091-2; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TAKASHIMA T, 1993, J IMMUNOL, V150, P3002; Teisserenc H, 1997, IMMUNOL LETT, V57, P183, DOI 10.1016/S0165-2478(97)00072-2; WATANABE S, 1987, J AM ACAD DERMATOL, V17, P1006, DOI 10.1016/S0190-9622(87)70290-4; WILLEMSEN M, 1995, J AM ACAD DERMATOL, V33, P887, DOI 10.1016/0190-9622(95)90429-8; Zimmer J, 1998, J EXP MED, V187, P117, DOI 10.1084/jem.187.1.117; Zimmer J, 1999, EUR J IMMUNOL, V29, P1286, DOI 10.1002/(SICI)1521-4141(199904)29:04<1286::AID-IMMU1286>3.0.CO;2-L	21	100	100	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1598	1603		10.1016/S0140-6736(99)04206-3	http://dx.doi.org/10.1016/S0140-6736(99)04206-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560675				2022-12-24	WOS:000083551000012
J	Rayson, D				Rayson, D			Lisa's stories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Rayson, Daniel/W-2800-2019	Rayson, Daniel/0000-0002-2438-3128					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1605	1606		10.1001/jama.282.17.1605	http://dx.doi.org/10.1001/jama.282.17.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553770				2022-12-24	WOS:000083368400001
J	Paul, REL; Coulson, TN; Raibaud, A; Brey, PT				Paul, REL; Coulson, TN; Raibaud, A; Brey, PT			Sex determination in malaria parasites	SCIENCE			English	Article							TRANSMISSION-BLOCKING IMMUNITY; LOCAL MATE COMPETITION; PLASMODIUM-GALLINACEUM; ERYTHROPOIETIN; ANTIBODIES; CHICKENS; BIOLOGY; RATIOS	A century ago, W. G. MacCallum identified distinct male and female forms in malaria parasites of both birds and humans. Since then, scientists have been punted by the high female-to-male ratios of parasites in Plasmodium infections and by the mechanism of sex determination. The sex ratio of malaria parasites was shown to become progressively more male as conditions that allow motility and subsequent fertilization by the male parasites become adverse. This resulted from an increased immune response against male gametes, which coincides with intense host erythropoietic activity. Natural and artificial induction of erythropoiesis in vertebrate hosts provoked a shift toward male parasite production. This change in parasite sex ratio led to reduced reproductive success in the parasite, which suggests that sex determination is adaptive and is regulated by the hematologic state of the host.	Inst Pasteur, Lab Biochim & Biol Mol Insectes, F-75724 Paris 15, France; Zool Soc London, Inst Zool, London NW1 4RY, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Zoological Society of London	Paul, REL (corresponding author), Inst Pasteur, Lab Biochim & Biol Mol Insectes, 25 Rue Dr Roux, F-75724 Paris 15, France.	topotito@pasteur.fr						CARTER R, 1979, EXP PARASITOL, V47, P194, DOI 10.1016/0014-4894(79)90073-0; CARTER R, 1979, EXP PARASITOL, V47, P185, DOI 10.1016/0014-4894(79)90072-9; Carter R., 1988, MALARIA PRINCIPLES P, P253; CHARNOV E L, 1982; CRAWLEY MJ, 1993, GUM ECOLOGISTS; Day KP, 1998, PARASITOLOGY, V116, pS95, DOI 10.1017/S0031182000084985; ElHassan AMA, 1997, EUR J HAEMATOL, V59, P299, DOI 10.1111/j.1600-0609.1997.tb01690.x; Garnham P.C.C., 1966, MALARIA PARASITES OT; GEIRINGER E, 1961, P SOC EXP BIOL MED, V106, P752, DOI 10.3181/00379727-106-26464; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HAWKING F, 1972, PARASITOLOGY, V65, P189, DOI 10.1017/S003118200004498X; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; MCGUIRE MJ, 1993, FUNDAMENTALS CLIN HE, P117; MILLEDGE JS, 1985, J APPL PHYSIOL, V59, P360, DOI 10.1152/jappl.1985.59.2.360; PAGEL H, 1992, ADV EXP MED BIOL, V317, P515; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Paul REL, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P153; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; READ AF, 1995, P ROY SOC B-BIOL SCI, V260, P359, DOI 10.1098/rspb.1995.0105; ROSSE WF, 1966, BLOOD-J HEMATOL, V27, P654, DOI 10.1182/blood.V27.5.654.654; SCHALL JJ, 1989, PARASITOLOGY, V98, P343, DOI 10.1017/S0031182000061412; SCHINDLER SL, 1987, COMP BIOCHEM PHYS A, V87, P533, DOI 10.1016/0300-9629(87)90356-2; SHUTLER D, 1995, P NATL ACAD SCI USA, V92, P6748, DOI 10.1073/pnas.92.15.6748; Shutler D, 1998, OIKOS, V82, P417, DOI 10.2307/3546363; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; Wilson K, 1996, FUNCT ECOL, V10, P592, DOI 10.2307/2390169	27	101	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					128	131		10.1126/science.287.5450.128	http://dx.doi.org/10.1126/science.287.5450.128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615046				2022-12-24	WOS:000084578400051
J	Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL				Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL			Are there excess Sharons in genitourinary clinics?	BRITISH MEDICAL JOURNAL			English	Article									Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Med Stat & Comp, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Foley, E (corresponding author), Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England.							Merry E., 1995, 1 NAMES DEFINITIVE G	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1615	1615		10.1136/bmj.319.7225.1615	http://dx.doi.org/10.1136/bmj.319.7225.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600963	Green Published, Bronze			2022-12-24	WOS:000084562600017
J	Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L				Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L			A mutation in the C-elegans EXP-2 potassium channel that alters feeding behavior	SCIENCE			English	Article							GATED K+ CHANNEL; CAENORHABDITIS-ELEGANS; ION PERMEATION; INACTIVATION; GENE	The nematode pharynx has a potassium channel with unusual properties, which allows the muscles to repolarize quickly and with the proper delay. Here, the Caenorhabditis elegans exp-2 gene is shown to encode this channel. EXP-2 is a Kv-type (voltage-activated) potassium channel that has inward-rectifying properties resembling those of the structurally dissimilar human ether-a-go-go-related gene (HERG) channel. Null and gain-of-function mutations affect pharyngeal muscle excitability in ways that are consistent with the electrophysiological behavior of the channel, and thereby demonstrate a direct Link between the kinetics of this unusual channel and behavior.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Davis, MW (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	wdavis@biology.utah.edu		Davis, Mikel/0000-0003-1867-1593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL046154, R01HL046154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46154, R37 HL046154, R01 HL046154] Funding Source: Medline; NINDS NIH HHS [NS28407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], COMMUNICATION; AVERY L, 1993, GENETICS, V133, P897; BYERLY L, 1979, J PHYSIOL-LONDON, V288, P263; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARY RB, 1994, J CELL SCI, V107, P1609; Davis MW, 1995, J NEUROSCI, V15, P8408; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FLEISCHHAUER R, IN PRESS J NEUROSCI; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; MALONE C, COMMUNICATION; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OWENS S, COMMUNICATION; PANYI G, 1995, BIOPHYS J, V69, P896, DOI 10.1016/S0006-3495(95)79963-5; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Sulston J, 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1990, GENETICS, V124, P855; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Williams BD, 1995, METHOD CELL BIOL, V48, P81; ZUHLKE RD, 1994, RECEPTOR CHANNEL, V2, P237	22	44	47	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2501	2504		10.1126/science.286.5449.2501	http://dx.doi.org/10.1126/science.286.5449.2501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617464	Green Accepted			2022-12-24	WOS:000084429700047
J	Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M				Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M			Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; CD40 LIGAND; FUNCTIONAL CD40; SMOOTH-MUSCLE; A-BETA; PROTEIN; EXPRESSION; MICE; PRECURSOR	Alzheimer's disease (AD) has a substantial inflammatory component, and activated microglia may play a central role in neuronal degeneration, CD40 expression was increased on cultured microglia treated with freshly solublized amyloid-beta (A beta, 500 nanomolar) and on microglia from a transgenic murine model of AD (Tg APP(sw)). Increased tumor necrosis factor alpha production and induction of neuronal injury occurred when A beta-stimulated microglia were treated with CD40 ligand (CD40L), Microglia from Tg APP(sw) mice deficient for CD4OL demonstrated reduction in activation, suggesting that the CD40-CD40L interaction is necessary for A beta-induced microglial activation. Finally, abnormal tau phosphorylation was reduced in Tg APP(sw) animals deficient for CD40L, suggesting that the CD40-CD40L interaction is an early event in AD pathogenesis.	Univ S Florida, Roskamp Inst, Tampa, FL 33613 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	State University System of Florida; University of South Florida; University of Kentucky; University of Kentucky; Howard Hughes Medical Institute; Yale University	Mullan, M (corresponding author), Univ S Florida, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.		Mattson, Mark P/F-6038-2012; Tan, Jun/I-5339-2012	Paris, Daniel/0000-0002-9622-0846; Mullan, Michael/0000-0002-1473-7527				Castillo GM, 1997, J NEUROCHEM, V69, P2452; Combs CK, 1999, J NEUROSCI, V19, P928; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; Ellis RJ, 1996, NEUROLOGY, V46, P1592, DOI 10.1212/WNL.46.6.1592; Genis I, 1999, J NEUROCHEM, V72, P206, DOI 10.1046/j.1471-4159.1999.0720206.x; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUBERMAN M, 1994, J NEUROIMMUNOL, V52, P147, DOI 10.1016/0165-5728(94)90108-2; James ND, 1996, NEUROBIOL AGING, V17, P235, DOI 10.1016/0197-4580(95)02068-3; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Oleana VH, 1998, NEUROREPORT, V9, P1451, DOI 10.1097/00001756-199805110-00037; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Sempowski GD, 1997, J IMMUNOL, V158, P4670; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	307	322	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2352	2355		10.1126/science.286.5448.2352	http://dx.doi.org/10.1126/science.286.5448.2352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600748				2022-12-24	WOS:000084318500065
J	Povar, GJ; Snyder, L				Povar, GJ; Snyder, L		Ethics & Human Rights Comm	Selling products out of the office	ANNALS OF INTERNAL MEDICINE			English	Article								The sale of products from the physician's office raises several ethical issues and may affect the trust necessary to sustain the patient-physician relationship. When deciding whether to sell products out of the office and, if so, which ones, physicians should carefully consider such criteria as the urgency of the patient's need, the clinical relevance to the patient's condition, the adequacy of evidence to support, use of the product, and geographic and time constraints for the patient in otherwise obtaining the product. Physicians should make full disclosure about their financial interests in selling the product and inform patients about alternatives for purchasing the product. Charges for products sold through the office should be limited to the reasonable costs incurred in making them available.	Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, Philadelphia, PA USA; Cameron Med Grp, Silver Spring, MD 20910 USA		Snyder, L (corresponding author), Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA USA.							[Anonymous], 1990, NEW MED OLD ETHICS; BRODY H, 1992, HEALERS POWER; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012	4	7	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					863	864		10.7326/0003-4819-131-11-199912070-00012	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610634				2022-12-24	WOS:000084053200011
J	Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D				Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D			Activation tagging of the floral inducer FT	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; LATE-FLOWERING MUTANTS; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; BOVINE BRAIN; TIME GENES; INITIATION; ARCHITECTURE; EXPRESSION; SEQUENCE	FLOWERING LOCUS T (FT), which acts in parallel with the meristem-identity gene LEAFY (LFY) to induce flowering of Arabidopsis, was isolated by activation tagging. Like LFY, FT acts partially downstream of CONSTANS (CO), which promotes flowering in response to long days. Unlike many other floral regulators, the deduced sequence of the FT protein does not suggest that it directly controls transcription or transcript processing. Instead, it is similar to the sequence of TERMINAL FLOWER 1 (TFL1), an inhibitor of flowering that also shares sequence similarity with membrane-associated mammalian proteins.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Noble Research Institute; Howard Hughes Medical Institute; Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kardailsky, Igor/AAK-8850-2021; Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021; Ahn, Ji Hoon/A-4141-2011	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Ahn, Ji Hoon/0000-0003-0347-3922; Harrison, Maria J/0000-0001-8716-1875				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; Hempel FD, 1997, DEVELOPMENT, V124, P3845; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Nilsson O, 1998, GENETICS, V150, P403; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	25	1061	1205	7	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1962	1965		10.1126/science.286.5446.1962	http://dx.doi.org/10.1126/science.286.5446.1962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583961				2022-12-24	WOS:000084003400054
J	Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL				Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL			Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the PreBotzinger complex	SCIENCE			English	Article							PRE-BOTZINGER COMPLEX; LATERAL TEGMENTAL FIELD; INFANT-DEATH-SYNDROME; STEM IN-VITRO; BRAIN-STEM; SUBNUCLEAR ORGANIZATION; CEREBROSPINAL-FLUID; INSPIRATORY NEURONS; GENERATION; MAMMALS	Neurokinin-1 receptor (NK1R) and mu-opioid receptor (mu OR) agonists affected respiratory rhythm when injected directly into the preBotzinger Complex (preBotC), the hypothesized site for respiratory rhythmogenesis in mammals. These effects were mediated by actions on preBotC rhythmogenic neurons. The distribution of NK1R(+) neurons anatomically defined the preBotC. Type 1 neurons in the preBotC, which have rhythmogenic properties, expressed both NK1Rs and mu ORs, whereas type 2 neurons expressed only NK1Rs. These findings suggest that the preBotC is a definable anatomic structure with unique physiological function and that a subpopulation of neurons expressing both NK1Rs and mu ORs generate respiratory rhythm and modulate respiratory frequency.	Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Interdept Program Neurosci PHD, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gray, PA (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Box 951763, Los Angeles, CA 90095 USA.		feldman, jack/AAO-7505-2021	feldman, jack/0000-0003-3692-9412; Rekling, Jens C./0000-0002-8568-2332	NHLBI NIH HHS [R01 HL040959-12, R01 HL040959, HL40959, HL37941] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040959, R37HL037941, R01HL037941] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; BONHAM AC, 1995, RESP PHYSIOL, V101, P219, DOI 10.1016/0034-5687(95)00045-F; Brockhaus J, 1998, EUR J NEUROSCI, V10, P3823, DOI 10.1046/j.1460-9568.1998.00396.x; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; Carpentier V, 1998, NEUROSCIENCE, V86, P159, DOI 10.1016/S0306-4522(98)00002-5; COQUEREL A, 1992, NEUROCHEM INT, V20, P97, DOI 10.1016/0197-0186(92)90131-A; DOBBINS EG, 1994, J COMP NEUROL, V347, P64, DOI 10.1002/cne.903470106; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P212, DOI 10.1002/cne.902940206; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; FELDMAN JL, 1988, ANNU REV PHYSIOL, V50, P593; FELDMAN JL, 1989, ANN NY ACAD SCI, V563, P114, DOI 10.1111/j.1749-6632.1989.tb42194.x; FIELDS HL, 1985, PHILOS T ROY SOC B, V308, P361, DOI 10.1098/rstb.1985.0037; FLEDMAN JL, 1986, HDB PHYSL NERVOUS SY, P463; Fletcher E C, 1997, Cardiologia, V42, P469; FLETCHER EC, 1986, ABNORMALITIES RESPIR, P203; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; GRAY P, UNPUB; Hsieh JH, 1998, J AUTONOM NERV SYST, V73, P7, DOI 10.1016/S0165-1838(98)00117-9; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120, DOI 10.1152/jappl.1996.80.6.2120; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N, 1999, NATURE, V400, P360, DOI 10.1038/22540; MCCRIMMON DR, 1995, REGULATION BREATHING, V79, P151; MONNIER A, 1998, SOC NEUR ABSTR, V346, P5; Onimaru H, 1997, JPN J PHYSIOL, V47, P385, DOI 10.2170/jjphysiol.47.385; ORLOWSKI JP, 1986, PEDIATRICS, V78, P233; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Rekling JC, 1996, J NEUROPHYSIOL, V75, P811, DOI 10.1152/jn.1996.75.2.811; Rekling JC, 1996, J NEUROPHYSIOL, V75, P795, DOI 10.1152/jn.1996.75.2.795; REKLING JC, UNPUB; Shao XM, 1997, J NEUROPHYSIOL, V77, P1853, DOI 10.1152/jn.1997.77.4.1853; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Thalhofer S, 1997, RESPIRATION, V64, P2	34	469	477	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1566	1568		10.1126/science.286.5444.1566	http://dx.doi.org/10.1126/science.286.5444.1566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567264	Green Accepted			2022-12-24	WOS:000083768300060
J	Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF				Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF			The amygdala modulates prefrontal cortex activity relative to conditioned fear	NATURE			English	Article							BASOLATERAL AMYGDALA; DOPAMINE NEURONS; RAT; ORGANIZATION; PROJECTIONS; NUCLEUS; STRESS; NEUROENDOCRINE; RESPONSES; THALAMUS	Animals learn that a tone can predict the occurrence of an electric shock through classical conditioning. Mice or rats trained in this manner display fear responses, such as freezing behaviour, when they hear the conditioned tone. Studies using amygdalectomized rats have shown that the amygdala is required for both the acquisition and expression of learned fear responses(1-3) Freezing to a conditioned tone is enhanced following damage, to the dorsal part of the medial prefrontal cortex(4), indicating that this area may be involved in fear reduction, Here we show that prefrontal neurons reduce their spontaneous activity in the presence of a conditioned aversive tone as a function of the degree of fear, The depression in prefrontal spontaneous activity is related to amygdala activity but not to the freezing response itself. These data indicate that, in the presence of threatening stimuli, the amygdala controls both fear expression and prefrontal neuronal activity. They suggest that abnormal amygdala-induced modulation of prefrontal neuronal activity may be involved in the pathophysiology of certain forms of anxiety disorder.	Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, F-33405 Talence, France; Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Southern California	Garcia, R (corresponding author), Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, Ave Fac, F-33405 Talence, France.		anand, amit/A-7222-2009					Bechara A, 1999, J NEUROSCI, V19, P5473; Campeau S, 1997, NEUROSCIENCE, V78, P1087, DOI 10.1016/S0306-4522(96)00632-X; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, P255; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; FERRON A, 1984, BRAIN RES, V302, P257, DOI 10.1016/0006-8993(84)90238-5; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; FUXE K, 1974, BRAIN RES, V82, P349, DOI 10.1016/0006-8993(74)90618-0; Garcia R, 1998, EUR J NEUROSCI, V10, P457, DOI 10.1046/j.1460-9568.1998.00027.x; GARDNER RC, 1994, ONT SYMP P, V7, P1; Goldstein LE, 1996, J NEUROSCI, V16, P4787; GONZALES C, 1990, J COMP NEUROL, V297, P182; HERRY C, IN PRESS J NEUROPHYS; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LEDOUX JE, 1990, J NEUROSCI, V10, P1043; LINDVALL O, 1974, BRAIN RES, V81, P325, DOI 10.1016/0006-8993(74)90947-0; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; MCDONALD AJ, 1987, J COMP NEUROL, V262, P46, DOI 10.1002/cne.902620105; MCDONALD AJ, 1991, NEUROSCIENCE, V44, P1, DOI 10.1016/0306-4522(91)90247-L; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; PAPINI MR, 1993, J EXP PSYCHOL ANIM B, V19, P342, DOI 10.1037/0097-7403.19.4.342; PEREZJARANAY JM, 1991, BRAIN RES, V564, P97, DOI 10.1016/0006-8993(91)91357-7; RESCORLA RA, 1969, PSYCHOL BULL, V72, P77, DOI 10.1037/h0027760; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; THOMAS E, 1980, EXP NEUROL, V69, P50, DOI 10.1016/0014-4886(80)90142-9; TURNER BH, 1991, J COMP NEUROL, V313, P295, DOI 10.1002/cne.903130208	30	265	268	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					294	296		10.1038/46286	http://dx.doi.org/10.1038/46286			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	257ZP	10580500				2022-12-24	WOS:000083813700050
J	Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T				Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T			Tbx5 and the retinotectum projection	SCIENCE			English	Article							T-BOX GENES; TYROSINE KINASE; VISUAL-SYSTEM; EXPRESSION; RETINA; CHICK; FAMILY; DIFFERENTIATION; ARBORIZATION; EVOLUTION	Dorsal and ventral aspects of the eye are distinct from the early stages of development. The developing eye cup grows dorsally, and the choroidal fissure is formed on its ventral side. Retinal axone from the dorsal and ventral retina project to the ventral and dorsal tectum, respectively. Misexpression of the Tbx5 gene induced dorsalization of the ventral side of the eye and altered projections of retinal ganglion cell axons. Thus, Tbx5 is involved in eye morphogenesis and is a topographic determinant of the visual projections between retina and tectum.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Tohoku Univ, Dept Mol Neurobiol, Sendai, Miyagi 98077, Japan	Nara Institute of Science & Technology; University of California System; University of California San Diego; Tohoku University	Ogura, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		MOMOSE, Tsuyoshi/D-2257-2011	Momose, Tsuyoshi/0000-0002-3806-3408				Agulnik SI, 1996, GENETICS, V144, P249; Barbieri AM, 1999, P NATL ACAD SCI USA, V96, P10729, DOI 10.1073/pnas.96.19.10729; Braisted JE, 1997, DEV BIOL, V191, P14, DOI 10.1006/dbio.1997.8706; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CROSSLAND WJ, 1979, J COMP NEUROL, V185, P87, DOI 10.1002/cne.901850106; Dudley AT, 1997, DEV DYNAM, V208, P349; DUDLEY AT, 1997, GENE DEV, V11, P3254; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GIBSONBROWN JJ, 1998, MECH DEVELOP, V74, P65; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; JACOBSON M, 1967, SCIENCE, V155, P1106, DOI 10.1126/science.155.3766.1106; KOSHIBATAKEUCHI K, UNPUB; MEY J, 1992, J HIRNFORSCH, V33, P673; Momose T, 1999, DEV GROWTH DIFFER, V41, P335; MOTGAN BA, 1996, METHOD CELL BIOL, V51, P185; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NORNES HO, 1990, DEVELOPMENT, V109, P797; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Ohsaki K, 1999, GENES CELLS, V4, P267, DOI 10.1046/j.1365-2443.1999.00257.x; Ohuchi H, 1998, DEVELOPMENT, V125, P51; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; Schmitt EA, 1996, J COMP NEUROL, V371, P222, DOI 10.1002/(SICI)1096-9861(19960722)371:2<222::AID-CNE3>3.0.CO;2-4; Szel A, 1996, MICROSC RES TECHNIQ, V35, P445; SZEL A, 1992, J COMP NEUROL, V325, P327, DOI 10.1002/cne.903250302; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	35	202	207	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					134	137		10.1126/science.287.5450.134	http://dx.doi.org/10.1126/science.287.5450.134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615048				2022-12-24	WOS:000084578400053
J	Leibovici, L				Leibovici, L			Alternative (complementary) medicine: a cuckoo in the nest of empiricist reed warblers	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Rabin Med Ctr, Dept Internal Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Internal Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	leibovic@post.tau.ac.il						Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Mock DW, 1999, NATURE, V397, P647, DOI 10.1038/17679; Rigas B, 1999, LANCET, V354, P1634, DOI 10.1016/S0140-6736(99)06034-1; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P836, DOI 10.1136/bmj.319.7213.836; Zollman C, 1999, BRIT MED J, V319, P1558, DOI 10.1136/bmj.319.7224.1558; ZOLLMAN C, 1999, BRIT MED J, V319, P1254; ZOLLMAN C, 1999, BRIT MED J, V319, P1176; ZOLLMAN C, 1999, BRIT MED J, V319, P973; ZOLLMAN C, 1999, BRIT MED J, V319, P1419; ZOLLMAN C, 1999, BRIT MED J, V319, P1115	16	15	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1629	1631		10.1136/bmj.319.7225.1629	http://dx.doi.org/10.1136/bmj.319.7225.1629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600974	Green Published			2022-12-24	WOS:000084562600025
J	Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P				Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P			A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSFER-RNA LIGASE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; MISSENSE MUTATIONS; PATHWAY; KINASE	The unfolded protein response (UPR) mediates signaling from the endoplasmic reticulum to the nucleus. In yeast, a key regulatory step in the UPR is the spliceosome-independent splicing of HAC1 mRNA encoding a UPR-specific transcription factor, which is initiated by the transmembrane kinase/endoribonuclease Ire1. We show that yeast HAC1 mRNA is correctly spliced in mammalian cells upon UPR induction and that mammalian Ire1 can precisely cleave both splice junctions. Surprisingly, UPR induction leads to proteolytic cleavage of Ire1, releasing fragments containing the kinase and nuclease domains that accumulate in the nucleus. Nuclear localization and UPR induction are reduced in presenilin-1 knockout cells. These results suggest that the salient features of the UPR are conserved among eukaryotic cells and that presenilin-1 controls Ire1 proteolysis in mammalian cells.	Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HAZE K, 1999, IN PRESS MOL BIOL CE; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	42	237	250	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					691	702		10.1016/S0092-8674(00)81667-0	http://dx.doi.org/10.1016/S0092-8674(00)81667-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619423	Bronze			2022-12-24	WOS:000084488200003
J	Smith, DM; Tabin, CJ				Smith, DM; Tabin, CJ			Developmental biology - BMP signalling specifies the pyloric sphincter	NATURE			English	Article							GUT		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Smith, DM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Natsume T, 1997, J BIOL CHEM, V272, P11535; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; Zakany J, 1999, NATURE, V401, P761, DOI 10.1038/44511; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	11	34	36	2	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					748	749		10.1038/45439	http://dx.doi.org/10.1038/45439			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617196				2022-12-24	WOS:000084330500044
J	Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH				Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH			Binding of paxillin to alpha(4) integrins modifies integrin-dependent biological responses	NATURE			English	Article							SUBUNIT CYTOPLASMIC DOMAINS; FOCAL ADHESION KINASE; CELL-MIGRATION; PROTEIN; SRC; ASSOCIATION; ROLES; FYN	The alpha(4) integrins are indispensable for embryogenesis, haematopoiesis and immune responses(1,2), possibly because a4 regulates cellular functions differently from other integrins through its cytoplasmic tail(3). We used novel mimics(4) of the alpha(4) tail to identify molecules that could account for alpha(4)-specific signalling. Here we report that the alpha(4) tail, but not several other alpha-subunit tails, binds tightly to the signalling adaptor paxillin, Paxillin physically associated with alpha(4) integrins in Jurkat T cells at high stoichiometry, and joining the alpha(4) tail to alpha(IIb) resulted in a complex of integrin alpha(IIb)beta(3) With paxillin. This association markedly enhanced the rates of alpha(IIb)beta(3)-dependent phosphorylation of focal adhesion kinase and cell migration. It also reduced cell spreading, focal adhesion and stress fibre formation. A point mutation within the alpha(4) tail that disrupts paxillin binding reversed all of these effects. Furthermore, alpha(4)beta(1)-dependent adhesion to VCAM-1 led to spreading of mouse embryonic fibroblasts derived from paxillin-null but not from wild-type mice. Thus, the tight association of paxillin with the alpha(4) tail leads to distinct biochemical and biological responses to integrin-mediated cell adhesion.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN YP, 1994, BLOOD, V84, P1857; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Hagmann J, 1998, J CELL SCI, V111, P2181; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	29	278	291	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					676	681		10.1038/45264	http://dx.doi.org/10.1038/45264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604475				2022-12-24	WOS:000084189800069
J	Lancaster, CRD; Kroger, A; Auer, M; Michel, H				Lancaster, CRD; Kroger, A; Auer, M; Michel, H			Structure of fumarate reductase from Wolinella succinogenes at 2.2 angstrom resolution	NATURE			English	Article							PHOSPHORYLATIVE ELECTRON-TRANSPORT; SITE-DIRECTED MUTAGENESIS; FREE R-VALUE; SUCCINATE-DEHYDROGENASE; VIBRIO-SUCCINOGENES; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; COMPLEX; REFINEMENT; EXPRESSION	Fumarate reductase couples the reduction of fumarate to succinate to the oxidation of quinol to quinone, in a reaction opposite to that catalysed by the related complex II of the respiratory chain (succinate dehydrogenase). Here we describe the crystal structure at 2.2 Angstrom resolution of the three protein subunits containing fumarate reductase from the anaerobic bacterium Wolinella succinogenes, Subunit A contains the site of fumarate reduction and a covalently bound flavin adenine dinucleotide prosthetic group. Subunit B contains three iron-sulphur centres, The menaquinol-oxidizing subunit C consists of five membrane-spanning, primarily helical segments and binds two haem b molecules. On the basis of the structure, we propose a pathway of electron transfer from the dihaem cytochrome b to the site of fumarate reduction and a mechanism of fumarate reduction. The relative orientations of the soluble and membrane-embedded subunits of succinate:quinone oxidoreductases appear to be unique.	Max Planck Inst Biophys, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Lancaster, CRD (corresponding author), Max Planck Inst Biophys, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	lancaster@mpibp-frankfurt.mpg.de	Lancaster, C. Roy/E-4313-2010	Lancaster, C. Roy D./0000-0002-2814-0051				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRONDER M, 1982, ARCH MICROBIOL, V131, P216, DOI 10.1007/BF00405882; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V30, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLACHMANN R, 1988, EUR J BIOCHEM, V175, P221, DOI 10.1111/j.1432-1033.1988.tb14187.x; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KORTNER C, 1990, MOL MICROBIOL, V4, P855, DOI 10.1111/j.1365-2958.1990.tb00657.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1978, BIOCHIM BIOPHYS ACTA, V505, P129, DOI 10.1016/0304-4173(78)90010-1; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 1999, BIOCHEM SOC T, V27, P591, DOI 10.1042/bst0270591; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P304; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Simon J, 1998, EUR J BIOCHEM, V251, P418, DOI 10.1046/j.1432-1327.1998.2510418.x; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSIOTIS G, 1994, PRACTICAL GUIDE MEMB, P149; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UNDEN G, 1980, FEBS LETT, V117, P323, DOI 10.1016/0014-5793(80)80972-0; UNDEN G, 1980, BIOCHIM BIOPHYS ACTA, V591, P275, DOI 10.1016/0005-2728(80)90159-0; UNDEN G, 1984, BIOCHIM BIOPHYS ACTA, V767, P460, DOI 10.1016/0005-2728(84)90044-6; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	50	304	315	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					377	385		10.1038/46483	http://dx.doi.org/10.1038/46483			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586875				2022-12-24	WOS:000083913600046
J	Halperin, DT; Bailey, RC				Halperin, DT; Bailey, RC			Male circumcision and HIV infection: 10 years and counting	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; RISK; MEN; TRANSMISSION; PREVENTION		Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA; Univ Illinois, Dept Anthropol, Chicago, IL 60612 USA; Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA USA; Univ Calif San Francisco, Med Anthropol Program, San Francisco, CA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bailey, RC (corresponding author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA.							BAILEY RC, 1999, PHASE 1 2 TRIAL INTE; Caldwell JC, 1996, SCI AM, V274, P62, DOI 10.1038/scientificamerican0396-62; CAMERON DW, 1989, LANCET, V2, P403; DEVINCENZI I, 1994, AIDS, V8, P153, DOI 10.1097/00002030-199402000-00002; Fleiss PM, 1998, SEX TRANSM INFECT, V74, P364, DOI 10.1136/sti.74.5.364; GREEN EC, 1993, TROP DOCT, V23, P182, DOI 10.1177/004947559302300423; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Kelly R, 1999, AIDS, V13, P399, DOI 10.1097/00002030-199902250-00013; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; MOSES S, 1994, SEX TRANSM DIS, V21, P201, DOI 10.1097/00007435-199407000-00004; Moses S, 1998, SEX TRANSM INFECT, V74, P368, DOI 10.1136/sti.74.5.368; MOSES S, 1995, HLTH TRANSITION REV, V5, P100; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; SEED J, 1995, J ACQ IMMUN DEF SYND, V8, P83; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; Urassa M, 1997, AIDS, V11, P73, DOI 10.1097/00002030-199701000-00011	16	147	157	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1813	1815		10.1016/S0140-6736(99)03421-2	http://dx.doi.org/10.1016/S0140-6736(99)03421-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577659				2022-12-24	WOS:000083853000045
J	Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P				Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P			Synovial fluid analysis for diagnosis of intercritical gout	ANNALS OF INTERNAL MEDICINE			English	Article							MONOSODIUM URATE CRYSTALS; KNEE JOINTS; CLASSIFICATION; CRITERIA	Background: The diagnosis of gout in the intercritical phase can be difficult. Objective: To determine whether synovial fluid analysis allows the diagnosis of intercritical gout. Design: Cross-sectional study. Setting: Outpatient rheumatology clinics. Patients: 101 patients with gout. Intervention: Arthrocentesis of 80 knees and 21 first metatarsophalangeal joints teach joint from a different patient) that had been inflamed but were currently asymptomatic. Measurements: Frequency with which arthrocentesis yielded synovial fluid; presence of monosodium urate crystals in the synovial fluid sample; and, for synovial fluid with crystals, the number of microscope fields that had to be scanned before crystals were found. Results: Synovial fluid was obtained from 91 of 101 joints. The fluid from all 43 patients not receiving hypouricemic agents contained monosodium urate crystals. These crystals were found in the synovial fluid of only 34 of 48 patients receiving hypouricemic agents. In 90% of the synovial fluid samples that contained crystals, crystals were seen in the first five microscope fields examined. Conclusions: Arthrocentesis of asymptomatic knees and first metatarsophalangeal joints and synovial fluid analysis are simple procedures that facilitate the diagnosis of gout during intercritical periods.	Gen Hosp Univ Alicante, Alicante 03010, Spain; Hosp Marina Baja, Alicante 03570, Spain; Hosp Gen Elche, Alicante, Spain	General University Hospital of Alicante	Pascual, E (corresponding author), Gen Hosp Univ Alicante, Maestro Alonso 109, Alicante 03010, Spain.	e.pascual@san.gva.es	Vela Casasempere, Paloma/HCH-3831-2022	Vela Casasempere, Paloma/0000-0001-8566-5172; Pascual, Eliseo/0000-0002-3056-4478				AGUDELO CA, 1979, ARTHRITIS RHEUM, V22, P559, DOI 10.1002/art.1780220521; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1137; BOMALASKI JS, 1986, ARTHRITIS RHEUM, V29, P1480, DOI 10.1002/art.1780291209; GORDON TP, 1982, J RHEUMATOL, V9, P967; Hunder GG, 1998, ANN INTERN MED, V129, P417, DOI 10.7326/0003-4819-129-5-199809010-00013; KENNEDY TD, 1984, J ROY SOC MED, V77, P747, DOI 10.1177/014107688407700907; PASCUAL E, 1991, ARTHRITIS RHEUM, V34, P141, DOI 10.1002/art.1780340203; Pascual E, 1996, BRIT J RHEUMATOL, V35, P306; PHELPS P, 1968, J AMER MED ASSOC, V203, P508, DOI 10.1001/jama.203.7.508; ROUAULT T, 1982, ARTHRITIS RHEUM, V25, P209, DOI 10.1002/art.1780250215; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; WEINBERGER A, 1979, ANN INTERN MED, V91, P56, DOI 10.7326/0003-4819-91-1-56; WOLFE F, 1991, J RHEUMATOL, V18, P1232; WYNGAARDEN JB, 1976, GOUT HYPERURICEMIA	14	149	153	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					756	759		10.7326/0003-4819-131-10-199911160-00007	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577299				2022-12-24	WOS:000083680100006
J	McAlister, FA; Straus, SE; Sackett, DL				McAlister, FA; Straus, SE; Sackett, DL		CARE-COAD1 Grp	Why we need large, simple studies of the clinical examination: the problem and a proposed solution	LANCET			English	Editorial Material							OBSTRUCTIVE AIRWAYS DISEASE; FORCED EXPIRATORY TIME; DEEP-VEIN THROMBOSIS; PHYSICAL-EXAMINATION; RESEARCH NETWORKS; PATIENT; DIAGNOSIS; HISTORY; PROBABILITY		Univ Alberta Hosp, Edmonton, AB T6G ZB7, Canada; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Evidence Based Med, Oxford OX3 9DU, England	University of Alberta; University of Oxford	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E324 WMC,8440-112 St, Edmonton, AB T6G ZB7, Canada.		McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				Anand SS, 1998, JAMA-J AM MED ASSOC, V279, P1094, DOI 10.1001/jama.279.14.1094; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; CROMBIE D L, 1963, J Coll Gen Pract, V6, P579; DETSKY A, 1994, JAMA-J AM MED ASSOC, V271, P1114; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; FLEMING KA, 1997, EVIDENCE BASED MED, V2, P132; FLETCHER CM, 1952, P ROY SOC MED, V45, P577; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GOLDSTEIN LB, 1994, JAMA-J AM MED ASSOC, V271, P1114, DOI 10.1001/jama.271.14.1114; GREEN LA, 1994, J FAM PRACTICE, V38, P400; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; HEPPER NG, 1969, ARCH ENVIRON HEALTH, V19, P806, DOI 10.1080/00039896.1969.10666934; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; KING DK, 1989, ANN INTERN MED, V110, P451, DOI 10.7326/0003-4819-110-6-451; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; MANNINO DM, 1993, ARCH INTERN MED, V153, P1892, DOI 10.1001/archinte.153.16.1892; MARINI JJ, 1979, AM REV RESPIR DIS, V120, P1069; MULROW CD, 1986, J GEN INTERN MED, V1, P364, DOI 10.1007/BF02596418; NAIRN J R, 1969, British Journal of Diseases of the Chest, V63, P29, DOI 10.1016/S0007-0971(69)80041-0; NAYLOR CD, 1994, JAMA-J AM MED ASSOC, V271, P1859, DOI 10.1001/jama.271.23.1859; NIEBAUER L, 1994, J FAM PRACTICE, V38, P425; Nutting PA, 1996, J FAM PRACTICE, V42, P199; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; PARDEE NE, 1980, CHEST, V77, P354, DOI 10.1378/chest.77.3.354; PATEL A, 1992, CLIN RES, V40, pA370; PETERSDORF RG, 1983, NEW ENGL J MED, V309, P1053, DOI 10.1056/NEJM198310273091711; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; Sackett DL, 1997, EVIDENCE BASED MED P; SANDLER G, 1980, AM HEART J, V100, P928, DOI 10.1016/0002-8703(80)90076-9; SCHAPIRA RM, 1993, JAMA-J AM MED ASSOC, V270, P731, DOI 10.1001/jama.270.6.731; SCHEINHORN DJ, 1982, SOUTHERN MED J, V75, P434, DOI 10.1097/00007611-198204000-00014; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; SURPRENANT EL, 1967, DIS CHEST, V52, P760, DOI 10.1378/chest.52.6.760; TURNBULL JM, 1995, JAMA-J AM MED ASSOC, V274, P1299, DOI 10.1001/jama.274.16.1299; van Schayck C P, 1991, Scand J Prim Health Care, V9, P232, DOI 10.3109/02813439109018525; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Whited JD, 1998, JAMA-J AM MED ASSOC, V279, P696, DOI 10.1001/jama.279.9.696; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, JAMA-J AM MED ASSOC, V267, P2645, DOI 10.1001/jama.267.19.2645; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114	47	79	80	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1721	1724		10.1016/S0140-6736(99)01174-5	http://dx.doi.org/10.1016/S0140-6736(99)01174-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568588				2022-12-24	WOS:000083652800042
J	Francastel, C; Walters, MC; Groudine, M; Martin, DIK				Francastel, C; Walters, MC; Groudine, M; Martin, DIK			A functional enhancer suppresses silencing of a transgene and prevents its localization close to centromeric heterochromatin	CELL			English	Article							BETA-GLOBIN LOCUS; POSITION-EFFECT VARIEGATION; PROTEIN DNA INTERACTIONS; TRANSCRIPTION FACTORS; NUCLEAR-ORGANIZATION; GENE-EXPRESSION; CONTROL REGION; CHROMATIN; DROSOPHILA; YEAST	To explore the mechanism by which enhancers maintain gene expression, we have assessed the ability of an enhancer and derivative mutants to influence silencing and nuclear location of a transgene. Using site-specific recombination to place different constructs at the same integration sites, we find that disruption of Gore enhancer motifs impairs the enhancer's ability to suppress silencing. FISH analysis reveals that active transgenes linked to a functional enhancer localize away from centromeres. However, enhancer mutations that result in increased rates of transgene silencing fail to localize the transgene away from centromeric heterochromatin, even when the transgene is in an active state. These mutations thus dissociate transcriptional activity and subnuclear location. Together, our results suggest that the functional enhancer antagonizes gene silencing by preventing localization of a gene near centromeric heterochromatin.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Groudine, M (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gregory PD, 1998, EUR J BIOCHEM, V251, P9, DOI 10.1046/j.1432-1327.1998.2510009.x; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walters MC, 1999, MOL CELL BIOL, V19, P3714; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	41	209	211	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					259	269		10.1016/S0092-8674(00)81657-8	http://dx.doi.org/10.1016/S0092-8674(00)81657-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555142	Bronze			2022-12-24	WOS:000083440600004
J	Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D				Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D			Genetic definition and sequence analysis of Arabidopsis centromeres	SCIENCE			English	Article							REPETITIVE DNA; RNA GENES; THALIANA; RECOMBINATION; PROTEINS; REGIONS; RETROTRANSPOSONS; HETEROCHROMATIN; CONSTRUCTION; EUKARYOTES	High-precision genetic mapping was used to define the regions that contain centromere functions on each natural chromosome in Arabidopsis thaliana. These regions exhibited dramatic recombinational repression and contained complex DNA surrounding large arrays of 180-base pair repeats. Unexpectedly, the DNA within the centromeres was not merely structural but also encoded several expressed genes. The regions flanking the centromeres were densely populated by repetitive elements yet experienced normal levels of recombination. The genetically defined centromeres were well conserved among Arabidopsis ecotypes but displayed Limited sequence homology between different chromosomes, excluding repetitive DNA. This investigation provides a platform for dissecting the role of individual sequences in centromeres in higher eukaryotes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Inst Genom Res, Rockville, MD 20850 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UJ, Norfolk, England; Sanger Ctr, Cambridge CB10 1SA, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA	University of Chicago; J. Craig Venter Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Wellcome Trust Sanger Institute; Cold Spring Harbor Laboratory; Washington University (WUSTL)	Preuss, D (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57 St, Chicago, IL 60637 USA.	dpreuss@midway.uchicago.edu	Kuromori, Takashi/G-7862-2013; Copenhaver, Gregory/AFL-9831-2022; Copenhaver, Gregory P/A-7549-2014; Copenhaver, Gregory/AAH-2031-2022; Marra, Marco A/B-5987-2008	Kuromori, Takashi/0000-0003-3232-7262; Copenhaver, Gregory/0000-0002-7962-3862; Copenhaver, Gregory P/0000-0002-7962-3862; Copenhaver, Gregory/0000-0002-7962-3862; Marra, Marco A/0000-0001-7146-7175; McCombie, W. Richard/0000-0003-1899-0682				BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bevan M, 1999, BIOESSAYS, V21, P110, DOI 10.1002/(SICI)1521-1878(199902)21:2&lt;110::AID-BIES5&gt;3.0.CO;2-V; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; CALLIS J, 1995, GENETICS, V139, P921; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; CHARLESWORTH B, 1986, GENETICS, V112, P947, DOI 10.1093/genetics/112.4.947; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Choo KHA, 1998, GENOME RES, V8, P81, DOI 10.1101/gr.8.2.81; Chye ML, 1997, PLANT MOL BIOL, V35, P893, DOI 10.1023/A:1005947804227; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Copenhaver GP, 1999, CURR OPIN PLANT BIOL, V2, P104, DOI 10.1016/S1369-5266(99)80021-1; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; FLEIG U, 1995, NUCLEIC ACIDS RES, V23, P922, DOI 10.1093/nar/23.6.922; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heslop-Harrison JS, 1999, PLANT CELL, V11, P31, DOI 10.1105/tpc.11.1.31; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; INOHARA N, 1991, J BIOL CHEM, V266, P7333; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kaszas E, 1996, EMBO J, V15, P5246, DOI 10.1002/j.1460-2075.1996.tb00910.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KONIECZNY A, 1991, GENETICS, V127, P801; KUHN RM, 1991, P NATL ACAD SCI USA, V88, P1306, DOI 10.1073/pnas.88.4.1306; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; LIN X, IN PRESS NATURE; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Murata M, 1997, PLANT J, V12, P31, DOI 10.1046/j.1365-313X.1997.12010031.x; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Pelissier T, 1996, GENETICA, V97, P141, DOI 10.1007/BF00054621; PREUSS D, 1994, SCIENCE, V264, P1458, DOI 10.1126/science.8197459; Puechberty J, 1999, GENOMICS, V56, P274, DOI 10.1006/geno.1999.5742; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TSAY YF, 1993, SCIENCE, V260, P342, DOI 10.1126/science.8385803; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; WAMBUTT R, IN PRESS NATURE; Wright DA, 1996, GENETICS, V142, P569	46	348	380	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2468	2474		10.1126/science.286.5449.2468	http://dx.doi.org/10.1126/science.286.5449.2468			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617454				2022-12-24	WOS:000084429700037
J	Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH				Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH			Emergency department triage strategies for acute chest pain using creatine Kinase-MB and troponin I assays: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN; ROOM	Background: Evaluation of acute chest pain is highly variable. Objective: To evaluate the cost-effectiveness of strategies using cardiac markers and noninvasive tests for myocardial ischemia. Design: Cost-effectiveness analysis. Data Sources: Prospective data from 1066 patients with chest pain and from the published literature. Target Population: Patients admitted with acute chest pain. Time Horizon: Lifetime. Perspective: Societal. Interventions: Creatine kinase (CK)-MB mass assay alone; CK-MB mass assay followed by cardiac troponin assay if the CK-MB value is normal; CK-MB mass assay followed by troponin I assay if the CK-MB value is normal and electrocardiography shows ischemic changes; both CK-MB mass and troponin I assays; and troponin I assay alone. These strategies were evaluated alone or in combination with early exercise testing. Outcome Measures: Lifetime cost, life expectancy (in years), and incremental cost-effectiveness. Results of Base-Case Analysis: For patients 55 to 64 years of age, measurement of CK-MB mass followed by exercise testing in appropriate patients was the most competitive strategy ($43000 per year of life saved). Measurement of CK-MB mass followed by troponin I measurement had an incremental cost-effectiveness ratio of $47400 per year of life saved for patients 65 to 74 years of age; it was also the most cost-effective strategy when early exercise testing could not be performed, CK-MB values were normal, and ischemic changes were seen on electrocardiography. Results of Sensitivity Analysis: Results were influenced by age, probability of myocardial infarction, and medical costs. Conclusions: Measurement of CK-MB mass plus early exercise testing is a cost-effective initial strategy for younger patients and those with a low to moderate probability of myocardial infarction. Troponin I measurement can be a cost-effective second test in higher-risk subsets of patients if the CK-MB level is normal and early exercise testing is not an option.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Lee, TH (corresponding author), Partners Community Healthcare Inc, Suite 1150,Prudential Tower, Boston, MA 02119 USA.	thlee@partners.org	Polanczyk, Carisi CAP/D-6208-2013	Sacks, David/0000-0003-3100-0735				Anderson F P, 1998, Clin Lab Manage Rev, V12, P63; APPLE FS, 1995, CLIN CHIM ACTA, V237, P59, DOI 10.1016/0009-8981(95)06064-K; BODOR GS, 1992, CLIN CHEM, V38, P2203; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Green GB, 1998, ANN EMERG MED, V31, P19, DOI 10.1016/S0196-0644(98)70276-8; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Johnson PA, 1999, AM HEART J, V137, P1137, DOI 10.1016/S0002-8703(99)70374-1; Keffer JH, 1997, AM J CLIN PATHOL, V107, P398; Kirk JD, 1998, ANN EMERG MED, V32, P1, DOI 10.1016/S0196-0644(98)70091-5; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Krumholz HM, 1998, AM HEART J, V135, P523, DOI 10.1016/S0002-8703(98)70331-X; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; LAVE JR, 1994, MED CARE, V32, pJS77; LEE T, 1990, COMMON DIAGNOSTIC TE, P36; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; Mair J, 1997, CLIN CHIM ACTA, V257, P99, DOI 10.1016/S0009-8981(96)06436-4; Mair J, 1996, CLIN CHIM ACTA, V245, P19, DOI 10.1016/0009-8981(95)06168-1; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; O'Brien JA, 1998, DIABETES CARE, V21, P1122, DOI 10.2337/diacare.21.7.1122; Polanczyk CA, 1999, AM J CARDIOL, V83, P1175, DOI 10.1016/S0002-9149(99)00055-7; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; Polanczyk CA, 1998, J AM COLL CARDIOL, V32, P8, DOI 10.1016/S0735-1097(98)00176-4; Stinett AA, 1996, COST EFFECTIVENESS H, P349; Tosteson ANA, 1996, CIRCULATION, V94, P143, DOI 10.1161/01.CIR.94.2.143; Tucker JF, 1997, ACAD EMERG MED, V4, P13, DOI 10.1111/j.1553-2712.1997.tb03637.x; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; *US BUR CENS, 1997, STAT ABSTR US, P89; Wu AHB, 1996, CLIN CHEM, V42, P651	32	36	37	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					909	+		10.7326/0003-4819-131-12-199912210-00002	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610641				2022-12-24	WOS:000084374400001
J	Kopans, DB				Kopans, DB			Breast-cancer screening with ultrasonography	LANCET			English	Editorial Material							US; WOMEN		Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kopans, DB (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.							BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Buchberger W, 1999, AM J ROENTGENOL, V173, P921, DOI 10.2214/ajr.173.4.10511149; FEIG SA, 1995, CANCER, V75, P2412, DOI 10.1002/1097-0142(19950515)75:10<2412::AID-CNCR2820751005>3.0.CO;2-4; GORDON PB, 1993, RADIOLOGY, V189, P573, DOI 10.1148/radiology.189.2.8210392; GORDON PB, 1995, CANCER, V76, P626, DOI 10.1002/1097-0142(19950815)76:4<626::AID-CNCR2820760413>3.0.CO;2-Z; Kolb TM, 1998, RADIOLOGY, V207, P191, DOI 10.1148/radiology.207.1.9530316; KOPANS DB, 1985, RADIOLOGY, V157, P505, DOI 10.1148/radiology.157.2.3901112; Shapiro S, 1988, PERIODIC SCREENING B	9	33	38	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2096	2097		10.1016/S0140-6736(99)90400-2	http://dx.doi.org/10.1016/S0140-6736(99)90400-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609810				2022-12-24	WOS:000084318200004
J	Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A				Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A			Crystal structure of Thermotoga maritima ribosome recycling factor: A tRNA mimic	SCIENCE			English	Article							ELONGATION-FACTOR-G; COMPLETE GENOME SEQUENCE; RELEASE FACTOR RF3; PROTEIN-BIOSYNTHESIS; TERMINATION COMPLEX; FACTOR RRF; GUANOSINE TRIPHOSPHATE; TRANSFER-RNAS; DISSOCIATION; RESOLUTION	Ribosome recycling factor (RRF), together with elongation factor G (EF-G), catalyzes recycling of ribosomes after one round of protein synthesis. The crystal structure of RRF was determined at 2.55 angstrom resolution. The protein has an unusual fold where domain I is a Long three-helix bundle and domain II is a three-layer beta/alpha/beta sandwich. The molecule superimposes almost perfectly with a transfer RNA (tRNA) except that the amino acid-binding 3' end is missing. The mimicry suggests that RRF interacts with the posttermination ribosomal complex in a similar manner to a tRNA, leading to disassembly of the complex. The structural arrangement of this mimicry is entirely different from that of other cases of Less pronounced mimicry of tRNA so far described.	Lund Univ, Ctr Chem & Chem Engn, SE-22100 Lund, Sweden; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	Lund University; University of Pennsylvania	Liljas, A (corresponding author), Lund Univ, Ctr Chem & Chem Engn, POB 124, SE-22100 Lund, Sweden.	anders.liljas@mbfys.ln.se	Al-karadaghi, Salam/F-1492-2011	Al-karadaghi, Salam/0000-0001-8608-0635; Selmer, Maria/0000-0001-9079-2774				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Grentzmann G, 1998, RNA, V4, P973, DOI 10.1017/S1355838298971576; GUALERZI C, 1971, BIOCHEM BIOPH RES CO, V45, P1312, DOI 10.1016/0006-291X(71)90162-8; Heurgue-Hamard V, 1998, EMBO J, V17, P808, DOI 10.1093/emboj/17.3.808; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; ISHITSUKA H, 1970, J BIOL CHEM, V245, P3346; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; Janosi L, 1996, BIOCHIMIE, V78, P959, DOI 10.1016/S0300-9084(97)86718-1; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; JANOSI L, IN PRESS J MOL BIOL; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaji A, 1998, BIOCHEM BIOPH RES CO, V250, P1, DOI 10.1006/bbrc.1998.9168; KAJI A, 1999, ACTA CRYSTALLOGR D, V55, P2049; Kanai T, 1998, EUR J BIOCHEM, V256, P212, DOI 10.1046/j.1432-1327.1998.2560212.x; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURBERG M, COMMUNICATION; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OGAWA K, 1975, EUR J BIOCHEM, V58, P411, DOI 10.1111/j.1432-1033.1975.tb02388.x; OUZOUNIS C, 1995, PROTEIN SCI, V4, P2424, DOI 10.1002/pro.5560041121; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; RYOJI M, 1981, P NATL ACAD SCI-BIOL, V78, P5973, DOI 10.1073/pnas.78.10.5973; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1	53	146	151	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2349	2352		10.1126/science.286.5448.2349	http://dx.doi.org/10.1126/science.286.5448.2349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600747				2022-12-24	WOS:000084318500064
J	Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J				Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J			Inhibition of msl-2 splicing by Sex-lethal reveals interaction between U2AF(35) and the 3 ' splice site AG	NATURE			English	Article							DOSAGE COMPENSATION GENE; PRE-MESSENGER-RNA; MAMMALIAN INTRONS; CATALYTIC STEP; DROSOPHILA; PROTEIN; EXPRESSION; SELECTION; ENCODES	The protein Sex-lethal (SXL) controls dosage compensation in Drosophila by inhibiting the splicing and translation of male-specific-lethal-2 (msl-2) transcripts(1-6) Here we report that splicing inhibition of msl-2 requires a binding site for SXL at the polypyrimidine (poly(Y)) tract associated with the 3' splice site, and an unusually long distance between the poly(Y) tract and the conserved AG dinucleotide at the 3' end of the intron, Only this combination allows efficient blockage of U2 small nuclear ribonucleoprotein particle binding and displacement of the large subunit of the U2 auxiliary factor (U2AF(65)) from the poly(Y) tract by SXL, Crosslinking experiments with ultraviolet light indicate that the small subunit of U2AF (U2AF(35)) contacts the AG dinucleotide only when located in proximity to the poly(Y) tract. This interaction stabilizes U2AF65 binding such that SXL can no longer displace it from the poly(Y) tract. Our results reveal a novel function for U2AF35, a critical role for the 3' splice site AG at the earliest steps of spliceosome assembly and the need for a weakened U2AF(35)-AG interaction to regulate intron removal.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Valcarcel, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Bilbao Cortes, Daniel/0000-0003-1630-8811; Guth-Gundel, Sabine/0000-0001-9115-1397				BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; Gebauer F, 1998, RNA, V4, P142; GREENFIELD BH, 1991, ISOKINET EXERC SCI, V1, P207; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Umen JG, 1995, RNA, V1, P869; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	22	225	234	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					838	841		10.1038/45602	http://dx.doi.org/10.1038/45602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617208				2022-12-24	WOS:000084330500072
J	Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM				Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM			Eukaryotic type II chaperonin CCT interacts with actin through specific subunits	NATURE			English	Article							COMPLEX POLYPEPTIDE-1 TCP-1; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; THERMOSOME; PROTEIN; IMAGES	Chaperonins assist the folding of other proteins(1). Type II chaperonins, such as chaperonin containing TCP-1(CCT), are found in archaea and in the eukaryotic cytosol(2). They are hexadecameric or nonadecameric oligomers composed of one to eight different polypeptides. Whereas type I chaperonins like GroEL are promiscuous, assisting in the folding of many other proteins(1) only a small number of proteins, mainly actin and tubulin, have been described as natural substrates of CCT, This specificity may be related to the divergence of the eight CCT subunits(3). Here we have obtained a three-dimensional reconstruction of the complex between CCT and alpha-actin by cryo-electron microscopy and image processing. This shows that cr-actin interacts with the apical domains of either of two CCT subunits. Immunolabelling of CCT-substrate complexes with antibodies against two specific CCT subunits showed that actin binds to CCT using two specific and distinct interactions: the small domain of actin binds to CCT delta and the large domain to CCT beta or CCT epsilon (both in position 1,4 with respect to delta). These results indicate that the binding of actin to CCT is both subunit-specific and geometry-dependent, Thus, the substrate recognition mechanism of eukaryotic CCT may differ from that of prokaryotic GroEL.	CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Almeria, Dept Arquitectura Comp & Elect, Almeria 04120, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Universidad de Almeria	Valpuesta, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.		Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019; Fernandez, Jose-Jesus/A-5084-2008; Llorca, Oscar/K-1144-2014; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009	Valpuesta, José M/0000-0001-7468-8053; Fernandez, Jose-Jesus/0000-0003-2222-3355; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; 				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; Marabini R, 1998, ULTRAMICROSCOPY, V72, P53, DOI 10.1016/S0304-3991(97)00127-7; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Rommelaere H, 1999, BIOCHEMISTRY-US, V38, P3246, DOI 10.1021/bi9815905; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1999, MOL CHAPERONES FOLDI, P555	19	224	226	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					693	696		10.1038/45294	http://dx.doi.org/10.1038/45294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604479				2022-12-24	WOS:000084189800073
J	Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M				Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M			Conserved regulation of proximodistal limb axis development by Meis1/Hth	NATURE			English	Article							HOMEOBOX GENE; VERTEBRATE LIMB; FEEDBACK LOOP; MESSENGER-RNA; EXPRESSION; EXTRADENTICLE; DROSOPHILA; BUD; DIFFERENTIATION; TRANSLOCATION	Vertebrate limbs grow out from the flanks of embryos, with their main axis extending proximodistally from the trunk. Distinct limb domains, each with specific traits, are generated in a proximal-to-distal sequence during development(1). Diffusible factors expressed from signalling centres promote the outgrowth of limbs and specify their dorsoventral and anteroposterior axes(2-4). However, the molecular mechanism by which limb cells acquire their proximodistal (P-D) identity is unknown(1). Here we describe the role of the homeobox genes Meis1/2 and Pbx1 in the development of mouse, chicken and Drosophila limbs. We find that Meis1/2 expression is restricted to a proximal domain, coincident with the previously reported domain in which Pbx1 is localized to the nucleus(5), and resembling the distribution of the Drosophila homologues homothorax (hth)(5,6) and extradenticle (exd)(7); that Meis1 regulates Pbx1 activity by promoting nuclear import of the Pbx1 protein; and that ectopic expression of Meis1 in chicken and hth in Drosophila disrupts distal limb development and induces distal-to-proximal transformations. We suggest that restriction of Meis1/Hth to proximal regions of the vertebrate and insect limb is essential to specify cell fates and differentiation patterns along the P-D axis of the limb.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Torres, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain.		Mercader, Nadia/L-2728-2014; Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Mercader, Nadia/0000-0002-0905-6399; Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767; Serrano, Antonio/0000-0003-1993-640X; Morata, Gines/0000-0003-3274-5173				Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CAPDEVILA J, IN PRESS MOL CELL; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; CELIS JFD, 1997, DEVELOPMENT, V124, P3241; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1999, DEVELOPMENT, V126, P3407; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu J, 1999, DEVELOPMENT, V126, P109; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	31	240	241	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					425	429		10.1038/46580	http://dx.doi.org/10.1038/46580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586884				2022-12-24	WOS:000083913600060
J	Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA				Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA			The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; DNA-SEQUENCE; INFECTED-CELLS; CODING CONTENT; ATHEROSCLEROSIS; EXPRESSION; VIRUS	Human cytomegalovirus (HCMV) infection of smooth muscle cells (SMCs) in vivo has been linked to a viral etiology of vascular disease. In this report, we demonstrate that HCMV infection of primary arterial SMCs results in significant cellular migration. Ablation of the chemokine receptor, US28, abrogates SMC migration, which is rescued only by expression of the viral homolog and not a cellular G protein-coupled receptor (GPCR). Expression of US28 in the presence of CC chemokines including RANTES or MCP-1 was sufficient to promote SMC migration by both chemokinesis and chemotaxis, which was inhibited by protein tyrosine kinase inhibitors. US28-mediated SMC migration provides a molecular basis for the correlative evidence that links HCMV to the acceleration of vascular disease.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Program Infect Dis, Seattle, WA 98104 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA	Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Nelson, JA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.	nelsonj@ohsu.edu			NIAID NIH HHS [AI 21640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Bruning JH, 1994, TRANSPLANT INT S1, V7, P365; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Cary LA, 1996, J CELL SCI, V109, P1787; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; FABRICANT CG, 1983, FED PROC, V42, P2476; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; ILLC D, 1995, NATURE, V377, P539; Inagami T, 1999, J AM SOC NEPHROL, V10, pS2; Jarvis MA, 1999, J VIROL, V73, P4552, DOI 10.1128/JVI.73.6.4552-4560.1999; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalani AS, 1999, VIROLOGY, V256, P233, DOI 10.1006/viro.1999.9617; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LU M, 1996, J VIROL, V70, P6097; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; Mellado M, 1998, J IMMUNOL, V161, P805; Melnick JL, 1998, INFECT MED, V15, P479; MELNICK JL, 1983, LANCET, V2, P644; Michelson S, 1997, J VIROL, V71, P6495, DOI 10.1128/JVI.71.9.6495-6500.1997; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhou YF, 1999, BIOCHEM BIOPH RES CO, V256, P608, DOI 10.1006/bbrc.1999.0387	61	331	345	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					511	520		10.1016/S0092-8674(00)81539-1	http://dx.doi.org/10.1016/S0092-8674(00)81539-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589679	Bronze			2022-12-24	WOS:000083986300010
J	Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM				Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM			Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand	NATURE			English	Article							RHEUMATOID-ARTHRITIS; OSTEOCLAST; RECEPTOR; CYTOKINE; DENSITY; BIOLOGY; TRANCE; FAMILY; MICE	Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)(1-3). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system(3-5). The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts(4,6). OPGL expression in T cells is induced by antigen receptor engagement(7), which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation, These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; St Michaels Hosp, Dept Med Genet & Microbiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON, Canada	Amgen; Amgen; Amgen; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52; CONWAY JG, 1995, J EXP MED, V182, P449, DOI 10.1084/jem.182.2.449; Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0.CO;2-A; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Josien R, 1999, J IMMUNOL, V162, P2562; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muller-Ladner U, 1998, Curr Opin Rheumatol, V10, P212; OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016-5085(85)90212-4; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075	24	1459	1566	2	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					304	309		10.1038/35005552	http://dx.doi.org/10.1038/35005552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580503	Bronze			2022-12-24	WOS:000083813700053
J	Calin, A; Brophy, S; Blake, D				Calin, A; Brophy, S; Blake, D			Impact of sex on inheritance of ankylosing spondylitis: a cohort study	LANCET			English	Article							HLA; SUSCEPTIBILITY; ARTHRITIS; HLA-B27	Background Ankylosing spondylitis is a genetically determined and commonly familial disorder. Men and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for every woman with the disease. We investigated the influence of the sex of the index case on disease penetrance within families. Methods The ages at which 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database of 4400 cases. Index patients with children or siblings who were old enough to have obtained a diagnosis (50% and 75% rates) were assessed for prevalence of disease among relatives. Confirmation of diagnosis for affected relatives was sought for all offspring and a random 25% selection of siblings. Findings Ankylosing spondylitis was more prevalent among children (odds ratio 1.9 [95% CI 1.2-3.0], p < 0.005) and siblings (1.5 [1.2-1.9], p < 0.0001) of female index cases than among those of male cases. Analyses restricted to index cases with a young age at onset (less than or equal to 21 years) indicated that children of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p = 0.013) than did children of men at similar age at onset. 38% of children of female cases had disease compared with 8% of male cases. There was no difference in sex distribution among affected children or siblings of female patients with ankylosing spondylitis. By contrast, the sons and brothers of male patients had a higher prevalence of the disease (odds ratio 2.6 [1.4-5.2], p = 0.003) than did daughters and sisters (1.7 [1.3-2.2], p < 0.0001). Interpretation The influence of female sex is greater than that of male sex in determining increased susceptibility to ankylosing spondylitis in children. The striking maternal effect is greatest for women with young age at onset, which is not seen in men. The sex ratio of affected children depends on the sex of the affected parent.	Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England	Royal National Hospital for Rheumatic Diseases (RNHRD)	Calin, A (corresponding author), Royal Natl Hosp Rheumat Dis, Upper Borough Walls, Bath BA1 1RL, Avon, England.			Brophy, Sinead/0000-0001-7417-2858				ARMSTRONG BD, 1985, BR J RHEUMATOL, V24, P277; Bennett PH, 1968, POPULATION STUDIES R; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1995, BR J RHEUMATOL S1, V34, P76; CALIN A, 1983, ARTHRITIS RHEUM, V26, P1460, DOI 10.1002/art.1780261207; CALIN A, 1985, CLIN RHEUM DIS, V11, P41; CALIN A, 1993, OXFORD TXB RHEUMATOL, V2; CALIN A, 1998, SPONDYLARTHRITIDES; CHO Y, 1997, GASTROENTEROLOGY, V112, pA948; LYNN AH, 1995, AM J HUM GENET, V57, P150; MACKAY K, 1997, ARTHRITIS RHEUM, V40, P561; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; Nair RP, 1997, HUM MOL GENET, V6, P1349, DOI 10.1093/hmg/6.8.1349; Simmons WA, 1997, J IMMUNOL, V159, P2750; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; Tromp G, 1996, AM J HUM GENET, V59, P1097; VANDERLINDEN SM, 1984, ARTHRITIS RHEUM, V27, P241	17	68	69	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1687	1690		10.1016/S0140-6736(99)03219-5	http://dx.doi.org/10.1016/S0140-6736(99)03219-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568571				2022-12-24	WOS:000083652800012
J	Muller-Trutwin, M; Barre-Sinoussi, F				Muller-Trutwin, M; Barre-Sinoussi, F			Towards improvements in molecular tools for diagnosis and management of HIV infections	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION; GROUP-O; QUANTIFICATION		Inst Pasteur, Dept Virol, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Muller-Trutwin, M (corresponding author), Inst Pasteur, Dept Virol, F-75724 Paris 15, France.		Barre-Sinoussi, Françoise/G-8355-2011	Muller-Trutwin, Michaela/0000-0002-3854-2396				Alaeus A, 1999, AIDS RES HUM RETROV, V15, P889, DOI 10.1089/088922299310593; Alaeus A, 1997, AIDS, V11, P859, DOI 10.1097/00002030-199707000-00004; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; FRANSEN K, 1994, MOL CELL PROBE, V8, P317, DOI 10.1006/mcpr.1994.1043; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; HU D, 1998, AIDS OTHER MANIFESTA, P27; Le Corfec E, 1999, TRANSFUSION, V39, P1141, DOI 10.1046/j.1537-2995.1999.39101141.x; LEPONT F, 1995, TRANSFUSION, V35, P542; LOUSSERTAJAKA I, 1995, LANCET, V346, P912, DOI 10.1016/S0140-6736(95)92762-X; Parekh B, 1999, AIDS RES HUM RETROV, V15, P133, DOI 10.1089/088922299311556; Respess RA, 1997, J CLIN MICROBIOL, V35, P1284, DOI 10.1128/JCM.35.5.1284-1286.1997; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Triques K, 1999, J CLIN MICROBIOL, V37, P110, DOI 10.1128/JCM.37.1.110-116.1999; Wilber JC, 1997, IMMUNOL INVEST, V26, P9, DOI 10.3109/08820139709048911; Yang CF, 1999, J CLIN MICROBIOL, V37, P2581, DOI 10.1128/JCM.37.8.2581-2586.1999	15	5	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1660	1662		10.1016/S0140-6736(99)00211-1	http://dx.doi.org/10.1016/S0140-6736(99)00211-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568563				2022-12-24	WOS:000083652800004
J	Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P				Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P			A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C-elegans	CELL			English	Article							POWDERY MILDEW INTERACTION; PROGRAMMED CELL-DEATH; OXIDATIVE BURST; GENE ML-A12; PLANTS; ARABIDOPSIS; PATHOGEN; FINGER; LOCUS; RESPONSES	Barley Rar1 is a convergence point in the signaling of resistance to powdery mildew, triggered by multiple race-specific resistance (R) genes. Rar1 is shown to function upstream of H2O2 accumulation in attacked host cells, which precedes localized host cell death. We isolated Rar1 by map-based cloning. The sequence of the deduced 25.5 kDa protein reveals two copies of a 60-amino acid domain, CHORD, conserved in tandem organization in protozoa, plants, and metazoa. CHORD defines a novel eukaryotic Zn2+-binding domain. Silencing of the C. elegans CHORD-containing gene, chp, results in semisterility and embryo lethality, suggesting an essential function of the wild-type gene in nematode development. Our findings indicate that plant R genes have recruited a fundamental cellular control element for signaling of disease resistance and cell death.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schulze-Lefert, P (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.	schlet@bbsrc.ac.uk	Azevedo, Cristina/Y-4296-2019; Shirasu, Ken/ABF-5306-2020; Shirasu, Ken/A-4455-2010; Schulze-Lefert, Paul/A-7746-2008; Schulze-Lefert, Paul/B-6707-2011	Azevedo, Cristina/0000-0002-6997-1265; Shirasu, Ken/0000-0002-0349-3870; Shirasu, Ken/0000-0002-0349-3870; 				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BENDAHMANE A, 1999, IN PRESS BIOTECHNIQU; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; EDWARDS A, 1999, IN PRESS EUR J BIOCH; FALK A, 1999, P NATL ACAD SCI USA, V95, P10306; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huckelhoven R, 1999, PLANT PHYSIOL, V119, P1251, DOI 10.1104/pp.119.4.1251; Jones DA, 1997, ADV BOT RES, V24, P89; JORGENSEN JH, 1988, GENOME, V30, P129, DOI 10.1139/g88-022; Jorgensen JH, 1996, GENOME, V39, P492, DOI 10.1139/g96-063; KIM JS, 1994, ANAL BIOCHEM, V219, P165, DOI 10.1006/abio.1994.1251; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Lahaye T, 1998, MOL GEN GENET, V260, P92, DOI 10.1007/s004380050874; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MARTIN W, 1989, NATURE, V339, P46, DOI 10.1038/339046a0; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schiffer R, 1997, MOL PLANT MICROBE IN, V10, P830, DOI 10.1094/MPMI.1997.10.7.830; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; TORP J, 1986, CAN J GENET CYTOL, V28, P725, DOI 10.1139/g86-102; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WEI F, 1999, IN PRESS GENETICS	42	280	311	2	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					355	366		10.1016/S0092-8674(00)81522-6	http://dx.doi.org/10.1016/S0092-8674(00)81522-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571178	Bronze			2022-12-24	WOS:000083709300003
J	Smith, O				Smith, O			Development - Whirling derivshes	SCIENCE			English	Editorial Material																		Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1311	1311		10.1126/science.286.5443.1311	http://dx.doi.org/10.1126/science.286.5443.1311			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10610537				2022-12-24	WOS:000083675500031
J	Troemel, ER; Sagasti, A; Bargmann, CI				Troemel, ER; Sagasti, A; Bargmann, CI			Lateral signaling mediated by axon contact and calcium entry regulates asymmetric odorant receptor expression in C-elegans	CELL			English	Article							NUCLEOTIDE-GATED CHANNEL; CAENORHABDITIS-ELEGANS; SENSORY NEURONS; CHEMOSENSORY RECEPTORS; SYNAPTIC PLASTICITY; GENE; PROTEIN; ENCODES; GUIDANCE; SYSTEM	C. elegans detects several odorants with the bilaterally symmetric pair of AWC olfactory neurons. A stochastic, coordinated decision ensures that the candidate odorant receptor gene str-2 is expressed in only one AWC neuron in each animal-either the left or the right neuron, but never both. An interaction between the two AWC neurons generates asymmetric str-2 expression in a process that requires normal axon guidance and probably AWC axon contact. This interaction induces str-a expression by reducing calcium signaling through a voltage-dependent Ca2+ channel and the CaM kinase II UNC-43. CaMKII activity acts as a switch in the initial decision to express str-2; thus, calcium signals can define distinct cell types during neuronal development. A cGMP signaling pathway that is used in olfaction maintains str-2 expression after the initial decision has been made.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	cori@itsa.ucsf.edu		Bargmann, Cornelia/0000-0002-8484-0618				Anderson P, 1995, METHOD CELL BIOL, V48, P31; BAIER H, 1994, P NATL ACAD SCI USA, V91, P11646, DOI 10.1073/pnas.91.24.11646; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BLAIR SS, 1990, J NEUROSCI, V10, P3183; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chou WH, 1999, DEVELOPMENT, V126, P607; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; GOVIND CK, 1992, J NEUROBIOL, V23, P1423, DOI 10.1002/neu.480231006; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; GRUNERT U, 1994, J COMP NEUROL, V348, P607, DOI 10.1002/cne.903480410; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1995, J CELL BIOL, V129, P1081, DOI 10.1083/jcb.129.4.1081; Papatsenko D, 1997, DEVELOPMENT, V124, P1665; REINER DJ, 1999, IN PRESS NATURE; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Sagasti A, 1999, GENE DEV, V13, P1794, DOI 10.1101/gad.13.14.1794; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STARICH TA, 1993, GENETICS, V133, P527; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WEINSHENKER DZ, 1999, IN PRESS J NEUROSCI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zallen JA, 1999, DEVELOPMENT, V126, P3679; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZORAN MJ, 1993, DEV BIOL, V158, P163, DOI 10.1006/dbio.1993.1176	54	207	241	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					387	398		10.1016/S0092-8674(00)81525-1	http://dx.doi.org/10.1016/S0092-8674(00)81525-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571181	Bronze			2022-12-24	WOS:000083709300006
J	Gerber, AP; Keller, W				Gerber, AP; Keller, W			An adenosine deaminase that generates inosine at the wobble position of tRNAs	SCIENCE			English	Article							TRANSITION-STATE ANALOG; CYTIDINE DEAMINASE; TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; MUTATIONS; ENZYME; MECHANISM	Several transfer RNAs (tRNAs) contain inosine (I) at the first. position of their anticodon (position 34): this modification is thought. to enlarge the codon recognition capacity during protein synthesis. The tRNA-specific adenosine deaminase of Saccharomyces cerevisiae that forms I-34 in tRNAs is described. The heteroclimeric enzyme consists of two sequence-related subunits (Tad2p/ADAT2 and Tad3p/ADAT3), both of which contain cytidine deaminase (CDA) motifs. Each subunit is encoded by an essential gene (TAD2 and TAD3), indicating that I-34 is an indispensable base modification in elongating tRNAs. These results provide an evolutionary Link between the CDA superfamily and RNA-dependent adenosine deaminases (ADARs/ADATs).	Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Basel	Keller, W (corresponding author), Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland.	walter.keller@unibas.ch		Gerber, Andre/0000-0002-2398-6592				Amrani N, 1996, MOL GEN GENET, V252, P552, DOI 10.1007/BF02172401; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Carlow D, 1998, BIOCHEMISTRY-US, V37, P11873, DOI 10.1021/bi980959n; Carter Jr C. W., 1998, MODIFICATION EDITING, P363; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Grosjean H, 1996, BIOCHIMIE, V78, P488, DOI 10.1016/0300-9084(96)84755-9; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLEY RW, 1965, J BIOL CHEM, V240, P2122; Keller W, 1999, FEBS LETT, V452, P71, DOI 10.1016/S0014-5793(99)00590-6; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; OConnell MA, 1997, CURR BIOL, V7, pR437, DOI 10.1016/S0960-9822(06)00212-0; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	25	222	236	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1146	1149		10.1126/science.286.5442.1146	http://dx.doi.org/10.1126/science.286.5442.1146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550050				2022-12-24	WOS:000083534200040
J	Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE				Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE			A short Fe-Fe distance in peroxodiferric ferritin: Control of Fe substrate versus cofactor decay?	SCIENCE			English	Article							X-RAY ABSORPTION; DINUCLEAR IRON CENTER; METHANE MONOOXYGENASE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; MODEL COMPLEXES; O-2 ACTIVATION; DIAMOND CORE; INTERMEDIATE; ENZYMES	The reaction of oxygen with protein diiron sites is important in bioorganic syntheses and biomineralization. An unusually short Fe-Fe distance of 2.53 angstroms was found in the diiron (mu-1,2 peroxodiferric) intermediate that forms in the early steps of ferritin biomineralization. This distance suggests the presence of a unique triply bridged structure. The Fe-Fe distances in the mu-1,2 peroxodiferric complexes that were characterized previously are much longer (3.1 to 4.0 angstroms). The 2.53 angstrom Fe-Fe distance requires a small Fe-O-O angle (similar to 106 degrees to 107 degrees). This geometry should favor decay of the peroxodiferric complex by the release of H2O2 and mu-oxo or mu-hydroxo diferric biomineral precursors rather than by oxidation of the organic substrate. Geometrical differences may thus explain how diiron sites can function either as a substrate (in ferritin biomineralization) or as a cofactor (in O-2 activation).	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Michigan System; University of Michigan; Emory University; Emory University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Penner-Hahn, JE (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	jeph@umidh.edu	Krebs, Carsten/D-4773-2009; Penner-Hahn, James/GYD-3750-2022	Krebs, Carsten/0000-0002-3302-7053; Penner-Hahn, James/0000-0003-0314-1274	NIGMS NIH HHS [GM-45205, GM-58778, GM-47295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM058778, R01GM045205] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; Bollinger JM, 1998, J AM CHEM SOC, V120, P1094, DOI 10.1021/ja973651c; BOSSEK U, 1990, J AM CHEM SOC, V112, P6387, DOI 10.1021/ja00173a031; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Brunold TC, 1998, J AM CHEM SOC, V120, P5674, DOI 10.1021/ja980129x; Caudle MT, 1996, INORG CHEM, V35, P3577, DOI 10.1021/ic951462u; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; Dong YH, 1997, J AM CHEM SOC, V119, P12683, DOI 10.1021/ja973115k; Dong YH, 1996, ANGEW CHEM INT EDIT, V35, P618, DOI 10.1002/anie.199606181; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Ha Y, 1999, J BIOL INORG CHEM, V4, P243, DOI 10.1007/s007750050310; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; LARSON E, 1992, INORG CHEM, V31, P373, DOI 10.1021/ic00029a008; LING JS, 1994, J AM CHEM SOC, V116, P7682, DOI 10.1021/ja00096a027; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU WT, 1993, INORG CHEM, V32, P4102, DOI 10.1021/ic00071a023; Moenne-Loccoz P, 1999, BIOCHEMISTRY-US, V38, P5290, DOI 10.1021/bi990095l; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; Ookubo T, 1996, J AM CHEM SOC, V118, P701, DOI 10.1021/ja953705n; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Riggs-Gelasco PJ, 1998, J AM CHEM SOC, V120, P849, DOI 10.1021/ja9718230; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; RIGGSGELASCO PJ, 1994, THESIS U MICHIGAN; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Treffry A, 1998, FEBS LETT, V432, P213, DOI 10.1016/S0014-5793(98)00867-9; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; Valentine AM, 1999, J AM CHEM SOC, V121, P3876, DOI 10.1021/ja9839522; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	39	157	162	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					122	125		10.1126/science.287.5450.122	http://dx.doi.org/10.1126/science.287.5450.122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615044				2022-12-24	WOS:000084578400049
J	Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M				Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M			Protein interaction mapping in C-elegans using proteins involved in vulval development	SCIENCE			English	Article							PAPILLOMAVIRUS TYPE-16 E1; CELL-CYCLE REGULATORS; MAP KINASE CASCADE; CAENORHABDITIS-ELEGANS; GENOME; EXPRESSION; PATHWAY; MEMBERS; LIN-15; FAMILY	Protein interaction mapping using large-scale two-hybrid analysis has been proposed as a way to functionally annotate large numbers of uncharacterized proteins predicted by complete genome sequences. This approach was examined in Caenorhabditis elegans, starting with 27 proteins involved in vulval development. The resulting map reveals both known and new potential interactions and provides a functional annotation for approximately 100 uncharacterized gene products. A protein interaction mapping project is now feasible for C. elegans on a genome-wide scale and should contribute to the understanding of molecular mechanisms in this organism and in human diseases.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Life Technol Inc, Rockville, MD 20850 USA; Lab LSR IMAG, F-38402 St Martin Dheres, France	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Thermo Fisher Scientific	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, 44 Binney St, Boston, MA 02115 USA.	Marc_Vidal@DFCI.Harvard.edu	Thierry-Mieg, Nicolas/M-6007-2014	Thierry-Mieg, Nicolas/0000-0002-7667-2853	NATIONAL CANCER INSTITUTE [R21CA081658] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715] Funding Source: NIH RePORTER; NCI NIH HHS [1 R21 CA81658 A 01] Funding Source: Medline; NHGRI NIH HHS [1 RO1 HG01715-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		[Anonymous], 1997, NATURE, V387, pS; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHOI KY, 1994, CELL, V78, P499; CLARK SG, 1994, GENETICS, V137, P987; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURBIN R, 1994, COMPUTATIONAL METHOD; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FERGUSON EL, 1989, GENETICS, V123, P109; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; HARTLEY JL, UNPUB; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu X., UNPUB; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; PRINTEN JA, 1994, GENETICS, V138, P609; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RHODES MA, UNPUB; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Solari F, 1999, DEVELOPMENT, V126, P2483; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thomas JH, 1999, DEVELOPMENT, V126, P3449; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1997, ADV MOLEC BIOL, P109; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; WALHOUT AJM, IN PRESS METHODS ENZ; WALHOUT ALJM, UNPUB; Walhout M, 1998, AM J HUM GENET, V63, P955, DOI 10.1086/302078; Wood WB, 1988, NEMATODE CAENORHABDI; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yasugi T, 1997, J VIROL, V71, P5942, DOI 10.1128/JVI.71.8.5942-5951.1997; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	58	567	645	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					116	122		10.1126/science.287.5450.116	http://dx.doi.org/10.1126/science.287.5450.116			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615043				2022-12-24	WOS:000084578400048
J	Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC				Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC			DNA topoisomerase II beta and neural development	SCIENCE			English	Article							HUMAN FIBROBLASTS; INHIBITORS; REPAIR; RECOMBINATION; CEREVISIAE; EXCISION; SOMITE; MUSCLE; YEAST; RDNA	DNA topoisomerase II beta is shown to have an unsuspected and critical role in neural development. Neurogenesis was normal in II beta mutant mice, but motor axons failed to contact skeletal muscles, and sensory axons failed to enter the spinal cord. Despite an absence of innervation, clusters of acetylcholine receptors were concentrated in the central region of skeletal muscles, thereby revealing patterning mechanisms that are autonomous to skeletal muscle. The defects in motor axon growth in II beta mutant mice resulted in a breathing impairment and death of the pups shortly after birth.	NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	New York University; Harvard University	Yang, X (corresponding author), NYU, Sch Med, Skirball Inst Mol Med, 540 1st Ave, New York, NY 10016 USA.				NINDS NIH HHS [NS27963, NS36193, R01 NS036193, R01 NS041311-03, NS10537, R01 NS041311, R01 NS036193-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010537, R01NS041311, R37NS036193, R01NS027963, R01NS036193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; CHEN M, 1995, ONCOL RES, V7, P103; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Dereuddre S, 1997, CANCER RES, V57, P4301; Dietrich S, 1998, DEVELOPMENT, V125, P2235; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODEMENT P, 1987, DEVELOPMENT, V101, P697; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hogan B, 1994, MANIPULATING MOUSE E; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Kablar B, 1999, DEV BIOL, V208, P93, DOI 10.1006/dbio.1998.9184; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kobayashi M, 1998, MOL CELL BIOL, V18, P6737, DOI 10.1128/MCB.18.11.6737; LEWIS J, 1981, J EMBRYOL EXP MORPH, V64, P211; Ordahl CP, 1998, BIOESSAYS, V20, P357, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;357::AID-BIES1&gt;3.0.CO;2-L; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; POPANDA O, 1992, CARCINOGENESIS, V13, P2321, DOI 10.1093/carcin/13.12.2321; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLIAMS PE, 1971, J CELL SCI, V9, P751; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; Yang X., UNPUB	32	289	296	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					131	134		10.1126/science.287.5450.131	http://dx.doi.org/10.1126/science.287.5450.131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615047				2022-12-24	WOS:000084578400052
J	Chen, LL; Sigler, PB				Chen, LL; Sigler, PB			The crystal structure of a GroEL/peptide complex: Plasticity as a basis for substrate diversity	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; POLYPEPTIDE BINDING; VIRAL PEPTIDES; CENTRAL CAVITY; PROTEIN; CONFORMATIONS; 2.8-ANGSTROM; INTERMEDIATE; RESOLUTION; MECHANISM	The chaperonin GroEL is a double toriodal assembly that with its cochaperonin GroES facilitates protein folding with an ATP-dependent mechanism. Nonnative conformations of diverse protein substrates bind to the apical domains surrounding the opening of the double toroid's central cavity. Using phage display, we have selected peptides with high affinity for the isolated apical domain. We have determined the crystal structures of the complexes formed by the most strongly bound peptide with the isolated apical domain, and with GroEL. The peptide interacts with the groove between paired or helices in a manner similar to that of the GroES mobile loop. Our structural analysis, combined with other results, suggests that various modes of molecular plasticity are responsible for tight promiscuous binding of nonnative substrates and their release into the shielded cis assembly.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06511 USA.				NIGMS NIH HHS [GM15225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015225, R01GM015225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chatellier J, 1999, J MOL BIOL, V292, P163, DOI 10.1006/jmbi.1999.3040; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1996, CHAPERONINS; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; Ma JP, 1998, P NATL ACAD SCI USA, V95, P8502, DOI 10.1073/pnas.95.15.8502; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	47	200	204	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					757	768		10.1016/S0092-8674(00)81673-6	http://dx.doi.org/10.1016/S0092-8674(00)81673-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619429	hybrid			2022-12-24	WOS:000084488200009
J	Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L				Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L			Microorganisms in the accreted ice of Lake Vostok, Antarctica	SCIENCE			English	Article							MICROBIAL ECOLOGY; ORGANIC-CARBON; EUROPA; SEAWATER; BACTERIA; OCEAN; WATER	Analysis of a portion of Vostok ice core number 5G, which is thought to contain frozen water derived from Lake Vostok, Antarctica (a body of liquid water located beneath about 4 kilometers of glacial ice), revealed between 2 x 10(2) and 3 x 10(2) bacterial cells per milliliter and Low concentrations of potential growth nutrients, Lipopolysaccharide (a Gram-negative bacterial cell biomarker) was also detected at concentrations consistent with the cell enumeration data, which suggests a predominance of Gram-negative bacteria. At Least a portion of the microbial assemblage was viable, as determined by the respiration of carbon-14-labeled acetate and glutose substrates during incubations at 3 degrees C and 1 atmosphere. These accreted ice data suggest that Lake Vostok may contain viable microorganisms.	Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	University of Hawaii System; University of Hawaii Manoa; University of Quebec; University of Quebec Montreal	Karl, DM (corresponding author), Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				Abyzov SS, 1998, MICROBIOLOGY+, V67, P451; AZAM F, 1979, SCIENCE, V203, P451, DOI 10.1126/science.203.4379.451; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Chapman CR, 1999, SCIENCE, V283, P338, DOI 10.1126/science.283.5400.338; CHRISTIAN JR, 1994, J GEOPHYS RES-OCEANS, V99, P14269, DOI 10.1029/94JC00681; DALZIEL I, 1999, LAK VOST WORKSH FIN, P17; Fukuda R, 1998, APPL ENVIRON MICROB, V64, P3352; HOBBIE JE, 1969, LIMNOL OCEANOGR, V14, P528, DOI 10.4319/lo.1969.14.4.0528; HOLMHANSEN O, 1975, NASA, P75; JANNASCH HW, 1979, BIOSCIENCE, V29, P592, DOI 10.2307/1307765; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl David M., 1998, P29; KARL DM, 1982, APPL ENVIRON MICROB, V44, P891, DOI 10.1128/AEM.44.4.891-902.1982; KARL DM, 1980, MICROBIOL REV, V44, P739, DOI 10.1128/MMBR.44.4.739-796.1980; KARL DM, 1980, SCIENCE, V207, P1345, DOI 10.1126/science.207.4437.1345; Karl DM, 1995, MICR EXTREM UNUSUAL, P35; KENNICUTT MC, 1999, LAK VOST WORKSH FIN, P26; Legrand M, 1997, REV GEOPHYS, V35, P219, DOI 10.1029/96RG03527; MAEDA M, 1979, J APPL BACTERIOL, V47, P175, DOI 10.1111/j.1365-2672.1979.tb01182.x; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MONGER BC, 1993, APPL ENVIRON MICROB, V59, P905, DOI 10.1128/AEM.59.3.905-911.1993; Noble RT, 1998, AQUAT MICROB ECOL, V14, P113, DOI 10.3354/ame014113; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PETIT JR, 1999, LAK VOST WORKSH FIN, P16; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; Qian JG, 1996, ANAL CHEM, V68, P3090, DOI 10.1021/ac960370z; SHACKELFORD RP, 1998, THESIS U HAWAII; SHARP JH, 1995, MAR CHEM, V48, P91, DOI 10.1016/0304-4203(94)00040-K; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Takacs CD, 1998, MICROBIAL ECOL, V36, P239, DOI 10.1007/s002489900111; WATSON SW, 1977, APPL ENVIRON MICROB, V33, P940, DOI 10.1128/AEM.33.4.940-946.1977; WATSON SW, 1979, NATIVE AQUATIC BACTE, P82	35	235	252	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2144	2147		10.1126/science.286.5447.2144	http://dx.doi.org/10.1126/science.286.5447.2144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591643				2022-12-24	WOS:000084157300048
J	Maechler, P; Wollheim, CB				Maechler, P; Wollheim, CB			Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis	NATURE			English	Article							BRAIN SYNAPTIC VESICLES; PANCREATIC BETA-CELLS; SECRETORY VESICLE; RAT-BRAIN; CA2+; DEHYDROGENASE; TRANSPORT; FORMS	The hormone insulin is stored in secretory granules and released from the pancreatic beta-cells by exocytosis(1). In the consensus model of glucose-stimulated insulin secretion, ATP is generated by mitochondrial metabolism, promoting closure of ATP-sensitive potassium (K-ATP) channels, which depolarizes the plasma membrane(2,3). Subsequently, opening of voltage-sensitive Ca2+ channels increases the cytosolic Ca2+ concentration ([Ca2+](c)) which constitutes the main trigger initiating insulin exocytosis(1,3.4), Nevertheless, the Ca2+ signal alone is not sufficient for sustained secretion. Furthermore, glucose elicits a secretory response under conditions of damped, elevated [Ca2+](c) (refs 5, 6), A mitochondrial messenger must therefore exist which is distinct from ATP(7,8). We have identified this as glutamate, We show that glucose generates glutamate from beta-cell mitochondria, A membrane-permeant glutamate analogue sensitizes the glucose-evoked secretory response, acting downstream of mitochondrial metabolism. In permeabilized cells, under conditions of fixed [Ca2+](c), added glutamate directly stimulates insulin exocytosis, independently of mitochondrial function. Glutamate uptake by the secretory granules is likely to be involved, as inhibitors of vesicular glutamate transport suppress the glutamate-evoked exocytosis. These results demonstrate that glutamate acts as an intracellular messenger that couples glucose metabolism to insulin secretion.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Maechler, P (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.	pierre.maechler@medecine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; Janjic D, 1996, PANCREAS, V13, P166, DOI 10.1097/00006676-199608000-00008; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Ozkan ED, 1998, JPN J PHARMACOL, V77, P1, DOI 10.1254/jjp.77.1; ROISIN MP, 1980, FEBS LETT, V115, P143, DOI 10.1016/0014-5793(80)80745-9; ROSETH S, 1995, J NEUROCHEM, V65, P96; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SENER A, 1994, AM J PHYSIOL-ENDOC M, V267, pE573, DOI 10.1152/ajpendo.1994.267.4.E573; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	29	412	418	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					685	689		10.1038/45280	http://dx.doi.org/10.1038/45280			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604477	Green Published			2022-12-24	WOS:000084189800071
J	Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A				Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A			Linking spontaneous activity of single cortical neurons and the underlying functional architecture	SCIENCE			English	Article							CAT VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; ELECTRICAL-ACTIVITY; ONGOING ACTIVITY; CEREBRAL-CORTEX; ORGANIZATION; PATTERNS; CONNECTIONS; DYNAMICS; STATES	The relation between the activity of a single neocortical neuron and the dynamics of the network in which it is embedded was explored by single-unit recordings and real-time optical imaging. The firing rate of a spontaneously active single neuron strongly depends on the instantaneous spatial pattern of ongoing population activity in a Large cortical area. Very similar spatial patterns of population activity were observed both when the neuron fired spontaneously and when it was driven by its optimal stimulus. The evoked patterns could be used to reconstruct the spontaneous activity of single neurons.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Ctr Studies Higher Brain Funct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Grinvald, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, POB 26, IL-76100 Rehovot, Israel.		tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ABELES M, 1995, P NATL ACAD SCI USA, V92, P8616, DOI 10.1073/pnas.92.19.8616; Abeles M., 1982, LOCAL CORTICAL CIRCU; Ahmed B, 1998, CEREB CORTEX, V8, P462, DOI 10.1093/cercor/8.5.462; Amit DJ, 1997, CEREB CORTEX, V7, P237, DOI 10.1093/cercor/7.3.237; Amit DJ, 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; ARIELI A, 1992, INFORMATION PROCESSI, P123; BenYishai R, 1997, J COMPUT NEUROSCI, V4, P57, DOI 10.1023/A:1008816611284; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; Hansel D., 1998, METHODS NEURONAL MOD, P499; Hertz J, 1991, INTRO THEORY NEURAL; HUBEL DH, 1977, NATURE, V269, P328, DOI 10.1038/269328a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IIJIMA T, 1992, NEUROSCIENCE, V51, P211, DOI 10.1016/0306-4522(92)90486-L; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; MALACH R, 1994, CEREB CORTEX, V4, P151, DOI 10.1093/cercor/4.2.151; NODA H, 1970, BRAIN RES, V18, P672; ORBACH HS, 1983, J NEUROSCI, V3, P2251; PAISLEY AC, 1984, PROG NEUROBIOL, V22, P155, DOI 10.1016/0301-0082(84)90024-8; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANSEVERINO E R, 1973, Brain Research, V54, P225; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SHOHAM D, IN PRESS NEURON; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; SINGER W, 1994, INT REV NEUROBIOL, V37, P153; SOFTKY WR, 1993, J NEUROSCI, V13, P334; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Tsodyks M., 1995, NETWORK, V6, P1; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724; WEBB AC, 1976, PROC R SOC SER B-BIO, V194, P239, DOI 10.1098/rspb.1976.0076	46	506	510	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1943	1946		10.1126/science.286.5446.1943	http://dx.doi.org/10.1126/science.286.5446.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583955				2022-12-24	WOS:000084003400048
J	Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP				Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP			The DNA sequence of human chromosome 22	NATURE			English	Article							WHOLE-GENOME SHOTGUN; CPG ISLANDS; YAC CONTIG; MAP; ORGANIZATION; GENES; CONSTRUCTION; REGION; MOUSE; 22Q11	Knowledge of the complete genomic DNA sequence of an organism allows a systematic approach to defining its genetic components. The genomic sequence provides access to the complete structures of all genes, including those without known function, their control elements, and, by inference, the proteins they encode, as well as all other biologically important sequences. Furthermore, the sequence is a rich and permanent source of information for the design of further biological studies of the organism and for the study of evolution through cross-species sequence comparison. The power of this approach has been amply demonstrated by the determination of the sequences of a number of microbial and model organisms, The next step is to obtain the complete sequence of the entire human genome. Here we report the sequence of the euchromatic part of human chromosome 22. The sequence obtained consists of 12 contiguous segments spanning 33.4 megabases, contains at least 545 genes and 134 pseudogenes, and provides the first view of the complex chromosomal landscapes that will be found in the rest of the genome.	Sanger Ctr, Cambridge CB10 1SA, England; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Karolinska Hosp, Dept Mol Med, Clin Genet Unit, S-17176 Stockholm, Sweden; CALTECH, Div Biol, Pasadena, CA 91125 USA	Wellcome Trust Sanger Institute; Keio University; University of Oklahoma System; University of Oklahoma - Norman; Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Alberta; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska University Hospital; California Institute of Technology	Dunham, I (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	idl@sanger.ac.uk	Wilson, Richard K./AAF-4139-2019; McClay, Joseph/C-9931-2009; Hubbard, Tim J.P./AAT-4571-2020; Spraggon, Lee/E-5900-2012; Tapia-Páez, Isabel/ABD-7197-2021; Evans, Kathryn KL/I-5910-2012; Mardis, Elaine/W-2202-2019; Hubbard, Tim J/C-2567-2008; Durbin, Richard/AAE-7178-2019; Deschamps, Stephane/R-3806-2019; Tapia-Páez, Isabel/N-1210-2013; Kedra, Darek/H-7641-2012; Sasaki, Takashi/AAD-1461-2019; McDermid, Heather/A-2666-2014	Wilson, Richard K./0000-0002-1992-1358; McClay, Joseph/0000-0002-3628-2447; Hubbard, Tim J.P./0000-0002-1767-9318; Hubbard, Tim J/0000-0002-1767-9318; Durbin, Richard/0000-0002-9130-1006; Kedra, Darek/0000-0002-9723-4465; Morrow, Bernice/0000-0002-8076-4726; Dunham, Ian/0000-0003-2525-5598; Fosker, Christine/0000-0002-3799-9474; Koculi, Eda/0000-0001-9477-555X; Tapia-Paez, Isabel/0000-0002-0535-4233; Hunt, Adrienne/0000-0002-1227-0310; Hunt, Sarah/0000-0002-8350-1235; McDermid, Heather/0000-0001-7535-0927; Steward, Charles/0000-0001-8829-5349; Sasaki, Takashi/0000-0002-6275-046X; Pan, Huaqin/0000-0002-7166-108X; Davidson, Claire/0000-0002-4910-8202; Bridgeman, Anne/0000-0002-9478-6125; Lewis, Suzanna/0000-0002-8343-612X; Evans, Kathryn/0000-0002-7884-5877				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bentley DR, 1996, SCIENCE, V274, P533, DOI 10.1126/science.274.5287.533; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.genet.23.1.637; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUCAN M, 1993, HUM MOL GENET, V2, P1245, DOI 10.1093/hmg/2.8.1245; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Collins JE, 1997, GENOME RES, V7, P522, DOI 10.1101/gr.7.5.522; COLLINS JE, 1995, NATURE, V377, P367; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, GENOME ANAL, V3, P1; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; EPPIG JT, 1995, CURR OPIN GENET DEV, V5, P709, DOI 10.1016/0959-437X(95)80002-M; Felsenfeld A, 1999, GENOME RES, V9, P1; Gill M, 1996, AM J MED GENET, V67, P40, DOI 10.1002/(SICI)1096-8628(19960216)67:1<40::AID-AJMG6>3.0.CO;2-W; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Guyer M, 1998, GENOME RES, V8, P413; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Johnson A, 1999, GENOMICS, V57, P306, DOI 10.1006/geno.1999.5757; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; McDermid HE, 1996, GENOME RES, V6, P1149, DOI 10.1101/gr.6.12.1149; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Ning Y, 1996, HUM GENET, V97, P765; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; Saccone S, 1996, GENE, V174, P85, DOI 10.1016/0378-1119(96)00392-7; *SANG CTR WASH U G, 1998, GENOME RES, V8, P1097; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Seroussi E, 1999, GENOME RES, V9, P803, DOI 10.1101/gr.9.9.803; SOLOVYEV V, 1997, ISMB, V5, P294; Southard-Smith EM, 1999, MAMM GENOME, V10, P744, DOI 10.1007/s003359901083; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zu L, 1999, AM J HUM GENET, V64, P594, DOI 10.1086/302247	50	854	1310	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					489	495		10.1038/990031	http://dx.doi.org/10.1038/990031			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591208	hybrid			2022-12-24	WOS:000084013200045
J	Francis, LP				Francis, LP			Legal eights to health care at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Francis, LP (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							*US DEP HHS, 1988, HLTH US 1998	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2079	2079		10.1001/jama.282.21.2079	http://dx.doi.org/10.1001/jama.282.21.2079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591395				2022-12-24	WOS:000083908700032
J	Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P				Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P			Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy - Findings for 5 large cohorts of young adult and middle-aged men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; BLOOD-PRESSURE; ATHEROSCLEROSIS; PRAVASTATIN; PREVENTION; EVENTS; TRIAL	Context Three major coronary risk factors-serum cholesterol level, blood pressure, and smoking-increase incidence of coronary heart disease (CHD) and related end points. In previous investigations, risks for low-risk reference groups were estimated statistically because samples contained too few such people to measure risk. Objective To measure long-term mortality rates for individuals with favorable levels for all 3 major risk factors, compared with others. Design Two prospective studies, involving 5 cohorts based on age and sex, that enrolled persons with a range of risk factors. Low risk was defined as serum cholesterol level less than 5.17 mmol/L (<200 mg/dL), blood pressure less than or equal to 120/80 mm Hg, and no current cigarette smoking. All persons with a history of diabetes, myocardial infarction (MI), or, in 3 of 5 cohorts, electrocardiogram (ECG) abnormalities, were excluded. Setting and Participants In 18 US cities, a total of 72 144 men aged 35 through 39 years and 270 671 men aged 40 through 57 years screened (1973-1975) for the Multiple Risk Factor Intervention Trial (MRFIT); in Chicago, a total of 10 025 men aged 18 through 39 years, 7490 men aged 40 through 59 years, and 6229 women aged 40 through 59 years screened (1967-1973) for the Chicago Heart Association Detection Project in Industry (CHA) (N=366 559). Main Outcome Measures Cause-specific mortality during 16 (MRFIT) and 22 (CHA) years, relative risks (RRs) of death, and estimated greater life expectancy, comparing low-risk subcohorts vs others by age strata; Results Low-risk persons comprised only 4.8% to 9.9% of the cohorts. All 5 low-risk groups experienced significantly and markedly lower CHD and cardiovascular disease death rates than those who had elevated cholesterol level, or blood pressure, or smoked. For example, age-adjusted RRs of CHD mortality ranged from 0.08 for CHA men aged 18 to 39 years to 0.23 for CHA men aged 40 through 59 years. The age-adjusted relative risks (RRs) for all cardiovascular disease mortality ranged from 0.15 for MRFIT men aged 35 through 39 years to 0.28 for CHA men aged 40 through 59 years. The age-adjusted RR for all-cause mortality rate ranged from 0.42 for CHA men aged 40 through 59 years to 0.60 for CHA women aged 40 through 59 years. Estimated greater life expectancy for low-risk groups ranged from 5.8 years for CHA women aged 40 through 59 years to 9.5 years for CHA men aged 18 through 39 years. Conclusions Based on these very large cohort studies, for individuals with favorable levels of cholesterol and blood pressure who do not smoke and do not have diabetes, MI, or ECG abnormalities, long-term mortality is much lower and longevity is much greater. A substantial increase in the proportion of the population at lifetime low risk could contribute decisively to ending the CMD epidemic.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Stamler, J (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1101 D335, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715, R01HL021010] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cutler JA, 1997, AM J CLIN NUTR, V65, P184; Daviglus ML, 1998, NEW ENGL J MED, V339, P1122, DOI 10.1056/NEJM199810153391606; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Lowe LP, 1998, ARCH INTERN MED, V158, P2007, DOI 10.1001/archinte.158.18.2007; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; National Research Council (US) Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; PEDERSEN TR, 1994, LANCET, V344, P1383; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROSE G, 1992, J EPIDEMIOL COMMUN H, V46, P75, DOI 10.1136/jech.46.1.75; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1997, AM J CLIN NUTR, V65, P626, DOI 10.1093/ajcn/65.2.626S; Stamler J, 1998, JAMA-J AM MED ASSOC, V279, P878, DOI 10.1001/jama.279.11.878; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; Stamler J., 1967, LECT PREVENTIVE CARD; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; World Health Organization, 1977, INT CLASS DIS; [No title captured]; [No title captured]; [No title captured]	32	513	533	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2012	2018		10.1001/jama.282.21.2012	http://dx.doi.org/10.1001/jama.282.21.2012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591383	Bronze			2022-12-24	WOS:000083908700020
J	Niklason, LE				Niklason, LE			Medical technology - Replacement arteries made to order	SCIENCE			English	Article							CULTURED VASCULAR CELLS; HUMAN BLOOD-VESSEL		Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA	Duke University; Duke University	Niklason, LE (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.							BREGMAN D, 1974, J SURG RES, V16, P624, DOI 10.1016/0022-4804(74)90095-X; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kim SS, 1999, J PEDIATR SURG, V34, P124, DOI 10.1016/S0022-3468(99)90241-5; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Liu SQ, 1998, ATHEROSCLEROSIS, V140, P365, DOI 10.1016/S0021-9150(98)00143-9; Liu SQ, 1999, CRIT REV BIOMED ENG, V27, P75, DOI 10.1615/CritRevBiomedEng.v27.i1-2.30; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	14	74	82	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1493	1494		10.1126/science.286.5444.1493	http://dx.doi.org/10.1126/science.286.5444.1493			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610551				2022-12-24	WOS:000083768300035
J	Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C				Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C			Control of endemic methicillin-resistant Staphylococcus aureus - A cost-benefit analysis in an intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL INFECTIONS; BACTEREMIA; IMPACT; MRSA; EPIDEMIOLOGY; ERADICATION; PREVALENCE; PREVENTION; MORTALITY; OUTBREAK	Context Despite the success of some countries in controlling endemic methicillin-resistant Staphylococcus aureus (MRSA), such programs have not been implemented for some hospitals with endemic infection because of concerns that these programs would be costly and of limited benefit. Objective To compare the costs and benefits of an MRSA control program in an endemic setting. Design and Setting Case-control study conducted at a medical intensive care unit (ICU) of a French university hospital with a 4% prevalence of MRSA carriage at ICU admission. Patients Twenty-seven randomly selected patients who had ICU-acquired MRSA infection between January 1993 and June 1997, matched to 27 controls hospitalized during the same period without MRSA infection. Main Outcome Measures Intensive care unit costs attributable to MRSA infection, computed from excess therapeutic intensity in cases using estimates from a cost model derived in the same ICU, were compared with costs of the control program, derived from time-motion study of nurses and physicians. The threshold for MRSA carriage that would make the control strategy dominant was determined; sensitivity analyses varied rates of MRSA transmission and ratio of infection to transmission, length of ICU stay, and costs of isolation precautions. Results The mean cost attributable to MRSA infection was US $9275 (median, $5885; interquartile range, $1400-$16720). Total costs of the control program ranged from $340 to $1480 per patient. A 14% reduction in MRSA infection rate resulted in the control program being beneficial. In sensitivity analyses, the control strategy was dominant for a prevalence of MRSA carriage on ICU admission ranging from 1% to 7%, depending on costs of control measures and MRSA transmission, for infection rates greater than 50% following transmission. Conclusions In this example of a hospital with endemic MRSA infection, selective screening and isolation of carriers on ICU admission are beneficial compared with no isolation.	Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Hop Henri Mondor, Med Intens Care Unit, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Brun-Buisson, C (corresponding author), Hop Henri Mondor, Assistance Publ Hop Paris, Unite Hyg & Prevent Infect, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	christian.brun-buisson@hmn.ap-hop.paris.fr						AubryDamon H, 1997, CLIN INFECT DIS, V25, P647, DOI 10.1086/513749; Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; BOYCE JM, 1983, J INFECT DIS, V148, P763, DOI 10.1093/infdis/148.4.763; Chaix C, 1999, PHARMACOECONOMICS, V15, P573, DOI 10.2165/00019053-199915060-00005; COHEN SH, 1991, AM J MED, V91, pS233, DOI 10.1016/0002-9343(91)90374-7; DRUMMOND M, 1989, METHODS EC EVALUATIO, P18; EMMERSON M, 1994, SCAND J INFECT DIS, P47; Girou E, 1998, CLIN INFECT DIS, V27, P543, DOI 10.1086/514695; HALEY RW, 1995, J INFECT DIS, V171, P614, DOI 10.1093/infdis/171.3.614; Harbarth S, 1998, ARCH INTERN MED, V158, P182, DOI 10.1001/archinte.158.2.182; Humphreys H, 1997, J HOSP INFECT, V36, P167, DOI 10.1016/S0195-6701(97)90191-2; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552; Jernigan JA, 1995, INFECT CONT HOSP EP, V16, P686; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Miranda DR, 1997, INTENS CARE MED, V23, P760, DOI 10.1007/s001340050406; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; RAO N, 1988, INFECT CONT HOSP EP, V9, P255, DOI 10.1086/645848; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P670, DOI 10.1136/bmj.307.6905.670; RomeroVivas J, 1995, CLIN INFECT DIS, V21, P1417, DOI 10.1093/clinids/21.6.1417; STAMM AM, 1993, AM J INFECT CONTROL, V21, P70, DOI 10.1016/0196-6553(93)90227-U; Sznajder M, 1998, INTENS CARE MED, V24, P582, DOI 10.1007/s001340050619; TABLAN OC, 1995, INFECT CONT HOSP EP, V16, P105; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; VandenbrouckeGrauls CMJE, 1996, INFECT CONT HOSP EP, V17, P512; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; WESTH H, 1992, CLIN INFECT DIS, V14, P1186, DOI 10.1093/clinids/14.6.1186	34	249	257	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1745	1751		10.1001/jama.282.18.1745	http://dx.doi.org/10.1001/jama.282.18.1745			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568647	Bronze			2022-12-24	WOS:000083471400029
J	Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ				Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ		Welsh Antibiotic Study Grp	Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Publ Hlth Lab, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Cardiff CF14 4XW, S Glam, Wales; Bro Taf Hlth Author, Cardiff CF1 4TW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Med Comp & Stat, Cardiff CF1 3NS, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University; Cardiff University	Howard, AJ (corresponding author), Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales.	tony.howard@phls.wales.nhs.uk						AMYES SGB, 1989, J MED MICROBIOL, V28, P73, DOI 10.1099/00222615-28-2-73; LONDON N, 1994, J ANTIMICROB CHEMOTH, V34, P239, DOI 10.1093/jac/34.2.239; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES	3	152	155	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1999	319	7219					1239	1240		10.1136/bmj.319.7219.1239	http://dx.doi.org/10.1136/bmj.319.7219.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550088	Bronze, Green Published			2022-12-24	WOS:000083625600025
J	Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S				Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S			The chicken B locus is a minimal essential major histocompatibility complex	NATURE			English	Article							MHC CLASS-I; CELL-INTERACTION; POLYMORPHISM; TRANSPORTERS; MOLECULES; GENE; RAT	Here we report the sequence of the region that determines rapid allograft rejection in chickens, the chicken major histocompatibility complex (MHC). This 92-kilobase region of the B locus(1-4) contains only 19 genes, making the chicken MHC roughly 20-fold smaller than the human MHC5. Virtually all the genes have counterparts in the human MHC, defining a minimal essential set of MHC genes conserved over 200 million years of divergence between birds and mammals. They are organized differently, with the class III region genes located outside the class II and class I region genes. The absence of proteasome genes(5,6) is unexpected and might explain unusual peptide-binding specificities of chicken class I molecules. The presence of putative natural killer receptor gene(s)(5,7) is unprecedented and might explain the importance of the B locus in the response to the herpes virus responsible for Marek's diseases(8-10). The small size and simplicity of the chicken MHC allows co-evolution of genes as haplotypes over considerable periods of time, and makes it possible to study the striking MHC-determined pathogen-specific disease resistances(8-10) at the molecular level.	Inst Anim Hlth, Compton RG20 7NN, England; Sanger Ctr, Hinxton CB10 1SA, England; Inst Anim Physiol, D-80539 Munich, Germany; CNRS, UPR420, Villejuif, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Wellcome Trust Sanger Institute; University of Munich; Centre National de la Recherche Scientifique (CNRS)	Kaufman, J (corresponding author), Inst Anim Hlth, Compton RG20 7NN, England.	jim.kaufman@bbsrc.ac.uk	Walker, Brian/A-4984-2013; Gobel, Thomas/A-9919-2009	Walker, Brian/0000-0002-8615-6254; Kaufman, Jim/0000-0002-7216-8422	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bacon L D, 1987, Prog Clin Biol Res, V238, P219; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; BRILES WE, 1950, GENETICS, V35, P633; BRILES WE, 1983, SCIENCE, V219, P977, DOI 10.1126/science.6823560; Bumstead N, 1998, AVIAN PATHOL, V27, pS78, DOI 10.1080/03079459808419296; Frangoulis B, 1999, IMMUNOGENETICS, V49, P328, DOI 10.1007/s002510050500; GERMAIN RN, 1985, CELL, V43, P233, DOI 10.1016/0092-8674(85)90028-5; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; Henry J, 1999, IMMUNOL TODAY, V20, P285, DOI 10.1016/S0167-5699(98)01418-2; Joly E, 1998, CURR BIOL, V8, P169, DOI 10.1016/S0960-9822(98)70065-X; Kandil E, 1996, J IMMUNOL, V156, P4245; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; KAUFMAN J, 1991, CRIT REV IMMUNOL, V11, P113; KAUFMAN J, 1996, MAJOR HISTOCOMPATIBI; Kaufman J., 1995, ADV AVIAN IMMUNOLOGY, P119; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Miller MM, 1996, P NATL ACAD SCI USA, V93, P3958, DOI 10.1073/pnas.93.9.3958; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Nonaka M, 1997, P NATL ACAD SCI USA, V94, P5789, DOI 10.1073/pnas.94.11.5789; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P101, DOI 10.1007/BF01572280; Pharr GT, 1998, IMMUNOGENETICS, V47, P350, DOI 10.1007/s002510050369; PINK JRL, 1977, IMMUNOGENETICS, V5, P203, DOI 10.1007/BF01570477; PLACHY J, 1992, CRIT REV IMMUNOL, V12, P47; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SKJODT K, 1985, TISSUE ANTIGENS, V25, P278, DOI 10.1111/j.1399-0039.1985.tb00450.x; Thorpe KL, 1996, IMMUNOGENETICS, V44, P391, DOI 10.1007/s002510050142; VAINIO O, 1984, IMMUNOGENETICS, V19, P131, DOI 10.1007/BF00387856; VAINIO O, 1988, J IMMUNOL, V140, P2864	29	486	514	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					923	925		10.1038/44856	http://dx.doi.org/10.1038/44856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553909				2022-12-24	WOS:000083464700061
J	Tsutakawa, SE; Jingami, H; Morikawa, K				Tsutakawa, SE; Jingami, H; Morikawa, K			Recognition of a TG mismatch: The crystal structure of very short patch repair endonuclease in complex with a DNA duplex	CELL			English	Article							ESCHERICHIA-COLI K-12; POLYMERASE-I; MINOR-GROOVE; BASE-PAIRS; PROTEIN; BINDING; MECHANISM; GENE; VSR; TRANSCRIPTION	The crystal structure of very short patch repair (Vsr) endonuclease, in complex with Mg2+ and with duplex DNA containing a TG mismatch, has been determined at 2.3 Angstrom resolution. In E. coli, the enzyme recognizes a TG mismatched base pair, generated after spontaneous deamination of methylated cytosines, and cleaves the phosphate backbone on the 5' side of the thymine. Extensive interactions between the DNA and the protein characterize a novel recognition mechanism, where three aromatic residues intercalate from the major groove into the DNA to strikingly deform the base pair stacking. With the presence of a cleaved DNA intermediate in the active center, the structure of the Vsr/DNA complex provides detailed insights into the catalytic mechanism for endonuclease activity.	Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 565, Japan; Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 565, Japan		Morikawa, K (corresponding author), Biomol Engn Res Inst, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 565, Japan.	morikawa@beri.co.jp		Tsutakawa, Susan/0000-0002-4918-4571				Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P4925, DOI 10.1093/nar/26.21.4925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1998, NAT STRUCT BIOL, V5, P697, DOI 10.1038/1394; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; GLASNER W, 1995, J MOL BIOL, V245, P1; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, J MOL BIOL, V190, P605, DOI 10.1016/0022-2836(86)90246-9; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Miller MD, 1999, J MOL BIOL, V288, P975, DOI 10.1006/jmbi.1999.2729; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Rasmussen LJ, 1998, CONT CANC RES, P205; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOHAIL A, 1990, J BACTERIOL, V172, P4214, DOI 10.1128/jb.172.8.4214-4221.1990; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	48	87	90	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					615	623		10.1016/S0092-8674(00)81550-0	http://dx.doi.org/10.1016/S0092-8674(00)81550-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612397	Bronze			2022-12-24	WOS:000084278700008
J	Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B				Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B			Induction of autophagy and inhibition of tumorigenesis by beclin 1	NATURE			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; CELLS; MECHANISMS; BRCA1; YEAST; FIBROBLASTS; VACUOLE	The process of autophagy, or bulk degradation of cellular proteins through an autophagosomic-lysosomal pathway(1), is important in normal growth control and may be defective in tumour cells(2) However, little is known about the genetic mediators of autophagy in mammalian cells or their role in tumour development. The mammalian gene encoding Beclin 1 (ref. 3), a novel Bcl-2-interacting, coiled-coil protein, has structural similarity to the yeast autophagy gene, apg6/vps30 (refs 4, 5), and is mono-allelically deleted in 40-75% of sporadic human breast cancers and ovarian cancers(6). Here we show using gene-transfer techniques, that beclin 1 promotes autophagy in autophagy-defective yeast with a targeted disruption of agp6/vps30, and in human MCF7 breast carcinoma cells. The autophagy-promoting activity of beclin 1 in MCF7 cells is associated with inhibition of MCF7 cellular proliferation, in vitro clonigenicity and tumorigenesis in nude mice. Furthermore, endogenous Beclin 1 protein expression is frequently low in human breast epithelial carcinoma cell lines and tissue, but is expressed ubiquitously at high levels in normal breast epithelia. Thus, beclin 1 is a mammalian autophagy gene that can inhibit tumorigenesis and is expressed at decreased levels in human breast carcinoma. These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Clin Mol Biol, D-81377 Munich, Germany	Columbia University; Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Levine, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	levine@cuccfa.ccc.columbia.edu	Kempkes, Bettina/B-3322-2013					Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADLEY MO, 1977, J BIOL CHEM, V252, P5310; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; EBLE R, 1992, BIOTECHNIQUES, V13, P18; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; GRONOSTAJSKI RM, 1984, J CELL PHYSIOL, V119, P127, DOI 10.1002/jcp.1041190120; GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JIANG W, 1993, ONCOGENE, V8, P3447; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501; KNECHT E, 1984, EXP CELL RES, V154, P224, DOI 10.1016/0014-4827(84)90682-7; LEE HK, 1992, ARCH BIOCHEM BIOPHYS, V296, P271, DOI 10.1016/0003-9861(92)90572-E; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; MITCHENER JS, 1976, AM J PATHOL, V83, P485; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; OTSUKA H, 1978, EXP CELL RES, V112, P127, DOI 10.1016/0014-4827(78)90533-5; ROMMENS JM, 1995, GENOMICS, V28, P530, DOI 10.1006/geno.1995.1185; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	27	2600	2801	4	415	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					672	676		10.1038/45257	http://dx.doi.org/10.1038/45257			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604474				2022-12-24	WOS:000084189800068
J	Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME				Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME			Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; CATHEPSIN-D; MUTATION; DEFICIENCY; CLEAVAGE; NEURONS; GENE	Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease(1-3). Cleavage of APP by unidentified proteases, referred to as beta- and gamma-secretases(4-7), generates the amyloid beta-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients(8). The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage. Here we identify a new membrane-bound aspartyl protease (Asp2) with beta-secretase activity. The Asp2 gene is expressed widely in brain and other tissues. Decreasing the expression of Asp2 in cells reduces amyloid beta-peptide production and blocks the accumulation of the carboxy-terminal APP fragment that is created by beta-secretase cleavage. Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden(3). Thus, Asp2 is a new protein target for drugs that are designed to block the production of amyloid beta-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.	Pharmacia & Upjohn Inc, Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Genom, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Pharmacol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Neurobiol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Bioinformat, S-11287 Stockholm, Sweden	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacia Corporation	Yan, RQ (corresponding author), Pharmacia & Upjohn Inc, Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.			Yan, Riqiang/0000-0001-7195-7617				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P372; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; Glenner G., 1984, SCIENCE, V255, P728; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HUSSAIN I, MOL CELL NEUROSCI; LADROR US, 1994, J BIOL CHEM, V269, P18422; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NEILL D, 1994, J NEUROSCI RES, V39, P482, DOI 10.1002/jnr.490390415; Pirttila T, 1998, NEUROSCI LETT, V249, P21, DOI 10.1016/S0304-3940(98)00381-4; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tatnell PJ, 1998, FEBS LETT, V441, P43, DOI 10.1016/S0014-5793(98)01522-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	19	1282	1402	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					533	537		10.1038/990107	http://dx.doi.org/10.1038/990107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591213				2022-12-24	WOS:000084013200057
J	Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J				Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J			Discovery of molecular hydrogen in a high-velocity cloud of the Galactic halo	NATURE			English	Article							GAS; ABSORPTION; ORIGIN; IUE	The Milky Way's halo contains clouds of neutral hydrogen with high radial velocities which do not follow the general rotational motion of the Galaxy(1). Few distances to these high-velocity clouds are known(2,3), so even gross properties such as total mass are hard to determine. As a consequence, there is no generally accepted theory regarding their origin, One idea(4,5) is that they result from gas that has cooled after being ejected from the Galaxy through fountain-like flows powered by supernovae; another is that they are composed of gas, poor in heavy elements, which is falling onto the disk of the Milky Way from intergalactic space(6,7). The presence of molecular hydrogen, whose formation generally requires the presence of dust (and therefore gas, enriched in heavy elements), could help to distinguish between these possibilities. Here we report the discovery of molecular hydrogen absorption in a high-velocity cloud along the hue of sight to the Large Magellanic Cloud. We also derive for the same cloud an iron abundance which is half of the solar value. From these data, we conclude that gas in this cloud originated in the disk of the Milky Way.	Univ Bonn, Sternwarte, D-53121 Bonn, Germany; Univ Tubingen, Inst Astron & Astrophys, D-72076 Tubingen, Germany	University of Bonn; Eberhard Karls University of Tubingen	Richter, P (corresponding author), Univ Bonn, Sternwarte, Hugel 71, D-53121 Bonn, Germany.							Akeson RL, 1999, ASTROPHYS J, V523, P163, DOI 10.1086/307728; Barnstedt J, 1999, ASTRON ASTROPHYS SUP, V134, P561, DOI 10.1051/aas:1999156; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; Bomans DJ, 1996, ASTRON ASTROPHYS, V313, P101; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; BURTON MG, 1992, ASTROPHYS J, V399, P563, DOI 10.1086/171947; DEBOER KS, 1990, ASTRON ASTROPHYS, V233, P523; DEBOER KS, 1987, SCI ACCOMPLISHMENTS, P485; FIELD GB, 1966, ANNU REV ASTRON ASTR, V4, P207, DOI 10.1146/annurev.aa.04.090166.001231; GREWING M, 1981, MITT ASTRON GES, V52, P79; JURA M, 1975, ASTROPHYS J, V197, P575, DOI 10.1086/153545; MCGEE RX, 1986, P ASTRON SOC AUST, V6, P358, DOI 10.1017/S1323358000027077; MORTON DC, 1975, ASTROPHYS J, V204, P1; Nichols JS, 1996, ASTRON J, V111, P517, DOI 10.1086/117803; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; PEI YCC, 1995, ASTROPHYS J, V454, P69, DOI 10.1086/176466; Putman ME, 1999, PUBL ASTRON SOC AUST, V16, P70, DOI 10.1071/AS99070; SAVAGE BD, 1981, ASTROPHYS J, V243, P460, DOI 10.1086/158613; SAVAGE BD, 1977, ASTROPHYS J, V216, P291, DOI 10.1086/155471; SHAPIRO PR, 1976, ASTROPHYS J, V205, P762, DOI 10.1086/154332; Spitzer L.  Jr., 1974, Astrophysical Journal. Letters to the Editor, V191, pL127, DOI 10.1086/181567; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; WAKKER BP, 1991, ASTRON ASTROPHYS, V250, P499	24	53	53	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					386	387		10.1038/46492	http://dx.doi.org/10.1038/46492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586876	Green Submitted			2022-12-24	WOS:000083913600047
J	Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ				Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ			Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; GP120 ENVELOPE GLYCOPROTEIN; CELLULAR RECEPTORS; SIALIC-ACID; SUBGROUP-C; DOMAIN; ATTACHMENT; SEROTYPES; TYPE-2	The human adenovirus serotype 5 (Ad5) is used widely for applications in human gene therapy. Cellular attachment of Ad5 is mediated by binding of the carboxyl-terminal knob of its fiber coat protein to the Coxsackie adenovirus receptor (CAR) protein. However, Ad5 binding to CAR hampers the development of adenovirus vectors capable of specifically targeting (diseased) tissues or organs, Through sequence analysis and mutagenesis, a conserved receptor-binding region was identified on the side of three divergent CAR-binding knobs. The feasibility of simultaneous CAR ablation and redirection of an adenovirus to a new receptor is demonstrated.	GenVec Inc, Gaithersburg, MD 20879 USA		Roelvink, PW (corresponding author), GenVec Inc, 65 W Watkins Mill Rd, Gaithersburg, MD 20879 USA.			Kovesdi, Imre/0000-0002-0322-3969				BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Brough DE, 1996, J VIROL, V70, P6497, DOI 10.1128/JVI.70.9.6497-6501.1996; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HORWITZ MS, 1990, VIROLOGY, V2, P1679; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Roelvink PW, 1996, J VIROL, V70, P7614, DOI 10.1128/JVI.70.11.7614-7621.1996; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROELVINK PW, UNPUB; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SCHNURR D, 1993, INTERVIROLOGY, V36, P79, DOI 10.1159/000150325; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xia D, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P39; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	25	320	337	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1568	1571		10.1126/science.286.5444.1568	http://dx.doi.org/10.1126/science.286.5444.1568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567265				2022-12-24	WOS:000083768300061
J	Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH				Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH			Light-to-moderate alcohol consumption and the risk of stroke among US male physicians.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; TISSUE PLASMINOGEN-ACTIVATOR; CARDIOVASCULAR MORTALITY; CAROTID ATHEROSCLEROSIS; JAPANESE POPULATION; CIGARETTE-SMOKING; SHAPED CURVE; BRITISH MEN; LIPOPROTEINS; HYPERTENSION	Background: Several studies have shown U- or J-shaped relations between alcohol consumption and the risk of stroke. We evaluated the effect of light-to-moderate alcohol intake on the risk of stroke, with separate analyses of ischemic stroke and hemorrhagic stroke. Methods: Our analyses were based on a prospective cohort study of 22,071 male physicians, 40 to 84 years old, who were participating in the Physicians' Health Study. At base line, the participants reported that they had no history of stroke, transient ischemic attack, or myocardial infarction and were free of cancer. Alcohol intake, reported by 21,870 participants at base line, ranged from none or almost none to two or more drinks per day. Results: During an average of 12.2 years of follow-up, 679 strokes were reported. As compared with participants who had less than one drink per week, those who drank more had a reduced overall risk of stroke (relative risk, 0.79; 95 percent confidence interval, 0.66 to 0.94) and a reduced risk of ischemic stroke (relative risk, 0.77; 95 percent confidence interval, 0.63 to 0.94). There was no statistically significant association between alcohol consumption and hemorrhagic stroke. The overall relative risks of stroke for the men who had one drink per week, two to four drinks per week, five or six drinks per week, or one or more drinks per day were 0.78 (95 percent confidence interval, 0.59 to 1.04), 0.75 (95 percent confidence interval, 0.58 to 0.96), 0.83 (95 percent confidence interval, 0.62 to 1.11), and 0.80 (95 percent confidence interval, 0.64 to 0.99), respectively, in an analysis in which we controlled for major risk factors for stroke. Conclusions: Light-to-moderate alcohol consumption reduces the overall risk of stroke and the risk of ischemic stroke in men. The benefit is apparent with as little as one drink per week. Greater consumption, up to one drink per day, does not increase the observed benefit. (N Engl J Med 1999;341:1557-64.) (C) 1999, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA; Dept Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Univ Munster, Inst Epidemiol & Social Med, Munster, Germany; Univ Munster, Dept Neurol, Munster, Germany; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; University of Munster; University of Munster; University of Miami	Ajani, UA (corresponding author), Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	uajani@rics.bwh.harvard.edu		Kase, Carlos/0000-0002-3047-5010	NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34944, CA 40360] Funding Source: Medline; NHLBI NIH HHS [HL 26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, STROKE, V20, P448, DOI 10.1161/01.STR.20.4.448; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DUARTE APT, 1995, THROMB RES, V78, P107, DOI 10.1016/0049-3848(95)00039-9; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Fields C E, 1998, Semin Vasc Surg, V11, P181; Flegal K M, 1985, Recent Dev Alcohol, V3, P165; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLUECK CJ, 1995, J LAB CLIN MED, V125, P319; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; JUVELA S, 1995, STROKE, V26, P1558, DOI 10.1161/01.STR.26.9.1558; KASTURI R, 1992, STROKE, V23, P1257, DOI 10.1161/01.STR.23.9.1257; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kiechl S, 1998, STROKE, V29, P900, DOI 10.1161/01.STR.29.5.900; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; Klag M J, 1993, Ann Epidemiol, V3, P442; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; LANDOLFI R, 1984, BLOOD, V64, P679; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; PALMER AJ, 1995, J HYPERTENS, V13, P957, DOI 10.1097/00004872-199509000-00004; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; Quyyumi Arshed A., 1998, American Journal of Medicine, V105, p32S, DOI 10.1016/S0002-9343(98)00209-5; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REED DM, 1988, STROKE, V19, P820, DOI 10.1161/01.STR.19.7.820; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD S, 1993, HLTH ISSUES RELATED, P81; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RODGERS H, 1993, STROKE, V24, P1473, DOI 10.1161/01.STR.24.10.1473; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; RUF JC, 1995, ARTERIOSCL THROM VAS, V15, P140, DOI 10.1161/01.ATV.15.1.140; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WATTS GF, 1995, QJM-MON J ASSOC PHYS, V88, P321; WILLIAMS GD, 1985, J STUD ALCOHOL, V46, P223, DOI 10.15288/jsa.1985.46.223; WOLF PA, 1988, ANN NEUROL, V24, P177	66	219	225	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1557	1564		10.1056/NEJM199911183412101	http://dx.doi.org/10.1056/NEJM199911183412101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564684				2022-12-24	WOS:000083717000001
J	Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL				Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL			Structural insights into phosphoinositide 3-kinase catalysis and signalling	NATURE			English	Article							PROTEIN-KINASE; RAS; PHOSPHORYLATION; PI-3-KINASE; DOMAIN	Phosphoinositide 3-kinases (PI3Ks) are ubiquitous lipid kinases that function both as signal transducers downstream of cell-surface receptors and in constitutive intracellular membrane and protein trafficking pathways. All PI3Ks are dual-specificity enzymes with a lipid kinase activity which phosphorylates phosphoinositides at the 3-hydroxyl, and a protein kinase activity. The products of PI3K-catalysed reactions, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), PtdIns(3,4)P-2 and PtdIns(3)P, are second messengers in a variety of signal transduction pathways, including those essential to cell proliferation, adhesion, survival, cytoskeletal rearrangement and vesicle trafficking(1.2). Here we report the 2.2 Angstrom X-ray crystallographic structure of the catalytic subunit of PI3K gamma, the class I enzyme that is activated by heterotrimeric G-protein beta gamma subunits and pas. PI3K gamma has a modular organization centred around a helical-domain spine, with C2 and catalytic domains positioned to interact with phospholipid membranes,:md a Ras-binding domain placed against the catalytic domain where if could drive allosteric activation of the enzyme.	MRC Ctr, MRC Lab Mol Biol, Cambridge CB2 2QH, England; Babraham Inst, Cambridge CB2 4AT, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Williams, RL (corresponding author), MRC Ctr, MRC Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk		Williams, Roger/0000-0001-7754-4207; Perisic, Olga/0000-0002-3842-2896; stephens, len/0000-0002-2771-3487	MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MOODIE SA, 1995, ONCOGENE, V11, P447; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	31	387	405	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					313	320		10.1038/46319	http://dx.doi.org/10.1038/46319			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580505				2022-12-24	WOS:000083813700055
J	Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW				Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW			Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHIARI-II MALFORMATION; SPINAL-CORD INJURY; IN-UTERO; DEFORMITY; CHILDREN; BIFIDA; LEVEL	Context Hindbrain herniation occurs in a large percentage of children with myelomeningocele and is the leading cause of death in this population. The effect of early fetal closure of myelomeningocele on hindbrain herniation is unknown. Objective To determine whether early fetal closure of myelomeningocele affects hindbrain herniation, Design Case series of patients undergoing fetal myelomeningocele closure with serial measurements of hindbrain herniation and a mean follow-up of 182 days, Setting Tertiary care medical center. Participants Ten patients undergoing fetal myelomeningocele closure at 22 to 25 weeks' gestation between March 1998 and February 1999. Main Outcome Measures Need for shunt placement; degree of hindbrain herniation (grades 0-3) found on magnetic resonance imaging (MRI) performed prior to surgery and 3 and 6 weeks after fetal surgery, as well as shortly after birth; gestational age at delivery. Results All initial fetal MRI scans performed at 19 to 24 weeks' gestation showed significant (grade 3) cerebellar herniation and absence of spinal fluid spaces around the cerebellum Six fetuses were delivered electively at 36 weeks' gestation after lung maturity was established. The other 4 were delivered prematurely, at 25, 30, 30, and 31 weeks of gestation, and the 25-week gestation neonate died. All 9 surviving neonates showed improvement in the hindbrain hernia at the 3-week postoperative fetal scan (grade 2, n = 4; grade 1, n = 5). On the postnatal scan, all patients showed grade 1 hindbrain herniation. Only 1 patient required placement of a ventriculoperitoneal shunt. Conclusion In this series of patients, fetal myelomeningocele closure resulted in improvement in hindbrain herniation as demonstrated by serial MRI scans.	Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pediat Gen & Thorac Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Neuroradiol Sect, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Sutton, LN (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Crombleholme, Timothy/Y-1477-2019					Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; Bannister CM, 1998, EUR J PEDIATR SURG, V8, P15, DOI 10.1055/s-2008-1071245; BELL WO, 1987, J NEUROSURG, V66, P812, DOI 10.3171/jns.1987.66.6.0812; BONO R, 1993, ITAL J NEUROL SCI, V14, P553, DOI 10.1007/BF02339214; Bruner JP, 1999, AM J OBSTET GYNECOL, V180, P153, DOI 10.1016/S0002-9378(99)70167-5; Coniglio SJ, 1996, DEV MED CHILD NEUROL, V38, P675; Dias M S, 1993, Neurosurg Clin N Am, V4, P715; Dias MS, 1999, PEDIATR NEUROSURG, V30, P108, DOI 10.1159/000028773; ELGAMMAL T, 1988, AM J ROENTGENOL, V150, P163, DOI 10.2214/ajr.150.1.163; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HOFFMAN HJ, 1987, NEUROSURGERY, V21, P347, DOI 10.1227/00006123-198709000-00012; Hutchins GM, 1996, PEDIATR PATHOL LAB M, V16, P701, DOI 10.1080/107710496175327; KOLLIAS SS, 1992, RADIOLOGY, V185, P109, DOI 10.1148/radiology.185.1.1523291; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; McLone DG, 1998, NEUROSURG CLIN N AM, V9, P111; MCLONE DG, 1992, AM J NEURORADIOL, V13, P463; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; OHARA IB, 1999, ATLAS ANESTHESIA; OSAKA K, 1978, J NEUROSURG, V49, P711, DOI 10.3171/jns.1978.49.5.0711; PATTEN BM, 1953, AM J ANAT, V93, P365, DOI 10.1002/aja.1000930304; Quinn TM, 1997, OBSTET GYN CLIN N AM, V24, P143, DOI 10.1016/S0889-8545(05)70294-1; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WOLPERT SM, 1988, AM J NEURORADIOL, V9, P1075; XU XM, 1991, J COMP NEUROL, V313, P103, DOI 10.1002/cne.903130108	27	298	305	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1826	1831		10.1001/jama.282.19.1826	http://dx.doi.org/10.1001/jama.282.19.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573273	Bronze			2022-12-24	WOS:000083615700025
J	Novack, DH				Novack, DH			Roxanne	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Med Coll Penn & Hahnemann Univ, Div Med Educ, Philadelphia, PA 19129 USA	Drexel University	Novack, DH (corresponding author), Med Coll Penn & Hahnemann Univ, Div Med Educ, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Dennis.Novack@drexel.edu							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					784	785		10.7326/0003-4819-131-10-199911160-00012	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577304				2022-12-24	WOS:000083680100011
J	Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS				Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS			Physician counseling about exercise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; LIFE-STYLE; US ADULTS; HEALTH; MORTALITY; DISEASE; SMOKING; RECOMMENDATIONS; INTERVENTION; ASSOCIATION	Context The increase in sedentary lifestyle may contribute to the rise in obesity nationally. Although guidelines suggest that physicians counsel all patients about exercise, physicians counsel only a minority of their patients. Whether patient factors influence physician counseling is not well established. Objectives To examine and to identify factors associated with exercise counseling by US physicians. Design and Setting National population-based supplemental (Year 2000) survey to the 1995 National Health Interview Survey. Participants Of the 17 317 respondents to the Year 2000 supplemental survey, 9711 adults had seen a physician in the previous year, and 9299 responded when asked about physician counseling on exercise. Main Outcome Measure Physician counseling to begin or to continue to exercise. Results Of 9299 respondents, 34% reported being counseled about exercise at their last visit. After adjustment for other sociodemographic and clinical factors, women were slightly more likely to be counseled, with an adjusted odds ratio (AOR) of 1.15 (95% confidence interval [CI], 1.02-1.29). Physicians counseled older patients (>30 years) more often than younger patients; those aged 40 to 49 years were counseled most often (AOR, 1.71 [95% CI, 1.34-2.20]). Patients with incomes above $50 000, those with higher levels of physical activity, college graduates, and patients who were overweight to obese (body mass index: 25 to greater than or equal to 30 kg/m(2)) were more likely to be counseled, as were patients with cardiac disease (AOR, 1.81 [95% CI, 1.52-2.14]) and diabetes (AOR, 1.87 [95% CI, 1.46-2.38]), Counseling did not vary by physician specialty or patient race. Conclusion The rate of physician counseling about exercise is low nationally. Physicians appear to counsel as secondary prevention and are less likely to counsel patients at risk for obesity. The failure to counsel younger, disease-free adults and those from lower socioeconomic groups may represent important missed opportunities for primary prevention.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wee, CC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.				BHP HRSA HHS [5T32PE11001] Funding Source: Medline	BHP HRSA HHS		BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bull FC, 1998, AM J PREV MED, V15, P85, DOI 10.1016/S0749-3797(98)00040-3; BURTON LC, 1995, PREV MED, V24, P492, DOI 10.1006/pmed.1995.1078; COULTER A, 1995, BRIT MED J, V310, P1099; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Eaton CB, 1998, BRIT J SPORT MED, V32, P11, DOI 10.1136/bjsm.32.1.11; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KOCH GG, 1975, INT STAT REV, V43, P59, DOI 10.2307/1402660; Kreuter MW, 1997, PREV MED, V26, P825, DOI 10.1006/pmed.1997.0216; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; *NAT CTR HLTH STAT, 1997, CD ROM SER, V10; OCKENE JK, 1994, J GEN INTERN MED, V9, P379, DOI 10.1007/BF02629517; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; REED BD, 1991, AM J PREV MED, V7, P410, DOI 10.1016/S0749-3797(18)30880-8; *RES TRIANGL I, 1992, SUDAAN US MAN REL 5; Rosenberg IH, 1998, ANN INTERN MED, V129, P133, DOI 10.7326/0003-4819-129-2-199807150-00015; Swinburn BA, 1998, AM J PUBLIC HEALTH, V88, P288, DOI 10.2105/AJPH.88.2.288; Taira DA, 1997, JAMA-J AM MED ASSOC, V278, P1412, DOI 10.1001/jama.278.17.1412; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1993, INT J OBESITY, V17, P279; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; 1998, MMWR MORB MORTAL WKL, V47, P91	32	239	239	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1583	1588		10.1001/jama.282.16.1583	http://dx.doi.org/10.1001/jama.282.16.1583			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546701	Bronze			2022-12-24	WOS:000083277800029
J	Coulehan, J				Coulehan, J			An alternative view: listening to patients	LANCET			English	Article									SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Coulehan, J (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, L3-086, Stony Brook, NY 11794 USA.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1467	1468		10.1016/S0140-6736(05)77604-2	http://dx.doi.org/10.1016/S0140-6736(05)77604-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543688				2022-12-24	WOS:000083277400042
J	Fulton, S; Woodside, B; Shizgal, P				Fulton, S; Woodside, B; Shizgal, P			Modulation of brain reward circuitry by leptin	SCIENCE			English	Article							MELANIN-CONCENTRATING HORMONE; HYPOTHALAMIC SELF-STIMULATION; RECEPTOR MESSENGER-RNA; FOOD-RESTRICTED RATS; OBESE GENE; LATERAL HYPOTHALAMUS; FEEDING-BEHAVIOR; NEUROPEPTIDE-Y; BODY-WEIGHT; PROTEIN	Leptin, a hormone secreted by fat cells, suppresses food intake and promotes weight Loss, To assess the action of this hormone on brain reward circuitry, changes in the rewarding effect of Lateral hypothalamic stimulation were measured after leptin administration. At five stimulation sites near the fornix, the effectiveness of the rewarding electrical stimulation was enhanced by chronic food restriction and attenuated by intracerebroventricular infusion of leptin. In contrast, the rewarding effect of stimulating neighboring sites was insensitive to chronic food restriction and was enhanced by leptin in three of four cases. These opposing effects of Leptin may mirror complementary changes in the rewarding effects of feeding and of competing behaviors.	Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Shizgal, P (corresponding author), Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.	shizgal@CSBN.concordia.ca	Shizgal, Peter/V-5602-2019; Shizgal, Peter/H-9823-2013	Shizgal, Peter/0000-0003-4265-0792; 				ABRAHAMSEN GC, 1995, BRAIN RES, V695, P186, DOI 10.1016/0006-8993(95)00764-H; Arvanitogiannis A, 1999, PHYSIOL BEHAV, V65, P805; Arvanitogiannis A, 1996, PHYSIOL BEHAV, V59, P795, DOI 10.1016/0031-9384(95)02157-4; BLUNDELL JE, 1968, NATURE, V219, P627, DOI 10.1038/219627a0; Broberger C, 1998, J COMP NEUROL, V402, P460; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CARR KD, 1993, BRAIN RES, V607, P141, DOI 10.1016/0006-8993(93)91499-I; CONOVER KL, 1994, BEHAV NEUROSCI, V108, P559; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; De Vaca SC, 1998, PHYSIOL BEHAV, V64, P251, DOI 10.1016/S0031-9384(98)00050-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Elmquist JK, 1998, J COMP NEUROL, V395, P535; FULTON S, UNPUB; GALLISTEL CR, 1987, PHARMACOL BIOCHEM BE, V26, P731, DOI 10.1016/0091-3057(87)90605-8; Gillard ER, 1998, J NEUROSCI, V18, P2646; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Horvath TL, 1999, J NEUROSCI, V19, P1072; LEIBOWITZ SF, 1979, BRAIN RES, V172, P115, DOI 10.1016/0006-8993(79)90899-0; LEIBOWITZ SF, 1975, BRAIN RES, V98, P529, DOI 10.1016/0006-8993(75)90371-6; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; OLDS ME, 1963, J COMP NEUROL, V120, P259, DOI 10.1002/cne.901200206; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; STANLEY BG, 1993, BRAIN RES, V604, P304; Watts AG, 1999, J NEUROSCI, V19, P6111, DOI 10.1523/JNEUROSCI.19-14-06111.1999; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	33	316	317	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					125	128		10.1126/science.287.5450.125	http://dx.doi.org/10.1126/science.287.5450.125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615045				2022-12-24	WOS:000084578400050
J	Marian, AJ				Marian, AJ			Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy	LANCET			English	Article							EXPRESSION; MUTATIONS; DEATH	Myocardial contractility is generally believed to be increased in hypertrophic cardiomyopathy. I propose the opposite-that cardiac myocyte contractility Is decreased in this disorder. Accordingly, the contractile deficit provides the primary stimulus for increased expression of trophic factors in the heart, which leads to hypertrophy, interstitial fibrosis, and other phenotypes. Variation among individuals in expression of trophic factors would account for the variability of phenotypes. Gene transfer studies in cardiac myocytes showing impaired contractility and increased expression of trophic factors in the myocardium of patients with hypertrophic cardiomyopathy support this hypothesis. Testing of the hypothesis would require measurement of contractility of cardiac myocytes isolated from patients with hypertrophic cardiomyopathy, identification of the main trophic factors in the hearts of these patients, and investigation of whether their inhibition can prevent or lead to regression of the cardiac phenotypes.	Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA	Baylor College of Medicine	Marian, AJ (corresponding author), Baylor Coll Med, Dept Med, Cardiol Sect, 1 Baylor Plaza,543E, Houston, TX 77030 USA.			Marian, AJ/0000-0002-1252-7120	NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abchee A, 1997, J INVEST MED, V45, P191; Brugada R, 1997, J INVEST MED, V45, P542; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; Hasegawa K, 1996, HYPERTENSION, V27, P259, DOI 10.1161/01.HYP.27.2.259; HIROTA Y, 1982, AM J CARDIOL, V50, P990, DOI 10.1016/0002-9149(82)90407-6; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; Li RK, 1997, CIRCULATION, V96, P874; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; MARIAN AJ, 1993, LANCET, V342, P1073; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; Tesson F, 1997, J MOL CELL CARDIOL, V29, P831, DOI 10.1006/jmcc.1996.0332; WYNNE J, 1992, HEART DISEASE TXB CA, P1394	15	168	197	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					58	60		10.1016/S0140-6736(99)06187-5	http://dx.doi.org/10.1016/S0140-6736(99)06187-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615904				2022-12-24	WOS:000085049200041
J	Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM				Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM			Effect of socioeconomic deprivation on waiting time for cardiac surgery: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article						a	REVASCULARIZATION RATES; CORONARY; ACCESS	Objective To determine whether the priority given to patients referred for cardiac surgery is associated with socioeconomic status. Design Retrospective study with multivariate logistic regression analysis of the association between deprivation and classification of urgency with allowance for age, sex, and type of operation. Multivariate linear regression analysis was used to determine association between deprivation and waiting time within each category of urgency, with allowance for age, sex, and type of operation. Setting NHS waiting lists in Scotland. Participants 26 642 patients waiting for cardiac surgery, 1 January 1986 to 31 December 1997. Main outcome measures Deprivation as measured by Carstairs deprivation category. Time spent on NHS waiting list. Results Patients who were most deprived tended to be younger and were more likely to be female. Patients in deprivation categories 6 and 7 (most deprived) waited about three weeks longer for surgery than those in category 1 (mean difference 24 days, 95% confidence interval 15 to 32), Deprived patients had an odds ratio of 0.5 (0.46 to 0.61) for having their operations classified as urgent compared with the least deprived, after allowance for age, sex, and type of operation. When urgent and routine cases were considered separately, there was no significant difference in waiting times between the most and least deprived categories. Conclusions Socioeconomically deprived patients are thought to be more likely to develop coronary heart disease but are less likely to be investigated and offered surgery once it has developed. Such patients may be further disadvantaged by having to wait longer for surgery because of being given lower priority.	Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland; Monklands Hosp, Dept Cardiol, Airdrie ML6 0JS, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	Royal Infirmary of Edinburgh; Monklands Hospital; University of Glasgow	Pell, JP (corresponding author), Greater Glasgow Hlth Board, Dalian House,350 St Vincents St, Glasgow G3 8YU, Lanark, Scotland.		Ford, Ian/ABE-6145-2020	Pell, Jill/0000-0002-8898-7035				BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; Carstairs V., 1991, DEPRIVATION HLTH SCO; DREVER F, 1996, POPUL TRENDS, V86, P15; DREVER F, 1997, HLTH INEQUALITIES; FINDLAY IN, 1990, BRIT HEART J, V64, P43; FINDLAY IN, 1991, BRIT HEART J, V66, pA70; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; KAGUSKAR S, 1997, CORONARY HEART DIS S; Keskimaki I, 1997, EUR J PUBLIC HEALTH, V7, P392, DOI 10.1093/eurpub/7.4.392; MacLeod MCM, 1999, HEART, V81, P252, DOI 10.1136/hrt.81.3.252; Manson-Siddle CJ, 1998, J EPIDEMIOL COMMUN H, V52, P507, DOI 10.1136/jech.52.8.507; *OFF POP CENS SURV, 1995, 1991 CENS; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3	14	84	84	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					15	18		10.1136/bmj.320.7226.15	http://dx.doi.org/10.1136/bmj.320.7226.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617517	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-24	WOS:000084621600014
J	Watkins, SJ				Watkins, SJ			Conviction by mathematical error? Doctors and lawyers should get probability theory right	BRITISH MEDICAL JOURNAL			English	Editorial Material							INFANT-DEATH-SYNDROME; SUBSEQUENT SIBLINGS; RECURRENCE RISK; SUDDEN		Stockport Hlth Author, Stockport SK7 5BY, England		Watkins, SJ (corresponding author), Stockport Hlth Author, Stockport SK7 5BY, England.							BEAL SM, 1988, ARCH DIS CHILD, V63, P924, DOI 10.1136/adc.63.8.924; EMERY JL, 1986, LANCET, V1, P313; GUNTHEROTH WG, 1990, J PEDIATR-US, V116, P520, DOI 10.1016/S0022-3476(05)81596-3; IRGENS LM, 1984, J PEDIATR-US, V104, P349, DOI 10.1016/S0022-3476(84)81093-8; McKenzie G, 1984, BR J SOC PREV MED, V25, P119; Oyen N, 1996, AM J EPIDEMIOL, V144, P300, DOI 10.1093/oxfordjournals.aje.a008925; PETERSON DR, 1986, J PEDIATR-US, V108, P911, DOI 10.1016/S0022-3476(86)80926-X; REESE A, 1999, STAT JUSTICE; WOLKIND S, 1993, ACTA PAEDIATR, V82, P873, DOI 10.1111/j.1651-2227.1993.tb12583.x	9	30	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					2	3		10.1136/bmj.320.7226.2	http://dx.doi.org/10.1136/bmj.320.7226.2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617504	Green Published			2022-12-24	WOS:000084621600002
J	Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE				Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE			Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa	LANCET			English	Article							FAILURE	Background Recurrent epidemics of meningococcal disease have been reported throughout the African meningitis belt since description of the disease in 1912, Meningococcal polysaccharide vaccines can effectively prevent disease but the optimum strategy for their use in this setting has been controversial. We used data from an outbreak of meningococcal disease in northern Ghana in 1997 to assess the potential effect of different vaccination strategies. Methods We identified all reported cases of meningococcal meningitis and estimated the number of cases and deaths that could have been prevented by vaccination through use of a simple mathematical model. We then assessed the potential effect of different vaccination strategies and the burden of these strategies on the public-health system. Findings In the three affected regions in northern Ghana there were 18 703 cases and 1356 deaths reported between November, 1996, and May, 1997. Vaccination began in the third week of February and continued to April, reaching 72% of the at-risk population and preventing an estimated 23% of cases and 18% of deaths. A strategy of routine childhood and adult immunisation would have prevented 61% of cases had this same rate of vaccine coverage been achieved and maintained before the epidemic. If vaccination had started after the onset of the epidemic in January, as currently advocated by WHO guidelines, a similar proportion (61%) of cases could have been prevented. Interpretation Prevention of epidemics of meningococal disease in west Africa will be difficult until long-lasting conjugate vaccines capable of interrupting transmission of Neisseria meningitidis can be incorporated into routine infant-immunisation schedules, Until then, the strategy of surveillance and response advocated by WHO is as effective and more practical than a strategy of routine childhood and adult vaccination with currently available polysaccharide vaccines.	Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Surveillance, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ghana Minist Hlth, Accra, Ghana	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Rosenstein, NE (corresponding author), Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS-C23, Atlanta, GA 30333 USA.		Sackey, Samuel Oko/I-9207-2019					ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297; CAMPAGNE G, 1997, INT C ANT AG CHEM SA; *COMM DIS CTR, 1999, MMWR-MORBID MORTAL W, V48, P513; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Kaninda AV, 1997, LANCET, V350, P1708, DOI 10.1016/S0140-6736(05)64315-2; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; Lapeyssonnie L., 1963, B WHO              S, V28, P3; LEAKE JAD, 1998, INT C EM INF DIS ATL; MOORE PS, 1992, INT J EPIDEMIOL, V21, P155, DOI 10.1093/ije/21.1.155; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; REIDO FX, 1995, PEDIATR INFECT DIS J, V14, P643; REINGOLD AL, 1985, LANCET, V2, P114; Robbins JB, 1997, LANCET, V350, P880, DOI 10.1016/S0140-6736(97)03227-3; SMITH AW, 1988, T ROY SOC TROP MED H, V82, P312, DOI 10.1016/0035-9203(88)90459-2; SPIEGEL A, 1993, B WORLD HEALTH ORGAN, V71, P311; TWUMASI PA, 1995, J INFECT DIS, V171, P632, DOI 10.1093/infdis/171.3.632; VARAINE F, 1997, T R SOC TROP MED HYG, V51, P3; Veeken H, 1998, B WORLD HEALTH ORGAN, V76, P135; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; Wenger J, 1997, LANCET, V350, P1709, DOI 10.1016/S0140-6736(05)64316-4; *WHO, 1995, CONTR MEN DIS WHO PR; WILKINS J, 1979, PEDIATRICS, V94, P828; World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P313	26	58	59	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					30	33		10.1016/S0140-6736(99)03366-8	http://dx.doi.org/10.1016/S0140-6736(99)03366-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615888				2022-12-24	WOS:000085049200013
J	Cheetham, GMT; Steitz, TA				Cheetham, GMT; Steitz, TA			Structure of a transcribing T7 RNA polymerase initiation complex	SCIENCE			English	Article							DNA-POLYMERASE; T7-RNA POLYMERASE; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; BINDING-SITES; PROMOTER; BACTERIOPHAGE-T7; REPLICATION; MITOCHONDRIAL	The structure of a T7 RNA polymerase (T7 RNAP) initiation complex captured transcribing a trinucleotide of RNA from a 17-base pair promoter DNA containing a 5-nucleotide single-strand template extension was determined at a resolution of 2.4 angstroms, Binding of the upstream duplex portion of the promoter occurs in the same manner as that in the open promoter complex. but the single-stranded template is repositioned to place the +4 base at the catalytic active site. Thus, synthesis of RNA in the initiation phase Leads to accumulation or "scrunching" of the template in the enclosed active site pocket of T7 RNAP, Only three base pairs of heteroduplex are formed before the RNA peels off the template.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lykke-Andersen J, 1998, NUCLEIC ACIDS RES, V26, P5630, DOI 10.1093/nar/26.24.5630; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; RECHINSKY VO, 1992, FEBS LETT, V306, P129, DOI 10.1016/0014-5793(92)80983-N; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2	37	277	290	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2305	2309		10.1126/science.286.5448.2305	http://dx.doi.org/10.1126/science.286.5448.2305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600732				2022-12-24	WOS:000084318500049
J	Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ				Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ			Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGENIC DETERMINANTS; MAXIMUM-LIKELIHOOD; E-GLYCOPROTEIN; DNA-SEQUENCES; IDENTIFICATION; EVOLUTION; TREES; KUNJIN; GENE	In Late summer 1999, an outbreak of human encephalitis occurred in the northeastern United States that was concurrent with extensive mortality in crows (Corvus species) as well as the deaths of several exotic birds at a zoological park in the same area. Complete genome sequencing of a flavivirus isolated from the brain of a dead Chilean flamingo (Phoenicopterus chilensis), together with partial sequence analysis of envelope glycoprotein (E-glycoprotein) genes amplified from several other species including mosquitoes and two fatal human cases, revealed that West Nile (WN) virus circulated in natural transmission cycles and was responsible for the human disease. Antigenic mapping with E-glycoprotein-specific monoclonal antibodies and E-glycoprotein phylogenetic analysis confirmed these viruses as WN. This North American WN virus was most closely related to a WN virus isolated from a dead goose in Israel in 1998.	Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA; Inst Pasteur, Unite Arbovirus & Virus Fievres Hemorragiques, F-75724 Paris 15, France; USA, Med Res Inst Infect Dis, Div Virol & Pathol, Frederick, MD 21701 USA; USA, Med Res Inst Infect Dis, Div Virol, Frederick, MD 21701 USA; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; USDA, Natl Vet Serv Labs, Anim & Plant Hlth Inspect Serv, Ames, IA 50010 USA; Minist Agr & Rural Dev, Kimron Vet Inst, Div Avian Dis, IL-50250 Bet Dagan, Israel; New York State Dept Environm Conservat, Div Fish Wildlife & Marine Resources, Wildlife Pathol Unit, Delmar, NY 12054 USA; Wildlife Conservat Soc, Bronx, NY 10460 USA	Centers for Disease Control & Prevention - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Queensland; United States Department of Agriculture (USDA); Kimron Veterinary Institute; Wildlife Conservation Society	Lanciotti, RS (corresponding author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA.		Smith, Jane/B-6254-2009; /S-4986-2019	/0000-0002-5918-2190; Roehrig, John/0000-0001-7581-0479				ADAMS SC, 1995, VIROLOGY, V206, P49, DOI 10.1016/S0042-6822(95)80018-2; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548; GOULD EA, 1990, ARCH VIROL, V1, P137; HALL RA, 1991, IMMUNOL CELL BIOL, V69, P47, DOI 10.1038/icb.1991.7; HAWKES RA, 1988, J GEN VIROL, V69, P1105, DOI 10.1099/0022-1317-69-5-1105; HENCHAL EA, 1985, AM J TROP MED HYG, V34, P162, DOI 10.4269/ajtmh.1985.34.162; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1983, VIROLOGY, V128, P118, DOI 10.1016/0042-6822(83)90323-9; ROEHRIG JT, 1990, AM J TROP MED HYG, V42, P394, DOI 10.4269/ajtmh.1990.42.394; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; RZHETSKY A, 1993, MOL BIOL EVOL, V10, P1073; SAVAGE HM, IN PRESS AM J TROP M; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872	21	1164	1243	1	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2333	2337		10.1126/science.286.5448.2333	http://dx.doi.org/10.1126/science.286.5448.2333			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600742				2022-12-24	WOS:000084318500059
J	Lee, SH; Hava, DL; Waldor, MK; Camilli, A				Lee, SH; Hava, DL; Waldor, MK; Camilli, A			Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TOXIN-COREGULATED PILUS; SUICIDE VECTOR; EL-TOR; REGULON; CONSTRUCTION; COLONIZATION; ACTIVATION; IDENTIFY; PROMOTER	The temporal expression patterns of the critical Vibrio cholerae virulence genes, tcpA and ctxA, were determined during infection using a recombinase reporter. TcpA was induced biphasically in two temporally and spatially separable events in the small intestine, whereas ctxA was induced monophasically only after, and remarkably, dependent upon, tcpA expression; however, this dependence was not observed during in vitro growth. The requirements of the virulence regulators, ToxR, TcpP, and ToxT, for expression of tcpA and ctxA were determined and were found to differ significantly during infection versus during growth in vitro. These results illustrate the importance of examining virulence gene expression in the context of bona fide host-pathogen interactions.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA	Tufts University; Tufts University	Camilli, A (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.				NIAID NIH HHS [AI 42347, AI 07422, AI 40262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040262, R01AI042347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angelichio MJ, 1999, INFECT IMMUN, V67, P3733, DOI 10.1128/IAI.67.8.3733-3739.1999; Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CAMILLI A, 1994, P NATL ACAD SCI USA, V91, P2634, DOI 10.1073/pnas.91.7.2634; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; Chakrabarti S, 1999, INFECT IMMUN, V67, P1025, DOI 10.1128/IAI.67.3.1025-1033.1999; Champion GA, 1997, MOL MICROBIOL, V23, P323, DOI 10.1046/j.1365-2958.1997.2191585.x; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Davis BM, 1999, J BACTERIOL, V181, P6779, DOI 10.1128/JB.181.21.6779-6787.1999; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; HIGGINS DE, 1994, MOL MICROBIOL, V14, P17, DOI 10.1111/j.1365-2958.1994.tb01263.x; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; IWANAGA M, 1986, MICROBIOL IMMUNOL, V30, P1075, DOI 10.1111/j.1348-0421.1986.tb03037.x; Klose KE, 1998, J BACTERIOL, V180, P303, DOI 10.1128/JB.180.2.303-316.1998; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Medrano AI, 1999, INFECT IMMUN, V67, P2178, DOI 10.1128/IAI.67.5.2178-2183.1999; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schuhmacher DA, 1999, J BACTERIOL, V181, P1508, DOI 10.1128/JB.181.5.1508-1514.1999; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SUN D, 1991, INFECT IMMUN, V59, P114, DOI 10.1128/IAI.59.1.114-118.1991; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	30	220	232	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					625	634		10.1016/S0092-8674(00)81551-2	http://dx.doi.org/10.1016/S0092-8674(00)81551-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612398	Bronze			2022-12-24	WOS:000084278700009
J	Beck, T; Hall, MN				Beck, T; Hall, MN			The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; KINASE; RAPAMYCIN; PROTEINS; MODULES; STRESS; GROWTH; MSN2P	The rapamycin-sensitive TOR signalling pathway in Saccharomyces cerevisiae activates a cell-growth program in response to nutrients such as nitrogen and carbon(1-4). The TOR1 and TOR2 kinases (TOR) control cytoplasmic protein synthesis and degradation through the conserved TAP42 protein(5-8). Upon phosphorylation by TOR, TAP42 binds and possibly inhibits type 2A and type-2A-related phosphatases(6-8); however, the mechanism by which TOR controls nuclear events such as global repression of starvation-specific transcription is unknown. Here we show that TOR prevents transcription of genes expressed upon nitrogen limitation by promoting the association of the GATA transcription factor GLN3 with the cytoplasmic protein URE2. The binding of GLN3 to URE2 requires TOR-dependent phosphorylation of GLN3, Phosphorylation and cytoplasmic retention of GLN3 are also dependent on the TOR effector TAP42, and are antagonized by the type-2A-related phosphatase SIT4. TOR inhibits expression of carbon-source-regulated genes by stimulating the binding of the transcriptional activators MSN2 and MSN4 to the cytoplasmic 14-3-3 protein BMH2, Thus, the TOR signalling pathway broadly controls nutrient metabolism by sequestering several transcription factors in the cytoplasm.	Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland.			Hall, Michael N/0000-0002-2998-0757				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Hara K, 1998, J BIOL CHEM, V273, P22160; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHERMAN F, 1991, P3; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	26	771	789	3	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					689	692		10.1038/45287	http://dx.doi.org/10.1038/45287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604478				2022-12-24	WOS:000084189800072
J	Henney, JE				Henney, JE			Review of generic bioequivalence studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-24	WOS:000083908700005
J	Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV				Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV			Visualization of dioxygen bound to copper during enzyme catalysis	SCIENCE			English	Article							SERUM AMINE OXIDASE; CRYSTAL-STRUCTURE; BENZYLAMINE OXIDASE; ESCHERICHIA-COLI; HALF-REACTION; PIG PLASMA; MECHANISM; TOPAQUINONE; RESOLUTION; CRYSTALLOGRAPHY	X-ray crystal structures of three species related to the oxidative half of the reaction of the copper-containing quinoprotein amine oxidase from Escherichia coli have been determined. Crystals were freeze-trapped either anaerobically or aerobically after exposure to substrate, and structures were determined to resolutions between 2.1 and 2.4 angstroms. The oxidation state of the quinone cofactor was investigated by single-crystal spectrophotometry. The structures reveal the site of bound dioxygen and the proton transfer pathways involved in oxygen reduction. The quinone cofactor is regenerated from the iminoquinone intermediate by hydrolysis involving Asp(383), the catalytic base in the reductive half-reaction. Product aldehyde inhibits the hydrolysis, making release of product the rate-determining step of the reaction in the crystal.	Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden	University of Leeds; Uppsala University	Wilmot, CM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			McPherson, Michael/0000-0002-0719-6427				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1997, SPOCK; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES P, UNPUB, P66115; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; Murray JM, 1999, BIOCHEMISTRY-US, V38, P8217, DOI 10.1021/bi9900469; NYLEN U, 1974, ACTA CHEM SCAND B, VB 28, P1153, DOI 10.3891/acta.chem.scand.28b-1153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PREUT H, 1987, ACTA CRYSTALLOGR C, V43, P374, DOI 10.1107/S0108270187095726; RINALDI A, 1984, BIOCHEM BIOPH RES CO, V120, P242, DOI 10.1016/0006-291X(84)91440-2; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TANIZAWA K, 1995, J BIOCHEM, V118, P671, DOI 10.1093/oxfordjournals.jbchem.a124962; TAYLOR CE, 1972, BIOCHEM J, V130, P713, DOI 10.1042/bj1300713; TSOUCARIS G, 1961, ACTA CRYSTALLOGR, V14, P909, DOI 10.1107/S0365110X61002679; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Wilmot CM, 1997, BIOCHEMISTRY-US, V36, P1608, DOI 10.1021/bi962205j; YADAV KDS, 1981, EUR J BIOCHEM, V114, P139	34	136	137	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1724	1728		10.1126/science.286.5445.1724	http://dx.doi.org/10.1126/science.286.5445.1724			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576737				2022-12-24	WOS:000083912200035
J	Hildebrand, JD; Soriano, P				Hildebrand, JD; Soriano, P			Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice	CELL			English	Article							ABNORMAL BRAIN-DEVELOPMENT; EMBRYONIC STEM-CELLS; E-CADHERIN; ALPHA-CATENIN; XENOPUS-LAEVIS; F-ACTIN; GENE; DEFECTS; NEURULATION; ADHESION	Using gene trap mutagenesis, we have identified a mutation in mice that causes exencephaly, acrania, facial clefting, and spina bifida, all of which can be attributed to failed neural tube closure. This mutation is designated shroom (shrm) because the neural folds "mushroom" outward and do not converge at the dorsal midline. shrm encodes a PDZ domain protein that is involved at several levels in regulating aspects of cytoarchitecture. First, endogenous Shrm localizes to adherens junctions and the cytoskeleton. Second, ectopically expressed Shrm alters the subcellular distribution of F-actin. Third, Shrm directly binds F-actin. Finally, cytoskeletal polarity within the neuroepithelium is perturbed in mutant embryos. In concert, these observations suggest that Shrm is a critical determinant of the cellular architecture required for proper neurulation.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1100 Fairview Ave N, Seattle, WA 98109 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Bubeck P, 1997, J CELL SCI, V110, P1361; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen JM, 1996, P NATL ACAD SCI USA, V93, P6275, DOI 10.1073/pnas.93.13.6275; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOLDEN JA, 1995, PEDIATRICS, V95, P506; Grapin-Botton A, 1998, DEVELOPMENT, V125, P1173; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hogan B, 1994, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARFUNKEL P, 1971, DEV BIOL, V25, P30, DOI 10.1016/0012-1606(71)90018-2; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; OYAMA T, 1994, CANCER RES, V54, P6282; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SAKAI Y, 1989, ANAT RECORD, V223, P194, DOI 10.1002/ar.1092230212; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; Smith JL, 1997, TRENDS NEUROSCI, V20, P510, DOI 10.1016/S0166-2236(97)01121-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; STANISSTREET M, 1990, POSTIMPLANTATION MAM; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ybot-Gonzalez P, 1999, DEV DYNAM, V215, P273, DOI 10.1002/(SICI)1097-0177(199907)215:3<273::AID-AJA9>3.0.CO;2-H; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	54	264	270	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					485	497		10.1016/S0092-8674(00)81537-8	http://dx.doi.org/10.1016/S0092-8674(00)81537-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589677	Bronze			2022-12-24	WOS:000083986300008
J	Xiao, T; Towb, P; Wasserman, SA; Sprang, SR				Xiao, T; Towb, P; Wasserman, SA; Sprang, SR			Three-dimensional structure of a complex between the death domains of Pelle and Tube	CELL			English	Article							DROSOPHILA EMBRYO; DORSOVENTRAL POLARITY; NMR STRUCTURE; MACROMOLECULAR STRUCTURES; TNF RECEPTOR; PROTEIN; DORSAL; MUTAGENESIS; KINASE; TRANSDUCTION	The interaction of the serine/threonine kinase Pelle and adaptor protein Tube through their N-terminal death domains leads to the nuclear translocation of the transcription factor Dorsal and activation of zygotic patterning genes during Drosophila embryogenesis. Crystal structure of the Pelle and Tube death domain heterodimer reveals that the two death domains adopt a six-helix bundle fold and are arranged in an open-ended linear array with plastic interfaces mediating their interactions. The Tube death domain has an insertion between helices 2 and 3, and a C-terminal tail making significant and indispensable contacts in the heterodimer. In vivo assays of Pelle and Tube mutants confirmed that the integrity of the major heterodimer interface is critical to the activity of these molecules.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.	sprang@chop.swmed.edu	Xiao, Tsan Sam/A-8590-2010; Xiao, Tsan/I-7616-2013	Xiao, Tsan Sam/0000-0001-9688-475X; Xiao, Tsan/0000-0001-9688-475X	NIDDK NIH HHS [R01 DK046371] Funding Source: Medline; NIGMS NIH HHS [R01 GM050545, GM50545] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050545] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; HECHT PM, 1993, GENETICS, V135, P405; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1993, O VERSION 5 9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Sambrook JFE, 1989, MOL CLONING LAB MANU; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Towb P, 1998, DEVELOPMENT, V125, P2443; Wieschaus E., 1986, P199; YANG W, 1990, J BIOL CHEM, V265, P13553	48	150	153	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					545	555		10.1016/S0092-8674(00)81542-1	http://dx.doi.org/10.1016/S0092-8674(00)81542-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589682	Green Accepted, Bronze			2022-12-24	WOS:000083986300013
J	Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW				Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW			Transmission of chronic nociception by spinal neurons expressing the substance P receptor	SCIENCE			English	Article							NEUROKININ-1 RECEPTORS; TRACT NEURONS; DORSAL HORN; RAT; PAIN; CORD; INFLAMMATION; HYPERALGESIA; MODEL	Substance P receptor (SPR)-expressing spinal neurons were ablated with the selective cytotoxin substance P-saporin. Loss of these neurons resulted in a reduction of thermal hyperalgesia and mechanical allodynia associated with persistent neuropathic and inflammatory pain states. This Loss appeared to be permanent. Responses to mildly painful stimuli and morphine analgesia were unaffected by this treatment. These results identify a target for treating persistent pain and suggest that the small population of SPR-expressing neurons in the dorsal horn of the spinal cord plays a pivotal role in the generation and maintenance of chronic neuropathic and inflammatory pain.	Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Mol Neurobiol Lab 151, Minneapolis, MN 55417 USA; Adv Targeting Syst, San Diego, CA 92121 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Mantyh, PW (corresponding author), Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA.			Lappi, Douglas/0000-0003-4239-7387	NIDCR NIH HHS [DEO 7288] Funding Source: Medline; PHS HHS [23970, 31223] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CALVINO B, 1990, PHYSIOL BEHAV, V47, P907, DOI 10.1016/0031-9384(90)90018-Y; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306-4522(98)00276-0; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KOCHER L, 1987, PAIN, V29, P363, DOI 10.1016/0304-3959(87)90051-0; Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052-199810000-00014; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MAYER DJ, 1975, PAIN, V1, P51, DOI 10.1016/0304-3959(75)90004-4; MILLAN MJ, 1988, PAIN, V35, P299, DOI 10.1016/0304-3959(88)90140-6; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PORRO CA, 1991, EXP BRAIN RES, V83, P549; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0	25	346	360	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1558	1561		10.1126/science.286.5444.1558	http://dx.doi.org/10.1126/science.286.5444.1558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567262				2022-12-24	WOS:000083768300058
J	Vanzetta, I; Grinvald, A				Vanzetta, I; Grinvald, A			Increased cortical oxidative metabolism due to sensory stimulation: Implications for functional brain imaging	SCIENCE			English	Article							HUMAN VISUAL-CORTEX; POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD OXYGENATION; RETINOTOPIC ORGANIZATION; GLUCOSE CONSUMPTION; FLUORESCENCE DECAY; INTRINSIC SIGNALS; NEURONAL-ACTIVITY; OCULAR-DOMINANCE; NEURAL ACTIVITY	Modern functional brain mapping relies on interactions of neuronal electrical activity with the cortical microcirculation. The existence of a highly localized, stimulus-evoked initial deoxygenation has remained a controversy. Here, the activity-dependent oxygen tension changes in the microcirculation were measured directly, using oxygen-dependent phosphorescence quenching of an exogenous indicator. The first event after sensory stimulation was an increase in oxygen consumption, followed by an increase in blood flow. Because oxygen consumption and neuronal activity are colocalized but the delayed blood flow is not, functional magnetic resonance imaging focused on this initial phase will yield much higher spatial resolution, ultimately enabling the noninvasive visualization of fundamental processing modules in the human brain.	Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Vanzetta, I (corresponding author), Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel.							BARTFELD E, 1992, P NATL ACAD SCI USA, V89, P11905, DOI 10.1073/pnas.89.24.11905; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLOMQVIST G, 1994, ACTA PHYSIOL SCAND, V151, P29, DOI 10.1111/j.1748-1716.1994.tb09718.x; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; CHANCE B, 1962, NATURE, V195, P956, DOI 10.1038/195956a0; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; FILHO IPT, 1993, AM J PHYSIOL, V265, pH1434; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1987, J NEUROSCI, V7, P913; Frahm J, 1997, ADV EXP MED BIOL, V413, P195; Fransson P, 1998, MAGNET RESON MED, V39, P912, DOI 10.1002/mrm.1910390608; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Fujita H, 1999, J CEREBR BLOOD F MET, V19, P266, DOI 10.1097/00004647-199903000-00004; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; GRINVALD A, 1972, P NATL ACAD SCI USA, V69, P2273, DOI 10.1073/pnas.69.8.2273; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Hubener M, 1997, J NEUROSCI, V17, P9270; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; Kerger H, 1997, ANESTHESIOLOGY, V86, P372, DOI 10.1097/00000542-199702000-00012; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802, DOI 10.1152/ajpheart.1995.268.2.H802; KETY SS, 1955, AM SOC PHYS ABSTR, V85; KIM DS, 1999, NEUR ABSTR, V25, P783; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Kruger G, 1996, MAGNET RESON MED, V35, P797, DOI 10.1002/mrm.1910350602; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; LINDAUER U, 1999, NEUR ABSTR, V25, P1639; LIPTON P, 1973, BIOCHEM J, V136, P999, DOI 10.1042/bj1360999; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; Lo LW, 1997, ADV EXP MED BIOL, V428, P651; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Malonek D, 1997, P NATL ACAD SCI USA, V94, P14826, DOI 10.1073/pnas.94.26.14826; Marota JJA, 1999, MAGNET RESON MED, V41, P247, DOI 10.1002/(SICI)1522-2594(199902)41:2<247::AID-MRM6>3.0.CO;2-U; Mayhew J, 1999, NEUROIMAGE, V10, P304, DOI 10.1006/nimg.1999.0460; Mayhew J, 1998, NEUROIMAGE, V7, P49, DOI 10.1006/nimg.1997.0311; Menon RS, 1997, J NEUROPHYSIOL, V77, P2780, DOI 10.1152/jn.1997.77.5.2780; Menon RS, 1999, MAGNET RESON MED, V41, P230, DOI 10.1002/(SICI)1522-2594(199902)41:2<230::AID-MRM3>3.0.CO;2-O; Nemoto M, 1999, J CEREBR BLOOD F MET, V19, P246, DOI 10.1097/00004647-199903000-00002; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PAWLOWSKI M, 1999, ADV EXP MED BIOL, V316, P179; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; Roy C S, 1890, J Physiol, V11, P85; RUMSEY WL, 1988, SCIENCE, V241, P1649, DOI 10.1126/science.3420417; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shmuel A, 1996, J NEUROSCI, V16, P6945; SHTOYERMAN E, UNPUB; SILVER IA, 1978, CEREBRAL VASCULAR SM, V56, P49; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TSO DY, 1990, SCIENCE, V240, P333; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Vafaee MS, 1999, J CEREBR BLOOD F MET, V19, P272, DOI 10.1097/00004647-199903000-00005; VANZETTA L, UNPUB; VINOGRADOV SA, 1994, ADV EXP MED BIOL, V361, P67; Wang G, 1996, SCIENCE, V272, P1665, DOI 10.1126/science.272.5268.1665; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; Wilson D F, 1987, Adv Exp Med Biol, V215, P71; WILSON DF, 1988, J BIOL CHEM, V263, P2712; WILSON DF, 1993, ADV EXP MED BIOL, V333, P225; Yacoub E, 1999, MAGN RESON MED, V41, P436, DOI 10.1002/(SICI)1522-2594(199903)41:3<436::AID-MRM2>3.0.CO;2-#	72	235	240	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1555	1558		10.1126/science.286.5444.1555	http://dx.doi.org/10.1126/science.286.5444.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567261				2022-12-24	WOS:000083768300057
J	[Anonymous]				[Anonymous]			Cell surgery	SCIENCE			English	Editorial Material																		Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1498	1498		10.1126/science.286.5444.1498	http://dx.doi.org/10.1126/science.286.5444.1498			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610553				2022-12-24	WOS:000083768300039
J	Cortez, D; Wang, Y; Qin, J; Elledge, SJ				Cortez, D; Wang, Y; Qin, J; Elledge, SJ			Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks	SCIENCE			English	Article							SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; NUCLEAR PHOSPHOPROTEIN; GEL-ELECTROPHORESIS; TARGETED DISRUPTION; GAMMA-IRRADIATION; MEIOTIC CELLS; C-ABL	The Brca1 (breast cancer gene 1) tumor suppressor protein is phosphorylated in response to DNA damage, Results from this study indicate that the checkpoint protein kinase ATM (mutated in ataxia telangiectasia) was required for phosphorylation of Brca1 in response to ionizing radiation. ATM resides in a complex with Brca1 and phosphorylated Brca1 in vivo and in vitro in a region that contains clusters of serine-glutamine residues. Phosphorylation of this domain appears to be functionally important because a mutated Brca1 protein lacking two phosphorylation sires failed to rescue the radiation hypersensitivity of a Brca1-deficient cell line. Thus, phosphorylation of Brca1 by the checkpoint kinase ATM may be critical for proper responses to DNA double-strand breaks and may provide a molecular explanation far the role of ATM in breast cancer.	Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; CORTEZ D, UNPUB; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Goggins M, 1996, CANCER RES, V56, P5360; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAYNAHAN ME, IN PRESS MOL CELL; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaughn JP, 1996, CANCER RES, V56, P4590; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	52	815	841	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1162	1166		10.1126/science.286.5442.1162	http://dx.doi.org/10.1126/science.286.5442.1162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550055				2022-12-24	WOS:000083534200045
J	Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G				Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G			Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis	ANNALS OF INTERNAL MEDICINE			English	Article							SYDNEY SYSTEM; INFECTION; CLASSIFICATION; FERRITIN	Background: Iron deficiency anemia is the most common form of anemia worldwide. Recent studies have suggested an association between Helicobacter pylori infection and iron deficiency. Objective: To investigate the effects of eradicating H. pylori with combination antibiotic therapy on iron deficiency anemia in patients with H. pylori-associated gastritis. Design: Case series. Setting: University hospital. Patients: 30 patients with a long history of iron deficiency anemia in whom H. pylori-associated gastritis was the only pathologic gastrointestinal finding detected. Intervention: Eradication therapy with two antibiotics and discontinuation of iron replacement therapy. Measurements: Complete blood count ferritin levels, and gastroscopy with biopsy to evaluate H. pylori status. Results: At 6 months, 75% of patients had recovered from anemia (P < 0.001), ferritin values increased from 5.7 +/- 0.7 mu g/L to 24.5 +/- 5.2 mu g/L (95% CI, 8.85 to 29.97). After 12 months, 91.7% of patients had recovered from anemia. Conclusions: Cure of H, pylori infection is associated with reversal of iron dependence and recovery from iron deficiency anemia.	Univ Roma La Sapienza, Rome, Italy	Sapienza University Rome	Annibale, B (corresponding author), Univ Rome, Policlin Umberto I, Dept Clin Med 2, I-00161 Rome, Italy.		Annibale, Bruno/A-5372-2008	Annibale, Bruno/0000-0001-9120-5957; Marignani, Massimo/0000-0002-8912-9972				BAIRD IM, 1959, Q J MED, V28, P21; BANERJEE S, 1994, GUT, V35, P317, DOI 10.1136/gut.35.3.317; BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; Carnicer J, 1997, J PEDIATR GASTR NUTR, V25, P441, DOI 10.1097/00005176-199710000-00017; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOIG P, 1993, J BACTERIOL, V175, P557, DOI 10.1128/JB.175.2.557-560.1993; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUFOUR C, 1993, J PEDIATR GASTR NUTR, V17, P225, DOI 10.1097/00005176-199308000-00018; HALLEBERG L, 1993, DAVIDSON PASSMORE HU, P174; HUSSON MO, 1993, INFECT IMMUN, V61, P2694, DOI 10.1128/IAI.61.6.2694-2697.1993; LAINE L, 1998, SLEISENGER FORDTRANS, P198; Marignani M, 1996, CURR THER RES CLIN E, V57, P544, DOI 10.1016/S0011-393X(96)80064-6; Marignani M, 1999, AM J GASTROENTEROL, V94, P766; Marignani M, 1997, SCAND J GASTROENTERO, V32, P617, DOI 10.3109/00365529709025109; Meining A, 1997, VIRCHOWS ARCH, V431, P11, DOI 10.1007/s004280050063; Milman N, 1998, GASTROENTEROLOGY, V115, P268, DOI 10.1016/S0016-5085(98)70192-1; Peach HG, 1998, MED J AUSTRALIA, V169, P188, DOI 10.5694/j.1326-5377.1998.tb140218.x; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; ZAITOUN AM, 1994, J CLIN PATHOL, V47, P810, DOI 10.1136/jcp.47.9.810; Zhang ZW, 1998, GUT, V43, P322, DOI 10.1136/gut.43.3.322	20	172	178	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					668	672		10.7326/0003-4819-131-9-199911020-00006	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577329				2022-12-24	WOS:000083446200005
J	Weissmann, C; Aguzzi, A				Weissmann, C; Aguzzi, A			Perspectives: Neurobiology - PrP's double causes trouble	SCIENCE			English	Editorial Material							SCRAPIE; PROTEIN; LESIONS; GENE		St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, London W2 1PG, England; Univ Spital Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland	Imperial College London; University of Zurich; University Zurich Hospital	Weissmann, C (corresponding author), St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, Praed St, London W2 1PG, England.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COZZIO A, UNPUB; FLECHSIG E, UNPUB; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Nishida N, 1999, LAB INVEST, V79, P689; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Weissmann C, 1996, CURR BIOL, V6, P1359, DOI 10.1016/S0960-9822(96)00729-4; WESTAWAY D, COMMUNICATION	13	80	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					914	915		10.1126/science.286.5441.914	http://dx.doi.org/10.1126/science.286.5441.914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10577243				2022-12-24	WOS:000083368500033
J	Yan, J; Magnasco, MO; Marko, JF				Yan, J; Magnasco, MO; Marko, JF			A kinetic proofreading mechanism for disentanglement of DNA by topoisomerases	NATURE			English	Article							STEADY-STATE ANALYSIS; ESCHERICHIA-COLI; ATP HYDROLYSIS; DOUBLE HELIX; TRANSPORT; TOPOLOGY	Cells must remove all entanglements between their replicated chromosomal DNAs to segregate them during cell division. Entanglement removal is done by ATP-driven enzymes that pass DNA strands through one another, called type II topoisomerases. In vitro, some type II topoisomerases can reduce entanglements much more than expected, given the assumption that they pass DNA segments through one another in a random way(1). These type II topoisomerases (of less than 10 nm in diameter) thus use ATP hydrolysis to sense and remove entanglements spread along flexible DNA strands of up to 3,000 nm long. Here we propose a mechanism for this, based on the higher rate of collisions along entangled DNA strands, relative to collision rates on disentangled DNA strands. We show theoretically that if a type II topoisomerase requires an initial 'activating' collision before a second strand-passing collision, the probability of entanglement may be reduced to experimentally observed levels. This proposed two-collision reaction is similar to 'kinetic proofreading' models of molecular recognition(2,3).	Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rockefeller University	Marko, JF (corresponding author), Univ Illinois, Dept Phys, 845 W Taylor St, Chicago, IL 60607 USA.		Marko, John F./AAY-7111-2021; Yan, Jie/G-2725-2012	Marko, John F./0000-0003-4151-9530; Yan, Jie/0000-0002-8555-7291				DEGUCHI T, 1994, J KNOT THEOR RAMIF, V3, P321; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KLENIN KV, 1988, J BIOMOL STRUCT DYN, V5, P1173, DOI 10.1080/07391102.1988.10506462; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; Vologodskii A, 1998, P 2 ANN INT C COMP M, P266; WORCEL A, 1972, J MOL BIOL, V71, P127, DOI 10.1016/0022-2836(72)90342-7	16	97	97	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					932	935		10.1038/44872	http://dx.doi.org/10.1038/44872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553912				2022-12-24	WOS:000083464700064
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Immunotherapy - PEG antibodies	SCIENCE			English	Article									Mednavcom, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednavcom, Byfield, MA 01922 USA.							Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717	1	6	6	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					434	434		10.1126/science.286.5439.434	http://dx.doi.org/10.1126/science.286.5439.434			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577206				2022-12-24	WOS:000083121200037
J	Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH				Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH			Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission	CELL			English	Article							AMINO-ACID TRANSPORTER; VESICULAR GABA TRANSPORTER; GLUTAMINE TRANSPORT; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; CEREBRAL-CORTEX; GLIAL-CELLS; RAT-LIVER; ARABIDOPSIS; IMMUNOCYTOCHEMISTRY	The amino acid glutamine has a central role in nitrogen metabolism. Although the molecular mechanisms responsible for its transport across cell membranes remain poorly understood, classical amino acid transport system N appears particularly important. Using intracellular pH measurements, we have now identified an orphan protein related to a vesicular neurotransmitter transporter as system N. Functional analysis shows that this protein (SN1) involves H+ exchange as well as Na+ cotransport and, under physiological conditions, mediates glutamine efflux as well as uptake. Together with the pattern of SN1 expression, these unusual properties suggest novel physiological roles for system N in nitrogen metabolism and synaptic transmission.	Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Cell Biol, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Biomed Sci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oslo	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA.		Krrr, Daa/ABG-2688-2020	Krrr, Daa/0000-0003-4468-3029; Storm-Mathisen, Jon/0000-0002-2930-3262				ALBRECHT J, 1989, NEUROPHARMACOLOGY, V28, P885, DOI 10.1016/0028-3908(89)90183-4; Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Bender D.A., 1975, AMINO ACID METABOLIS; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; CONTI F, 1994, J HISTOCHEM CYTOCHEM, V42, P717, DOI 10.1177/42.6.7910617; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Fishman RA., 1992, CEREBROSPINAL FLUID; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; Gundersen V, 1996, EUR J NEUROSCI, V8, P758, DOI 10.1111/j.1460-9568.1996.tb01261.x; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HUNDAL HS, 1987, J PHYSIOL-LONDON, V393, P283, DOI 10.1113/jphysiol.1987.sp016824; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KANNER BI, 1994, J EXP BIOL, V196, P237; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pouyssegur J, 1987, Methods Enzymol, V151, P131, DOI 10.1016/S0076-6879(87)51014-X; RAMAHAROBANDRO N, 1982, BRAIN RES, V244, P113, DOI 10.1016/0006-8993(82)90909-X; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Rose CR, 1998, J NEUROSCI, V18, P3554; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1984, J NEUROCHEM, V43, P1438, DOI 10.1111/j.1471-4159.1984.tb05406.x; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORMMATHISEN J, 1986, MED BIOL, V64, P127; Tamarappoo BK, 1997, J NEUROCHEM, V68, P954; TATE SS, 1973, ENZYMES GLUTAMINE ME, P77; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Xiang JM, 1998, BRAIN RES, V783, P37, DOI 10.1016/S0006-8993(97)01194-3; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	52	260	266	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					769	780		10.1016/S0092-8674(00)81674-8	http://dx.doi.org/10.1016/S0092-8674(00)81674-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619430	Bronze			2022-12-24	WOS:000084488200010
J	Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G				Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G			Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis	CELL			English	Article							NMR STRUCTURE; CELL-DEATH; PROTEIN; ACTIVATION; MITOCHONDRIA; MUTAGENESIS; RESONANCE; INHIBITOR; CASPASE-3; DYNAMICS	Apoptotic DNA fragmentation and chromatin condensation are mediated by the caspase-activated DFF40/ CAD nuclease, which is chaperoned and inhibited by DFF45/ICAD. CIDE proteins share a homologous regulatory CIDE-N domain with DFF40/CAD and DFF45/ ICAD. Here we report the solution structure of CIDE-N of human CIDE-B. We show that the CIDE-N of CIDE-B interacts with CIDE-N domains of both DFF40 and DFF45. The binding epitopes are similar and map to a highly charged bipolar surface region of CIDE-B. Furthermore, we demonstrate that the CIDE-N of CIDE-B regulates enzymatic activity of the DFF40/ DFF45 complex in vitro. Based on these results and mutagenesis data, we propose a model for the CIDE-N/ CIDE-N complex and discuss the role of this novel bipolar interaction in mediating downstream events of apoptosis.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Inst Mol & Cell Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Harvard University; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu	Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Zhou, Pei/O-6704-2019	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; Zhou, Pei/0000-0002-7823-3416	NIGMS NIH HHS [GM 38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BRUNGER AT, 1994, XPLOR MANUAL 3 851 S; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	95	97	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					747	755		10.1016/S0092-8674(00)81672-4	http://dx.doi.org/10.1016/S0092-8674(00)81672-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619428	Bronze			2022-12-24	WOS:000084488200008
J	Koenig, RE				Koenig, RE			AIDS in paradise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		GOMEZ E, 1996, ESTIMACIONES PROYECC	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2195	2196		10.1001/jama.282.23.2195	http://dx.doi.org/10.1001/jama.282.23.2195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605958				2022-12-24	WOS:000084138600001
J	Senzaki, K; Ogawa, M; Yagi, T				Senzaki, K; Ogawa, M; Yagi, T			Proteins of the CNR family are multiple receptors for reelin	CELL			English	Article							DEVELOPING CEREBELLAR CORTEX; CAJAL-RETZIUS CELLS; HIPPOCAMPAL DEVELOPMENT; EXPRESSION; MOUSE; ORGANIZATION; MIGRATION; NEURONS; BRAIN; MICE	Layering and positioning of neurons require Reelin-and Src family-associated mammalian Disabled (mDab1). Cadherin-related neuronal receptor (CNR) genes are expressed in neurons of the cortical layer, but not in Cajal-Retzius cells expressing Reelin. This leads us to hypothesize that CNRs bound to Fyn of the Src family are receptors for Reelin. Herein we confirm the association and colocalization of CNR proteins with Reelin. This binding is blocked by CR-50 antibody against Reelin, as well as by monoclonal antibodies produced against CNRs. Both disturb the signaling pathway from Reelin to mDab1 and the positioning of cortical neurons in vitro. These results strongly suggest that the CNR family proteins are multiple Reelin receptors. In addition, differential conservation of the Reelin-binding domain among terrestrial vertebrates may be pertinent to the diversity or complexity of brains.	Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan; RIKEN, Lab Cell Culture Dev, Brain Sci Inst, Wako, Saitama 35101, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); RIKEN	Yagi, T (corresponding author), Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan.	yagi@nips.ac.jp						Alcantara S, 1998, J NEUROSCI, V18, P7779; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DELONG GR, 1970, DEV BIOL, V22, P563, DOI 10.1016/0012-1606(70)90169-7; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Komuro H, 1998, J NEUROSCI, V18, P1478; Marin-Padilla M, 1998, TRENDS NEUROSCI, V21, P64, DOI 10.1016/S0166-2236(97)01164-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; Prince VE, 1998, DEVELOPMENT, V125, P407; Rakic P, 1996, P NATL ACAD SCI USA, V93, P9218, DOI 10.1073/pnas.93.17.9218; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RIVAS RJ, 1995, J NEUROSCI, V15, P981; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; YAGI T, 1993, ONCOGENE, V8, P3343; Yagi T, 1999, BIOCHEM PHARMACOL, V57, P845; [No title captured]	42	241	244	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					635	647		10.1016/S0092-8674(00)81552-4	http://dx.doi.org/10.1016/S0092-8674(00)81552-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612399	Bronze			2022-12-24	WOS:000084278700010
J	Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM				Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM			Predicting the evolution of human influenza A	SCIENCE			English	Article							VIRUS HEMAGGLUTININ	Eighteen codons in the HA1 domain of the hemagglutinin genes of human influenza A subtype H3 appear to be under positive selection to change the amino acid they encode. Retrospective tests show that viral Lineages undergoing the greatest number of mutations in the positively selected codons were the progenitors of future H3 Lineages in 9 of 11 recent influenza seasons. Codons under positive selection were associated with antibody combining site A or B or the sialic acid receptor binding site. However, not all codons in these sites had predictive value. Monitoring new H3 isolates for additional changes in positively selected codons might help identify the most fit extant viral strains that arise during antigenic drift.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Ctr Dis Control & Prevent, Influenza Branch, Atlanta, GA 30333 USA	University of California System; University of California Irvine; Centers for Disease Control & Prevention - USA	Bush, RM (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.			Subbarao, Kanta/0000-0003-1713-3056				BENDER CM, UNPUB; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Cox NJ, 1995, SEMIN VIROL, V6, P359, DOI 10.1016/S1044-5773(05)80013-7; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; SWOFFORD DL, PAUP PHYLOGENETIC AN; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.immunol.8.1.737	8	368	390	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1921	1925		10.1126/science.286.5446.1921	http://dx.doi.org/10.1126/science.286.5446.1921			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583948				2022-12-24	WOS:000084003400041
J	Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC				Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC			Requirement for B cell linker protein (BLNK) in B cell development	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; SYK TYROSINE KINASE; POSITIVE SELECTION; MICE LACKING; AGAMMAGLOBULINEMIA; ZAP-70; GENE; BTK; DEFICIENCY; ACTIVATION	Linker proteins function as molecular scaffolds to Localize enzymes with substrates. In B cells, B cell Linker protein (BLNK) Links the B cell receptor (BCR)activated Syk kinase to the phosphoinositide and mitogen-activated kinase pathways. To examine the in vivo role of BLNK, mice deficient in BLNK were generated. B cell development in BLNK-/- mice was blocked at the transition from B220(+) CD43(+) progenitor B to B220(+) CD43(-) precursor B cells. Only a small percentage of immunoglobulin M++ (IgM(++)), but not mature IgM(lo)lgD(hi), B cells were detected in the periphery. Hence, BLNK is an essential component of BCR signaling pathways and is required to promote B cell development.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Chan, AC (corresponding author), Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA.		Childs, James E/B-4002-2012	Chiu, Christopher W./0000-0001-9744-991X	NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042787] Funding Source: NIH RePORTER; NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI42787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gangi-Peterson L, 1998, MOL IMMUNOL, V35, P55, DOI 10.1016/S0161-5890(98)00008-X; Goitsuka R, 1998, J IMMUNOL, V161, P5804; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; PAPPU R, UNPUB; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	37	237	241	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1949	1954		10.1126/science.286.5446.1949	http://dx.doi.org/10.1126/science.286.5446.1949			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583957				2022-12-24	WOS:000084003400050
J	Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG				Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG		Late Effects Working Party Europea; European Late Effect Project Grp	Malignant neoplasms in long-term survivors of bone marrow transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						neoplasms; bone marrow transplantation; immunosuppression; cyclosporine; age factors; graft vs host disease	TOTAL-BODY IRRADIATION; SEVERE APLASTIC-ANEMIA; SECONDARY MALIGNANCIES; LEUKEMIA; CANCERS; TUMORS; RISK	Background: Patients who receive bone marrow transplants have increased risk for new malignant conditions because of several risk factors, including conditioning with radiation and chemotherapy, immune stimulation, and malignant primary disease. The occurrence of and risk factors for malignant neoplasm in long-term survivors must be assessed. Objective: To determine the risk and define potential risk factors for new malignant conditions in long-term survivors after marrow transplantation. Design: Retrospective multicenter study. Setting: Study of the Late Effects Working Party with 45 transplantation centers cooperating in the European Cooperative Group for Blood and Marrow Transplantation. Patients: 1036 consecutive patients who underwent transplantation for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, or severe aplastic anemia. Transplantation was done before December 1985, and patients had survived more than 5 years. Measurements: Reports on malignant neoplasms were evaluated, and the incidence was compared to that in the general population. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, development of acute and chronic graft-versus-host disease, and treatment of chronic graft-versus-host disease were evaluated as variables. Results: Median follow-up since transplantation was 10.7 years (range, 5 to 22.1 years). Malignant neoplasms were seen in 53 patients; the actuarial incidence (+/- SE) was 3.5% +/- 0.6% at 10 years and 12.8% +/- 2.6% at 15 years. The rate of new malignant disease was 3.8-fold higher than that in an age-matched control population (P < 0.001). The most frequent malignant diseases were neoplasms of the skin (14 patients), oral cavity (7 patients), uterus (including cervix) (5 patients), thyroid gland (5 patients), breast (4 patients), and glial tissue (3 patients). Median age of patients and their donors was 21 years. Malignant neoplasms were more frequent in older patients and in patients with chronic graft-versus-host disease. Older patient age and treatment of chronic graft-versus-host disease with cyclosporine were significant risk factors for new malignant neoplasms after bone marrow transplantation. Conclusions: The spectrum of neoplasms and immunosuppressive treatment with cyclosporine for chronic graft-versus-host disease as dominant risk factors indicate that immunosuppression is the major cause of malignant neoplasms in patients receiving marrow transplants.	Univ Munich, Dept Med 3, Hematopoiet Cell Transplantat Unit, Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Radiobiol, D-81377 Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Hematopoiet Cell Transplantat Med Clin 3, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Kolb, HJ (corresponding author), Univ Munich, Hematopoiet Cell Transplantat Med Clin 3, Marchioninistr 15, D-81377 Munich, Germany.		Ljungman, Per/M-4946-2019					Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; BORTIN MM, 1992, JAMA-J AM MED ASSOC, V268, P607; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DEEG HJ, 1980, BLOOD, V55, P233; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; DEEG HJ, 1983, INT J RADIAT ONCOL, V9, P1505, DOI 10.1016/0360-3016(83)90325-5; GRATWOHL A, 1994, BONE MARROW TRANSPL, V13, P5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; Kolb H J, 1990, Radiother Oncol, V18 Suppl 1, P51, DOI 10.1016/0167-8140(90)90178-Y; LISHNER M, 1990, CANCER-AM CANCER SOC, V65, P473, DOI 10.1002/1097-0142(19900201)65:3<473::AID-CNCR2820650316>3.0.CO;2-V; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LOWSKY R, 1994, J CLIN ONCOL, V12, P2187, DOI 10.1200/JCO.1994.12.10.2187; MUIR C, 1987, 5 CONTINENTS; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PIERGA JY, 1994, RADIOTHER ONCOL, V30, P55, DOI 10.1016/0167-8140(94)90009-4; SEROTA FT, 1983, INT J RADIAT ONCOL, V9, P1941, DOI 10.1016/0360-3016(83)90366-8; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1994, TRANSPLANTATION, V57, P1413, DOI 10.1097/00007890-199405270-00001	25	188	189	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					738	+		10.7326/0003-4819-131-10-199911160-00004	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577296				2022-12-24	WOS:000083680100003
J	Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ				Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ			Detection of nonthermal melting by ultrafast X-ray diffraction	SCIENCE			English	Article							LATTICE INSTABILITY; LASER; SI; GE; TRANSITIONS; DYNAMICS; DISORDER; DIAMOND; SILICON; PULSES	Using ultrafast, time-resolved, 1.54 angstrom x-ray diffraction, thermal and ultrafast nonthermal melting of germanium, involving passage through nonequilibrium extreme states of matter, was observed. Such ultrafast, optical-pump, x-ray diffraction probe measurements provide a way to study many other transient processes in physics, chemistry, and biology, including direct observation of the atomic motion by which many solid-state processes and chemical and biochemical reactions take place.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Nonlinear Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Appl Mech Engn Sci, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Inst Laser & Plasmaphys, D-45117 Essen, Germany; Leibniz Univ Hannover, Inst Halbleitertech, D-30167 Hannover, Germany; Leibniz Univ Hannover, Inst Festkorperphys, D-30167 Hannover, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Duisburg Essen; Leibniz University Hannover; Leibniz University Hannover	Siders, CW (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	csiders@ucsd.edu	Siders, Craig/AFU-8557-2022; Sokolowski-Tinten, Klaus/A-5415-2015; Toth, Csaba/AAD-3106-2019; von Hoegen, Michael Horn/E-4969-2012	von Hoegen, Michael Horn/0000-0003-0324-3457; Guo, Ting/0000-0002-6700-0967; Toth, Csaba/0000-0002-4599-4550				Barty CPJ, 1996, OPT LETT, V21, P668, DOI 10.1364/OL.21.000668; BLOEMBERGEN N, 1992, NATURE, V356, P110, DOI 10.1038/356110a0; CAVALLERI A, 1999, QUANT EL LAS SCI C Q; Chin AH, 1998, SPRINGER SERIES CHEM, V63, P401; DOWNER MC, 1986, PHYS REV LETT, V56, P761, DOI 10.1103/PhysRevLett.56.761; FABRICIUS N, 1986, SOLID STATE COMMUN, V58, P239, DOI 10.1016/0038-1098(86)90209-7; GALLI G, 1990, SCIENCE, V250, P1547, DOI 10.1126/science.250.4987.1547; HORNVONHOEGEN M, 1994, APPL PHYS A-MATER, V59, P503, DOI 10.1007/BF00348268; HORNVONHOEGEN M, 1994, PHYS REV B, V50, P10811, DOI 10.1103/PhysRevB.50.10811; Huang L, 1998, PHYS REV LETT, V80, P185, DOI 10.1103/PhysRevLett.80.185; LARSON BC, 1982, PHYS REV LETT, V48, P337, DOI 10.1103/PhysRevLett.48.337; Larsson J, 1998, APPL PHYS A-MATER, V66, P587, DOI 10.1007/s003390050719; LINDENBERG AM, 1999, QELS 99 SESS QTHJ4 B; LIU JM, 1982, OPT LETT, V7, P196, DOI 10.1364/OL.7.000196; MUMANE MM, 1991, SCIENCE, V25, P531; REITZE DH, 1992, PHYS REV B, V45, P2677, DOI 10.1103/PhysRevB.45.2677; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rose-Petruck C, 1999, NATURE, V398, P310, DOI 10.1038/18631; ROUSSE A, 1999, C LAS EL CLEO 99 SES; SAETA P, 1991, PHYS REV LETT, V67, P1023, DOI 10.1103/PhysRevLett.67.1023; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; SHANK CV, 1983, PHYS REV LETT, V50, P454, DOI 10.1103/PhysRevLett.50.454; Sokolowski-Tinten K, 1998, PHYS REV LETT, V81, P224, DOI 10.1103/PhysRevLett.81.224; Sokolowski-Tinten K, 1998, PHYS REV B, V58, P11805, DOI 10.1103/PhysRevB.58.R11805; SOKOLOWSKITINTEN K, 1995, PHYS REV B, V51, P14186, DOI 10.1103/PhysRevB.51.14186; Spaepen F., 1982, Laser annealing of semiconductors, P15; STAMPFLI P, 1990, PHYS REV B, V42, P7163, DOI 10.1103/PhysRevB.42.7163; STAMPFLI P, 1992, PHYS REV B, V46, P10686, DOI 10.1103/PhysRevB.46.10686; STAMPFLI P, 1994, PHYS REV B, V49, P7299, DOI 10.1103/PhysRevB.49.7299; TOM HWK, 1988, PHYS REV LETT, V60, P1438, DOI 10.1103/PhysRevLett.60.1438; VANVECHTEN JA, 1979, PHYS LETT A, V74, P422, DOI 10.1016/0375-9601(79)90242-1; VONDERLINDE D, 1990, RESONANCES; Wood R F, 1984, PULSED LASER PROCESS, V23	33	458	465	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1340	1342		10.1126/science.286.5443.1340	http://dx.doi.org/10.1126/science.286.5443.1340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558985				2022-12-24	WOS:000083675500037
J	Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A				Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A		China-US Collaborative Project Neu	Prevention of neural-tube defects with folic acid in China	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; DIETARY-FOLATE; PREVALENCE; RISK	Background Periconceptional use of multivitamins containing folic acid can reduce a woman's risk of having a baby with a neural-tube defect. Methods As part of a public health campaign conducted from 1993 to 1995 in an area of China with high rates of neural-tube defects (the northern region) and one with low rates (the southern region), we evaluated the outcomes of pregnancy in women who were asked to take a pill containing 400 mu g of folic acid alone daily from the time of their premarital examination until the end of their first trimester of pregnancy. Results Among the fetuses or infants of 130,142 women who took folic acid at any time before or during pregnancy and 117,689 women who had not taken folic acid, we identified 102 and 173, respectively, with neural-tube defects. Among the fetuses or infants of women who registered before their last menstrual period and who did not take any folic acid, the rates of neural-tube defects were 4.8 per 1000 pregnancies of at least 20 weeks' gestation in the northern region and 1.0 per 1000 in the southern region. Among the fetuses or infants of the women with periconceptional use of folic acid, the rates were 1.0 per 1000 in the northern region and 0.6 per 1000 in the southern region. The greatest reduction in risk occurred among the fetuses or infants of a subgroup of women in the northern region with periconceptional use who took folic acid pills more than 80 percent of the time. In the southern region the reduction in risk among the fetuses or infants of women with periconceptional use of folic acid was also significant (reduction in risk, 41 percent; 95 percent confidence interval, 3 to 64 percent). Conclusions Periconceptional intake of 400 mg of folic acid daily can reduce the risk of neural-tube defects in areas with high rates of these defects and in areas with low rates. (N Engl J Med 1999;341:1485-90.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Beijing Med Univ, Natl Ctr Maternal & Infant Hlth, Beijing 100083, Peoples R China; Beijing Med Univ, Dept Hlth Care Epidemiol, Beijing 100083, Peoples R China	Centers for Disease Control & Prevention - USA; Peking University; Peking University	Berry, RJ (corresponding author), Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-45, Atlanta, GA 30341 USA.			Berry, Robert/0000-0002-7162-5046				[Anonymous], 1991, MMWR MORB MORTAL WKL, V40, P513; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Cornel MC, 1997, TERATOLOGY, V55, P134; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Moore CA, 1997, AM J MED GENET, V73, P113; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; MURRAY CJL, 1996, GLOBAL BURDEN DIS IN, V10; Olney R, 1998, MENT RETARD DEV D R, V4, P241, DOI 10.1002/(SICI)1098-2779(1998)4:4<241::AID-MRDD2>3.3.CO;2-P; SAS Institute, 1997, SAS STAT SOFTW CHANG; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1980, LANCET, V1, P339; SMITHELLS RW, 1983, LANCET, V1, P1027; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; XIAO KZ, 1990, INT J EPIDEMIOL, V19, P978	18	1034	1099	4	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1485	1490		10.1056/NEJM199911113412001	http://dx.doi.org/10.1056/NEJM199911113412001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559448				2022-12-24	WOS:000083625800001
J	Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB				Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB			Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study	LANCET			English	Article							CONGENITAL-MALFORMATIONS; INVITRO FERTILIZATION; CRYOPRESERVED EMBRYOS; SINGLETON PREGNANCIES; ASSISTED CONCEPTION; BIRTHS; REGISTRY; TWINS; HEALTH	Background In-vitro fertilisation is an effective treatment for infertility, but there is concern about the health of children. We investigated, in a retrospective registry study, malformations, cancers, and deaths In the complete Swedish in-vitro-fertilisation birth cohort compared with the general population. Methods We collected data from all in-vitro-fertilisation clinics in Sweden and compared the obstetric outcomes of babies (n=5856) born between 1982 and 1995 with all babies born in the general population (n=1 505 724) during the same period, according to data from the Swedish Medical Birth Registry and the Registry of Congenital Malformations. We investigated the incidence of childhood cancer through the Swedish Cancer Registry. Data were stratified for maternal age, parity, previous subfertility, year of birth, and multiple of pregnancies. Findings Multiple births occurred in 27% of pregnancies compared with 1% in the control group. In the in-vitro-fertilisation group, more babies were born preterm (<37 weeks) than controls (30.3 vs 6.3%) and more had low birthweights (<2500 g, 27.4 vs 4.6%). The perinatal mortality was 1.9% in the in-vitro fertilisation group and 11% in the controls. For in-vitro-fertilisation singletons, the risk ratios, adjusted for year of birth, for very preterm birth (<32 weeks) and very low birthweight (<1500 g) were 3.54 (95% CI 2.90-4.32) and 4.39 (3.62-5.32), respectively. Malformations occurred in 5.4% of all babies in the in-vitro fertilisation group (1.39 [1.25-1.54]), and the rates of neural-tube defects and oesophageal atresia were higher than those in the controls. There was no increase in childhood cancer in the in-vitro-fertilisation group. Interpretation A high frequency of multiple births and maternal characteristics were the main factors that led to adverse outcomes, and not the in-vitro-fertilisation technique itself. The clinical practice of in-vitro-fertilisation needs to be changed to lower the rate of multiple pregnancy.	Sophiahemmet, S-11486 Stockholm, Sweden; Carl von Linneklin, Uppsala, Sweden; Socialstyrelsen, Epidemiol Ctr, Gothenburg, Sweden; Fertil Ctr, Gothenburg, Sweden; Sahlgrens Univ Hosp, Gothenburg, Sweden	National Board of Health & Welfare; Sahlgrenska University Hospital	Nygren, KG (corresponding author), Sophiahemmet, POB 5605, S-11486 Stockholm, Sweden.							BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; Bonduelle M, 1996, HUM REPROD, V11, P131, DOI 10.1093/humrep/11.suppl_4.131; BONDUELLE M, 1998, PROSPECTIVE FOLLOW U; Bustillo M, 1999, FERTIL STERIL, V71, P798; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DEMOUZON J, 1997, J ASSIST REPROD GE S, V14, P251; DEROM R, 1995, MULTIPLE PREGNANCY; Dhont M, 1997, J ASSIST REPROD GEN, V14, P575, DOI 10.1023/A:1022576500894; DOYLE P, 1992, HUM REPROD, V7, P425, DOI 10.1093/oxfordjournals.humrep.a137663; DOYLE PE, 1991, J EPIDEMIOL COMMUN H, V45, P43, DOI 10.1136/jech.45.1.43; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; GHAZI HA, 1991, FERTIL STERIL, V55, P726; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; KALLEN B, 1986, ACTA GENET MED GEMEL, V35, P167; LANCASTER PAL, 1987, LANCET, V2, P1392; LANCASTER PAL, 1985, BRIT MED J, V291, P1160; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; Reubinoff BE, 1997, FERTIL STERIL, V67, P1077, DOI 10.1016/S0015-0282(97)81442-2; ROBERT E, 1993, REPROD TOXICOL, V7, P405, DOI 10.1016/0890-6238(93)90085-L; STEPTOE PC, 1978, LANCET, V2, P366; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; von During V, 1995, Tidsskr Nor Laegeforen, V115, P2054; WANG JX, 1994, HUM REPROD, V9, P141, DOI 10.1093/oxfordjournals.humrep.a138304; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Wennerholm UB, 1998, LANCET, V351, P1085, DOI 10.1016/S0140-6736(97)08247-0; WHITE L, 1990, LANCET, V336, P1577, DOI 10.1016/0140-6736(90)93350-X	29	505	519	4	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1579	1585		10.1016/S0140-6736(99)04345-7	http://dx.doi.org/10.1016/S0140-6736(99)04345-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560671				2022-12-24	WOS:000083551000008
J	Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM				Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM			A biochemical genomics approach for identifying genes by the activity of their products	SCIENCE			English	Article							TRANSFER-RNA LIGASE; SACCHAROMYCES-CEREVISIAE; SPLICE JUNCTION; YEAST; 2'-PHOSPHATE; PURIFICATION; EXPRESSION; PHOSPHATE; CLONING	For the identification of yeast genes specifying biochemical activities, a genomic strategy that is rapid, sensitive, and widely applicable was developed with an array of 6144 individual yeast strains, each containing a different yeast open reading frame (ORF) fused to glutathione S-transferase (GSI). For the identification of ORF-associated activities, strains were grown in defined pools, and GST-ORFs were purified. Then, pools were assayed for activities, and active pools were deconvoluted to identify the source strains. Three previously unknown ORF-associated activities were identified with this strategy: a cyclic phosphodiesterase that acts on adenosine diphosphate-ribose 1 "-2 " cyclic phosphate (Appr>p), an Appr-1 "-p-processing activity, and a cytochrome c methyltransferase.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Phizicky, EM (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA.	eric_phizicky@urmc.rochester.edu	McCraith, Stephen/AAX-9625-2020; Torres, Filipa/G-9742-2016; Grayhack, Elizabeth J/G-4386-2012	Grayhack, Elizabeth J/0000-0003-2400-5490	NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NIGMS NIH HHS [GM52347] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052347] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; LIAO HH, 1979, J BACTERIOL, V138, P853, DOI 10.1128/JB.138.3.853-860.1979; MACREADIE IG, 1991, GENE, V104, P107, DOI 10.1016/0378-1119(91)90474-P; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; Spinelli SL, 1999, J BIOL CHEM, V274, P2637, DOI 10.1074/jbc.274.5.2637; Spinelli SL, 1997, RNA, V3, P1388	18	331	347	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1153	1155		10.1126/science.286.5442.1153	http://dx.doi.org/10.1126/science.286.5442.1153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550052				2022-12-24	WOS:000083534200042
J	Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ				Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ			Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION; PROLONGED SUPPRESSION; COMBINATION THERAPY; VIRAL LOAD; INFECTION; TYPE-1; ZIDOVUDINE; RESERVOIR; INDINAVIR	Context Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART. Objective To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART. Design Prospective cohort study conducted from November 1998 to May 1999. Setting Academic medical center. Patients Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. Main Outcome Measures Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level. Results In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated, Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable. Conclusions These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA; Penn Hosp, Philadelphia, PA 19107 USA; Med Coll Penn & Hahnemann Univ, Partnership Comprehens Care, Philadelphia, PA USA	Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Drexel University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA.	roger.j.pomerantz@mail.tju.edu			NIAID NIH HHS [AI38666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1987, NEW ENGL J MED, V317, P278; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628; Martinez MA, 1999, VIROLOGY, V256, P180, DOI 10.1006/viro.1999.9601; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1999, HIV ADV RES THER, V9, P17; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; ZHANG ZQ, 1999, 6 C RETR OPP INF FEB; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	39	362	368	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1627	1632		10.1001/jama.282.17.1627	http://dx.doi.org/10.1001/jama.282.17.1627			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553788	Bronze			2022-12-24	WOS:000083368400027
J	Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R				Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R			Renal effects of low-level environmental cadmium exposure: 5-year follow-up of a subcohort from the Cadmibel study	LANCET			English	Article							BLOOD-PRESSURE; TUBULAR DYSFUNCTION; GENERAL-POPULATION; POLLUTED AREA; BODY BURDEN; MORTALITY; INHABITANTS; RESIDENTS; REDUCTION; DISEASES	Background The clinical relevance of renal effects of cadmium in people exposed in the environment remains uncertain. This study examined the evolution of renal effects observed in a population exposed to cadmium in the environment. Methods 208 men and 385 women surveyed in 1985-89 (Cadmium in Belgium study [Cadmibel]; baseline) were reexamined on average 5 years later (Public health and environmental exposure to cadmium study [PheeCad]; follow-up). Urinary and blood cadmium and markers of renal tubular dysfunction and glomerular effects were measured. The association between cadmium body burden and renal factors was examined by multivariate logistic and linear regression. Findings In men, mean urinary cadmium excretion and blood cadmium concentration measured at follow-up were 7.5 nmol/24 h (SD 1.9) and 6.1 nmol/L (2.2), reductions of 16% and 35% from baseline, respectively. In women, the corresponding values were 7.6 nmol/24 h (1.9) and 7.8 nmol/L (2.1), reductions of 14% and 28% from baseline. No indication of progressive renal damage was found and the overall results suggest that the effects of low environmental exposure to cadmium on the kidney are weak, stable, or reversible. Interpretation Subclinical renal effects that have been reported in Belgium in patients with increased cadmium body burden are not associated with progressive renal dysfunction and most likely represent non-adverse manifestations.	Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, B-1200 Brussels, Belgium; Univ Zurich, ISPMZ, Abt Arbeits & Umweltmed, CH-8006 Zurich, Switzerland	Universite Catholique Louvain; University of Zurich	Lison, D (corresponding author), Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, Clos Chapelle aux Champs 30-54, B-1200 Brussels, Belgium.		BERNARD, Alfred M/A-6511-2010; Lison, Dominique/A-8985-2010	BERNARD, Alfred M/0000-0003-3171-3743; Lison, Dominique/0000-0001-6557-2518				Agency for Toxic Substance and Disease Registry, 1997, TOX PROF CADM; Buchet JP, 1996, OCCUP ENVIRON MED, V53, P320, DOI 10.1136/oem.53.5.320; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; Cirillo M, 1998, ARCH INTERN MED, V158, P1933, DOI 10.1001/archinte.158.17.1933; GANONG WF, 1997, REV MED PHYSL, P264; Goetz FC, 1997, AM J EPIDEMIOL, V145, P91; HERBER RFM, 1994, PURE APPL CHEM, V66, P915, DOI 10.1351/pac199466040915; INSKIP H, 1982, LANCET, V1, P896; IWATA K, 1991, TOHOKU J EXP MED, V164, P93, DOI 10.1620/tjem.164.93; IWATA K, 1993, ARCH ENVIRON HEALTH, V48, P157, DOI 10.1080/00039896.1993.9940814; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; KIDO T, 1988, ARCH ENVIRON HEALTH, V43, P213, DOI 10.1080/00039896.1988.9934935; LAUWERYS R, 1981, LANCET, V1, P383; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; Massey LK, 1996, J BONE MINER RES, V11, P731; NAKAGAWA H, 1993, ARCH ENVIRON HEALTH, V48, P428, DOI 10.1080/00039896.1993.10545965; NISHIJO M, 1994, ENVIRON RES, V64, P112, DOI 10.1006/enrs.1994.1010; NISHIJO M, 1995, OCCUP ENVIRON MED, V52, P181, DOI 10.1136/oem.52.3.181; NOGAWA K, 1984, ENVIRON HEALTH PERSP, V54, P163, DOI 10.2307/3429803; Roels HA, 1997, AM J IND MED, V31, P645, DOI 10.1002/(SICI)1097-0274(199705)31:5<645::AID-AJIM21>3.3.CO;2-M; ROELS HA, 1991, BRIT J IND MED, V48, P365; SARTOR FA, 1992, ARCH ENVIRON HEALTH, V47, P347, DOI 10.1080/00039896.1992.9938373; Shigematsu I., 1982, KANKYO HOKEN REPORT, V48, P118; Shigematsu I., 1980, KANKYO HOKEN REPOR 2, V46, P1; STAESSEN J, 1991, AM J EPIDEMIOL, V134, P257, DOI 10.1093/oxfordjournals.aje.a116079; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140-6736(98)09356-8; STAESSEN JA, 1994, LANCET, V343, P1523, DOI 10.1016/S0140-6736(94)92936-X; Tsuchiya K, 1992, IARC Sci Publ, P35	30	108	110	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1508	1513		10.1016/S0140-6736(99)91145-5	http://dx.doi.org/10.1016/S0140-6736(99)91145-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551497				2022-12-24	WOS:000083411300011
J	van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S				van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S			A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein	NATURE			English	Article							CRYSTAL-STRUCTURE; TYPE-2 FIBER; RECEPTOR; CRYSTALLOGRAPHY; ATTACHMENT; DOMAIN; LONG	Human adenoviruses(1) are responsible for respiratory, gastroenteric and ocular infections(2) and can serve as gene therapy vectors(3). They form icosahedral particles with 240 copies of the trimeric hexon protein arranged on the planes and a penton complex at each of the twelve vertices. The penton consists of a pentameric base, implicated in virus internalization(4), and a protruding trimeric fibre, responsible for receptor attachment(5). The fibres are homo-trimeric proteins containing an aminoterminal penton base attachment domain, a long, thin central shaft and a carboxy-terminal cell attachment or head domain. The shaft domain contains a repeating sequence motif with an invariant glycine or proline and a conserved pattern of hydrophobic residues(6). Here we describe the crystal structure at 2.4 Angstrom resolution of a recombinant protein containing the four distal repeats of the adenovirus type 2 fibre shaft plus the receptor-binding head domain. The structure reveals a novel triple beta-spiral fibrous fold for the shaft. Implications for folding of fibrous proteins (mis-folding of shaft peptides leads to amyloid-like fibrils) and for the design of a new class of artificial, silk-like fibrous materials are discussed.	Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 1, France	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cusack, S (corresponding author), Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, BP 156, F-38042 Grenoble 9, France.	cusack@embl-grenoble.fr	van Raaij, Mark J/B-3678-2009; MITRAKI, Anna/A-6034-2014	van Raaij, Mark J/0000-0002-4781-1375; Cusack, Stephen/0000-0002-9324-0796				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; Chroboczek J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P163; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HESS M, 1995, J MOL BIOL, V252, P379, DOI 10.1006/jmbi.1995.0504; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; LOUIS N, 1994, THESIS U J FOURIER G; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; OBRIEN JP, 1993, ACS SYM SER, V544, P104; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUIGROK RWH, 1994, J GEN VIROL, V75, P2069, DOI 10.1099/0022-1317-75-8-2069; SCHENK TS, 1996, FIELDS VIROLOGY, P2111; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STOUTEN PFW, 1992, J MOL BIOL, V226, P1073, DOI 10.1016/0022-2836(92)91053-R; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	264	275	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					935	938		10.1038/44880	http://dx.doi.org/10.1038/44880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553913				2022-12-24	WOS:000083464700065
J	Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN				Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN			Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; PHYSICAL-ACTIVITY; ATTRIBUTABLE RISK; ALL-CAUSE; HEALTH; TRIAL; WOMEN	Context Recent guidelines for treatment of overweight and obesity include recommendations for risk stratification by disease conditions and cardiovascular disease (CVD) risk factors, but the role of physical inactivity is not prominent in these recommendations. Objective To quantify the influence of low cardiorespiratory fitness, an objective marker of physical inactivity, on CVD and all-cause mortality in normal-weight, overweight, and obese men and compare low fitness with other mortality predictors. Design Prospective observational data from the Aerobics Center Longitudinal Study. Setting Preventive medicine clinic in Dallas, Tex. Participants A total of 25 714 adult men (average age, 43.8 years [SD, 10.1 years]) who received a medical examination during 1970 to 1993, with mortality follow-up to December 31, 1994, Main Outcome Measures Cardiovascular disease and all-cause mortality based on mortality predictors (baseline CVD, type 2 diabetes mellitus, high serum cholesterol level, hypertension, current cigarette smoking, and low cardiorespiratory fitness) stratified by body mass index. Results During the study period, there were 1025 deaths (439 due to CVD) during 258 781 man-years of follow up. Overweight and obese men with baseline CVD or CVD risk factors were at higher risk for all-cause and CVD mortality compared with normal-weight men without these predictors. Using normal-weight men without CVD as the referent, the strongest predictor of CVD death in obese men was baseline CVD (age- and examination year-adjusted relative risk [RR], 14.0; 95% confidence interval [CI], 9.4-20.8); RRs for obese men with diabetes mellitus, high cholesterol, hypertension, smoking, and low fitness were similar and ranged from 4.4 (95% CI, 2.7-7.1) for smoking to 5.0 (95% CI, 3.6-7.0) for low fitness. Relative risks for all-cause mortality in obese men ranged from 2.3 (95% CI, 1.7-2.9) for men with hypertension to 4.7 (95% CI, 3.6-6.1) for those with CVD at baseline. Relative risk for all-cause mortality in obese men with low fitness was 3.1 (95% CI, 2.5-3.8) and in obese men with diabetes mellitus 3.1 (95 % CI, 2.3-4.2) and as slightly higher than the RRs for obese men who smoked or had high cholesterol levels. Low fitness was an independent predictor of mortality in all body mass index groups after adjustment for other mortality predictors. Approximately 50% (n = 1674) of obese men had low fitness, which led to a population-attributable risk of 39% for CVD mortality and 44% for all-cause mortality. Baseline CVD had population attributable risks of 51% and 27% for CVD and all-cause mortality, respectively. Conclusions In this analysis, low cardiorespiratory fitness was a strong and independent predictor of CVD and all-cause mortality and of comparable importance with that of diabetes mellitus and other CVD risk factors.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX USA; Westat Corp, Rockville, MD USA; Stanford Univ, Sch Med, Stanford, CA USA	Cooper Institute; Cooper Institute; Westat; Stanford University	Blair, SN (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	sblair@cooperinst.org	wright, beth/V-7496-2019		NIA NIH HHS [AG06945] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, JAMA, V276, P241; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Bouchard C., 1994, PHYSICAL ACTIVITY FI, P106; Bouchard C., 1986, SPORT HUMAN GENETICS, P59; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; Calfas KJ, 1997, PREV MED, V26, P297, DOI 10.1006/pmed.1997.0141; COX DR, 1972, J R STAT SOC B, V34, P187; Dorn JM, 1997, AM J EPIDEMIOL, V146, P919, DOI 10.1093/oxfordjournals.aje.a009218; Dunn AL, 1998, MED SCI SPORT EXER, V30, P1076, DOI 10.1097/00005768-199807000-00009; Dunn AL, 1997, PREV MED, V26, P883, DOI 10.1006/pmed.1997.0218; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FROHLICH ED, 1988, CIRCULATION, V77, pA502; Gavin JR, 1997, DIABETES CARE, V20, P1183; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Kampert JB, 1996, ANN EPIDEMIOL, V6, P452, DOI 10.1016/S1047-2797(96)00059-2; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; *NIH, 1997, NIH PUBL; *NIH NAT HEART LUN, 1998, CLIN GUID ID EV TREA, P1; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; Rothman K. J., 2008, MODERN EPIDEMIOLOGY; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WALTER SD, 1983, AM J EPIDEMIOL, V117, P598, DOI 10.1093/oxfordjournals.aje.a113582; WHO, 1998, WHO TECHN REP SER	30	746	767	1	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1547	1553		10.1001/jama.282.16.1547	http://dx.doi.org/10.1001/jama.282.16.1547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546694	Bronze			2022-12-24	WOS:000083277800022
J	Zakany, J; Duboule, D				Zakany, J; Duboule, D			Hox genes and the making of sphincters	NATURE			English	Article							COMPLEX; EXPRESSION; MICE		Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Zakany, J (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			duboule, denis/0000-0001-9961-2960				BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Kondo T, 1996, DEVELOPMENT, V122, P2651; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sekimoto T, 1998, GENES CELLS, V3, P51, DOI 10.1046/j.1365-2443.1998.00167.x; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	13	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					761	762		10.1038/44511	http://dx.doi.org/10.1038/44511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548099				2022-12-24	WOS:000083368700040
J	Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G				Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G			Cortical mechanisms of human imitation	SCIENCE			English	Article							AUTOMATED IMAGE REGISTRATION; GRASP REPRESENTATIONS; PREMOTOR CORTEX; AREA 5; MONKEY; BRAIN; CONSCIOUSNESS; LOCALIZATION; RECOGNITION; VALIDATION	How does imitation occur? How can the motor plans necessary for imitating an action derive from the observation of that: action? Imitation may be based on a mechanism directly matching the observed action onto an internal motor representation of that action ("direct matching hypothesis"). To test this hypothesis, normal human participants were asked to observe and imitate a finger movement and to perform the same movement after spatial or symbolic cues. Brain activity was measured with functional magnetic resonance imaging. If the direct matching hypothesis is correct, there should be areas that become active during finger movement; regardless of how it is evoked, and their activation should increase when the same movement is elicited by the observation of an identical movement made by another individual. Two areas with these properties were found in the left; inferior frontal cortex (opercular region) and the rostral-most region of the right superior parietal lobule.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Max Planck Inst Psychol Res, Dept Cognit & Act, D-80802 Munich, Germany; Univ Parma, Inst Human Physiol, I-43100 Parma, Italy	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Max Planck Society; University of Parma	Iacoboni, M (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA.		Brass, Marcel/J-7082-2012; Galantucci, Bruno/E-5770-2010; Bekkering, Harold/A-6357-2009	Brass, Marcel/0000-0002-3364-4019; 				Berlucchi G, 1997, TRENDS NEUROSCI, V20, P560, DOI 10.1016/S0166-2236(97)01136-3; Binkofski F, 1999, EUR J NEUROSCI, V11, P3276, DOI 10.1046/j.1460-9568.1999.00753.x; Binkofski F, 1999, EXP BRAIN RES, V128, P210, DOI 10.1007/s002210050838; BRASS M, IN PRESS ACTA PSYCHO; BRASS M, IN PRESS BRAIN COGN; BRYNE RW, 1995, THINKING APE EVOLUTI; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; De Renzi E., 1990, HDB CLIN NEUROPSYCHO, V2, P245; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; FRITH C, 1995, BEHAV BRAIN SCI, V18, P682, DOI 10.1017/S0140525X00040474; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Georgieff N, 1998, CONSCIOUS COGN, V7, P465, DOI 10.1006/ccog.1998.0367; Gewirtz J.L, 1969, HDB SOCIALIZATION TH, P57; GEWIRTZ JL, 1968, PSYCHOL REV, V75, P374, DOI 10.1037/h0026378; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Goldenberg G, 1997, NEUROPSYCHOLOGIA, V35, P333, DOI 10.1016/S0028-3932(96)00085-1; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Grezes J, 1998, COGN NEUROPSYCHOL, V15, P553, DOI 10.1080/026432998381023; Head H, 1920, BRAIN, V43, P87, DOI 10.1093/brain/43.2.87; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; KEPHART NC, 1971, SLOW LEARNER CLASSRO; Krams M, 1998, EXP BRAIN RES, V120, P386, DOI 10.1007/s002210050412; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MELTZOFF AN, 1983, CHILD DEV, V54, P702, DOI 10.2307/1130058; Menon RS, 1999, TRENDS COGN SCI, V3, P207, DOI 10.1016/S1364-6613(99)01329-7; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pawlby S. J, 1977, STUDIES MOTHER INFAN, P203; Petrides M., 1994, HDB NEUROPSYCHOLOGY, V9, P17; Piaget J., 1962, PLAY DREAMS IMITATIO; Preuss Todd M., 1995, P1227; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1999, ARCH ITAL BIOL, V137, P85; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; SCHOFIELD WN, 1976, Q J EXP PSYCHOL, V28, P571, DOI 10.1080/14640747608400584; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; von Bonin G., 1947, NEOCORTEX MACACA MUL; Woods R. P., 1996, QUANTIFICATION BRAIN, P353, DOI [10.1016/B978-012389760-2/50070-0, DOI 10.1016/B978-012389760-2/50070-0]; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Woods RP, 1999, HUM BRAIN MAPP, V8, P73, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<73::AID-HBM1>3.0.CO;2-7; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Zaidel E, 1996, BRAIN, V119, P2155, DOI 10.1093/brain/119.6.2155-a	47	1848	1895	5	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2526	2528		10.1126/science.286.5449.2526	http://dx.doi.org/10.1126/science.286.5449.2526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617472				2022-12-24	WOS:000084429700055
J	Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW				Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW			Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis - A case series	ANNALS OF INTERNAL MEDICINE			English	Article							URSODEOXYCHOLIC ACID; CONTROLLED TRIAL	Background: No established medical therapy alters the progressive course of primary sclerosing cholangitis. Objective: To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis. Design: Case series. Setting: University hospital in Mainz, Germany. Patients: 15 patients with primary sclerosing cholangitis. Intervention: Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day). Measurements: Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a >30% change in stenosis was considered significant). Results: After a median observation period of 41 months (range, 3 to 81 months), liver enzyme levels declined significantly in all patients. Six of 10 patients with follow-up liver biopsies showed histologic improvement. Significant radiographic deterioration was seen in only 1 of 10 patients who had endoscopic retrograde cholangiography. In 7 patients previously treated with UDCA alone, liver enzyme levels declined significantly only after immunosuppressive therapy was added. Adverse drug reactions led to the withdrawal of study medications in 2 patients. Conclusions: Combined immunosuppressive therapy may alter the progression of primary sclerosing cholangitis. Our observations suggest a benefit from adding immunosuppressive drugs to UDCA therapy. A randomized trial is warranted.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Lohse, AW (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, Langenbeckstr 1, D-55131 Mainz, Germany.			Schramm, Christoph/0000-0002-4264-1928				BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; BURGERT SL, 1984, GASTROENTEROLOGY, V86, P1037; CHAPMAN RW, 1991, SEMIN LIVER DIS, V11, P1, DOI 10.1055/s-2008-1040415; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; HAYASHI H, 1990, GASTROENTEROLOGY, V99, P533, DOI 10.1016/0016-5085(90)91038-8; JAVETT SL, 1971, LANCET, V1, P810; Kaplan MM, 1997, NEW ENGL J MED, V336, P719, DOI 10.1056/NEJM199703063361009; KNOX TA, 1994, GASTROENTEROLOGY, V106, P494, DOI 10.1016/0016-5085(94)90610-6; LARUSSO NF, 1988, GASTROENTEROLOGY, V95, P1036, DOI 10.1016/0016-5085(88)90180-1; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; MENDEL R, 1985, RADIOLOGE, V25, P83; MYERS RN, 1970, AM J GASTROENTEROL, V53, P527; OLSSON R, 1995, GASTROENTEROLOGY, V108, P1199, DOI 10.1016/0016-5085(95)90220-1; Stiehl A, 1997, J HEPATOL, V26, P560, DOI 10.1016/S0168-8278(97)80421-7; VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P455; WAGNER A, 1971, LANCET, V2, P663; WIESNER RH, 1994, MAYO CLIN PROC, V69, P969, DOI 10.1016/S0025-6196(12)61822-9; WIESNER RH, 1991, HEPATOLOGY, V14, pA63	20	79	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					943	946		10.7326/0003-4819-131-12-199912210-00006	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610645				2022-12-24	WOS:000084374400005
J	Mindel, A; Tideman, R				Mindel, A; Tideman, R			HPV transmission - still feeling the way	LANCET			English	Editorial Material							CHILDREN; WARTS		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia.			Mindel, Adrian/0000-0002-8780-9982				FAIRLEY CK, 1995, EPIDEMIOL INFECT, V115, P169, DOI 10.1017/S0950268800058234; FERENCZY A, 1989, OBSTET GYNECOL, V74, P950; Handley J, 1997, PEDIATR DERMATOL, V14, P339, DOI 10.1111/j.1525-1470.1997.tb00976.x; Koutsky LA, 1999, SEXUALLY TRANSMITTED, P347; Matters R, 1998, Commun Dis Intell, V22, P52; ORIEL JD, 1992, GENITOURIN MED, V68, P80; ORIEL JD, 1994, SCARS VENUS HIST VEN, P149; SHAH K V, 1990, P1651; Sonnex C, 1999, SEX TRANSM INFECT, V75, P317, DOI 10.1136/sti.75.5.317; Wen LM, 1999, SEX TRANSM INFECT, V75, P312, DOI 10.1136/sti.75.5.312	10	4	5	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2097	2098		10.1016/S0140-6736(99)00367-0	http://dx.doi.org/10.1016/S0140-6736(99)00367-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609811				2022-12-24	WOS:000084318200005
J	Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR			Transmissible and genetic prion diseases share a common pathway of neurodegeneration	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; WILD-TYPE; SCRAPIE; PROTEIN; ENCEPHALOPATHY; PATHOGENESIS; PATHOLOGY; HAMSTERS; RODENTS; BRAINS	Prion diseases can be infectious, sporadic and genetic(1-4). The infectious forms of these diseases, including bovine spongiform encephalopathy and Creutzfeldt-Jakob disease, are usually characterized by the accumulation in the brain of the transmissible pathogen, an abnormally folded isoform of the prion protein (PrP) termed PrPSc. However, certain inherited PrP mutations appear to cause neurodegeneration in the absence of PrPSc (refs 5-8), working instead by favoured synthesis of (PrP)-Pr-Ctm, a transmembrane form of PrP (ref. 9). The relationship between the neurodegeneration seen in transmissible prion diseases involving PrPSc and that associated with (PrP)-Pr-Ctm has remained unclear. Here we find that the effectiveness of accumulated PrPSc in causing neurodegenerative disease depends upon the predilection of host-encoded PrP to be made in the (PrP)-Pr-Ctm form. Furthermore, the time course of PrPSc accumulation in transmissible prion disease is followed closely by increased generation of (PrP)-Pr-Ctm. Thus, the accumulation of PrPSc appears to modulate in trans the events involved in generating or metabolising (PrP)-Pr-Ctm. Together, these data suggest that the events of (PrP)-Pr-Ctm-mediated neurodegeneration may represent a common step in the pathogenesis of genetic and infectious prion diseases.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X				BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; CHANDLER RL, 1961, LANCET, V1, P1378; CZUB M, 1986, J GEN VIROL, V67, P2005, DOI 10.1099/0022-1317-67-9-2005; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Johnston AR, 1998, NEUROBIOL DIS, V5, P188, DOI 10.1006/nbdi.1998.0194; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PATTISON IH, 1968, RES VET SCI, V9, P408; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Wong K, 1996, NEUROLOGY, V47, P741, DOI 10.1212/WNL.47.3.741	30	235	241	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					822	826		10.1038/45574	http://dx.doi.org/10.1038/45574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617204				2022-12-24	WOS:000084330500068
J	Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG				Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG			Gender-dependent differences in outcome after the treatment of infection in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; RISK-FACTORS; MECHANICAL VENTILATION; MORTALITY; WOMEN; SEPSIS; IMPACT; MEN; MANAGEMENT; SEVERITY	Context While it is established that management strategies and outcomes differ by gender for many diseases, its effect on infection has not been adequately studied. Objective To investigate the role of gender among hospitalized patients treated for infection. Design Observational cohort study conducted during a 26-month period from December 1996 through January 1999. Setting University-affiliated hospital. Participants A total of 892 patients in the surgical units of the hospital with 1470 consecutive infectious episodes (782 in men and 688 in women). Main Outcome Measures Mortality during hospitalization by gender for infection episodes overall and for specific infectious sites, including lung, peritoneum, bloodstream, catheter, urine, surgical site, and skin/soft tissue. Results Among all infections, there was no significant difference in mortality based on gender (men, 11.1% vs women, 14.2%; P = .07). After logistic regression analysis, factors independently associated with mortality included higher APACHE (Acute Physiology and Chronic Health Evaluation) II score; older age, malignancy, blood transfusion, and diagnosis of infection more than 7 days after admission, but not gender (female odds ratio [OR] for death, 1.32; 95% confidence interval [CI],0.90-1.94; P = .16). Mortality was higher in women for lung (men, 18% vs women, 34%; P = .002) and soft tissue (men, 2% vs women, 10%; P less than or equal to .05) infection; for other infectious sites, mortality did not differ by gender. Factors associated with mortality due to pneumonia by logistic regression included higher APACHE II score, malignancy, diabetes mellitus, diagnosis of infection more than 7 days after admission, older age, transplantation, and female gender (OR for death, 2.25; 95% CI, 1.17-4.32; P = .02). Conclusions Although gender may not be predictive of mortality among all infections, women appear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for other comorbidities.	Univ Virginia, Hlth Sci Ctr, Dept Surg, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Sawyer, RG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Surg, Box 10005, Charlottesville, VA 22906 USA.			Sawyer, Robert/0000-0002-8155-2661				Angele MK, 1998, ARCH SURG-CHICAGO, V133, P1281, DOI 10.1001/archsurg.133.12.1281; BONE CR, 1992, AM REV RESPIR DIS, V146, P528, DOI 10.1164/ajrccm/146.2.528; Elliott DC, 1996, ANN SURG, V224, P672, DOI 10.1097/00000658-199611000-00011; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kollef MH, 1997, CHEST, V112, P666, DOI 10.1378/chest.112.3.666; KOLLEF MH, 1993, HEART LUNG, V22, P442; KUBO SH, 1995, J HEART LUNG TRANSPL, V14, P409; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MORO ML, 1994, INFECT CONT HOSP EP, V15, P253; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; Pittet D, 1997, P ASSOC AM PHYSICIAN, V109, P58; Rello J, 1997, CRIT CARE MED, V25, P1862, DOI 10.1097/00003246-199711000-00026; SARIS GE, 1994, J THORAC CARDIOVASC, V108, P240; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Singh N, 1998, CHEST, V114, P1129, DOI 10.1378/chest.114.4.1129; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; Stroud L, 1996, INFECT CONT HOSP EP, V17, P576; TOFLER GH, 1989, AM J CARDIOL, V64, P256, DOI 10.1016/0002-9149(89)90476-1; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021; Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008	24	90	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2143	2148		10.1001/jama.282.22.2143	http://dx.doi.org/10.1001/jama.282.22.2143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591336	Bronze			2022-12-24	WOS:000083971400033
J	Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B				Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B			HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus-1; ritonavir; saquinavir; protease inhibitors; genotype	IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; IN-VIVO; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; ZIDOVUDINE RESISTANCE; COMBINATION THERAPY; CONTROLLED TRIAL; PLUS SAQUINAVIR; CELL COUNTS	Background: Tests for resistance to HIV drugs are available for clinical use; however, their predictive Value has not been fully assessed. Objectives: To determine HIV-1 genotypic predictors of a virologic response to saquinavir-ritonavir therapy in patients in whom at least one previous protease inhibitor-containing regimen had failed and to compare the predictive value of baseline genotype with that of standard clinical evaluation. Design: Retrospective clinical cohort study. Setting: University-based HIV clinic. Patients: 54 H.IV-1-infected adults treated with saquinavir-ritonavir who had experienced virologic failure while receiving a protease inhibitor-containing regimen for at least 3 months. Measurements: HIV-1 reverse transcriptase and protease gene sequences, CD4 cell counts, clinical characteristics, detailed antiretroviral treatment history, and plasma HIV-1 RNA levels at baseline and at three follow-up time points (median, 4, 12, and 26 weeks). Virologic failure was defined as a plasma HIV RNA level greater than 1000 copies/mL. Results: In 22 patients (41%), a plasma HIV-1 RNA level less than 500 copies/mL was achieved by week 12; in 15 patients (28%), this response was maintained through week 26. Clinical characteristics predicting a poorer response included a diagnosis of AIDS, Tower CD4 cell count, and higher plasma HIV RNA level (P < 0.03). Number of previous nucleoside reverse transcriptase inhibitors, previous protease inhibitor therapy, and duration of previous protease inhibitor therapy were predictors of poorer response (P < 0.01). Multivariate regression models revealed that protease mutations present at the initiation of saquinavir-ritonavir therapy were the strongest predictors of virologic response. A model of clinical features explained up to 45% of the variation in virologic outcomes by week 12, whereas the explained variance was 71% when genotypic predictors were included. Conclusions: In patients in whom protease inhibitor-containing antiretroviral therapy fails, HIV-1 genotype is predictive of virologic response to subsequent therapy. This predictive capacity adds to that of standard clinical evaluation.	Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University	Zolopa, AR (corresponding author), Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Grant Bldg,Room S-156, Stanford, CA 94305 USA.	azolopa@stanford.edu	Merigan, Thomas/AGQ-7464-2022	Montoya, Jose G/0000-0002-3378-8071; katzenstein, david/0000-0002-8593-4560	NIAID NIH HHS [R01 AI046148, R01 AI046148-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAXTER JD, 1999, P 6 C RETR OPP INF C; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHATTERJEE S, 1988, SENSITIVITY REGRESSI, P117; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1997, 1 INT WORKSH HIV RES, P31; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1997, LANCET, V349, P1489, DOI 10.1016/S0140-6736(05)62092-2; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; EASTMAN PS, 1995, J CLIN MICROBIOL, V33, P2777, DOI 10.1128/JCM.33.10.2777-2780.1995; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIGAN PR, IN PRESS AID; Hazuda D, 1997, NAT MED, V3, P836, DOI 10.1038/nm0897-836; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LANIER ER, 1999, ANTIVIR THER S, V4, P56; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; *LOS AL NAT LAB, 1997, HUM RETR AIDS COMP A; MAYERS DL, 1997, 1 INT WORKSH HIV RES, P52; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; PATRICK AK, 1998, 2 INT WORKSH HIV DRU, P39; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; SHAFER RW, 1995, J INFECT DIS, V172, P70, DOI 10.1093/infdis/172.1.70; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Vella S, 1998, AIDS Clin Care, V10, P17; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; 1998, ANN INT MED, V128, P1079	56	173	178	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					813	+		10.7326/0003-4819-131-11-199912070-00003	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610625	Green Accepted			2022-12-24	WOS:000084053200002
J	Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB				Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB			Axon routing across the midline controlled by the Drosophila Derailed receptor	NATURE			English	Article							GROWTH CONE GUIDANCE; NEURONAL PATHWAY SELECTION; CNS MIDLINE; COMMISSURAL AXONS; GENETIC-ANALYSIS; NERVOUS-SYSTEM; PROTEIN; ENCODES; MEMBER; EXPRESSION	In nervous systems with symmetry about the midline, many neurons project axons from one side to the other. Although several of the components controlling midline crossing have been identified(1-4), little is known about how axons choose the appropriate pathway when crossing. For example, in the Drosophila embryo axons cross the midline in one of two distinct tracts, the anterior or posterior commissure (AC or PC, respectively). Here we show that the Derailed (Drl) receptor tyrosine kinase is expressed by neurons that project in the AC, and that in the absence of Drl such neurons often project abnormally into the PC. Conversely, misexpression of Drl in PC neurons forces them to cross in the AC. The behaviour of Drl-misexpressing neurons and the in vivo binding pattern of a soluble Drl receptor probe indicate that Drl acts as a guidance receptor for a repellent ligand present in the PC. Our results show that Drl is a novel component in the control of midline crossing.	Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	Salk Institute	Thomas, JB (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA.							Bonkowsky JL, 1999, MECH DEVELOP, V82, P181, DOI 10.1016/S0925-4773(99)00007-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Dittrich R, 1997, DEVELOPMENT, V124, P2515; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; Higashijima S, 1996, DEVELOPMENT, V122, P527; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KIDD T, 1999, DROSOPHILA CELL, V96, P785; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Moreau-Fauvarque C, 1998, MECH DEVELOP, V78, P47, DOI 10.1016/S0925-4773(98)00147-6; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Simon AF, 1998, MECH DEVELOP, V76, P45, DOI 10.1016/S0925-4773(98)00104-X; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6	30	105	106	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					540	544		10.1038/990122	http://dx.doi.org/10.1038/990122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591215				2022-12-24	WOS:000084013200059
J	Callahan, D				Callahan, D			Aging, death, and population health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hastings Ctr, Garrison, NY 10524 USA		Callahan, D (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.							CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Larson E B, 1999, Jt Comm J Qual Improv, V25, P480	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2077	2077		10.1001/jama.282.21.2077	http://dx.doi.org/10.1001/jama.282.21.2077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591393	hybrid			2022-12-24	WOS:000083908700030
J	Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW				Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW			The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes	NATURE			English	Article							INFERRING COMPLEX PHYLOGENIES; NUCLEOTIDE-SEQUENCES; GENE RBCL; ORIGIN; PLANTS; POLLEN	Angiosperms have dominated the Earth's vegetation since the mid-Cretaceous (90 million years ago)(1), providing much of our food, fibre, medicine and timber, yet their origin and early evolution have remained enigmatic for over a century(2-8). One part of the enigma lies in the difficulty of identifying the earliest angiosperms; the other involves the uncertainty regarding the sister group of angiosperms among extant and fossil gymnosperms. Here we report a phylogenetic analysis of DNA sequences of five mitochondrial, plastid and nuclear genes (total aligned length 8,733 base pairs), from all basal angiosperm and gymnosperm lineages (105 species, 103 genera and 63 families). Our study demonstrates that Amborella, Nymphaeales and Illiciales-Trimeniaceae-Austrobaileya represent the first stage of angiosperm evolution, with Amborella being sister to all other angiosperms. We also show that Gnetales are related to the conifers and are not sister to the angiosperms, thus refuting the Anthophyte Hypothesis(1). These results have far-reaching implications for our understanding of diversification, adaptation, genome evolution and development of the angiosperms.	Univ Zurich, Inst Systemat Bot, CH-8008 Zurich, Switzerland; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Smithsonian Inst, Lab Mol Systemat, Washington, DC 20560 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	University of Zurich; Washington State University; Smithsonian Institution; Royal Botanic Gardens, Kew	Qiu, YL (corresponding author), Univ Zurich, Inst Systemat Bot, Zollikerstr 107, CH-8008 Zurich, Switzerland.		Soltis, Pamela S/L-5184-2015; Zimmer, Elizabeth/G-3890-2011; Soltis, Pamela S/GNH-5557-2022; Chase, Mark W/A-6642-2011; Soltis, Douglas/L-5957-2015	Zimmer, Elizabeth/0000-0003-3949-4290; Soltis, Pamela S/0000-0001-9310-8659; Savolainen, Vincent/0000-0001-5350-9984; Kim, Sangtae/0000-0002-1821-4707				Arber EAN, 1907, J LINN SOC BOT, V38, P29, DOI [10.1111/j.1095-8339.1907.tb01074.x, DOI 10.1111/J.1095-8339.1907.TB01074.X]; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Cronquist A., 1988, EVOLUTION CLASSIFICA; DARWIN C, 1903, MORE LETT C DARWIN R, V2, P26; Darwin C., 1903, MORE LETT C DARWIN R, VII, P20; Donoghue MJ, 1989, EVOLUTION SYSTEMATIC, V40A, P17; DOYLE JA, 1969, J ARNOLD ARBORETUM, V50, P1; DOYLE JA, 1978, ANNU REV ECOL SYST, V9, P365, DOI 10.1146/annurev.es.09.110178.002053; Endress PK, 1997, BOT J LINN SOC, V125, P93, DOI 10.1111/j.1095-8339.1997.tb02250.x; ENDRESS PK, 1986, PLANT SYST EVOL, V152, P1, DOI 10.1007/BF00985348; Friis EM, 1999, ANN MO BOT GARD, V86, P259, DOI 10.2307/2666179; FRIIS EM, 1994, PL SYST EVOL S, V8, P31; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hamby RK, 1992, MOL SYSTEMATICS PLAN, P50, DOI [10.1007/978-1-4615-3276-7_4, DOI 10.1007/978-1-4615-3276-7_4]; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; MARTIN PG, 1991, ANN MO BOT GARD, V78, P296, DOI 10.2307/2399564; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Naylor GJP, 1997, NATURE, V388, P527, DOI 10.1038/41460; PARKINSON CL, IN PRESS CURR BIOL; QIU YL, 1993, ANN MO BOT GARD, V80, P587, DOI 10.2307/2399848; Qiu YL, 1999, TRENDS PLANT SCI, V4, P26, DOI 10.1016/S1360-1385(98)01361-2; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Sun G, 1998, SCIENCE, V282, P1692, DOI 10.1126/science.282.5394.1692; Swofford D.L., 1998, PAUP 4 0B2 PHYLOGENE; Takhtajan A, 1969, FLOWERING PLANTS ORI; TAYLOR DW, 1990, SCIENCE, V247, P702, DOI 10.1126/science.247.4943.702; VONWETTSTEIN RR, 1907, HDB SYSTEMATISCHEN B, V2; WALKER JW, 1984, ANN MO BOT GARD, V71, P464, DOI 10.2307/2399035; WALKER JW, 1983, SCIENCE, V220, P1273, DOI 10.1126/science.220.4603.1273	32	666	722	6	136	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					404	407		10.1038/46536	http://dx.doi.org/10.1038/46536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586879				2022-12-24	WOS:000083913600054
J	Kumana, CR; Cheung, BMY; Lauder, IJ				Kumana, CR; Cheung, BMY; Lauder, IJ			Gauging the impact of statins using number needed to treat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; PREVENTION; HYPERCHOLESTEROLEMIA; PRAVASTATIN		Univ Hong Kong, Dept Med, Hong Kong, Peoples R China; Univ Hong Kong, Dept Stat, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Kumana, CR (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P45; ABRAMOWICZ M, 1996, MED LETT, V38, P67; *AD TREATM PAN 2, 1994, CIRCULATION, V89, P1329; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; ILLINGWORTH DR, 1994, CLIN THER, V16, P366; *JOINT FORM COMM L, 1995, BR NATL FORMULARY, V29, P107; Kumana C. R., 1998, Hong Kong Medical Journal, V4, P158; OSE L, 1995, CLIN DRUG INVEST, V10, P127, DOI 10.2165/00044011-199510030-00001; OWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615; PEDERSEN TR, 1994, LANCET, V344, P1383; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONS LA, 1994, INSERT AUSTR SCHEDUL; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	18	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1899	1901		10.1001/jama.282.20.1899	http://dx.doi.org/10.1001/jama.282.20.1899			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580441				2022-12-24	WOS:000083763400002
J	Mayberry, JC				Mayberry, JC			Prevention of the abdominal compartment syndrome	LANCET			English	Editorial Material							PRESSURE; TRAUMA		Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA	Oregon Health & Science University	Mayberry, JC (corresponding author), Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA.			Mayberry, John/0000-0001-6978-9079				Behrman SW, 1998, J TRAUMA, V45, P227, DOI 10.1097/00005373-199808000-00005; BRADLEY SE, 1947, J CLIN INVEST, V26, P1010, DOI 10.1172/JCI101867; CALDWELL CB, 1987, J SURG RES, V43, P14, DOI 10.1016/0022-4804(87)90041-2; Ciresi DL, 1999, AM SURGEON, V65, P720; GROSS RE, 1948, SURGERY, V24, P277; Ivatury RR, 1998, J TRAUMA, V44, P1016, DOI 10.1097/00005373-199806000-00014; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; Ogilvie WH, 1940, LANCET, V2, P253; OLERUD S, 1953, ACTA PHYSL SCAN S109, V30, P4; RICHARDSON JD, 1976, J SURG RES, V20, P401, DOI 10.1016/0022-4804(76)90112-8	11	27	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1749	1750		10.1016/S0140-6736(99)00407-9	http://dx.doi.org/10.1016/S0140-6736(99)00407-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577634				2022-12-24	WOS:000083853000007
J	Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS				Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS			Hepatitis B vaccination among children in inner-city public housing, 1991-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION COVERAGE; INFANTS	Context In 1991, the Advisory Committee on Immunization Practices recommended universal vaccination of infants against hepatitis B virus (HBV), with series initiation within days of birth. Objective To determine HBV vaccine coverage in a low-income urban population and to examine whether HBV immunization within the first month of life affects subsequent vaccine receipt. Design Cohort study based on immunization records collected in the Pediatric Immunization Program. Setting Large public housing development in Chicago, ill. Participants All 1143 children who were born between 1991 and 1997 and enrolled between 1993 and mid-1998, with follow-up to age 35 months. Main Outcome Measures On-time vaccine receipt of HBV vaccine doses, diphtheria-tetanus-pertussis vaccine (DTP) dose 1, and the 4:3:1 series (4 doses of DTP vaccine, 3 doses of poliomyelitis vaccine, and 1 dose of measles-containing vaccine), analyzed by year. Results On-time HBV vaccination increased quickly following new guidelines and reached a plateau of about 50% coverage for those born in or after 1995, Since 1994, more children (64%) received the first HBV vaccine dose on time than any other vaccine. Children who received a dose of HBV vaccine during their first month of life were more likely to receive the first DTP vaccine dose on time (60.1%) than those who did not get an HBV vaccine dose during the first month (36.4%; chi(2) = 53.7; P<.001). Children who received the first HBV vaccine dose during their first month were more likely than those receiving it at age 1 to 2 months to complete 3 HBV doses by 19 months (70.6% vs 51.1%; chi(2) = 11.6; P =.001) and to complete the 4:3:1 series by age 19 months (49.8% vs 37.9%; chi(2) = 4.0; P = .05). Conclusions In this inner-city population, HBV vaccine has been received at rates similar to those of other vaccines within 3 years of issuance of new recommendations. Of note, immunization with HBV vaccine at birth was associated with timely receipt of other vaccines and, therefore, may have the potential to increase vaccination among groups less likely to be up-to-date on early childhood vaccines.	Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lauderdale, DS (corresponding author), Univ Chicago, Dept Hlth Studies, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.							Bolton P, 1998, PUBLIC HEALTH REP, V113, P527; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P818; *CDC, 1991, MMWR-MORBID MORTAL W, V4, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P563; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780; *CHIC DEP PUBL HLT, 1995, R TAYL IN; FREED GL, 1994, PEDIATRICS, V93, P747; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; GOLDSTEIN KP, IN PRESS PEDIATRICS; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; Ross A, 1998, PEDIATRICS, V101, P970, DOI 10.1542/peds.101.6.970; WILLIAMS IT, 1995, PEDIATRICS, V96, P439	14	36	37	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1725	1730		10.1001/jama.282.18.1725	http://dx.doi.org/10.1001/jama.282.18.1725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568644	Bronze			2022-12-24	WOS:000083471400026
J	Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG				Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG			Focal adhesion motility revealed in stationary fibroblasts	SCIENCE			English	Article							CONTRACTILITY; INHIBITORS; INTEGRINS; MIGRATION; CONTACTS; DYNAMICS; MATRIX	Focal adhesions (FAs) are clustered integrins and associated proteins that mediate cell adhesion and signaling. A green fluorescent protein-pi integrin chimera was used to label FAs in Living cells. in stationary cells, FAs were highly motile, moving linearly for several plaque lengths toward the cell center. FA motility was independent of cell density and resulted from contraction of associated actin fibers. In migrating cells, FAs were stationary and only moved in the tail. FA motility in stationary cells suggests that cell movement may be regulated by a clutch-like mechanism by which the affinity of integrins to substrate may be altered in response to migratory cues.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042026, R01GM044585] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42026, GM44585] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DANOWSKI BA, 1989, J CELL SCI, V93, P255; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZZARD CS, 1976, J CELL SCI, V21, P129; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mikhailov A, 1998, CELL MOTIL CYTOSKEL, V41, P325, DOI 10.1002/(SICI)1097-0169(1998)41:4<325::AID-CM5>3.0.CO;2-D; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215	13	284	287	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1172	1174		10.1126/science.286.5442.1172	http://dx.doi.org/10.1126/science.286.5442.1172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550057				2022-12-24	WOS:000083534200047
J	Galarreta, M; Hestrin, S				Galarreta, M; Hestrin, S			A network of fast-spiking cells in the neocortex connected by electrical synapses	NATURE			English	Article							RAT FRONTAL-CORTEX; NONPYRAMIDAL CELLS; INHIBITORY INTERNEURONS; GABAERGIC INTERNEURONS; GAMMA-OSCILLATION; NEURONAL NETWORKS; CORTICAL-NEURONS; IN-VITRO; HIPPOCAMPUS; SYNCHRONIZATION	Encoding of information in the cortex is thought to depend on synchronous firing of cortical neurons(1,2). Inhibitory neurons are known to be critical in the coordination of cortical activity(3-5), but how interaction among inhibitory cells promotes synchrony is not well understood(4,6-12). To address this issue directly, we have recorded simultaneously from pairs of fast-spiking (FS) cells, a type of gamma-aminobutyric acid (GABA)-containing neocortical interneuron(13). Here we report a high occurrence of electrical coupling among FS cells. Electrical synapses were not found among pyramidal neurons or between FS cells and other cortical cells. Some FS cells were interconnected by both electrical and GABAergic synapses. We show that communication through electrical synapses allows excitatory signalling among inhibitory cells and promotes their synchronous spiking. These results indicate that electrical synapses establish a network of fast-spiking cells in the neocortex which may play a key role in coordinating cortical activity.	Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Hestrin, S (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	shaul@nb.utmem.edu	Hestrin, Shaul/F-4410-2010	Vargas-Caballero, Mariana/0000-0003-2326-4001				Angulo MC, 1999, J NEUROSCI, V19, P1566; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; BRAGIN A, 1995, J NEUROSCI, V15, P47; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; Bush P, 1996, J COMPUT NEUROSCI, V3, P91, DOI 10.1007/BF00160806; Cauli B, 1997, J NEUROSCI, V17, P3894; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; CONNORS BW, 1983, J NEUROSCI, V3, P773; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; HUBEL DH, 1959, J PHYSIOL-LONDON, V147, P226, DOI 10.1113/jphysiol.1959.sp006238; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; KAWAGUCHI Y, 1993, J NEUROPHYSIOL, V70, P387, DOI 10.1152/jn.1993.70.1.387; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Rinzel J, 1998, SCIENCE, V279, P1351, DOI 10.1126/science.279.5355.1351; Ritz R, 1997, CURR OPIN NEUROBIOL, V7, P536, DOI 10.1016/S0959-4388(97)80034-7; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; SLOPER JJ, 1972, BRAIN RES, V44, P640, DOI 10.1016/0006-8993(72)90327-7; Stevens CF, 1998, NAT NEUROSCI, V1, P210, DOI 10.1038/659; Strata F, 1997, J NEUROSCI, V17, P1435; Tamas G, 1998, J NEUROSCI, V18, P4255; Traub RD, 1996, NATURE, V383, P621, DOI 10.1038/383621a0; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Zhang Y, 1998, J NEUROSCI, V18, P9256	30	734	743	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					72	75		10.1038/47029	http://dx.doi.org/10.1038/47029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573418				2022-12-24	WOS:000083638600044
J	Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R				Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R			Late diagnosis of congenital dislocation of the hip and presence of a screening programme: South Australian population-based study	LANCET			English	Article							DEVELOPMENTAL DYSPLASIA; RISK-FACTORS; MANAGEMENT	Background The Medical Research Council Working Party on Congenital Dislocation of the Hip have reported an ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip (CDH) of 0.78 per 1000 livebirths, which is similar to the incidence of CDH before the start of the UK screening programme. The report showed that CDH had not been detected by routine screening before age 3 months in 70% of children reported to the national orthopaedic surveillance scheme. This report raised concerns about the merit of screening at birth for CDH. We aimed to find out the incidence of an operative procedure for CDH in the first 5 years of life among children born in South Australia between 1988 and 1993, and the proportion of these patients that were detected at age 3 months or older. Methods The state's database for inpatient separations between January, 1988, and April, 1998 was searched. Case records were examined for the age and circumstances of diagnosis, and type of operative procedures. Prevalence rates of CDH were obtained from the South Australian Birth Defects Register, which receives notifications from a statutory perinatal data collection of birth defects detected at birth and subsequent voluntary notifications for children up to age 5 years. Findings Of the 55 children born in South Australia between 1988 and 1993 identified as having non-teratological CDH and operative procedures, only 22 (40%) had been diagnosed at age 3 months or order. 18 had an open reduction of the hip joint or osteotomy, or both, and the remainder had arthrograms, closed reductions, and/or tenotomy. The prevalence of non-teratological CDH in children was 7.74 per 1000 livebirths. The incidence of surgery for CDH in the first 5 years of life was 0.46 per 1000 livebirths (95% CI 0.34-0.59) and only 0.19 per 1000 livebirths (0.11-0.26) for those diagnosed late (age 3 months or older). These children diagnosed late represented 2.4% of ail known cases of CDH. Interpretation Only 2.4% of known cases of CDH in children born in South Australia had been detected late and required surgery. These results shaw that a screening programme for CDH can be successful, contrary to the findings of the UK Medical Research Council Working Party.	Dept Human Serv, Pregnancy Outcome Unit, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Orthopaed Surg, N Adelaide, SA 5006, Australia; Womens & Childrens Hosp, S Australian Birth Defects Register, N Adelaide, SA 5006, Australia		Chan, A (corresponding author), Dept Human Serv, Pregnancy Outcome Unit, POB 6 Rundle Mall, Adelaide, SA 5000, Australia.							BERMAN L, 1986, BRIT MED J, V293, P719, DOI 10.1136/bmj.293.6549.719; BURGER BJ, 1990, LANCET, V336, P1549, DOI 10.1016/0140-6736(90)93317-I; Chan A, 1997, ARCH DIS CHILD-FETAL, V76, pF94, DOI 10.1136/fn.76.2.F94; CUNNINGHAM KT, 1984, LANCET, V1, P668; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dunn P, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(98)26030-2; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; FREDENSBORG N, 1976, ACTA PAEDIATR SCAND, V65, P323, DOI 10.1111/j.1651-2227.1976.tb04893.x; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; Hiertonn T, 1968, J Bone Joint Surg Br, V50, P542; JONES D, 1977, J BONE JOINT SURG BR, V59, P318, DOI 10.1302/0301-620X.59B3.893510; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; McKee L, 1998, BRIT MED J, V316, P1265; MCKINNON B, 1984, J PEDIATR ORTHOPED, V4, P422, DOI 10.1097/01241398-198408000-00006; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; PALMEN K, 1984, ACTA ORTHOP SCAND, V55, P1; PATERSON DC, 1976, CLIN ORTHOP RELAT R, P28; Raffle AE, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(05)60288-7; *US DEP HHS, 1980, INT CLASS DIS, V1; *US DEP HHS, 1980, INT CLASS DIS, V3; WALKER G, 1971, BRIT MED J, V3, P147, DOI 10.1136/bmj.3.5767.147; Wilson JMG, 1968, 34 WHO PUBL HLTH, V34; Wynne-Davies R, 1970, J Bone Joint Surg Br, V52, P704; Yiv BC, 1997, J PAEDIATR CHILD H, V33, P151, DOI 10.1111/j.1440-1754.1997.tb01019.x; 1991, LANCET, V337, P947	25	48	49	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1514	1517		10.1016/S0140-6736(98)12469-8	http://dx.doi.org/10.1016/S0140-6736(98)12469-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551498				2022-12-24	WOS:000083411300012
J	Lee, DD; Seung, HS				Lee, DD; Seung, HS			Learning the parts of objects by non-negative matrix factorization	NATURE			English	Article							BLIND SEPARATION; RECOGNITION; ALGORITHM; REPRESENTATION	Is perception of the whole based on perception of its parts? There is psychological(1) and physiological(2,3) evidence for parts-based representations in the brain, and certain computational theories of object recognition rely on such representations(4,5). But little is known about how brains or computers might learn the parts of objects. Here we demonstrate an algorithm for non-negative matrix factorization that is able to learn parts of faces and semantic features of text. This is in contrast to other methods, such as principal components analysis and vector quantization, that learn holistic, not parts-based, representations. Non-negative matrix factorization is distinguished from the other methods by its use of non-negativity constraints. These constraints lead to a parts-based representation because they allow only additive, not subtractive, combinations. When non-negative matrix factorization is implemented as a neural network, parts-based representations emerge by virtue of two properties: the firing rates of neurons are never negative and synaptic strengths do not change sign.	AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; Massachusetts Institute of Technology (MIT)	Seung, HS (corresponding author), AT&T Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Lee, Daniel D./B-5753-2013					Bartlett MS, 1998, P SOC PHOTO-OPT INS, V3299, P528, DOI 10.1117/12.320144; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FOLDIAK P, 1995, HDB BRAIN THEORY NEU, P895; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; JUTTEN C, 1991, SIGNAL PROCESS, V24, P1, DOI 10.1016/0165-1684(91)90079-X; Landauer TK, 1997, PSYCHOL REV, V104, P211, DOI 10.1037/0033-295X.104.2.211; Lee DD, 1997, ADV NEUR IN, V9, P515; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; LUCY LB, 1974, ASTRON J, V79, P745, DOI 10.1086/111605; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Paatero P, 1997, CHEMOMETR INTELL LAB, V37, P23, DOI 10.1016/S0169-7439(96)00044-5; PALMER SE, 1977, COGNITIVE PSYCHOL, V9, P441, DOI 10.1016/0010-0285(77)90016-0; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; SALTON G, 1983, INTRO MODERN INFORMA; SAUL L, 1997, P 2 C EMP METH NAT L, P81; Shepp L A, 1982, IEEE Trans Med Imaging, V1, P113, DOI 10.1109/TMI.1982.4307558; TURK M, 1991, J COGNITIVE NEUROSCI, V3, P71, DOI 10.1162/jocn.1991.3.1.71; Ullman S., 1996, HIGH LEVEL VISION OB	22	7733	8368	59	787	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					788	791		10.1038/44565	http://dx.doi.org/10.1038/44565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	250BG	10548103				2022-12-24	WOS:000083368700052
J	Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC				Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC			Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes	NATURE			English	Article							PEYERS-PATCHES; M-CELLS; TYPHIMURIUM; IDENTIFICATION; MUTANTS; IMMUNIZATION; CONSTRUCTION; EXPRESSION; MUTATIONS; INFECTION	Specialized epithelia known as M cells overlying the lymphoid follicles of Peyer's patches are important in the mucosal immune system, but also provide a portal of entry for pathogens such as Salmonella typhimurium, Mycobacterium bovis, Shigella flexneri, Yersinia enterocolitica and reoviruses(1-4). Penetration of intestinal M cells and epithelial cells by Salmonella typhimurium requires the invasion genes of Salmonella Pathogenicity Island 1 (SPI1)(3,5-9) SPI1-deficient S, typhimurium strains gain access to the spleen following oral administration and cause lethal infection in mice(5) without invading M cells(3,9) or localizing in Payer's patches(10), which indicates that Salmonella uses an alternative strategy to disseminate from the gastrointestinal tract, Here we report that Salmonella is transported from the gastrointestinal tract to the bloodstream by CD18-expressing phagocytes, and that CD18-deficient mice are resistant to dissemination of Salmonella to the liver and spleen after oral administration. This CD18-dependent pathway of extraintestinal dissemination may be important for the development of systemic immunity to gastrointestinal pathogens, because oral challenge with SPI1-deficient S. typhimurium elicits a specific systemic Ige humoral immune response, despite an inability to stimulate production of specific mucosal IgA.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Natl Jewish Ctr Immunol & Resp Med, Dept Immunol, Denver, CO 80262 USA; Texas A&M Univ, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Dept Med, Denver, CO 80262 USA; NCI, Cel Regulat & Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Texas A&M University System; Texas A&M University College Station; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fang, FC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.	ferric.fang@uchsc.edu	Valdivia, Raphael/R-5377-2019; Baumler, Andreas J/H-2301-2011	Valdivia, Raphael/0000-0003-0961-073X; Baumler, Andreas J/0000-0001-9152-7809; Parks, W. Tony/0000-0001-7341-3277; Fang, Ferric/0000-0002-3243-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044486] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autenrieth IB, 1996, INFECT IMMUN, V64, P1357, DOI 10.1128/IAI.64.4.1357-1368.1996; Baumler AJ, 1997, INFECT IMMUN, V65, P2254; Baumler AJ, 1996, P NATL ACAD SCI USA, V93, P279, DOI 10.1073/pnas.93.1.279; BERGGREN RE, 1995, J ACQ IMMUN DEF SYND, V10, P489; Bernstein CN, 1996, CLIN EXP IMMUNOL, V106, P160; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; CONLAN JW, 1994, INFECT IMMUN, V62, P2702, DOI 10.1128/IAI.62.7.2702-2706.1994; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GERICHTER C. B., 1960, JOUR HYG, V58, P307; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; KINDER SA, 1993, GENE, V136, P271, DOI 10.1016/0378-1119(93)90478-L; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1998, AM J PHYSIOL-GASTR L, V274, pG785, DOI 10.1152/ajpgi.1998.274.5.G785; OSKOUI R, 1993, ARCH INTERN MED, V153, P517, DOI 10.1001/archinte.153.4.517; PEHHEITER KL, 1997, MOL MICROBIOL, V24, P697; RAHN K, 1992, MOL CELL PROBE, V6, P271, DOI 10.1016/0890-8508(92)90002-F; Shang XZ, 1998, EUR J IMMUNOL, V28, P1970, DOI 10.1002/(SICI)1521-4141(199806)28:06<1970::AID-IMMU1970>3.0.CO;2-H; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Valentine PJ, 1998, INFECT IMMUN, V66, P3378, DOI 10.1128/IAI.66.7.3378-3383.1998; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; WILSON RW, 1993, J IMMUNOL, V151, P1571; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	508	517	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					804	808		10.1038/44593	http://dx.doi.org/10.1038/44593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548107				2022-12-24	WOS:000083368700056
